Document

0001179929-20-000026.txt : 20200214 0001179929-20-000026.hdr.sgml : 20200214 20200214150803 ACCESSION NUMBER: 0001179929-20-000026 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 133 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200214 DATE AS OF CHANGE: 20200214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MOLINA HEALTHCARE, INC. CENTRAL INDEX KEY: 0001179929 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 134204626 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31719 FILM NUMBER: 20618518 BUSINESS ADDRESS: STREET 1: 200 OCEANGATE, SUITE 100 CITY: LONG BEACH STATE: CA ZIP: 90802 BUSINESS PHONE: 5624353666 MAIL ADDRESS: STREET 1: 200 OCEANGATE, SUITE 100 CITY: LONG BEACH STATE: CA ZIP: 90802 FORMER COMPANY: FORMER CONFORMED NAME: MOLINA HEALTHCARE INC DATE OF NAME CHANGE: 20020812 10-K 1 moh-12312019x10k.htm 10-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

(Mark One)



☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019



☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 1-31719

MOLINA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)



Delaware		13-4204626
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

200 Oceangate, Suite 100, Long Beach, California 90802

(Address of principal executive offices)

(562) 435-3666

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:



Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, $0.001 Par Value	MOH	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☒ Yes ☐ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes ☒ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	☒	Accelerated filer	☐	Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

The aggregate market value of Common Stock held by non-affiliates of the registrant as of June 30, 2019, the last business day of our most recently completed second fiscal quarter, was approximately $8,928.7 million (based upon the closing price for shares of the registrant’s Common Stock as reported by the New York Stock Exchange, Inc. on June 30, 2019).

As of February 7, 2020, approximately 60,800,000 shares of the registrant’s Common Stock, $0.001 par value per share, were outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s Proxy Statement for the 2020 Annual Meeting of Stockholders to be held on May 7, 2020, are incorporated by reference into Part III of this Form 10-K, to the extent described therein.

MOLINA HEALTHCARE, INC. 2019 FORM 10-K

TABLE OF CONTENTS



		Page

Part I
Item Number
1.	Business	2

1A.	Risk Factors	17

1B.	Unresolved Staff Comments	Not Applicable.

2.	Properties	30

3.	Legal Proceedings	30

4.	Mine Safety Disclosures	Not Applicable.

Part II

5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	30

6.	Selected Consolidated Financial Data	32

7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	33

7A.	Quantitative and Qualitative Disclosures About Market Risk	46

8.	Financial Statements and Supplementary Data	47

9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	Not Applicable.

9A.	Controls and Procedures	90

9B.	Other Information	94

Part III

10.	Directors, Executive Officers and Corporate Governance	94

11.	Executive Compensation	94

12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	94

13.	Certain Relationships and Related Transactions, and Director Independence	94

14.	Principal Accountant Fees and Services	94

Part IV

15.	Exhibits and Financial Statement Schedules	95

16.	Form 10-K Summary	Not Applicable.

Signatures

FORWARD LOOKING STATEMENTS

This Annual Report on Form 10-K (this “Form 10-K”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Many of the forward-looking statements are located under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as “guidance,” “future,” “anticipates,” “believes,” “estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” and similar terms. Readers are cautioned not to place undue reliance on any forward-looking statements, as forward-looking statements are not guarantees of future performance and the Company’s actual results may differ significantly due to numerous known and unknown risks and uncertainties. Those known risks and uncertainties include, but are not limited to, the risk factors identified in the section of this Form 10-K titled “Risk Factors,” as well as the following:


•	the numerous political, judicial, and market-based uncertainties associated with the Affordable Care Act (the “ACA”) or “Obamacare,” including the ultimate outcome of the Texas et al. v. U.S. et al. matter;


•	the market dynamics surrounding the ACA Marketplaces, including but not limited to uncertainties associated with the elasticity of demand for our products based on our pricing, risk adjustment requirements, the potential for disproportionate enrollment of higher acuity members, and the discontinuation of premium tax credits;


•	subsequent adjustments to reported premium revenue based upon subsequent developments or new information, including changes to estimated amounts payable or receivable related to Marketplace risk adjustment;


•	effective management of our medical costs;


•	our ability to predict with a reasonable degree of accuracy utilization rates, including utilization rates associated with seasonal flu patterns or other newly emergent diseases such as coronavirus;


•	significant budget pressures on state governments and their potential inability to maintain current rates, to implement expected rate increases, or to maintain existing benefit packages or membership eligibility thresholds or criteria;


•	the full reimbursement of the ACA health insurer fee, or HIF;


•	the success of our efforts to retain existing or awarded government contracts, and the success of any requests for proposal protest filings or defenses, including the recently announced Texas STAR+PLUS contract awards and pending Texas STAR/CHIP request for proposal;


•	the ability to manage our operations, including maintaining and creating adequate internal systems and controls relating to authorizations, approvals, provider payments, and the overall success of our care management initiatives;


•	our receipt of adequate premium rates to support increasing pharmacy costs, including costs associated with specialty drugs and costs resulting from formulary changes that allow the option of higher-priced non-generic drugs;


•	our ability to operate profitably in an environment where the trend in premium rate increases lags behind the trend in increasing medical costs;


•	the interpretation and implementation of federal or state medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements;


•	our estimates of amounts owed for such cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions;


•	the Medicaid expansion medical cost corridor, and any other retroactive adjustment to revenue where methodologies and procedures are subject to interpretation or dependent upon information about the health status of participants other than Molina members;


•	the interpretation and implementation of at-risk premium rules and state contract performance requirements regarding the achievement of certain quality measures, and our ability to recognize revenue amounts associated therewith;


•	cyber-attacks or other privacy or data security incidents resulting in an inadvertent unauthorized disclosure of protected health information;


•	the success of our health plan in Puerto Rico, including the resolution of the debt crisis and the effect of the PROMESA law, the effects of political and regulatory instability, and the impact of any future significant weather events;


•	the success and renewal of our duals demonstration programs in California, Illinois, Michigan, Ohio, South Carolina, and Texas;

Molina Healthcare, Inc. 2019 Form 10-K | 1


•	the accurate estimation of incurred but not reported or paid medical costs across our health plans;


•	efforts by states to recoup previously paid and recognized premium amounts;


•	our ability to consummate, integrate, and realize benefits from acquisitions;


•	complications, member confusion, eligibility re-determinations, or enrollment backlogs related to the renewal of Medicaid coverage, as well as the chilling effect of the new so-called public charge rule;


•	government audits, reviews, comment letters, or potential investigations, and any fine, sanction, enrollment freeze, monitoring program, or premium recovery that may result therefrom;


•	changes with respect to our provider contracts and the loss of providers;


•	approval by state regulators of dividends and distributions by our health plan subsidiaries;


•	changes in funding under our contracts as a result of regulatory changes, programmatic adjustments, or other reforms;


•	high dollar claims related to catastrophic illness;


•	the favorable resolution of litigation, arbitration, or administrative proceedings, including litigation involving the ACA to which we are not a direct party;


•	the relatively small number of states in which we operate health plans, including the greater scale and revenues of our California, Ohio, Texas, and Washington health plans;


•	the availability of adequate financing on acceptable terms to fund and capitalize our expansion and growth, repay our outstanding indebtedness at maturity and meet our liquidity needs;


•	the failure to comply with the financial or other covenants in our credit agreement or the indentures governing our outstanding notes;


•	the sufficiency of funds on hand to pay the amounts due upon maturity of our outstanding notes;


•	the failure of a state in which we operate to renew its federal Medicaid waiver;


•	changes generally affecting the managed care industry;


•	increases in government surcharges, taxes, and assessments;


•	newly emergent viruses or widespread epidemics, public catastrophes or terrorist attacks, and associated public alarm;


•	the unexpected loss of the leadership of one or more of our senior executives; and


•	increasing competition and consolidation in the Medicaid industry.

Each of the terms “Molina Healthcare, Inc.” “Molina Healthcare,” “Company,” “we,” “our,” and “us,” as used herein, refers collectively to Molina Healthcare, Inc. and its wholly owned subsidiaries, unless otherwise stated. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

Molina Healthcare, Inc. 2019 Form 10-K | 2

OVERVIEW

ABOUT MOLINA HEALTHCARE

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). Molina was founded in 1980 as a provider organization serving low-income families in Southern California. We were originally organized in California as a health plan holding company and reincorporated in Delaware in 2002.

Through our locally operated health plans in 14 states and the Commonwealth of Puerto Rico, we served approximately 3.3 million members as of December 31, 2019. These health plans are generally operated by our respective wholly owned subsidiaries in those states, each of which is licensed as a health maintenance organization (“HMO”).

FINANCIAL HIGHLIGHTS



	2019	2018
	(Dollars in millions, except per-share amounts)

Total Revenue	$16,829	$18,890
Medical Care Ratio (“MCR”) ⁽¹⁾	85.8%	85.9%
Pre-Tax Margin ⁽²⁾	5.8%	5.3%
After-Tax Margin ⁽²⁾	4.4%	3.7%
Net Income per Diluted Share	$11.47	$10.61

_______________________


(1)	Medical care ratio represents medical care costs as a percentage of premium revenue.


(2)	Pre-tax margin represents income before income taxes as a percentage of total revenue. After-tax margin represents net income as a percentage of total revenue.

2019 EXECUTIVE SUMMARY

We believe Molina’s turnaround continues to progress—margin recovery is complete, margin sustainability is well under way, and the pivot to growth has begun.

We believe that management has demonstrated this progress through its accomplishments in 2019, which have included, among others:


•	We improved our Medicaid and Medicare margins, and earned exceptionally high Marketplace margins. These results were achieved by:


◦	Focusing on managed care fundamentals, including utilization management and claims payment integrity;


◦	Improving our administrative cost structure by, among other initiatives, outsourcing certain capabilities, including information technology; and


◦	Optimizing at-risk revenue by improving organizational capabilities and analytical tools and techniques.


•	Execution of a capital plan that has produced a strong and stable balance sheet, with a simplified capital structure and strong cash flows to support growth, including the harvesting of excess capital from our wholly owned subsidiaries to the parent company.

•

Enhancement of our business and corporate development teams and processes, resulting in two recent transactions. In the fourth quarter of 2019, we entered into an agreement to purchase certain assets of a New York health plan that serves approximately 46,000 Medicaid members; and we entered into an agreement to purchase an Illinois Medicaid managed care organization that serves approximately 50,000 Medicaid and managed long-term services and supports (“MLTSS”) members in Cook County. We expect both acquisitions to close in the first half of 2020.

Molina Healthcare, Inc. 2019 Form 10-K | 3

Our business footprint, as of December 31, 2019, is illustrated in the map below.

OUR SEGMENTS

We currently have two reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve.

Refer to Notes to Consolidated Financial Statements, Note 18, “Segments,” for further information, including segment revenue and profit information, and Note 2, “Significant Accounting Policies” for premium revenue information by health plan.

MEMBERSHIP BY PROGRAM



	As of December 31,
	2019	2018
Medicaid	2,956,000	3,361,000
Medicare	101,000	98,000
Marketplace	274,000	362,000
Total	3,331,000	3,821,000

Molina Healthcare, Inc. 2019 Form 10-K | 4

MEMBERSHIP BY HEALTH PLAN



	As of December 31,
	2019	2018
California	565,000	608,000
Florida ⁽¹⁾	132,000	313,000
Illinois	224,000	224,000
Michigan	362,000	383,000
New Mexico ⁽¹⁾	23,000	222,000
Ohio	288,000	302,000
Puerto Rico	176,000	252,000
South Carolina	131,000	120,000
Texas	341,000	423,000
Washington	832,000	781,000
Other ⁽²⁾	257,000	193,000
Total	3,331,000	3,821,000

__________________


(1)	Due to RFP losses in 2018, our Medicaid contracts in New Mexico and in all but two regions in Florida terminated in late 2018 and early 2019, respectively. We continue to serve Medicare and Marketplace members in both New Mexico and Florida, as well as Medicaid members in two regions in Florida.


(2)	“Other” includes the Idaho, Mississippi, New York, Utah, and Wisconsin health plans, which are individually insignificant to our consolidated operating results.

MISSION

We improve the health and lives of our members by delivering high-quality health care.

VISION

We will distinguish ourselves as the low cost, most effective and reliable health plan delivering government-sponsored care.

STRATEGY

In 2019, we entered a new phase in our turnaround strategy by pivoting our focus to a disciplined and steady approach to growth. Organic growth, which includes leveraging our existing health plan portfolio and winning new territories, is our highest priority. The strategic initiatives that will drive long-term organic growth include:


•	Increasing our market share in our Medicaid, Medicare, and Marketplace programs;


•	Adding adjacent Medicaid geographies;


•	Pursuing Medicaid benefit additions;


•	Increasing market share of other programs within our existing Medicaid footprint; and


•	Winning Medicaid bids in new states, and in re-procurements in our existing states.

In addition to organic growth, we will consider targeted inorganic growth opportunities that provide a strategic fit, leverage operational synergies, and lead to incremental earnings accretion. This will include “bolt-on” membership opportunities in our current states and health plans in new states. As noted above, we entered into two acquisition agreements in the fourth quarter of 2019, pursuant to which we expect to add Medicaid membership in Illinois and New York in 2020.

We will continue our focus on margin sustainability, as we did in 2019, by executing on managed care fundamentals, improving our administrative cost structure, and optimizing at-risk revenue.

From a long-term outlook perspective, we expect:


•	Premium revenue growth of 10% to 12%;


•	Total company after-tax margins in the range of 3.8% to 4.2%;


•	Long-term net income growth of 9% to 11%; and


•	Earnings per diluted share growth of 12% to 15% after deploying the excess capital generated.

Molina Healthcare, Inc. 2019 Form 10-K | 5

OUR BUSINESS

MEDICAID

Overview

Medicaid was established in 1965 under the U.S. Social Security Act to provide health care and long-term care services and support to low-income Americans. Although jointly funded by federal and state governments, Medicaid is a state-operated and state-implemented program. Subject to federal laws and regulations, states have significant flexibility to structure their own programs in terms of eligibility, benefits, delivery of services, and provider payments. As a result, there are 56 separate Medicaid programs—one for each U.S. state, each U.S. territory, and the District of Columbia.

The federal government guarantees matching funds to states for qualifying Medicaid expenditures based on each state’s federal medical assistance percentage (“FMAP”). A state’s FMAP is calculated annually and varies inversely with average personal income in the state. The approximate average FMAP across all jurisdictions is currently 60%, and currently ranges from a federally established FMAP floor of 50% to as high as 77%.

We participate in the following Medicaid programs:


•	Temporary Assistance for Needy Families (“TANF”) - This is the most common Medicaid program. It primarily covers low-income families with children.


•	Medicaid Aged, Blind or Disabled (“ABD”) - ABD programs cover low-income persons with chronic physical disabilities or behavioral health impairments. ABD beneficiaries typically use more services than those served by other Medicaid programs because of their critical health issues.


•	Children’s Health Insurance Program (“CHIP”) - CHIP is a joint federal and state matching program that provides health care coverage to children whose families earn too much to qualify for Medicaid coverage. States have the option of administering CHIP through their Medicaid programs.


•	Medicaid Expansion - In states that have elected to participate, Medicaid Expansion provides eligibility to nearly all low-income individuals under age 65 with incomes at or below 138% of the federal poverty line.

Our state Medicaid contracts typically have terms of three to five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (“RFP”) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.

In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled; and regions or service areas.

Status of Significant Contracts

Our Medicaid contracts with each of the states of California, Ohio, Texas and Washington accounted for 10% or more of our consolidated Medicaid premium revenues in each of the years ended December 31, 2019, and 2018. The current status of each of these contracts is described below.

California. Our managed care contracts with the California Department of Health Care Services (“DHCS”) cover six regions in central and southern California (including the Los Angeles region covered under a separate direct subcontract with Health Net). These contracts are effective through December 31, 2020, and are expected to be renewed annually until the effectiveness of new forms of contract following RFP awards. DHCS has publicly indicated it expects to release a new Medicaid RFP in late 2020, with new contracts effective in 2023. As of December 31, 2019, we served approximately 506,000 Medicaid members in California, representing premium revenue of approximately $1,830 million in 2019.

Ohio. Our managed care contract with the Ohio Department of Medicaid (“ODM”) covers the entire state of Ohio. The contract is effective through June 30, 2020, and we expect to receive another one-year contract effective July 1, 2020. In early 2019, the governor of Ohio asked ODM to initiate a process to re-procure the Ohio Medicaid program related to this contract. The re-procurement of the Ohio Medicaid program is currently projected to begin early in the second half of 2020, although ODM has not committed to or confirmed a specific timeline at this time. As of December 31, 2019, we served approximately 264,000 Medicaid members in Ohio, representing premium revenue of approximately $1,870 million in 2019.

Molina Healthcare, Inc. 2019 Form 10-K | 6

Texas. In October 2019, the Texas Health and Human Services Commission (“HHSC”) awarded contracts to our Texas health plan for the ABD program (known in Texas as “STAR+PLUS”) in two service areas, consisting of one legacy service area and one new service area. This would be a reduction from our current footprint of six service areas. We believe the initial term of each contract is expected to be three years, and such contracts are currently anticipated to be operational beginning on January 1, 2021, at the earliest. Under our existing STAR+PLUS and related Medicare-Medicaid Plan (“MMP”) contracts, we served approximately 97,000 members as of December 31, 2019, representing premium revenue of approximately $2,062 million in 2019. We are currently exercising our protest rights of the STAR+PLUS RFP awards with HHSC.

In 2019, our Texas health plan submitted an RFP response for the TANF and CHIP programs (known in Texas as “STAR/CHIP”). HHSC has announced that the STAR/CHIP contract awards are delayed to late February 2020. Under our existing STAR/CHIP contracts, we served approximately 114,000 members as of December 31, 2019, representing premium revenue of approximately $315 million in 2019.

Washington. Our managed care contract with the Washington State Health Care Authority (“HCA”) covers all ten regions of the state’s Apple Health Integrated Managed Care program, and is effective through December 31, 2020. We expect the HCA to exercise its renewal option for at least one year, through December 31, 2021. As of December 31, 2019, we served approximately 803,000 Medicaid members in Washington, representing premium revenue of approximately $2,370 million in 2019.

A loss of any of our significant Medicaid contracts could have a material adverse effect on our business, financial condition, cash flows, and results of operations.

Other Recent Developments

New Mexico. On January 24, 2020, the Navajo Nation in New Mexico passed legislation for the nation’s first Native American tribe to create a managed health care entity with Molina Healthcare as its partner to operate the plan. The Naat’aanii Development Corporation, the business arm of the Navajo Nation, is expected to contract with us to work toward a managed health care offering under New Mexico’s Medicaid program. The new entity is designed to improve access and quality of health care on the largest Native American reservation. There are approximately 75,000 members of the Navajo Nation living in New Mexico who are eligible for Medicaid. If the parties are able to finalize their contract, the program is expected to be operational by 2021.

Kentucky. On December 2, 2019, we announced that our Kentucky health plan subsidiary had been selected as an awardee pursuant to the Kentucky Medicaid managed care organizations RFP issued by the Kentucky Finance and Administration Cabinet in May 2019. However, in late December 2019, the newly elected Governor of Kentucky announced that he was canceling the Medicaid contracts that had been awarded by the outgoing Governor, including the contract that had been awarded to our Kentucky health plan subsidiary, and that he was reissuing the RFP for rebidding. We submitted a bid under the new RFP on February 6, 2020.

Illinois. On December 31, 2019, we entered into a definitive agreement to purchase NextLevel Health Partners, Inc., a Medicaid managed care organization. Upon the closing of this transaction, expected to occur in the first half of 2020, we will assume the right to serve approximately 50,000 Medicaid and Managed Long-Term Services and Supports members in Cook County, Illinois. The purchase price of approximately $50 million will be funded with available cash, and the closing is subject to customary closing conditions.

New York. In October 2019, we entered into a definitive agreement to acquire certain assets of YourCare Health Plan, Inc. Upon the closing of this transaction, expected to occur in the first half of 2020, we will serve approximately 46,000 Medicaid members in seven counties in western New York. The purchase price of approximately $40 million will be funded with available cash, and the closing is subject to customary closing conditions.

Member Enrollment and Marketing

Most states allow eligible Medicaid members to select the Medicaid plan of their choice. This opportunity to choose a plan is typically afforded to the member at the time of first enrollment and, at a minimum, annually thereafter. In some of the states in which we operate, a substantial majority of new Medicaid members voluntarily select a plan with the remainder subject to the auto-assignment process described below, while in other states less than half of new members voluntarily choose a plan.

Our Medicaid health plans may benefit from auto-assignment of individuals who do not choose a plan, but for whom participation in managed care programs is mandatory. Each state differs in its approach to auto-assignment, but one or more of the following criteria is typical in auto-assignment algorithms: a Medicaid beneficiary's previous enrollment with a health plan or experience with a particular provider contracted with a health plan, enrolling family

Molina Healthcare, Inc. 2019 Form 10-K | 7

members in the same plan, a plan's quality or performance status, a plan’s network and enrollment size, awarding all auto-assignments to a plan with the lowest bid in a county or region, and equal assignment of individuals who do not choose a plan in a specified county or region.

Our Medicaid marketing efforts are regulated by the states in which we operate, each of which imposes different requirements for, or restrictions on, Medicaid sales and marketing. These requirements and restrictions are revised from time to time. None of the jurisdictions in which we operate permit direct sales by Medicaid health plans.

MEDICARE

Overview

Medicare Advantage. Medicare is a federal program that provides eligible persons age 65 and over and some disabled persons with a variety of hospital, medical insurance, and prescription drug benefits. Medicare is funded by Congress, and administered by the Centers for Medicare and Medicaid Services (“CMS”). Medicare beneficiaries may enroll in a Medicare Advantage plan, under which managed care plans contract with CMS to provide benefits that are comparable to original Medicare. Such benefits are provided in exchange for a fixed per-member per-month (“PMPM”) premium payment that varies based on the county in which a member resides, the demographics of the member, and the member’s health condition. Since 2006, Medicare beneficiaries have had the option of selecting a prescription drug benefit from an existing Medicare Advantage plan. The drug benefit, available to beneficiaries for a monthly premium, is subject to certain cost sharing depending upon the specific benefit design of the selected plan.

Medicare-Medicaid Plans, or MMPs. Over 12 million low-income elderly and disabled people qualify for both the Medicare and Medicaid programs (“dual eligible” individuals). These beneficiaries are more likely than other Medicare beneficiaries to be frail, live with multiple chronic conditions, and have functional and cognitive impairments. Medicare is their primary source of health insurance coverage. Medicaid supplements Medicare by paying for services not covered by Medicare, such as dental care and long-term care services and supports, and by helping to cover Medicare’s premiums and cost-sharing requirements. Together, these two programs help to shield very low-income Medicare beneficiaries from potentially unaffordable out-of-pocket medical and long-term care costs. To coordinate care and deliver services in a more financially efficient manner, some states have undertaken demonstration programs to integrate Medicare and Medicaid services for dual-eligible individuals. The health plans participating in such demonstrations are referred to as MMPs. We operate MMPs in six states, as described further below.

Contracts

We enter into Medicare and MMP contracts with CMS, in partnership with each state’s department of health and human services. Such contracts typically have terms of one to two years.

Status of MMP Contracts

Our California, Illinois and Ohio MMP contracts have been extended, each with one-year renewal terms, through December 31, 2022. These contracts represented aggregate revenues of approximately $888 million in 2019.

Our current Michigan, South Carolina and Texas MMP contracts are active through December 31, 2020. These contracts represented aggregate revenues of approximately $701 million in 2019. The current status of these contracts is as follows:


•	Michigan. The Michigan Medicaid agency has submitted a formal letter of intent to extend the MMP program for three years through 2023.


•	South Carolina. We have received information that CMS has granted a three-year extension through 2023.


•	Texas. We have received information that HHSC intends to extend the MMP program through 2023, pending a formal letter to CMS. However, our participation in the Texas MMP program is contingent upon the outcome of the STAR+PLUS RFP award discussed above.

Member Enrollment and Marketing

Our Medicare members may be enrolled through auto-assignment, as described above in “Medicaid—Member Enrollment and Marketing,” or by enrolling in our plans with the assistance of insurance agents employed by Molina, outside brokers, or via the Internet.

Our Medicare marketing and sales activities are regulated by CMS and the states in which we operate. CMS has oversight over all marketing materials used by Medicare Advantage plans, and in some cases has imposed advance approval requirements. CMS generally limits sales activities to those conveying information regarding

Molina Healthcare, Inc. 2019 Form 10-K | 8

benefits, describing the operations of our managed care plans, and providing information about eligibility requirements.

We employ our own insurance agents and contract with independent, licensed insurance agents to market our Medicare Advantage products. We have continued to expand our use of independent agents because the cost of these agents is largely variable and we believe the use of independent, licensed agents is more conducive to the shortened Medicare selling season and the open enrollment period. The activities of our independent, licensed insurance agents are also regulated by CMS. We also use direct mail, mass media and the Internet to market our Medicare Advantage products.

MARKETPLACE

Overview

Effective January 1, 2014, the Affordable Care Act (“ACA”) authorized the creation of Marketplace insurance exchanges, allowing individuals and small groups to purchase federally subsidized health insurance. We offer Marketplace plans in many of the states where we offer Medicaid health plans. Our plans allow our Medicaid members to stay with their providers as they transition between Medicaid and the Marketplace. Additionally, our plans remove financial barriers to quality care and seek to minimize members' out-of-pocket expenses. In 2020, we are participating in the Marketplace in all of our markets except Idaho, Illinois, New York, and Puerto Rico.

We expect membership attrition to be lower than in past years and thus we expect to end 2020 with approximately 310,000 members, a 13% increase over year-end 2019. We also expect revenues to increase in 2020 due to the increased membership; however, we expect that the Marketplace MCR will be higher in 2020 compared with 2019 as a result of our lowering prices in an effort to be more competitive and the impact of higher rebates due to more health plans not meeting the minimum medical loss ratio.

Contracts

We enter into contracts with CMS annually for the state Marketplace programs. These contracts have a one-year term ending on December 31, and must be renewed annually.

Member Enrollment and Marketing

Our Marketplace members enroll in our plans with the assistance of insurance agents employed by Molina, outside brokers, vendors, direct to consumer marketing and via the Internet.

While our Marketplace sales activities are regulated by CMS (such as eligibility determinations), our marketing activities are regulated by the individual states in which we operate. Some states require us to obtain prior approval of our marketing materials, others simply require us to provide them with copies of our marketing materials, and some states do not request our marketing materials. We are able to freely contact our members and provide them with marketing materials as long as those materials are fair and do not discriminate.

Our Marketplace sales and marketing strategy is to provide high quality, affordable, compliant and consumer centric Marketplace products through a variety of distribution channels. Our Marketplace products are displayed on the Federally Facilitated Marketplace (“FFM”) and the State Based Marketplace (“SBM”) in the states in which we participate in the Marketplace. We also contract with independent, licensed insurance agents to market our Marketplace products. The activities of our independently licensed insurance agents are also regulated by both CMS and the departments of insurance in the states in which we participate. Our sales cycle typically peaks during the annual Open Enrollment Period (“OEP”) as defined and regulated by CMS and the applicable FFM and SBM.

Molina Healthcare, Inc. 2019 Form 10-K | 9

BASIS FOR PREMIUM RATES

The following table presents our consolidated premium revenue by program for the periods indicated:



	Year Ended December 31,
	2019		2018
	(In millions)
Medicaid	$	12,466	$	13,623
Medicare	2,243		2,074
Marketplace	1,499		1,915
Total	$	16,208	$	17,612

Medicaid

Under our Medicaid contracts, state government agencies pay our health plans fixed PMPM rates that vary by state, line of business, demographics and, in most instances, health risk factors. CMS requires these rates to be actuarially sound. In exchange for the payment received, Molina arranges, pays for, and manages health care services provided to Medicaid beneficiaries. Therefore, our health plans are at risk for the medical costs associated with their members’ health care. Payments to us under each of our Medicaid contracts are subject to each state’s annual appropriation process. The amount of the premiums paid to our health plans may vary substantially between states and among various government programs. For the year ending December 31, 2019, Medicaid program PMPM premium revenues ranged from $180.00 to $1,540.00.

Medicare

Under Medicare Advantage, managed care plans contract with CMS to provide benefits in exchange for a fixed PMPM premium payment that varies based on health plan star rating and member demographics, including county residence and health risk factors. CMS also considers inflation, changes in utilization patterns and average per capita fee-for-service Medicare costs in the calculation of the fixed PMPM premium payment. Amounts payable to us under the Medicare Advantage contracts are subject to annual revision by CMS, including any federal budget cuts or tax changes applicable to Medicare. We elect to participate in each Medicare service area or region on an annual basis. Medicare Advantage premiums paid to us are subject to federal government reviews and audits which can result, and have resulted, in retroactive and prospective premium adjustments. Compared with our Medicaid plans, Medicare Advantage and MMP contracts generate higher average PMPM revenues and health care costs. For the year ended December 31, 2019, Medicare program PMPM premium revenues ranged from $1,110.00 to $3,410.00.

Marketplace

For Marketplace, we develop each state’s premium rates during the spring of each year for policies effective in the following calendar year. Premium rates are based on our estimates of utilization of services and unit costs, anticipated member risk acuity and related federal risk adjustment transfer amounts, and non-benefit expenses such as administrative costs, taxes, and fees. The premium rates are filed for approval with the various state and federal authorities in accordance with the rules and regulations applicable to the ACA individual market, including, but not limited to, minimum loss ratio thresholds and adjustments for permissible rate variations by age, geographic area, and variations in plan design. For the year ending December 31, 2019, Marketplace program PMPM premium revenues ranged from $340.00 to $1,070.00.

LEGISLATIVE AND POLITICAL ENVIRONMENT

PRESSURES ON MEDICAID FUNDING

Due to states’ budget challenges and political agendas at both the state and federal levels, there are a number of different legislative proposals being considered, some of which would involve significantly reduced federal or state spending on the Medicaid program, constitute a fundamental change to the federal role in health care and, if enacted, could have a material adverse effect on our business, financial condition, cash flows, or results of operations. These proposals include elements such as the following, as well as numerous other potential changes and reforms:


•	Changes in the entitlement nature of Medicaid (and perhaps Medicare as well) by capping future increases

Molina Healthcare, Inc. 2019 Form 10-K | 10

in federal health spending for these programs, and shifting much more of the risk for health costs in the future to states and consumers;


•	Reversing the ACA’s expansion of Medicaid that enables states to cover low-income childless adults;


•	Changing Medicaid to a state block grant program, including potentially capping spending on a per-enrollee basis;


•	Requiring Medicaid beneficiaries to work; and


•	Limiting the amount of lifetime benefits for Medicaid beneficiaries.

AFFORDABLE CARE ACT

Repeal of ACA Taxes

In December 2019, the President signed into law the “Further Consolidated Appropriations Act, 2020,” which repeals several ACA excise taxes, including the Health Insurer Fee (“HIF”) effective for years after 2020.

The HIF will be assessed in 2020, following a moratorium in 2019.

Status of Constitutionality Court Case

In December 2018, in a case brought by the state of Texas and nineteen other states, a federal judge in Texas held that the ACA’s individual mandate is unconstitutional. He further held that since the individual mandate is inseverable from the entire body of the ACA, the entire ACA is unconstitutional. The effect of his ruling was stayed pending the appeal of the ruling to the Fifth Circuit Court of Appeals. In December 2019, a three-judge panel of the Fifth Circuit Court of Appeal, in a two to one decision, affirmed the District Court’s ruling that the individual mandate is unconstitutional, but remanded the case back to the District Court for additional analysis and findings regarding severability and the consideration of additional arguments. Any decision by the District Court is expected to be appealed once again to the Fifth Circuit Court. In addition, the intervenor defendant states led by California have sought immediate appeal of the case to the U.S. Supreme Court. Any final, non-appealable determination that the ACA is unconstitutional could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

Other Proposed Changes and Reforms

Other proposed changes and reforms to the ACA have included, or may include the following:


•	Prohibiting the federal government from operating Marketplaces;


•	Eliminating the advanced premium tax credits, and cost sharing reductions for low income individuals who purchase their health insurance through the Marketplaces;


•	Expanding and encouraging the use of private health savings accounts;


•	Providing for insurance plans that offer fewer and less extensive health insurance benefits than under the ACA’s essential health benefits package, including broader use of catastrophic coverage plans, or short-term health insurance;


•	Establishing and funding high risk pools or reinsurance programs for individuals with chronic or high cost conditions; and


•	Allowing insurers to sell insurance across state lines.

The passage of any of these changes or other reforms could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

PUBLIC CHARGE

On January 27, 2020, the U.S. Supreme Court lifted a nationwide injunction preventing the Department of Homeland Security (“DHS”) from enforcing an “Inadmissibility on Public Charge Grounds” final rule from going into effect. DHS is now permitted to implement and enforce the final rule and will do so effective February 24, 2020, while litigation continues in lower courts, except in the state of Illinois, where a preliminary injunction is still in place.

The final rule changes policies used to determine whether immigration applicants are likely to become a “public charge,” or persons that become dependent on certain government benefits. Under longstanding policy, the federal government can deny applicants entry into the U.S. or adjustment to their immigration status if it is determined that such applicants are likely to become a public charge. Under the final rule, officials will consider the use of certain previously excluded programs, including Medicaid, in public charge determinations.

DHS has estimated that only approximately 140,000 immigration applicants would be impacted by the rule; however, the changes may lead to widespread decreases in participation in Medicaid and other programs. Various

Molina Healthcare, Inc. 2019 Form 10-K | 11

states have mounted educational efforts to keep their members informed and to minimize the effect of the final rule. Our states with the largest immigrant populations include California, Texas, and Illinois.

OPERATIONS

QUALITY

Our long-term success depends, to a significant degree, on the quality of the services we provide. As of December 31, 2019, 11 of our health plans were accredited by the National Committee for Quality Assurance (“NCQA”), including the Multicultural Health Care Distinction, which is awarded to organizations that meet or exceed NCQA’s rigorous requirements for multicultural health care.

For the states where our health plans are accredited by the NCQA and/or have Medicare Star Ratings, the table below presents such health plans’ NCQA status, as well as their current scores as part of the Medicare Star Ratings, which measures the quality of Medicare plans across the country using a 5-star rating system.

We believe that these objective measures of quality are important to state Medicaid agencies, as a growing number of states link reimbursement and patient assignment to quality scores. Additionally, Medicare pays quality bonuses to health plans that achieve high quality.

PROVIDERS

We arrange health care services for our members through contracts with a vast network of providers, including independent physicians and physician groups, hospitals, ancillary providers, and pharmacies. We strive to ensure that our providers have the appropriate expertise and cultural and linguistic experience.

The quality, depth and scope of our provider network are essential if we are to ensure quality, cost-effective care for our members. In partnering with quality, cost-effective providers, we utilize clinical and financial information derived by our medical informatics function, as well as the experience we have gained in serving Medicaid members, to gain insight into the needs of both our members and our providers.

Molina Healthcare, Inc. 2019 Form 10-K | 12

Physicians

We contract with both primary care physicians and specialists, many of whom are organized into medical groups or independent practice associations. Primary care physicians provide office-based primary care services. Primary care physicians may be paid under capitation or fee-for-service contracts and may receive additional compensation by providing certain preventive care services. Under capitation payment arrangements, health care providers receive fixed, pre-arranged monthly payments per enrolled member, whereas under fee-for-service payment arrangements, health care providers are paid a fee for each particular service rendered. Our specialists care for patients for a specific episode or condition, usually upon referral from a primary care physician, and are usually compensated on a fee-for-service basis. When we contract with groups of physicians on a capitated basis, we monitor their solvency.

Hospitals

We generally contract with hospitals that have significant experience dealing with the medical needs of the Medicaid population. We reimburse hospitals under a variety of payment methods, including fee-for-service, per diems, diagnostic-related groups, capitation, and case rates.

Ancillary Providers

Our ancillary agreements provide coverage of medically-necessary care, including laboratory services, home health, physical, speech and occupational therapy, durable medical equipment, radiology, ambulance and transportation services, and are reimbursed on a capitation and fee-for-service basis.

Pharmacy

We outsource pharmacy benefit management services, including claims processing, pharmacy network contracting, rebate processing and mail and specialty pharmacy fulfillment services.

The following table illustrates consolidated medical care costs by type for the periods indicated:



	Year Ended December 31,
	2019						2018
	Amount		PMPM		% of Total		Amount		PMPM		% of Total
	(In millions, except PMPM amounts)
Fee-for-service	$	10,453	$	256.34	75.1	%	$	11,278	$	232.15	74.5	%
Pharmacy	1,681		41.23		12.1		2,138		44.01		14.1
Capitation	1,149		28.17		8.3		1,184		24.38		7.8
Other ⁽¹⁾	622		15.25		4.5		537		11.05		3.6
Total	$	13,905	$	340.99	100.0	%	$	15,137	$	311.59	100.0	%

_____________________


(1)	“Other” includes all medically-related administrative costs, certain provider incentive costs, provider claims, and other health care expenses. Medically-related administrative costs include, for example, expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses.

MEDICAL MANAGEMENT

Our mission is to improve the health and lives of our members by delivering high-quality health care. We believe our singular focus on government-sponsored health care enables us to identify and implement efficiencies that distinguish us as the low-cost, high-quality health plan of choice. We emphasize primary care physicians as the central point of delivery for routine and preventive care, coordination of referrals to specialists, and appropriate assessment of the need for hospital care. This model has proved to be an effective method of coordinating medical care for our members.

Utilization Management

Our goal is to optimize access to low-cost, high-quality care. This is achieved by sound clinical policy based on current evidence-based practices. Additionally, we continuously monitor utilization patterns and strive to identify new opportunities to reduce cost and improve quality of care. Our utilization management process serves as a bridge to identify at-risk members for referral into internally developed case management programs such as “Transitions of Care,” which facilitates post-discharge safety and appropriate outcomes.

Molina Healthcare, Inc. 2019 Form 10-K | 13

Population Management

We believe high-quality, affordable care is achieved through a variety of programs tailored to our members’ emerging needs. Individuals are identified for interventions, and programs are customized, based on predictive analytics and our member assessment process. These tools ensure that the appropriate level of services and support are provided to address physical health, behavioral health, and social determinants of health. This comprehensive and customized approach is designed to help members achieve their goals and improve their overall quality of life.

Pharmacy Management

Our pharmacy programs are designed to make us a trusted partner in improving member health and healthcare affordability. We strategically partner with physicians and other healthcare providers who treat our members. This collaboration results in drug formularies and clinical initiatives that promote improved patient care. We employ full-time pharmacists and pharmacy technicians who work closely with providers to educate them about our formulary products, clinical programs, and the importance of cost-effective care.

INFORMATION TECHNOLOGY

We have partnered with third parties to support our information technology systems. This makes our operations vulnerable to adverse effects if such third parties fail to perform adequately. In February 2019, we entered into a master services agreement with a third party vendor who manages certain of our information technology infrastructure services including, among other things, our information technology operations, end-user services, and data centers. As a result of the agreement, we were able to reduce our administrative expenses, while improving the reliability of our information technology functions, and maintain targeted levels of service and operating performance. A segment of the infrastructure services is provided on our premises, while other portions of the infrastructure services are performed at the vendor’s facilities.

CENTRALIZED SERVICES

We provide certain centralized medical and administrative services to our subsidiaries pursuant to administrative services agreements that include, but are not limited to, information technology, product development and administration, underwriting, claims processing, customer service, certain care management services, human resources, marketing, purchasing, risk management, actuarial, underwriting, finance, accounting, legal and public relations.

COMPETITIVE CONDITIONS AND ENVIRONMENT

We face varying levels of competition. Healthcare reform proposals may cause organizations to enter or exit the market for government-sponsored health programs. However, the licensing requirements and bidding and contracting procedures in some states may present partial barriers to entry into our industry.

We compete for government contracts, renewals of those government contracts, members, and providers. State agencies consider many factors in awarding contracts to health plans. Among such factors are the health plan’s provider network, quality scores, medical management, degree of member satisfaction, timeliness of claims payment, and financial resources. Potential members typically choose a health plan based on a specific provider being a part of the network, the quality of care and services available, accessibility of services, and reputation or name recognition of the health plan. We believe factors that providers consider in deciding whether to contract with a health plan include potential member volume, payment methods, timeliness and accuracy of claims payment, and administrative service capabilities.

Molina Healthcare, Inc. 2019 Form 10-K | 14

Medicaid

The Medicaid managed care industry is subject to ongoing changes as a result of healthcare reform, business consolidations and new strategic alliances. We compete with national, regional, and local Medicaid service providers, principally on the basis of size, location, quality of the provider network, quality of service, and reputation. Our primary competitors in the Medicaid managed care industry include Centene Corporation, UnitedHealth Group Incorporated, Anthem, Inc., Aetna Inc., and other large not-for-profit health care organizations. Competition can vary considerably from state to state.

Medicare

The Medicare market is highly competitive across the country, with large competitors, such as UnitedHealth Group Incorporated, Humana Inc., and Aetna Inc., holding significant market share.

Marketplace

Low-income members who receive government subsidies comprise the vast majority of Marketplace membership, which is served by a limited number of health plans. Our primary competitor for low-income Marketplace membership is Centene Corporation.

REGULATION

Our health plans are highly regulated by both state and federal government agencies. Regulation of managed care products and healthcare services varies from jurisdiction to jurisdiction, and changes in applicable laws and rules occur frequently. Regulatory agencies generally have discretion to issue regulations and interpret and enforce laws and rules. Such agencies have become increasingly active in recent years in their review and scrutiny of health insurers and managed care organizations, including those operating in the Medicaid and Medicare programs.

HIPAA AND THE HITECH ACT

In 1996, Congress enacted the Health Insurance Portability and Accountability Act (“HIPAA”). All health plans are subject to HIPAA, including ours. HIPAA generally requires health plans to:


•	Establish the capability to receive and transmit electronically certain administrative health care transactions, such as claims payments, in a standardized format;


•	Afford privacy to patient health information; and


•	Protect the privacy of patient health information through physical and electronic security measures.

In 2009, the Health Information Technology for Economic and Clinical Health Act (“HITECH”) imposed requirements on uses and disclosures of health information; included requirements for HIPAA business associate agreements; extended parts of HIPAA privacy and security provisions to business associates; added data breach notification requirements for covered entities and business associates and reporting requirements to the U.S. Department of Health and Human Services (“HHS”) and, in some cases, to the media; strengthened enforcement; and imposed higher financial penalties for HIPAA violations. In the conduct of our business, depending on the circumstances, we may act as either a covered entity or a business associate. HIPAA privacy regulations do not preempt more stringent state laws and regulations that may apply to us.

We maintain an internal HIPAA compliance program, which we believe complies with HIPAA privacy and security regulations, and have dedicated resources to monitor compliance with this program.

Healthcare reform created additional tools for fraud prevention, including increased oversight of providers and suppliers participating or enrolling in Medicaid, CHIP, and Medicare. Those enhancements included mandatory licensure for all providers, and site visits, fingerprinting, and criminal background checks for higher risk providers.

FRAUD AND ABUSE LAWS AND THE FALSE CLAIMS ACT

Molina Healthcare, Inc. 2019 Form 10-K | 15

known, that information we provide to form the basis for a claim for government payment is false or fraudulent, and some courts have permitted False Claims Act suits to proceed if the claimant was out of compliance with program requirements.

Fraud, waste and abuse prohibitions encompass a wide range of operating activities, including kickbacks or other inducements for referral of members or for the coverage of products (such as prescription drugs) by a plan, billing for unnecessary medical services by a provider, upcoding, payments made to excluded providers, improper marketing, and the violation of patient privacy rights. In particular, there has recently been increased scrutiny by the Department of Justice on health plans’ risk adjustment practices, particularly in the Medicare program. Companies involved in public healthcare programs such as Medicaid and Medicare are required to maintain compliance programs to detect and deter fraud, waste and abuse, and are often the subject of fraud, waste and abuse investigations and audits. The regulations and contractual requirements applicable to participants in these public-sector programs are complex and subject to change.

The federal government has taken the position that claims presented in violation of the federal anti-kickback statute may be considered a violation of the federal False Claims Act. In addition, under the federal civil monetary penalty statute, the HHS’ Office of Inspector General has the authority to impose civil penalties against any person who, among other things, knowingly presents, or causes to be presented, certain false or otherwise improper claims. Qui tam actions under federal and state law can be brought by any individual on behalf of the government. Qui tam actions have increased significantly in recent years, causing greater numbers of healthcare companies to have to defend a false claim action, pay fines, or be excluded from the Medicare, Medicaid, or other state or federal healthcare programs as a result of an investigation arising out of such action.

LICENSING AND SOLVENCY

Our health plans are generally licensed by the insurance departments in the states in which they operate, except our California health plan, which is licensed by the California Department of Managed Health Care, and our New York health plan, which is licensed as a prepaid health services plan by the New York State Department of Health.

Our health plans are subject to stringent requirements to maintain a minimum amount of statutory capital determined by statute or regulation, and restrictions that limit their ability to pay dividends to us. For further information, refer to the Notes to Consolidated Financial Statements, Note 17, “Commitments and Contingencies—Regulatory Capital Requirements and Dividend Restrictions.”

OTHER INFORMATION

EMPLOYEES

As of December 31, 2019, we had approximately 10,000 employees. Our employee base is multicultural and reflects the diverse membership we serve.

AVAILABLE INFORMATION

Our principal executive offices are located at 200 Oceangate, Suite 100, Long Beach, California 90802, and our telephone number is (562) 435-3666. The Company also maintains corporate offices in New York City, New York.

You can access our website at www.molinahealthcare.com to learn more about our Company. From that site, you can download and print copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, along with amendments to those reports. You can also download our Corporate Governance Guidelines, board of directors committee charters, and Code of Business Conduct and Ethics. We make periodic reports and amendments available, free of charge, as soon as reasonably practicable after we file or furnish these reports to the U.S. Securities and Exchange Commission (“SEC”). We will also provide a copy of any of our corporate governance policies published on our website free of charge, upon request. To request a copy of any of these documents, please submit your request to: Molina Healthcare, Inc., 200 Oceangate, Suite 100, Long Beach, California 90802, Attn: Investor Relations. Information on or linked to our website is neither part of nor incorporated by reference into this Form 10-K or any other SEC filings.

Molina Healthcare, Inc. 2019 Form 10-K | 16

RISK FACTORS

You should carefully consider the risks described below and all of the other information set forth in this Form 10-K, including our consolidated financial statements and accompanying notes. These risks and other factors may affect our forward-looking statements, including those we make in this Form 10-K or elsewhere, such as in press releases, presentations to securities analysts or investors, or other communications made by or with the approval of one of our executive officers. The risks described below are not the only risks facing our Company. Additional risks that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. If any of the following risks actually occurs, our business, financial condition, results of operations, and future prospects could be materially and adversely affected. In that event, among other effects, the trading price of our common stock could decline, and you could lose part or all of your investment.

We operate in an uncertain political and judicial environment which creates uncertainties with regard to our future prospects.

Currently, there are a number of different legislative proposals being considered which would involve significantly reduced federal spending on the Medicaid program or would otherwise constitute a fundamental change in the federal role in health care. Changes to or the repeal of the ACA, or the adoption of new health care regulatory laws, could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

If the responsive bids of our health plans for new or renewed Medicaid contracts are not successful, or if our government contracts are terminated or are not renewed on favorable terms or at all, our premium revenues could be materially reduced and our operating results could be negatively impacted.

We currently derive our premium revenues from health plans that operate in 14 states and the Commonwealth of Puerto Rico. Our premium revenues constituted 96% of our total revenue in the year ended December 31, 2019. Measured by premium revenue by health plan, our top four health plans were in California, Ohio, Texas, and Washington, with aggregate premium revenue of $10.5 billion, or approximately 65% of total premium revenue, in the year ended December 31, 2019. If we are unable to continue to operate in any of our existing jurisdictions, or if our current operations in those jurisdictions or any portions of those jurisdictions are significantly curtailed or terminated entirely, our revenues could decrease materially.

Many of our government contracts are effective only for a fixed period of time and will only be extended for an additional period of time if the contracting entity elects to do so. When such contracts expire, they may be opened for bidding by competing healthcare providers (many of which have greater financial resources and greater name recognition than us), and there is no guarantee that the contracts will be renewed or extended. Even if our contracts are renewed or extended, there can be no assurance that they will be renewed or extended on the same terms or without a reduction in the applicable service areas. For example, in October 2019, our Texas health plan was notified that its contract for the STAR+PLUS program was being renewed but with a significant reduction in the service areas covered by that contract, and our contract for the STAR/CHIP program in Texas is also subject to the outcome of a pending RFP. In addition, as stated above, our contracts in Ohio and California are expected to be subject to re-procurement later in 2020. Further, on January 15, 2020, the Florida District Court of Appeal held oral argument on the appeal brought by Best Care alleging that AHCA’s award of Region 8 to Molina Healthcare of Florida was illegal in that it allegedly exceeded the statutory cap of four health plan awardees. We expect a ruling from the appellate court in the first half of 2020. An adverse ruling could have a material adverse effect on the results of operations of our Florida health plan.

Even if our responsive bids are successful, the bids may be based upon assumptions regarding enrollment, utilization, medical costs, or other factors which could result in the contract being less profitable than we had expected or could result in a net loss. Furthermore, our contracts contain certain provisions regarding, among other

Molina Healthcare, Inc. 2019 Form 10-K | 17

things, eligibility, enrollment and dis-enrollment processes for covered services, eligible providers, periodic financial and information reporting, quality assurance and timeliness of claims payment, and are subject to cancellation if we fail to perform in accordance with the standards set by regulatory agencies.

If we lose contracts that constitute a significant amount of our revenue, we will lose the administrative cost efficiencies that are inherent in a larger revenue base. In such circumstances, we may not be able to reduce fixed costs proportionally with our lower revenue, and the financial impact of lost contracts may exceed the net income ascribed to those contracts.

We currently spread the cost of centralized services over a large revenue base. Many of our administrative costs are fixed in nature, and will be incurred at the same level regardless of the size of our revenue base. If we lose contracts that constitute a significant amount of our revenue, we may not be able to reduce the expense of centralized services in a manner that is proportional to that loss of revenue. In such circumstances, not only will our total dollar margins decline, but our percentage margins, measured as a percentage of revenue, will also decline. This loss of cost efficiency, and the resulting stranded administrative costs, could have a material and adverse impact on our business, financial condition, cash flows, or results of operations.

If, in the interests of maintaining or improving longer term profitability, we decide to exit voluntarily certain state contractual arrangements, make changes to our provider networks, or make changes to our administrative infrastructure, we may incur disruptions to our business that could materially reduce our premium revenues and our net income.

Decisions that we make with regard to retaining or exiting our portfolio of state and federal contracts, and changes to the manner in which we serve the members attached to those contracts, could generate substantial expenses associated with the run out of existing operations and the restructuring of those operations that remain. Such expenses could include, but would not be limited to, goodwill and intangible asset impairment charges, restructuring costs, additional medical costs incurred due to the inability to leverage long-term relationships with medical providers, and costs incurred to finish the run out of businesses that have ceased to generate revenue, all of which could materially reduce our premium revenues and net income.

A failure to accurately estimate incurred but not paid medical care costs may negatively impact our results of operations.

Because of the time lag between when medical services are actually rendered by our providers and when we receive, process, and pay a claim for those medical services, we must continually estimate our medical claims liability at particular points in time, and establish claims reserves related to such estimates. Our estimated reserves for such incurred but not paid (“IBNP”) medical care costs are based on numerous assumptions. We estimate our medical claims liabilities using actuarial methods based on historical data adjusted for claims receipt and payment experience (and variations in that experience), changes in membership, provider billing practices, health care service utilization trends, cost trends, product mix, seasonality, prior authorization of medical services, benefit changes, known outbreaks of disease or increased incidence of illness such as influenza, provider contract changes, changes to Medicaid fee schedules, and the incidence of high dollar or catastrophic claims. Our ability to accurately estimate claims for our newer lines of business or populations is negatively impacted by the more limited experience we have had with those newer lines of business or populations.

The IBNP estimation methods we use and the resulting reserves that we establish are reviewed and updated, and adjustments, if deemed necessary, are reflected in the current period. Given the numerous uncertainties inherent in such estimates, our actual claims liabilities for a particular quarter or other period could differ significantly from the amounts estimated and reserved for that quarter or period. Our actual claims liabilities have varied and will continue to vary from our estimates, particularly in times of significant changes in utilization, medical cost trends, and populations and markets served.

If our actual liability for claims payments is higher than previously estimated, our earnings in any particular quarter or annual period could be negatively affected. Our estimates of IBNP may be inadequate in the future, which would negatively affect our results of operations for the relevant time period. Furthermore, if we are unable to accurately estimate IBNP, our ability to take timely corrective actions may be limited, further exacerbating the extent of the negative impact on our results.

If we fail to accurately predict and effectively manage our medical care costs, our operating results could be materially and adversely affected.

Our profitability depends to a significant degree on our ability to accurately predict and effectively manage our medical care costs. Historically, our medical care ratio, meaning our medical care costs as a percentage of our premium revenue, has fluctuated substantially, and has varied across our health plans. Because the premium

Molina Healthcare, Inc. 2019 Form 10-K | 18

payments we receive are generally fixed in advance and we operate with a narrow profit margin, relatively small changes in our medical care ratio can create significant changes in our overall financial results. For example, if our overall medical care ratio of 85.8% for the year ended December 31, 2019, had been one percentage point higher, or 86.8%, our net income per diluted share for the year ended December 31, 2019 would have been approximately $9.52 rather than our actual net income per diluted share of $11.47, a difference of $1.95.

Many factors may affect our medical care costs, including:


•	the level of utilization of health care services,


•	changes in the underlying risk acuity of our membership,


•	unexpected patterns in the annual flu season,


•	increases in hospital costs,


•	increased incidences or acuity of high dollar claims related to catastrophic illnesses or medical conditions for which we do not have adequate reinsurance coverage,


•	increased maternity costs,


•	changes in state eligibility certification methodologies,


•	relatively low levels of hospital and specialty provider competition in certain geographic areas,


•	increases in the cost of pharmaceutical products and services,


•	changes in health care regulations and practices,


•	epidemics,


•	new medical technologies, and


•	other various external factors.

Many of these factors are beyond our control. The inability to forecast and manage our medical care costs or to establish and maintain a satisfactory medical care ratio, either with respect to a particular health plan or across the consolidated entity, could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

Continuing changes in health care laws, and in the health care industry, make it difficult to develop actuarially sound rates.

Comprehensive changes to the U.S. healthcare system make it more difficult for us to manage our business, and increase the likelihood that the assumptions we make with respect to our future operations and results will prove to be inaccurate. The continuing pace of change has made it difficult for us to develop actuarially sound rates because we have limited historical information on which to develop these rates. In the absence of significant historical information to develop actuarial rates, we must make certain assumptions. These assumptions may subsequently prove to be inaccurate. For example, rates of utilization could be significantly higher than we projected, or the assumptions of policymakers about the amount of savings that could be achieved through the use of utilization management in managed care could be flawed. Moreover, our lack of actuarial experience for a particular program, region, or population, could cause us to set our reserves at an inadequate level.

Our stock price may be significantly impacted by volatility associated with the November 2020 election.

Health care is expected to be a central issue in the November 2020 Presidential and Congressional elections. Several Presidential and Congressional candidates are advocating significant changes and reforms in the U.S. health care system, including changes with regard to the Medicaid and Medicare programs, the ACA, and how health care is funded. Other proposed legislation relates to surprising medical billing and drug pricing. The focus among Democratic presidential candidates on Medicare for All, a single payer system that would eliminate reliance on private health care companies, or other health care reforms and associated legislative and programmatic uncertainty tends to create significant price volatility among health care stocks, including the trading price of the stock of the Company. Such volatility may become especially acute as the November election draws closer and perceptions emerge as to how the election of a particular candidate, or how the control of the U.S Senate or the House of Representatives, will impact the chances of adoption in 2021 of reform legislation pertaining to healthcare.

If we are unable to collect the health insurer fee (“HIF”) reimbursement for 2020 from our state partners, our business, financial condition, cash flows, or results of operations could be materially and adversely affected.

Because Medicaid is a government funded program, Medicaid health plans must request reimbursement for the HIF from respective state partners to offset the impact of this tax. When states reimburse us for the amount of the HIF, that reimbursement is itself subject to income tax, the HIF, and applicable state premium taxes. Because the HIF is not deductible for income tax purposes, our net income is reduced by the full amount of the assessment. The 2020 HIF assessment, related to our Medicaid business, is currently estimated to be $217 million, with an expected tax

Molina Healthcare, Inc. 2019 Form 10-K | 19

gross-up effect from the reimbursement of the assessment of approximately $63 million. Therefore, the total reimbursement needed as a result of the Medicaid-related HIF is currently estimated to be approximately $280 million. The delay or failure of our state partners to reimburse us in full for the 2020 HIF and its related tax effects could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

An impairment charge with respect to our recorded goodwill, or our finite-lived intangible assets, could have a material impact on our financial results.

As of December 31, 2019, the carrying amounts of goodwill and intangible assets, net, amounted to $143 million, and $29 million, respectively.

Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment on an annual basis and more frequently if impairment indicators are present. Such events or circumstances may include experienced or expected operating cash-flow deterioration or losses, significant losses of membership, loss of state funding, loss of state contracts, and other factors. Goodwill is impaired if the carrying amount of the reporting unit (one of our state health plans) exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit.

Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts). Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment.

An event or events could occur that would cause us to revise our estimates and assumptions used in analyzing the value of our goodwill, and intangible assets, net. For example, if the responsive bid of one or more of our health plans is not successful, we will lose our Medicaid contract in the applicable state or states. If such state health plans have recorded goodwill and intangible assets, net, the contract loss would result in a non-cash impairment charge. Such a non-cash impairment charge could have a material adverse impact on our financial results.

A reversal of the Medicaid Expansion would have a negative impact on our business.

In the states that have elected to participate, the ACA provided for the expansion of the Medicaid program to offer eligibility to nearly all individuals under age 65 with incomes at or below 138% of the federal poverty line. Since January 1, 2014, several of our health plans have participated in the Medicaid Expansion program under the ACA. At December 31, 2019, our membership included approximately 605,000 Medicaid Expansion members, or 18% of our total membership. If the Medicaid Expansion is reversed by repeal of the ACA or otherwise, we could lose this membership, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

Our participation in the Marketplace creates certain risks which could adversely impact our business, financial position, and results of operations.

The ACA authorized the creation of state insurance marketplaces (the “Marketplace”), allowing individuals and small groups to purchase federally subsidized health insurance. As of December 31, 2019, we participated in the individual Marketplace in nine states, which represented approximately 8% of our total membership.

As described above, challenges to the constitutionality of the ACA are currently being litigated. The perceived instability and impending changes in the Marketplace could further promote reduced participation among the uninsured. Further, the withdrawal of cost sharing subsidies and/or premium tax credits, the elimination of the individual mandate to purchase health insurance, the use of special enrollment periods, or any announcement that some or all of our health plans will be leaving the Marketplace, could additionally impact Marketplace enrollment. These market and political dynamics may increase the risk that our Marketplace products will be selected by individuals who have a higher risk profile or utilization rate than we anticipated when we established the pricing for our Marketplace products, leading to financial losses. In addition, because of the immaturity and volatility of the Marketplace markets, it is difficult to predict the full effect of pricing changes. For 2020, we had lowered our Marketplace pricing in an effort to gain market share, but fewer members enrolled with our health plans than we had expected.

Molina Healthcare, Inc. 2019 Form 10-K | 20

The Medicare-Medicaid Duals Demonstration Pilot Programs could be discontinued or altered, resulting in a loss of premium revenue.

To coordinate care for those who qualify to receive both Medicare and Medicaid services (the “dual eligibles”), and to deliver services to these individuals in a more financially efficient manner, under the direction of CMS some states implemented demonstration pilot programs to integrate Medicare and Medicaid services for the dual eligibles. The health plans participating in such demonstrations are referred to as Medicare-Medicaid Plans (“MMPs”). We operate MMPs in six states: California, Illinois, Michigan, Ohio, South Carolina, and Texas. At December 31, 2019, our membership included approximately 58,000 integrated MMP members, representing approximately 2% of our total membership. However, the capitation paid to us for dual eligibles is significantly higher than the capitation paid for other members, representing 10% of our total premium revenues in 2019. If the states running the MMP pilot programs conclude that the demonstration pilot programs are not delivering better coordinated care and reduced costs, they could decide to discontinue or substantially alter such programs, resulting in a reduction to our premium revenues.

Our health plans operate with very low profit margins, and small changes in operating performance or slight changes to our accounting estimates will have a disproportionate impact on our reported net income.

A substantial portion of our premium revenue is subject to contract provisions pertaining to medical cost expenditure floors and corridors, administrative cost and profit ceilings, premium stabilization programs, and cost-plus and performance-based reimbursement programs. Many of these contract provisions are complex, or are poorly or ambiguously drafted, and thus are subject to differing interpretations by us and the relevant government agency with whom we contract. If the applicable government agency disagrees with our interpretation or implementation of a particular contract provision, we could be required to adjust the amount of our obligation under that provision. Any such adjustment could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

In addition, many of our contracts contain provisions pertaining to at-risk premiums that require us to meet certain quality performance measures to earn all of our contract revenues. If we are unsuccessful in achieving the stated performance measure, we will be unable to recognize the revenue associated with that measure, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

We are subject to retroactive adjustment to our Medicaid premium revenue as a result of retroactive risk adjustment; retroactive changes to contract terms and the resolution of differing interpretations of those terms; the difficulty of estimating performance-based premium; and retroactive adjustments to “blended” premium rates to reflect the actual mix of members captured in those blended rates.

The complexity of some of our Medicaid contract provisions, imprecise language in those contracts, the desire of state Medicaid agencies in some circumstances to retroactively adjust for the acuity of the medical needs of our members, and state delays in processing rate changes, can create uncertainty around the amount of revenue we should recognize. Any circumstance such as those described above could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

If we are unable to deliver quality care, and maintain good relations with the physicians, hospitals, and other providers with whom we contract, or if we are unable to enter into cost-effective contracts with such providers, our profitability could be adversely affected.

We contract with physicians, hospitals, and other providers as a means to ensure access to healthcare services for our members, to manage medical care costs and utilization, and to better monitor the quality of care being delivered. We compete with other health plans to contract with these providers. We believe providers select plans in which they participate based on criteria including reimbursement rates, timeliness and accuracy of claims payment, potential to deliver new patient volume and/or retain existing patients, effectiveness of resolution of calls and complaints, and other factors. There can be no assurance that we will be able to successfully attract and retain providers to maintain a competitive network in the geographic areas we serve. In addition, in any particular market, providers could refuse to contract with us, demand higher payments, or take other actions which could result in higher medical care costs, disruption to provider access for current members, a decline in our growth rate, or difficulty in meeting regulatory or accreditation requirements.

The Medicaid program generally pays doctors and hospitals at levels well below those of Medicare and private insurance. Large numbers of doctors, therefore, do not accept Medicaid patients. In the face of fiscal pressures, some states may reduce rates paid to providers, which may further discourage participation in the Medicaid program.

Molina Healthcare, Inc. 2019 Form 10-K | 21

In some markets, certain providers, particularly hospitals, physician/hospital organizations, and some specialists, may have significant market positions or even monopolies. If these providers refuse to contract with us or utilize their market position to negotiate favorable contracts which are disadvantageous to us, our profitability in those areas could be adversely affected.

Some providers that render services to our members are not contracted with our health plans. In those cases, there is no pre-established understanding between the provider and our health plan about the amount of compensation that is due to the provider. In some states, the amount of compensation is defined by law or regulation, but in most instances it is either not defined or it is established by a standard that is not clearly translatable into dollars. In such instances, providers may claim they are underpaid for their services and may either litigate or arbitrate their dispute with our health plan. The uncertainty of the amount to pay to such providers and the possibility of subsequent adjustment of the payment could adversely affect our business, financial condition, cash flows, or results of operations.

The exorbitant cost of specialty drugs and new generic drugs could have a material adverse effect on the level of our medical costs and our results of operations.

Introduction of new high cost specialty drugs and sudden costs spikes for existing drugs increase the risk that the pharmacy cost assumptions used to develop our capitation rates are not adequate to cover the actual pharmacy costs, which jeopardizes the overall actuarial soundness of our rates. Bearing the high costs of new specialty drugs or the high cost inflation of generic drugs without an appropriate rate adjustment or other reimbursement mechanism has an adverse impact on our financial condition and results of operations. In addition, evolving regulations and state and federal mandates regarding coverage may impact the ability of our health plans to continue to receive existing price discounts on pharmaceutical products for our members. Other factors affecting our pharmaceutical costs include, but are not limited to, geographic variation in utilization of new and existing pharmaceuticals, and changes in discounts. Although we will continue to work with state Medicaid agencies in an effort to ensure that we receive appropriate and actuarially sound reimbursement for all new drug therapies and pharmaceuticals trends, there can be no assurance that we will be successful in this regard.

We rely on the accuracy of eligibility lists provided by state governments. Inaccuracies in those lists would negatively affect our results of operations.

Premium payments to our health plans are based upon eligibility lists produced by state governments. From time to time, states require us to reimburse them for premiums paid to us based on an eligibility list that a state later discovers contains individuals who are not in fact eligible for a government sponsored program or are eligible for a different premium category or a different program. Alternatively, a state could fail to pay us for members for whom we are entitled to payment. Our results of operations would be adversely affected as a result of such reimbursement to the state if we make or have made related payments to providers and are unable to recoup such payments from the providers. Further, when a state implements new programs to determine eligibility, establishes new processes to assign or enroll eligible members into health plans, or chooses new subcontractors, there is an increased potential for an unanticipated impact on the overall number of members assigned to managed care health plans. Whenever a state effects an eligibility redetermination for any reason, there is generally an associated reduction in Medicaid membership, which could have an adverse effect on our premium revenues and results of operations.

The insolvency of a delegated provider could obligate us to pay its referral claims, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

Many of our primary care physicians and a small portion of our specialists and hospitals are paid on a capitated basis. Under capitation arrangements, we pay a fixed amount per member per month to the provider without regard to the frequency, extent, or nature of the medical services actually furnished. Due to insolvency or other circumstances, such providers may be unable or unwilling to pay claims they have incurred with third parties in connection with referral services provided to our members. The inability or unwillingness of delegated providers to pay referral claims presents us with both immediate financial risk and potential disruption to member care, as well as potential loss of members. Depending on states’ laws, we may be held liable for such unpaid referral claims even though the delegated provider has contractually assumed such risk. Additionally, competitive pressures or practical regulatory considerations may force us to pay such claims even when we have no legal obligation to do so; or we have already paid claims to a delegated provider and such payments cannot be recouped when the delegated provider becomes insolvent. Liabilities incurred or losses suffered as a result of provider insolvency or other circumstances could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

Molina Healthcare, Inc. 2019 Form 10-K | 22

State and federal budget deficits may result in Medicaid, CHIP, or Medicare funding cuts which could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

Nearly all of our premium revenues come from the joint federal and state funding of the Medicaid, Medicare, and CHIP programs. The states in which we operate regularly face significant budgetary pressures. As discussed below, such budgetary pressures are particularly intense in the Commonwealth of Puerto Rico. State budgetary pressures may result in unexpected Medicaid, CHIP, or Medicare rate cuts which could reduce our revenues and profit margins. Moreover, some federal deficit reduction or entitlement reform proposals would fundamentally change the structure and financing of the Medicaid program. A number of these proposals include both tax increases and spending reductions in discretionary programs and mandatory programs, such as Social Security, Medicare, and Medicaid.

We are unable to determine how any future congressional spending cuts will affect Medicare and Medicaid reimbursement. We believe there will continue to be legislative and regulatory proposals at the federal and state levels directed at containing or lowering the cost of health care that, if adopted, could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

The Commonwealth of Puerto Rico may fail to pay the premiums of our Puerto Rico health plan, which could negatively impact our business, financial condition, cash flows, or results of operations.

The government of Puerto Rico continues to struggle with major fiscal and liquidity challenges. The extreme financial difficulties faced by the Commonwealth may make it very difficult for ASES, the Puerto Rico Medicaid agency, to pay our Puerto Rico health plan under the terms of the parties’ Medicaid contract. As of December 31, 2019, our Puerto Rico health plan served approximately 176,000 members, and had recognized premium revenue of approximately $133 million in the fourth quarter of 2019. A default by ASES on its payment obligations under our Medicaid contract, or a determination by ASES to terminate our contract based on insufficient funds available, could result in our having paid, or in our having to pay, provider claims in amounts for which we are not paid reimbursement, and could make it unfeasible for our Puerto Rico health plan to continue to operate. A default by ASES or termination of our Puerto Rico Medicaid contract could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

Receipt of inadequate or significantly delayed premiums could negatively affect our business, financial condition, cash flows, or results of operations.

Our premium revenues consist of fixed monthly payments per member, and supplemental payments for other services such as maternity deliveries. These premiums are fixed by contract, and we are obligated during the contract periods to provide healthcare services as established by the state governments. We use a large portion of our revenues to pay the costs of healthcare services delivered to our members. If premiums do not increase when expenses related to healthcare services rise, our medical margins will be compressed, and our earnings will be negatively affected. A state could increase hospital or other provider rates without making a commensurate increase in the rates paid to us, or could lower our rates without making a commensurate reduction in the rates paid to hospitals or other providers. In addition, if the actuarial assumptions made by a state in implementing a rate or benefit change are incorrect or are at variance with the particular utilization patterns of the members of one or more of our health plans, our medical margins could be reduced. Any of these rate adjustments in one or more of the states in which we operate could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

Furthermore, a state or commonwealth undergoing a budget crisis may significantly delay the premiums paid to one of our health plans. Any significant delay in the monthly payment of premiums to any of our health plans could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

If a state fails to renew its federal waiver application for mandated Medicaid enrollment into managed care or such application is denied, our membership in that state will likely decrease.

States may only mandate Medicaid enrollment into managed care under federal waivers or demonstrations. Waivers and programs under demonstrations are approved for two- to five-year periods and can be renewed on an ongoing basis if the state applies and the waiver request is approved or renewed by CMS. We have no control over this renewal process. If a state in which we operate does not renew its mandated program or the federal government denies the state’s application for renewal, our business would suffer as a result of a likely decrease in membership.

Molina Healthcare, Inc. 2019 Form 10-K | 23

Large-scale medical emergencies in one or more states in which we operate our health plans could significantly increase utilization rates and medical costs.

Large-scale medical emergencies can take many forms and be associated with widespread illness or medical conditions. For example, natural disasters, such as a major earthquake or wildfire in California, or a major hurricane affecting Florida, Puerto Rico, South Carolina or Texas, could have a significant impact on the health of a large number of our covered members. Other conditions that could impact our members include a virulent influenza season or epidemic, newly emergent mosquito-borne illnesses, such as the Zika virus, the West Nile virus, or the Chikungunya virus, or new viruses such as the coronavirus, conditions for which vaccines may not exist, are not effective, or have not been widely administered.

In addition, federal and state law enforcement officials have issued warnings about potential terrorist activity involving biological or other weapons of mass destruction. All of these conditions, and others, could have a significant impact on the health of the population of wide-spread areas. We seek to set our IBNP reserves appropriately to account for anticipatable spikes in utilization, such as for the flu season. However, if one of the states in which we operate were to experience a large-scale natural disaster, a viral epidemic or pandemic, a significant terrorism attack, or some other large-scale event affecting the health of a large number of our members, our covered medical expenses in that state would rise, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

If state regulators do not approve payments of dividends and distributions by our subsidiaries, it may negatively affect our ability to meet our debt service and other obligations.

We are a corporate parent holding company and hold most of our assets in, and conduct most of our operations through, our direct subsidiaries. As a holding company, our results of operations depend on the results of operations of our subsidiaries. Moreover, we are dependent on dividends or other intercompany transfers of funds from our subsidiaries to meet our debt service and other obligations. The ability of our subsidiaries to pay dividends or make other payments or advances to us will depend on their operating results and will be subject to applicable laws and restrictions contained in agreements governing the debt of such subsidiaries. In addition, our health plan subsidiaries are subject to laws and regulations that limit the amount of ordinary dividends and distributions that they can pay to us without prior approval of, or notification to, state regulators. In California, our health plan may dividend, without notice to or approval of the California Department of Managed Health Care, amounts by which its tangible net equity exceeds 130% of the tangible net equity requirement. In general, our other health plans must give thirty days’ advance notice and the opportunity to disapprove “extraordinary” dividends to the respective state departments of insurance for amounts that exceed either (a) ten percent of surplus or net worth at the prior year end or (b) the net income for the prior year, depending on the respective state statute. The discretion of the state regulators, if any, in approving or disapproving a dividend is not clearly defined. Our health plans generally must provide notice to the applicable state regulator prior to paying a dividend or other distribution to us. Our parent company received $1,373 million, $288 million, and $245 million in dividends from its regulated health plan subsidiaries during 2019, 2018 and 2017, respectively. The aggregate additional amounts our health plan subsidiaries could have paid us at December 31, 2019 and 2018, without approval of the regulatory authorities, were approximately $41 million and $126 million, respectively. If the regulators were to deny or significantly restrict our subsidiaries’ requests to pay dividends to us, the funds available to our Company as a whole would be limited, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations. For example, we could be hindered in our ability to make debt service payments under our senior notes or credit agreement.

Our use and disclosure of personally identifiable information and other non-public information, including protected health information, is subject to federal and state privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm.

State and federal laws and regulations including, but not limited to, HIPAA and the Gramm-Leach-Bliley Act, govern the collection, dissemination, use, privacy, confidentiality, security, availability, and integrity of personally identifiable information (“PII”), including protected health information (“PHI”). HIPAA establishes basic national privacy and security standards for protection of PHI by covered entities and business associates, including health plans such as ours. HIPAA requires covered entities like us to develop and maintain policies and procedures for PHI that is used or disclosed, and to adopt administrative, physical, and technical safeguards to protect PHI. HIPAA also implemented the use of standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic health care transactions, including activities associated with the billing and collection of health care claims.

Molina Healthcare, Inc. 2019 Form 10-K | 24

Mandatory penalties for HIPAA violations range from $100 to $50,000 per violation, and up to $1.5 million per violation of the same standard per calendar year. A single breach incident can result in violations of multiple standards, resulting in penalties in excess of $1.5 million. If a person knowingly or intentionally obtains or discloses PHI in violation of HIPAA requirements, criminal penalties may also be imposed. HIPAA authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs, and attorneys’ fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. We have experienced HIPAA breaches in the past, including breaches affecting over 500 individuals.

New health information standards, whether implemented pursuant to HIPAA, congressional action, or otherwise, could have a significant effect on the manner in which we must handle healthcare related data, and the cost of complying with these standards could be significant. If we do not comply with existing or new laws and regulations related to PHI, PII, or non-public information, we could be subject to criminal or civil sanctions. Any security breach involving the misappropriation, loss, or other unauthorized disclosure or use of confidential member information, whether by us or a third party, such as our vendors, could subject us to civil and criminal penalties, divert management’s time and energy, and have a material adverse effect on our business, financial condition, cash flows, or results of operations.

We are subject to extensive fraud and abuse laws that may give rise to lawsuits and claims against us, the outcome of which may have a material adverse effect on our business, financial condition, cash flows, or results of operations.

Because we receive payments from federal and state governmental agencies, we are subject to various laws commonly referred to as “fraud and abuse” laws, including federal and state anti-kickback statutes, prohibited referrals, and the federal False Claims Act, which permit agencies and enforcement authorities to institute a suit against us for violations and, in some cases, to seek treble damages, criminal and civil fines, penalties, and assessments. Violations of these laws can also result in exclusion, debarment, temporary or permanent suspension from participation in government health care programs, or the institution of corporate integrity agreements. Liability under such federal and state statutes and regulations may arise if we know, or it is determined that we should have known, that information we provide to form the basis for a claim for government payment is false or fraudulent, and some courts have permitted False Claims Act suits to proceed if the claimant was out of compliance with program requirements. Fraud, waste and abuse prohibitions encompass a wide range of operating activities, including kickbacks or other inducements for referral of members or for the coverage of products (such as prescription drugs) by a plan, billing for unnecessary medical services by a provider, upcoding, payments made to excluded providers, improper marketing, and the violation of patient privacy rights. In particular, there has recently been increased scrutiny by the Department of Justice on health plans’ risk adjustment practices, particularly in the Medicare program. Companies involved in public healthcare programs such as Medicaid and Medicare are required to maintain compliance programs to detect and deter fraud, waste and abuse, and are often the subject of fraud, waste and abuse investigations and audits. The regulations and contractual requirements applicable to participants in these public-sector programs are complex and subject to change. The federal government has taken the position that claims presented in violation of the federal anti-kickback statute may be considered a violation of the federal False Claims Act. In addition, under the federal civil monetary penalty statute, the U.S. Department of Health and Human Services’ (“HHS”) Office of Inspector General has the authority to impose civil penalties against any person who, among other things, knowingly presents, or causes to be presented, certain false or otherwise improper claims. Qui tam actions under federal and state law can be brought by any individual on behalf of the government. Qui tam actions have increased significantly in recent years, causing greater numbers of healthcare companies to have to defend a false claim action, pay fines, or be excluded from the Medicare, Medicaid, or other state or federal healthcare programs as a result of an investigation arising out of such action. We have been the subject of qui tam actions in the past and other qui tam actions may be filed against us in the future. If we are subject to liability under a qui tam or other actions, our business, financial condition, cash flows, or results of operations could be adversely affected.

Failure to attain profitability in any newly acquired health plans or new start-up operations could negatively affect our results of operations.

Start-up costs associated with a new business can be substantial. For example, to obtain a certificate of authority to operate as a health maintenance organization in most jurisdictions, we must first establish a provider network, have infrastructure and required systems in place, and demonstrate our ability to obtain a state contract and process claims. Often, we are also required to contribute significant capital to fund mandated net worth requirements, performance bonds or escrows, or contingency guaranties. If we are unsuccessful in obtaining the certificate of

Molina Healthcare, Inc. 2019 Form 10-K | 25

authority, winning the bid to provide services, or attracting members in sufficient numbers to cover our costs, the new business could fail. We also could be required by the state or commonwealth to continue to provide services for some period of time without sufficient revenue to cover our ongoing costs or to recover our start-up costs.

Even if we are successful in acquiring or establishing a profitable health plan in a new jurisdiction, increasing membership, revenues, and medical costs would trigger increased mandated net worth requirements which could substantially exceed the net income generated by the health plan. Rapid growth in an existing jurisdiction will also result in increased net worth requirements. In such circumstances, we may not be able to fund on a timely basis, or at all, the increased net worth requirements with our available cash resources. The expenses associated with starting up a health plan in a new jurisdiction, expanding a health plan in an existing jurisdiction, or acquiring a new health plan, could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

Failure to maintain effective internal controls over financial reporting could have a material adverse effect on our business, operating results, and stock price, and could subject us to sanctions by regulatory authorities.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. We have identified material weaknesses in our internal control over financial reporting in the past, which have subsequently been remediated. If additional material weaknesses in our internal control over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements and we could be required to restate our financial results.

The Sarbanes-Oxley Act of 2002 requires, among other things, that we maintain effective internal control over financial reporting. In particular, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on, and our independent registered public accounting firm to attest to, our internal controls over financial reporting as required by Section 404 of the Sarbanes-Oxley Act of 2002. Our future testing, or the subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses. If we are unable to comply with the requirements of Section 404 in a timely manner, or if we or our independent registered public accounting firm identify deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by the New York Stock Exchange, SEC, or other regulatory authorities which could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

We are dependent on the leadership of our chief executive officer and other executive officers and key employees.

In late 2017, the board hired Joe Zubretsky as our chief executive officer. Mr. Zubretsky, in turn, has hired other senior level executives. Under the leadership and direction of Mr. Zubretsky, our executive team launched a vigorous turnaround plan, including many profit improvement initiatives. Our turnaround plan and operational improvements are highly dependent on the efforts of Mr. Zubretsky and our other key executive officers and employees. The loss of their leadership, expertise, and experience could negatively impact our operations. Our ability to replace them or any other key employee may be difficult and may take an extended period of time because of the limited number of individuals in the healthcare industry who have the breadth and depth of skills and experience necessary to operate and lead a business such as ours. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain, or motivate these personnel. If we are unsuccessful in recruiting, retaining, managing, and motivating such personnel, our business, financial condition, cash flows, or results of operations could be adversely affected.

We face various risks inherent in the government contracting process that could materially and adversely affect our business and profitability, including periodic routine and non-routine reviews, audits, and investigations by government agencies.

We are subject to various risks inherent in the government contracting process. These risks include routine and non-routine governmental reviews, audits, and investigations, and compliance with government reporting requirements. Violation of the laws, regulations, or contract provisions governing our operations, or changes in interpretations of those laws and regulations, could result in the imposition of civil or criminal penalties, the cancellation of our government contracts, the suspension or revocation of our licenses, the exclusion from participation in government sponsored health programs, or the revision and recoupment of past payments made based on audit findings. If we are unable to correct any noted deficiencies, or become subject to material fines or other sanctions, we could suffer a substantial reduction in profitability, and could also lose one or more of our

Molina Healthcare, Inc. 2019 Form 10-K | 26

government contracts. In addition, government receivables are subject to government audit and negotiation, and government contracts are vulnerable to disagreements with the government. The final amounts we ultimately receive under government contracts may be different from the amounts we initially recognize in our financial statements.

If we sustain a cyber-attack or suffer privacy or data security breaches that disrupt our information systems or operations, or result in the dissemination of sensitive personal or confidential information, we could suffer increased costs, exposure to significant liability, reputational harm, loss of business, and other serious negative consequences.

As part of our normal operations, we routinely collect, process, store, and transmit large amounts of data, including sensitive personal information as well as proprietary or confidential information relating to our business or third parties. To ensure information security, we have implemented controls designed to protect the confidentiality, integrity and availability of this data and the systems that store and transmit such data. However, our information technology systems and safety control systems are subject to a growing number of threats from computer programmers, hackers, and other adversaries that may be able to penetrate our network security and misappropriate our confidential information or that of third parties, create system disruptions, or cause damage, security issues, or shutdowns. They also may be able to develop and deploy viruses, worms, and other malicious software programs that attack our systems or otherwise exploit security vulnerabilities. Because the techniques used to circumvent, gain access to, or sabotage security systems can be highly sophisticated and change frequently, they often are not recognized until launched against a target, and may originate from less regulated and remote areas around the world. We may be unable to anticipate these techniques or implement adequate preventive measures, resulting in potential data loss and damage to our systems. Our systems are also subject to compromise from internal threats such as improper action by employees, including malicious insiders, or by vendors, counterparties, and other third parties with otherwise legitimate access to our systems. Our policies, employee training (including phishing prevention training), procedures and technical safeguards may not prevent all improper access to our network or proprietary or confidential information by employees, vendors, counterparties, or other third parties. Our facilities may also be vulnerable to security incidents or security attacks, acts of vandalism or theft, misplaced or lost data, human errors, or other similar events that could negatively affect our systems and our and our members’ data.

Moreover, we face the ongoing challenge of managing access controls in a complex environment. The process of enhancing our protective measures can itself create a risk of systems disruptions and security issues. Given the breadth of our operations and the increasing sophistication of cyberattacks, a particular incident could occur and persist for an extended period of time before being detected. The extent of a particular cyberattack and the steps that we may need to take to investigate the attack may take a significant amount of time before such an investigation could be completed and full and reliable information about the incident is known. During such time, the extent of any harm or how best to remediate it might not be known, which could further increase the risks, costs, and consequences of a data security incident. In addition, our systems must be routinely updated, patched, and upgraded to protect against known vulnerabilities. The volume of new software vulnerabilities has increased substantially, as has the importance of patches and other remedial measures. In addition to remediating newly identified vulnerabilities, previously identified vulnerabilities must also be updated. We are at risk that cyber attackers exploit these known vulnerabilities before they have been addressed. The complexity of our systems and platforms, the increased frequency at which vendors are issuing security patches to their products, our need to test patches, and in some instances, coordinate with third-parties before they can be deployed, all could further increase our risks.

Our business depends on our information and medical management systems, and our inability to effectively integrate, manage, update, and keep secure our information and medical management systems could disrupt our operations.

Our business is dependent on effective and secure information systems that assist us in, among other things, processing provider claims, monitoring utilization and other cost factors, supporting our medical management techniques, providing data to our regulators, and implementing our data security measures. Our members and providers also depend upon our information systems for enrollment, primary care and specialist physician roster access, membership verifications, claims status, and other information. If we experience a reduction in the performance, reliability, or availability of our information and medical management systems, our operations, ability to pay claims, ability to produce timely and accurate reports, and ability to maintain proper security measures could be adversely affected.

Molina Healthcare, Inc. 2019 Form 10-K | 27

entered into a master services agreement with a third party vendor who manages certain of our information technology infrastructure services including, among other things, our information technology operations, end-user services, and data centers. If any licensor or vendor of any technology which is integral to our operations were to become insolvent or otherwise fail to support the technology sufficiently, our operations could be negatively affected.

Our information systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards, changing customer preferences and increased security risks. Any inability or failure by us or our vendors to properly maintain our information management systems could result in operational disruptions, loss of existing members, providers, and customers, difficulty in attracting new members, providers, and customers, disputes with members, providers, and customers, regulatory or other legal or compliance problems, and significant increases in administrative expenses and/or other adverse consequences.

We are subject to risks associated with outsourcing services and functions to third parties.

We contract with third party vendors and service providers who provide services to us and our subsidiaries or to whom we delegate selected functions. Some of these third-parties have direct access to our systems. Our arrangements with third party vendors and service providers may make our operations vulnerable if those third parties fail to satisfy their obligations to us, including their obligations to maintain and protect the security and confidentiality of our information and data or the information and data relating to our members or customers. We are also at risk of a data security incident involving a vendor or third party, which could result in a breakdown of such third party’s data protection processes or cyber-attackers gaining access to our infrastructure through the third party. To the extent that a vendor or third party suffers a data security incident that compromises its operations, we could incur significant costs and possible service interruption. In addition, we may have disagreements with our third party vendors or service providers regarding relative responsibilities for any such failures or incidents under applicable business associate agreements or other applicable outsourcing agreements. Any contractual remedies and/or indemnification obligations we may have for vendor or service provider failures or incidents may not be adequate to fully compensate us for any losses suffered as a result of any vendor’s failure to satisfy its obligations to us or under applicable law. Our outsourcing arrangements could be adversely impacted by changes in vendors’ or service providers’ operations or financial condition or other matters outside of our control. Violations of, or noncompliance with, laws and/or regulations governing our business or noncompliance with contract terms by third party vendors and service providers could increase our exposure to liability to our members, providers, or other third parties, or could result in sanctions and/or fines from the regulators that oversee our business. In turn, this could increase the costs associated with the operation of our business or have an adverse impact on our business and reputation. Moreover, if these vendor and service provider relationships were terminated for any reason, we may not be able to find alternative partners in a timely manner or on acceptable financial terms, and may incur significant costs and/or experience significant disruption to our operations in connection with any such vendor or service provider transition. As a result, we may not be able to meet the full demands of our members or customers and, in turn, our business, financial condition, and results of operations may be harmed. In addition, we may not fully realize the anticipated economic and other benefits from our outsourcing projects or other relationships we enter into with third party vendors and service providers, as a result of regulatory restrictions on outsourcing, unanticipated delays in transitioning our operations to the third party, vendor or service provider noncompliance with contract terms, unanticipated costs or expenses, or violations of laws and/or regulations, or otherwise. This could result in substantial costs or other operational or financial problems that could have a material adverse effect on our business, financial condition, cash flows, or results of operations.

Any changes to the laws and regulations governing our business, or the interpretation and enforcement of those laws or regulations, could require us to modify our operations and could negatively impact our operating results.

Our business is extensively regulated by the federal government and the states in which we operate. The laws and regulations governing our operations are generally intended to benefit and protect health plan members and providers rather than managed care organizations. The government agencies administering these laws and regulations have broad latitude in interpreting and applying them. These laws and regulations, along with the terms of our government contracts, regulate how we do business, what services we offer, and how we interact with members and the public. For instance, some states mandate minimum medical expense levels as a percentage of premium revenues. These laws and regulations, and their interpretations, are subject to frequent change. The interpretation of certain contract provisions by our governmental regulators may also change. Changes in existing laws or regulations, or their interpretations, or the enactment of new laws or regulations, could reduce our profitability by imposing additional capital requirements, increasing our liability, increasing our administrative and

Molina Healthcare, Inc. 2019 Form 10-K | 28

other costs, increasing mandated benefits, forcing us to restructure our relationships with providers, requiring us to implement additional or different programs and systems, or making it more difficult to predict future results. Changes in the interpretation of our contracts could also reduce our profitability if we have detrimentally relied on a prior interpretation.

Our encounter data may be inaccurate or incomplete, which could have a material adverse effect on our results of operations, financial condition, cash flows and ability to bid for, and continue to participate in, certain programs.

Our contracts require the submission of complete and correct encounter data. The accurate and timely reporting of encounter data is increasingly important to the success of our programs because more states are using encounter data to determine compliance with performance standards and to set premium rates. We have expended and may continue to expend additional effort and incur significant additional costs to collect or correct inaccurate or incomplete encounter data and have been, and continue to be exposed to, operating sanctions and financial fines and penalties for noncompliance. In some instances, our government clients have established retroactive requirements for the encounter data we must submit. There also may be periods of time in which we are unable to meet existing requirements. In either case, it may be prohibitively expensive or impossible for us to collect or reconstruct this historical data.

We have experienced challenges in obtaining complete and accurate encounter data, due to difficulties with providers and third-party vendors submitting claims in a timely fashion in the proper format, and with state agencies in coordinating such submissions. As states increase their reliance on encounter data, these difficulties could adversely affect the premium rates we receive and how membership is assigned to us and subject us to financial penalties, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations, and on our ability to bid for, and continue to participate in, certain programs.

Actions by activist stockholders or others could divert management’s time and energy.

We may be subject to actions or proposals from activist stockholders or others that may not align with our business strategies or the interests of our other stockholders. Responding to such actions could be costly and time-consuming, and divert the attention of our senior management team. In addition, such actions may cause periods of fluctuation in our stock price based on temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business, which could also increase our cost of capital.

Because our corporate headquarters are located in Southern California, our business operations may be significantly disrupted as a result of a major earthquake or wildfire.

Our corporate headquarters are located in Long Beach, California. In addition, some of our health plans’ claims are processed in Long Beach, California. Southern California is exposed to a statistically greater risk of a major earthquake and wildfires than most other parts of the United States. If a major earthquake or wildfire were to strike Southern California, our corporate functions and claims processing could be significantly impaired for a substantial period of time. If there is a major Southern California earthquake or wildfire, there can be no assurances that our disaster recovery plan will be successful or that the business operations of our health plans, including those that are remote from any such event, would not be substantially impacted.

We face claims related to litigation which could result in substantial monetary damages.

We are subject to a variety of legal actions, including provider claims, employment related disputes, healthcare regulatory law-based litigation, breach of contract actions, qui tam or False Claims Act actions, and securities class actions. If we incur liability materially in excess of the amount for which we have insurance coverage, our profitability would suffer. Even if any claims brought against us are unsuccessful or without merit, we may have to defend ourselves against such claims. The defense of any such actions may be time-consuming and costly, and may distract our management’s attention. Such legal actions could have a material adverse effect on our business, financial condition, results of operations, and cash flows.

Molina Healthcare, Inc. 2019 Form 10-K | 29

PROPERTIES

We own and lease certain real properties to support the business operations of our reportable segments. While we believe our current and anticipated facilities are adequate to meet our operational needs in the near term, we continually evaluate the adequacy of our properties for our anticipated future needs.

LEGAL PROCEEDINGS

Refer to the Notes to Consolidated Financial Statements, Note 17, “Commitments and Contingencies—Legal Proceedings,” for a discussion of legal proceedings.

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

STOCK REPURCHASE PROGRAMS

Purchases of common stock made by us, or on our behalf during the quarter ended December 31, 2019, including shares withheld by us to satisfy our employees’ income tax obligations, are set forth below:



	Total Number of Shares Purchased ⁽¹⁾	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs ⁽²⁾	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs ⁽²⁾
October 1 — October 31	—	$	—	—	$	—
November 1 — November 30	—	$	—	—	$	—
December 1 — December 31	—	$	—	399,761	$	446,000,000
	—	$	—	399,761

_______________________

(1)

During the three months ended December 31, 2019, we withheld a nominal number of shares of common stock to settle employee income tax obligations for releases of awards granted under the Molina Healthcare, Inc. 2011 Equity Incentive Plan. In 2019, this plan was amended, restated and merged into the Molina Healthcare, Inc. 2019 Equity Incentive Plan. For further information refer to Notes to Consolidated Financial Statements, Note 14, “Stockholders' Equity.”

(2)

In early December 2019, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This program is funded by existing cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase is determined by management, based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 400,000 shares of our common stock for $54 million in December 2019 (average cost of $135.30 per share).

STOCK PERFORMANCE GRAPH

The following graph and related discussion are being furnished solely to accompany this Annual Report on Form 10-K pursuant to Item 201(e) of Regulation S-K and shall not be deemed to be “soliciting materials” or to be “filed” with the U.S. Securities and Exchange Commission (“SEC”) (other than as provided in Item 201) nor shall this information be incorporated by reference into any future filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language contained therein, except to the extent that we specifically incorporate it by reference into a filing.

The following line graph compares the percentage change in the cumulative total return on our common stock against the cumulative total return of the Standard & Poor’s Corporation Composite 500 Index (the “S&P 500”) and a peer group index for the five-year period from December 31, 2014 to December 31, 2019. The comparison assumes $100 was invested on December 31, 2014, in our common stock and in each of the foregoing indices and assumes reinvestment of dividends. The stock performance shown on the graph below represents historical stock performance and is not necessarily indicative of future stock price performance.

Molina Healthcare, Inc. 2019 Form 10-K | 30

The peer group index consists of Centene Corporation (CNC), Cigna Corporation (CI), DaVita HealthCare Partners, Inc. (DVA), Humana Inc. (HUM), Magellan Health, Inc. (MGLN), Team Health Holdings, Inc. (TMH), Tenet Healthcare Corporation (THC), Triple-S Management Corporation (GTS), Universal American Corporation (UAM), Universal Health Services, Inc. (UHS) and WellCare Health Plans, Inc. (WCG).

STOCK TRADING SYMBOL AND DIVIDENDS

Our common stock is listed on the New York Stock Exchange under the trading symbol “MOH.” As of February 7, 2020, there were 12 registered holders of record of our common stock, including Cede & Co. To date we have not paid cash dividends on our common stock. We currently intend to retain any future earnings to fund our projected business operations. However, we intend to periodically evaluate our cash position to determine whether to pay a cash dividend in the future. Our ability to pay dividends is partially dependent on, among other things, our receipt of cash dividends from our regulated subsidiaries. The ability of our regulated subsidiaries to pay dividends to us is limited by the state departments of insurance in the states in which we operate or may operate, as well as requirements of the government-sponsored health programs in which we participate. Additionally, the indentures governing our outstanding senior notes and credit agreement contain various covenants that limit our ability to pay dividends on our common stock. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements and contractual and regulatory restrictions. For more information regarding restrictions on the ability of our regulated subsidiaries to pay dividends to us, please see the Notes to Consolidated Financial Statements, Note 17, “Commitments and Contingencies—Regulatory Capital Requirements and Dividend Restrictions.”

Molina Healthcare, Inc. 2019 Form 10-K | 31

SELECTED FINANCIAL DATA



	Year Ended December 31,
	2019			2018			2017			2016			2015
	(In millions, except per-share data, percentages and membership)
Consolidated Operating Results:
Premium revenue	$	16,208		$	17,612		$	18,854		$	16,445		$	13,261
Total revenue	16,829			18,890			19,883			17,782			14,178
Operating income (loss)	1,044			1,131			(555		)	306			387
Income (loss) before income taxes	972			999			(612		)	205			322
Net income (loss)	737			707			(512		)	52			143
Net income (loss) per share - Basic ⁽¹⁾	$	11.85		$	11.57		$	(9.07	)	$	0.93		$	2.75
Net income (loss) per share - Diluted ⁽¹⁾	$	11.47		$	10.61		$	(9.07	)	$	0.92		$	2.58
Weighted average shares - Basic	62.2			61.1			56.4			55.4			52.2
Weighted average shares - Diluted	64.2			66.6			56.4			56.2			55.6
Operating Statistics:
Medical care ratio ⁽²⁾	85.8		%	85.9		%	90.6		%	89.8		%	88.9		%
G&A ratio ⁽³⁾	7.7		%	7.1		%	8.0		%	7.8		%	8.1		%
Effective income tax rate	24.2		%	29.2		%	(16.4		)%	74.8		%	55.5		%
Pre-tax margin ⁽³⁾	5.8		%	5.3		%	(3.1		)%	1.2		%	2.3		%
After-tax margin ⁽³⁾	4.4		%	3.7		%	(2.6		)%	0.3		%	1.0		%
Ending Membership by Government Program (as of December 31):
Medicaid	2,956,000			3,361,000			3,537,000			3,605,000			3,235,000
Medicare	101,000			98,000			101,000			96,000			93,000
Marketplace	274,000			362,000			815,000			526,000			205,000
Total	3,331,000			3,821,000			4,453,000			4,227,000			3,533,000
Balance Sheet Data (in millions, as of December 31):
Cash and cash equivalents	$	2,452		$	2,826		$	3,186		$	2,819		$	2,329
Total assets ⁽⁴⁾	6,787			7,154			8,471			7,449			6,576
Medical claims and benefits payable	1,854			1,961			2,192			1,929			1,685
Long-term debt, including current portion ⁽⁵⁾	1,486			1,458			2,169			1,645			1,609
Total liabilities ^(5),(6)	4,827			5,507			7,134			5,800			5,019
Stockholders’ equity	1,960			1,647			1,337			1,649			1,557

_______________________________


(1)	Source data for calculations in thousands.


(2)	Medical care ratio represents medical care costs as a percentage of premium revenue.


(3)	G&A ratio represents general and administrative expenses as a percentage of total revenue. Pre-tax margin represents income (loss) before income taxes as a percentage of total revenue. After-tax margin represents net income (loss) as a percentage of total revenue.


(4)	Includes operating and finance lease right-of-use assets in 2019, with no comparable amounts presented in prior years. Refer to the Notes to Consolidated Financial Statements, Note 2, “Significant Accounting Policies,” for a discussion of the adoption of the new leasing standard and location of related disclosures.


(5)	Includes finance lease liabilities in 2019, and lease financing obligations in the years 2015 through 2018.


(6)	Includes operating lease liabilities in 2019, with no comparable amounts presented in prior years.

Molina Healthcare, Inc. 2019 Form 10-K | 32

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (“MD&A”)

Management’s discussion and analysis of financial condition and results of operations as of and for the years ended December 31, 2019 and 2018, are presented in the sections that follow. Our MD&A as of and for the year ended December 31, 2017, may be found in our 2018 Annual Report on Form 10-K, which prior disclosure is incorporated by reference herein.

OVERVIEW

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). Through our locally operated health plans in 14 states and the Commonwealth of Puerto Rico, we served approximately 3.3 million members as of December 31, 2019. These health plans are generally operated by our respective wholly owned subsidiaries in those states, each of which is licensed as a health maintenance organization (“HMO”).

2019 HIGHLIGHTS

For 2019, we met or exceeded our expectations:


•	Premium revenue was $16.2 billion in 2019, down from $17.6 billion in 2018, and was in line with our expectations given the previously announced losses of Medicaid membership in New Mexico and Florida.


•	The medical care ratio (“MCR”) was 85.8% in 2019, compared to 85.9% in 2018, as our cost containment efforts continued to control medical care costs while ensuring the highest quality of care for our members.


•	We improved our Medicaid and Medicare margins, and earned exceptionally high Marketplace margins.


•	The G&A expense ratio was 7.7% in 2019 compared to 7.1% in 2018, as we leveraged our fixed cost base while beginning to invest in growth.

All in, this performance resulted in net income of $737 million and earnings per diluted share of $11.47 in 2019, compared to net income of $707 million and earnings per diluted share of $10.61 in 2018.

In a year when premium revenue decreased by 8% due to legacy contract losses, we were able to deliver a 4.4% after-tax margin and earnings per diluted share growth of 8% in 2019, a testament to our early-stage focus on margins.

During the year, we improved an already strong balance sheet and capital structure, while the business continued to generate significant excess cash flow.


•	In the fourth quarter of 2019, we harvested an additional $305 million of dividends from our operating subsidiaries, bringing the total for 2019 to $1,373 million. As of December 31, 2019, unrestricted cash and investments at the parent company was $997 million.


•	In early December 2019, our board of directors authorized a share repurchase program of up to $500 million. Through February 7, 2019, under a Rule 10b5-1 trading plan, we have purchased approximately 1.9 million shares for $257 million, in the aggregate, under this program.

We made progress in the second half of 2019 on our pivot to growth strategy. In the past few months, we announced two acquisitions, YourCare in New York, and NextLevel Health in Illinois. These acquisitions of financially under-performing health plans have stable membership and revenue, but provide opportunity for margin improvement, operating leverage, and membership growth.


•	In the YourCare acquisition, we will serve approximately 46,000 Medicaid members in seven counties in the western New York, with premium revenue for the full year 2019 of approximately $285 million. The purchase price is approximately $40 million.


•	In the NextLevel Health acquisition, we will serve approximately 50,000 Medicaid and Managed Long-Term Services and Supports members in Cook County, Illinois, with premium revenue for the full year 2019 of approximately $270 million. The purchase price is approximately $50 million.

We expect to fund these acquisitions with available cash, and both are expected to close in the first half of 2020, enhancing our premium revenue growth rate for 2020.

Molina Healthcare, Inc. 2019 Form 10-K | 33

FINANCIAL SUMMARY



	Year Ended December 31,
	2019			2018
	(Dollars in millions, except per-share amounts)
Premium revenue	$	16,208		$	17,612
Premium tax revenue	489			417
Health insurer fees reimbursed	—			329
Investment income and other revenue	132			125

Medical care costs	$	13,905		$	15,137
General and administrative expenses	1,296			1,333
Premium tax expenses	489			417
Health insurer fees	—			348
Restructuring costs	6			46
Loss on sales of subsidiaries, net of gain	—			(15		)
Operating income	1,044			1,131

Interest expense	$	87		$	115
Other (income) expenses, net	(15		)	17
Income before income taxes	972			999
Income tax expense	235			292
Net income	737			707

Net income per diluted share	$	11.47		$	10.61

Operating Statistics:
Ending total membership	3,331,000			3,821,000
MCR ⁽¹⁾	85.8		%	85.9		%
G&A ratio ⁽²⁾	7.7		%	7.1		%
Premium tax ratio ⁽¹⁾	2.9		%	2.3		%
Effective income tax rate	24.2		%	29.2		%
After-tax margin ⁽²⁾	4.4		%	3.7		%

__________________


(1)	MCR represents medical care costs as a percentage of premium revenue; premium tax ratio represents premium tax expenses as a percentage of premium revenue plus premium tax revenue.


(2)	G&A ratio represents general and administrative expenses as a percentage of total revenue. After-tax margin represents net income as a percentage of total revenue.

Molina Healthcare, Inc. 2019 Form 10-K | 34

CONSOLIDATED RESULTS

NET INCOME AND OPERATING INCOME

Net income amounted to $737 million, or $11.47 per diluted share in 2019, compared with net income of $707 million, or $10.61 per diluted share in 2018. The year over year comparison for net income is impacted by significantly higher costs in 2018 relating to restructuring activities, interest expense, debt repayment and the loss on sales of subsidiaries, as well as the non-deductible HIF incurred in 2018 and the moratorium of the HIF in 2019. Operating income was lower in 2019 compared with 2018, mainly due to the impact of a year-over-year decline in premium revenue.

PREMIUM REVENUE

Premium revenue decreased $1,404 million, or 8%, in 2019, when compared with 2018. Member months declined 18%, partially offset by a per-member per-month (“PMPM”) revenue increase of 10%. The premium revenue decline was primarily in the Medicaid and Marketplace programs.

The decline in Medicaid premium revenue was driven primarily by membership losses resulting from the loss of our New Mexico Medicaid contract, along with the resizing of the Florida Medicaid contract, as reported throughout 2018. This was partially offset by Medicaid premium rate increases, and the impact of the $81 million reduction in premium revenue relating to retroactive California Medicaid Expansion risk corridor adjustments that were recognized in 2018.

The decline in Marketplace premium revenue was primarily due to lower membership, and a relatively smaller benefit from prior year Marketplace risk adjustment in 2019 compared with 2018, partially offset by premium rate increases.

MEDICAL CARE RATIO

The consolidated MCR decreased slightly to 85.8% in 2019, from 85.9% in 2018. The improvement was due to a decrease in the Medicaid MCR, partially offset by increases in the Medicare and Marketplace MCRs.

The consolidated MCR in the year ended December 31, 2018, would have been 86.3%, excluding the retroactive California Medicaid Expansion risk corridor adjustment noted above, and the combined $137 million impact of the favorable Marketplace risk adjustment and cost sharing reimbursement (“CSR”) settlements related to 2017 dates of service.

PREMIUM TAX REVENUE AND EXPENSES

The premium tax ratio (premium tax expense as a percentage of premium revenue plus premium tax revenue) increased to 2.9% in 2019 from 2.3% in 2018. The increase is mainly attributed to the state of Michigan’s implementation of an insurance provider assessment in 2019, and the state of Illinois’ implementation of a managed care organization provider assessment in the third quarter of 2019.

INVESTMENT INCOME AND OTHER REVENUE

Investment income and other revenue increased to $132 million in 2019, compared with $125 million in 2018, mainly due to gains realized on the sale of certain investments and improved annualized portfolio yields in 2019.

GENERAL AND ADMINISTRATIVE (“G&A”) EXPENSES

The G&A expense ratio increased to 7.7% in 2019 compared with 7.1% in 2018, due mainly to the year-over-year decline in total revenues.

HEALTH INSURER FEES (“HIF”)

There are no health insurer fees (“HIF”) expensed or reimbursed in 2019 due to the moratorium under Public Law No. 115-120. In 2018, the HIF amounted to $348 million, and HIF reimbursements amounted to $329 million.

RESTRUCTURING COSTS

In 2019, we incurred restructuring costs of $6 million, mainly due to increases in estimated costs related to lease terminations recorded in connection with the implementation of our restructuring and profit improvement plan in 2017 (the “2017 Restructuring Plan”).

Molina Healthcare, Inc. 2019 Form 10-K | 35

In 2018, we incurred restructuring costs of $46 million, including $37 million of additional costs related to the 2017 Restructuring Plan, and $9 million related to the IT restructuring plan that commenced in 2018.

LOSS ON SALES OF SUBSIDIARIES, NET OF GAIN

In 2018, we recognized a $15 million loss in connection with the sales of our Medicaid management information systems (“MMIS”) subsidiary, which produced a pretax gain of $37 million, and our behavioral health subsidiary, which produced a pretax loss of $52 million.

INTEREST EXPENSE

Interest expense declined to $87 million in 2019, compared with $115 million in 2018. As further described below in “Liquidity,” we reduced the principal amount outstanding of our convertible senior notes by $240 million in 2019, and reduced total debt by $759 million in 2018. The decrease in interest expense in 2019 was partially offset by interest expense attributable to $220 million borrowed under our Term Loan Facility in 2019.

Interest expense includes non-cash interest expense relating to the amortization of the discount on our long-term debt obligations, which amounted to $5 million and $22 million in 2019 and 2018, respectively. The decline in 2019 is due to repayment of our convertible senior notes throughout 2018 and 2019. See further discussion in Notes to Consolidated Financial Statements, Note 11, “Debt.”

OTHER (INCOME) EXPENSES, NET

In 2019, we recognized a gain on debt repayment of $15 million, and in 2018, we recognized losses on debt repayment of $22 million, in connection with convertible senior notes repayment transactions. In 2018, the losses included a $12 million loss on repayment of the 1.125% convertible senior notes due 2020, and a $10 million loss on repayment of the 1.625% convertible senior notes due 2044 that were settled in 2018. The impact of the 1.125% convertible senior notes in both years was due to mark-to-market valuations on the partial terminations of the Call Spread Overlay executed in connection with the related debt repayments. These transactions are described further in Notes to Consolidated Financial Statements, Note 11, “Debt.”

INCOME TAXES

Income tax expense amounted to $235 million in 2019, or 24.2% of pretax income, compared with an income tax expense of $292 million in 2018, or 29.2% of the pretax income. The effective tax rate was higher in 2018 due to higher non-deductible expenses in 2018, primarily related to the non-deductible HIF.

REPORTABLE SEGMENTS

HOW WE ASSESS PERFORMANCE

We derive our revenues primarily from health insurance premiums. Our primary customers are state Medicaid agencies and the federal government.

The key metrics used to assess the performance of our Health Plans segment are premium revenue, margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying margin, or the amount earned by the Health Plans segment after medical costs are deducted from premium revenue, is the most important measure of earnings reviewed by management.

Margin for our Health Plans segment is referred to as “Medical Margin.” Medical Margin amounted to $2.3 billion and $2.5 billion in 2019 and 2018, respectively. Management’s discussion and analysis of the changes in the individual components of Medical Margin is presented below under “Financial Performance.”

See Notes to Consolidated Financial Statements, Note 18, “Segments,” for more information.

HEALTH PLANS

The Health Plans segment consists of health plans operating in 14 states and the Commonwealth of Puerto Rico.

Molina Healthcare, Inc. 2019 Form 10-K | 36

As of December 31, 2019, these health plans served approximately 3.3 million members eligible for Medicaid, Medicare, and other government-sponsored health care programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies.

TRENDS AND UNCERTAINTIES

For a discussion of Health Plans segment’s trends, uncertainties and other developments, refer to “Item 1. Business—Our Business,” and “—Legislative and Political Environment.”

FINANCIAL PERFORMANCE

The tables below summarize premium revenue, Medical Margin, and MCR by state health plan and by government program for the periods indicated (in millions, except percentages):



	Year Ended December 31,
	2019						2018
	Premium Revenue		Medical Margin		MCR		Premium Revenue		Medical Margin		MCR
	Premium Revenue		Medical Margin		MCR		Premium Revenue		Medical Margin		MCR
California	$	2,266	$	429	81.0	%	$	2,150	$	301	86.0	%
Florida	734		144		80.4		1,790		277		84.5
Illinois	1,002		130		87.0		793		123		84.4
Michigan	1,624		293		82.0		1,601		267		83.3
New Mexico⁽¹⁾	—		—		—		1,356		142		89.6
Ohio	2,553		267		89.6		2,388		309		87.1
Puerto Rico	474		54		88.8		696		60		91.4
South Carolina	583		72		87.6		495		66		86.8
Texas	2,991		377		87.4		3,244		559		82.8
Washington	2,695		305		88.7		2,361		222		90.6
Other ⁽¹⁾⁽²⁾	1,286		232		82.0		738		149		79.6
Total	$	16,208	$	2,303	85.8	%	$	17,612	$	2,475	85.9	%

______________________


(1)	In 2019, “Other” includes the New Mexico health plan. The New Mexico health plan’s Medicaid contract terminated on December 31, 2018, and therefore its 2019 results are not individually significant to our consolidated operating results.


(2)	“Other” includes the Idaho, Mississippi, New York, Utah and Wisconsin health plans, whose results are not individually significant to our consolidated operating results.

Health Plan Performance

In summary, we believe our health plan portfolio continued to perform well in 2019, despite headwinds from lower membership from contract losses in Florida and New Mexico, and cost pressures in certain Medicaid markets. Comments relating to California, Ohio, Texas and Washington, our largest health plans from a premium revenue standpoint, follow:

Our California health plan continues to perform well in its diversified book of business in one of the more complex network environments in the country, and the MCR is performing in the low 80s as a result of a stable premium rate environment and effective medical cost management. Medical Margin in 2018 was unfavorably impacted by the $81 million reduction in premium revenue relating to retroactive California Medicaid Expansion risk corridor adjustments.

In Ohio, we have meaningful market share at approximately 12%, and are generating solid Medical Margins. However, the Medical Margin decreased and the MCR increased in 2019 due to higher medical care costs from the carve in of the behavioral health benefit and a higher acuity mix of members due to redetermination efforts by the state. We expect that these higher medical care costs will eventually be factored into future premium rate considerations by the state.

Our Texas health plan experienced a decline in both premium revenues and Medical Margin in 2019, due to the overall decline in Marketplace membership, and a higher Marketplace MCR due to higher medical care costs.

In Washington, premium revenues increased in 2019 due to significant membership growth following our successful re-procurement, and the introduction of the new integrated behavioral health benefit. We have a well-diversified portfolio of products and our Medical Margin performance improved year-over-year due to the premium growth and

Molina Healthcare, Inc. 2019 Form 10-K | 37

improved MCR. The MCR improved, despite some pressure in medical costs, due to the increased focus on medical care management.



	Year Ended December 31,
	2019						2018
	Premium Revenue		Medical Margin		MCR		Premium Revenue		Medical Margin		MCR
	Premium Revenue		Medical Margin		MCR		Premium Revenue		Medical Margin		MCR
Medicaid	$	12,466	$	1,497	88.0	%	$	13,623	$	1,365	90.0	%
Medicare	2,243		330		85.3		2,074		322		84.5
Marketplace	1,499		476		68.2		1,915		788		58.9
Total	$	16,208	$	2,303	85.8	%	$	17,612	$	2,475	85.9	%

Medicaid Program

Medicaid premium revenue decreased $1,157 million in 2019, mainly due to membership losses resulting from the termination of our Medicaid contracts in New Mexico and in all but two regions in Florida in late 2018 and early 2019, respectively, partially offset by net rate increases in certain other markets.

The Medical Margin of our Medicaid program increased $132 million, or 10%, in 2019 when compared with 2018, despite the decrease in premium revenues. The increase was due to improvement in the overall Medicaid MCR, which more than offset the impact of lower premium revenue.

The Medicaid MCR decreased to 88.0% in 2019, from 90.0% in 2018, or 200 basis points. The decrease in the Medicaid MCR in 2019 was due to improvements across all programs. The MCR for TANF and CHIP improved due to PMPM premium revenue increases. The improved MCR for the ABD program was principally driven by increases in premium revenue PMPM, lower pharmacy costs from re-contracted pharmacy benefits management, and our continued focus on medical cost management.

The decrease in the Medicaid Expansion MCR in 2019, when compared with 2018, was mainly due to the impact of the $81 million reduction in premium revenue recognized in 2018, relating to retroactive California Medicaid Expansion risk corridor adjustments.

Medicare Program

Medicare premium revenue increased by $169 million in 2019, primarily due to an 8% increase in premium revenue PMPM. PMPMs improved due to increased revenue resulting from risk scores that are more commensurate with the acuity of our population. Member months were essentially flat in 2019 compared to 2018.

The Medical Margin for Medicare increased $8 million, or 2%, in 2019 when compared with 2018, primarily due to the increase in premium revenue discussed above.

The Medicare MCR increase was primarily due to the increase in medical care costs PMPM, which was partially offset by the increase in the premium revenue PMPM discussed above. The increase in medical care costs PMPM is mainly attributed to fluctuations of medical care costs in certain markets.

Marketplace Program

Marketplace premium revenue decreased $416 million in 2019, driven by lower membership, partially offset by premium rate increases and increased premiums tied to risk scores. Marketplace membership declined from 362,000 at December 31, 2018, to 274,000 at December 31, 2019. Additionally, the decrease in premiums in 2019 reflects a relatively smaller benefit from prior year Marketplace risk adjustment settlements in 2019, when compared with 2018.

The Marketplace Medical Margin decreased $312 million in 2019, when compared with 2018, primarily due to a decrease in premium revenues, and the increase in the Marketplace MCR. Additionally, the decrease in Medical Margin in 2019 was partially driven by the impact of the $81 million CSR reimbursement recognized in 2018. The CSR benefit related to 2017 dates of service and was recognized following the federal government’s confirmation that the reconciliation would be performed on an annual basis. In the fourth quarter of 2017, we had assumed a nine-month reconciliation of this item pending confirmation of the time period to which the 2017 reconciliation would be applied.

Molina Healthcare, Inc. 2019 Form 10-K | 38

The Marketplace MCR increased 930 basis points in 2019, which is mainly attributable to the impact of the $81 million CSR reimbursement recognized in 2018, and the relatively smaller benefit from prior year Marketplace risk adjustment settlements in 2019, when compared with 2018, as discussed above.

OTHER

The Other segment includes the historical results of the MMIS and behavioral health subsidiaries we sold in late 2018, as well as certain corporate amounts not allocated to the Health Plans segment. Beginning in 2019, we no longer report service revenue or cost of service revenue as a result of the sales of the MMIS and behavioral health subsidiaries noted above. In 2019 and 2018, the Other segment margin was insignificant to our consolidated results of operations.

LIQUIDITY AND FINANCIAL CONDITION

LIQUIDITY

We manage our cash, investments, and capital structure to meet the short- and long-term obligations of our business while maintaining liquidity and financial flexibility. We forecast, analyze, and monitor our cash flows to enable prudent investment management and financing within the confines of our financial strategy.

We maintain liquidity at two levels: 1) the regulated health plan subsidiaries; and 2) the parent company. Our regulated health plan subsidiaries generate significant cash flows from premium revenue. Such cash flows are our primary source of liquidity. Thus, any future decline in our profitability may have a negative impact on our liquidity. We generally receive premium revenue a short time before we pay for the related health care services. The majority of the assets held by our regulated health plan subsidiaries is in the form of cash, cash equivalents, and investments.

When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plan subsidiaries is generally paid in the form of dividends to our parent company to be used for general corporate purposes. The regulated health plan subsidiaries paid dividends to the parent company amounting to $1,373 million in 2019, and $288 million in 2018. The parent company contributed capital of $43 million and $145 million in 2019 and 2018, respectively, to our regulated health plan subsidiaries to satisfy statutory net worth requirements.

Cash, cash equivalents and investments at the parent company amounted to $997 million and $170 million as of December 31, 2019, and 2018, respectively. The increase in 2019 was mainly due to the dividends received from regulated health plan subsidiaries, as described above, and proceeds from borrowings under the Term Loan Facility. These cash inflows were partially offset by principal repayments of our outstanding 1.125% Convertible Notes and common stock purchases, as described further below in “Cash Flow Activities.”

Investments

We generally invest cash of our regulated subsidiaries that exceeds our expected short-term obligations in longer term, investment-grade, marketable debt securities to improve our overall investment return. These investments are purchased pursuant to board approved investment policies which conform to applicable state laws and regulations.

Our investment policies are designed to provide liquidity, preserve capital, and maximize total return on invested assets, all in a manner consistent with state requirements that prescribe the types of instruments in which our subsidiaries may invest. These investment policies require that our investments have final maturities of less than 10 years, or less than 10 years average life for structured securities. Professional portfolio managers operating under documented guidelines manage our investments and a portion of our cash equivalents. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels.

Our restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities; we have the ability to hold such restricted investments until maturity. All of our unrestricted investments are classified as current assets.

Molina Healthcare, Inc. 2019 Form 10-K | 39

Cash Flow Activities

Our cash flows are summarized as follows:



	Year Ended December 31,
	2019			2018			Change
	(In millions)
Net cash provided by (used in) operating activities	$	427		$	(314	)	$	741
Net cash (used in) provided by investing activities	(293		)	1,143			(1,436		)
Net cash used in financing activities	(552		)	(1,193		)	641
Net decrease in cash, cash equivalents, and restricted cash and cash equivalents	$	(418	)	$	(364	)	$	(54	)

Operating Activities

We typically receive capitation payments monthly, in advance of payments for medical claims; however, government agencies may adjust their payment schedules, positively or negatively impacting our reported cash flows from operating activities in any given period. For example, government agencies may delay our premium payments, or they may prepay the following month’s premium payment.

Net cash provided by operations was $427 million in 2019, compared with $314 million of net cash used in 2018. The $741 million increase in cash flow was mainly due to the impact of timing of premium receipts and settlements with government agencies, the latter being primarily related to the final 2017 CSR settlement paid in 2019.

Investing Activities

Net cash used in investing activities was $293 million in 2019, compared with $1,143 million of net cash provided in 2018, a decrease in cash flow of $1,436 million. The year over year decline was primarily due to increased purchases of investments, net of lower proceeds from sales and maturities of investments, in the year ended December 31, 2019.

Financing Activities

Net cash used in financing activities was $552 million in 2019, compared with $1,193 million in 2018. In 2019, net cash paid for the aggregate 1.125% Convertible Notes-related transactions amounted to $730 million, and we paid $47 million for common stock purchases, partially offset by proceeds of $220 million borrowed under the Term Loan Facility. In 2018, net cash used in financing activities included net cash paid for the aggregate 1.125% Convertible Notes-related transactions of $837 million, a $300 million repayment of the Credit Facility, and $64 million repayment of the 1.625% Convertible Notes.

FINANCIAL CONDITION

We believe that our cash resources, borrowing capacity available under our Credit Agreement as discussed further below in “Future Sources and Uses of Liquidity—Future Sources,” and internally generated funds will be sufficient to support our operations, regulatory requirements, debt repayment obligations and capital expenditures for at least the next 12 months.

On a consolidated basis, as of December 31, 2019, our working capital was $2,698 million compared with $2,216 million as of December 31, 2018. At December 31, 2019, our cash and investments amounted to $4,477 million, compared with $4,629 million of cash and investments at December 31, 2018.

Because of the statutory restrictions that inhibit the ability of our health plans to transfer net assets to us, the amount of retained earnings readily available to pay dividends to our stockholders is generally limited to cash, cash equivalents and investments held by our unregulated parent. For more information, see the “Liquidity” discussion presented earlier in this section of the MD&A.

Regulatory Capital and Dividend Restrictions

Each of our regulated HMO subsidiaries must maintain a minimum amount of statutory capital determined by statute or regulations. Such statutes, regulations and capital requirements also restrict the timing, payment and amount of dividends and other distributions, loans or advances that may be paid to us as the sole stockholder. To the extent our HMO subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based upon current statutes and regulations, the minimum capital and surplus (net assets) requirement for these subsidiaries was estimated to be approximately $1,110 million at December 31, 2019,

Molina Healthcare, Inc. 2019 Form 10-K | 40

compared with $1,040 million at December 31, 2018. Our HMO subsidiaries were in compliance with these minimum capital requirements as of both dates.

Under applicable regulatory requirements, the amount of dividends that may be paid by our HMO subsidiaries without prior approval by regulatory authorities as of December 31, 2019, is approximately $41 million in the aggregate. Our HMO subsidiaries may pay dividends over this amount, but only after approval is granted by the regulatory authorities.

Debt Ratings

Our 5.375% Notes and 4.875% Notes are rated “BB-” by Standard & Poor’s, and “B2” by Moody’s Investor Service, Inc. A downgrade in our ratings could adversely affect our borrowing capacity and increase our borrowing costs.

Financial Covenants

Our Credit Agreement contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. Such ratios, presented below, are computed as defined by the terms of the Credit Agreement.



Credit Agreement Financial Covenants	Required Per Agreement	As of December 31, 2019

Net leverage ratio	<4.0x	1.0x
Interest coverage ratio	>3.5x	14.5x

In addition, the indentures governing the 4.875% Notes, the 5.375% Notes, and the 1.125% Convertible Notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. As of December 31, 2019, we were in compliance with all covenants under the Credit Agreement and the indentures governing our outstanding notes.

FUTURE SOURCES AND USES OF LIQUIDITY

Future Sources

Our Health Plans segment regulated subsidiaries generate significant cash flows from premium revenue, which we generally receive a short time before we pay for the related health care services. Such cash flows are our primary source of liquidity. Thus, any future decline in our profitability may have a negative impact on our liquidity.

Dividends from Subsidiaries. When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plans is generally paid in the form of dividends to our unregulated parent company to be used for general corporate purposes. For more information on our regulatory capital requirements and dividend restrictions, refer to Notes to Consolidated Financial Statements, Note 17, “Commitments and Contingencies—Regulatory Capital Requirements and Dividend Restrictions,” and Note 20, “Condensed Financial Information of Registrant—Note C - Dividends and Capital Contributions.”

Credit Agreement Borrowing Capacity. As of December 31, 2019, we had available borrowing capacity of $380 million under the Term Loan Facility, following our draw down of $220 million in the first half of 2019. Under the Term Loan Facility, we may request up to ten advances, each in a minimum principal amount of $50 million, until July 31, 2020. In addition, we have available borrowing capacity of $499 million under our Credit Facility. See further discussion in the Notes to Consolidated Financial Statements, Note 11, “Debt.”

Savings from the IT Restructuring Plan. Management’s margin recovery plan identified and implemented various profit improvement initiatives. This included the plan to restructure our information technology department (the “IT Restructuring Plan”) in 2018, which is reported in the Other segment. In connection with this plan, in early 2019, we entered into services agreements with an outsourcing vendor who manages certain of our information technology services. The IT Restructuring Plan is substantially complete. We reduced annualized run-rate expenses by approximately $14 million in 2019, and expect to reduce such expenses by approximately $25 million to $30 million by the end of the fifth full year of the contract. Such savings, when achieved, reduce Other segment general and administrative expenses in our consolidated statements of operations. Further details of the restructuring plans, including costs associated with such plans, are described in the Notes to Consolidated Financial Statements, Note 15, “Restructuring Costs.”

Molina Healthcare, Inc. 2019 Form 10-K | 41

Future Uses

Common Stock Purchases. In early December 2019, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This program is funded by existing cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase is determined by management, based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law.

As described in the Notes to Consolidated Financial Statements, Note 14, “Stockholders' Equity,” pursuant to a Rule 10b5-1 trading plan, we purchased approximately 400,000 shares of our common stock for $54 million in December 2019 (average cost of $135.30 per share), including approximately 55,000 shares purchased for $7 million in late December 2019, and settled in early January 2020. In January 2020 through February 7, 2020, we purchased 1,533,000 shares for $203 million (average cost of 132.69 per share).

Acquisitions. Our strategic focus has shifted to a disciplined and steady approach to growth. Organic growth, which includes leveraging our existing health plan portfolio and winning new territories, is our highest priority. In addition to organic growth, we will consider targeted inorganic growth opportunities that provide a strategic fit, leverage operational synergies, and lead to incremental earnings accretion. This will include “bolt-on” membership opportunities in our current states and health plans in new states. As noted below, we entered into two acquisition agreements in the fourth quarter of 2019, pursuant to which we expect to add Medicaid membership in Illinois and New York in 2020.

On December 31, 2019, we entered into a definitive agreement to purchase NextLevel Health Partners, Inc., a Medicaid managed care organization. Upon the closing of this transaction, expected to occur in the first half of 2020, we will assume the right to serve approximately 50,000 Medicaid and Managed Long-Term Services and Supports members in Cook County, Illinois. The purchase price of approximately $50 million will be funded with available cash, and the closing is subject to customary closing conditions.

In October 2019, we entered into a definitive agreement to acquire certain assets of YourCare Health Plan, Inc. Upon the closing of this transaction, expected to occur in the first half of 2020, we will serve approximately 46,000 Medicaid members in seven counties in western New York. The purchase price of approximately $40 million will be funded with available cash, and the closing is subject to customary closing conditions.

Regulatory Capital Requirements and Dividend Restrictions. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with minimum statutory capital requirements.

1.125% Convertible Notes. On January 15, 2020, we repaid the 1.125% Convertible Notes for $39 million, which amount reflected final settlement of both the principal amount outstanding and the 1.125% Conversion Option. Refer to the Notes to Consolidated Financial Statements, Note 11, “Debt,” for a detailed discussion of our convertible notes, including recent transactions.

CRITICAL ACCOUNTING ESTIMATES

When we prepare our consolidated financial statements, we use estimates and assumptions that may affect reported amounts and disclosures. Actual results could differ from these estimates, and some differences could be material. Our most significant accounting estimates, which include a higher degree of judgment and/or complexity, include the following:


•	Medical claims and benefits payable. See discussion below, and refer to the Notes to Consolidated Financial Statements, Notes 2, “Significant Accounting Policies,” and 10, “Medical Claims and Benefits Payable” for more information.


•	Contractual provisions that may adjust or limit revenue or profit. For a comprehensive discussion of this topic, including amounts recorded in our consolidated financial statements, refer to the Notes to Consolidated Financial Statements, Note 2, “Significant Accounting Policies.”


•	Quality incentives. For a comprehensive discussion of this topic, including amounts recorded in our consolidated financial statements, refer to the Notes to Consolidated Financial Statements, Note 2, “Significant Accounting Policies.”


•	Goodwill and intangible assets, net. At December 31, 2019, goodwill and intangible assets, net, represented approximately 3% of total assets and 9% of total stockholders’ equity, compared with 3% and

Molina Healthcare, Inc. 2019 Form 10-K | 42

12%, respectively, at December 31, 2018. For a comprehensive discussion of this topic, including amounts recorded in our consolidated financial statements, refer to the Notes to Consolidated Financial Statements, Note 2, “Significant Accounting Policies,” and Note 9, “Goodwill and Intangible Assets, Net.”

MEDICAL CARE COSTS, MEDICAL CLAIMS AND BENEFITS PAYABLE

Medical care costs are recognized in the period in which services are provided and include fee-for-service claims, pharmacy benefits, capitation payments to providers, and various other medically-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Such medical care costs include amounts paid by us as well as estimated medical claims and benefits payable for costs that were incurred but not paid as of the reporting date (“IBNP”). Pharmacy benefits represent payments for members' prescription drug costs, net of rebates from drug manufacturers. We estimate pharmacy rebates based on historical and current utilization of prescription drugs and contractual provisions. Capitation payments represent monthly contractual fees paid to providers, who are responsible for providing medical care to members, which could include medical or ancillary costs like dental, vision and other supplemental health benefits. Such capitation costs are fixed in advance of the periods covered and are not subject to significant accounting estimates. Other medical care costs include all medically-related administrative costs, amounts due to providers pursuant to risk-sharing or other incentive arrangements, provider claims, and other healthcare expenses. Examples of medically-related administrative costs include expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses. Additionally, we include an estimate for the cost of settling claims incurred through the reporting date in our medical claims and benefits payable liability.

Medical claims and benefits payable consist mainly of fee-for-service IBNP, unpaid pharmacy claims, capitation costs, other medical costs, including amounts payable to providers pursuant to risk-sharing or other incentive arrangements and amounts payable to providers on behalf of certain state agencies for certain state assessments in which we assume no financial risk. IBNP includes the costs of claims incurred as of the balance sheet date which have been reported to us, and our best estimate of the cost of claims incurred but not yet reported to us. We also include an additional reserve to ensure that our overall IBNP liability is sufficient under moderately adverse conditions. We reflect changes in these estimates in the consolidated results of operations in the period in which they are determined.

The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors (measures the cumulative percentage of claims expense that will ultimately be paid for a given month of service based on historical payment patterns) and the assumed healthcare cost trend (the year-over-year change in per-member per-month medical care costs) to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.

For claims incurred more than three months before the financial statement date, we mainly use estimated completion factors to estimate the ultimate cost of those claims. Completion factors measure the cumulative percentage of claims expense that will ultimately be paid for a given month of service based on historical claims payment patterns. We analyze historical claims payment patterns by comparing claim incurred dates to claim payment dates to estimate completion factors. The estimated completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claims cost for a given month’s incurred claim activity. The difference between the estimated ultimate claims cost and the claims paid through the financial statement date represents our estimate of claims remaining to be paid as of the financial statement date and is included in our IBNP liability.

For claims incurred within three months before the financial statement date, actual claims paid are a less reliable measure of our ultimate cost since a large portion of medical claims are not submitted to us until several months after services have been submitted. Accordingly, we estimate our IBNP liability for claims incurred during these months based on a blend of estimated completion factors and assumed medical care cost trend. The assumed medical care cost trend represents the year-over-year change in per-member per-month medical care costs, which can be affected by many factors including, but not limited to, our ability and practices to manage medical and pharmaceutical costs, changes in level and mix of services utilized, mix of benefits offered, including the impact of co-pays and deductibles, changes in medical practices, changes in member demographics, catastrophes and epidemics, and other relevant factors.

Molina Healthcare, Inc. 2019 Form 10-K | 43

Actuarial standards of practice generally require a level of confidence such that our overall best estimate of the IBNP liability has a greater probability of being adequate versus being insufficient, where the liability is sufficient to account for moderately adverse conditions. Adverse conditions are situations that may cause actual claims to be higher than the otherwise estimated value of such claims at the time of the estimate, such as changes in the magnitude or severity of claims, uncertainties related to our entry into new geographical markets or provision of services to new populations, changes in state-controlled fee schedules, and modifications or upgrades to our claims processing systems and practices. Therefore, in many situations, the claim amounts ultimately settled will be less than the estimate that satisfies the actuarial standards of practice.

When subsequent actual claims payments are less than we estimated, we recognize a benefit for favorable prior period development that is reported as part of “Components of medical care costs related to: “Prior periods” in the table presented in Note 10, “Medical Claims and Benefits Payable.” Our reserving practice is to consistently recognize the actuarial best estimate including a provision for moderately adverse conditions for each current period. This provision is reported as part of “Components of medical care costs related to: Current period” in the table presented in Note 10. Assuming stability in the size of our membership, the use of this consistent methodology, during any given period, usually results in the replenishment of reserves at a level that generally offsets the benefit of favorable prior period development in that period. In the case of material growth or decline of membership, replenishment can exceed or fall short of the favorable development, assuming all other factors remain unchanged.

Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. The following table reflects the hypothetical change in our estimate of claims liability as of December 31, 2019 that would result if we change our completion factors for the fourth through the twelfth months preceding December 31, 2019, by the percentages indicated. A reduction in the completion factor results in an increase in medical claims liabilities. Dollar amounts are in millions.



Increase (Decrease) in Estimated Completion Factors	Increase (Decrease) in Medical Claims and Benefits Payable
(6)%	$	472
(4)%	315
(2)%	157
2%	(157		)
4%	(315		)
6%	(472		)

The following table reflects the hypothetical change in our estimate of claims liability as of December 31, 2019 that would result if we alter our assumed medical care cost trend factors by the percentages indicated. An increase in the PMPM costs results in an increase in medical claims liabilities. Dollar amounts are in millions.



(Decrease) Increase in Trended Per Member Per Month Cost Estimates	(Decrease) Increase in Medical Claims and Benefits Payable
(6)%	$	(159	)
(4)%	(106		)
(2)%	(53		)
2%	53
4%	106
6%	159

There are many related factors working in conjunction with one another that determine the accuracy of our estimates, some of which are qualitative in nature rather than quantitative. Therefore, we are seldom able to quantify the impact that any single factor has on a change in estimate. Given the variability inherent in the reserving

Molina Healthcare, Inc. 2019 Form 10-K | 44

process, we will only be able to identify specific factors if they represent a significant departure from expectations. As a result, we do not expect to be able to fully quantify the impact of individual factors on changes in estimates.

RECENTLY ISSUED ACCOUNTING STANDARDS

Refer to the Notes to Consolidated Financial Statements, Note 2, “Significant Accounting Policies,” for a discussion of recent accounting pronouncements that affect us.

CONTRACTUAL OBLIGATIONS

In the table below, we present our contractual obligations as of December 31, 2019. Some of the amounts included in this table are based on management’s estimates and assumptions about these obligations, including their duration, the possibility of renewal, anticipated actions by third parties, and other factors. Because these estimates and assumptions are necessarily subjective, the contractual obligations we will actually pay in future periods may vary from those reflected in the table.

Additionally, we have a variety of other contractual agreements related to acquiring services used in our operations. However, we believe these other agreements do not contain material non-cancelable commitments. We are not a party to off-balance sheet financing arrangements.



	Total ⁽¹⁾		2020		2021-2022		2023-2024		2025 and after
	(In millions)
Medical claims and benefits payable	$	1,854	1,854		$	—	$	—	$	—
Principal amount of debt ⁽²⁾	1,262		18		738		176		330
Amounts due government agencies	664		664		—		—		—
Finance leases	400		23		45		43		289
Purchase commitments	255		90		99		51		15
Interest on long-term debt	230		63		120		40		7
Operating leases	80		28		34		15		3
Total	$	4,745	$	2,740	$	1,036	$	325	$	644

_______________________________


(1)	As of December 31, 2019, we have recorded approximately $20 million of unrecognized tax benefits. The table does not contain this amount because we cannot reasonably estimate when or if such amount may be settled. For further information, refer to Notes to Consolidated Financial Statements, Note 13, “Income Taxes.”


(2)	Represents the principal amounts due on the 1.125% Convertible Notes due 2020, 5.375% Notes due 2022, Term Loan Facility due 2024, and 4.875% Notes due 2025. The 1.125% Convertible Notes due 2020 were settled in January 2020. For further information, refer to Notes to Consolidated Financial Statements, Note 11, “Debt.”

INFLATION

We use various strategies to mitigate the negative effects of healthcare cost inflation. Specifically, our health plans try to control medical care costs through contracts with independent providers of healthcare services. Through these contracted providers, our health plans emphasize preventive healthcare and appropriate use of specialty and hospital services. There can be no assurance, however, that our strategies to mitigate medical care cost inflation will be successful. Competitive pressures, new healthcare and pharmaceutical product introductions, demands from healthcare providers and customers, applicable regulations, or other factors may affect our ability to control medical care costs.

Molina Healthcare, Inc. 2019 Form 10-K | 45

COMPLIANCE COSTS

Our health plans are regulated by both state and federal government agencies. Regulation of managed care products and healthcare services is an evolving area of law that varies from jurisdiction to jurisdiction. Regulatory agencies generally have discretion to issue regulations and interpret and enforce laws and rules. Changes in applicable laws and rules occur frequently. Compliance with such laws and rules may lead to additional costs related to the implementation of additional systems, procedures and programs that we have not yet identified.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our earnings and financial position are exposed to financial market risk relating to changes in interest rates, and the resulting impact on investment income and interest expense.

Substantially all of our investments and restricted investments are subject to interest rate risk and will decrease in value if market interest rates increase. Assuming a hypothetical and immediate 1% increase in market interest rates at December 31, 2019, the fair value of our fixed income investments would decrease by approximately $49 million. Declines in interest rates over time will reduce our investment income.

For further information on fair value measurements and our investment portfolio, please refer to the Notes to Consolidated Financial Statements, Note 4, “Fair Value Measurements,” and Note 5, “Investments.”

Borrowings under our Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case the applicable margin. As of December 31, 2019, $220 million was outstanding under the Term Loan Facility. See Notes to Consolidated Financial Statements, Note 11, “Debt,” for more information.

Molina Healthcare, Inc. 2019 Form 10-K | 46

MOLINA HEALTHCARE, INC.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA



	Page
Consolidated Statements of Operations	48
Consolidated Statements of Comprehensive Income (Loss)	48
Consolidated Balance Sheets	49
Consolidated Statements of Stockholders’ Equity	50
Consolidated Statements of Cash Flows	51
Notes to Consolidated Financial Statements	53

Molina Healthcare, Inc. 2019 Form 10-K | 47

CONSOLIDATED STATEMENTS OF OPERATIONS



	Year Ended December 31,
	2019			2018			2017
	(In millions, except per-share data)
Revenue:
Premium revenue	$	16,208		$	17,612		$	18,854
Premium tax revenue	489			417			438
Health insurer fees reimbursed	—			329			—
Service revenue	—			407			521
Investment income and other revenue	132			125			70
Total revenue	16,829			18,890			19,883
Operating expenses:
Medical care costs	13,905			15,137			17,073
General and administrative expenses	1,296			1,333			1,594
Premium tax expenses	489			417			438
Health insurer fees	—			348			—
Depreciation and amortization	89			99			137
Restructuring costs	6			46			234
Cost of service revenue	—			364			492
Impairment losses	—			—			470
Total operating expenses	15,785			17,744			20,438
Loss on sales of subsidiaries, net of gain	—			(15		)	—
Operating income (loss)	1,044			1,131			(555		)
Other expenses, net:
Interest expense	87			115			118
Other (income) expenses, net	(15		)	17			(61		)
Total other expenses, net	72			132			57
Income (loss) before income tax expense (benefit)	972			999			(612		)
Income tax expense (benefit)	235			292			(100		)
Net income (loss)	$	737		$	707		$	(512	)

Net income (loss) per share:
Basic	$	11.85		$	11.57		$	(9.07	)
Diluted	$	11.47		$	10.61		$	(9.07	)
Weighted average shares outstanding:
Basic	62			61			56
Diluted	64			67			56

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)



	Year Ended December 31,
	2019		2018			2017
	(In millions)
Net income (loss)	$	737	$	707		$	(512	)
Other comprehensive income (loss):
Unrealized investment income (loss)	16		(3		)	(5		)
Less: effect of income taxes	4		(1		)	(2		)
Other comprehensive income (loss), net of tax	12		(2		)	(3		)
Comprehensive income (loss)	$	749	$	705		$	(515	)

See accompanying notes.

Molina Healthcare, Inc. 2019 Form 10-K | 48

CONSOLIDATED BALANCE SHEETS



	December 31,
	2019		2018
	(Dollars in millions, except per-share amounts)
ASSETS
Current assets:
Cash and cash equivalents	$	2,452	$	2,826
Investments	1,946		1,681
Receivables	1,406		1,330
Prepaid expenses and other current assets	134		149
Derivative asset	29		476
Total current assets	5,967		6,462
Property, equipment, and capitalized software, net	385		241
Goodwill and intangible assets, net	172		190
Restricted investments	79		120
Deferred income taxes	79		117
Other assets	105		24
Total assets	$	6,787	$	7,154

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable	$	1,854	$	1,961
Amounts due government agencies	664		967
Accounts payable and accrued liabilities	455		390
Deferred revenue	249		211
Current portion of long-term debt	18		241
Derivative liability	29		476
Total current liabilities	3,269		4,246
Long-term debt	1,237		1,020
Finance lease liabilities	231		197
Other long-term liabilities	90		44
Total liabilities	4,827		5,507
Stockholders’ equity:
Common stock, $0.001 par value per share; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018	—		—
Preferred stock, $0.001 par value per share; 20 million shares authorized, no shares issued and outstanding	—		—
Additional paid-in capital	175		643
Accumulated other comprehensive income (loss)	4		(8		)
Retained earnings	1,781		1,012
Total stockholders’ equity	1,960		1,647
Total liabilities and stockholders’ equity	$	6,787	$	7,154

See accompanying notes.

Molina Healthcare, Inc. 2019 Form 10-K | 49

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY



	Common Stock			Additional Paid-in Capital			Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Total
	Outstanding	Amount		Additional Paid-in Capital			Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Total
	(In millions)
Balance at December 31, 2016	57	$	—	$	841		$	(2	)	$	810		$	1,649
Net loss	—	—		—			—			(512		)	(512		)
Exchange of convertible senior notes	3	—		161			—			—			161
Other comprehensive loss, net	—	—		—			(3		)	—			(3		)
Share-based compensation	—	—		42			—			—			42
Balance at December 31, 2017	60	—		1,044			(5		)	298			1,337
Net income	—	—		—			—			707			707
Adoption of new accounting standards	—	—		—			(1		)	7			6
Partial termination of warrants	—	—		(550		)	—			—			(550		)
Exchange of convertible senior notes	2	—		108			—			—			108
Conversion of convertible senior notes	—	—		4			—			—			4
Other comprehensive loss, net	—	—		—			(2		)	—			(2		)
Share-based compensation	—	—		37			—			—			37
Balance at December 31, 2018	62	—		643			(8		)	1,012			1,647
Net income	—	—		—			—			737			737
Common stock purchases	—	—		(1		)	—			(53		)	(54		)
Adoption of new accounting standard	—	—		—			—			85			85
Partial termination of warrants	—	—		(514		)	—			—			(514		)
Other comprehensive income, net	—	—		—			12			—			12
Share-based compensation	—	—		47			—			—			47
Balance at December 31, 2019	62	$	—	$	175		$	4		$	1,781		$	1,960

See accompanying notes.

Molina Healthcare, Inc. 2019 Form 10-K | 50

CONSOLIDATED STATEMENTS OF CASH FLOWS



	Year Ended December 31,
	2019			2018			2017
	(In millions)
Operating activities:
Net income (loss)	$	737		$	707		$	(512	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	89			127			178
Deferred income taxes	10			(6		)	(94		)
Share-based compensation	39			27			46
Amortization of convertible senior notes and finance lease liabilities	5			22			32
(Gain) loss on debt extinguishment	(15		)	22			14
Loss on sales of subsidiaries, net of gain	—			15			—
Non-cash restructuring charges	—			17			60
Impairment losses	—			—			470
Other, net	(5		)	4			21
Changes in operating assets and liabilities:
Receivables	(76		)	(530		)	103
Prepaid expenses and other current assets	28			6			(56		)
Medical claims and benefits payable	(107		)	(226		)	263
Amounts due government agencies	(303		)	(574		)	341
Accounts payable and accrued liabilities	2			45			(12		)
Deferred revenue	38			(21		)	(34		)
Income taxes	(15		)	51			(16		)
Net cash provided by (used in) operating activities	427			(314		)	804
Investing activities:
Purchases of investments	(2,536		)	(1,444		)	(2,697		)
Proceeds from sales and maturities of investments	2,302			2,445			1,759
Purchases of property, equipment and capitalized software	(57		)	(30		)	(86		)
Net cash received from sale of subsidiaries	—			190			—
Other, net	(2		)	(18		)	(38		)
Net cash (used in) provided by investing activities	(293		)	1,143			(1,062		)
Financing activities:
Repayment of principal amount of convertible senior notes	(240		)	(362		)	—
Cash paid for partial settlement of conversion option	(578		)	(623		)	—
Cash received for partial settlement of call option	578			623			—
Cash paid for partial termination of warrants	(514		)	(549		)	—
Proceeds from borrowings under term loan facility	220			—			—
Common stock purchases	(47		)	—			—
Repayment of credit facility	—			(300		)	—
Proceeds from senior notes offerings, net of issuance costs	—			—			325
Proceeds from borrowings under credit facility	—			—			300
Other, net	29			18			11
Net cash (used in) provided by financing activities	(552		)	(1,193		)	636
Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents	(418		)	(364		)	378
Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period	2,926			3,290			2,912
Cash and cash equivalents, and restricted cash and cash equivalents at end of period	$	2,508		$	2,926		$	3,290

See accompanying notes.

Molina Healthcare, Inc. 2019 Form 10-K | 51

CONSOLIDATED STATEMENTS OF CASH FLOWS

(continued)



	Year Ended December 31,
	2019			2018			2017
	(In millions)

Supplemental cash flow information:

Cash paid during the period for:
Income taxes	$	239		$	240		$	7
Interest	$	78		$	93		$	78

Schedule of non-cash investing and financing activities:

Convertible senior notes exchange transaction:
Common stock issued in exchange for convertible senior notes	$	—		$	131		$	193
Component of convertible senior notes allocated to additional paid-in capital, net of income taxes	—			(23		)	(32		)
Net increase to additional paid-in capital	$	—		$	108		$	161

Common stock used for stock-based compensation	$	(7	)	$	(6	)	$	(22	)

Common stock purchases not settled at end of period	$	7		$	—		$	—

Details of sales of subsidiaries:
Decrease in carrying amount of assets	$	—		$	(327	)	$	—
Decrease in carrying amount of liabilities	—			85			—
Transaction costs	—			(15		)	—
Cash received from buyers	—			242			—
Loss on sale of subsidiaries, net of gain	$	—		$	(15	)	$	—

Details of change in fair value of derivatives, net:
Gain on call option	$	132		$	577		$	255
Loss on conversion option	(132		)	(577		)	(255		)
Change in fair value of derivatives, net	$	—		$	—		$	—

See accompanying notes.

Molina Healthcare, Inc. 2019 Form 10-K | 52

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Basis of Presentation

Organization and Operations

Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). We currently have two reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve.

The Health Plans segment consists of health plans operating in 14 states and the Commonwealth of Puerto Rico. As of December 31, 2019, these health plans served approximately 3.3 million members eligible for Medicaid, Medicare, and other government-sponsored health care programs for low-income families and individuals including Marketplace members, most of whom receive government subsidies for premiums. The health plans are generally operated by our respective wholly owned subsidiaries in those states, each of which is licensed as a health maintenance organization (“HMO”).

Recent Developments – Health Plans Segment

Molina Healthcare, Inc. 2019 Form 10-K | 53

Consolidation and Presentation

The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Financial information related to subsidiaries acquired during any year is included only for periods subsequent to their acquisition. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the periods presented have been included; such adjustments consist of normal recurring adjustments.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:


•	The determination of medical claims and benefits payable of our Health Plans segment;


•	Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;


•	Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;


•	Settlements under risk or savings sharing programs;


•	The assessment of long-lived and intangible assets, and goodwill, for impairment;


•	The determination of reserves for potential absorption of claims unpaid by insolvent providers;


•	The determination of reserves for the outcome of litigation;


•	The determination of valuation allowances for deferred tax assets; and


•	The determination of unrecognized tax benefits.

2. Significant Accounting Policies

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.



	December 31,
	2019		2018		2017
	(In millions)
Cash and cash equivalents	$	2,452	$	2,826	$	3,186
Restricted cash and cash equivalents, non-current	56		100		95
Restricted cash and cash equivalents, current	—		—		9
Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows	$	2,508	$	2,926	$	3,290

Investments

Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (“AFS”) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders’ equity as other comprehensive income, net of applicable income taxes. Held-to-maturity securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses and unrealized losses judged to be other than temporary with respect to available-for-sale and held-to-maturity securities are included in the determination of net income (loss). The cost of securities sold is determined using the specific-identification method.

Our investment policy requires that all of our investments have final maturities of less than 10 years, or less than 10 years average life for structured securities. Investments and restricted investments are subject to interest rate risk

Molina Healthcare, Inc. 2019 Form 10-K | 54

and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.

In general, our AFS securities are classified as current assets without regard to the securities’ contractual maturity dates because they may be readily liquidated. We monitor our investments for other-than-temporary impairment. For comprehensive discussions of the fair value and classification of our investments, see Note 4, “Fair Value Measurements,” and Note 5, “Investments.”

Long-Lived Assets, including Intangible Assets

Long-lived assets consist primarily of property, equipment, capitalized software (see Note 7, “Property, Equipment, and Capitalized Software, Net”), and intangible assets resulting from acquisitions. Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts). Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between five and 15 years.

Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset’s (or asset group’s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed. Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment. Refer to Note 9, “Goodwill and Intangible Assets, Net,” for further details.

Leases

Right-of-use (“ROU”) assets represent our right to use the underlying assets over the lease term, and lease liabilities represent our obligation for lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. If applicable, we account for lease and non-lease components within a lease as a single lease component.

Because most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Finance lease payments reduce finance lease liabilities, the related ROU assets are amortized on a straight-line basis over the lease term, and interest expense is recognized using the effective interest method.

The significant majority of our operating leases consist of long-term operating leases for office space. Short-term leases (those with terms of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. For certain leases that represent a portfolio of similar assets, such as a fleet of vehicles, we apply a portfolio approach to account for the related ROU assets and liabilities, rather than account for such assets and the related liabilities individually. A nominal number of our lease agreements include rental payments that adjust periodically for inflation. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

For further information, including the amount and location of the ROU assets and lease liabilities recognized in the accompanying consolidated balance sheet, see Note 8, “Leases.” For further information regarding our adoption and implementation of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), see “Recent Accounting Pronouncements Adopted,” below.

Goodwill and Business Combinations

Molina Healthcare, Inc. 2019 Form 10-K | 55

exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit.

When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, the dynamic economic and political environments in which we operate, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. If our qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, we perform the quantitative assessment. We may also elect to bypass the qualitative assessment and proceed directly to the quantitative assessment. If performing a quantitative assessment, we generally estimate the fair values of our reporting units by applying the income approach, using discounted cash flows.

For the annual impairment test under a quantitative assessment, the base year in the reporting units’ discounted cash flows is derived from the annual financial planning cycle, which commences in the fourth quarter of the year. When computing discounted cash flows, we make assumptions about a wide variety of internal and external factors, and consider what the reporting unit’s selling price would be in an orderly transaction between market participants at the measurement date. Significant assumptions include financial projections of free cash flow (including significant assumptions about membership, premium rates, healthcare and operating cost trends, contract renewal and the procurement of new contracts, capital requirements and income taxes), long-term growth rates for determining terminal value beyond the discretely forecasted periods, and discount rates. When determining the discount rate, we consider the overall level of inherent risk of the reporting unit, and the expected rate an outside investor would expect to earn. As part of a quantitative assessment, we may also apply the asset liquidation method to estimate the fair value of individual reporting units, which is computed as total assets minus total liabilities, excluding intangible assets and deferred taxes. Finally, we apply a market approach to reconcile the value of our reporting units to our consolidated market value. Under the market approach, we consider publicly traded comparable company information to determine revenue and earnings multiples which are used to estimate our reporting units’ fair values. The assumptions used are consistent with those used in our long-range business plan and annual planning process. However, if these assumptions differ from actual results, the outcome of our goodwill impairment tests could be adversely affected.

Accounting for business combinations requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within our consolidated statements of operations. Refer to Note 9, “Goodwill and Intangible Assets, Net,” for further details.

Premium Revenue

Premium revenue is generated from our Health Plans segment contracts, including agreements with other managed care organizations for which we operate as a subcontractor. Premium revenue is generally received based on per member per month (“PMPM”) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. The state Medicaid programs and the federal Medicare program periodically adjust premiums. Additionally, many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.

Molina Healthcare, Inc. 2019 Form 10-K | 56

The following table summarizes premium revenue by health plan for the periods presented:



	Year Ended December 31,
	2019				2018				2017
	Amount		% of Total		Amount		% of Total		Amount		% of Total
	(Dollars in millions)
California	$	2,266	14.0	%	$	2,150	12.2	%	$	2,701	14.3	%
Florida	734		4.5		1,790		10.2		2,568		13.6
Illinois	1,002		6.2		793		4.5		593		3.1
Michigan	1,624		10.0		1,601		9.1		1,596		8.5
New Mexico ⁽¹⁾	—		—		1,356		7.7		1,368		7.3
Ohio	2,553		15.8		2,388		13.6		2,216		11.8
Puerto Rico	474		2.9		696		3.9		732		3.9
South Carolina	583		3.6		495		2.8		445		2.4
Texas	2,991		18.5		3,244		18.4		2,813		14.9
Washington	2,695		16.6		2,361		13.4		2,608		13.8
Other ⁽¹⁾	1,286		7.9		738		4.2		1,214		6.4
Total	$	16,208	100.0	%	$	17,612	100.0	%	$	18,854	100.0	%

_______________________

(1)

“Other” includes the Idaho, Mississippi, New York, Utah and Wisconsin health plans, which are not individually significant to our consolidated operating results. In 2019, “Other” also includes the New Mexico health plan. The New Mexico health plan’s Medicaid contract terminated on December 31, 2018, and therefore its results are not individually significant to our consolidated operating results in 2019.

Certain components of premium revenue are subject to accounting estimates and fall into the following categories:

Contractual Provisions That May Adjust or Limit Revenue or Profit

Medicaid Program

Medical Cost Floors (Minimums), and Medical Cost Corridors. A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. In the aggregate, we recorded liabilities under the terms of such contract provisions of $74 million and $103 million at December 31, 2019, and December 31, 2018, respectively. Approximately $69 million and $87 million of the liabilities accrued at December 31, 2019, and December 31, 2018, respectively, relates to our participation in Medicaid Expansion programs.

In certain circumstances, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold. Receivables relating to such provisions were insignificant at December 31, 2019, and December 31, 2018.

Profit Sharing and Profit Ceiling. Our contracts with certain states contain profit-sharing or profit ceiling provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any. Liabilities for profits in excess of the amount we are allowed to retain under these provisions were insignificant at December 31, 2019, and December 31, 2018.

Retroactive Premium Adjustments. State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we must adjust our premium revenue in the period in which we learn of the adjustment, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.

Medicare Program

Risk Adjusted Premiums: Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members’ risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members’ health status, risk scores and CMS practices. Consolidated balance sheet amounts related to anticipated Medicare risk adjusted premiums and Medicare Part D settlements were insignificant at December 31, 2019, and December 31, 2018.

Molina Healthcare, Inc. 2019 Form 10-K | 57

Minimum MLR: The Affordable Care Act (“ACA”) has established a minimum annual medical loss ratio (“Minimum MLR”) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations. The amounts payable for the Medicare Minimum MLR were insignificant at December 31, 2019, and December 31, 2018.

Marketplace Program

Risk Adjustment: Under this program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of operations. As of December 31, 2019, Marketplace risk adjustment payables amounted to $368 million and related receivables amounted to $63 million, for a net payable of $305 million. As of December 31, 2018, Marketplace risk adjustment payables amounted to $466 million and related receivables amounted to $34 million, for a net payable of $432 million.

Minimum MLR: The ACA has established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations. Aggregate balance sheet amounts related to the Minimum MLR were insignificant at December 31, 2019, and December 31, 2018.

A summary of the categories of amounts due government agencies is as follows:



	December 31,
	2019		2018
	(In millions)
Medicaid program:
Medical cost floors and corridors	$	74	$	103
Other amounts due to states	84		81
Marketplace program:
Risk adjustment	368		466
Cost sharing reduction	—		183
Other	138		134
Total	$	664	$	967

Quality Incentives

At many of our health plans, revenue ranging from approximately 1% to 4% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. As described in Note 1, “Organization and Basis of Presentation–Use of Estimates,” recognition of quality incentive premium revenue is subject to the use of estimates.

Molina Healthcare, Inc. 2019 Form 10-K | 58

The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods.



	Year Ended December 31,
	2019			2018			2017
	(In millions)
Maximum available quality incentive premium - current period	$	186		$	182		$	150

Amount of quality incentive premium revenue recognized in current period:
Earned current period	$	156		$	133		$	97
Earned prior periods	38			31			10
Total	$	194		$	164		$	107

Quality incentive premium revenue recognized as a percentage of total premium revenue	1.2		%	0.9		%	0.6		%

Medical Care Costs, Medical Claims and Benefits Payable

The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors and the assumed healthcare cost trend to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.

Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. Each reporting period, the recognized IBNP liability represents our best estimate of the total amount of unpaid claims incurred as of the balance sheet date using a consistent methodology in estimating our IBNP liability. We believe our current estimates are reasonable and adequate; however, the development of our estimate is a continuous process that we monitor and update as more complete claims payment information and healthcare cost trend data becomes available. Actual medical care costs may be less than we previously estimated (favorable development) or more than we previously estimated (unfavorable development), and any differences could be material. Any adjustments to reflect favorable development would be

Molina Healthcare, Inc. 2019 Form 10-K | 59

recognized as a decrease to medical care costs, and any adjustments to reflect unfavorable development would be recognized as an increase to medical care costs, in the period in which the adjustments are determined.

Refer to Note 10, “Medical Claims and Benefits Payable,” for a table presenting the components of the change in our medical claims and benefits payable, for all periods presented in the accompanying consolidated financial statements.

Reinsurance

We limit our risk of catastrophic losses by maintaining high deductible reinsurance coverage. Such reinsurance coverage does not relieve us of our primary obligation to our policyholders. We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. Reinsurance premiums amounted to $17 million, $16 million, and $20 million for the years ended December 31, 2019, 2018, and 2017, respectively. Reinsurance recoveries amounted to $18 million, $33 million, and $24 million for the years ended December 31, 2019, 2018, and 2017, respectively. Reinsurance recoverable of $21 million, $31 million, and $16 million, as of December 31, 2019, 2018, and 2017, respectively, is included in “Receivables” in the accompanying consolidated balance sheets.

Marketplace Cost Share Reduction (“CSR”)

In the year ended December 31, 2018, we recognized a benefit of approximately $81 million in reduced medical care costs related to 2017 dates of service, as a result of the federal government’s confirmation that the reconciliation of 2017 Marketplace CSR subsidies would be performed on an annual basis. In the fourth quarter of 2017, we had assumed a nine-month reconciliation of this item pending confirmation of the time period to which the 2017 reconciliation would be applied.

Premium Deficiency Reserves on Loss Contracts

We assess the profitability of our contracts to determine if it is probable that a loss will be incurred in the future by reviewing current results and forecasts. For purposes of this assessment, contracts are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. A premium deficiency is recognized if anticipated future medical care and administrative costs exceed anticipated future premium revenue, investment income and reinsurance recoveries. No premium deficiency reserves were recorded as of December 31, 2019 and 2018.

Income Taxes

We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates expected to be in effect during the year in which the basis differences reverse. Valuation allowances are established when management determines it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. For further discussion and disclosure, see Note 13, “Income Taxes.”

Taxes Based on Premiums

Health Insurer Fee (“HIF”). The federal government under the ACA imposes an annual fee, or excise tax, on health insurers for each calendar year. The HIF is based on a company’s share of the industry’s net premiums written during the preceding calendar year and is non-deductible for income tax purposes. We recognize expense for the HIF over the year on a straight-line basis. Within our Medicaid program, we must secure additional reimbursement from our state partners for this added cost. We recognize the related revenue when we have obtained a contractual commitment or payment from a state to reimburse us for the HIF, and such HIF revenue is recognized ratably throughout the year. The Consolidated Appropriations Act of 2016 provided for the HIF moratorium in 2017, and Public Law No. 115-120 provided for the HIF moratorium in 2019. Therefore, there were no health insurer fees reimbursed, nor health insurer fees incurred, in those years.

Premium and Use Tax. Certain of our health plans are assessed a tax based on premium revenue collected. The premium revenues we receive from these states include the premium tax assessment. We have reported these taxes on a gross basis, as premium tax revenue and as premium tax expenses in the consolidated statements of operations.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those

Molina Healthcare, Inc. 2019 Form 10-K | 60

investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents and U.S. Treasury securities.

Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate. See further information below, under “Recent Accounting Pronouncements Not Yet Adopted” regarding our adoption of ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, effective January 1, 2020.

Risks and Uncertainties

Our profitability depends in large part on our ability to accurately predict and effectively manage medical care costs. We continually review our medical costs in light of our underlying claims experience and revised actuarial data. However, several factors could adversely affect medical care costs. These factors, which include changes in health care practices, inflation, new technologies, major epidemics, natural disasters, and malpractice litigation, are beyond our control and may have an adverse effect on our ability to accurately predict and effectively control medical care costs. Costs in excess of those anticipated could have a material adverse effect on our financial condition, results of operations, or cash flows.

We operate health plans primarily as a direct contractor with the states (or Commonwealth), and in Los Angeles County, California, as a subcontractor to another health plan holding a direct contract with the state. We are therefore dependent upon a small number of contracts to support our revenue. The loss of any one of those contracts could have a material adverse effect on our financial position, results of operations, or cash flows. In addition, our ability to arrange for the provision of medical services to our members is dependent upon our ability to develop and maintain adequate provider networks. Our inability to develop or maintain such networks might, in certain circumstances, have a material adverse effect on our financial position, results of operations, or cash flows.

Recent Accounting Pronouncements Adopted

Leases. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Topic 842, which was subsequently modified by several ASUs issued in 2017 and 2018. Topic 842 was issued to increase transparency and comparability among organizations by requiring the recognition of ROU assets and lease liabilities on the balance sheet. Most prominent among the changes in Topic 842 is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. In addition, Topic 842’s disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. Topic 842’s transition provisions are applied using a modified retrospective approach; entities may elect whether to apply the transition provisions, including disclosure requirements, at the beginning of the earliest comparative period presented or on the adoption date.

We adopted Topic 842 effective January 1, 2019, and elected to apply the transition provisions as of that date. Accordingly, we recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings on January 1, 2019. In addition, we elected the available practical expedients and implemented internal controls and information systems functionality to enable the preparation of financial information on adoption.

As indicated in the accompanying consolidated statements of stockholders’ equity, the cumulative effect adjustment was an increase of $85 million to retained earnings ($110 million, net of $25 million deferred income tax expense), relating primarily to the transition provisions for sale-leaseback arrangements that did not qualify for sale treatment. Accordingly, such arrangements were de-recognized and recorded as finance lease ROU assets and lease liabilities. The difference between the de-recognized assets and lease financing obligations resulted in an increase to retained earnings. The recognition of these arrangements as finance lease ROU assets and lease liabilities will not materially impact our consolidated results of operations over the terms of the leases.

Software Licenses. In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. We early adopted ASU 2018-15 effective January 1, 2019, using the prospective method, with no material impact to our financial condition, results of operations or cash flows. Adoption of this guidance may be significant to us in the future depending on the extent to which we use cloud computing arrangements that qualify as service contracts.

Molina Healthcare, Inc. 2019 Form 10-K | 61

Recent Accounting Pronouncements Not Yet Adopted

Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which was subsequently modified by several ASUs issued in 2018 and 2019. This standard introduces a new current expected credit loss (“CECL”) model for measuring expected credit losses for certain types of financial instruments measured at amortized cost and replaces the incurred loss model. The CECL model requires an entity to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount the entity expects to collect over the instrument’s contractual life after consideration of historical experience, current conditions, and reasonable and supportable forecasts. This standard also introduces targeted changes to the AFS debt securities impairment model. It eliminates the concept of other-than-temporary impairment and requires an entity to determine whether any impairment is the result of a credit loss or other factors. We will adopt Topic 326 effective January 1, 2020, using the modified retrospective approach. Under this method we will recognize the cumulative effect of adopting the standard as an adjustment to the opening balance of retained earnings on January 1, 2020.

Under Topic 326, we will record an allowance for credit losses for financial assets subject to the CECL model. The most significant type of financial instrument reported in our consolidated balance sheets, subject to the CECL model, is “Receivables.” As of December 31, 2019, approximately 75%, or $1,056 million of the receivables balance constitutes receivables from state and federal government agencies. Based on our analysis, we believe that the credit risk associated with such receivables is nominal due to a very low risk of default.

The AFS debt securities impairment model will apply to “Investments” reported in our consolidated balance sheets. We believe that the credit risk associated with our non-government issued Investments is nominal due to the high quality of such investments.

The adoption of Topic 326 will be immaterial to our consolidated results of operations and financial condition.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.

Molina Healthcare, Inc. 2019 Form 10-K | 62

3. Net Income (Loss) Per Share

The following table sets forth the calculation of basic and diluted net income (loss) per share:



	Year Ended December 31,
	2019		2018		2017
	(In millions, except net income (loss) per share)
Numerator:
Net income (loss)	$	737	$	707	$	(512	)
Denominator:
Shares outstanding at the beginning of the period	62.1		59.3		55.8
Weighted-average number of shares issued:
Exchange of convertible senior notes ⁽¹⁾	—		1.4		0.1
Conversion of convertible senior notes ⁽¹⁾	—		0.2		—
Stock-based compensation	0.1		0.2		0.5
Denominator for basic net income (loss) per share	62.2		61.1		56.4
Effect of dilutive securities:
Warrants ⁽²⁾	1.4		4.8		—
Convertible senior notes ⁽¹⁾	—		0.4		—
Stock-based compensation	0.6		0.3		—
Denominator for diluted net income (loss) per share	64.2		66.6		56.4

Net income (loss) per share: ⁽³⁾
Basic	$	11.85	$	11.57	$	(9.07	)
Diluted	$	11.47	$	10.61	$	(9.07	)

Potentially dilutive common shares excluded from calculations: ⁽²⁾
Warrants	—		—		1.9
Convertible senior notes ⁽¹⁾	—		—		0.4
Stock-based compensation	—		—		0.3

_______________________________


(1)	“Convertible senior notes” in this table refer to the 1.625% convertible senior notes due 2044 that were settled in 2018.

(2)

For more information regarding the warrants, including partial termination transactions, refer to Note 14, “Stockholders' Equity.” The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. Certain potentially dilutive common shares issuable are not included in the computation of diluted net income (loss) per share because to do so would have been anti-dilutive.


(3)	Source data for calculations in thousands.

4. Fair Value Measurements

We consider the carrying amounts of current assets and current liabilities (not including derivatives and the current portion of long-term debt) to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to a three-tier fair value hierarchy as follows:

Level 1 — Observable Inputs. Level 1 financial instruments are actively traded and therefore the fair value for these securities is based on quoted market prices for identical securities in active markets.

Level 2 — Directly or Indirectly Observable Inputs. Fair value for these investments is determined using a market approach based on quoted prices for similar securities in active markets or quoted prices for identical securities in inactive markets.

Molina Healthcare, Inc. 2019 Form 10-K | 63

Level 3 — Unobservable Inputs. Level 3 financial instruments are valued using unobservable inputs that represent management’s best estimate of what market participants would use in pricing the financial instrument at the measurement date. Our Level 3 financial instruments consist primarily of derivative financial instruments.

The derivatives include the 1.125% Call Option derivative asset and the 1.125% Conversion Option derivative liability (for detailed descriptions of these instruments, see Note 12. “Derivatives”). These derivatives are not actively traded and are valued based on an option pricing model that uses observable and unobservable market data for inputs. Significant market data inputs used to determine fair value as of December 31, 2019, included the price of our common stock, the time to maturity of the derivative instruments, the risk-free interest rate, and the implied volatility of our common stock. The 1.125% Call Option asset and the 1.125% Conversion Option liability were designed such that changes in their fair values offset, with minimal impact to the consolidated statements of operations. Therefore, the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is mitigated.

The net changes in fair value of Level 3 financial instruments were insignificant to our results of operations for the years ended December 31, 2019, and 2018.

Our financial instruments measured at fair value on a recurring basis at December 31, 2019, were as follows:



	Total		Level 1		Level 2		Level 3
	(In millions)
Corporate debt securities	$	1,178	$	—	$	1,178	$	—
Mortgage-backed securities	420		—		420		—
Asset-backed securities	127		—		127		—
U.S. Treasury notes	86		—		86		—
Municipal securities	78		—		78		—
Government-sponsored enterprise securities (“GSEs”)	49		—		49		—
Foreign securities	7		—		7		—
Certificates of deposit	1		—		1		—
Subtotal	1,946		—		1,946		—
1.125% Call Option derivative asset	29		—		—		29
Total assets	$	1,975	$	—	$	1,946	$	29

1.125% Conversion Option derivative liability	$	29	$	—	$	—	$	29
Total liabilities	$	29	$	—	$	—	$	29

Our financial instruments measured at fair value on a recurring basis at December 31, 2018, were as follows:



	Total		Level 1		Level 2		Level 3
	(In millions)
Corporate debt securities	$	1,123	$	—	$	1,123	$	—
Asset-backed securities	82		—		82		—
U.S. Treasury notes	181		—		181		—
Municipal securities	114		—		114		—
GSEs	163		—		163		—
Foreign securities	4		—		4		—
Certificates of deposit	14		—		14		—
Subtotal	1,681		—		1,681		—
1.125% Call Option derivative asset	476		—		—		476
Total assets	$	2,157	$	—	$	1,681	$	476

1.125% Conversion Option derivative liability	$	476	$	—	$	—	$	476
Total liabilities	$	476	$	—	$	—	$	476

Molina Healthcare, Inc. 2019 Form 10-K | 64

Fair Value Measurements – Disclosure Only

The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets. The carrying amount and estimated fair value of the Term Loan Facility is classified as a Level 3 financial instrument, because certain inputs used to determine its fair value are not observable. As of December 31, 2019, the carrying amount of the Term Loan Facility approximated fair value because its interest rate is a variable rate that approximates rates currently available to us.



	December 31, 2019				December 31, 2018
	Carrying		Fair Value		Carrying		Fair Value
	Amount		Fair Value		Amount		Fair Value
	(In millions)
5.375% Notes	$	696	$	745	$	694	$	674
4.875% Notes	327		340		326		301
Term Loan Facility	220		220		—		—
1.125% Convertible Notes ⁽¹⁾	12		42		240		732
Total	$	1,255	$	1,347	$	1,260	$	1,707

_______________________________


(1)	The fair value of the 1.125% Conversion Option (the embedded cash conversion option), which is reflected in the fair value amounts presented above, amounted to $29 million and $476 million as of December 31, 2019 and 2018, respectively. For more information, including information on debt repayments in 2019 and 2020, see Note 11, “Debt,” and Note 12, “Derivatives.”

5. Investments

Available-for-Sale Investments

We consider all of our investments classified as current assets to be available-for-sale. The following tables summarize our current investments as of the dates indicated:



	December 31, 2019
	Amortized		Gross Unrealized				Estimated
	Cost		Gains		Losses		Fair Value
	(In millions)
Corporate debt securities	$	1,174	$	5	$	1	$	1,178
Mortgage-backed securities	420		1		1		420
Asset-backed securities	126		1		—		127
U.S. Treasury notes	86		—		—		86
Municipal securities	78		—		—		78
GSEs	49		—		—		49
Foreign securities	7		—		—		7
Certificates of deposit	1		—		—		1
Total	$	1,941	$	7	$	2	$	1,946

Molina Healthcare, Inc. 2019 Form 10-K | 65



	December 31, 2018
	Amortized Cost		Gross Unrealized				Estimated Fair Value
	Amortized Cost		Gains		Losses		Estimated Fair Value
	(In millions)
Corporate debt securities	$	1,131	$	—	$	8	$	1,123
Asset-backed securities	83		—		1		82
U.S. Treasury notes	181		—		—		181
Municipal securities	115		—		1		114
GSEs	164		—		1		163
Foreign securities	4		—		—		4
Certificates of deposit	14		—		—		14
Total	$	1,692	$	—	$	11	$	1,681

The contractual maturities of our current investments as of December 31, 2019 are summarized below:



	Amortized Cost		Estimated Fair Value
	(In millions)
Due in one year or less	$	453	$	453
Due after one year through five years	957		962
Due after five years through ten years	171		171
Due after ten years	360		360
Total	$	1,941	$	1,946

Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains amounted to $13 million in the year ended December 31, 2019. Gross realized investment losses were insignificant in the year ended December 31, 2019. Gross realized investment gains and losses for the years ended December 31, 2018 and 2017 were insignificant.

We have determined that unrealized losses at December 31, 2019 and 2018 are temporary in nature, because the change in market value for these securities resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.

The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December 31, 2019:



	In a Continuous Loss Position for Less than 12 Months					In a Continuous Loss Position for 12 Months or More
	Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions
	(Dollars in millions)
Corporate debt securities	$	222	$	1	167	$	—	$	—	—
Mortgage-backed securities	143		1		72	—		—		—
Total	$	365	$	2	239	$	—	$	—	—

Molina Healthcare, Inc. 2019 Form 10-K | 66



	In a Continuous Loss Position for Less than 12 Months					In a Continuous Loss Position for 12 Months or More
	Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions
	(Dollars in millions)
Corporate debt securities	$	509	$	3	285	$	412	$	5	298
Asset-backed securities	—		—		—	68		1		52
Municipal securities	—		—		—	87		1		90
GSEs	—		—		—	127		1		76
Total	$	509	$	3	285	$	694	$	8	516

Held-to-Maturity Investments

Pursuant to the regulations governing our Health Plans segment subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulation in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as “Restricted investments” in the accompanying consolidated balance sheets.

We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value, and mature in one year or less. The following table presents the balances of restricted investments:



	December 31,
	2019		2018
	(In millions)
Florida	$	12	$	32
New Mexico	21		43
Ohio	12		12
Puerto Rico	11		10
Other	23		23
Total Health Plans segment	$	79	$	120

6. Receivables

Receivables consist primarily of amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for doubtful accounts is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.



	December 31,
	2019		2018
	(In millions)
Government receivables	$	1,056	$	872
Pharmacy rebate receivables	150		146
Health insurer fee reimbursement receivables	5		141
Other	195		171
Total	$	1,406	$	1,330

Molina Healthcare, Inc. 2019 Form 10-K | 67

7. Property, Equipment, and Capitalized Software, Net

Property and equipment are stated at historical cost. Replacements and major improvements are capitalized, and repairs and maintenance are charged to expense as incurred. Furniture and equipment are generally depreciated using the straight-line method over estimated useful lives ranging from three to seven years. Software developed for internal use is capitalized. Software is generally amortized over its estimated useful life of three years. Leasehold improvements are amortized over the term of the lease, or over their useful lives from five to 10 years, whichever is shorter. Buildings are depreciated over their estimated useful lives of 31.5 to 40 years.

A summary of property, equipment, and capitalized software is as follows:



	December 31,
	2019			2018
	(In millions)
Capitalized software	$	421		$	373
Furniture and equipment	213			231
Building and improvements	49			154
Land	4			16
Total cost	687			774
Less: accumulated amortization - capitalized software	(351		)	(320		)
Less: accumulated depreciation and amortization - furniture, equipment, building, and improvements	(179		)	(213		)
Total accumulated depreciation and amortization	(530		)	(533		)
ROU assets - finance leases	228			—
Property, equipment, and capitalized software, net	$	385		$	241

The following table presents all depreciation and amortization recognized in our consolidated statements of operations:



	Year Ended December 31,
	2019		2018		2017
	(In millions)
Recorded in depreciation and amortization:
Amortization of capitalized software	$	33	$	42	$	64
Depreciation and amortization of furniture, equipment, building, and improvements	21		36		42
Amortization of intangible assets	18		21		31
Amortization of finance leases	17		—		—
Subtotal	89		99		137
Recorded in cost of service revenue:
Amortization of capitalized software and deferred contract costs	—		28		41
Total depreciation and amortization recognized	$	89	$	127	$	178

8. Leases

As discussed in Note 2, “Significant Accounting Policies,” we elected the Topic 842 transition provision that allows entities to continue to apply the legacy guidance in Topic 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. Accordingly, the Topic 842 disclosures below are presented as of and for the year ended December 31, 2019, only.

We are a party to operating and finance leases primarily for our corporate and health plan offices. Our operating leases have remaining lease terms up to 9 years, some of which include options to extend the leases for up to 10 years. As of December 31, 2019, the weighted average remaining operating lease term is 4 years.

Molina Healthcare, Inc. 2019 Form 10-K | 68

Our finance leases have remaining lease terms of 2 years to 19 years, some of which include options to extend the leases for up to 25 years. As of December 31, 2019, the weighted average remaining finance lease term is 16 years.

As of December 31, 2019, the weighted-average discount rate used to compute the present value of lease payments was 5.6% for operating lease liabilities, and 6.5% for finance lease liabilities. The components of lease expense were as follows:



	Year Ended December 31, 2019
	(In millions)
Operating lease expense	$	34

Finance lease expense:
Amortization of ROU assets	$	17
Interest on lease liabilities	15
Total finance lease expense	$	32

Rental expense related to operating leases amounted to $62 million and $75 million for the years ended December 31, 2018 and 2017, respectively.

Supplemental consolidated cash flow information related to leases follows:



	Year Ended December 31, 2019
	(In millions)
Cash used in operating activities:
Operating leases	$	36
Finance leases	15
Cash used in financing activities:
Finance leases	6
ROU assets recognized in exchange for lease obligations:
Operating leases	99
Finance leases	245

Molina Healthcare, Inc. 2019 Form 10-K | 69

Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:



	December 31, 2019
	(In millions)
Operating leases:
ROU assets
Other assets	$	65
Lease liabilities
Accounts payable and accrued liabilities (current)	$	25
Other long-term liabilities (non-current)	48
Total operating lease liabilities	$	73
Finance leases:
ROU assets
Property, equipment, and capitalized software, net	$	228
Lease liabilities
Accounts payable and accrued liabilities (current)	$	8
Finance lease liabilities (non-current)	231
Total finance lease liabilities	$	239

Maturities of lease liabilities as of December 31, 2019, were as follows:



	Operating Leases			Finance Leases
	(In millions)
2020	$	28		$	23
2021	20			24
2022	14			21
2023	10			21
2024	5			22
Thereafter	3			289
Subtotal - undiscounted lease payments	80			400
Less imputed interest	(7		)	(161		)
Total	$	73		$	239

9. Goodwill and Intangible Assets, Net

Goodwill

The following table presents the changes in the carrying amounts of goodwill by segment, for the periods presented.



	Health Plans		Other			Total
	(In millions)
Balance, December 31, 2017	$	143	$	43		$	186
Acquisitions	—		—			—
Dispositions	—		(43		)	(43		)
Impairment and other	—		—			—
Balance, December 31, 2018	143		—			143
Acquisitions	—		—			—
Dispositions	—		—			—
Impairment and other	—		—			—
Balance, December 31, 2019	$	143	$	—		$	143

Molina Healthcare, Inc. 2019 Form 10-K | 70

For the Health Plans segment, gross goodwill amounted to $445 million, and accumulated impairment losses amounted to $302 million, at each of December 31, 2019, and 2018.

2017 Impairment Losses. As a result of reporting unit quantitative goodwill assessments using discounted cash flows and/or asset liquidation analyses, we recorded goodwill impairment losses of $244 million and $190 million for the Health Plans segment and Other segment, respectively, in the year ended December 31, 2017. The Health Plans segment impairment losses were due primarily to certain health plans’ Medicaid contract terminations, and insufficient estimated future cash flows. The Other segment impairment losses were due to the expectation of fewer future benefits, and related lower cash flows, to be derived from certain subsidiaries. Such subsidiaries were disposed in 2018.

Intangible Assets, Net

The following table provides the details of identified intangible assets, by major class, for the periods indicated:



	December 31, 2019						December 31, 2018
	Cost		Accumulated Amortization		Carrying Amount		Cost		Accumulated Amortization		Carrying Amount
	(In millions)
Contract rights and licenses	$	179	$	156	$	23	$	201	$	162	$	39
Provider networks	20		14		6		20		12		8
Total	$	199	$	170	$	29	$	221	$	174	$	47

As of December 31, 2019, we estimate that our intangible asset amortization will be approximately $14 million in 2020, $5 million in 2021, and $3 million in 2022, 2023 and 2024. For a presentation of our intangible assets by reportable segment, refer to Note 18, “Segments.”

2017 Impairment Losses. For the reasons described above, reporting unit undiscounted cash flow analyses produced intangible asset impairment losses of $25 million and $11 million for the Health Plans segment and Other segment, respectively, in the year ended December 31, 2017.

Molina Healthcare, Inc. 2019 Form 10-K | 71

10. Medical Claims and Benefits Payable

The following table provides the details of our medical claims and benefits payable as of the dates indicated.



	December 31,
	2019		2018		2017
	(In millions)
Fee-for-service claims incurred but not paid (“IBNP”)	$	1,406	$	1,562	$	1,717
Pharmacy payable	126		115		112
Capitation payable	55		52		67
Other	267		232		296
Total	$	1,854	$	1,961	$	2,192

“Other” medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of operations. Non-risk provider payables amounted to $132 million, $107 million and $122 million, as of December 31, 2019, 2018, and 2017, respectively.

The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for “Components of medical care costs related to: Prior periods” represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the period were (more) less than the actual amount of the liability based on information (principally the payment of claims) developed since that liability was first reported.



	Year Ended December 31,
	2019			2018			2017
	(In millions)
Medical claims and benefits payable, beginning balance	$	1,961		$	2,192		$	1,929
Components of medical care costs related to:
Current period	14,176			15,478			17,037
Prior periods ⁽¹⁾	(271		)	(341		)	36
Total medical care costs	13,905			15,137			17,073

Change in non-risk and other provider payables	24			13			(106		)

Payments for medical care costs related to:
Current period	12,554			13,671			15,130
Prior periods	1,482			1,710			1,574
Total paid	14,036			15,381			16,704
Medical claims and benefits payable, ending balance	$	1,854		$	1,961		$	2,192

________________


(1)	December 31, 2018, includes the 2018 benefit of the 2017 Marketplace CSR reimbursement of $81 million.

The following tables provide information about incurred and paid claims development as of December 31, 2019, as well as cumulative claims frequency and the total of incurred but not paid claims liabilities. The cumulative claim frequency is measured by claim event, and includes claims covered under capitated arrangements.



Incurred Claims and Allocated Claims Adjustment Expenses							Total IBNP		Cumulative number of reported claims
Benefit Year	2017		2018		2019		Total IBNP		Cumulative number of reported claims

	(Unaudited)		(Unaudited)
	(In millions)
2017	$	17,037	$	16,728	$	16,704	$	18	119
2018			15,478		15,245		25		110
2019					14,176		1,348		93
					$	46,125	$	1,391

Molina Healthcare, Inc. 2019 Form 10-K | 72



Cumulative Paid Claims and Allocated Claims Adjustment Expenses
Benefit Year	2017		2018		2019

	(Unaudited)		(Unaudited)
	(In millions)
2017	$	15,130	$	16,671	$	16,686
2018			13,752		15,220
2019					12,554
					$	44,460

The following table represents a reconciliation of claims development to the aggregate carrying amount of the liability for medical claims and benefits payable.



	2019
	(In millions)
Incurred claims and allocated claims adjustment expenses	$	46,125
Less: cumulative paid claims and allocated claims adjustment expenses	(44,460		)
All outstanding liabilities before 2017	15
Non-risk and other provider payables	174
Medical claims and benefits payable	$	1,854

Our estimates of medical claims and benefits payable recorded at December 31, 2018, 2017 and 2016 developed favorably (unfavorably) by approximately $271 million, $341 million and $(36) million in 2019, 2018 and 2017, respectively.

The favorable prior year development recognized in 2019 was primarily due to lower than expected utilization of medical services by our Medicaid members, and improved operating performance. Consequently, the ultimate costs recognized in 2019 were lower than our original estimates in 2018, which was not discernible until additional information was provided, and as claims payments were processed.

The favorable prior year development recognized in 2018 includes a benefit of approximately $81 million in reduced medical care costs relating to Marketplace CSR subsidies for 2017 dates of service. The remainder of the favorable prior period development was primarily due to lower than expected utilization of medical services by our Medicaid and Marketplace members and improved operating performance. The differences between our original estimates in 2017 and the ultimate costs in 2018 were not discernable until additional information was provided to us in 2018 and the effect became clearer over time as claim payments were processed.

The unfavorable prior year development in 2017 was primarily due to higher than expected costs for settling certain claims with certain providers in states where we had recently commenced operations, such as in Illinois and Puerto Rico, or had instituted significant changes due to provider contract changes, such as in Florida and New Mexico. The differences between our original estimates in 2016 and the ultimate costs in 2017 were not discernible until additional information was provided to us in 2017, and the effect became clearer over time as claim payments were processed.

Molina Healthcare, Inc. 2019 Form 10-K | 73

11. Debt

Contractual maturities of debt, as of December 31, 2019, are illustrated in the following table. All amounts represent the principal amounts of the debt instruments outstanding.



	Total		2020		2021		2022		2023		2024		Thereafter

	(In millions)
5.375% Notes	$	700	$	—	$	—	$	700	$	—	$	—	$	—
4.875% Notes	330		—		—		—		—		—		330
Term Loan Facility	220		6		16		22		22		154		—
1.125% Convertible Notes	12		12		—		—		—		—		—
Total	$	1,262	$	18	$	16	$	722	$	22	$	154	$	330

All debt is held at the parent which is reported, for segment purposes, in the Other segment. The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets:



	December 31,
	2019			2018
	(In millions)
Current portion of long-term debt:
1.125% Convertible Notes, net of unamortized discount	$	12		$	241
Term Loan Facility	6			—
Lease financing obligations	—			1
Debt issuance costs	—			(1		)
Total, current portion	$	18		$	241
Non-current portion of long-term debt:
5.375% Notes	$	700		$	700
4.875% Notes	330			330
Term Loan Facility	214			—
Debt issuance costs	(7		)	(10		)
Total, non-current portion	$	1,237		$	1,020

Credit Agreement

We are party to a Credit Agreement, which provides for an unsecured delayed draw term loan facility (the “Term Loan Facility”), and an unsecured $500 million revolving credit facility (the “Credit Facility”). Borrowings under our Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.

The Credit Agreement contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. As of December 31, 2019, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. Effective as of the date of the Sixth Amendment to the Credit Agreement described below, there are no guarantors as parties to the Credit Agreement.

Term Loan Facility. In January 2019, we entered into a Sixth Amendment to the Credit Agreement that provided for a delayed draw Term Loan Facility in the aggregate principal amount of $600 million, under which we may request up to ten advances, each in a minimum principal amount of $50 million, until July 31, 2020. The Term Loan Facility will amortize in quarterly installments, commencing on September 30, 2020, equal to the principal amount of the Term Loan Facility outstanding multiplied by rates ranging from 1.25% to 2.50% (depending on the applicable fiscal quarter) for each fiscal quarter. The Term Loan Facility expires on January 31, 2024; any remaining outstanding balance under the Term Loan Facility will be due and payable on that date. As of December 31, 2019, $220 million was outstanding under the Term Loan Facility. Each advance under the Term Loan Facility results in a permanent reduction to its borrowing capacity; therefore, our borrowing capacity under the Term Loan Facility as of December 31, 2019, was $380 million.

Molina Healthcare, Inc. 2019 Form 10-K | 74

Credit Facility. The Credit Facility expires on January 31, 2022; therefore, any amounts outstanding under the Credit Facility will be due and payable on that date. As of December 31, 2019, no amounts were outstanding under the Credit Facility, and outstanding letters of credit amounting to $1 million reduced our remaining borrowing capacity under the Credit Facility to $499 million.

5.375% Notes due 2022

We have $700 million aggregate principal amount of senior notes (the “5.375% Notes”) outstanding as of December 31, 2019, which are due November 15, 2022, unless earlier redeemed. Interest at a rate of 5.375% per annum, is payable semiannually in arrears on May 15 and November 15. The 5.375% Notes contain customary non-financial covenants and change of control provisions.

4.875% Notes due 2025

We had $330 million aggregate principal amount of senior notes (the “4.875% Notes”) outstanding as of December 31, 2019, which are due June 15, 2025, unless earlier redeemed. Interest at a rate of 4.875% per annum, is payable semiannually in arrears on June 15 and December 15. The 4.875% Notes contain customary non-financial covenants and change of control provisions.

1.125% Cash Convertible Senior Notes due 2020

In the years ended December 31, 2019 and 2018, we entered into privately negotiated note purchase agreements and, in 2019, received conversion requests, with certain holders of our outstanding 1.125% cash convertible senior notes due January 15, 2020 (the “1.125% Convertible Notes”). For each transaction, the difference between the principal amount extinguished and the total cash paid primarily represented the settlement of the 1.125% Convertible Notes’ embedded cash conversion option feature at fair value (which is a derivative liability we refer to as the “1.125% Conversion Option”).

During 2019, we paid $794 million to settle $240 million aggregate principal amount, or $232 million aggregate carrying amount, of the 1.125% Convertible Notes. During 2018, we paid $911 million to settle $298 million aggregate principal amount, or $278 million aggregate carrying amount of the 1.125% Convertible Notes. In both years, the cash payments included settlement of the related 1.125% Conversion Option, and the mark-to-market valuation adjustments discussed below.

In the years ended December 31, 2019 and 2018, we recorded a (gain) loss on debt extinguishment of approximately $(15) million and $12 million, respectively, for the 1.125% Convertible Notes transactions (net of accelerated original issuance discount amortization), primarily relating to mark-to-market valuations on the partial terminations of the Call Spread Overlay executed in connection with the related debt repayments. These amounts are reported in “Other (income) expenses, net” in the accompanying consolidated statements of operations. No common shares were issued in connection with the transaction.

In connection with the 1.125% Convertible Notes transactions, we also entered into privately negotiated agreements in 2019, to partially terminate the Call Spread Overlay, defined and further discussed in Notes 12, “Derivatives,” and 14, “Stockholders' Equity.” The net cash proceeds from the Call Spread Overlay partial termination transactions partially offset the cash paid to settle the 1.125% Convertible Notes.

As of December 31, 2019, $12 million aggregate principal amount of the 1.125% Convertible Notes were outstanding. Interest at a rate of 1.125% per annum is payable semiannually in arrears on January 15 and July 15. The 1.125% Convertible Notes are convertible only into cash, and not into shares of our common stock or any other securities. The initial conversion rate is 24.5277 shares of our common stock per $1,000 principal amount, or approximately $40.77 per share of our common stock. Holders may convert their 1.125% Convertible Notes under certain circumstances and upon conversion, in lieu of receiving shares of our common stock, a holder will receive an amount in cash, per $1,000 principal amount, equal to the settlement amount, determined in the manner set forth in the indenture. We may not redeem the 1.125% Convertible Notes prior to the maturity date. The 1.125% Convertible Notes matured on January 15, 2020; therefore, they were reported in current portion of long-term debt as of December 31, 2019. (See “Subsequent Event,” below.)

Concurrent with the issuance of the 1.125% Convertible Notes, the 1.125% Conversion Option was separated from the 1.125% Convertible Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations until the 1.125% Conversion Option settled. This initial liability simultaneously reduced the carrying value of the 1.125% Convertible Notes’ principal amount (effectively an original issuance discount), which was amortized to the principal amount through the recognition of non-cash interest expense over the expected life of the debt. The effective interest rate of 6% approximates the interest rate we would have incurred had we issued nonconvertible debt with otherwise similar terms. As of December 31, 2019, the

Molina Healthcare, Inc. 2019 Form 10-K | 75

1.125% Convertible Notes had a remaining amortization period of less than one month, and their ‘if-converted’ value exceeded their principal amount by approximately $26 million and $581 million as of December 31, 2019, and 2018, respectively.

Interest cost recognized relating to our convertible senior notes for the periods presented was as follows:



	Years Ended December 31,
	2019		2018		2017
	(In millions)
Contractual interest at coupon rate	$	1	$	6	$	11
Amortization of the discount	5		21		32
Total	$	6	$	27	$	43

Subsequent Event

In January 2020, we paid $39 million to settle the outstanding 1.125% Convertible Notes, which amount included settlement of the 1.125% Conversion Option.

Cross-Default Provisions

The indentures governing the 4.875% Notes and the 5.375% Notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture.

12. Derivatives

The following table summarizes the fair values and the presentation of our derivative financial instruments (defined and discussed individually below) in the consolidated balance sheets:



		December 31,
	Balance Sheet Location	2019		2018
		(In millions)
Derivative asset:
1.125% Call Option	Current assets: Derivative asset	$	29	$	476
Derivative liability:
1.125% Conversion Option	Current liabilities: Derivative liability	$	29	$	476

Our derivative financial instruments do not qualify for hedge treatment; therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations, and reported in “Other (income) expenses, net.” Gains and losses for our derivative financial instruments are presented individually in the accompanying consolidated statements of cash flows, “Supplemental cash flow information.”

1.125% Convertible Notes Call Spread Overlay

Concurrent with the issuance of the 1.125% Convertible Notes in 2013, we entered into privately negotiated hedge transactions (collectively, the “1.125% Call Option”) and warrant transactions (collectively, the “1.125% Warrants”), with certain of the initial purchasers of the 1.125% Convertible Notes (the “Counterparties”). We refer to these transactions collectively as the Call Spread Overlay. Under the Call Spread Overlay, the cost of the 1.125% Call Option we purchased to cover the cash outlay upon conversion of the 1.125% Convertible Notes was reduced by proceeds from the sale of the 1.125% Warrants. Assuming full performance by the Counterparties (and 1.125% Warrants strike prices in excess of the conversion price of the 1.125% Convertible Notes), these transactions are intended to offset cash payments in excess of the principal amount of the 1.125% Convertible Notes due upon any conversion of such notes.

In the year ended December 31, 2019, in connection with the 1.125% Convertible Notes purchases (described in Note 11, “Debt”), we entered into privately negotiated termination agreements with each of the Counterparties to partially terminate the Call Spread Overlay, in notional amounts corresponding to the aggregate principal amount of the 1.125% Convertible Notes purchased. In the year ended December 31, 2019, we received $578 million for the

Molina Healthcare, Inc. 2019 Form 10-K | 76

settlement of the 1.125% Call Option (which is a derivative asset), and paid $514 million for the partial termination of the 1.125% Warrants, for an aggregate net cash receipt of $64 million from the Counterparties.

1.125% Call Option

The 1.125% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to cash settlement features until the 1.125% Call Option settles or expires. For further discussion of the inputs used to determine the fair value of the 1.125% Call Option, refer to Note 4, “Fair Value Measurements.”

1.125% Conversion Option

The embedded cash conversion option within the 1.125% Convertible Notes is accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations until the cash conversion option settles or expires. For further discussion of the inputs used to determine the fair value of the 1.125% Conversion Option, refer to Note 4, “Fair Value Measurements.”

As of December 31, 2019, the 1.125% Call Option and the 1.125% Conversion Option were classified as a current asset and current liability, respectively, because the 1.125% Convertible Notes matured on January 15, 2020.

Subsequent Event

As described in Note 11, “Debt,” we repaid the aggregate principal amount of the 1.125% Convertible Notes, including settlement of the related 1.125% Conversion Option. In addition, in January 2020 we received $27 million for the settlement of the 1.125% Call Option.

13. Income Taxes

Income tax expense (benefit) consisted of the following:



	Year Ended December 31,
	2019			2018			2017
	(In millions)
Current:
Federal	$	204		$	272		$	(9	)
State	12			18			3
Foreign	9			8			—
Total current	225			298			(6		)
Deferred:
Federal	5			(3		)	(85		)
State	6			(3		)	(9		)
Foreign	(1		)	—			—
Total deferred	10			(6		)	(94		)
Income tax expense (benefit)	$	235		$	292		$	(100	)

The Tax Cuts and Jobs Act of 2017 (“TCJA”), in part, reduced the U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018. TCJA’s change in the federal rate required that we revalue deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally the new 21% federal corporate tax rate plus applicable state tax rate. We applied the guidance in SEC Staff Accounting Bulletin No. 118 when accounting for the enactment-date effects of the TCJA in 2017 and throughout 2018.

As of December 31, 2017, we recorded a provisional amount of $54 million for the revaluation of deferred tax assets and liabilities because we had not yet completed our accounting for all of the enactment-date income tax effects of the TJCA under ASC 740, Income Taxes. Upon further analysis of certain aspects of the TCJA and refinement of our calculations in the year ended December 31, 2018, we reduced this provisional amount by $4 million, which is included as a component of income tax expense in the accompanying consolidated statement of operations. As of December 31, 2018, the accounting for all of the enactment-date income tax effects of the TCJA was complete.

Molina Healthcare, Inc. 2019 Form 10-K | 77

A reconciliation of the U.S. federal statutory income tax rate to the combined effective income tax rate is as follows:



	Year Ended December 31,
	2019		2018		2017
Statutory federal tax (benefit) rate	21.0	%	21.0	%	(35.0	)%
State income provision (benefit), net of federal	1.4		1.2		(0.7	)
Nondeductible health insurer fee (“HIF”)	—		7.3		—
Nondeductible compensation	1.2		0.7		2.8
Nondeductible goodwill impairment	—		—		6.6
Worthless stock deduction	—		(1.0	)	—
Revaluation of net deferred tax assets	—		(0.4	)	8.8
Other	0.6		0.4		1.1
Effective tax expense (benefit) rate	24.2	%	29.2	%	(16.4	)%

The effective tax rate was not impacted by the HIF in 2019 and 2017, given the HIF moratorium in each of those years. Our effective tax rate is based on expected income (loss), statutory tax rates, and tax planning opportunities available to us in the various jurisdictions in which we operate. Management estimates and judgments are required in determining our effective tax rate. We are routinely under audit by federal, state, or local authorities regarding the timing and amount of deductions, nexus of income among various tax jurisdictions, and compliance with federal, state, foreign, and local tax laws.

Deferred tax assets and liabilities are classified as non-current. Significant components of our deferred tax assets and liabilities as of December 31, 2019 and 2018 were as follows:



	December 31,
	2019			2018
	(In millions)
Accrued expenses and reserve liabilities	$	35		$	39
Other accrued medical costs	11			12
Net operating losses	13			16
Fixed assets and intangibles	26			30
Unearned premiums	11			9
Lease financing obligation	5			30
Tax credit carryover	11			12
Other	—			3
Valuation allowance	(24		)	(28		)
Total deferred income tax assets, net of valuation allowance	88			123
Prepaid expenses	(6		)	(6		)
Other	(3		)	—
Total deferred income tax liabilities	(9		)	(6		)
Net deferred income tax asset	$	79		$	117

At December 31, 2019, we had state net operating loss carryforwards of $310 million, which begin expiring in 2028.

At December 31, 2019, we had California research and development and enterprise zone tax credit carryovers of $8 million, which will begin to expire in 2024, and foreign tax credit carryovers of $5 million, which expire in 2030.

We evaluate the need for a valuation allowance taking into consideration the ability to carry back and carry forward tax credits and losses, available tax planning strategies and future income, including reversal of temporary differences. We have determined that as of December 31, 2019, $24 million of deferred tax assets did not satisfy the recognition criteria. Therefore, we decreased our valuation allowance by $4 million, from $28 million at December 31, 2018, to $24 million as of December 31, 2019.

Molina Healthcare, Inc. 2019 Form 10-K | 78

We recognize tax benefits only if the tax position is more likely than not to be sustained. We are subject to income taxes in the United States, Puerto Rico, and numerous state jurisdictions. Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. We establish reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these reserves in light of changing facts and circumstances, such as the outcome of tax audits. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate.

The roll forward of our unrecognized tax benefits is as follows:



	Year Ended December 31,
	2019			2018			2017
	(In millions)
Gross unrecognized tax benefits at beginning of period	$	(20	)	$	(13	)	$	(11	)
Increases in tax positions for current year				(9		)	(1		)
Increases in tax positions for prior years	—			—			(4		)
Decreases in tax positions for prior years	—			—			3
Lapse in statute of limitations				2			—
Gross unrecognized tax benefits at end of period	$	(20	)	$	(20	)	$	(13	)

The total amount of unrecognized tax benefits at December 31, 2019, 2018 and 2017 that, if recognized, would affect the effective tax rates is $18 million, $18 million, and $12 million, respectively. We expect that during the next 12 months it is reasonably possible that unrecognized tax benefit liabilities may decrease by as much as $5 million due to resolution of a state refund claim. The state refund claim will not result in a cash payment for income taxes if our claim is denied.

Our continuing practice is to recognize interest and/or penalties related to unrecognized tax benefits in income tax expense. Amounts accrued for the payment of interest and penalties as of December 31, 2019, 2018 and 2017 were insignificant.

We are under examination by the IRS for calendar years 2015 through 2017 and may be subject to examination for calendar year 2018. With a few exceptions, which are immaterial in the aggregate, we no longer are subject to state, local, and Puerto Rico tax examinations for years before 2015.

14. Stockholders' Equity

Stock Purchase Program

Subsequent Event

In January 2020 through February 7, 2020, we purchased 1,533,000 shares for $203 million (average cost of $132.69 per share).

1.125% Warrants

In connection with the Call Spread Overlay transaction described in Note 12, “Derivatives,” in 2013, we issued 13.5 million of the 1.125% Warrants with a strike price of $53.8475 per share. Under certain circumstances, beginning in April 2020, if the price of our common stock were to exceed the strike price of the 1.125% Warrants, we would be obligated to issue shares of our common stock subject to a share delivery cap. The 1.125% Warrants could separately have a dilutive effect to the extent that the market value per share of our common stock exceeds the applicable strike price of the 1.125% Warrants. Refer to Note 3, “Net Income (Loss) Per Share,” for dilution

Molina Healthcare, Inc. 2019 Form 10-K | 79

information for the periods presented. We will not receive any additional proceeds if the 1.125% Warrants are exercised. Following the transactions described below, approximately 310,000 of the 1.125% Warrants were outstanding at December 31, 2019.

As described in Note 12, “Derivatives,” in the year ended December 31, 2019, we entered into privately negotiated termination agreements with each of the Counterparties to partially terminate the Call Spread Overlay, in notional amounts corresponding to the aggregate principal amount of the 1.125% Convertible Notes purchased. In the year ended December 31, 2019, we paid $514 million to the Counterparties for the termination of 5.9 million of the 1.125% Warrants outstanding which resulted in a reduction of additional paid-in-capital for the same amount.

Share-Based Compensation

Total share-based compensation expense is presented in the following table. Except as described in the note to the table, we record share-based compensation as “General and administrative expenses” in the accompanying consolidated statements of operations.



	Year Ended December 31,
	2019				2018				2017
	(In millions)
	Pretax Charges		Net-of-Tax Amount		Pretax Charges		Net-of-Tax Amount		Pretax Charges ⁽¹⁾		Net-of-Tax Amount
RSAs, PSAs and PSUs (defined below)	$	29	$	28	$	17	$	17	$	39	$	35
Employee stock purchase plan and stock options	10		9		10		9		7		5
Total	$	39	$	37	$	27	$	26	$	46	$	40

_______________________


(1)	Includes $23 million relating to acceleration of share-based compensation for former executives in the year ended December 31, 2017. This amount is reported in “Restructuring costs” in the accompanying consolidated statements of operations.

Equity Incentive Plans

In the second quarter of 2019, our stockholders approved the Molina Healthcare, Inc. 2019 Equity Incentive Plan (the “2019 EIP”). The 2019 EIP provides for awards, in the form of restricted and performance stock awards (“RSAs” and “PSAs”), performance units (“PSUs”), stock options, and other stock– or cash–based awards, to eligible persons who perform services for us. The 2019 EIP will remain in effect until its termination by the board of directors; provided, however, that all awards will be granted no later than May 8, 2029. Concurrent with the adoption of the 2019 EIP, the Molina Healthcare, Inc. 2011 Equity Incentive Plan was amended, restated and merged into the 2019 EIP. A maximum of 2.9 million shares of our common stock may be issued under the 2019 EIP.

Stock-based awards. RSAs, PSAs and PSUs are granted with a fair value equal to the market price of our common stock on the date of grant, and generally vest in equal annual installments over periods up to four years from the date of grant. Certain PSUs may vest in their entirety at the end of three-year performance periods, if their performance conditions are met. We generally recognize expense for RSAs, PSAs and PSUs on a straight-line basis. Activity for stock-based awards in the year ended December 31, 2019 is summarized below:



	RSAs		PSAs		PSUs		Total Shares		Weighted Average Grant Date Fair Value
Unvested balance as of December 31, 2018	399,795		3,132		201,383		604,310		$	71.50
Granted	243,353		—		146,425		389,778		136.23
Vested	(139,828	)	(3,132	)	(10,528	)	(153,488	)	73.98
Forfeited	(55,640	)	—		(13,202	)	(68,842	)	90.45
Unvested balance as of December 31, 2019	447,680		—		324,078		771,758		$	102.01

As of December 31, 2019, total unrecognized compensation expense related to unvested RSAs and PSUs was $49 million, which we expect to recognize over a remaining weighted-average period of 2.2 years, and 1.6 years, respectively. This unrecognized compensation cost assumes an estimated forfeiture rate of 15.9% for non-executive employees as of December 31, 2019, based on actual forfeitures over the last 4 years.

Molina Healthcare, Inc. 2019 Form 10-K | 80

The total grant date fair value of awards granted and vested is presented in the following table:



	Year Ended December 31,
	2019		2018		2017
	(In millions)
Granted:
RSAs	$	33	$	28	$	20
PSUs	20		16		16
Total granted	$	53	$	44	$	36
Vested:
RSAs	$	19	$	15	$	23
PSAs	—		3		15
PSUs	2		—		9
Total vested	$	21	$	18	$	47

Stock Options. Stock option awards generally have an exercise price equal to the fair market value of our common stock on the date of grant, vest in equal annual installments over periods up to four years from the date of grant, and have a maximum term of ten years from the date of grant. Stock option activity for the year ended December 31, 2019 is summarized below:



	Shares	Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual term
				(In millions)		(Years)
Stock options outstanding as of December 31, 2018	405,000	$	64.79
Granted	—	—
Exercised	—	—
Stock options outstanding as of December 31, 2019	405,000	64.79		$	29	7.4
Stock options exercisable and expected to vest as of December 31, 2019	405,000	64.79		$	29	7.4
Exercisable as of December 31, 2019	280,000	63.65		$	20	7.3

The weighted-average grant date fair value per share of stock options awarded in 2017 was $41.43. We estimate the fair value of each stock option award on the grant date using the Black-Scholes option pricing model. To determine the fair value of the stock options awarded in 2017 we applied a risk-free interest rate of 2.3%, expected volatility of 38.4%, dividend yield of 0% and expected life of 8.4 years. No stock options were granted in 2019 and 2018.

As of December 31, 2019, total unrecognized compensation expense related to unvested stock options was $4 million, which we expect to recognize over a weighted-average period of 0.8 years. The total intrinsic value of options exercised during the year ended December 31, 2017 was $2 million. No stock options were exercised in 2019 and 2018. The following is a summary of information about stock options outstanding and exercisable at December 31, 2019:



	Options Outstanding				Options Exercisable
	Number Outstanding	Weighted Average Remaining Contractual Life (Years)	Weighted-Average Exercise Price		Number Exercisable	Weighted-Average Exercise Price
Range of Exercise Prices
$33.02	30,000	3.2	$	33.02	30,000	$	33.02
$67.33	375,000	7.8	67.33		250,000	67.33
Total	405,000				280,000

Molina Healthcare, Inc. 2019 Form 10-K | 81

Employee Stock Purchase Plans (“ESPPs”)

In the second quarter of 2019, our stockholders approved the Molina Healthcare, Inc. 2019 Employee Stock Purchase Plan (the “2019 ESPP”), which superseded the Molina Healthcare, Inc. 2011 Employee Stock Purchase Plan (the “2011 ESPP”). A maximum of 3.0 million shares of our common stock may be issued under the 2019 ESPP, the terms of which are substantially similar to the 2011 ESPP. The 2019 ESPP will continue until the earliest of: termination of the 2019 ESPP by the board of directors (which may occur at any time); issuance of all of the shares reserved for issuance under the 2019 ESPP; or May 8, 2029.

Under our ESPPs, eligible employees may purchase common shares at 85% of the lower of the fair market value of our common stock on either the first or last trading day of each six-month offering period. Each participant is limited to a maximum purchase of $25,000 (as measured by the fair value of the stock acquired) per year through payroll deductions. We estimate the fair value of the stock issued using the Black-Scholes option pricing model. For the years ended December 31, 2019, 2018, and 2017, the inputs to this model were as follows: risk-free interest rates of approximately 0.6% to 2.3%; expected volatilities ranging from approximately 31% to 45%, dividend yields of 0%, and an average expected life of 0.5 years. We issued approximately 142,000, 216,000 and 351,000 shares of our common stock under the ESPPs during the years ended December 31, 2019, 2018, and 2017, respectively.

In connection with our employee stock plans, approximately 242,000 shares and 365,000 shares of common stock were purchased or vested, net of shares used to settle employees’ income tax obligations, during the years ended December 31, 2019, and 2018, respectively.

15. Restructuring Costs

Restructuring costs are reported by the same name in the accompanying consolidated statements of operations.

IT Restructuring Plan

Management’s margin recovery plan identified and implemented various profit improvement initiatives. This included the plan to restructure our information technology department (the “IT Restructuring Plan”) in 2018, which is reported in the Other segment. In connection with this plan, in early 2019, we entered into services agreements with an outsourcing vendor who manages certain of our information technology services.

As of December 31, 2019, the IT Restructuring Plan was substantially complete. Under this plan, we incurred cumulative restructuring costs of $12 million, including $7 million of one-time termination benefits and $5 million of other restructuring costs (primarily consulting fees). The final amount of costs incurred is lower than the $20 million we originally estimated and reported in our Annual Report on Form 10-K for the year ended December 31, 2018. Because more of our IT employees transitioned to our outsourcing vendor than originally contemplated, such employees were no longer included in the IT Restructuring Plan, resulting in lower one-time termination costs.

As of December 31, 2018, $6 million was accrued under the IT Restructuring Plan, primarily for one-time termination benefits that require cash settlement. In the year ended December 31, 2019, we incurred $3 million of other restructuring costs, paid $5 million to settle one-time termination benefits, and paid $3 million to settle other restructuring costs. As of December 31, 2019, $1 million was accrued under the IT Restructuring Plan.

2017 Restructuring Plan

As of December 31, 2018, $18 million was accrued for the restructuring and profitability improvement plan approved by the board of directors in June 2017 (the “2017 Restructuring Plan”). In the year ended December 31, 2019, we incurred $3 million of restructuring costs for adjustments to previously recorded lease contract termination costs, and paid $9 million to settle one-time termination and lease contract termination costs. As of December 31, 2019, $12 million was accrued for lease contract termination costs under the 2017 Restructuring Plan. We expect to continue to settle these liabilities through 2025, unless the leases are terminated sooner.

16. Employee Benefit Plans

We sponsor defined contribution 401(k) plans that cover substantially all employees of our company and its subsidiaries. Eligible employees are permitted to contribute up to the maximum amount allowed by law. We generally match up to the first 4% of compensation contributed by employees. Expense recognized in connection with our contributions to the 401(k) plans amounted to $28 million, $36 million, and $43 million in the years ended December 31, 2019, 2018, and 2017, respectively.

Molina Healthcare, Inc. 2019 Form 10-K | 82

We also have a non-qualified deferred compensation plan for certain key employees. Under this plan, eligible participants may defer up to 100% of their base salary and 100% of their bonus to provide tax-deferred growth. The funds deferred are invested in corporate-owned life insurance, under a rabbi trust.

17. Commitments and Contingencies

Regulatory Capital Requirements and Dividend Restrictions

Our health plans, which are operated by our respective wholly owned subsidiaries in those states, are subject to state laws and regulations that, among other things, require the maintenance of minimum levels of statutory capital, as defined by each state. The National Association of Insurance Commissioners (“NAIC”), has adopted rules which, if implemented by the states, set minimum capitalization requirements for insurance companies, HMOs, and other entities bearing risk for health care coverage. The requirements take the form of risk-based capital (“RBC”) rules which may vary from state to state. All of the states in which our health plans operate, except California, Florida and New York, have adopted these rules. Such requirements, if adopted by California, Florida and New York, may increase the minimum capital required for those states. Regulators in some states may also enforce capital requirements that require the retention of net worth in excess of amounts formally required by statute or regulation. As of December 31, 2019, our health plans had aggregate statutory capital and surplus of approximately $1,852 million compared with the required minimum aggregate statutory capital and surplus of approximately $1,110 million. All of our health plans were in compliance with the minimum capital requirements at December 31, 2019. We have the ability and commitment to provide additional capital to each of our health plans when necessary to ensure that statutory capital and surplus continue to meet regulatory requirements.

Such statutes, regulations and informal capital requirements also restrict the timing, payment, and amount of dividends and other distributions that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based on current statutes and regulations, the net assets in these subsidiaries (after intercompany eliminations) which may not be transferable to us in the form of loans, advances, or cash dividends was approximately $1,811 million at December 31, 2019, and $2,262 million at December 31, 2018. Because of the statutory restrictions that inhibit the ability of our health plans to transfer net assets to us, the amount of retained earnings readily available to pay dividends to our stockholders is generally limited to cash, cash equivalents and investments held by the parent company – Molina Healthcare, Inc. Such cash, cash equivalents and investments amounted to $997 million and $170 million as of December 31, 2019 and 2018, respectively.

Legal Proceedings

The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously billed and collected revenues.

We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.

Professional Liability Insurance

We carry medical professional liability insurance for health care services rendered in the primary care institutions that we manage. In addition, we also carry errors and omissions insurance for all Molina entities.

18. Segments

Molina Healthcare, Inc. 2019 Form 10-K | 83

segment, which was insignificant to our consolidated results of operations in 2018 and 2019, includes the historical results of the MMIS and behavioral health subsidiaries we sold in late 2018, as well as certain corporate amounts not allocated to the Health Plans segment.

Margin is the appropriate earnings measure for our reportable segments, based on how our chief operating decision maker currently reviews results, assesses performance, and allocates resources.

The key metrics used to assess the performance of our Health Plans segment are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying margin, or the amount earned by the Health Plans segment after medical costs are deducted from premium revenue, is the most important measure of earnings reviewed by management. Margin for our Health Plans segment is referred to as “Medical Margin.”



	Health Plans		Other		Consolidated
	(In millions)
2019
Total revenue	$	16,815	$	14	16,829
Margin	2,303		—		2,303
Goodwill, and intangible assets, net	172		—		172
Total assets	5,265		1,522		6,787
2018
Total revenue	$	18,471	$	419	$	18,890
Margin	2,475		43		2,518
Goodwill, and intangible assets, net	190		—		190
Total assets	6,165		989		7,154
2017
Total revenue	$	19,352	$	531	$	19,883
Margin	1,781		29		1,810
Goodwill, and intangible assets, net	212		43		255
Total assets	6,347		2,124		8,471

The following table reconciles margin by segment to consolidated income (loss) before income tax expense (benefit):



	Year Ended December 31,
	2019			2018			2017
	(In millions)
Margin:
Health Plans	$	2,303		$	2,475		$	1,781
Other	—			43			29
Total margin	2,303			2,518			1,810
Add: other operating revenues ⁽¹⁾	621			871			508
Less: other operating expenses ⁽²⁾	(1,880		)	(2,243		)	(2,873		)
Less: loss on sales of subsidiaries, net of gain	—			(15		)	—
Operating income (loss)	1,044			1,131			(555		)
Less: other expenses, net	72			132			57
Income (loss) before income tax expense (benefit)	$	972		$	999		$	(612	)

______________________


(1)	Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income and other revenue.


(2)	Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, impairment losses, and restructuring costs.

Molina Healthcare, Inc. 2019 Form 10-K | 84

19. Quarterly Results of Operations (Unaudited)

The following table summarizes quarterly unaudited results of operations for the periods presented.



	For The Quarter Ended
	March 31, 2019		June 30, 2019		Sept. 30, 2019		December 31, 2019
	(In millions, except per-share data)
Total revenue	$	4,119	$	4,193	$	4,243	$	4,274
Margin	581		583		561		578
Net income	198		196		175		168

Net income per share - Basic ⁽¹⁾	$	3.19	$	3.15	$	2.81	$	2.70
Net income per share - Diluted ⁽¹⁾	$	2.99	$	3.06	$	2.75	$	2.67



	For The Quarter Ended
	March 31, 2018		June 30, 2018		Sept. 30, 2018		December 31, 2018
	(In millions, except per-share data)
Total revenue	$	4,646	$	4,883	$	4,697	$	4,664
Margin	615		673		566		664
Gain (loss) on sales of subsidiaries	—		—		37		(52		)
Net income	107		202		197		201

Net income per share - Basic ⁽¹⁾	$	1.79	$	3.29	$	3.22	$	3.24
Net income per share - Diluted ⁽¹⁾	$	1.64	$	3.02	$	2.90	$	3.01

________________________


(1)	The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method and is based on the weighted-average common share equivalents outstanding during each quarter. Accordingly, the sum of the quarterly net income per share amounts may not agree to the total for the year.

Molina Healthcare, Inc. 2019 Form 10-K | 85

20. Condensed Financial Information of Registrant

The condensed balance sheets as of December 31, 2019 and 2018, and the related condensed statements of operations, comprehensive income (loss) and cash flows for each of the three years in the period ended December 31, 2019 for our parent company Molina Healthcare, Inc. (the “Registrant”), are presented below.

Condensed Balance Sheets



	December 31,
	2019		2018
	(In millions, except per-share data)
ASSETS
Current assets:
Cash and cash equivalents	$	836	$	70
Investments	161		100
Receivables	2		2
Due from affiliates	49		90
Prepaid expenses and other current assets	46		47
Derivative asset	29		476
Total current assets	1,123		785
Property, equipment, and capitalized software, net	327		176
Goodwill and intangible assets, net	13		13
Investments in subsidiaries	2,225		2,768
Deferred income taxes	10		39
Advances to related parties and other assets	76		40
Total assets	$	3,774	$	3,821
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable	$	—	$	4
Accounts payable and accrued liabilities	260		223
Current portion of long-term debt	18		241
Derivative liability	29		476
Total current liabilities	307		944
Long-term debt	1,237		1,020
Finance lease liabilities	231		197
Other long-term liabilities	39		13
Total liabilities	1,814		2,174
Stockholders’ equity:
Common stock, $0.001 par value; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018	—		—
Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding	—		—
Additional paid-in capital	175		643
Accumulated other comprehensive income (loss)	4		(8		)
Retained earnings	1,781		1,012
Total stockholders’ equity	1,960		1,647
Total liabilities and stockholders’ equity	$	3,774	$	3,821

See accompanying notes.

Molina Healthcare, Inc. 2019 Form 10-K | 86

Condensed Statements of Operations



	Year Ended December 31,
	2019			2018			2017
	(In millions)
Revenue:
Administrative services fees	$	1,038		$	1,138		$	1,317
Investment income and other revenue	18			17			16
Total revenue	1,056			1,155			1,333
Expenses:
General and administrative expenses	937			1,007			1,082
Depreciation and amortization	63			69			93
Other operating expenses	—			8			16
Restructuring costs	4			35			153
Impairment losses	—			—			39
Total operating expenses	1,004			1,119			1,383
Gain on sale of subsidiary	—			37			—
Operating income (loss)	52			73			(50		)
Interest expense	87			114			117
Other (income) expense, net	(15		)	17			(61		)
Loss before income tax (benefit) expense and equity in net earnings (losses) of subsidiaries	(20		)	(58		)	(106		)
Income tax expense (benefit)	9			(14		)	8
Net loss before equity in net earnings (losses) of subsidiaries	(29		)	(44		)	(114		)
Equity in net earnings (losses) of subsidiaries	766			751			(398		)
Net income (loss)	$	737		$	707		$	(512	)

Condensed Statements of Comprehensive Income (Loss)



	Year Ended December 31,
	2019		2018			2017
	(In millions)
Net income (loss)	$	737	$	707		$	(512	)
Other comprehensive income (loss):
Unrealized investment income (loss)	16		(3		)	(5		)
Less: effect of income taxes	4		(1		)	(2		)
Other comprehensive income (loss), net of tax	12		(2		)	(3		)
Comprehensive income (loss)	$	749	$	705		$	(515	)

See accompanying notes.

Molina Healthcare, Inc. 2019 Form 10-K | 87

Condensed Statements of Cash Flows



	Year Ended December 31,
	2019			2018			2017
	(In millions)
Operating activities:
Net cash provided by operating activities	$	64		$	118		$	166
Investing activities:
Capital contributions to subsidiaries	(43		)	(145		)	(370		)
Dividends received from subsidiaries	1,373			298			286
Purchases of investments	(152		)	(136		)	(331		)
Proceeds from sales and maturities of investments	93			388			156
Purchases of property, equipment and capitalized software	(56		)	(22		)	(67		)
Net cash received from sale of subsidiaries	—			242			—
Change in amounts due to/from affiliates	38			6			(49		)
Other, net	1			—			—
Net cash provided by (used in) investing activities	1,254			631			(375		)
Financing activities:
Repayment of principal amount of convertible notes	(240		)	(362		)	—
Cash paid for partial settlement of conversion option	(578		)	(623		)	—
Cash received for partial settlement of call option	578			623			—
Cash paid for partial termination of warrants	(514		)	(549		)	—
Proceeds from borrowings under term loan facility	220			—			—
Common stock purchases	(47		)	—			—
Repayment of credit facility	—			(300		)	—
Proceeds from senior notes offerings, net of issuance costs	—			—			325
Proceeds from borrowings under credit facility	—			—			300
Other, net	29			19			11
Net cash (used in) provided by financing activities	(552		)	(1,192		)	636
Net (decrease) increase in cash and cash equivalents	766			(443		)	427
Cash and cash equivalents at beginning of period	70			513			86
Cash and cash equivalents at end of period	$	836		$	70		$	513

See accompanying notes.

Notes to Condensed Financial Information of Registrant

Note A - Basis of Presentation

The Registrant was incorporated in 2002. Prior to that date, Molina Healthcare of California (formerly known as Molina Medical Centers) operated as a California health plan and as the parent company for three other state health plans. In June 2003, the employees and operations of the corporate entity were transferred from Molina Healthcare of California to the Registrant.

The Registrant’s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries since the date of acquisition. The accompanying condensed financial information of the Registrant should be read in conjunction with the consolidated financial statements and accompanying notes.

Note B - Transactions with Subsidiaries

The Registrant provides certain centralized medical and administrative services to our subsidiaries pursuant to administrative services agreements that include, but are not limited to, information technology, product development and administration, underwriting, claims processing, customer service, certain care management services, human resources, marketing, purchasing, risk management, actuarial, underwriting, finance, accounting, legal and public

Molina Healthcare, Inc. 2019 Form 10-K | 88

relations. Fees are based on the fair market value of services rendered and are recorded as operating revenue. Payment is subordinated to the subsidiaries’ ability to comply with minimum capital and other restrictive financial requirements of the states in which they operate. Charges in 2019, 2018, and 2017 for these services amounted to $1,038 million, $1,137 million, and $1,317 million, respectively, and are included in operating revenue.

The Registrant and its subsidiaries are included in the consolidated federal and state income tax returns filed by the Registrant. Income taxes are allocated to each subsidiary in accordance with an intercompany tax allocation agreement. The agreement allocates income taxes in an amount generally equivalent to the amount which would be expensed by the subsidiary if it filed a separate tax return. Net operating loss benefits are paid to the subsidiary by the Registrant to the extent such losses are utilized in the consolidated tax returns.

Note C - Dividends and Capital Contributions

When the Registrant receives dividends from its subsidiaries, such amounts are recorded as a reduction to the investments in the respective subsidiaries.

For all periods presented, the Registrant made capital contributions to certain subsidiaries primarily to comply with minimum net worth requirements and to fund business combinations. Such amounts have been recorded as an increase in investment in the respective subsidiaries.

Molina Healthcare, Inc. 2019 Form 10-K | 89

CONTROLS AND PROCEDURES

MANAGEMENT’S EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), that are designed to provide reasonable assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of any possible controls and procedures.

Under the supervision and with the participation of our management, including our chief executive officer and our chief financial officer, we carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Form 10-K pursuant to Rule 13a-15(b) and Rule 15d-15(b) of the Exchange Act. Based on this evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2019, at the reasonable assurance level. In addition, management concluded that our consolidated financial statements included in this Annual Report on Form 10-K are fairly stated in all material respects in accordance with U.S. generally accepted accounting principles (“GAAP”) for each of the periods presented herein.

MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our financial statements.

Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness of our internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management concluded that we maintained effective internal control over financial reporting as of December 31, 2019, based on criteria described in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

Ernst & Young, LLP, the independent registered public accounting firm who audited our Consolidated Financial Statements included in this Form 10-K, has issued a report on our internal control over financial reporting, which is included herein.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) during the quarter ended December 31, 2019, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Molina Healthcare, Inc. 2019 Form 10-K | 90

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of Molina Healthcare, Inc.

Opinion on Internal Control over Financial Reporting

We have audited Molina Healthcare, Inc.’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the “COSO criteria”). In our opinion, Molina Healthcare, Inc. (the “Company”) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets of the Company as of December 31, 2019 and 2018 and the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and our report dated February 14, 2020, expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ ERNST & YOUNG LLP

Los Angeles, California

February 14, 2020

Molina Healthcare, Inc. 2019 Form 10-K | 91

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of Molina Healthcare, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Molina Healthcare, Inc. (the “Company”) as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity and cash flows, for each of the three years in the period ended December 31, 2019, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 14, 2020 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company‘s management. Our responsibility is to express an opinion on the Company‘s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Valuation of incurred but not paid fee-for-service claims

Description of the Matter

As of December 31, 2019, the Company’s liability for fee-for-service claims incurred but not paid (“IBNP”) comprised $1,406 million of the $1,854 million of Medical Claims and Benefits Payable. As discussed in Note 10 to the consolidated financial statements, the Company’s IBNP liability is determined using actuarial methods that include a number of factors and assumptions, including completion factors, which seek to measure the cumulative percentage of claims expense that will have been paid for a given month of service as of the reporting date, based on historical payment patterns, and assumed health care cost trend factors, which represent an estimate of claims expense based on recent claims expense levels and healthcare cost levels. There is a significant uncertainty inherent in determining management’s best estimate of completion and trend factors, w

Molina Healthcare, Inc. 2019 Form 10-K | 92

hich are used to calculate actuarial estimates of incurred but not paid claims.

Auditing management’s best estimate of the IBNP liability was complex and required the involvement of our actuarial specialists due to the highly judgmental nature of completion and trend factor assumptions used in the valuation process. These assumptions have a significant effect on the valuation of the IBNP liability.

How We Addressed the Matter in Our Audit

We obtained an understanding, evaluated the design, and tested the operating effectiveness of the Company’s controls over the process for estimating the IBNP liability. This included testing management review controls over completion and trend factor assumptions, and management’s review and approval of actuarial methods used to calculate IBNP liability, including the data inputs and outputs of those models.

To test IBNP liability, our audit procedures included, among others, testing the completeness and accuracy of data used in the calculation by testing reconciliations of underlying claims and membership data recorded in source systems to the actuarial reserving calculations, and comparing a sample of claims to source documentation. With the assistance of EY actuarial specialists, we evaluated the Company’s selection and weighting of actuarial methods by comparing the weightings used in the current estimate to those used in prior periods and those used in the industry for the specific types of insurance. To evaluate significant assumptions used by management in the actuarial methods, we compared assumptions to current and historical claims trends, to those used historically and to current industry benchmarks. We also compared management’s recorded IBNP liability to a range of reasonable IBNP estimates calculated independently by our EY actuarial specialists. Additionally, we performed a review of the prior period estimates using subsequent claims development, and we reviewed and evaluated management’s disclosures surrounding fee-for-service claims IBNP.

/s/ ERNST & YOUNG LLP

We have served as the Company’s auditor since 2000.

Los Angeles, California

February 14, 2020

Molina Healthcare, Inc. 2019 Form 10-K | 93

OTHER INFORMATION

None.

DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

Information required by Item 10 of Part III will be included in our Proxy Statement relating to our 2020 Annual Meeting of Stockholders, and is incorporated herein by reference. This information is included in the following sections of the Proxy Statement:


•	PROPOSAL 1 - Election of Directors


•	Information About Director Nominees


•	Information About Directors Continuing in Office


•	Additional Information About Directors


•	Corporate Governance and Board of Directors Matters


•	Information About the Executive Officers of the Company


•	Section 16(a) Beneficial Ownership Reporting Compliance

Information relating to our Code of Business Conduct and Ethics and compliance with Section 16(a) of the 1934 Act is set forth in our Proxy Statement relating to our 2020 Annual Meeting of Stockholders and is incorporated herein by reference. To the extent permissible under NYSE rules, we intend to disclose amendments to our Code of Business Conduct and Ethics, as well as waivers of the provisions thereof, on our investor relations website under the heading “Investor Information—Corporate Governance” at molinahealthcare.com.

EXECUTIVE COMPENSATION

Information required by Item 11 of Part III will be included in our Proxy Statement relating to our 2020 Annual Meeting of Stockholders in the section entitled “Executive Compensation,” and is incorporated herein by reference.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS

Information required by Item 12 of Part III will be included in our Proxy Statement relating to our 2020 Annual Meeting of Stockholders in the section entitled “Security Ownership of Certain Beneficial Owners and Management,” and is incorporated herein by reference.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Information required by Item 13 of Part III will be included in our Proxy Statement relating to our 2020 Annual Meeting of Stockholders in the sections entitled “Related Party Transactions,” and “Corporate Governance and Board of Directors Matters—Director Independence,” and is incorporated herein by reference.

PRINCIPAL ACCOUNTANT FEES AND SERVICES

Information required by Item 14 of Part III will be included in our Proxy Statement relating to our 2020 Annual Meeting of Stockholders in the section entitled “Fees Paid to Independent Registered Public Accounting Firm,” and is incorporated herein by reference.

Molina Healthcare, Inc. 2019 Form 10-K | 94

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA


(1)	The consolidated financial statements are included in this report in the section entitled “Financial Statements and Supplementary Data.”


(2)	Financial Statement Schedules:

Schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions, are inapplicable, or the required information is included in the consolidated financial statements, and therefore have been omitted.

EXHIBITS

Reference is made to the accompanying “Index to Exhibits.”

Molina Healthcare, Inc. 2019 Form 10-K | 95

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the undersigned registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 14th day of February, 2020.



	MOLINA HEALTHCARE, INC.

	By:		/s/ Joseph M. Zubretsky
			Joseph M. Zubretsky
			Chief Executive Officer (Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities as indicated, as of February 14, 2020.



Signature		Title

/s/ Joseph M. Zubretsky		Chief Executive Officer, President and Director
Joseph M. Zubretsky		(Principal Executive Officer)

/s/ Thomas L. Tran		Chief Financial Officer and Treasurer
Thomas L. Tran		(Principal Financial Officer)

/s/ Maurice S. Hebert		Chief Accounting Officer
Maurice S. Hebert		(Principal Accounting Officer)

/s/ Garrey E. Carruthers		Director
Garrey E. Carruthers, Ph.D.

/s/ Daniel Cooperman		Director
Daniel Cooperman

/s/ Barbara L. Brasier		Director
Barbara L. Brasier

/s/ Steven J. Orlando		Director
Steven J. Orlando

/s/ Ronna E. Romney		Director
Ronna E. Romney

/s/ Richard M. Schapiro		Director
Richard M. Schapiro

/s/ Dale B. Wolf		Chairman of the Board
Dale B. Wolf

/s/ Richard C. Zoretic		Director
Richard C. Zoretic

Molina Healthcare, Inc. 2019 Form 10-K | 96

INDEX TO EXHIBITS

The following exhibits, which are furnished with this Annual Report on Form 10-K (this “Form 10-K”) or incorporated herein by reference, are filed as part of this annual report.

The agreements included or incorporated by reference as exhibits to this Form 10-K may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties were made solely for the benefit of the other parties to the applicable agreement and (i) were not intended to be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii) may have been qualified in such agreement by disclosures that were made to the other party in connection with the negotiation of the applicable agreement; (iii) may apply contract standards of “materiality” that are different from “materiality” under the applicable securities laws; and (iv) were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement. The Company acknowledges that, notwithstanding the inclusion of the foregoing cautionary statements, it is responsible for considering whether additional specific disclosures of material information regarding material contractual provisions are required to make the statements in this Form 10-K not misleading.



Number	Description	Method of Filing
2.1	Purchase and Sale Agreement, dated as of June 26, 2018, by and between Molina Healthcare, Inc. and DXC Technology Company**	Filed as Exhibit 2.1 to registrant’s Form 8-K filed June 27, 2018
3.1	Certificate of Incorporation	Filed as Exhibit 3.2 to registrant’s Registration Statement on Form S-1 filed December 30, 2002
3.2	Certificate of Amendment to Certificate of Incorporation	Filed as Appendix A to registrant’s Definitive Proxy Statement on Form DEF 14A filed March 25, 2013
3.3	Certificate of Amendment to Certificate of Incorporation	Filed as Appendix A to registrant’s Definitive Proxy Statement on Form DEF 14A filed March 25, 2019
3.4	Sixth Amended and Restated Bylaws of Molina Healthcare, Inc.	Filed as Exhibit 3.3 to registrant’s Form 10-K filed February 19, 2019
4.1	Indenture dated November 10, 2015, by and among Molina Healthcare, Inc., the guarantor parties thereto and U.S. Bank National Association, as Trustee	Filed as Exhibit 4.1 to registrant’s Form 8-K filed November 10, 2015
4.2	Form of 5.375% Senior Notes due 2022	Filed as Exhibit 4.1 to registrant’s Form 8-K filed November 10, 2015
4.3	Form of Guarantee pursuant to Indenture, dated as of November 10, 2015, by and among Molina Healthcare, Inc., the guarantors party thereto and U.S. Bank National Association, as Trustee	Filed as Exhibit 4.1 to registrant’s Form 8-K filed November 10, 2015
4.4	First Supplemental Indenture, dated as of February 16, 2016, by and among Molina Healthcare, Inc., the guarantors party thereto and U.S. Bank National Association, as Trustee	Filed as Exhibit 4.1 to registrant’s Form 8-K filed February 18, 2016
4.5	Indenture, dated June 6, 2017, by and among Molina Healthcare, Inc., the Guarantors party thereto and U.S. Bank National Association, as Trustee	Filed as Exhibit 1.1 to registrant’s Form 8-K filed June 6, 2017
4.6	Form of 4.875% Senior Notes (included in Exhibit 4.1 to registrant’s Form 8-K filed June 6, 2017).	Filed as Exhibit 1.1 to registrant’s Form 8-K filed June 6, 2017
4.7	Form of Guarantees (included in Exhibit 4.1 to registrant’s Form 8-K filed June 6, 2017)	Filed as Exhibit 1.1 to registrant’s Form 8-K filed June 6, 2017
10.1	Base Warrants Confirmation, dated as of February 11, 2013, between Molina Healthcare, Inc. and JPMorgan Chase Bank, National Association, London Branch	Filed as Exhibit 10.3 to registrant’s Form 8-K filed February 15, 2013
10.2	Base Warrants Confirmation, dated as of February 11, 2013, between Molina Healthcare, Inc. and Bank of America, N.A.	Filed as Exhibit 10.4 to registrant’s Form 8-K filed February 15, 2013
10.3	Additional Base Warrants Confirmation, dated as of February 13, 2013, between Molina Healthcare, Inc. and JPMorgan Chase Bank, National Association, London Branch	Filed as Exhibit 10.7 to registrant’s Form 8-K filed February 15, 2013
10.4	Additional Base Warrants Confirmation, dated as of February 13, 2013, between Molina Healthcare, Inc. and Bank of America, N.A.	Filed as Exhibit 10.8 to registrant’s Form 8-K filed February 15, 2013

Molina Healthcare, Inc. 2019 Form 10-K | 97



Number	Description	Method of Filing
10.5	Amended and Restated Base Warrants Confirmation, dated as of April 22, 2013, between Molina Healthcare, Inc. and JPMorgan Chase Bank, National Association, London Branch	Filed as Exhibit 10.1 to registrant’s Form 10-Q filed May 3, 2013
10.6	Amended and Restated Base Warrants Confirmation, dated as of April 22, 2013, between Molina Healthcare, Inc. and Bank of America, N.A.	Filed as Exhibit 10.2 to registrant’s Form 10-Q filed May 3, 2013
10.7	Additional Amended and Restated Base Warrants Confirmation, dated as of April 22, 2013, between Molina Healthcare, Inc. and JPMorgan Chase Bank, National Association, London Branch	Filed as Exhibit 10.3 to registrant’s Form 10-Q filed May 3, 2013
10.8	Additional Amended and Restated Base Warrants Confirmation, dated as of April 22, 2013, between Molina Healthcare, Inc. and Bank of America, N.A.	Filed as Exhibit 10.4 to registrant’s Form 10-Q filed May 3, 2013
10.9	Sixth Amendment to Credit Agreement, dated as of January 31, 2019, by and among Molina Healthcare, Inc., the Guarantors party thereto, the Lenders party thereto and SunTrust Bank, in its capacity as Administrative Agent, including the amended and restated Credit Agreement attached as Exhibit A thereto, the amended and restated Schedule I to the Credit Agreement attached as Exhibit B thereto and the amended and restated Exhibit 2.5 to the Credit Agreement attached as Exhibit C thereto	Filed as Exhibit 10.1 to registrant’s Form 8-K filed January 31, 2019
*10.10	Molina Healthcare, Inc. 2011 Employee Stock Purchase Plan	Filed as Exhibit 10.6 to registrant’s Form 10-K filed February 26, 2015
*10.11	Molina Healthcare, Inc. 2011 Equity Incentive Plan	Filed as Exhibit 10.8 to registrant’s Form 10-K filed February 26, 2014
*10.12	2011 Equity Incentive Plan - Form of Stock Option Agreement (Director)	Filed as Exhibit 10.2 to registrant’s Form 10-Q filed May 4, 2017
*10.13	2011 Equity Incentive Plan - Form of Restricted Stock Award Agreement (Employee)	Filed as Exhibit 10.3 to registrant’s Form 10-Q filed May 4, 2017
*10.14	2011 Equity Incentive Plan - Form of Performance Unit Award Agreement 1 (Executive Officer)	Filed as Exhibit 10.4 to registrant’s Form 10-Q filed May 4, 2017
*10.15	2011 Equity Incentive Plan - Form of Performance Unit Award Agreement 2 (Executive Officer)	Filed as Exhibit 10.5 to registrant’s Form 10-Q filed May 4, 2017
*10.16	2019 Employee Stock Purchase Plan	Filed as Appendix B to registrant’s Definitive Proxy Statement on Form DEF 14A filed March 25, 2019
*10.17	Molina Healthcare, Inc. 2019 Equity Incentive Plan	Filed as Appendix B to registrant’s Definitive Proxy Statement on Form DEF 14A filed March 25, 2019
*10.18	2019 Equity Incentive Plan - Form of Restricted Stock Award Agreement (Employee/Officer with No Employment Agreement)	Filed as Exhibit 10.1 to registrant’s Form 10-Q filed July 31, 2019
*10.19	2019 Equity Incentive Plan - Form of Performance Stock Unit Award Agreement (Employee/Officer with No Employment Agreement)	Filed as Exhibit 10.2 to registrant’s Form 10-Q filed July 31, 2019
*10.20	2019 Equity Incentive Plan - Form of Restricted Stock Award Agreement (Officer with Employment Agreement)	Filed as Exhibit 10.3 to registrant’s Form 10-Q filed July 31, 2019
*10.21	2019 Equity Incentive Plan - Form of Performance Stock Unit Award Agreement (Officer with Employment Agreement)	Filed as Exhibit 10.4 to registrant’s Form 10-Q filed July 31, 2019
*10.22	Molina Healthcare, Inc. Amended and Restated Change in Control Severance Plan	Filed as Exhibit 10.1 to registrant’s Form 10-K filed February 19, 2019
*10.23	Form of Indemnification Agreement	Filed as Exhibit 10.14 to registrant’s Form 10-K filed March 14, 2007
*10.24	Molina Healthcare, Inc. Amended and Restated Deferred Compensation Plan (2018)	Filed as Exhibit 10.2 to registrant’s Form 10-Q filed August 1, 2018
*10.25	Amendment No. One to the Molina Healthcare, Inc. Amended and Restated Deferred Compensation Plan (2018)	Filed herewith
*10.26	Employment Agreement with Jeff Barlow dated June 14, 2013	Filed as Exhibit 10.3 to registrant’s Form 8-K filed June 14, 2013
*10.27	Change in Control Agreement with Jeff D. Barlow, dated as of September 18, 2012	Filed as Exhibit 10.16 to registrant’s Form 10-K filed February 28, 2013

Molina Healthcare, Inc. 2019 Form 10-K | 98



Number	Description	Method of Filing
*10.28	Employment Agreement, dated October 9, 2017, by and between Molina Healthcare, Inc. and Joseph M. Zubretsky	Filed as Exhibit 10.1 to registrant’s Form 8-K filed October 10, 2017
*10.29	Offer Letter, dated May 4, 2018, by and between Molina Healthcare, Inc. and Thomas L. Tran	Filed as Exhibit 10.1 to registrant’s Form 8-K filed May 24, 2018
+10.30	Master Services Agreement for Information Technology Services, dated February 4, 2019, by and between Molina Healthcare, Inc. and Infosys Limited	Filed as Exhibit 10.36 to registrant’s Form 10-K filed February 19, 2019
10.31	First Amendment, dated August 1, 2019, to the Master Services Agreement for Information Technology Services, dated February 4, 2019, by and between Molina Healthcare, Inc. and Infosys Limited	Filed as Exhibit 10.1 to registrant’s Form 10-Q filed October 30, 2019
21.1	List of subsidiaries	Filed herewith
23.1	Consent of Independent Registered Public Accounting Firm	Filed herewith
31.1	Section 302 Certification of Chief Executive Officer	Filed herewith
31.2	Section 302 Certification of Chief Financial Officer	Filed herewith
32.1	Certificate of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith
32.2	Certificate of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith
101.INS	XBRL Taxonomy Instance Document	Filed herewith
101.SCH	XBRL Taxonomy Extension Schema Document	Filed herewith
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith
101.LAB	XBRL Taxonomy Extension Label Linkbase Document	Filed herewith
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith



*	Management contract or compensatory plan or arrangement required to be filed (and/or incorporated by reference) as an exhibit to this Annual Report on Form 10-K pursuant to Item 15(b) of Form 10-K.
**	Certain schedules and exhibits to this agreement have been omitted in accordance with Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.
+	Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange Commission under Rule 24b-2. The omitted confidential material has been filed separately. The location of the redacted confidential information is indicated in the exhibit as “[redacted]”.

Molina Healthcare, Inc. 2019 Form 10-K | 99

EX-10.25 2 moh-12312019xex1025.htm EXHIBIT 10.25 Exhibit

AMENDMENT NO. ONE

TO THE

MOLINA HEALTHCARE, INC.

AMENDED AND RESTATED

DEFERRED COMPENSATION PLAN (2018)

Section 7 of the Molina Healthcare, Inc. Amended and Restated Deferred Compensation Plan (2018) effective for amounts earned and deferred on or after January 1, 2018 (the “Plan”) allows Molina Healthcare, Inc. (the “Company”) to amend the terms of the Plan, at any time by resolution of the Plan Committee. Accordingly, the Plan Committee amends the Plan as follows, effective, unless otherwise specified herein, for Written Elections for amounts earned and deferred on or after January 1, 2020.


1.	A new Section 1.8 is added to read as follows:

“Eligible Employee means a Key Employee who has been designated by the Plan Committee or its designee as eligible to participate in the Plan.”


2.	Existing Sections 1.8 through 1.15 are renumbered as Sections 1.9 through 1.16 and references to such sections in the remainder of the Plan are updated accordingly.


3.	Section 1.9, as renumbered, is amended to read as follows:

“Key Employee means an employee of the Company or a Subsidiary, who is (A) a member of a select group of management or highly compensated employees within the meaning of §2520.104-23 of the Department of Labor Regulations, and (B) projected to receive Plan Year Compensation (base pay plus bonus), plus amounts deferred to any 401(k) plan, deferred compensation plan, or cafeteria plan maintained by the Company, of $200,000 or more.”


4.	Section 1.10, as renumbered, is amended to read as follows:

“Participant means (A) an Eligible Employee who timely files a Written Election pursuant to Section 2.3, below, and (B) a former employee who, at the time of his Separation from Service, death, or Disability, retains, or whose beneficiary retains, benefits earned under the Plan in accordance with its terms. A Participant is considered an Active Participant in the Plan (even if the Participant no longer satisfies the requirements of Section 1.9(B) but subject to the right of the Plan Committee or its designee to no longer designate such employee as an Eligible Employee) until the Participant separates from service under the terms of this Plan.”


5.	Section 1.14, as renumbered, is amended to read as follows:

“Plan Year Compensation means base salary, annual bonus, commissions, PTO cashout and other cash compensation earned during the Plan Year (or portion thereof in which the Eligible Employee is a Participant in this Plan) other than reimbursements and expense allowances, cash stipends, sign-on bonus, relocation bonus and retention bonus. Plan Year Compensation excludes all equity-based compensation.”


6.	Section 1.16, as renumbered, is deleted.


7.	Section 1.19 is amended to read as follows:

“Trustee means the institutional trustee under the terms of the Trust Agreement established in connection with this Plan.”


8.	Section 2.1 is amended to read as follows:

“Eligibility. Employees who are newly designated as Eligible Employees will be provided written notice of eligibility and enrollment materials for entry into the Plan. A Participant will remain eligible to participate in the Plan for each subsequent Plan Year unless notified otherwise by the Plan Committee.”


9.	Section 2.2 is amended to read as follows:

“Entry Date. An Eligible Employee becomes a Participant on the first day of the calendar quarter immediately following receipt of notice of eligibility; provided, that, the Eligible Employee timely submits a Written Election in accordance with Section 2.3. An Eligible Employee who fails to meet the requirements of Section 2.3 shall become a Participant on the first day of the next Plan Year following timely submission of a Written Election as specified in Section 2.3.”


10.	The first paragraph of Section 2.3 is amended to read as follows:

“Written Election by Participant. A newly Eligible Employee may defer Plan Year Compensation to be earned in the same Plan Year of his or her initial eligibility by submitting a Written Election in accordance with the procedures approved by the Plan Committee not later than 30 days after he or she first receives enrollment materials under Section 2.1. Such election becomes irrevocable on the 30th day after he or she first receives enrollment materials and is effective for the first payroll period beginning in the next calendar quarter. To the extent the election applies to an item of Plan Year Compensation earned over more than one payroll period that commenced prior to the beginning of such calendar quarter, the maximum deferrable amount of such Plan Year Compensation is a fraction of such compensation with the numerator equal to the number of days from the beginning of the calendar quarter in which the Written Election is effective and the denominator is the total number of days in the service period. In no event will the amount of an item of deferrable Plan Year Compensation exceed the limits set forth in Section 3.1.

All Participants may submit Written Elections applicable to Plan Year Compensation earned in the next following Plan Year by submitting Written Elections no later than the last day of the current Plan Year. A Written Election applicable to Plan Year Compensation earned over more than one Plan Year shall be made before the Plan Year in which the service period applicable to such Plan Year Compensation begins and shall remain in effect for all Plan Years in which the related services are performed. Elections for the next Plan Year become irrevocable on the last day of the current Plan Year.

In order to be valid for purposes of Code Section 409A, all Written Elections must contain the items set forth in Section 2.3(a), except subparagraph (iii); provided, however, a Participant’s initial election in Section 2.3(a) subparagraphs (iv) and (v) shall remain in effect for all subsequent Plan Years unless changed in accordance with Section 2.3(e). Valid elections (those meeting the requirements of this Section 2.3) are referred to herein as ‘Written Elections’.”


11.	Section 2.3(a) is amended to read as follows:


“a.	Such Written Election shall be made on the form presented to the Participant by the Plan Committee or its designee and shall set forth:


i.	his election to participate in this Plan under the terms hereof;


ii.	the amount of Plan Year Compensation the Participant has determined to defer under the Plan for the Plan Year, pursuant to Section 3.1 below;


iii.	the investment vehicles into which the Participant desires to have his Account attributable to deferral of Plan Year Compensation invested, as provided in Section 3.5 below, and the percentage of such Account allocated to each elected investment vehicle;


iv.	the date on which distribution of his benefit is to be made or commence, which is the earlier of: (a) the date specified for an In-Service Withdrawal; or (b) the date he separates from service with the Company or a Subsidiary for any reason; and


v.	the form in which his benefit is to be distributed upon an In-Service Withdrawal, Separation from Service, Disability or death.”


12.	Section 2.3(b) is amended to read as follows:

“Beginning with the 2020 enrollment for the 2021 Plan Year, Written Elections will continue in effect for subsequent Plan Years, unless revoked or modified in writing by the Participant or the Plan Committee prior to the last day of the current Plan Year.

A Written Election is deemed to be revoked for a subsequent Plan Year if the Participant is notified in writing prior to the last day of the current Plan Year that he or she is no longer an Eligible Employee. Written Elections shall be irrevocable on and after the first day of the Plan Year for which the election was made, unless the Written Election is cancelled during the current Plan Year due to an Unforeseeable Financial Emergency in accordance with Section 5.5.”


13.	Section 2.4 is amended to read as follows:

“Duration of Participation. Any Eligible Employee who has become a Participant at any time shall remain a Participant, even though he is no longer an Active Participant, until his entire benefit under the terms of the Plan has been paid to him (or to his Beneficiary in the event of his death), at which time he ceases to be a Participant.”


14.	The first sentence of Section 3.1 is amended to read as follows:

“A Participant may elect to defer (i) up to 75% of Plan Year Compensation consisting of base pay and PTO cashout (referred to herein as “base pay”) and (ii) up to 90% of all other Plan Year Compensation (referred to herein as “bonus pay”).”


15.	Section 3.3 is amended to read as follows:

“Allocation of Participant Contributions. All amounts which a Participant elects to defer under the terms of this Plan shall be allocated to his Account as of the payroll date on which such amounts

otherwise would have been paid. Each such Participant Deferral Account shall be credited with earnings as provided in Section 3.5 below.”


16.	Section 6.2(a) is amended to read as follows:

“Separation from Service Benefit, Disability Benefit, and Death Benefit payments shall commence no later than sixty-five (65) days following the date on which the Participant retires, terminates service, becomes disabled, or dies; provided, however, any election made by a Participant prior to January 1, 2020 to have his Separation from Service Benefit distributions commence on a specified date subsequent to his termination of employment shall commence on such date;”


17.	Section 6.4 is amended to read as follows:

“Limited Cashout. Notwithstanding any Written Election made by the Participant, if, upon the Participant’s Separation from Service, such Participant’s accrued benefit under the Plan (and any other deferred compensation plan required to be aggregated with this Plan) does not exceed the then-current limit under Section 402(g)(1)(B) of the Code, the Company shall distribute such Participant’s accrued benefit under the Plan in a single lump sum payment to the Participant (or the Beneficiary, if the Participant is deceased) within sixty-five (65) days following the Participant’s Separation from Service, provided that such distribution results in a termination and complete liquidation of such Participant’s interest under the Plan (and any other deferred compensation plan required to be aggregated by this Plan).”

Except as amended hereby, the terms of the Plan shall remain in full force and effect.

MOLINA HEALTHCARE, INC.

By: /s/ Joseph M. Zubretsky

Name: Joseph M. Zubretsky

Title: President and Chief Executive Officer

EX-22.1 3 moh-12312019xex211.htm EXHIBIT 22.1 Exhibit

EXHIBIT 21.1

LIST OF SUBSIDIARIES



Name	Jurisdiction of Incorporation
Blitz IL MergeSub, Inc.*	Delaware
Molina Healthcare Data Center, LLC	New Mexico
Molina Healthcare of Arizona, Inc.*	Arizona
Molina Healthcare of California	California
Molina Healthcare of Florida, Inc.	Florida
Molina Healthcare of Georgia, Inc.*	Georgia
Molina Healthcare of Illinois, Inc.	Illinois
Molina Healthcare of Kentucky, Inc.*	Kentucky
Molina Healthcare of Louisiana, Inc.*	Louisiana
Molina Healthcare of Maryland, Inc.*	Maryland
Molina Healthcare of Michigan, Inc.	Michigan
Molina Healthcare of Mississippi, Inc.	Mississippi
Molina Healthcare of Nevada, Inc.*	Nevada
Molina Healthcare of New Mexico, Inc.	New Mexico
Molina Healthcare of New York, Inc.	New York
Molina Healthcare of North Carolina, Inc.*	North Carolina
Molina Healthcare of Ohio, Inc.	Ohio
Molina Healthcare of Oklahoma, Inc.*	Oklahoma
Molina Healthcare of Pennsylvania, Inc.*	Pennsylvania
Molina Healthcare of Puerto Rico, Inc.	Puerto Rico/Nevada
Molina Healthcare of South Carolina, Inc.	South Carolina
Molina Healthcare of Tennessee, Inc.*	Tennessee
Molina Healthcare of Texas, Inc.	Texas
Molina Healthcare of Texas Insurance Company	Texas
Molina Healthcare of Utah, Inc.	Utah
Molina Healthcare of Virginia, Inc.*	Virginia
Molina Healthcare of Washington, Inc.	Washington
Molina Healthcare of Wisconsin, Inc.	Wisconsin
Molina Clinical Services, LLC	Delaware
Molina Holdings Corporation*	New York
Molina Hospital Management, LLC	California
Molina Pathways, LLC	Delaware
Molina Care Connections, LLC+	Texas
Molina Youth Academy*	California
Oceangate Reinsurance, Inc.*	Utah
Pathways Community Corrections, LLC	Delaware


*	Non-operational entity


+	Wholly owned subsidiary of Molina Pathways, LLC

EX-23.1 4 moh-12312019ex231.htm EXHIBIT 23.1 Exhibit

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:


1.	Registration Statement (Form S-3 No. 333-204558) of Molina Healthcare, Inc.;


2.	Registration Statement (Form S-8 No. 333-174912) pertaining to the Molina Healthcare, Inc. 2011 Equity Incentive Plan and 2011 Employee Stock Purchase Plan; and


3.	Registration Statement (Form S-8 No. 333-231385) pertaining to the Molina Healthcare, Inc. 2019 Equity Incentive Plan and 2019 Employee Stock Purchase Plan,

of our reports dated February 14, 2020, with respect to the consolidated financial statements of Molina Healthcare, Inc., and the effectiveness of internal control over financial reporting of Molina Healthcare, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2019.

/s/ ERNST & YOUNG LLP

Los Angeles, California

February 14, 2020

EX-31.1 5 moh-12312019xex311.htm EXHIBIT 31.1 Exhibit

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a)/15d-14(a)

UNDER THE SECURITIES EXCHANGE

ACT OF 1934, AS AMENDED

I, Joseph M. Zubretsky, certify that:

1. I have reviewed the report on Form 10-Q for the period ended December 31, 2019 of Molina Healthcare, Inc.;

2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;

3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation; and

(d) Disclosed in the report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and to the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.




Dated: February 14, 2020		/s/ Joseph M. Zubretsky
		Joseph M. Zubretsky
		Chief Executive Officer, President and Director

EX-31.2 6 moh-12312019xex312.htm EXHIBIT 31.2 Exhibit

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a)/15d-14(a)

UNDER THE SECURITIES EXCHANGE

ACT OF 1934, AS AMENDED

I, Thomas L. Tran, certify that:

1. I have reviewed the report on Form 10-Q for the period ended December 31, 2019 of Molina Healthcare, Inc.;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have:

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and to the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.




Dated: February 14, 2020		/s/ Thomas L. Tran
		Thomas L. Tran
		Chief Financial Officer and Treasurer

EX-32.1 7 moh-12312019xex321.htm EXHIBIT 32.1 Exhibit

EXHIBIT 32.1

CERTIFICATE PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the report of Molina Healthcare, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2019 (the “Report”), I, Joseph M. Zubretsky, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




Dated: February 14, 2020		/s/ Joseph M. Zubretsky
		Joseph M. Zubretsky
		Chief Executive Officer, President and Director

EX-32.2 8 moh-12312019xex322.htm EXHIBIT 32.2 Exhibit

EXHIBIT 32.2

CERTIFICATE PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the report of Molina Healthcare, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2019 (the “Report”), I, Thomas L. Tran, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




Dated: February 14, 2020		/s/ Thomas L. Tran
		Thomas L. Tran
		Chief Financial Officer and Treasurer

EX-101.SCH 9 moh-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2118100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Condensed Financial Information of Registrant link:presentationLink link:calculationLink link:definitionLink 2421403 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2421402 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 2421406 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 2421405 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2421404 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2421407 - Disclosure - Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2321301 - Disclosure - Condensed Financial Information of Registrant (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Debt - Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Debt - Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Debt - Interest Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Debt - Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Debt - Schedule of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Debt - Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Derivatives link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Derivatives (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - Employee Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Fair Value Measurements - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Goodwill and Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Goodwill and Intangible Assets, Net - Balances of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Goodwill and Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Income Taxes - Provision for income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Investments - Available-for-Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2406406 - Disclosure - Investments - Balances of Restricted Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Investments - Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Investments - Schedule of Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Leases - Components of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Leases - Lease Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Leases - Lease Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Leases Leases link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Leases - Supplemental Cash Flow (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Medical Claims and Benefits Payable link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Medical Claims and Benefits Payable - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Medical Claims and Benefits Payable - Components of the Change (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2411407 - Disclosure - Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Medical Claims and Benefits Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Net Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Organization and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Property, Equipment, and Capitalized Software, Net link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Property, Equipment, and Capitalized Software, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Property, Equipment, and Capitalized Software, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Quarterly Results of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Quarterly Results of Operations (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Quarterly Results of Operations (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Receivables link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Receivables (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Restructuring Costs link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Segments link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Segments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Segments - Schedule of Operating Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Significant Accounting Policies - Due to Government Agencies (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - Significant Accounting Policies - Quality Incentive Premium Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Significant Accounting Policies - Schedule of Premium Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Stockholders' Equity - Components of Share-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - Stockholders' Equity - Fair Value of Awards Granted and Vested (Details) link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - Stockholders' Equity - Restricted and Performance Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Stockholders' Equity - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Stockholders' Equity - Stock Options by Exercise Price (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 moh-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 moh-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 moh-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Leases [Abstract] Operating lease expense Operating Lease, Cost Finance lease expense: Finance Lease, Liability, Payment, Due [Abstract] Amortization of ROU assets Finance Lease, Right-of-Use Asset, Amortization Interest on lease liabilities Finance Lease, Interest Expense Total finance lease expense Finance Lease, Cost Finance Lease, Cost Accounting Policies [Abstract] Cash and cash equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Restricted cash and cash equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Summarized premium revenue Revenue from External Customers by Geographic Areas [Table Text Block] Amounts due to government agencies Reserves Reported to Other Agencies [Table Text Block] Quality incentive premium revenue recognized Quality Incentive Premium Revenue Recognized [Table Text Block] Quality incentive premium revenue recognized. Income Tax Disclosure [Abstract] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] State State and Local Jurisdiction [Member] Foreign Foreign Tax Authority [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Change in tax rate, deferred tax asset, income tax expense (benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Deferred Tax Asset, Income Tax Expense Measurement period adjustment, income tax expense (benefit) Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit) Operating loss carryforwards Operating Loss Carryforwards Tax credit carryovers Tax Credit Carryforward, Amount Deferred tax assets Tax Credit Carryforward, Valuation Allowance Decrease in deferred tax asset valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Valuation allowance Deferred Tax Assets, Valuation Allowance Impact on effective tax rate if tax benefits are recognized Unrecognized Tax Benefits that Would Impact Effective Tax Rate Liability for unrecognized tax benefits, potential decrease Decrease in Unrecognized Tax Benefits is Reasonably Possible Equity [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] RSAs, PSAs and PSUs (defined below) Restricted and Performance Stock [Member] Restricted and Performance Stock [Member] Employee stock purchase plan and stock options Employee Stock Purchase Plan and Stock Options [Member] Employee Stock Purchase Plan and Stock Options [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Pretax Charges Share-based Payment Arrangement, Expense Net-of-Tax Amount Share-based Payment Arrangement, Expense, after Tax Restructuring settled without cash Share-based Payment Arrangement, Accelerated Cost Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Furniture and equipment Furniture and Fixtures [Member] Software Computer Software, Intangible Asset [Member] Leasehold improvements Leasehold Improvements [Member] Building and improvements Building and Building Improvements [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Useful life of property plant and equipment Property, Plant and Equipment, Useful Life Unrecognized tax benefits roll forward Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Gross unrecognized tax benefits at beginning of period Unrecognized Tax Benefits Increases in tax positions for current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Increases in tax positions for prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Decreases in tax positions for prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Lapse in statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Gross unrecognized tax benefits at end of period Medicaid program: Medicaid Program [Abstract] Medicaid Program [Abstract] Medical cost floors and corridors Amounts Due to Government Agencies, Medical Cost Floors and Corridors Amounts Due to Government Agencies, Medical Cost Floors and Corridors Other amounts due to states Amounts Due to Government Agencies, Amounts Due State Amounts Due to Government Agencies, Amounts Due State Marketplace program: Marketplace Program [Abstract] Marketplace Program [Abstract] Risk adjustment Amounts Due to Government Agencies, Risk Adjustment Amounts Due to Government Agencies, Risk Adjustment Cost sharing reduction Amounts Due to Government Agencies, Cost Sharing Reduction Amounts Due to Government Agencies, Cost Sharing Reduction Other Amounts Due to Government Agencies, Other Amounts Due to Government Agencies, Other Total Medical Premium Liability Due To Agency Medical Premium Liability Due to Agency Investments, Debt and Equity Securities [Abstract] Investments Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Contractual maturities of investments Investments Classified by Contractual Maturity Date [Table Text Block] Available-for-sale investments Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block] Balances of restricted investments Restrictions On Investments [Table Text Block] Restrictions On Investments [Table Text Block] RSAs Restricted Stock [Member] PSAs Performance Shares [Member] PSUs Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unvested, shares beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unvested, shares end of period (in shares) Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Unvested, beginning balance (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unvested, ending balance (USD per share) Summary of property and equipment and depreciation and amortization recognized Property, Plant and Equipment [Table Text Block] Statement of Cash Flows [Abstract] Statement [Table] Statement [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Call Option Call Option, Derivative Asset [Member] Call Option, Derivative Asset [Member] Conversion Option Embedded Derivative Financial Instruments [Member] Statement [Line Items] Statement [Line Items] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income (loss) Net Income (Loss) Attributable to Parent Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Deferred income taxes Increase (Decrease) in Deferred Income Taxes Share-based compensation Share-based Payment Arrangement, Noncash Expense Amortization of convertible senior notes and finance lease liabilities Amortization Of Debt Discount (Premium) And Sale Leaseback Financing Obligation Amortization of Debt Discount (Premium) and Sale Leaseback Financing Obligation (Gain) loss on debt extinguishment Gain (Loss) on Extinguishment of Debt Loss on sales of subsidiaries, net of gain Gain (Loss) on Disposition of Business Non-cash restructuring charges Non-cash Restructuring Charges Non-cash Restructuring Charges Impairment losses Goodwill and Intangible Asset Impairment Other, net Other Operating Activities, Cash Flow Statement Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Receivables Increase (Decrease) in Receivables Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Medical claims and benefits payable Increase (Decrease) in Health Care Insurance Liabilities Amounts due government agencies Increase (Decrease) In Medical Premium Liability Due To Agency Increase (Decrease) in Medical Premium Liability Due to Agency Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Deferred revenue Increase (Decrease) in Contract with Customer, Liability Income taxes Increase (Decrease) in Income Taxes Payable Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of investments Payments to Acquire Marketable Securities Proceeds from sales and maturities of investments Proceeds from Sale and Maturity of Marketable Securities Purchases of property, equipment and capitalized software Payments to Acquire Property, Plant, and Equipment Net cash received from sale of subsidiaries Proceeds from Divestiture of Interest in Subsidiaries and Affiliates Other, net Payments for (Proceeds from) Other Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Repayment of principal amount of convertible senior notes Repayments of Convertible Debt Cash paid for partial settlement of conversion option Cash Paid For Settlement Of Conversion Option Cash Paid For Settlement Of Conversion Option Cash received for partial settlement of call option Proceeds from Convertible Debt Cash paid for partial termination of warrants Payments for Repurchase of Warrants Proceeds from borrowings under term loan facility Proceeds from Long-term Lines of Credit Common stock purchases Payments for Repurchase of Common Stock Repayment of credit facility Repayments of Lines of Credit Proceeds from senior notes offerings, net of issuance costs Proceeds from Issuance of Debt Proceeds from borrowings under credit facility Proceeds from Lines of Credit Other, net Proceeds from (Payments for) Other Financing Activities Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid during the period for: Cash Paid During The Period [Abstract] Cash Paid During The Period [Abstract] Income taxes Income Taxes Paid, Net Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Schedule of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Common stock issued in exchange for convertible senior notes Notes Issued Component of convertible senior notes allocated to additional paid-in capital, net of income taxes Notes Issued, Fair Value Adjustment Increase (Decrease) Notes Issued, Fair Value Adjustment Increase (Decrease) Net increase to additional paid-in capital Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature Common stock used for stock-based compensation Stock Issued Common stock purchases not settled at end of period Common Stock Purchases Not Settled At End Of Period Common Stock Purchases Not Settled At End Of Period Details of sales of subsidiaries: Proceeds from Divestiture of Interest in Subsidiaries and Affiliates [Abstract] Decrease in carrying amount of assets Increase (Decrease) in Carrying Amount of Assets Increase (Decrease) in Carrying Amount of Assets Decrease in carrying amount of liabilities Gain (Loss) on Disposition of Liabilities Gain (Loss) on Disposition of Liabilities Transaction costs Disposition of Business, Transaction Costs Disposition of Business, Transaction Costs Cash received from buyers Disposition of Business, Receivable from Buyer Disposition of Business, Receivable from Buyer Loss on sale of subsidiaries, net of gain Details of change in fair value of derivatives, net: Details of change in fair value of derivatives [Abstract] Details of change in fair value of derivatives Change in fair value of derivatives, net Derivative, Gain (Loss) on Derivative, Net Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivatives Derivative Instruments and Hedging Activities Disclosure [Text Block] Statutory federal tax (benefit) rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent State income provision (benefit), net of federal Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Nondeductible health insurer fee (“HIF”) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Health Insurance, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Health Insurance, Percent Nondeductible compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent Nondeductible goodwill impairment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent Worthless stock deduction Effective Income Tax Rate Reconciliation, Worthless Stock Deduction Effective Income Tax Rate Reconciliation, Worthless Stock Deduction Revaluation of net deferred tax assets Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Effective tax expense (benefit) rate Effective Income Tax Rate Reconciliation, Percent Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Segment Reporting [Abstract] Operating segment information Schedule of Segment Reporting Information, by Segment [Table Text Block] Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes Senior Notes [Member] Term Loan Facility Line of Credit [Member] Convertible Debt Convertible Debt [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 5.375% Notes Senior Notes Due 2022 [Member] Senior Notes Due 2022 [Member] 4.875% Notes 4.875% Senior Notes [Member] 4.875% Senior Notes [Member] Term Loan Facility Term Loan [Member] Term Loan [Member] 1.125% Convertible Notes Cash Convertible Senior Notes due 2020 [Member] Cash Convertible Senior Notes due 2020 [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Percentage of contractual interest rate Debt Instrument, Interest Rate, Stated Percentage Net carrying amount Long-term Debt, Gross 2020 Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 2021 Long-term Debt, Maturities, Repayments of Principal in Year Two 2022 Long-term Debt, Maturities, Repayments of Principal in Year Three 2023 Long-term Debt, Maturities, Repayments of Principal in Year Four 2024 Long-term Debt, Maturities, Repayments of Principal in Year Five Thereafter Long-term Debt, Maturities, Repayments of Principal after Year Five EX-101.PRE 13 moh-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 a2019performancegraph.jpg begin 644 a2019performancegraph.jpg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end GRAPHIC 15 footprint2019a01.jpg begin 644 footprint2019a01.jpg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end GRAPHIC 16 molinalogo2016a24.jpg begin 644 molinalogo2016a24.jpg M_]C_X 02D9)1@ ! 0$ > !X #_X1$&17AI9@ 34T *@ @ ! $[ ( M 4 (2H=I 0 ! (7IR= $ H 0UNH< < @, /@ M FMC.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T M82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z#IX;7!M971A/@T*(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_]L 0P '!04& M!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7&QXG(1L=)1T7&"(N(B4H M*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\ $0@ MP@(G P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q]5\5Z)HKF/4-0C24 M=8ER[#ZA6QE;1M(D\N?'^D3J>4S_"OH<=3VKRLDL26.23DD]Z M[J.$YUS3/G\=G"H3=.BKM;OH>WP_$CPS-+L-Z\7. TD+8/Y#^=='9WMKJ%NL M]C<1W$3='C8,/TKYLK2T37K_ ,/WRW.G3%>?GC/*2#T(_P FMIX*-O<9Q4,^ MJ&_M.%<8=#U1AU4UHUYC33LSZN$XSBI1=TPHHKS M/XA>.9H+F31M&F,93Y;F=#\V?[BGM[G\/6KITY5)&DY.3S1 M7HK!0MJV?,2S[$-@P/XBI:^?/#WB2_\ M#E\)[&0F,G][ Q^20>X]??M7NVD:K;ZUI4%_9G,4RYP>JGH0?<&N*O0=)WZ' MNX#,88Q-6M)=/\B[1117.>H%%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %07MRMG87%T_W M8(FD/T S_2IZH:]"USX6TE11[E"*<=7J1-M0;6Y\\W-Q+=W4MS<,7 MEF/BTE5T/NI ) KYREE>:5Y96+R.Q9F/4D]37T#XL@:X\(:I&F2WV9V '? S_2 MOGRNG IE@HHHKO/FPKTSX1:BY;4--=LIA9T'H?NM_P"RUYG7 M??".%F\17LX^ZEKL/'=G4C_T$USXE)TG<]+*Y2CC(6_K0]_M+S/V2Z@GQU\J0-C M\JGHV!--704444#/"/&WAR3P]K\JI&19W#&2W;'&.Z_4=/IBNSU&$2Q-SZ%3V(/8UYCJWPHU&"4MH]Q'=1=DE.QQ_0_7CZ5ZU#%1<;3=F?& MX_**L*CG05XOIU1P%%=9#\-/$TLFV2SCA&?O23H1_P".DFNU\,?#2TTB=+O5 M9%O;E"&1 ,1H?7G[Q^N/I6L\33@M[G'0RO%5I6Y6EW>A/\-_#KZ+H;75VFRZ MO2'*GJB#[H^O)/XCTKLJ**\>C)Z?4=#7O]9VM:'8Z_I[6FHQ;TZJP.&0^H/K6N'K> MREKLSCS' _7*=EI);?Y'SM17=ZI\*=6MI6.ES0WD6?E#-Y;CZYX_6L^#X:>) MII-LEG' /[TDZ$?^.DFO65>DU?F/CY9?BHRY73?W?JW_#[PZ^@^'] MUTFR[NR))5/5!_"I^@R?J357PO\ #BST29+S49%O;Q3E!M_=QGU /4^Y_*NU MKS\3B%-(ZEJM]K%V;G4;F2>0]"QX7V Z >PKJ_BM=/-XKC M@).R"V4 >Y))/\ORKB*]G"TE&"EU9\/FV*G5Q$J=_=CI8?#-+;S++!(\4B'* MNC$%3[$5ZS\/O&TVL2'2M7<-=JNZ&;O*!U!]QUSW&?3GR.M'P]=/9>)-.N(R M04N4SCN-P!'XC-:5J2J0=]SEP.*GAJR:>CW1]$U@:YK6M:0K2V^@+?VZ\EH+ ML[@/=-F?RS6_17B1:3U5S[ZI&4XVC*S^7ZGF1^,.#SH7/_7W_P#84?\ "XO^ MH%_Y.?\ V%:GCOP-#JEK+J6E0B._C!=T0<3COQ_>]^_2O'J].E2H58W2_,^3 MQF+S'"5.2<].CLM?P/3?^%Q?]0+_ ,G/_L*5?C"I8;]$('1^5?.U.21XI%>-F1U.593@@UG+!P?PNQUT<\Q$7^\2DON?]?(] MYUS6=:TE6EMM!74+Z;,_EFN1_X7#@\Z%S_U]_\ V%5O"/Q*G@FC ML?$,GG0,0J71^\G^]ZCWZ_6MWQSX(@U>SDU328U2^1=[+&.+@?\ Q7H>_2N= M4X4YWYGA_VOC?Y_P7^1Z$I/H7'.,9%ZRO\ )?H?1&E^(=)UD?\ $MOX9VQG M8#AQ_P !/-:5?,Z2/%(KQLR.IRK*<$'VKT'PC\2KBVFCLO$,AFMV.%NCR\?^ M]_>'OU^M*O$-MX5\+:AK5X1 MY=I"7"D_??HJ_BQ _&@#S_QS\=K#P9XLGT--(?46MXU,LR7(3:Y&=F-IZ CG M/4XQQ79> /&4?COPI'K45F;,/*\1A,GF8VG&8P[\YP.Y!]*!'3^*O'/A[P9:^=K^HQP.PS';K\T MLG^Z@Y_'I[UY#K/[38$C)X>\/[D_AFOIL$_\ 7_XJO"KV^U#7-5>ZOIYKV]N M7^9W)=W8]!_0"OICX8?!/3/#VGPZEXIM(;_6) '\J4!X[7T4 \,P[MV/3U(, MX'_AHSQL\;2Q:-I!BY.[[-,0!]?,J[IO[3>IHRC6/#UI.O\ $;69HC^ ;=7T M6JA%"H J@8 P *X?QS\)O#GC2SE9K6.PU,@F.^MXPK;O]L#[X^O/H10 SP? M\8_"?C"5+:"[:POWX6UO0$+GT5LE6^F<^U=Y7PEKVAWWAK7KK2=4C\JZM9-C M@=#W# ]P1@@^AKW#X(_%RXNKR#PIXHN&F:0;+"[D.6)_YY.3US_"?P[B@+'O MM>??$OXJI\.+S389=(;4%ODD8LMQY93:5&,;3G.[U%>@UX%^U#&QB\,2 ?*I MNE)SW/E8_D:!$C?M/VH4[/"TQ;' -Z #^.RO;=(O_P"U-%L=0,7D_:[>.?R] MV[9N4-C.!G&?2O@ROO+18VAT&PB?&Y+:-3CU"B@;+M%%% CSKXE?%E/ASJEA M:S:,]^EY"TGF+<>7M(.,8VG/YUQ;_M/VH0^7X6F9NP:^ !_'953]J"(B[\-2 M\;62Y4#OD&/_ !%>"4#/O>PNOMVFVUWL\OSX4EV9SMW '&>_6L[Q=KY\+>$[ M_6UM?MGV*,2&#S-F\9 /S8..#GIVK3LHVBL+>-QM9(E4CT(%>:?^TQI=QJ=O#?:#/:6LC[9;D7(D,0_O;0HR/7G./7I7M< M$\5U;QSVTJ30RJ'CD1@RNI&001U%? M>P_!;XM'PU'?$4W_$GF?%O._\ MRZ.3W/\ <)//H>>F:!V/IVBD4AE!4@@C(([TM BIJU\=,T6]OUB,YM;>281 MXW[5)VYP<9QCI7E/A3X_P^*O%6G:);^')87O9=AE:[#!!@DG&SGI[5ZCK_\ MR+>I_P#7I+_Z :^3?@E$)OC)H*L2 &F;CV@D/]*!GV%1110(*\6\8?M!CPSX MPU+1K/1(]1BLW\H3_:C'^\ &X$;3T;(_"O4/%_B"+PMX/U/6IMO^B0,R*W1I M#PB_BQ _&OAZXGENKF6XN',DTKEY';JS$Y)_.@:/MWP5XGB\8^#]/UR%!&;F M/]Y$#GRY 2K+^8/X8K=KP#]FGQ-_R%/#,[_]/ML"?HL@_P#0#CZU[_0(XG6_ MB-!IMV8;."V>%97A-W?W36\,DB??2,K'(SE>YV@ Y&<@XU_#GBJ+79#;RP"V MNA"MP@28317$3' DBD'WUSP> 0>H&1GS/6](UK6-)T+0O#Q\C6]#ENUNV;;F M,F-PDA#\E9=P(8 _>/<5TO@M8Y[KPY8V6G-8-H5A-'?P^9Y@MY'V 0[P2&+% M2^,Y "YQD4#/1J***!!1110 4444 %%%% 'EOQ:TB075IJ\:DQ,GD2D?PD$E M3^.3^5>;U])WEG;ZA9R6MY$LT$J[71AU%>8:Q\)KN.=GT2ZCFA)R(YSM=?;( M&#^E>GAL1%1Y)]#Y3-,LJRJNM15T]T>=UT7@72)-7\66@528K9Q/*V. %.0/ MQ.!6O9?"G6II@+R:VMHL_,VXNWX ?XBO2_#WARQ\-Z?]FL$)9N99G^](??\ MH*TK8F"BU%W9S8#*JTZJG55HKOU-:BBBO(/M KY^\7V:6'B_4K>( ()RR@= M&^;'ZU] UX/X]_Y'K4_]]?\ T!:[L%\;7D?/9\E["+\_T9SM%%%>J?'A1110 M 5[-\,=8DU+PTUK.Q>2Q?RP2?X",K^7(^@%>,UZ5\'G(GU9.Q6(_D7_QKEQ< M4Z3?8]?)ZCABXI=;K\+G'^,+..Q\8:E!" J"8LH'0;ANQ^M8M=%X]_Y'K4_] M]?\ T!:YVMZ>L%Z'!BDE7FEW?YA1115G.%%%% 'LGPOUA]0\./9S-NDL7"*3 M_P \SRO\F'T KMJ\N^#Y/VK51VV1HUXF)BHU6D??Y74E4P<'+T^YV.% M^-%]]@^$.N.IPTD:0CWWR*I_0FOCPJP4,5(#="1UKZ?_ &D;[[/\.K2T4_-= M:@@(]55')_7;7 _$ -8_9KL-:LXD5\\_M(>,#->6?A*S?Y(<75YM/5R/D0 M_0$MC_:7TKW3Q#KEKX:\.WVL:@<06<)D89P6/91[DX ]S7S+\+M$N_B5\6Y= M;UD>;!;3?;[MOX2^[]W&/;(Z?W5(H \PG@EM;B2WN$:.6)RCHPY5@<$'\:][ M_9@O!N\1V3'DBWE0?]]AO_9:\H^)=K]C^*'B.+UU"63_ +[8M_[-7=?LUWGD M_$"_M2<+<:+O$=S MXM\5W^M7A(:ZE)1"?]6@X5?P4 5];?%>\>Q^%'B&6,D,UH8LCT$?LPVJKIGB&[P-\DT M,6?0*K'_ -FKW>@&%%%% CP#]ICP[&JZ1XCA0+(S&RG8#[W!>/\ D_Z>E>!0 MS26\\"=? M_P"$H\$:3K)QYEU;JTN.@D'RN!_P(&O)?VG_ /D&^'?^NT_\DKIOV>;EI_A3 M'&W2WO9HUY[<-_-C7,_M/_\ (-\._P#7:?\ DE NI\[U][Z?_P @VV_ZXI_( M5\$5][Z?_P @VV_ZXI_(4 RQ1110(\ _:B_YE;_M[_\ :-?/]?0'[47_ #*W M_;W_ .T:^?Z"D??] MXQ_6@D^0M)\,ZGKFEZI?Z7 9X]+C66Y5?O!&)&X#OC&3[<]JR:]W_9AYU+Q' MG_GC!_-ZJ?&OX1?V-)/XG\,0?\2]VW7=I&O_ !['NZ@?P'N/X3[= HN?!#XN M?96@$^)[C]P2(]/NG/^K/:)CZ?W3VZ=,8^AJ^ *^C_@G\7/[4C@\+>)KC_3 MD 2QNG_Y;J!Q&Q_OCL>_UZ@F>RZM$)]%O8B<"2WD4D=LJ17RG\!$W?%_33MS MMAG.<=/W3#/Z_K7U??\ _(-N?^N+_P C7RQ^SW_R5B#_ *])OY"@#ZOHHIDL ML<$+RS.J1QJ6=V. H'))H$>#_M*^*=EOIOA>V?YI#]LN@#_",K&#]3N./85X M_P"(O!>H>'/#F@:Q> ^3K5NTR#;_ *LAN ?JA1A]3Z5M$S?%KXV?QF#4;W\8 M[9/Y$1K^?UKZ ^,GA6/7OA9>Q6L*B;2U%W;*H^Z(Q\RC_@&X8]<4#/F+P)XC M;PGXXTO6 Q$=O.!.!WB;Y7'_ 'R3CWQ7VXCK+&KQL&1@"K Y!![U\!U]=?!# MQ/\ \)'\-+..9]UUIA^QRYZX4?(?^^"!GU!H!G9ZIX>T?6FC?5M,M+QXAB-Y MH59D'< GD59L=/L]+LTM--M(+2W3[L,$81%^@'%6**!!1110 4444 %%%% ! M4%W]J^SDV!A\X=!,#M/MD=/UJ>B@35U8\YUGX@>(- N_L^IZ)!$6Y1Q(Q5QZ M@]ZSO^%O7_\ T"[?_OXU>CZUHUKKNE2V-ZF46LEC?3VD_ M$D$C1OCU!P:]+#QHU5K'5'RV95,9@YIQJ-Q?I_D=[_PMZ_\ ^@7;_P#?QJ4? M%Z^W#=I=N1W D85YW175]6I=CRO[4QG\_P"7^1ZS8?%O3YF"ZAI\]MG^*-A( M!_(_SKM-+UG3]9M_/TR[CN$[[3ROU!Y'XU\Y5:T[4KO2KU+O3YV@F0\,IZ^Q M'<>U8U,'!KW-#MP^>5H.U9M3_WU_P#0%KU[PIX@3Q)H M4=Z%"3 ^7,@Z*XZX]CD'\:\A\>_\CUJ?^^O_ * M882+C5:9WYU4C4PD)QV; M_1G.T445ZA\B%%%% !7I'P?_ ./O5?\ ;UZ1\'_P#C[U7_ '(_YM7/ MB?X+/3RK_?8?/\F_\CUJ?^^O_H"USM:TOXI5Y;\'_\ C[U7_+BOXS/N\G_P!RA\_S9\]_M.W^ZZ\/:=:,?XH6^[S MWQRI]U-7?A)XR_X0SQ]:W%Q)LT^[_P!&O,G@(QX?_@)P?IGUKVK]H3P<-:\' M)KUI'F\T@Y?:.7@8_-_WR<-[#=ZU\O4#/>?VC?&HFFM?"-A+E8B+F^*GJQ'[ MM/R.X_5?2O1/@QX.'A+X?VS3Q[;_ %("ZN+O#EQX2\67^BW8;=:RD(Y M'^LC/*-^*D&@2/A?$/[#= MR".WU:+[."QP!*#F/\^5'NPKZMH!A1110(\@_:1OUM_AW:6@;]Y=:@GR^JJC M$G\]OYU\OUZQ^T#XNC\0>-X]*LI!):Z.K1%E.0TS$>9^6%7ZJ:\^\+>'+WQ9 MXFL]&TY29KF0*6QD1K_$Y]@,F@H^H/@+IKZ?\);&20;6O)I;C!]"VT?F$!_& MN0_:?_Y!OAW_ *[3_P DKVW2].M](TFTTZR79;VD*0Q#T50 /Y5XE^T__P @ MWP[_ -=I_P"24"/G>OO?3_\ D&VW_7%/Y"O@BOO?3_\ D&VW_7%/Y"@&6*** M*!'@'[47_,K?]O?_ +1KY_KZ _:B_P"96_[>_P#VC7S_ $%(^_ZXWXN2+%\) M?$#-G!MMO'J64#^==E7!_&R4P_!O7F SE85_.>,?UH)/-/V8?^0EXB_ZXP?S M>OH9T62-DD4,C##*PR"/2OGG]F'_ )"7B+_KC!_-Z^AZ!L^6?C+\)F\(W;:Y MH,);1)W^>,W0]L^4([1R*\;%74Y5E."#ZU][W=I!?V0I/ M;SH8Y(G&5=2,$$5\E?%GX87'@+6?M%DKRZ'=N?L\IY\INOE,?4=CW'N#0"/5 M_A3\6D\5:%-H/B"94UJ"W812LW_'XH4\_P"^ .1WZ^N/._V=%!^*+D@$KI\I M&1T.Y*\L@GEMIXY[>1HI8V#(Z-AE(Z$$=#7JG[.?_)4)/^P=+_Z$E 'U/7F? MQX\5?\(]\.Y;*"3;=ZNQM4 /(CQF0_3'R_\ Z],KY+^-WB:3Q7\3);&R+2V M^FG[% B\[Y,_.0/4M\OOM% "_!?Q;X9\%:QJ&J^(Y)Q<-"(+410E\ G+D^AX M4?G7L3_M ^ W0H\UZRL,$&T)!%0:5^SUX/BTVS&J174]XL*?:"MR0KR8&[ ' M09S5V7X ^ I% 2PNHCGJEV_/YDT!H?+&KBQ76KT:0[O8>>_V9I%PQCR=N1ZX MQ7I7[/OBG^Q/'YTJ>3;:ZQ'Y6">!*N2A_'YE_P"!"K7QJ^%>E^"=+T[4_#J3 MBVEE:"Y$LF_#$90C\ _Z5Y)9W*?"FG:U;8"WD"NR@YV/T9?P8$?A6O02%%%% !1110 4444 %%%% !7S[X MM_Y'#5?^OI_YU]!5X!XS4)XTU0+_ ,_#'\^:[\%\;/G<^_@P]?T,2BBBO4/D M HHHH ],^#\S;]5A_AQ$X'H?F'^'Y5ROCW_D>M3_ -]?_0%KIO@__P ?>J_[ MD?\ -JYGQ[_R/6I_[Z_^@+7'#_>9>G^1[E=WRJE_B?ZG.T445V'AA1110 5Z M1\'_ /C[U7_;UZ1\'_ /C[U7__\CUJ?^^O_ * M<[6M+^''T.7%_P"\5/5_F%%%%6

XML 19 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Leases - Lease Maturities (Details)
$ in Millions

Dec. 31, 2019

USD ($)

Operating Leases

2020 $ 28

2021 20

2022 14

2023 10

2024 5

Thereafter 3

Subtotal - undiscounted lease payments 80

Less imputed interest (7)

Total operating lease liabilities 73

Finance Leases

2020 23

2021 24

2022 21

2023 21

2024 22

Thereafter 289

Subtotal - undiscounted lease payments 400

Less imputed interest (161)

Total finance lease liabilities $ 239

X

- References
No definition available.
+ Details

Name: us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R90.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended

Dec. 31, 2019

Feb. 07, 2020

Dec. 31, 2019

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2013

Jun. 30, 2019

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Repurchased of common stock $ 54,000,000

Cash paid for partial termination of 1.125% Warrants 514,000,000 $ 549,000,000 $ 0

Unrecognized compensation expense $ 49,000,000 $ 49,000,000 $ 49,000,000

Unrecognized compensation forfeited rate 15.90%

Weighted average grant date fair value of stock options granted (usd per share) $ 41.43

Common stock issued during period (in shares) 142,000 216,000 351,000

RSAs

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Maximum award vesting period 4 years

Weighted average period of unrecognized compensation expense 2 years 2 months 12 days

PSUs

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted average period of unrecognized compensation expense 1 year 7 months 6 days

Stock options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Maximum award vesting period 4 years

Unrecognized compensation expense $ 4,000,000 $ 4,000,000 $ 4,000,000

Weighted average period of unrecognized compensation expense 9 months 18 days

Stock option expiration period 10 years

Risk free interest rate 2.30%

Expected volatility rate 38.40%

Dividend yield 0.00%

Expected term of awards 8 years 4 months 24 days

Options exercised, intrinsic value $ 2,000,000

Employee Stock Purchase Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Dividend yield 0.00% 0.00% 0.00%

Expected term of awards 6 months 6 months 6 months

Employee purchase price as a percentage of stock price 85.00%

Maximum annual contribution per employee $ 25,000

Risk-free interest rate, minimum 0.60% 0.60% 0.60%

Risk-free interest rate, maximum 2.30% 2.30% 2.30%

Minimum expected volatility rate inputs for fair value measurement 31.00% 31.00% 31.00%

Maximum expected volatility rate inputs for fair value measurement 45.00% 45.00% 45.00%

2019 EIP

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares issued under ESPP (in shares) 2,900,000

2019 ESPP

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares issued under ESPP (in shares) 3,000,000.0

1.125% Warrants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stated interest rate 1.125% 1.125% 1.125%

Number of warrants issued (in shares) 13,500,000

Striking price of warrants (USD per share) $ 53.8475

Class of warrant 310,000 310,000 310,000

Cash paid for partial termination of 1.125% Warrants $ 514,000,000

Number of warrants terminated (in shares) 5,900,000

Common Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock authorized $ 500,000,000 $ 500,000,000 $ 500,000,000

Repurchased of common stock (in shares) 55,000 400,000

Repurchased of common stock $ 7,000,000 $ 54,000,000

Average cost (USD per share) $ 135.30

Share-based compensation (in shares) 242,000 365,000,000

Subsequent Event | Common Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Repurchased of common stock (in shares) 1,533,000

Repurchased of common stock $ 203,000,000

Average cost (USD per share) $ 132.69

X

- Definition
Class Of Warrant Or Right, Stated Interest Rate
+ References
No definition available.
+ Details

Name: moh_ClassOfWarrantOrRightStatedInterestRate

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Fair market value of common stock, Percentage.
+ References
No definition available.
+ Details

Name: moh_FairMarketValueOfCommonStockPercentage

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award maximum amount per employee.
+ References
No definition available.
+ Details

Name: moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Terminated, Number
+ References
No definition available.
+ Details

Name: moh_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsTerminatedNumber

Namespace Prefix: moh_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized compensation forfeited rate.
+ References
No definition available.
+ Details

Name: moh_UnrecognizedCompensationForfeitedRate

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of an employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of stock repurchase plan authorized.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramAuthorizedAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockRepurchasedDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockRepurchasedDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total cost of shares repurchased divided by the total number of shares repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockAcquiredAverageCostPerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=moh_EquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=moh_EmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=moh_CashConvertibleSeniorNotesDue2020WarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Receivables (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Financing Receivable, Past Due [Line Items]

Total receivables $ 1,406 $ 1,330

Government receivables

Financing Receivable, Past Due [Line Items]

Total receivables 1,056 872

Pharmacy rebate receivables

Financing Receivable, Past Due [Line Items]

Total receivables 150 146

Health insurer fee reimbursement receivables

Financing Receivable, Past Due [Line Items]

Total receivables 5 141

Other

Financing Receivable, Past Due [Line Items]

Total receivables $ 195 $ 171

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-06(3))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_HealthInsurerFeeReimbursementReceivablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Leases - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Lessee, Lease, Description [Line Items]

Operating lease term 9 years

Operating lease renewal term 10 years

Operating leases, weighted average remaining lease term 4 years

Finance lease renewal term 25 years

Finance leases, weighted average remaining lease term 16 years

Operating leases, weighted average discount rate 5.60%

Finance leases, weighted average discount rate 6.50%

Rent expense $ 62 $ 75

Minimum

Lessee, Lease, Description [Line Items]

Finance lease term 2 years

Maximum

Lessee, Lease, Description [Line Items]

Finance lease term 19 years

X

- Definition
Finance Lease, Remaining Lease Term
+ References
No definition available.
+ Details

Name: moh_FinanceLeaseRemainingLeaseTerm

Namespace Prefix: moh_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Operating Lease, Remaining Lease Term
+ References
No definition available.
+ Details

Name: moh_OperatingLeaseRemainingLeaseTerm

Namespace Prefix: moh_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average discount rate for finance lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeFinanceLeaseRenewalTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeaseDescriptionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R94.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Shares

Beginning balance, outstanding (in shares) 405,000

Granted (in shares) 0 0

Exercised (in shares) 0

Ending balance, outstanding (in shares) 405,000 405,000

Weighted Average Exercise Price

Beginning balance, outstanding (usd per share) $ 64.79

Granted (usd per share) 0

Exercised (usd per share) 0

Ending balance, outstanding (usd per share) $ 64.79 $ 64.79

Outstanding, Aggregate Intrinsic Value $ 29

Outstanding, Weighted Average Remaining Contractual term 7 years 4 months 24 days

Stock options exercisable and expected to vest (in shares) 405,000

Stock options exercisable and expected to vest (usd per share) $ 64.79

Exercisable (in shares) 280,000

Exercisable (usd per share) $ 63.65

Exercisable, Aggregate Intrinsic Value $ 20

Exercisable, Weighted Average Remaining Contractual term 7 years 3 months 18 days

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 24 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Jan. 01, 2019

Jan. 01, 2018

Property, Plant and Equipment [Line Items]

Final maturities of investments 10 years

Average maturity of investments 10 years

Medical premium liability based on medical costs threshold $ 74 $ 103

Amounts due government agencies 664 967

Risk adjustment payable 368 466

Risk adjustment receivable 63 34

Risk adjustment, net payable 305 432

Prepaid reinsurance premiums 17 16 $ 20

Reinsurance recoveries 18 33 24

Reinsurance recoverable for unpaid claims adjustments 21 31 $ 16

Adoption of new accounting standard $ 85 $ 6

Receivables from state and federal government agencies 1,406 1,330

Retained Earnings

Property, Plant and Equipment [Line Items]

Adoption of new accounting standard 85

Retained Earnings, Including Deferred Income Tax

Property, Plant and Equipment [Line Items]

Adoption of new accounting standard 110

Deferred Income Tax

Property, Plant and Equipment [Line Items]

Adoption of new accounting standard $ 25

CMS Subsidies

Property, Plant and Equipment [Line Items]

Disposal group, operating expense 81

Medicaid Expansion

Property, Plant and Equipment [Line Items]

Amounts due government agencies $ 69 87

Minimum

Property, Plant and Equipment [Line Items]

Useful life 5 years

Minimum | California, Illinois, New Mexico, Ohio, South Carolina, Texas, Washington, and Wisconsin

Property, Plant and Equipment [Line Items]

Percentage of additional incremental revenue earned 1.00%

Maximum

Property, Plant and Equipment [Line Items]

Useful life 15 years

Maximum | California, Illinois, New Mexico, Ohio, South Carolina, Texas, Washington, and Wisconsin

Property, Plant and Equipment [Line Items]

Percentage of additional incremental revenue earned 4.00%

Structured Securities

Property, Plant and Equipment [Line Items]

Average maturity of investments 10 years

Government receivables

Property, Plant and Equipment [Line Items]

Concentration risk, percentage 75.00%

Receivables from state and federal government agencies $ 1,056 $ 872

X

- Definition
Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable
+ References
No definition available.
+ Details

Name: moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)
+ References
No definition available.
+ Details

Name: moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable
+ References
No definition available.
+ Details

Name: moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Investments, Average Maturity Period
+ References
No definition available.
+ Details

Name: moh_InvestmentsAverageMaturityPeriod

Namespace Prefix: moh_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Investments, Maturity Period
+ References
No definition available.
+ Details

Name: moh_InvestmentsMaturityPeriod

Namespace Prefix: moh_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Medical Premium Liability Due to Agency
+ References
No definition available.
+ Details

Name: moh_MedicalPremiumLiabilityDueToAgency

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Medical Premiums Liability, Medical Care Costs Threshold
+ References
No definition available.
+ Details

Name: moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of additional incremental revenue earned.
+ References
No definition available.
+ Details

Name: moh_PercentageOfAdditionalIncrementalRevenueEarned

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_InsuranceRecoveries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The unexpired portion of premiums ceded on policies in force as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 340
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6485982&loc=d3e22818-158507

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 825
-Section 50
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195
+ Details

Name: us-gaap_PrepaidReinsurancePremiums

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-06(3))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 310
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (cc)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=moh_RetainedEarningsIncludingDeferredIncomeTaxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=moh_DeferredIncomeTaxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=moh_CMSSubsidiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=moh_MedicaidExpansionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=moh_StructuredSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 25 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Quarterly Results of Operations (Unaudited) (Tables)
12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Summary of quarterly results of operations
The following table summarizes quarterly unaudited results of operations for the periods presented.

For The Quarter Ended

March 31,
2019

June 30,
2019

Sept. 30, 2019

December 31,
2019

(In millions, except per-share data)
Total revenue
$
4,119

$
4,193

$
4,243

$
4,274

Margin
581

583

561

578

Net income
198

196

175

168

Net income per share - Basic ⁽¹⁾
$
3.19

$
3.15

$
2.81

$
2.70

Net income per share - Diluted ⁽¹⁾
$
2.99

$
3.06

$
2.75

$
2.67

For The Quarter Ended

March 31,
2018

June 30,
2018

Sept. 30, 2018

December 31,
2018

(In millions, except per-share data)
Total revenue
$
4,646

$
4,883

$
4,697

$
4,664

Margin
615

673

566

664

Gain (loss) on sales of subsidiaries
—

—

37

(52
)
Net income
107

202

197

201

Net income per share - Basic ⁽¹⁾
$
1.79

$
3.29

$
3.22

$
3.24

Net income per share - Diluted ⁽¹⁾
$
1.64

$
3.02

$
2.90

$
3.01

________________________
(1)
The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method and is based on the weighted-average common share equivalents outstanding during each quarter. Accordingly, the sum of the quarterly net income per share amounts may not agree to the total for the year.

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306
+ Details

Name: us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

JSON 26 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "moh-12312019x10k.htm": { "axisCustom": 0, "axisStandard": 32, "contextCount": 389, "dts": { "calculationLink": { "local": [ "moh-20191231_cal.xml" ] }, "definitionLink": { "local": [ "moh-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "moh-12312019x10k.htm" ] }, "labelLink": { "local": [ "moh-20191231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "moh-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml" ] }, "schema": { "local": [ "moh-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 861, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 53, "http://www.molinahealthcare.com/20191231": 1, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 59 }, "keyCustom": 83, "keyStandard": 532, "memberCustom": 38, "memberStandard": 64, "nsprefix": "moh", "nsuri": "http://www.molinahealthcare.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.molinahealthcare.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Net Income (Loss) Per Share", "role": "http://www.molinahealthcare.com/role/NetIncomeLossPerShare", "shortName": "Net Income (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419403 - Disclosure - Segments - Schedule of Operating Segment Information (Details)", "role": "http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails", "shortName": "Segments - Schedule of Operating Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2017Q4_us-gaap_StatementBusinessSegmentsAxis_moh_HealthPlansMember", "decimals": "-6", "lang": null, "name": "us-gaap:IntangibleAssetsNetIncludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419404 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)", "role": "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails", "shortName": "Segments - Reconciliation of Gross Margin to Consolidated Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-6", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420402 - Disclosure - Quarterly Results of Operations (Unaudited) (Details)", "role": "http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedDetails", "shortName": "Quarterly Results of Operations (Unaudited) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R103": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421402 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets (Details)", "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "shortName": "Condensed Financial Information of Registrant - Condensed Balance Sheets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember", "decimals": "-6", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R104": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "2421403 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details)", "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "shortName": "Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R105": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InterestAndDividendIncomeOperating", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421404 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Operations (Details)", "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "shortName": "Condensed Financial Information of Registrant - Condensed Statements of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember", "decimals": "-6", "lang": null, "name": "us-gaap:InsuranceAgencyManagementFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421405 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Loss) (Details)", "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails", "shortName": "Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421406 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details)", "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "shortName": "Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember", "decimals": "-6", "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421407 - Disclosure - Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details)", "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantNotesToCondensedFinancialInformationDetails", "shortName": "Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Fair Value Measurements", "role": "http://www.molinahealthcare.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Investments", "role": "http://www.molinahealthcare.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Receivables", "role": "http://www.molinahealthcare.com/role/Receivables", "shortName": "Receivables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Property, Equipment, and Capitalized Software, Net", "role": "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNet", "shortName": "Property, Equipment, and Capitalized Software, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Leases Leases", "role": "http://www.molinahealthcare.com/role/LeasesLeases", "shortName": "Leases Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Goodwill and Intangible Assets, Net", "role": "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNet", "shortName": "Goodwill and Intangible Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Medical Claims and Benefits Payable", "role": "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayable", "shortName": "Medical Claims and Benefits Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Debt", "role": "http://www.molinahealthcare.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Derivatives", "role": "http://www.molinahealthcare.com/role/Derivatives", "shortName": "Derivatives", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Statements of Operations", "role": "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "moh:HealthCareOrganizationPremiumTaxRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Income Taxes", "role": "http://www.molinahealthcare.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Stockholders' Equity", "role": "http://www.molinahealthcare.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Restructuring Costs", "role": "http://www.molinahealthcare.com/role/RestructuringCosts", "shortName": "Restructuring Costs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - Employee Benefit Plans", "role": "http://www.molinahealthcare.com/role/EmployeeBenefitPlans", "shortName": "Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Commitments and Contingencies", "role": "http://www.molinahealthcare.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Segments", "role": "http://www.molinahealthcare.com/role/Segments", "shortName": "Segments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120100 - Disclosure - Quarterly Results of Operations (Unaudited)", "role": "http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnaudited", "shortName": "Quarterly Results of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - Condensed Financial Information of Registrant", "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrant", "shortName": "Condensed Financial Information of Registrant", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "span", "div", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302302 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "span", "div", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "role": "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Net Income (Loss) Per Share (Tables)", "role": "http://www.molinahealthcare.com/role/NetIncomeLossPerShareTables", "shortName": "Net Income (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Investments (Tables)", "role": "http://www.molinahealthcare.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Receivables (Tables)", "role": "http://www.molinahealthcare.com/role/ReceivablesTables", "shortName": "Receivables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Property, Equipment, and Capitalized Software, Net (Tables)", "role": "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetTables", "shortName": "Property, Equipment, and Capitalized Software, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Leases (Tables)", "role": "http://www.molinahealthcare.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Goodwill and Intangible Assets, Net (Tables)", "role": "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetTables", "shortName": "Goodwill and Intangible Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Medical Claims and Benefits Payable (Tables)", "role": "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableTables", "shortName": "Medical Claims and Benefits Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Debt (Tables)", "role": "http://www.molinahealthcare.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Derivatives (Tables)", "role": "http://www.molinahealthcare.com/role/DerivativesTables", "shortName": "Derivatives (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Balance Sheets", "role": "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "lang": null, "name": "us-gaap:OtherAssetsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Income Taxes (Tables)", "role": "http://www.molinahealthcare.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.molinahealthcare.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - Segments (Tables)", "role": "http://www.molinahealthcare.com/role/SegmentsTables", "shortName": "Segments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320301 - Disclosure - Quarterly Results of Operations (Unaudited) (Tables)", "role": "http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedTables", "shortName": "Quarterly Results of Operations (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321301 - Disclosure - Condensed Financial Information of Registrant (Tables)", "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantTables", "shortName": "Condensed Financial Information of Registrant (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401401 - Disclosure - Organization and Basis of Presentation (Details)", "role": "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails", "shortName": "Organization and Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "D2019Q4Oct31_srt_CounterpartyNameAxis_moh_TexasHealthAndHumanServicesCommissionSTARPLUSProgramMember", "decimals": null, "lang": "en-US", "name": "moh:ContractTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "moh:InvestmentsMaturityPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - Significant Accounting Policies - Additional Information (Details)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "moh:InvestmentsMaturityPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - Significant Accounting Policies - Schedule of Premium Revenue (Details)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails", "shortName": "Significant Accounting Policies - Schedule of Premium Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_moh_HealthPlansMember", "decimals": "INF", "lang": null, "name": "moh:HealthCareOrganizationRevenuePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReservesReportedToOtherAgenciesTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "moh:AmountsDuetoGovernmentAgenciesMedicalCostFloorsandCorridors", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402406 - Disclosure - Significant Accounting Policies - Due to Government Agencies (Details)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails", "shortName": "Significant Accounting Policies - Due to Government Agencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReservesReportedToOtherAgenciesTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "moh:AmountsDuetoGovernmentAgenciesMedicalCostFloorsandCorridors", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "moh:QualityIncentivePremiumRevenueRecognizedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "moh:MaximumAvailableQualityIncentivePremiumCurrentYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402407 - Disclosure - Significant Accounting Policies - Quality Incentive Premium Revenue (Details)", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueDetails", "shortName": "Significant Accounting Policies - Quality Incentive Premium Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "moh:QualityIncentivePremiumRevenueRecognizedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "moh:MaximumAvailableQualityIncentivePremiumCurrentYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Net Income (Loss) Per Share (Details)", "role": "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails", "shortName": "Net Income (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_moh_CallOptionDerivativeAssetMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeFixedInterestRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)", "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)", "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails", "shortName": "Fair Value Measurements - Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Investments - Schedule of Investments (Details)", "role": "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails", "shortName": "Investments - Schedule of Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Investments - Contractual Maturities (Details)", "role": "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails", "shortName": "Investments - Contractual Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - Investments - Narrative (Details)", "role": "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails", "shortName": "Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406405 - Disclosure - Investments - Available-for-Sale (Details)", "role": "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails", "shortName": "Investments - Available-for-Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestrictedInvestmentsNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406406 - Disclosure - Investments - Balances of Restricted Investments (Details)", "role": "http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails", "shortName": "Investments - Balances of Restricted Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4_srt_StatementGeographicalAxis_stpr_FL", "decimals": "-6", "lang": null, "name": "us-gaap:RestrictedInvestmentsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-6", "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Receivables (Details)", "role": "http://www.molinahealthcare.com/role/ReceivablesDetails", "shortName": "Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_moh_PharmacyRebateReceivablesMember", "decimals": "-6", "lang": null, "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Property, Equipment, and Capitalized Software, Net - Additional Information (Details)", "role": "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails", "shortName": "Property, Equipment, and Capitalized Software, Net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details)", "role": "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails", "shortName": "Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "moh:DepreciationAndAmortizationOfCapitalizedSoftware", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details)", "role": "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails", "shortName": "Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "moh:DepreciationAndAmortizationOfCapitalizedSoftware", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "moh:OperatingLeaseRemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Leases - Narrative (Details)", "role": "http://www.molinahealthcare.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "moh:OperatingLeaseRemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Leases - Components of Lease Expense (Details)", "role": "http://www.molinahealthcare.com/role/LeasesComponentsOfLeaseExpenseDetails", "shortName": "Leases - Components of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Leases - Supplemental Cash Flow (Details)", "role": "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails", "shortName": "Leases - Supplemental Cash Flow (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "moh:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)", "role": "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "moh:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Leases - Lease Maturities (Details)", "role": "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails", "shortName": "Leases - Lease Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2018Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Goodwill and Intangible Assets, Net - Balances of Goodwill (Details)", "role": "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails", "shortName": "Goodwill and Intangible Assets, Net - Balances of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)", "role": "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "shortName": "Goodwill and Intangible Assets, Net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details)", "role": "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails", "shortName": "Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details)", "role": "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails", "shortName": "Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "moh:MedicalClaimsAndBenefitsPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - Medical Claims and Benefits Payable - Additional Information (Details)", "role": "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableAdditionalInformationDetails", "shortName": "Medical Claims and Benefits Payable - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "moh:MedicalClaimsAndBenefitsPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2018Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Medical Claims and Benefits Payable - Components of the Change (Details)", "role": "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails", "shortName": "Medical Claims and Benefits Payable - Components of the Change (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details)", "role": "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails", "shortName": "Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details)", "role": "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableCumulativePaidClaimsAndAllocatedClaimsAdjustmentExpensesDetails", "shortName": "Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member", "decimals": "-6", "lang": null, "name": "us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411407 - Disclosure - Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details)", "role": "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails", "shortName": "Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Debt - Maturities (Details)", "role": "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "shortName": "Debt - Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CapitalLeaseObligationsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - Debt - Schedule of Long-Term Debt (Details)", "role": "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "shortName": "Debt - Schedule of Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CapitalLeaseObligationsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Organization and Basis of Presentation", "role": "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Debt - Credit Agreement (Details)", "role": "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "shortName": "Debt - Credit Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4_us-gaap_DebtInstrumentAxis_moh_TermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "-6", "lang": null, "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4_us-gaap_DebtInstrumentAxis_moh_SeniorNotesDue2022Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Debt - Senior Notes (Details)", "role": "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails", "shortName": "Debt - Senior Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4_us-gaap_DebtInstrumentAxis_moh_SeniorNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - Debt - Convertible Notes (Details)", "role": "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "shortName": "Debt - Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD_us-gaap_DebtInstrumentAxis_moh_CashConvertibleSeniorNotesDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-6", "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "moh:ScheduleOfDebtInstrumentsInterestCostRecognizedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - Debt - Interest Cost (Details)", "role": "http://www.molinahealthcare.com/role/DebtInterestCostDetails", "shortName": "Debt - Interest Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "moh:ScheduleOfDebtInstrumentsInterestCostRecognizedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Derivatives (Details)", "role": "http://www.molinahealthcare.com/role/DerivativesDetails", "shortName": "Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Income Taxes - Provision for income taxes (Details)", "role": "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails", "shortName": "Income Taxes - Provision for income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2017Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2017Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414404 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)", "role": "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails", "shortName": "Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414405 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "role": "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2018Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)", "role": "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2016Q4", "decimals": "-6", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Significant Accounting Policies", "role": "http://www.molinahealthcare.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Stockholders' Equity - Additional Information (Details)", "role": "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "lang": null, "name": "moh:UnrecognizedCompensationForfeitedRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - Stockholders' Equity - Components of Share-based Compensation (Details)", "role": "http://www.molinahealthcare.com/role/StockholdersEquityComponentsOfShareBasedCompensationDetails", "shortName": "Stockholders' Equity - Components of Share-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415404 - Disclosure - Stockholders' Equity - Restricted and Performance Stock Activity (Details)", "role": "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails", "shortName": "Stockholders' Equity - Restricted and Performance Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)", "role": "http://www.molinahealthcare.com/role/StockholdersEquityFairValueOfAwardsGrantedAndVestedDetails", "shortName": "Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)", "role": "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails", "shortName": "Stockholders' Equity - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Stockholders' Equity - Stock Options by Exercise Price (Details)", "role": "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails", "shortName": "Stockholders' Equity - Stock Options by Exercise Price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416401 - Disclosure - Restructuring Costs (Details)", "role": "http://www.molinahealthcare.com/role/RestructuringCostsDetails", "shortName": "Restructuring Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4_us-gaap_RestructuringPlanAxis_moh_ITRestructuringMember", "decimals": "-6", "lang": null, "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417401 - Disclosure - Employee Benefit Plans (Details)", "role": "http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails", "shortName": "Employee Benefit Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418401 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.molinahealthcare.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - Segments - Narrative (Details)", "role": "http://www.molinahealthcare.com/role/SegmentsNarrativeDetails", "shortName": "Segments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "moh-12312019x10k.htm", "contextRef": "I2018Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - moh-12312019x10k.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - moh-12312019x10k.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 105, "tag": { "country_PR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "PUERTO RICO", "terseLabel": "Puerto Rico" } } }, "localname": "PR", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r564" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r563" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r561" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r565" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r565" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r565" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r566" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r565" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r565" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r565" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r565" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r560" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r562" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "moh_A2017RestructuringPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2017 Restructuring Plan [Member]", "label": "2017 Restructuring Plan [Member]", "terseLabel": "2017 Restructuring Plan" } } }, "localname": "A2017RestructuringPlanMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "moh_A4.875SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.875% Senior Notes [Member]", "label": "4.875% Senior Notes [Member]", "netLabel": "4.875% Notes", "terseLabel": "4.875% Notes", "verboseLabel": "4.875% Notes" } } }, "localname": "A4.875SeniorNotesMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "moh_AdvancesToRelatedPartiesAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Advances to related parties and other assets.", "label": "Advances To Related Parties And Other Assets", "verboseLabel": "Advances to related parties and other assets" } } }, "localname": "AdvancesToRelatedPartiesAndOtherAssets", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable", "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable", "terseLabel": "Risk adjustment, net payable" } } }, "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)", "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)", "negatedLabel": "Risk adjustment payable" } } }, "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable", "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable", "terseLabel": "Risk adjustment receivable" } } }, "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmortizationOfDebtDiscountPremiumAndSaleLeasebackFinancingObligation": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of Debt Discount (Premium) and Sale Leaseback Financing Obligation", "label": "Amortization Of Debt Discount (Premium) And Sale Leaseback Financing Obligation", "terseLabel": "Amortization of convertible senior notes and finance lease liabilities" } } }, "localname": "AmortizationOfDebtDiscountPremiumAndSaleLeasebackFinancingObligation", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueDetails": { "order": 1.0, "parentTag": "moh_QualityIncentivePremiumRevenueRecognized", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current year quality incentive premium revenue recognized.", "label": "Amount Of Current Year Quality Incentive Premium Revenue Recognized", "verboseLabel": "Earned current period" } } }, "localname": "AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueDetails": { "order": 2.0, "parentTag": "moh_QualityIncentivePremiumRevenueRecognized", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of quality incentive premium revenue recognized from prior year.", "label": "Amount Of Quality Incentive Premium Revenue Recognized From Prior Year", "verboseLabel": "Earned prior periods" } } }, "localname": "AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountOfQualityIncentivePremiumRevenueRecognizedInCurrentPeriodAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount Of Quality Incentive Premium Revenue Recognized In Current Period [Abstract]", "label": "Amount Of Quality Incentive Premium Revenue Recognized In Current Period [Abstract]", "terseLabel": "Amount of quality incentive premium revenue recognized in current period:" } } }, "localname": "AmountOfQualityIncentivePremiumRevenueRecognizedInCurrentPeriodAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueDetails" ], "xbrltype": "stringItemType" }, "moh_AmountsDuetoGovernmentAgenciesAmountsDueState": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails": { "order": 2.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amounts Due to Government Agencies, Amounts Due State", "label": "Amounts Due to Government Agencies, Amounts Due State", "terseLabel": "Other amounts due to states" } } }, "localname": "AmountsDuetoGovernmentAgenciesAmountsDueState", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountsDuetoGovernmentAgenciesCostSharingReduction": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails": { "order": 4.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amounts Due to Government Agencies, Cost Sharing Reduction", "label": "Amounts Due to Government Agencies, Cost Sharing Reduction", "terseLabel": "Cost sharing reduction" } } }, "localname": "AmountsDuetoGovernmentAgenciesCostSharingReduction", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountsDuetoGovernmentAgenciesMedicalCostFloorsandCorridors": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails": { "order": 1.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amounts Due to Government Agencies, Medical Cost Floors and Corridors", "label": "Amounts Due to Government Agencies, Medical Cost Floors and Corridors", "terseLabel": "Medical cost floors and corridors" } } }, "localname": "AmountsDuetoGovernmentAgenciesMedicalCostFloorsandCorridors", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountsDuetoGovernmentAgenciesOther": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails": { "order": 5.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amounts Due to Government Agencies, Other", "label": "Amounts Due to Government Agencies, Other", "terseLabel": "Other" } } }, "localname": "AmountsDuetoGovernmentAgenciesOther", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_AmountsDuetoGovernmentAgenciesRiskAdjustment": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails": { "order": 3.0, "parentTag": "moh_MedicalPremiumLiabilityDueToAgency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amounts Due to Government Agencies, Risk Adjustment", "label": "Amounts Due to Government Agencies, Risk Adjustment", "terseLabel": "Risk adjustment" } } }, "localname": "AmountsDuetoGovernmentAgenciesRiskAdjustment", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_AntidilutiveSecuritiesExcludedfromComputationofEPSShareBasedCompensationAmount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Antidilutive Securities Excluded from Computation of EPS, Share Based Compensation, Amount", "label": "Antidilutive Securities Excluded from Computation of EPS, Share Based Compensation, Amount", "terseLabel": "Stock-based compensation (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedfromComputationofEPSShareBasedCompensationAmount", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "moh_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Supplemental lease information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "moh_BasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis Of Presentation [Line Items]", "label": "Basis Of Presentation [Line Items]", "terseLabel": "Basis Of Presentation [Line Items]" } } }, "localname": "BasisOfPresentationLineItems", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "moh_BasisOfPresentationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis Of Presentation [Table]", "label": "Basis Of Presentation [Table]", "terseLabel": "Basis Of Presentation [Table]" } } }, "localname": "BasisOfPresentationTable", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "moh_CMSSubsidiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CMS Subsidies [Member]", "label": "CMS Subsidies [Member]", "terseLabel": "CMS Subsidies" } } }, "localname": "CMSSubsidiesMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableAdditionalInformationDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "California, Illinois, New Mexico, Ohio, South Carolina, Texas, Washington, and Wisconsin [Member]", "label": "California, Illinois, New Mexico, Ohio, South Carolina, Texas, Washington, and Wisconsin [Member]", "terseLabel": "California, Illinois, New Mexico, Ohio, South Carolina, Texas, Washington, and Wisconsin" } } }, "localname": "CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "moh_CallOptionDerivativeAssetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Call Option, Derivative Asset [Member]", "label": "Call Option, Derivative Asset [Member]", "netLabel": "1.125% Call Option", "terseLabel": "Call Option", "verboseLabel": "1.125% Call Option" } } }, "localname": "CallOptionDerivativeAssetMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "moh_CapitationClaimsPayable": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Capitation Claims Payable", "label": "Capitation Claims Payable", "terseLabel": "Capitation payable" } } }, "localname": "CapitationClaimsPayable", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "moh_CashConvertibleSeniorNotesDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Convertible Senior Notes due 2020 [Member]", "label": "Cash Convertible Senior Notes due 2020 [Member]", "terseLabel": "1.125% Convertible Notes", "verboseLabel": "1.125% Convertible Notes" } } }, "localname": "CashConvertibleSeniorNotesDue2020Member", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "moh_CashConvertibleSeniorNotesDue2020WarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Convertible Senior Notes Due 2020, Warrants [Member]", "label": "Cash Convertible Senior Notes Due 2020, Warrants [Member]", "terseLabel": "1.125% Warrants" } } }, "localname": "CashConvertibleSeniorNotesDue2020WarrantsMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "moh_CashPaidDuringThePeriodAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Paid During The Period [Abstract]", "label": "Cash Paid During The Period [Abstract]", "terseLabel": "Cash paid during the period for:" } } }, "localname": "CashPaidDuringThePeriodAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "moh_CashPaidForSettlementOfConversionOption": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash Paid For Settlement Of Conversion Option", "label": "Cash Paid For Settlement Of Conversion Option", "negatedTerseLabel": "Cash paid for partial settlement of conversion option" } } }, "localname": "CashPaidForSettlementOfConversionOption", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "moh_ChangesInAmountsDueToAndDueFromAffiliates": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Changes in amounts due to and due from affiliates.", "label": "Changes In Amounts Due To And Due From Affiliates", "verboseLabel": "Change in amounts due to/from affiliates" } } }, "localname": "ChangesInAmountsDueToAndDueFromAffiliates", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "moh_ClassOfWarrantOrRightStatedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Stated Interest Rate", "label": "Class Of Warrant Or Right, Stated Interest Rate", "terseLabel": "Stated interest rate" } } }, "localname": "ClassOfWarrantOrRightStatedInterestRate", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "moh_CommonStockPurchasesNotSettledAtEndOfPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Common Stock Purchases Not Settled At End Of Period", "label": "Common Stock Purchases Not Settled At End Of Period", "terseLabel": "Common stock purchases not settled at end of period" } } }, "localname": "CommonStockPurchasesNotSettledAtEndOfPeriod", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]", "label": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]", "verboseLabel": "Components of the change in medical claims and benefits payable" } } }, "localname": "ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableTables" ], "xbrltype": "textBlockItemType" }, "moh_ContractRightsandLicensingAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract Rights and Licensing Agreements [Member]", "label": "Contract Rights and Licensing Agreements [Member]", "terseLabel": "Contract rights and licenses" } } }, "localname": "ContractRightsandLicensingAgreementsMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails" ], "xbrltype": "domainItemType" }, "moh_ContractTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract Term", "label": "Contract Term", "terseLabel": "Contract term" } } }, "localname": "ContractTerm", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "durationItemType" }, "moh_ConvertibleSeniorNotesDue2044Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible Senior Notes Due 2044 [Member]", "label": "Convertible Senior Notes Due 2044 [Member]", "terseLabel": "Convertible Senior Notes" } } }, "localname": "ConvertibleSeniorNotesDue2044Member", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "moh_ConvertibleSeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible Senior Notes [Member]", "label": "Convertible Senior Notes [Member]", "terseLabel": "Convertible senior notes" } } }, "localname": "ConvertibleSeniorNotesMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "moh_CurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Current Assets [Member]", "label": "Current Assets [Member]", "terseLabel": "Current assets" } } }, "localname": "CurrentAssetsMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails" ], "xbrltype": "domainItemType" }, "moh_CurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Current Liabilities [Member]", "label": "Current Liabilities [Member]", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilitiesMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails" ], "xbrltype": "domainItemType" }, "moh_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Unrealized Loss Position [Abstract]", "label": "Debt Securities, Available-For-Sale, Unrealized Loss Position [Abstract]", "terseLabel": "Estimated Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails" ], "xbrltype": "stringItemType" }, "moh_DeferredCompensationPlanDeferralPercentageOfBasicSalary": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred compensation plan deferral percentage of basic salary.", "label": "Deferred Compensation Plan Deferral Percentage Of Basic Salary", "verboseLabel": "Deferred compensation plan deferral percentage of basic salary" } } }, "localname": "DeferredCompensationPlanDeferralPercentageOfBasicSalary", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "moh_DeferredCompensationPlanDeferralPercentageOfBonus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred compensation plan deferral percentage of bonus.", "label": "Deferred Compensation Plan Deferral Percentage Of Bonus", "verboseLabel": "Deferred compensation plan deferral percentage of bonus" } } }, "localname": "DeferredCompensationPlanDeferralPercentageOfBonus", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "moh_DeferredIncomeTaxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Income Tax [Member]", "label": "Deferred Income Tax [Member]", "terseLabel": "Deferred Income Tax" } } }, "localname": "DeferredIncomeTaxMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "moh_DeferredTaxAssetFixedAssetsandIntangibles": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Asset, Fixed Assets and Intangibles", "label": "Deferred Tax Asset, Fixed Assets and Intangibles", "terseLabel": "Fixed assets and intangibles" } } }, "localname": "DeferredTaxAssetFixedAssetsandIntangibles", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "moh_DepreciationAndAmortizationOfCapitalizedSoftware": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails": { "order": 1.0, "parentTag": "moh_DepreciationandAmortizationContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Depreciation, and amortization of capitalized software.", "label": "Depreciation And Amortization Of Capitalized Software", "verboseLabel": "Amortization of capitalized software" } } }, "localname": "DepreciationAndAmortizationOfCapitalizedSoftware", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "moh_DepreciationandAmortizationContinuingOperations": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Depreciation and Amortization, Continuing Operations", "label": "Depreciation and Amortization, Continuing Operations", "totalLabel": "Subtotal" } } }, "localname": "DepreciationandAmortizationContinuingOperations", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "moh_DetailsofchangeinfairvalueofderivativesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Details of change in fair value of derivatives", "label": "Details of change in fair value of derivatives [Abstract]", "terseLabel": "Details of change in fair value of derivatives, net:" } } }, "localname": "DetailsofchangeinfairvalueofderivativesAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "moh_DispositionofBusinessReceivablefromBuyer": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_GainLossOnSaleOfBusiness", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposition of Business, Receivable from Buyer", "label": "Disposition of Business, Receivable from Buyer", "terseLabel": "Cash received from buyers" } } }, "localname": "DispositionofBusinessReceivablefromBuyer", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "moh_DispositionofBusinessTransactionCosts": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_GainLossOnSaleOfBusiness", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposition of Business, Transaction Costs", "label": "Disposition of Business, Transaction Costs", "negatedTerseLabel": "Transaction costs" } } }, "localname": "DispositionofBusinessTransactionCosts", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Health Insurance, Percent", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Health Insurance, Percent", "terseLabel": "Nondeductible health insurer fee (\u201cHIF\u201d)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "moh_EffectiveIncomeTaxRateReconciliationWorthlessStockDeduction": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Worthless Stock Deduction", "label": "Effective Income Tax Rate Reconciliation, Worthless Stock Deduction", "terseLabel": "Worthless stock deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationWorthlessStockDeduction", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "moh_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "2019 ESPP" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "moh_EmployeeStockPurchasePlanandStockOptionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Stock Purchase Plan and Stock Options [Member]", "label": "Employee Stock Purchase Plan and Stock Options [Member]", "terseLabel": "Employee stock purchase plan and stock options" } } }, "localname": "EmployeeStockPurchasePlanandStockOptionsMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityComponentsOfShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "moh_EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Incentive Plan [Member]", "label": "Equity Incentive Plan [Member]", "terseLabel": "2019 EIP" } } }, "localname": "EquityIncentivePlanMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "moh_ExercisePriceRange1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range 1 [Member]", "label": "Exercise Price Range 1 [Member]", "terseLabel": "$33.02" } } }, "localname": "ExercisePriceRange1Member", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "moh_ExercisePriceRange2Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range 2 [Member]", "label": "Exercise Price Range 2 [Member]", "terseLabel": "$67.33" } } }, "localname": "ExercisePriceRange2Member", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "moh_FairMarketValueOfCommonStockPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair market value of common stock, Percentage.", "label": "Fair Market Value Of Common Stock Percentage", "terseLabel": "Employee purchase price as a percentage of stock price" } } }, "localname": "FairMarketValueOfCommonStockPercentage", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "moh_FinanceLeaseAssetsLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Lease, Assets, Lessee [Abstract]", "label": "Finance Lease, Assets, Lessee [Abstract]", "terseLabel": "ROU assets" } } }, "localname": "FinanceLeaseAssetsLesseeAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "moh_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/LeasesComponentsOfLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Cost", "label": "Finance Lease, Cost", "totalLabel": "Total finance lease expense" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/LeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "moh_FinanceLeaseLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Lease, Liabilities, Lessee [Abstract]", "label": "Finance Lease, Liabilities, Lessee [Abstract]", "terseLabel": "Lease liabilities" } } }, "localname": "FinanceLeaseLiabilitiesLesseeAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "moh_FinanceLeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Lease, Remaining Lease Term", "label": "Finance Lease, Remaining Lease Term", "terseLabel": "Finance lease term" } } }, "localname": "FinanceLeaseRemainingLeaseTerm", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "moh_GainLossonDispositionofLiabilities": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_GainLossOnSaleOfBusiness", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gain (Loss) on Disposition of Liabilities", "label": "Gain (Loss) on Disposition of Liabilities", "terseLabel": "Decrease in carrying amount of liabilities" } } }, "localname": "GainLossonDispositionofLiabilities", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "moh_GovernmentReceivablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Government Receivables [Member]", "label": "Government Receivables [Member]", "terseLabel": "Government receivables" } } }, "localname": "GovernmentReceivablesMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ReceivablesDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "moh_HealthCareOrganizationInsurerFeeExpense": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Health Care Organization, Insurer Fee Expense", "label": "Health Care Organization, Insurer Fee Expense", "terseLabel": "Health insurer fees" } } }, "localname": "HealthCareOrganizationInsurerFeeExpense", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "moh_HealthCareOrganizationInsurerFeeRevenue": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Health Care Organization, Insurer Fee Revenue", "label": "Health Care Organization, Insurer Fee Revenue", "terseLabel": "Health insurer fees reimbursed" } } }, "localname": "HealthCareOrganizationInsurerFeeRevenue", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "moh_HealthCareOrganizationNumberOfMembers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Health Care Organization, Number of Members", "label": "Health Care Organization, Number Of Members", "terseLabel": "Number of members served, approximately (in member)" } } }, "localname": "HealthCareOrganizationNumberOfMembers", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "moh_HealthCareOrganizationPremiumTaxRevenue": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Health Care Organization, Premium Tax Revenue", "label": "Health Care Organization, Premium Tax Revenue", "terseLabel": "Premium tax revenue" } } }, "localname": "HealthCareOrganizationPremiumTaxRevenue", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "moh_HealthCareOrganizationRevenuePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Health Care Organization, Revenue Percentage", "label": "Health Care Organization, Revenue Percentage", "terseLabel": "Premium revenue percentage" } } }, "localname": "HealthCareOrganizationRevenuePercentage", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "percentItemType" }, "moh_HealthInsurerFeeReimbursementReceivablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Health Insurer Fee Reimbursement Receivables [Member]", "label": "Health Insurer Fee Reimbursement Receivables [Member]", "terseLabel": "Health insurer fee reimbursement receivables" } } }, "localname": "HealthInsurerFeeReimbursementReceivablesMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ReceivablesDetails" ], "xbrltype": "domainItemType" }, "moh_HealthPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Health plans.", "label": "Health Plans [Member]", "terseLabel": "Health Plans", "verboseLabel": "Health Plans" } } }, "localname": "HealthPlansMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails", "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails", "http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "moh_ITRestructuringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "IT Restructuring [Member]", "label": "IT Restructuring [Member]", "terseLabel": "IT Restructuring" } } }, "localname": "ITRestructuringMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 1.0, "parentTag": "moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Income (Loss) Before Income Taxes And Equity In Net Income Of Subsidiaries", "label": "Income (Loss) Before Income Taxes And Equity In Net Income Of Subsidiaries", "totalLabel": "Loss before income tax (benefit) expense and equity in net earnings (losses) of subsidiaries" } } }, "localname": "IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Medical Premium Liability Due to Agency", "label": "Increase (Decrease) In Medical Premium Liability Due To Agency", "terseLabel": "Amounts due government agencies" } } }, "localname": "IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "moh_IncreaseDecreaseinCarryingAmountofAssets": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_GainLossOnSaleOfBusiness", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Carrying Amount of Assets", "label": "Increase (Decrease) in Carrying Amount of Assets", "terseLabel": "Decrease in carrying amount of assets" } } }, "localname": "IncreaseDecreaseinCarryingAmountofAssets", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "moh_InvestmentsAverageMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investments, Average Maturity Period", "label": "Investments, Average Maturity Period", "terseLabel": "Average maturity of investments" } } }, "localname": "InvestmentsAverageMaturityPeriod", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "moh_InvestmentsMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investments, Maturity Period", "label": "Investments, Maturity Period", "terseLabel": "Final maturities of investments" } } }, "localname": "InvestmentsMaturityPeriod", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense, Incurred Claims Including Acquisition Adjustment", "label": "Liability For Unpaid Claims And Claims Adjustment Expense, Incurred Claims Including Acquisition Adjustment", "terseLabel": "Incurred Claims and Allocated Claims Adjustment Expenses" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount", "terseLabel": "Fee-for-service claims incurred but not paid (\u201cIBNP\u201d)" } } }, "localname": "LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "moh_LineofCreditFacilityAmortizationPaymentPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line of Credit Facility, Amortization Payment Percentage", "label": "Line of Credit Facility, Amortization Payment Percentage", "terseLabel": "Amortization payment percentage" } } }, "localname": "LineofCreditFacilityAmortizationPaymentPercentage", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" ], "xbrltype": "percentItemType" }, "moh_LineofCreditFacilityMinimumThresholdforAdvancements": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line of Credit Facility, Minimum Threshold for Advancements", "label": "Line of Credit Facility, Minimum Threshold for Advancements", "terseLabel": "Minimum principal amount of advancements" } } }, "localname": "LineofCreditFacilityMinimumThresholdforAdvancements", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-Term Debt, Current Maturities, Net Of Unamortized Premium (Discount)", "label": "Long-Term Debt, Current Maturities, Net Of Unamortized Premium (Discount)", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount", "label": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount", "terseLabel": "Non-current portion of long-term debt" } } }, "localname": "LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "moh_MarketplaceProgramAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Marketplace Program [Abstract]", "label": "Marketplace Program [Abstract]", "terseLabel": "Marketplace program:" } } }, "localname": "MarketplaceProgramAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails" ], "xbrltype": "stringItemType" }, "moh_MaximumAvailableQualityIncentivePremiumCurrentYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum available quality incentive premium current year.", "label": "Maximum Available Quality Incentive Premium Current Year", "verboseLabel": "Maximum available quality incentive premium - current period" } } }, "localname": "MaximumAvailableQualityIncentivePremiumCurrentYear", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueDetails" ], "xbrltype": "monetaryItemType" }, "moh_MaximumContractTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum contract term.", "label": "Maximum Contract Term", "terseLabel": "Maximum contract term" } } }, "localname": "MaximumContractTerm", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "durationItemType" }, "moh_MedicaidExpansionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicaid Expansion [Member]", "label": "Medicaid Expansion [Member]", "terseLabel": "Medicaid Expansion" } } }, "localname": "MedicaidExpansionMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "moh_MedicaidProgramAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicaid Program [Abstract]", "label": "Medicaid Program [Abstract]", "terseLabel": "Medicaid program:" } } }, "localname": "MedicaidProgramAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails" ], "xbrltype": "stringItemType" }, "moh_MedicalClaimsAndBenefitsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Medical Claims and Benefits Payable", "label": "Medical Claims And Benefits Payable", "terseLabel": "Medical claims and benefits payable" } } }, "localname": "MedicalClaimsAndBenefitsPayable", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Medical Claims and Benefits Payable, Adjustments, Change in Provider", "label": "Medical Claims And Benefits Payable, Adjustments, Change In Provider", "terseLabel": "Change in non-risk and other provider payables" } } }, "localname": "MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails" ], "xbrltype": "monetaryItemType" }, "moh_MedicalPremiumLiabilityDueToAgency": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Medical Premium Liability Due to Agency", "label": "Medical Premium Liability Due To Agency", "terseLabel": "Amounts due government agencies", "totalLabel": "Total" } } }, "localname": "MedicalPremiumLiabilityDueToAgency", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails" ], "xbrltype": "monetaryItemType" }, "moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Medical Premiums Liability, Medical Care Costs Threshold", "label": "Medical Premiums Liability, Medical Care Costs Threshold", "terseLabel": "Medical premium liability based on medical costs threshold" } } }, "localname": "MedicalPremiumsLiabilityMedicalCareCostsThreshold", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "moh_MinimumContractTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum contract term.", "label": "Minimum Contract Term", "terseLabel": "Minimum contract terms" } } }, "localname": "MinimumContractTerm", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "durationItemType" }, "moh_MunicipalSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Municipal securities.", "label": "Municipal Securities [Member]", "netLabel": "Municipal securities", "terseLabel": "Municipal securities", "verboseLabel": "Municipal securities" } } }, "localname": "MunicipalSecuritiesMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "domainItemType" }, "moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income (Loss) From Continuing Operations Before Equity Method Investments, Extraordinary Items, Noncontrolling Interest", "label": "Net Income (Loss) From Continuing Operations Before Equity Method Investments, Extraordinary Items, Noncontrolling Interest", "totalLabel": "Net loss before equity in net earnings (losses) of subsidiaries" } } }, "localname": "NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "moh_NextLevelHealthPartnersInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NextLevel Health Partners, Inc. [Member]", "label": "NextLevel Health Partners, Inc. [Member]", "terseLabel": "NextLevel Health Partners, Inc." } } }, "localname": "NextLevelHealthPartnersInc.Member", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "moh_NoncashRestructuringCharges": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Non-cash Restructuring Charges", "label": "Non-cash Restructuring Charges", "terseLabel": "Non-cash restructuring charges" } } }, "localname": "NoncashRestructuringCharges", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "moh_NotesIssuedFairValueAdjustmentIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Notes Issued, Fair Value Adjustment Increase (Decrease)", "label": "Notes Issued, Fair Value Adjustment Increase (Decrease)", "terseLabel": "Component of convertible senior notes allocated to additional paid-in capital, net of income taxes" } } }, "localname": "NotesIssuedFairValueAdjustmentIncreaseDecrease", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "moh_NumberOfCountiesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Counties In Which Entity Operates", "label": "Number Of Counties In Which Entity Operates", "verboseLabel": "Number of countries" } } }, "localname": "NumberOfCountiesInWhichEntityOperates", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "moh_NumberOfMembersEligibleForTheHealthCarePrograms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of members eligible for the health care programs.", "label": "Number Of Members Eligible For The Health Care Programs", "verboseLabel": "Number of members eligible for the health care programs" } } }, "localname": "NumberOfMembersEligibleForTheHealthCarePrograms", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "moh_OperatingLeaseAssetsLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Lease, Assets, Lessee [Abstract]", "label": "Operating Lease, Assets, Lessee [Abstract]", "terseLabel": "ROU assets" } } }, "localname": "OperatingLeaseAssetsLesseeAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "moh_OperatingLeaseLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Lease, Liabilities, Lessee [Abstract]", "label": "Operating Lease, Liabilities, Lessee [Abstract]", "terseLabel": "Lease liabilities" } } }, "localname": "OperatingLeaseLiabilitiesLesseeAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "moh_OperatingLeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Lease, Remaining Lease Term", "label": "Operating Lease, Remaining Lease Term", "terseLabel": "Operating lease term" } } }, "localname": "OperatingLeaseRemainingLeaseTerm", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "moh_OtherClaimsPayable": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Claims Payable", "label": "Other Claims Payable", "terseLabel": "Other" } } }, "localname": "OtherClaimsPayable", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "moh_OtherGeographicalAreasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Geographical Areas.", "label": "Other Geographical Areas [Member]", "terseLabel": "Other" } } }, "localname": "OtherGeographicalAreasMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "moh_OtherReceivablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Receivables [Member]", "label": "Other Receivables [Member]", "terseLabel": "Other" } } }, "localname": "OtherReceivablesMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ReceivablesDetails" ], "xbrltype": "domainItemType" }, "moh_PercentageOfAdditionalIncrementalRevenueEarned": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of additional incremental revenue earned.", "label": "Percentage Of Additional Incremental Revenue Earned", "verboseLabel": "Percentage of additional incremental revenue earned" } } }, "localname": "PercentageOfAdditionalIncrementalRevenueEarned", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "moh_PharmacyClaimsPayable": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Pharmacy Claims Payable", "label": "Pharmacy Claims Payable", "terseLabel": "Pharmacy payable" } } }, "localname": "PharmacyClaimsPayable", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "moh_PharmacyRebateReceivablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharmacy Rebate Receivables [Member]", "label": "Pharmacy Rebate Receivables [Member]", "terseLabel": "Pharmacy rebate receivables" } } }, "localname": "PharmacyRebateReceivablesMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ReceivablesDetails" ], "xbrltype": "domainItemType" }, "moh_PremiumTaxExpenses": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "An assessment levied by a state government on the net premium income collected.", "label": "Premium Tax Expenses", "terseLabel": "Premium tax expenses" } } }, "localname": "PremiumTaxExpenses", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "moh_ProceedsFromBorrowingsUnderCreditFacility": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Borrowings Under Credit Facility", "label": "Proceeds From Borrowings Under Credit Facility", "verboseLabel": "Proceeds from borrowings under credit facility" } } }, "localname": "ProceedsFromBorrowingsUnderCreditFacility", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "moh_ProfessionalServicesFeesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Professional Services Fees [Member]", "label": "Professional Services Fees [Member]", "terseLabel": "Consulting Fees" } } }, "localname": "ProfessionalServicesFeesMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "moh_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization", "label": "Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization", "totalLabel": "Property, equipment, and capitalized software, net", "verboseLabel": "Property, equipment, and capitalized software, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "monetaryItemType" }, "moh_ProviderNetworksMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Provider networks.", "label": "Provider Networks [Member]", "netLabel": "Provider networks" } } }, "localname": "ProviderNetworksMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails" ], "xbrltype": "domainItemType" }, "moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Quality Incentive Premium Revenue As A Percentage Of Total Revenue", "label": "Quality Incentive Premium Revenue As A Percentage Of Total Revenue", "verboseLabel": "Quality incentive premium revenue recognized as a percentage of total premium revenue" } } }, "localname": "QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueDetails" ], "xbrltype": "percentItemType" }, "moh_QualityIncentivePremiumRevenueRecognized": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Quality incentive premium revenue recognized.", "label": "Quality Incentive Premium Revenue Recognized", "totalLabel": "Total quality incentive premium revenue recognized" } } }, "localname": "QualityIncentivePremiumRevenueRecognized", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueDetails" ], "xbrltype": "monetaryItemType" }, "moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Quality incentive premium revenue recognized.", "label": "Quality Incentive Premium Revenue Recognized [Table Text Block]", "verboseLabel": "Quality incentive premium revenue recognized" } } }, "localname": "QualityIncentivePremiumRevenueRecognizedTableTextBlock", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "moh_RecordedInCostOfServiceRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recorded In Cost Of Service Revenue [Abstract]", "label": "Recorded In Cost Of Service Revenue [Abstract]", "terseLabel": "Recorded in cost of service revenue:" } } }, "localname": "RecordedInCostOfServiceRevenueAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails" ], "xbrltype": "stringItemType" }, "moh_RecordedInDepreciationAndAmortizationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recorded In Depreciation And Amortization [Abstract]", "label": "Recorded In Depreciation And Amortization [Abstract]", "terseLabel": "Recorded in depreciation and amortization:" } } }, "localname": "RecordedInDepreciationAndAmortizationAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails" ], "xbrltype": "stringItemType" }, "moh_RestrictedandPerformanceStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted and Performance Stock [Member]", "label": "Restricted and Performance Stock [Member]", "terseLabel": "RSAs, PSAs and PSUs (defined below)" } } }, "localname": "RestrictedandPerformanceStockMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityComponentsOfShareBasedCompensationDetails", "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "domainItemType" }, "moh_RestrictionsOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restrictions On Investments [Table Text Block]", "label": "Restrictions On Investments [Table Text Block]", "terseLabel": "Balances of restricted investments" } } }, "localname": "RestrictionsOnInvestmentsTableTextBlock", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "moh_RetainedEarningsIncludingDeferredIncomeTaxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Retained Earnings, Including Deferred Income Tax [Member]", "label": "Retained Earnings, Including Deferred Income Tax [Member]", "terseLabel": "Retained Earnings, Including Deferred Income Tax" } } }, "localname": "RetainedEarningsIncludingDeferredIncomeTaxMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability [Abstract]", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability [Abstract]", "terseLabel": "ROU assets recognized in exchange for lease obligations:" } } }, "localname": "RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "stringItemType" }, "moh_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Risks and uncertainties.", "label": "Risks And Uncertainties [Policy Text Block]", "verboseLabel": "Risks and Uncertainties" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "moh_STARCHIPContractsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "STAR/CHIP Contracts [Member]", "label": "STAR/CHIP Contracts [Member]", "terseLabel": "STAR/CHIP Contracts" } } }, "localname": "STARCHIPContractsMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "moh_ScheduleOfDebtInstrumentsInterestCostRecognizedTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of debt instruments interest cost recognized.", "label": "Schedule Of Debt Instruments Interest Cost Recognized [Table Text Block]", "verboseLabel": "Interest costs" } } }, "localname": "ScheduleOfDebtInstrumentsInterestCostRecognizedTableTextBlock", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "moh_SeniorNotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes Due 2022 [Member]", "label": "Senior Notes Due 2022 [Member]", "netLabel": "5.375% Notes", "terseLabel": "5.375% Notes", "verboseLabel": "5.375% Senior Notes" } } }, "localname": "SeniorNotesDue2022Member", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value", "terseLabel": "Fair value of restricted shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityFairValueOfAwardsGrantedAndVestedDetails" ], "xbrltype": "monetaryItemType" }, "moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award maximum amount per employee.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Amount Per Employee", "terseLabel": "Maximum annual contribution per employee" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "moh_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsTerminatedNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Terminated, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Terminated, Number", "terseLabel": "Number of warrants terminated (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsTerminatedNumber", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Outstanding Liabilities Relating to Prior Years", "label": "Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Outstanding Liabilities Relating to Prior Years", "terseLabel": "All outstanding liabilities before 2017" } } }, "localname": "ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "moh_StructuredSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structured Securities [Member]", "label": "Structured Securities [Member]", "terseLabel": "Structured Securities" } } }, "localname": "StructuredSecuritiesMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "moh_TaxesBasedOnPremiumsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Taxes based on premiums.", "label": "Taxes Based On Premiums [Policy Text Block]", "verboseLabel": "Taxes Based on Premiums" } } }, "localname": "TaxesBasedOnPremiumsPolicyTextBlock", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "moh_TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan [Member]", "label": "Term Loan [Member]", "terseLabel": "Term Loan Facility", "verboseLabel": "Term Loan Facility" } } }, "localname": "TermLoanMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "moh_TexasHealthAndHumanServicesCommissionSTARPLUSProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Texas Health And Human Services Commission, STAR PLUS Program [Member]", "label": "Texas Health And Human Services Commission, STAR PLUS Program [Member]", "terseLabel": "Texas Health and Human Services Commission, STARPLUS Program" } } }, "localname": "TexasHealthAndHumanServicesCommissionSTARPLUSProgramMember", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "moh_UnrecognizedCompensationForfeitedRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Unrecognized compensation forfeited rate.", "label": "Unrecognized Compensation Forfeited Rate", "verboseLabel": "Unrecognized compensation forfeited rate" } } }, "localname": "UnrecognizedCompensationForfeitedRate", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "moh_WeightedAverageNumberofSharesIssuedConversionofSeniorNotes": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Number of Shares Issued, Conversion of Senior Notes", "label": "Weighted Average Number of Shares Issued, Conversion of Senior Notes", "terseLabel": "Conversion of convertible senior notes (in shares)" } } }, "localname": "WeightedAverageNumberofSharesIssuedConversionofSeniorNotes", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "moh_WeightedAverageNumberofSharesShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Number of Shares, Share Based Compensation", "label": "Weighted Average Number of Shares, Share Based Compensation", "terseLabel": "Stock-based compensation (in shares)" } } }, "localname": "WeightedAverageNumberofSharesShareBasedCompensation", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "moh_YourCareHealthPlanInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "YourCare Health Plan, Inc. [Member]", "label": "YourCare Health Plan, Inc. [Member]", "terseLabel": "YourCare Health Plan" } } }, "localname": "YourCareHealthPlanInc.Member", "nsuri": "http://www.molinahealthcare.com/20191231", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Financial Information Disclosure [Abstract]" } } }, "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "nsuri": "http://fasb.org/srt/2019-01-31", "xbrltype": "stringItemType" }, "srt_CondensedFinancialStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Condensed Financial Statements, Captions [Line Items]", "terseLabel": "Condensed Financial Statements, Captions [Line Items]" } } }, "localname": "CondensedFinancialStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r558", "r569" ], "lang": { "en-US": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CommitmentsAndContingenciesDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantNotesToCondensedFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CommitmentsAndContingenciesDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantNotesToCondensedFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r180", "r189" ], "lang": { "en-US": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r63", "r130", "r573" ], "lang": { "en-US": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r193", "r306", "r310", "r537" ], "lang": { "en-US": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableAdditionalInformationDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/LeasesNarrativeDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/LeasesNarrativeDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableAdditionalInformationDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ParentCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The registrant that controls, directly or indirectly, another entity (or entities). The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.", "label": "Parent Company [Member]", "terseLabel": "Parent Company" } } }, "localname": "ParentCompanyMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CommitmentsAndContingenciesDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantNotesToCondensedFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r190", "r306", "r308", "r534", "r535" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/LeasesNarrativeDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/LeasesNarrativeDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r567" ], "lang": { "en-US": { "role": { "documentation": "Information reported for future period.", "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "auth_ref": [ "r572" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.", "label": "Condensed Balance Sheet [Table Text Block]", "verboseLabel": "Condensed balance sheets" } } }, "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantTables" ], "xbrltype": "textBlockItemType" }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "auth_ref": [ "r572" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.", "label": "Condensed Cash Flow Statement [Table Text Block]", "verboseLabel": "Condensed statements of cash flows" } } }, "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantTables" ], "xbrltype": "textBlockItemType" }, "srt_ScheduleOfCondensedFinancialStatementsTable": { "auth_ref": [ "r141", "r400", "r571", "r574", "r575", "r576" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.", "label": "Condensed Financial Statements [Table]", "terseLabel": "Condensed Financial Statements [Table]", "verboseLabel": "Schedule of Condensed Financial Statements [Table]" } } }, "localname": "ScheduleOfCondensedFinancialStatementsTable", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "auth_ref": [ "r572" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.", "label": "Condensed Income Statement [Table Text Block]", "verboseLabel": "Condensed statements of income" } } }, "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantTables" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails", "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r192", "r306", "r309", "r536", "r553", "r557", "r568", "r570" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails", "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r279", "r475" ], "lang": { "en-US": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CALIFORNIA", "terseLabel": "California" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_FL": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "FLORIDA", "netLabel": "Florida", "terseLabel": "Florida" } } }, "localname": "FL", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_IL": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ILLINOIS", "terseLabel": "Illinois" } } }, "localname": "IL", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_MI": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "MICHIGAN", "terseLabel": "Michigan" } } }, "localname": "MI", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_NM": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW MEXICO", "netLabel": "New Mexico", "terseLabel": "New Mexico" } } }, "localname": "NM", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_NY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW YORK", "terseLabel": "New York" } } }, "localname": "NY", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "stpr_OH": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "OHIO", "terseLabel": "Ohio", "verboseLabel": "Ohio" } } }, "localname": "OH", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_SC": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SOUTH CAROLINA", "terseLabel": "South Carolina" } } }, "localname": "SC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_TX": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "TEXAS", "terseLabel": "Texas", "verboseLabel": "Texas" } } }, "localname": "TX", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "stpr_WA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "WASHINGTON", "terseLabel": "Washington" } } }, "localname": "WA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r57" ], "lang": { "en-US": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ReceivablesDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r43", "r258" ], "calculation": { "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails": { "order": 2.0, "parentTag": "moh_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTotalLabel": "Total accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r69", "r71", "r72" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)", "verboseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r68", "r72", "r73", "r405" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r31" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r294", "r300", "r386" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature", "terseLabel": "Exchange of convertible senior notes", "totalLabel": "Net increase to additional paid-in capital" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt", "terseLabel": "Conversion of convertible senior notes" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Partial termination of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r177" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "Other", "verboseLabel": "Other" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails", "http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r319", "r349", "r353" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Pretax Charges" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityComponentsOfShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, after Tax", "verboseLabel": "Net-of-Tax Amount" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityComponentsOfShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r94", "r115", "r443" ], "calculation": { "http://www.molinahealthcare.com/role/DebtInterestCostDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of the discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtInterestCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r115", "r245", "r251" ], "calculation": { "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails": { "order": 3.0, "parentTag": "moh_DepreciationandAmortizationContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of restricted net assets of consolidated and unconsolidated subsidiaries as of the end of the most recently completed fiscal year.", "label": "Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries", "verboseLabel": "Net assets of subsidiaries subject to restrictions" } } }, "localname": "AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive common shares excluded from calculations (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r214", "r313" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "netLabel": "Asset-backed securities", "terseLabel": "Asset-backed securities", "verboseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r184", "r485", "r509" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r16", "r17", "r59" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r428" ], "calculation": { "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Fair value of assets measured on recurring basis" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r206" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r204", "r227" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]", "terseLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r211" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth fiscal year through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost", "terseLabel": "Due after five years through ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r208", "r211", "r499" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value", "terseLabel": "Due after five years through ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r210" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost", "verboseLabel": "Due after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r208", "r210", "r498" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value", "verboseLabel": "Due after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "auth_ref": [ "r212" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Allocated and Single Maturity Date, Maturity, after 10 Years, Amortized Cost", "terseLabel": "Due after ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "auth_ref": [ "r208", "r212", "r500" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value", "terseLabel": "Due after ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]", "terseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r209" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost", "verboseLabel": "Due in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r208", "r209", "r497" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "verboseLabel": "Due in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "auth_ref": [ "r213" ], "calculation": { "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value", "totalLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r201", "r205", "r227" ], "calculation": { "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt securities, available-for-sale", "verboseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]", "terseLabel": "Total Number of Positions" } } }, "localname": "AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r321", "r351" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails", "http://www.molinahealthcare.com/role/StockholdersEquityComponentsOfShareBasedCompensationDetails", "http://www.molinahealthcare.com/role/StockholdersEquityFairValueOfAwardsGrantedAndVestedDetails", "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r415", "r420" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and improvements", "verboseLabel": "Building and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r394", "r395" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r397", "r398", "r399" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "verboseLabel": "Purchase price of assets" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r124", "r393" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Goodwill and Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalLeaseObligationsCurrent": { "auth_ref": [ "r23", "r447", "r448" ], "calculation": { "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.", "label": "Capital Lease Obligations, Current", "terseLabel": "Lease financing obligations" } } }, "localname": "CapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsNoncurrent": { "auth_ref": [ "r53", "r447", "r448" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.", "label": "Capital Lease Obligations, Noncurrent", "terseLabel": "Finance lease liabilities" } } }, "localname": "CapitalLeaseObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": { "auth_ref": [ "r559" ], "calculation": { "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails": { "order": 2.0, "parentTag": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.", "label": "Capitalized Computer Software, Accumulated Amortization", "negatedLabel": "Less: accumulated amortization - capitalized software" } } }, "localname": "CapitalizedComputerSoftwareAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r437", "r438" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r14", "r39", "r117" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "netLabel": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r19", "r118", "r124" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents, and investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r110", "r117", "r123" ], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r110", "r441" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "verboseLabel": "Schedule of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r502" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit", "verboseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r138", "r302", "r318" ], "lang": { "en-US": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Striking price of warrants (USD per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Class of warrant" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommercialMortgageBackedSecuritiesMember": { "auth_ref": [ "r213", "r313" ], "lang": { "en-US": { "role": { "documentation": "Securities collateralized by commercial real estate mortgage loans.", "label": "Commercial Mortgage Backed Securities [Member]", "terseLabel": "Mortgage-backed securities", "verboseLabel": "Mortgage-backed securities" } } }, "localname": "CommercialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r278", "r280" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r29", "r294" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r29" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "netLabel": "Common stock, $0.001 par value; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018", "verboseLabel": "Common stock, $0.001 par value per share; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r311", "r312", "r317", "r354" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "verboseLabel": "Employee Benefit Plans" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/EmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "Provision for income taxes" } } }, "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r76", "r78", "r79" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r246", "r249", "r396" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r164", "r505" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "verboseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r167", "r168", "r439", "r440" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": { "auth_ref": [ "r142", "r400" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.", "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]", "verboseLabel": "Condensed Financial Information of Registrant" } } }, "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrant" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r124", "r403", "r407", "r408" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation and Presentation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractTerminationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Contract Termination [Member]", "terseLabel": "Contract Termination" } } }, "localname": "ContractTerminationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r304", "r305", "r307" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "netLabel": "1.125% Convertible Notes", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r313", "r315", "r547" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "netLabel": "Corporate debt securities", "terseLabel": "Corporate debt securities", "verboseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r90" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "auth_ref": [ "r86" ], "calculation": { "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.", "label": "Cost, Amortization", "verboseLabel": "Amortization of capitalized software and deferred contract costs" } } }, "localname": "CostOfGoodsAndServicesSoldAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": { "auth_ref": [ "r86" ], "calculation": { "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.", "label": "Cost, Depreciation and Amortization", "totalLabel": "Total depreciation and amortization recognized" } } }, "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r87" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "negatedTerseLabel": "Less: Other operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Adoption of new accounting standards", "verboseLabel": "Adoption of new accounting standard" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r127", "r383", "r388" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r136", "r385" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r383", "r388" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r127", "r383", "r388" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r120", "r122" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Convertible debt, converted amount of instrument" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r120", "r122" ], "lang": { "en-US": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "terseLabel": "Number of warrants issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r23", "r24", "r25", "r486", "r488", "r508" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails", "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r25", "r285", "r488", "r508" ], "calculation": { "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Net carrying amount of debt", "totalLabel": "Net carrying amount", "verboseLabel": "Aggregate principal amount of notes outstanding" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Debt instrument conversion price per share (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r52", "r295", "r296", "r298" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Debt instrument, conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": { "auth_ref": [ "r288" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.", "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal", "terseLabel": "If-converted value in excess of principal on convertible debt" } } }, "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period", "verboseLabel": "Senior notes amortization period" } } }, "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r444", "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "verboseLabel": "Aggregate principal amount of notes outstanding" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r436" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Estimated fair values of long-term debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r51", "r289", "r444" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "verboseLabel": "Senior note effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "netLabel": "Percentage of contractual interest rate on notes", "verboseLabel": "Percentage of contractual interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails", "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r53", "r503" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Repayment of aggregate carrying amount" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Repayments of principal" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r53", "r132", "r295", "r297", "r298", "r299", "r443", "r444", "r446", "r504" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r216", "r230", "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "In a Continuous Loss Position for 12 Months or More" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r216", "r230" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "In a Continuous Loss Position for 12 Months or More" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "In a Continuous Loss Position for 12 Months or More" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r216", "r230", "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "In a Continuous Loss Position for Less than 12 Months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r216", "r230" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "In a Continuous Loss Position for Less than 12 Months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "terseLabel": "In a Continuous Loss Position for Less than 12 Months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r217" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain", "terseLabel": "Gross realized investment gains" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r215", "r229", "r233" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]", "verboseLabel": "Available-for-sale investments" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "verboseLabel": "Liability for unrecognized tax benefits, potential decrease" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r384", "r388" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsCurrentNet": { "auth_ref": [ "r58", "r445" ], "calculation": { "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Current, Net", "negatedLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsCurrentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r44", "r445" ], "calculation": { "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "negatedTerseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r384", "r388" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r377" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r115", "r127", "r384", "r388" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r26", "r27", "r374", "r487", "r507" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred income tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r384", "r388" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r377" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred income tax asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r375" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred income tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r355", "r381", "r382" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "verboseLabel": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r356", "r381", "r382" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r379", "r381", "r382" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryover" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r355", "r381", "r382" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "verboseLabel": "Other accrued medical costs" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r355", "r381", "r382" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "verboseLabel": "Accrued expenses and reserve liabilities" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": { "auth_ref": [ "r355", "r381", "r382" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent", "terseLabel": "Lease financing obligation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve": { "auth_ref": [ "r355", "r381", "r382" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the unearned premiums reserve.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Unearned Premiums Reserve", "verboseLabel": "Unearned premiums" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r376" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance", "verboseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r356", "r381", "r382" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities, Prepaid Expenses", "negatedLabel": "Prepaid expenses" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "verboseLabel": "Expense recognized in connection with contributions" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "verboseLabel": "Maximum matching contribution by employer under defined contribution plan" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r115", "r256" ], "calculation": { "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails": { "order": 2.0, "parentTag": "moh_DepreciationandAmortizationContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation and amortization of furniture, equipment, building, and improvements" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r115", "r256" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r115", "r182" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r61", "r62", "r436" ], "calculation": { "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "1.125% Call Option derivative asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r61" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative asset" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r60", "r64", "r418", "r480" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Derivative asset" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r60", "r64", "r418", "r480" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "verboseLabel": "Derivative liability" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFinancialInstrumentsAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).", "label": "Derivative Financial Instruments, Assets [Member]", "terseLabel": "1.125% Call Option derivative asset" } } }, "localname": "DerivativeFinancialInstrumentsAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "netLabel": "Percentage of contractual interest rate on derivative", "terseLabel": "Percentage of contractual interest rate on derivative", "verboseLabel": "Percentage of contractual interest rate on derivative" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r417" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Change in fair value of derivatives, net" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r416", "r419", "r422", "r423" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r427" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivatives" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/Derivatives" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r61", "r62", "r436" ], "calculation": { "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "1.125% Conversion Option derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r61" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r140", "r410", "r411", "r412", "r413", "r414", "r421", "r422", "r424", "r425", "r426" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r321", "r351" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "verboseLabel": "Stock based compensation expense" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "terseLabel": "Disposal group, operating expense" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableAdditionalInformationDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "verboseLabel": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r85", "r145", "r149", "r153", "r154", "r155", "r158", "r494", "r519" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Net income per share - Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails", "http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r85", "r145", "r149", "r153", "r154", "r155", "r158", "r494", "r519" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Net income per share - Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails", "http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r135", "r361", "r362" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective tax expense (benefit) rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r361", "r362", "r387" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory federal tax (benefit) rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r361", "r362", "r387" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Revaluation of net deferred tax assets" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r361", "r362", "r387" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "terseLabel": "Nondeductible goodwill impairment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r361", "r362", "r387" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent", "terseLabel": "Nondeductible compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r361", "r362", "r387" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r361", "r362", "r387" ], "calculation": { "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income provision (benefit), net of federal" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative instrument embedded in host contract.", "label": "Embedded Derivative Financial Instruments [Member]", "netLabel": "1.125% Conversion Option", "terseLabel": "Conversion Option", "verboseLabel": "1.125% Conversion Option" } } }, "localname": "EmbeddedDerivativeFinancialInstrumentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r350" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted average period of unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r428", "r429", "r430", "r433" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r428", "r429", "r430", "r432", "r433" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Fair value measurements of senior notes" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r428", "r429" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "verboseLabel": "Fair value of assets measured on recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r428", "r437", "r438" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r313", "r314", "r315", "r429", "r476" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r428", "r434" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r431" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r313", "r314", "r315", "r429", "r477" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r313", "r314", "r315", "r429", "r478" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r313", "r314", "r315", "r429", "r479" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r451", "r458", "r466" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesComponentsOfLeaseExpenseDetails": { "order": 2.0, "parentTag": "moh_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r453", "r460" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance lease expense:", "verboseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesComponentsOfLeaseExpenseDetails", "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r450", "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total finance lease liabilities", "totalLabel": "Total finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails", "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r450" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Accounts payable and accrued liabilities (current)" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Finance lease maturities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r450" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "netLabel": "Finance lease liabilities", "terseLabel": "Finance lease liabilities (non-current)", "verboseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Subtotal - undiscounted lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r452", "r460" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r449" ], "calculation": { "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "ROU assets - finance leases", "verboseLabel": "Property, equipment, and capitalized software, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r451", "r458", "r466" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesComponentsOfLeaseExpenseDetails": { "order": 1.0, "parentTag": "moh_FinanceLeaseCost", "weight": 1.0 }, "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails": { "order": 4.0, "parentTag": "moh_DepreciationandAmortizationContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of finance leases", "verboseLabel": "Amortization of ROU assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesComponentsOfLeaseExpenseDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r463", "r466" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance leases, weighted average discount rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r462", "r466" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases, weighted average remaining lease term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r229", "r231", "r232", "r233" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails", "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable, Past Due [Line Items]" } } }, "localname": "FinancingReceivableRecordedInvestmentPastDueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ReceivablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r250" ], "calculation": { "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "verboseLabel": "Future amortization expense, 2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "verboseLabel": "Future amortization expense, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "verboseLabel": "Future amortization expense, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "verboseLabel": "Future amortization expense, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "verboseLabel": "Future amortization expense, 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r246", "r247", "r250", "r253", "r482" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "verboseLabel": "Future Amortization Expenses" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r250", "r482" ], "calculation": { "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r246", "r249" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r250" ], "calculation": { "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r313", "r547" ], "lang": { "en-US": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Foreign securities", "verboseLabel": "Foreign securities" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and equipment", "verboseLabel": "Furniture and equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r115", "r406" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedTerseLabel": "Loss on sales of subsidiaries, net of gain", "netLabel": "Gain (loss) on sales of subsidiaries", "terseLabel": "Loss on sales of subsidiaries, net of gain", "totalLabel": "Loss on sale of subsidiaries, net of gain", "verboseLabel": "Less: loss on sales of subsidiaries, net of gain" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r115", "r291", "r292" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "(Gain) loss on debt extinguishment", "negatedTerseLabel": "(Gain) loss on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r92" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r234", "r236" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Acquisitions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Impairment losses", "verboseLabel": "Impairment losses" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "Goodwill and Intangible Assets, Net" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r124", "r248" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r237", "r241" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Gross goodwill" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r237", "r241" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Accumulated impairment loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r115", "r235", "r240", "r243" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedTerseLabel": "Impairment and other", "verboseLabel": "Goodwill impairment charges" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r239" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Dispositions" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r89" ], "calculation": { "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Margin", "verboseLabel": "Total margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails", "http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HealthCareCostsPolicyPolicyTextBlock": { "auth_ref": [ "r555" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for accruing health care costs for a prepaid health care service provider.", "label": "Health Care Costs, Policy [Policy Text Block]", "verboseLabel": "Medical Care Costs - Health Plans" } } }, "localname": "HealthCareCostsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_HealthCarePremiumMember": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Money received from insurance for service provided for maintenance, diagnosis and treatment of physical and mental health.", "label": "Health Care, Premium [Member]", "terseLabel": "Medical care costs" } } }, "localname": "HealthCarePremiumMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r115", "r254" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r134" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income tax expense (benefit)" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromSubsidiariesNetOfTax": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) of subsidiary attributable to the parent entity.", "label": "Income (Loss) from Subsidiaries, Net of Tax", "terseLabel": "Equity in net earnings (losses) of subsidiaries" } } }, "localname": "IncomeLossFromSubsidiariesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "verboseLabel": "Condensed Statements of Income" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r2", "r3", "r4", "r5", "r6", "r7", "r9", "r10", "r11", "r12", "r261", "r262" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r392" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r183", "r390" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 2.0, "parentTag": "moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)", "totalLabel": "Income tax expense (benefit)", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r80", "r124", "r359", "r360", "r372", "r373", "r378", "r391", "r556" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r119" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "verboseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r114" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r114" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r114" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r114" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities": { "auth_ref": [ "r114" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) in health care insurance liability balances during the period.", "label": "Increase (Decrease) in Health Care Insurance Liabilities", "verboseLabel": "Medical claims and benefits payable" } } }, "localname": "IncreaseDecreaseInHealthCareInsuranceLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r114" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r114" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Receivables" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r155" ], "calculation": { "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails": { "order": 4.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Warrants (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r152", "r157" ], "calculation": { "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Convertible senior notes (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r150", "r157" ], "calculation": { "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "verboseLabel": "Share-based compensation (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InsuranceAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Insurance [Abstract]" } } }, "localname": "InsuranceAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InsuranceAgencyManagementFee": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fees earned during the period for providing management services.", "label": "Insurance Agency Management Fee", "verboseLabel": "Administrative services fees" } } }, "localname": "InsuranceAgencyManagementFee", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InsuranceRecoveries": { "auth_ref": [ "r91" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.", "label": "Insurance Recoveries", "terseLabel": "Reinsurance recoveries" } } }, "localname": "InsuranceRecoveries", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InsuranceServicesRevenue": { "auth_ref": [ "r520" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.", "label": "Insurance Services Revenue", "terseLabel": "Service revenue" } } }, "localname": "InsuranceServicesRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible Assets, Net (Including Goodwill)", "terseLabel": "Goodwill and intangible assets, net", "verboseLabel": "Goodwill and intangible assets, net" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDividendIncomeOperating": { "auth_ref": [ "r495" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.", "label": "Interest and Dividend Income, Operating", "verboseLabel": "Investment income and other revenue" } } }, "localname": "InterestAndDividendIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCostsIncurredAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Interest Costs Incurred [Abstract]", "verboseLabel": "Interest cost recognized for the period relating to the:" } } }, "localname": "InterestCostsIncurredAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtInterestCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r82", "r181", "r442", "r445", "r496" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 2.0, "parentTag": "moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries", "weight": -1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r94", "r290" ], "calculation": { "http://www.molinahealthcare.com/role/DebtInterestCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Total interest cost recognized" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtInterestCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r96" ], "calculation": { "http://www.molinahealthcare.com/role/DebtInterestCostDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "verboseLabel": "Contractual interest coupon rate" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtInterestCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r108", "r111", "r119" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "verboseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "verboseLabel": "Contractual maturities of investments" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r40" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "terseLabel": "Investments in subsidiaries" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r219", "r483", "r501", "r552" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "verboseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Components of lease expense and supplemental consolidated cash flow information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Finance Lease, Description [Abstract]", "terseLabel": "Finance leases:" } } }, "localname": "LesseeFinanceLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseRenewalTerm1": { "auth_ref": [ "r456" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Renewal Term", "terseLabel": "Finance lease renewal term" } } }, "localname": "LesseeFinanceLeaseRenewalTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r457" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r455" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "Operating leases:" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Operating lease maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Subtotal - undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r465" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r456" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r47" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r35", "r489", "r513" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r428" ], "calculation": { "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r525", "r528" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.", "label": "Liability for Claims and Claims Adjustment Expense", "periodEndLabel": "Medical claims and benefits payable, ending balance", "periodStartLabel": "Medical claims and benefits payable, beginning balance", "totalLabel": "Total", "verboseLabel": "Medical claims and benefits payable" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]", "terseLabel": "Payments for medical care costs related to:" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "auth_ref": [ "r527" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails": { "order": 1.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "verboseLabel": "Current period" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "auth_ref": [ "r527" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails": { "order": 2.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "verboseLabel": "Prior periods" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount": { "auth_ref": [ "r538" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Estimated costs as of the balance sheet date of settling insured claims and costs incurred in the claims settlement process for claims that have not yet been submitted to the insurance company for reimbursement.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount", "verboseLabel": "Total IBNP" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "auth_ref": [ "r526" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "terseLabel": "Incurred Claims and Allocated Claims Adjustment Expenses", "totalLabel": "Total medical care costs" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]", "terseLabel": "Components of medical care costs related to:" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r25", "r488", "r508" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Amount outstanding under Letter of Credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Current borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r45", "r132" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "netLabel": "Term Loan Facility", "terseLabel": "Term Loan Facility", "verboseLabel": "Term Loan Facility" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "verboseLabel": "Receivables" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/Receivables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current", "totalLabel": "Total, current portion", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r143", "r281" ], "calculation": { "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five", "verboseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r143", "r281" ], "calculation": { "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "verboseLabel": "2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r143", "r281" ], "calculation": { "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "verboseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r143", "r281" ], "calculation": { "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "verboseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r143", "r281" ], "calculation": { "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "verboseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r143", "r281" ], "calculation": { "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "verboseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "netLabel": "Long-term debt", "totalLabel": "Total, non-current portion", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "verboseLabel": "Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r53", "r282" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r15", "r48" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r186", "r187" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Other Operating" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgageBackedSecuritiesMember": { "auth_ref": [ "r203", "r313", "r314", "r315", "r547" ], "lang": { "en-US": { "role": { "documentation": "Securities collateralized by mortgage loans.", "label": "Collateralized Mortgage Backed Securities [Member]", "terseLabel": "Mortgage-backed securities" } } }, "localname": "MortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r110" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash used in financing activities:", "verboseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r110" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r110", "r113", "r116" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash provided by operating activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash used in operating activities:", "verboseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r74", "r77", "r84", "r116", "r157", "r493", "r518" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails", "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails", "http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements Adopted and Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Less: other expenses, net", "negatedTotalLabel": "Total other expenses, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r120", "r121", "r122" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Notes Issued", "terseLabel": "Common stock issued in exchange for convertible senior notes" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments", "verboseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails", "http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states in which company operates (in state)" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OneTimeTerminationBenefitsMember": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.", "label": "One-time Termination Benefits [Member]", "verboseLabel": "One-Time Termination Benefits" } } }, "localname": "OneTimeTerminationBenefitsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 1.0, "parentTag": "moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 }, "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r459", "r466" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r450" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total operating lease liabilities", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails", "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r450" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Accounts payable and accrued liabilities (current)" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r450" ], "calculation": { "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Other long-term liabilities (non-current)" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r454", "r460" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r449" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Other assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r463", "r466" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases, weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r462", "r466" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases, weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r379" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r380" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r180", "r189" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r13", "r409" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "Organization and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r75", "r78", "r401", "r402", "r404" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss), net", "totalLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r66", "r69", "r218" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax", "terseLabel": "Unrealized investment income (loss)", "verboseLabel": "Unrealized investment income (loss)" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r67", "r70" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax", "terseLabel": "Less: effect of income taxes", "verboseLabel": "Less: effect of income taxes" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other expenses, net:" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 3.0, "parentTag": "moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expenses, net", "negatedTerseLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringCosts": { "auth_ref": [ "r115", "r265", "r271", "r275" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.", "label": "Other Restructuring Costs", "terseLabel": "Other restructuring costs" } } }, "localname": "OtherRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "auth_ref": [ "r112", "r527" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "totalLabel": "Total paid" } } }, "localname": "PaymentsForLossesAndLossAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r98", "r101", "r141" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r104" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Common stock purchases" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "auth_ref": [ "r104" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.", "label": "Payments for Repurchase of Warrants", "negatedTerseLabel": "Cash paid for partial termination of warrants", "verboseLabel": "Cash paid for partial termination of 1.125% Warrants" } } }, "localname": "PaymentsForRepurchaseOfWarrants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r109", "r267" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "terseLabel": "Payments for restructuring" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "auth_ref": [ "r99" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.", "label": "Payments to Acquire Additional Interest in Subsidiaries", "negatedTerseLabel": "Capital contributions to subsidiaries" } } }, "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r202" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r100" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, equipment and capitalized software" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "PSAs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityFairValueOfAwardsGrantedAndVestedDetails", "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r321", "r351" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare": { "auth_ref": [ "r521" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts.", "label": "Policyholder Benefits and Claims Incurred, Net, Health", "terseLabel": "Other operating expenses" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredHealthCare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r435" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Postemployment Benefits [Abstract]" } } }, "localname": "PostemploymentBenefitsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r28" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding", "verboseLabel": "Preferred stock, $0.001 par value per share; 20 million shares authorized, no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsEarnedNet": { "auth_ref": [ "r492", "r517", "r522", "r546" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.", "label": "Premiums Earned, Net", "terseLabel": "Premium revenue", "verboseLabel": "Premium revenue" } } }, "localname": "PremiumsEarnedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r16", "r37", "r38" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidReinsurancePremiums": { "auth_ref": [ "r524", "r548" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The unexpired portion of premiums ceded on policies in force as of the balance sheet date.", "label": "Prepaid Reinsurance Premiums", "terseLabel": "Prepaid reinsurance premiums" } } }, "localname": "PrepaidReinsurancePremiums", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r102" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Cash received for partial settlement of call option" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/DerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": { "auth_ref": [ "r97" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.", "label": "Proceeds from Divestiture of Interest in Subsidiaries and Affiliates", "terseLabel": "Net cash received from sale of subsidiaries" } } }, "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliatesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Proceeds from Divestiture of Interest in Subsidiaries and Affiliates [Abstract]", "terseLabel": "Details of sales of subsidiaries:" } } }, "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliatesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromDividendsReceived": { "auth_ref": [ "r107" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Dividends received on equity and other investments during the current period.", "label": "Proceeds from Dividends Received", "terseLabel": "Dividends received from subsidiaries" } } }, "localname": "ProceedsFromDividendsReceived", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r102" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from senior notes offerings, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r102", "r133" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from borrowings under credit facility" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r102" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Proceeds from borrowings under term loan facility" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r103", "r106", "r141" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of investments", "verboseLabel": "Proceeds from sales and maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]", "terseLabel": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableCumulativePaidClaimsAndAllocatedClaimsAdjustmentExpensesDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r43", "r259" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Property, Equipment, and Capitalized Software, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r42", "r257" ], "calculation": { "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Total cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r20", "r21", "r259", "r515" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, equipment, and capitalized software, net", "totalLabel": "Property, equipment, and capitalized software, net", "verboseLabel": "Property, equipment, and capitalized software, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails": { "order": 1.0, "parentTag": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of depreciation (related to long-lived, depreciable flight assets owned by the entity and used in the entity's principle business operations and capitalized assets classified as property, plant and equipment that are owned by the entity) that has been recognized in the income statement.", "label": "Property, Plant, and Equipment, Owned, Accumulated Depreciation", "negatedTerseLabel": "Less: accumulated depreciation and amortization - furniture, equipment, building, and improvements" } } }, "localname": "PropertyPlantAndEquipmentOwnedAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r41", "r124", "r259" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Long-Lived Assets" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r20", "r259" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Summary of property and equipment and depreciation and amortization recognized" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r20", "r257" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life of property plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "verboseLabel": "Quarterly Results of Operations (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r57" ], "lang": { "en-US": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ReceivablesDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r30", "r36", "r514", "r550" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "netLabel": "Receivables from state and federal government agencies", "terseLabel": "Total receivables", "verboseLabel": "Receivables" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/ReceivablesDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r124", "r195", "r198", "r199", "r200" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Receivables" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "verboseLabel": "Unrecognized tax benefits roll forward" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": { "auth_ref": [ "r506", "r523", "r525", "r528" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.", "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments", "terseLabel": "Reinsurance recoverable for unpaid claims adjustments" } } }, "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent": { "auth_ref": [ "r139", "r468" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date within one year where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Related Party Transaction, Due from (to) Related Party, Current", "terseLabel": "Due from affiliates" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedPartyCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantNotesToCondensedFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r105" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "negatedLabel": "Repayment of principal amount of convertible notes", "negatedTerseLabel": "Repayment of principal amount of convertible senior notes" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r105" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r105", "r133" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedTerseLabel": "Repayment of credit facility" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReservesReportedToOtherAgenciesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of reserves reported to other federal agencies or authorities.", "label": "Reserves Reported to Other Agencies [Table Text Block]", "terseLabel": "Amounts due to government agencies" } } }, "localname": "ReservesReportedToOtherAgenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r14", "r19", "r123" ], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash and cash equivalents, current" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r18", "r22", "r123", "r554" ], "calculation": { "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash and cash equivalents, non-current" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsNoncurrent": { "auth_ref": [], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.", "label": "Restricted Investments, Noncurrent", "verboseLabel": "Restricted investments" } } }, "localname": "RestrictedInvestmentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "RSAs" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails", "http://www.molinahealthcare.com/role/StockholdersEquityFairValueOfAwardsGrantedAndVestedDetails", "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "PSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails", "http://www.molinahealthcare.com/role/StockholdersEquityFairValueOfAwardsGrantedAndVestedDetails", "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring Costs" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCosts" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r266", "r268", "r274", "r276" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Cumulative restructuring costs" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r266", "r268", "r274", "r276" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Decrease to estimated expected costs remaining" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r115" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "netLabel": "Restructuring costs", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r267", "r272" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Accrued liabilities under restructuring plan" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r32", "r300", "r511" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "verboseLabel": "Summarized premium revenue" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r88", "r551" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "verboseLabel": "Services revenue from subsidiaries" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantNotesToCondensedFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r125", "r126" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "verboseLabel": "Premium Revenue - Health Plans" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r83", "r179", "r180", "r188" ], "calculation": { "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenue", "totalLabel": "Total revenue", "verboseLabel": "Add: Other operating revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails", "http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:", "verboseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "netLabel": "Term Loan Facility", "verboseLabel": "Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r461", "r466" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r461", "r466" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "verboseLabel": "Summary of accounts receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ReceivablesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "verboseLabel": "Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r385" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "verboseLabel": "Provision for income taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.", "label": "Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Condensed statements of comprehensive (loss)" } } }, "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r53", "r132", "r295", "r297", "r298", "r299", "r443", "r444", "r446", "r504" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "verboseLabel": "Long term debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "verboseLabel": "Significant components of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Fair values of derivative financial instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DerivativesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Summary of denominators for the computation of basic and diluted earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r149", "r151", "r155", "r158" ], "lang": { "en-US": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "verboseLabel": "Effective income tax rate reconciliation to the statutory federal income tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFinancingReceivablesPastDueTable": { "auth_ref": [ "r223", "r226" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about aging analysis for financing receivable.", "label": "Financing Receivable, Past Due [Table]" } } }, "localname": "ScheduleOfFinancingReceivablesPastDueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ReceivablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r246", "r249" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r246", "r249" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "verboseLabel": "Summary of identified intangible assets, by major class" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r242", "r244" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r242", "r244" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Held-to-maturity Securities [Line Items]", "terseLabel": "Schedule of Held-to-maturity Securities [Line Items]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity [Table]", "terseLabel": "Debt Securities, Held-to-maturity [Table]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r529" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "terseLabel": "Schedule of liability for unpaid claims and claims adjustment expense" } } }, "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "verboseLabel": "Maturities of long-term debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "verboseLabel": "Restricted and performance stock activity" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]", "terseLabel": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableCumulativePaidClaimsAndAllocatedClaimsAdjustmentExpensesDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r43", "r259" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "verboseLabel": "Summary of quarterly results of operations" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r129", "r469", "r470", "r471", "r472", "r473" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantNotesToCondensedFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r19", "r123", "r484", "r510" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Restricted cash and cash equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r269", "r270", "r273" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r81", "r83", "r192" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r178", "r184", "r185", "r186", "r242" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails", "http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r178", "r184", "r185", "r186", "r242" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "verboseLabel": "Operating segment information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r321", "r351" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails", "http://www.molinahealthcare.com/role/StockholdersEquityComponentsOfShareBasedCompensationDetails", "http://www.molinahealthcare.com/role/StockholdersEquityFairValueOfAwardsGrantedAndVestedDetails", "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Stock option plans, by exercise price range" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r326", "r338", "r341" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Stock options, activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails", "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails", "http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segments" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/Segments" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails", "http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtMaturitiesDetails", "http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails", "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r114" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "Share-based Payment Arrangement, Accelerated Cost", "terseLabel": "Restructuring settled without cash" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityComponentsOfShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Maximum award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r331" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Forfeited (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r334" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r334" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested, shares end of period (in shares)", "periodStartLabel": "Unvested, shares beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested, ending balance (USD per share)", "periodStartLabel": "Unvested, beginning balance (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "verboseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r340" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of restricted shares vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityFairValueOfAwardsGrantedAndVestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r346" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Maximum expected volatility rate inputs for fair value measurement" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Minimum expected volatility rate inputs for fair value measurement" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails", "http://www.molinahealthcare.com/role/StockholdersEquityComponentsOfShareBasedCompensationDetails", "http://www.molinahealthcare.com/role/StockholdersEquityFairValueOfAwardsGrantedAndVestedDetails", "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares issued under ESPP (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r340" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options exercised, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r339" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of stock options granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r328", "r351" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance, outstanding (in shares)", "periodStartLabel": "Beginning balance, outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance, outstanding (usd per share)", "periodStartLabel": "Beginning balance, outstanding (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r341" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Stock options exercisable and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Stock options exercisable and expected to vest (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r318", "r325" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails", "http://www.molinahealthcare.com/role/StockholdersEquityComponentsOfShareBasedCompensationDetails", "http://www.molinahealthcare.com/role/StockholdersEquityFairValueOfAwardsGrantedAndVestedDetails", "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r343" ], "lang": { "en-US": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Options Exercisable, Number Exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Options Outstanding, Number Outstanding" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Stock option expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r344", "r352" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term of awards" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r351" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable, Weighted Average Remaining Contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding, Weighted Average Remaining Contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options Exercisable, Weighted-Average Exercise Price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options Outstanding, Weighted-Average Exercise Price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options Outstanding, Weighted Average Remaining Contractual Life (Years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Shares outstanding at the beginning of the period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock": { "auth_ref": [ "r549" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for insurance products considered to be short-duration contracts because the contract provides insurance protection for a fixed period of short duration and enables the insurer to cancel the contract or to adjust the provisions of the contract at the end of any contract period, such as adjusting the amount of premiums charged or coverage provided, and on contracts on which amounts are paid but insurance risk is not transferred.", "label": "Short-Duration Insurance and Deposit Contracts [Text Block]", "verboseLabel": "Medical Claims and Benefits Payable" } } }, "localname": "ShortDurationInsuranceAndDepositContractsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortDurationInsuranceContractAccidentYear2019Member": { "auth_ref": [ "r531" ], "lang": { "en-US": { "role": { "documentation": "Accident year 2019 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-Duration Insurance Contract, Accident Year 2019 [Member]", "terseLabel": "Benefit Year 2019", "verboseLabel": "Benefit Year 2019" } } }, "localname": "ShortDurationInsuranceContractAccidentYear2019Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableCumulativePaidClaimsAndAllocatedClaimsAdjustmentExpensesDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member": { "auth_ref": [ "r531" ], "lang": { "en-US": { "role": { "documentation": "Accident year 2017 in which a covered event occurs under the terms of the short-duration insurance contract.", "label": "Short-duration Insurance Contracts, Accident Year 2017 [Member]", "terseLabel": "Benefit Year 2017" } } }, "localname": "ShortDurationInsuranceContractsAccidentYear2017Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableCumulativePaidClaimsAndAllocatedClaimsAdjustmentExpensesDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member": { "auth_ref": [ "r531" ], "lang": { "en-US": { "role": { "documentation": "Accident year 2018 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-duration Insurance Contracts, Accident Year 2018 [Member]", "terseLabel": "Benefit Year 2018" } } }, "localname": "ShortDurationInsuranceContractsAccidentYear2018Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableCumulativePaidClaimsAndAllocatedClaimsAdjustmentExpensesDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortdurationInsuranceContractsAccidentYearAxis": { "auth_ref": [ "r531" ], "lang": { "en-US": { "role": { "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract.", "label": "Short-duration Insurance Contracts, Accident Year [Axis]", "terseLabel": "Short-duration Insurance Contracts, Accident Year [Axis]" } } }, "localname": "ShortdurationInsuranceContractsAccidentYearAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableCumulativePaidClaimsAndAllocatedClaimsAdjustmentExpensesDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsAccidentYearDomain": { "auth_ref": [ "r531" ], "lang": { "en-US": { "role": { "documentation": "Accident year in which a covered event occurs under the terms of the short-duration insurance contract.", "label": "Short-duration Insurance Contracts, Accident Year [Domain]", "terseLabel": "Short-duration Insurance Contracts, Accident Year [Domain]" } } }, "localname": "ShortdurationInsuranceContractsAccidentYearDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableCumulativePaidClaimsAndAllocatedClaimsAdjustmentExpensesDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock": { "auth_ref": [ "r531" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.", "label": "Short-duration Insurance Contracts, Claims Development [Table Text Block]", "terseLabel": "Incurred and paid claims development" } } }, "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet": { "auth_ref": [ "r530" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net", "negatedLabel": "Less: cumulative paid claims and allocated claims adjustment expenses", "terseLabel": "Claims paid" } } }, "localname": "ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableCumulativePaidClaimsAndAllocatedClaimsAdjustmentExpensesDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet": { "auth_ref": [ "r531", "r532" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net", "verboseLabel": "Incurred claims and allocated claims adjustment expenses" } } }, "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems": { "auth_ref": [ "r532" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of aggregate reconciling items for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts.", "label": "Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Aggregate Reconciling Items", "terseLabel": "Non-risk and other provider payables" } } }, "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims": { "auth_ref": [ "r533" ], "lang": { "en-US": { "role": { "documentation": "Cumulative number of reported claims for short-duration insurance contracts.", "label": "Short-duration Insurance Contract, Cumulative Number of Reported Claims", "terseLabel": "Cumulative number of reported claims (in claim)" } } }, "localname": "ShortdurationInsuranceContractsNumberOfReportedClaims", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails" ], "xbrltype": "integerItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock": { "auth_ref": [ "r532" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.", "label": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]", "terseLabel": "Reconciliation of claims development to liability" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Capitalized software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r184", "r242", "r260", "r268", "r276", "r534" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails", "http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails", "http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails", "http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r56", "r294" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "verboseLabel": "Condensed Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "verboseLabel": "Condensed Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatutoryAccountingPracticesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statutory Accounting Practices [Line Items]", "terseLabel": "Statutory Accounting Practices [Line Items]" } } }, "localname": "StatutoryAccountingPracticesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance": { "auth_ref": [ "r512", "r539" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.", "label": "Statutory Accounting Practices, Statutory Capital and Surplus, Balance", "verboseLabel": "Aggregate statutory capital and surplus" } } }, "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired": { "auth_ref": [ "r540" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.", "label": "Statutory Accounting Practices, Statutory Capital and Surplus Required", "verboseLabel": "Required minimum statutory capital surplus" } } }, "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatutoryAccountingPracticesTable": { "auth_ref": [ "r516", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-US": { "role": { "documentation": "Detail by state, country, or other jurisdiction of domicile in which financial statements are filed reflecting statutory capital and surplus, net income and the differences between financial reports which are in conformity with generally accepted accounting principles and the statutory financial statements which also use state permitted or prescribed accounting practices.", "label": "Statutory Accounting Practices [Table]", "terseLabel": "Statutory Accounting Practices [Table]" } } }, "localname": "StatutoryAccountingPracticesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r120", "r121", "r122" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "negatedTerseLabel": "Common stock used for stock-based compensation" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r55", "r294", "r295", "r300" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "verboseLabel": "Exchange of convertible senior notes (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r28", "r29", "r294", "r300" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Common stock issued during period (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r28", "r29", "r294", "r300" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r28", "r29", "r294", "r300", "r330" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r28", "r29", "r300", "r320", "r339" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Common stock authorized" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r28", "r29", "r294", "r300" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Repurchased of common stock (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r28", "r29", "r294", "r300" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Common stock purchases", "terseLabel": "Repurchased of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r29", "r33", "r34", "r196" ], "calculation": { "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets", "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r474" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r474" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails", "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails", "http://www.molinahealthcare.com/role/DerivativesDetails", "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r363", "r371", "r373" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "verboseLabel": "Unrecognized tax benefits roll forward" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r526" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.", "label": "Current Year Claims and Claims Adjustment Expense", "verboseLabel": "Current period" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r526" ], "calculation": { "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.", "label": "Prior Year Claims and Claims Adjustment Expense", "terseLabel": "Prior periods", "verboseLabel": "Favorable (unfavorable) adjustment" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableAdditionalInformationDetails", "http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r379" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "verboseLabel": "Tax credit carryovers" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardValuationAllowance": { "auth_ref": [ "r376" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Tax Credit Carryforward, Valuation Allowance", "verboseLabel": "Deferred tax assets" } } }, "localname": "TaxCreditCarryforwardValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense": { "auth_ref": [ "r385" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of income tax expense for remeasurement of deferred tax asset from change in tax rate pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Deferred Tax Asset, Income Tax Expense", "terseLabel": "Change in tax rate, deferred tax asset, income tax expense (benefit)" } } }, "localname": "TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit": { "auth_ref": [ "r389" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of income tax expense (benefit) for measurement period adjustment from accounting for tax effect pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit)", "negatedTerseLabel": "Measurement period adjustment, income tax expense (benefit)" } } }, "localname": "TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyServiceMember": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Technology assistance, including but not limited to, training, installation, engineering, and software design.", "label": "Technology Service [Member]", "terseLabel": "Cost of service revenue" } } }, "localname": "TechnologyServiceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r481" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails", "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails", "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Average cost (USD per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r313", "r490" ], "lang": { "en-US": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "netLabel": "Government-sponsored enterprise securities (\u201cGSEs\u201d)", "terseLabel": "GSEs", "verboseLabel": "GSEs" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryNotesSecuritiesMember": { "auth_ref": [ "r491" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Notes Securities [Member]", "netLabel": "U.S. Treasury notes", "terseLabel": "U.S. Treasury notes" } } }, "localname": "USTreasuryNotesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails", "http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r357", "r366" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "negatedPeriodEndLabel": "Gross unrecognized tax benefits at end of period", "negatedPeriodStartLabel": "Gross unrecognized tax benefits at beginning of period" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r367" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "terseLabel": "Decreases in tax positions for prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r368" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "negatedTerseLabel": "Increases in tax positions for current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r367" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "negatedLabel": "Increases in tax positions for prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r369" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "terseLabel": "Lapse in statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r370" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "verboseLabel": "Impact on effective tax rate if tax benefits are recognized" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r162", "r163", "r165", "r166", "r169", "r170", "r171" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r358" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedTerseLabel": "Decrease in deferred tax asset valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r148", "r155" ], "calculation": { "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Denominator for diluted net (loss) income per share (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r146", "r147", "r157" ], "lang": { "en-US": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number of Shares Issued, Basic", "terseLabel": "Exchange of convertible senior notes (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:", "verboseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r146", "r155" ], "calculation": { "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Denominator for basic net income (loss) per share (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations", "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "verboseLabel": "Weighted-average number of shares issued:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3337-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e)(3)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1930-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8615-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8654-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8660-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8663-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8672-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6283291-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955255&loc=SL82922355-210448" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r278": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r312": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e34017-109320" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.EE.Q2(f))", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r392": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r427": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r467": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r483": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.6(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(c))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.1-5)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(d)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r501": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.23(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.1,4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.5)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=34713774&loc=d3e574992-122915" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "340", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6485982&loc=d3e22818-158507" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(cc)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671317-158438" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "40", "Subparagraph": "(SAB TOPIC 5.W)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=27015833&loc=d3e570705-122907" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24746-158529" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24790-158529" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=82848697&loc=d3e24938-158530" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=82848697&loc=d3e24959-158530" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(c)(3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r549": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "944", "URI": "http://asc.fasb.org/topic&trid=2303980" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=116637345&loc=SL114874292-224272" }, "r552": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r560": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r561": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r562": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r563": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r564": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r565": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r566": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r567": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r568": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r569": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r570": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r571": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "a", "Publisher": "SEC", "Section": "12", "Subsection": "04" }, "r572": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "i", "Publisher": "SEC", "Section": "3", "Subsection": "10" }, "r573": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r574": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "c", "Publisher": "SEC", "Section": "5", "Subparagraph": "Schedule I", "Subsection": "04" }, "r575": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "c", "Publisher": "SEC", "Section": "7", "Subparagraph": "Schedule II", "Subsection": "05" }, "r576": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "9", "Subsection": "06" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e526-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-03(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" } }, "version": "2.1" } XML 27 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Restructuring Costs
12 Months Ended

Dec. 31, 2019

Restructuring and Related Activities [Abstract]

Restructuring Costs Restructuring Costs
Restructuring costs are reported by the same name in the accompanying consolidated statements of operations.
IT Restructuring Plan
Management’s margin recovery plan identified and implemented various profit improvement initiatives. This included the plan to restructure our information technology department (the “IT Restructuring Plan”) in 2018, which is reported in the Other segment. In connection with this plan, in early 2019, we entered into services agreements with an outsourcing vendor who manages certain of our information technology services.
As of December 31, 2019, the IT Restructuring Plan was substantially complete. Under this plan, we incurred cumulative restructuring costs of $12 million, including $7 million of one-time termination benefits and $5 million of other restructuring costs (primarily consulting fees). The final amount of costs incurred is lower than the $20 million we originally estimated and reported in our Annual Report on Form 10-K for the year ended December 31, 2018. Because more of our IT employees transitioned to our outsourcing vendor than originally contemplated, such employees were no longer included in the IT Restructuring Plan, resulting in lower one-time termination costs.
As of December 31, 2018, $6 million was accrued under the IT Restructuring Plan, primarily for one-time termination benefits that require cash settlement. In the year ended December 31, 2019, we incurred $3 million of other restructuring costs, paid $5 million to settle one-time termination benefits, and paid $3 million to settle other restructuring costs. As of December 31, 2019, $1 million was accrued under the IT Restructuring Plan.
2017 Restructuring Plan
As of December 31, 2018, $18 million was accrued for the restructuring and profitability improvement plan approved by the board of directors in June 2017 (the “2017 Restructuring Plan”). In the year ended December 31, 2019, we incurred $3 million of restructuring costs for adjustments to previously recorded lease contract termination costs, and paid $9 million to settle one-time termination and lease contract termination costs. As of December 31, 2019, $12 million was accrued for lease contract termination costs under the 2017 Restructuring Plan. We expect to continue to settle these liabilities through 2025, unless the leases are terminated sooner.

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-URI http://asc.fasb.org/topic&trid=2175745
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Quarterly Results of Operations (Unaudited)
12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Quarterly Results of Operations (Unaudited) Quarterly Results of Operations (Unaudited)
The following table summarizes quarterly unaudited results of operations for the periods presented.

For The Quarter Ended

March 31,
2019

June 30,
2019

Sept. 30, 2019

December 31,
2019

(In millions, except per-share data)
Total revenue
$
4,119

$
4,193

$
4,243

$
4,274

Margin
581

583

561

578

Net income
198

196

175

168

Net income per share - Basic ⁽¹⁾
$
3.19

$
3.15

$
2.81

$
2.70

Net income per share - Diluted ⁽¹⁾
$
2.99

$
3.06

$
2.75

$
2.67

For The Quarter Ended

March 31,
2018

June 30,
2018

Sept. 30, 2018

December 31,
2018

(In millions, except per-share data)
Total revenue
$
4,646

$
4,883

$
4,697

$
4,664

Margin
615

673

566

664

Gain (loss) on sales of subsidiaries
—

—

37

(52
)
Net income
107

202

197

201

Net income per share - Basic ⁽¹⁾
$
1.79

$
3.29

$
3.22

$
3.24

Net income per share - Diluted ⁽¹⁾
$
1.64

$
3.02

$
2.90

$
3.01

________________________
(1)
The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method and is based on the weighted-average common share equivalents outstanding during each quarter. Accordingly, the sum of the quarterly net income per share amounts may not agree to the total for the year.

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-URI http://asc.fasb.org/topic&trid=2126967
+ Details

Name: us-gaap_QuarterlyFinancialInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 30 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Medical Claims and Benefits Payable (Tables)
12 Months Ended

Dec. 31, 2019

Insurance [Abstract]

Schedule of liability for unpaid claims and claims adjustment expense
The following table provides the details of our medical claims and benefits payable as of the dates indicated.

December 31,

2019

2018

2017

(In millions)
Fee-for-service claims incurred but not paid (“IBNP”)
$
1,406

$
1,562

$
1,717

Pharmacy payable
126

115

112

Capitation payable
55

52

67

Other
267

232

296

Total
$
1,854

$
1,961

$
2,192

Components of the change in medical claims and benefits payable
The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for “Components of medical care costs related to: Prior periods” represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the period were (more) less than the actual amount of the liability based on information (principally the payment of claims) developed since that liability was first reported.

Year Ended December 31,

2019

2018

2017

(In millions)
Medical claims and benefits payable, beginning balance
$
1,961

$
2,192

$
1,929

Components of medical care costs related to:

Current period
14,176

15,478

17,037

Prior periods ⁽¹⁾
(271
)

(341
)

36

Total medical care costs
13,905

15,137

17,073

Change in non-risk and other provider payables
24

13

(106
)

Payments for medical care costs related to:

Current period
12,554

13,671

15,130

Prior periods
1,482

1,710

1,574

Total paid
14,036

15,381

16,704

Medical claims and benefits payable, ending balance
$
1,854

$
1,961

$
2,192

________________
(1)
December 31, 2018, includes the 2018 benefit of the 2017 Marketplace CSR reimbursement of $81 million.

Incurred and paid claims development
The following tables provide information about incurred and paid claims development as of December 31, 2019, as well as cumulative claims frequency and the total of incurred but not paid claims liabilities. The cumulative claim frequency is measured by claim event, and includes claims covered under capitated arrangements.
Incurred Claims and Allocated Claims Adjustment Expenses

Total IBNP

Cumulative number of reported claims
Benefit Year

2017

2018

2019

(Unaudited)

(Unaudited)

(In millions)
2017

$
17,037

$
16,728

$
16,704

$
18

119

2018

15,478

15,245

25

110

2019

14,176

1,348

93

$
46,125

$
1,391

Cumulative Paid Claims and Allocated Claims Adjustment Expenses

Benefit Year

2017

2018

2019

(Unaudited)

(Unaudited)

(In millions)

2017

$
15,130

$
16,671

$
16,686

2018

13,752

15,220

2019

12,554

$
44,460

Reconciliation of claims development to liability
The following table represents a reconciliation of claims development to the aggregate carrying amount of the liability for medical claims and benefits payable.

2019

(In millions)

Incurred claims and allocated claims adjustment expenses

$
46,125

Less: cumulative paid claims and allocated claims adjustment expenses

(44,460
)

All outstanding liabilities before 2017

15

Non-risk and other provider payables

174

Medical claims and benefits payable

$
1,854

X

- Definition
Components Of Change In Medical Claims And Benefits Payable [Table Text Block]
+ References
No definition available.
+ Details

Name: moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock

Namespace Prefix: moh_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InsuranceAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438
+ Details

Name: us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438
+ Details

Name: us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Receivables (Tables)
12 Months Ended

Dec. 31, 2019

Receivables [Abstract]

Summary of accounts receivable

December 31,

2019

2018

(In millions)
Government receivables
$
1,056

$
872

Pharmacy rebate receivables
150

146

Health insurer fee reimbursement receivables
5

141

Other
195

171

Total
$
1,406

$
1,330

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3,4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Debt
12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Debt Debt
Contractual maturities of debt, as of December 31, 2019, are illustrated in the following table. All amounts represent the principal amounts of the debt instruments outstanding.

Total

2020

2021

2022

2023

2024

Thereafter

(In millions)
5.375% Notes
$
700

$
—

$
—

$
700

$
—

$
—

$
—

4.875% Notes
330

—

—

—

—

—

330

Term Loan Facility
220

6

16

22

22

154

—

1.125% Convertible Notes
12

12

—

—

—

—

—

Total
$
1,262

$
18

$
16

$
722

$
22

$
154

$
330

All debt is held at the parent which is reported, for segment purposes, in the Other segment. The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets:

December 31,

2019

2018

(In millions)
Current portion of long-term debt:

1.125% Convertible Notes, net of unamortized discount
$
12

$
241

Term Loan Facility
6

—

Lease financing obligations
—

1

Debt issuance costs
—

(1
)
Total, current portion
$
18

$
241

Non-current portion of long-term debt:

5.375% Notes
$
700

$
700

4.875% Notes
330

330

Term Loan Facility
214

—

Debt issuance costs
(7
)

(10
)
Total, non-current portion
$
1,237

$
1,020

Credit Agreement
We are party to a Credit Agreement, which provides for an unsecured delayed draw term loan facility (the “Term Loan Facility”), and an unsecured $500 million revolving credit facility (the “Credit Facility”). Borrowings under our Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.
The Credit Agreement contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. As of December 31, 2019, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. Effective as of the date of the Sixth Amendment to the Credit Agreement described below, there are no guarantors as parties to the Credit Agreement.
Term Loan Facility. In January 2019, we entered into a Sixth Amendment to the Credit Agreement that provided for a delayed draw Term Loan Facility in the aggregate principal amount of $600 million, under which we may request up to ten advances, each in a minimum principal amount of $50 million, until July 31, 2020. The Term Loan Facility will amortize in quarterly installments, commencing on September 30, 2020, equal to the principal amount of the Term Loan Facility outstanding multiplied by rates ranging from 1.25% to 2.50% (depending on the applicable fiscal quarter) for each fiscal quarter. The Term Loan Facility expires on January 31, 2024; any remaining outstanding balance under the Term Loan Facility will be due and payable on that date. As of December 31, 2019, $220 million was outstanding under the Term Loan Facility. Each advance under the Term Loan Facility results in a permanent reduction to its borrowing capacity; therefore, our borrowing capacity under the Term Loan Facility as of December 31, 2019, was $380 million.
Credit Facility. The Credit Facility expires on January 31, 2022; therefore, any amounts outstanding under the Credit Facility will be due and payable on that date. As of December 31, 2019, no amounts were outstanding under the Credit Facility, and outstanding letters of credit amounting to $1 million reduced our remaining borrowing capacity under the Credit Facility to $499 million.
5.375% Notes due 2022
We have $700 million aggregate principal amount of senior notes (the “5.375% Notes”) outstanding as of December 31, 2019, which are due November 15, 2022, unless earlier redeemed. Interest at a rate of 5.375% per annum, is payable semiannually in arrears on May 15 and November 15. The 5.375% Notes contain customary non-financial covenants and change of control provisions.
4.875% Notes due 2025
We had $330 million aggregate principal amount of senior notes (the “4.875% Notes”) outstanding as of December 31, 2019, which are due June 15, 2025, unless earlier redeemed. Interest at a rate of 4.875% per annum, is payable semiannually in arrears on June 15 and December 15. The 4.875% Notes contain customary non-financial covenants and change of control provisions.
1.125% Cash Convertible Senior Notes due 2020
In the years ended December 31, 2019 and 2018, we entered into privately negotiated note purchase agreements and, in 2019, received conversion requests, with certain holders of our outstanding 1.125% cash convertible senior notes due January 15, 2020 (the “1.125% Convertible Notes”). For each transaction, the difference between the principal amount extinguished and the total cash paid primarily represented the settlement of the 1.125% Convertible Notes’ embedded cash conversion option feature at fair value (which is a derivative liability we refer to as the “1.125% Conversion Option”).
During 2019, we paid $794 million to settle $240 million aggregate principal amount, or $232 million aggregate carrying amount, of the 1.125% Convertible Notes. During 2018, we paid $911 million to settle $298 million aggregate principal amount, or $278 million aggregate carrying amount of the 1.125% Convertible Notes. In both years, the cash payments included settlement of the related 1.125% Conversion Option, and the mark-to-market valuation adjustments discussed below.
In the years ended December 31, 2019 and 2018, we recorded a (gain) loss on debt extinguishment of approximately $(15) million and $12 million, respectively, for the 1.125% Convertible Notes transactions (net of accelerated original issuance discount amortization), primarily relating to mark-to-market valuations on the partial terminations of the Call Spread Overlay executed in connection with the related debt repayments. These amounts are reported in “Other (income) expenses, net” in the accompanying consolidated statements of operations. No common shares were issued in connection with the transaction.
In connection with the 1.125% Convertible Notes transactions, we also entered into privately negotiated agreements in 2019, to partially terminate the Call Spread Overlay, defined and further discussed in Notes 12, “Derivatives,” and 14, “Stockholders' Equity.” The net cash proceeds from the Call Spread Overlay partial termination transactions partially offset the cash paid to settle the 1.125% Convertible Notes.
As of December 31, 2019, $12 million aggregate principal amount of the 1.125% Convertible Notes were outstanding. Interest at a rate of 1.125% per annum is payable semiannually in arrears on January 15 and July 15. The 1.125% Convertible Notes are convertible only into cash, and not into shares of our common stock or any other securities. The initial conversion rate is 24.5277 shares of our common stock per $1,000 principal amount, or approximately $40.77 per share of our common stock. Holders may convert their 1.125% Convertible Notes under certain circumstances and upon conversion, in lieu of receiving shares of our common stock, a holder will receive an amount in cash, per $1,000 principal amount, equal to the settlement amount, determined in the manner set forth in the indenture. We may not redeem the 1.125% Convertible Notes prior to the maturity date. The 1.125% Convertible Notes matured on January 15, 2020; therefore, they were reported in current portion of long-term debt as of December 31, 2019. (See “Subsequent Event,” below.)
Concurrent with the issuance of the 1.125% Convertible Notes, the 1.125% Conversion Option was separated from the 1.125% Convertible Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations until the 1.125% Conversion Option settled. This initial liability simultaneously reduced the carrying value of the 1.125% Convertible Notes’ principal amount (effectively an original issuance discount), which was amortized to the principal amount through the recognition of non-cash interest expense over the expected life of the debt. The effective interest rate of 6% approximates the interest rate we would have incurred had we issued nonconvertible debt with otherwise similar terms. As of December 31, 2019, the
1.125% Convertible Notes had a remaining amortization period of less than one month, and their ‘if-converted’ value exceeded their principal amount by approximately $26 million and $581 million as of December 31, 2019, and 2018, respectively.
Interest cost recognized relating to our convertible senior notes for the periods presented was as follows:

Years Ended December 31,

2019

2018

2017

(In millions)
Contractual interest at coupon rate
$
1

$
6

$
11

Amortization of the discount
5

21

32

Total
$
6

$
27

$
43

Subsequent Event
In January 2020, we paid $39 million to settle the outstanding 1.125% Convertible Notes, which amount included settlement of the 1.125% Conversion Option.
Cross-Default Provisions
The indentures governing the 4.875% Notes and the 5.375% Notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Net Income (Loss) Per Share
12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Net Income (Loss) Per Share Net Income (Loss) Per Share
The following table sets forth the calculation of basic and diluted net income (loss) per share:

Year Ended December 31,

2019

2018

2017

(In millions, except net income (loss) per share)
Numerator:

Net income (loss)
$
737

$
707

$
(512
)
Denominator:

Shares outstanding at the beginning of the period
62.1

59.3

55.8

Weighted-average number of shares issued:

Exchange of convertible senior notes ⁽¹⁾
—

1.4

0.1

Conversion of convertible senior notes ⁽¹⁾
—

0.2

—

Stock-based compensation
0.1

0.2

0.5

Denominator for basic net income (loss) per share
62.2

61.1

56.4

Effect of dilutive securities:

Warrants ⁽²⁾
1.4

4.8

—

Convertible senior notes ⁽¹⁾
—

0.4

—

Stock-based compensation
0.6

0.3

—

Denominator for diluted net income (loss) per share
64.2

66.6

56.4

Net income (loss) per share: ⁽³⁾

Basic
$
11.85

$
11.57

$
(9.07
)
Diluted
$
11.47

$
10.61

$
(9.07
)

Potentially dilutive common shares excluded from calculations: ⁽²⁾

Warrants
—

—

1.9

Convertible senior notes ⁽¹⁾
—

—

0.4

Stock-based compensation
—

—

0.3

_______________________________
(1)
“Convertible senior notes” in this table refer to the 1.625% convertible senior notes due 2044 that were settled in 2018.
(2)
For more information regarding the warrants, including partial termination transactions, refer to Note 14, “Stockholders' Equity.” The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. Certain potentially dilutive common shares issuable are not included in the computation of diluted net income (loss) per share because to do so would have been anti-dilutive.
(3)
Source data for calculations in thousands.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Property, Equipment, and Capitalized Software, Net
12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Property, Equipment, and Capitalized Software, Net Property, Equipment, and Capitalized Software, Net
Property and equipment are stated at historical cost. Replacements and major improvements are capitalized, and repairs and maintenance are charged to expense as incurred. Furniture and equipment are generally depreciated using the straight-line method over estimated useful lives ranging from three to seven years. Software developed for internal use is capitalized. Software is generally amortized over its estimated useful life of three years. Leasehold improvements are amortized over the term of the lease, or over their useful lives from five to 10 years, whichever is shorter. Buildings are depreciated over their estimated useful lives of 31.5 to 40 years.
A summary of property, equipment, and capitalized software is as follows:

December 31,

2019

2018

(In millions)
Capitalized software
$
421

$
373

Furniture and equipment
213

231

Building and improvements
49

154

Land
4

16

Total cost
687

774

Less: accumulated amortization - capitalized software
(351
)

(320
)
Less: accumulated depreciation and amortization - furniture, equipment, building, and improvements
(179
)

(213
)
Total accumulated depreciation and amortization
(530
)

(533
)
ROU assets - finance leases
228

—

Property, equipment, and capitalized software, net
$
385

$
241

The following table presents all depreciation and amortization recognized in our consolidated statements of operations:

Year Ended December 31,

2019

2018

2017

(In millions)
Recorded in depreciation and amortization:

Amortization of capitalized software
$
33

$
42

$
64

Depreciation and amortization of furniture, equipment, building, and improvements
21

36

42

Amortization of intangible assets
18

21

31

Amortization of finance leases
17

—

—

Subtotal
89

99

137

Recorded in cost of service revenue:

Amortization of capitalized software and deferred contract costs
—

28

41

Total depreciation and amortization recognized
$
89

$
127

$
178

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R85.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes - Provision for income taxes (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Current:

Federal $ 204 $ 272 $ (9)

State 12 18 3

Foreign 9 8 0

Total current 225 298 (6)

Deferred:

Federal 5 (3) (85)

State 6 (3) (9)

Foreign (1) 0 0

Total deferred 10 (6) (94)

Income tax expense (benefit) $ 235 $ 292 $ (100)

X

- Definition
Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentFederalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_CurrentForeignTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817
+ Details

Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_DeferredForeignIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 36 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details)
$ in Millions
12 Months Ended

Dec. 31, 2019

USD ($)

claim

Dec. 31, 2018

USD ($)

Dec. 31, 2017

USD ($)

Product Information [Line Items]

Incurred Claims and Allocated Claims Adjustment Expenses $ 13,905 $ 15,137 $ 17,073

Incurred Claims and Allocated Claims Adjustment Expenses 46,125

Total IBNP 1,391

Benefit Year 2017

Product Information [Line Items]

Incurred Claims and Allocated Claims Adjustment Expenses 16,704 16,728 $ 17,037

Total IBNP $ 18

Cumulative number of reported claims (in claim) | claim 119,000,000

Benefit Year 2018

Product Information [Line Items]

Incurred Claims and Allocated Claims Adjustment Expenses $ 15,245 $ 15,478

Total IBNP $ 25

Cumulative number of reported claims (in claim) | claim 110,000,000

Benefit Year 2019

Product Information [Line Items]

Incurred Claims and Allocated Claims Adjustment Expenses $ 14,176

Total IBNP $ 1,348

Cumulative number of reported claims (in claim) | claim 93,000,000

X

- Definition
Liability For Unpaid Claims And Claims Adjustment Expense, Incurred Claims Including Acquisition Adjustment
+ References
No definition available.
+ Details

Name: moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Estimated costs as of the balance sheet date of settling insured claims and costs incurred in the claims settlement process for claims that have not yet been submitted to the insurance company for reimbursement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.W)
-URI http://asc.fasb.org/extlink&oid=27015833&loc=d3e570705-122907
+ Details

Name: us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ProductInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cumulative number of reported claims for short-duration insurance contracts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 4D
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116884468&loc=SL65671317-158438
+ Details

Name: us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2019Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Finite-Lived Intangible Assets [Line Items]

Cost $ 199 $ 221

Accumulated Amortization 170 174

Carrying Amount 29 47

Contract rights and licenses

Finite-Lived Intangible Assets [Line Items]

Cost 179 201

Accumulated Amortization 156 162

Carrying Amount 23 39

Provider networks

Finite-Lived Intangible Assets [Line Items]

Cost 20 20

Accumulated Amortization 14 12

Carrying Amount $ 6 $ 8

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ContractRightsandLicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ProviderNetworksMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R81.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Debt - Senior Notes (Details)

Dec. 31, 2019

USD ($)

5.375% Senior Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate on notes 5.375%

4.875% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate on notes 4.875%

Senior Notes | 5.375% Senior Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate on notes 5.375%

Aggregate principal amount of notes outstanding $ 700,000,000

Senior Notes | 4.875% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate on notes 4.875%

Aggregate principal amount of notes outstanding $ 330,000,000

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Debt - Schedule of Long-Term Debt (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Debt Instrument [Line Items]

Lease financing obligations $ 0 $ 1

Debt issuance costs 0 (1)

Total, current portion 18 241

Debt issuance costs (7) (10)

Total, non-current portion $ 1,237 1,020

1.125% Convertible Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 1.125%

5.375% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 5.375%

4.875% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 4.875%

Convertible Debt | 1.125% Convertible Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 1.125%

Current portion of long-term debt $ 12 241

Convertible Debt | 4.875% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 4.875%

Senior Notes | 1.125% Convertible Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 1.125%

Senior Notes | 5.375% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 5.375%

Non-current portion of long-term debt $ 700 700

Senior Notes | 4.875% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 4.875%

Non-current portion of long-term debt $ 330 330

Term Loan Facility | Term Loan Facility

Debt Instrument [Line Items]

Current portion of long-term debt 6 0

Non-current portion of long-term debt $ 214 $ 0

X

- Definition
Long-Term Debt, Current Maturities, Net Of Unamortized Premium (Discount)
+ References
No definition available.
+ Details

Name: moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount
+ References
No definition available.
+ Details

Name: moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of capital lease obligation due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399
+ Details

Name: us-gaap_DeferredFinanceCostsCurrentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredFinanceCostsNoncurrentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of long-term debt and lease obligation, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_TermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R89.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Unrecognized tax benefits roll forward

Gross unrecognized tax benefits at beginning of period $ (20) $ (13) $ (11)

Increases in tax positions for current year (9) (1)

Increases in tax positions for prior years 0 0 (4)

Decreases in tax positions for prior years 0 0 3

Lapse in statute of limitations 2 0

Gross unrecognized tax benefits at end of period $ (20) $ (20) $ (13)

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 10B
-URI http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(4)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 41 R107.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Operating activities:

Net cash provided by operating activities $ 427 $ (314) $ 804

Investing activities:

Purchases of investments (2,536) (1,444) (2,697)

Proceeds from sales and maturities of investments 2,302 2,445 1,759

Purchases of property, equipment and capitalized software (57) (30) (86)

Net cash received from sale of subsidiaries 0 190 0

Other, net (2) (18) (38)

Net cash provided by (used in) investing activities (293) 1,143 (1,062)

Financing activities:

Repayment of principal amount of convertible notes (240) (362) 0

Cash paid for partial settlement of conversion option (578) (623) 0

Cash received for partial settlement of call option 578 623 0

Cash paid for partial termination of warrants (514) (549) 0

Proceeds from borrowings under term loan facility 220 0 0

Common stock purchases (47) 0 0

Repayment of credit facility 0 (300) 0

Proceeds from senior notes offerings, net of issuance costs 0 0 325

Other, net 29 18 11

Net cash (used in) provided by financing activities (552) (1,193) 636

Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents (418) (364) 378

Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period 2,926 3,290 2,912

Cash and cash equivalents at end of period 2,508 2,926 3,290

Parent Company

Operating activities:

Net cash provided by operating activities 64 118 166

Investing activities:

Capital contributions to subsidiaries (43) (145) (370)

Dividends received from subsidiaries 1,373 298 286

Purchases of investments (152) (136) (331)

Proceeds from sales and maturities of investments 93 388 156

Purchases of property, equipment and capitalized software (56) (22) (67)

Net cash received from sale of subsidiaries 0 242 0

Change in amounts due to/from affiliates 38 6 (49)

Other, net 1 0 0

Net cash provided by (used in) investing activities 1,254 631 (375)

Financing activities:

Repayment of principal amount of convertible notes (240) (362) 0

Cash paid for partial settlement of conversion option (578) (623) 0

Cash received for partial settlement of call option 578 623 0

Cash paid for partial termination of warrants (514) (549) 0

Proceeds from borrowings under term loan facility 220 0 0

Common stock purchases (47) 0 0

Repayment of credit facility 0 (300) 0

Proceeds from senior notes offerings, net of issuance costs 0 0 325

Proceeds from borrowings under credit facility 0 0 300

Other, net 29 19 11

Net cash (used in) provided by financing activities (552) (1,192) 636

Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents 766 (443) 427

Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period 70 513 86

Cash and cash equivalents at end of period $ 836 $ 70 $ 513

X

- Definition
Cash Paid For Settlement Of Conversion Option
+ References
No definition available.
+ Details

Name: moh_CashPaidForSettlementOfConversionOption

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Changes in amounts due to and due from affiliates.
+ References
No definition available.
+ Details

Name: moh_ChangesInAmountsDueToAndDueFromAffiliates

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds From Borrowings Under Credit Facility
+ References
No definition available.
+ Details

Name: moh_ProceedsFromBorrowingsUnderCreditFacility

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash (inflow) outflow from investing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the purchase of noncontrolling interest during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for purchase of marketable security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562
+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Dividends received on equity and other investments during the current period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3337-108585
+ Details

Name: us-gaap_ProceedsFromDividendsReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromLongTermLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_RepaymentsOfLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Fair Value Measurements - Additional Information (Details)

Dec. 31, 2019

1.125% Call Option

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Percentage of contractual interest rate on derivative 1.125%

1.125% Conversion Option

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Percentage of contractual interest rate on derivative 1.125%

X

- Definition
Fixed interest rate related to the interest rate derivative.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeFixedInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=moh_CallOptionDerivativeAssetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Investments - Contractual Maturities (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Amortized Cost

Due in one year or less $ 453

Due after one year through five years 957

Due after five years through ten years 171

Due after ten years 360

Amortized Cost 1,941 $ 1,692

Estimated Fair Value

Due in one year or less 453

Due after one year through five years 962

Due after five years through ten years 171

Due after ten years 360

Estimated Fair Value $ 1,946

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth fiscal year through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 44 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies
12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Significant Accounting Policies Significant Accounting Policies
Cash and Cash Equivalents
Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.

December 31,

2019

2018

2017

(In millions)
Cash and cash equivalents
$
2,452

$
2,826

$
3,186

Restricted cash and cash equivalents, non-current
56

100

95

Restricted cash and cash equivalents, current
—

—

9

Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows
$
2,508

$
2,926

$
3,290

Investments
Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (“AFS”) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders’ equity as other comprehensive income, net of applicable income taxes. Held-to-maturity securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses and unrealized losses judged to be other than temporary with respect to available-for-sale and held-to-maturity securities are included in the determination of net income (loss). The cost of securities sold is determined using the specific-identification method.
Our investment policy requires that all of our investments have final maturities of less than 10 years, or less than 10 years average life for structured securities. Investments and restricted investments are subject to interest rate risk
and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.
In general, our AFS securities are classified as current assets without regard to the securities’ contractual maturity dates because they may be readily liquidated. We monitor our investments for other-than-temporary impairment. For comprehensive discussions of the fair value and classification of our investments, see Note 4, “Fair Value Measurements,” and Note 5, “Investments.”
Long-Lived Assets, including Intangible Assets
Long-lived assets consist primarily of property, equipment, capitalized software (see Note 7, “Property, Equipment, and Capitalized Software, Net”), and intangible assets resulting from acquisitions. Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts). Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between five and 15 years.
Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset’s (or asset group’s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed. Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment. Refer to Note 9, “Goodwill and Intangible Assets, Net,” for further details.
Leases
Right-of-use (“ROU”) assets represent our right to use the underlying assets over the lease term, and lease liabilities represent our obligation for lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. If applicable, we account for lease and non-lease components within a lease as a single lease component.
Because most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Finance lease payments reduce finance lease liabilities, the related ROU assets are amortized on a straight-line basis over the lease term, and interest expense is recognized using the effective interest method.
The significant majority of our operating leases consist of long-term operating leases for office space. Short-term leases (those with terms of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. For certain leases that represent a portfolio of similar assets, such as a fleet of vehicles, we apply a portfolio approach to account for the related ROU assets and liabilities, rather than account for such assets and the related liabilities individually. A nominal number of our lease agreements include rental payments that adjust periodically for inflation. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.
For further information, including the amount and location of the ROU assets and lease liabilities recognized in the accompanying consolidated balance sheet, see Note 8, “Leases.” For further information regarding our adoption and implementation of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), see “Recent Accounting Pronouncements Adopted,” below.
Goodwill and Business Combinations
Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment on an annual basis and more frequently if impairment indicators are present. Such events or circumstances may include experienced or expected operating cash-flow deterioration or losses, significant losses of membership, loss of state funding, loss of state contracts, and other factors. Goodwill is impaired if the carrying amount of the reporting unit (one of our state health plans)
exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit.
When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, the dynamic economic and political environments in which we operate, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. If our qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, we perform the quantitative assessment. We may also elect to bypass the qualitative assessment and proceed directly to the quantitative assessment. If performing a quantitative assessment, we generally estimate the fair values of our reporting units by applying the income approach, using discounted cash flows.
For the annual impairment test under a quantitative assessment, the base year in the reporting units’ discounted cash flows is derived from the annual financial planning cycle, which commences in the fourth quarter of the year. When computing discounted cash flows, we make assumptions about a wide variety of internal and external factors, and consider what the reporting unit’s selling price would be in an orderly transaction between market participants at the measurement date. Significant assumptions include financial projections of free cash flow (including significant assumptions about membership, premium rates, healthcare and operating cost trends, contract renewal and the procurement of new contracts, capital requirements and income taxes), long-term growth rates for determining terminal value beyond the discretely forecasted periods, and discount rates. When determining the discount rate, we consider the overall level of inherent risk of the reporting unit, and the expected rate an outside investor would expect to earn. As part of a quantitative assessment, we may also apply the asset liquidation method to estimate the fair value of individual reporting units, which is computed as total assets minus total liabilities, excluding intangible assets and deferred taxes. Finally, we apply a market approach to reconcile the value of our reporting units to our consolidated market value. Under the market approach, we consider publicly traded comparable company information to determine revenue and earnings multiples which are used to estimate our reporting units’ fair values. The assumptions used are consistent with those used in our long-range business plan and annual planning process. However, if these assumptions differ from actual results, the outcome of our goodwill impairment tests could be adversely affected.
Accounting for business combinations requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within our consolidated statements of operations. Refer to Note 9, “Goodwill and Intangible Assets, Net,” for further details.
Premium Revenue
Premium revenue is generated from our Health Plans segment contracts, including agreements with other managed care organizations for which we operate as a subcontractor. Premium revenue is generally received based on per member per month (“PMPM”) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. The state Medicaid programs and the federal Medicare program periodically adjust premiums. Additionally, many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.
The following table summarizes premium revenue by health plan for the periods presented:

Year Ended December 31,

2019

2018

2017

Amount

% of Total

Amount

% of Total

Amount

% of Total

(Dollars in millions)
California
$
2,266

14.0
%

$
2,150

12.2
%

$
2,701

14.3
%
Florida
734

4.5

1,790

10.2

2,568

13.6

Illinois
1,002

6.2

793

4.5

593

3.1

Michigan
1,624

10.0

1,601

9.1

1,596

8.5

New Mexico ⁽¹⁾
—

—

1,356

7.7

1,368

7.3

Ohio
2,553

15.8

2,388

13.6

2,216

11.8

Puerto Rico
474

2.9

696

3.9

732

3.9

South Carolina
583

3.6

495

2.8

445

2.4

Texas
2,991

18.5

3,244

18.4

2,813

14.9

Washington
2,695

16.6

2,361

13.4

2,608

13.8

Other ⁽¹⁾
1,286

7.9

738

4.2

1,214

6.4

Total
$
16,208

100.0
%

$
17,612

100.0
%

$
18,854

100.0
%

_______________________
(1)
“Other” includes the Idaho, Mississippi, New York, Utah and Wisconsin health plans, which are not individually significant to our consolidated operating results. In 2019, “Other” also includes the New Mexico health plan. The New Mexico health plan’s Medicaid contract terminated on December 31, 2018, and therefore its results are not individually significant to our consolidated operating results in 2019.
Certain components of premium revenue are subject to accounting estimates and fall into the following categories:
Contractual Provisions That May Adjust or Limit Revenue or Profit
Medicaid Program
Medical Cost Floors (Minimums), and Medical Cost Corridors. A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. In the aggregate, we recorded liabilities under the terms of such contract provisions of $74 million and $103 million at December 31, 2019, and December 31, 2018, respectively. Approximately $69 million and $87 million of the liabilities accrued at December 31, 2019, and December 31, 2018, respectively, relates to our participation in Medicaid Expansion programs.
In certain circumstances, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold. Receivables relating to such provisions were insignificant at December 31, 2019, and December 31, 2018.
Profit Sharing and Profit Ceiling. Our contracts with certain states contain profit-sharing or profit ceiling provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any. Liabilities for profits in excess of the amount we are allowed to retain under these provisions were insignificant at December 31, 2019, and December 31, 2018.
Retroactive Premium Adjustments. State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we must adjust our premium revenue in the period in which we learn of the adjustment, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.
Medicare Program
Risk Adjusted Premiums: Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members’ risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members’ health status, risk scores and CMS practices. Consolidated balance sheet amounts related to anticipated Medicare risk adjusted premiums and Medicare Part D settlements were insignificant at December 31, 2019, and December 31, 2018.
Minimum MLR: The Affordable Care Act (“ACA”) has established a minimum annual medical loss ratio (“Minimum MLR”) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations. The amounts payable for the Medicare Minimum MLR were insignificant at December 31, 2019, and December 31, 2018.
Marketplace Program
Risk Adjustment: Under this program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of operations. As of December 31, 2019, Marketplace risk adjustment payables amounted to $368 million and related receivables amounted to $63 million, for a net payable of $305 million. As of December 31, 2018, Marketplace risk adjustment payables amounted to $466 million and related receivables amounted to $34 million, for a net payable of $432 million.
Minimum MLR: The ACA has established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations. Aggregate balance sheet amounts related to the Minimum MLR were insignificant at December 31, 2019, and December 31, 2018.
A summary of the categories of amounts due government agencies is as follows:

December 31,

2019

2018

(In millions)
Medicaid program:

Medical cost floors and corridors
$
74

$
103

Other amounts due to states
84

81

Marketplace program:

Risk adjustment
368

466

Cost sharing reduction
—

183

Other
138

134

Total
$
664

$
967

Quality Incentives
At many of our health plans, revenue ranging from approximately 1% to 4% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. As described in Note 1, “Organization and Basis of Presentation–Use of Estimates,” recognition of quality incentive premium revenue is subject to the use of estimates.
The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods.

Year Ended December 31,

2019

2018

2017

(In millions)
Maximum available quality incentive premium - current period
$
186

$
182

$
150

Amount of quality incentive premium revenue recognized in current period:

Earned current period
$
156

$
133

$
97

Earned prior periods
38

31

10

Total
$
194

$
164

$
107

Quality incentive premium revenue recognized as a percentage of total premium revenue
1.2
%

0.9
%

0.6
%

Medical Care Costs, Medical Claims and Benefits Payable
Medical care costs are recognized in the period in which services are provided and include fee-for-service claims, pharmacy benefits, capitation payments to providers, and various other medically-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Such medical care costs include amounts paid by us as well as estimated medical claims and benefits payable for costs that were incurred but not paid as of the reporting date (“IBNP”). Pharmacy benefits represent payments for members' prescription drug costs, net of rebates from drug manufacturers. We estimate pharmacy rebates based on historical and current utilization of prescription drugs and contractual provisions. Capitation payments represent monthly contractual fees paid to providers, who are responsible for providing medical care to members, which could include medical or ancillary costs like dental, vision and other supplemental health benefits. Such capitation costs are fixed in advance of the periods covered and are not subject to significant accounting estimates. Other medical care costs include all medically-related administrative costs, amounts due to providers pursuant to risk-sharing or other incentive arrangements, provider claims, and other healthcare expenses. Examples of medically-related administrative costs include expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses. Additionally, we include an estimate for the cost of settling claims incurred through the reporting date in our medical claims and benefits payable liability.
Medical claims and benefits payable consist mainly of fee-for-service IBNP, unpaid pharmacy claims, capitation costs, other medical costs, including amounts payable to providers pursuant to risk-sharing or other incentive arrangements and amounts payable to providers on behalf of certain state agencies for certain state assessments in which we assume no financial risk. IBNP includes the costs of claims incurred as of the balance sheet date which have been reported to us, and our best estimate of the cost of claims incurred but not yet reported to us. We also include an additional reserve to ensure that our overall IBNP liability is sufficient under moderately adverse conditions. We reflect changes in these estimates in the consolidated results of operations in the period in which they are determined.
The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors and the assumed healthcare cost trend to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.
Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. Each reporting period, the recognized IBNP liability represents our best estimate of the total amount of unpaid claims incurred as of the balance sheet date using a consistent methodology in estimating our IBNP liability. We believe our current estimates are reasonable and adequate; however, the development of our estimate is a continuous process that we monitor and update as more complete claims payment information and healthcare cost trend data becomes available. Actual medical care costs may be less than we previously estimated (favorable development) or more than we previously estimated (unfavorable development), and any differences could be material. Any adjustments to reflect favorable development would be
recognized as a decrease to medical care costs, and any adjustments to reflect unfavorable development would be recognized as an increase to medical care costs, in the period in which the adjustments are determined.
Refer to Note 10, “Medical Claims and Benefits Payable,” for a table presenting the components of the change in our medical claims and benefits payable, for all periods presented in the accompanying consolidated financial statements.
Reinsurance
We limit our risk of catastrophic losses by maintaining high deductible reinsurance coverage. Such reinsurance coverage does not relieve us of our primary obligation to our policyholders. We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. Reinsurance premiums amounted to $17 million, $16 million, and $20 million for the years ended December 31, 2019, 2018, and 2017, respectively. Reinsurance recoveries amounted to $18 million, $33 million, and $24 million for the years ended December 31, 2019, 2018, and 2017, respectively. Reinsurance recoverable of $21 million, $31 million, and $16 million, as of December 31, 2019, 2018, and 2017, respectively, is included in “Receivables” in the accompanying consolidated balance sheets.
Marketplace Cost Share Reduction (“CSR”)
In the year ended December 31, 2018, we recognized a benefit of approximately $81 million in reduced medical care costs related to 2017 dates of service, as a result of the federal government’s confirmation that the reconciliation of 2017 Marketplace CSR subsidies would be performed on an annual basis. In the fourth quarter of 2017, we had assumed a nine-month reconciliation of this item pending confirmation of the time period to which the 2017 reconciliation would be applied.
Premium Deficiency Reserves on Loss Contracts
We assess the profitability of our contracts to determine if it is probable that a loss will be incurred in the future by reviewing current results and forecasts. For purposes of this assessment, contracts are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. A premium deficiency is recognized if anticipated future medical care and administrative costs exceed anticipated future premium revenue, investment income and reinsurance recoveries. No premium deficiency reserves were recorded as of December 31, 2019 and 2018.
Income Taxes
We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates expected to be in effect during the year in which the basis differences reverse. Valuation allowances are established when management determines it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. For further discussion and disclosure, see Note 13, “Income Taxes.”
Taxes Based on Premiums
Health Insurer Fee (“HIF”). The federal government under the ACA imposes an annual fee, or excise tax, on health insurers for each calendar year. The HIF is based on a company’s share of the industry’s net premiums written during the preceding calendar year and is non-deductible for income tax purposes. We recognize expense for the HIF over the year on a straight-line basis. Within our Medicaid program, we must secure additional reimbursement from our state partners for this added cost. We recognize the related revenue when we have obtained a contractual commitment or payment from a state to reimburse us for the HIF, and such HIF revenue is recognized ratably throughout the year. The Consolidated Appropriations Act of 2016 provided for the HIF moratorium in 2017, and Public Law No. 115-120 provided for the HIF moratorium in 2019. Therefore, there were no health insurer fees reimbursed, nor health insurer fees incurred, in those years.
Premium and Use Tax. Certain of our health plans are assessed a tax based on premium revenue collected. The premium revenues we receive from these states include the premium tax assessment. We have reported these taxes on a gross basis, as premium tax revenue and as premium tax expenses in the consolidated statements of operations.
Concentrations of Credit Risk
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those
investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents and U.S. Treasury securities.
Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate. See further information below, under “Recent Accounting Pronouncements Not Yet Adopted” regarding our adoption of ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, effective January 1, 2020.
Risks and Uncertainties
Our profitability depends in large part on our ability to accurately predict and effectively manage medical care costs. We continually review our medical costs in light of our underlying claims experience and revised actuarial data. However, several factors could adversely affect medical care costs. These factors, which include changes in health care practices, inflation, new technologies, major epidemics, natural disasters, and malpractice litigation, are beyond our control and may have an adverse effect on our ability to accurately predict and effectively control medical care costs. Costs in excess of those anticipated could have a material adverse effect on our financial condition, results of operations, or cash flows.
We operate health plans primarily as a direct contractor with the states (or Commonwealth), and in Los Angeles County, California, as a subcontractor to another health plan holding a direct contract with the state. We are therefore dependent upon a small number of contracts to support our revenue. The loss of any one of those contracts could have a material adverse effect on our financial position, results of operations, or cash flows. In addition, our ability to arrange for the provision of medical services to our members is dependent upon our ability to develop and maintain adequate provider networks. Our inability to develop or maintain such networks might, in certain circumstances, have a material adverse effect on our financial position, results of operations, or cash flows.
Recent Accounting Pronouncements Adopted
Leases. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Topic 842, which was subsequently modified by several ASUs issued in 2017 and 2018. Topic 842 was issued to increase transparency and comparability among organizations by requiring the recognition of ROU assets and lease liabilities on the balance sheet. Most prominent among the changes in Topic 842 is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. In addition, Topic 842’s disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. Topic 842’s transition provisions are applied using a modified retrospective approach; entities may elect whether to apply the transition provisions, including disclosure requirements, at the beginning of the earliest comparative period presented or on the adoption date.
We adopted Topic 842 effective January 1, 2019, and elected to apply the transition provisions as of that date. Accordingly, we recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings on January 1, 2019. In addition, we elected the available practical expedients and implemented internal controls and information systems functionality to enable the preparation of financial information on adoption.
As indicated in the accompanying consolidated statements of stockholders’ equity, the cumulative effect adjustment was an increase of $85 million to retained earnings ($110 million, net of $25 million deferred income tax expense), relating primarily to the transition provisions for sale-leaseback arrangements that did not qualify for sale treatment. Accordingly, such arrangements were de-recognized and recorded as finance lease ROU assets and lease liabilities. The difference between the de-recognized assets and lease financing obligations resulted in an increase to retained earnings. The recognition of these arrangements as finance lease ROU assets and lease liabilities will not materially impact our consolidated results of operations over the terms of the leases.
Software Licenses. In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. We early adopted ASU 2018-15 effective January 1, 2019, using the prospective method, with no material impact to our financial condition, results of operations or cash flows. Adoption of this guidance may be significant to us in the future depending on the extent to which we use cloud computing arrangements that qualify as service contracts.
Recent Accounting Pronouncements Not Yet Adopted
Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which was subsequently modified by several ASUs issued in 2018 and 2019. This standard introduces a new current expected credit loss (“CECL”) model for measuring expected credit losses for certain types of financial instruments measured at amortized cost and replaces the incurred loss model. The CECL model requires an entity to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount the entity expects to collect over the instrument’s contractual life after consideration of historical experience, current conditions, and reasonable and supportable forecasts. This standard also introduces targeted changes to the AFS debt securities impairment model. It eliminates the concept of other-than-temporary impairment and requires an entity to determine whether any impairment is the result of a credit loss or other factors. We will adopt Topic 326 effective January 1, 2020, using the modified retrospective approach. Under this method we will recognize the cumulative effect of adopting the standard as an adjustment to the opening balance of retained earnings on January 1, 2020.
Under Topic 326, we will record an allowance for credit losses for financial assets subject to the CECL model. The most significant type of financial instrument reported in our consolidated balance sheets, subject to the CECL model, is “Receivables.” As of December 31, 2019, approximately 75%, or $1,056 million of the receivables balance constitutes receivables from state and federal government agencies. Based on our analysis, we believe that the credit risk associated with such receivables is nominal due to a very low risk of default.
The AFS debt securities impairment model will apply to “Investments” reported in our consolidated balance sheets. We believe that the credit risk associated with our non-government issued Investments is nominal due to the high quality of such investments.
The adoption of Topic 326 will be immaterial to our consolidated results of operations and financial condition.
Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R103.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Financial Information of Registrant - Condensed Balance Sheets (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Current assets:

Cash and cash equivalents $ 2,452 $ 2,826 $ 3,186

Investments 1,946 1,681

Receivables 1,406 1,330

Prepaid expenses and other current assets 134 149

Derivative asset 29 476

Total current assets 5,967 6,462

Property, equipment, and capitalized software, net 241

Goodwill and intangible assets, net 172 190 255

Deferred income taxes 79 117

Total assets 6,787 7,154 8,471

Current liabilities:

Medical claims and benefits payable 1,854 1,961 2,192 $ 1,929

Accounts payable and accrued liabilities 455 390

Current portion of long-term debt 18 241

Derivative liability 29 476

Total current liabilities 3,269 4,246

Long-term debt 1,237 1,020

Finance lease liabilities 231

Finance lease liabilities 197

Other long-term liabilities 90 44

Total liabilities 4,827 5,507

Stockholders’ equity:

Common stock, $0.001 par value; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018 0 0

Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding 0 0

Additional paid-in capital 175 643

Accumulated other comprehensive income (loss) 4 (8)

Retained earnings 1,781 1,012

Total stockholders’ equity 1,960 1,647 $ 1,337 $ 1,649

Total liabilities and stockholders’ equity 6,787 7,154

Parent Company

Current assets:

Cash and cash equivalents 836 70

Investments 161 100

Receivables 2 2

Due from affiliates 49 90

Prepaid expenses and other current assets 46 47

Derivative asset 29 476

Total current assets 1,123 785

Property, equipment, and capitalized software, net 327 176

Goodwill and intangible assets, net 13 13

Investments in subsidiaries 2,225 2,768

Deferred income taxes 10 39

Advances to related parties and other assets 76 40

Total assets 3,774 3,821

Current liabilities:

Medical claims and benefits payable 0 4

Accounts payable and accrued liabilities 260 223

Current portion of long-term debt 18 241

Derivative liability 29 476

Total current liabilities 307 944

Long-term debt 1,237 1,020

Finance lease liabilities 231

Finance lease liabilities 197

Other long-term liabilities 39 13

Total liabilities 1,814 2,174

Stockholders’ equity:

Common stock, $0.001 par value; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018 0 0

Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding 0 0

Additional paid-in capital 175 643

Accumulated other comprehensive income (loss) 4 (8)

Retained earnings 1,781 1,012

Total stockholders’ equity 1,960 1,647

Total liabilities and stockholders’ equity $ 3,774 $ 3,821

X

- Definition
Advances to related parties and other assets.
+ References
No definition available.
+ Details

Name: moh_AdvancesToRelatedPartiesAndOtherAssets

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735
+ Details

Name: us-gaap_CapitalLeaseObligationsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredIncomeTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.
+ References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsNetIncludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in equity method investee and investment in and advance to affiliate.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (cc)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt and lease obligation, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investment in marketable security, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-06(3))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date within one year where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Cover Page - USD ($)
shares in Thousands, $ in Millions
12 Months Ended

Dec. 31, 2019

Feb. 07, 2020

Jun. 30, 2019

Cover page.

Document Type 10-K

Document Annual Report true

Document Period End Date Dec. 31, 2019

Document Transition Report false

Entity File Number 1-31719

Entity Registrant Name MOLINA HEALTHCARE, INC.

Entity Incorporation, State or Country Code DE

Entity Tax Identification Number 13-4204626

Entity Address, Address Line One 200 Oceangate

Entity Address, Address Line Two Suite 100

Entity Address, City or Town Long Beach

Entity Address, State or Province CA

Entity Address, Postal Zip Code 90802

City Area Code 562

Local Phone Number 435-3666

Title of 12(b) Security Common Stock, $0.001 Par Value

Trading Symbol MOH

Security Exchange Name NYSE

Entity Well-known Seasoned Issuer Yes

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Filer Category Large Accelerated Filer

Entity Small Business false

Entity Emerging Growth Company false

Entity Shell Company false

Entity Public Float $ 8,928.7

Entity Common Stock, Shares Outstanding 60,800

Documents Incorporated by Reference
Portions of the registrant’s Proxy Statement for the 2020 Annual Meeting of Stockholders to be held on May 7, 2020, are incorporated by reference into Part III of this Form 10-K, to the extent described therein.

Entity Central Index Key 0001179929

Amendment Flag false

Document Fiscal Year Focus 2019

Document Fiscal Period Focus FY

Current Fiscal Year End Date --12-31

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an annual report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 20-F, 40-F
-Number 240
-Section 15
-Subsection d-1
+ Details

Name: dei_DocumentAnnualReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1-
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Documents incorporated by reference.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-23
+ Details

Name: dei_DocumentsIncorporatedByReferenceTextBlock

Namespace Prefix: dei_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine2

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 47 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Balance Sheets (Parenthetical) - $ / shares

Dec. 31, 2019

Dec. 31, 2018

Statement of Financial Position [Abstract]

Common stock, par value (dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 150,000,000 150,000,000

Common stock, shares outstanding 62,000,000 62,000,000

Preferred stock, par value (dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 20,000,000 20,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R9999.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Label Element Value

AOCI Attributable to Parent [Member]

Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (1,000,000)

Retained Earnings [Member]

Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption 7,000,000

Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 85,000,000

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Goodwill and Intangible Assets, Net (Tables)
12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of goodwill
The following table presents the changes in the carrying amounts of goodwill by segment, for the periods presented.

Health Plans

Other

Total

(In millions)
Balance, December 31, 2017
$
143

$
43

$
186

Acquisitions
—

—

—

Dispositions
—

(43
)

(43
)
Impairment and other
—

—

—

Balance, December 31, 2018
143

—

143

Acquisitions
—

—

—

Dispositions
—

—

—

Impairment and other
—

—

—

Balance, December 31, 2019
$
143

$
—

$
143

Summary of identified intangible assets, by major class
The following table provides the details of identified intangible assets, by major class, for the periods indicated:

December 31, 2019

December 31, 2018

Cost

Accumulated
Amortization

Carrying Amount

Cost

Accumulated
Amortization

Carrying Amount

(In millions)
Contract rights and licenses
$
179

$
156

$
23

$
201

$
162

$
39

Provider networks
20

14

6

20

12

8

Total
$
199

$
170

$
29

$
221

$
174

$
47

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267
+ Details

Name: us-gaap_ScheduleOfGoodwillTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Investments (Tables)
12 Months Ended

Dec. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Investments The following tables summarize our current investments as of the dates indicated:

December 31, 2019

Amortized

Gross
Unrealized

Estimated

Cost

Gains

Losses

Fair Value

(In millions)
Corporate debt securities
$
1,174

$
5

$
1

$
1,178

Mortgage-backed securities
420

1

1

420

Asset-backed securities
126

1

—

127

U.S. Treasury notes
86

—

—

86

Municipal securities
78

—

—

78

GSEs
49

—

—

49

Foreign securities
7

—

—

7

Certificates of deposit
1

—

—

1

Total
$
1,941

$
7

$
2

$
1,946

December 31, 2018

Amortized Cost

Gross
Unrealized

Estimated Fair Value

Gains

Losses

(In millions)
Corporate debt securities
$
1,131

$
—

$
8

$
1,123

Asset-backed securities
83

—

1

82

U.S. Treasury notes
181

—

—

181

Municipal securities
115

—

1

114

GSEs
164

—

1

163

Foreign securities
4

—

—

4

Certificates of deposit
14

—

—

14

Total
$
1,692

$
—

$
11

$
1,681

Contractual maturities of investments
The contractual maturities of our current investments as of December 31, 2019 are summarized below:

Amortized
Cost

Estimated
Fair Value

(In millions)
Due in one year or less
$
453

$
453

Due after one year through five years
957

962

Due after five years through ten years
171

171

Due after ten years
360

360

Total
$
1,941

$
1,946

Available-for-sale investments
The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December 31, 2019:

In a Continuous Loss Position
for Less than 12 Months

In a Continuous Loss Position
for 12 Months or More

Estimated
Fair
Value

Unrealized
Losses

Total Number of Positions

Estimated
Fair
Value

Unrealized
Losses

Total Number of Positions

(Dollars in millions)
Corporate debt securities
$
222

$
1

167

$
—

$
—

—

Mortgage-backed securities
143

1

72

—

—

—

Total
$
365

$
2

239

$
—

$
—

—

The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December 31, 2018:

In a Continuous Loss Position
for Less than 12 Months

In a Continuous Loss Position
for 12 Months or More

Estimated
Fair
Value

Unrealized
Losses

Total Number of Positions

Estimated
Fair
Value

Unrealized
Losses

Total Number of Positions

(Dollars in millions)
Corporate debt securities
$
509

$
3

285

$
412

$
5

298

Asset-backed securities
—

—

—

68

1

52

Municipal securities
—

—

—

87

1

90

GSEs
—

—

—

127

1

76

Total
$
509

$
3

285

$
694

$
8

516

Balances of restricted investments The following table presents the balances of restricted investments:

December 31,

2019

2018

(In millions)
Florida
$
12

$
32

New Mexico
21

43

Ohio
12

12

Puerto Rico
11

10

Other
23

23

Total Health Plans segment
$
79

$
120

X

- Definition
Restrictions On Investments [Table Text Block]
+ References
No definition available.
+ Details

Name: moh_RestrictionsOnInvestmentsTableTextBlock

Namespace Prefix: moh_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Fair Value Measurements
12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements Fair Value Measurements
We consider the carrying amounts of current assets and current liabilities (not including derivatives and the current portion of long-term debt) to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to a three-tier fair value hierarchy as follows:
Level 1 — Observable Inputs. Level 1 financial instruments are actively traded and therefore the fair value for these securities is based on quoted market prices for identical securities in active markets.
Level 2 — Directly or Indirectly Observable Inputs. Fair value for these investments is determined using a market approach based on quoted prices for similar securities in active markets or quoted prices for identical securities in inactive markets.
Level 3 — Unobservable Inputs. Level 3 financial instruments are valued using unobservable inputs that represent management’s best estimate of what market participants would use in pricing the financial instrument at the measurement date. Our Level 3 financial instruments consist primarily of derivative financial instruments.
The derivatives include the 1.125% Call Option derivative asset and the 1.125% Conversion Option derivative liability (for detailed descriptions of these instruments, see Note 12. “Derivatives”). These derivatives are not actively traded and are valued based on an option pricing model that uses observable and unobservable market data for inputs. Significant market data inputs used to determine fair value as of December 31, 2019, included the price of our common stock, the time to maturity of the derivative instruments, the risk-free interest rate, and the implied volatility of our common stock. The 1.125% Call Option asset and the 1.125% Conversion Option liability were designed such that changes in their fair values offset, with minimal impact to the consolidated statements of operations. Therefore, the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is mitigated.
The net changes in fair value of Level 3 financial instruments were insignificant to our results of operations for the years ended December 31, 2019, and 2018.
Our financial instruments measured at fair value on a recurring basis at December 31, 2019, were as follows:

Total

Level 1

Level 2

Level 3

(In millions)
Corporate debt securities
$
1,178

$
—

$
1,178

$
—

Mortgage-backed securities
420

—

420

—

Asset-backed securities
127

—

127

—

U.S. Treasury notes
86

—

86

—

Municipal securities
78

—

78

—

Government-sponsored enterprise securities (“GSEs”)
49

—

49

—

Foreign securities
7

—

7

—

Certificates of deposit
1

—

1

—

Subtotal
1,946

—

1,946

—

1.125% Call Option derivative asset
29

—

—

29

Total assets
$
1,975

$
—

$
1,946

$
29

1.125% Conversion Option derivative liability
$
29

$
—

$
—

$
29

Total liabilities
$
29

$
—

$
—

$
29

Our financial instruments measured at fair value on a recurring basis at December 31, 2018, were as follows:

Total

Level 1

Level 2

Level 3

(In millions)
Corporate debt securities
$
1,123

$
—

$
1,123

$
—

Asset-backed securities
82

—

82

—

U.S. Treasury notes
181

—

181

—

Municipal securities
114

—

114

—

GSEs
163

—

163

—

Foreign securities
4

—

4

—

Certificates of deposit
14

—

14

—

Subtotal
1,681

—

1,681

—

1.125% Call Option derivative asset
476

—

—

476

Total assets
$
2,157

$
—

$
1,681

$
476

1.125% Conversion Option derivative liability
$
476

$
—

$
—

$
476

Total liabilities
$
476

$
—

$
—

$
476

Fair Value Measurements – Disclosure Only
The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets. The carrying amount and estimated fair value of the Term Loan Facility is classified as a Level 3 financial instrument, because certain inputs used to determine its fair value are not observable. As of December 31, 2019, the carrying amount of the Term Loan Facility approximated fair value because its interest rate is a variable rate that approximates rates currently available to us.

December 31, 2019

December 31, 2018

Carrying

Fair Value

Carrying

Fair Value

Amount

Amount

(In millions)
5.375% Notes
$
696

$
745

$
694

$
674

4.875% Notes
327

340

326

301

Term Loan Facility
220

220

—

—

1.125% Convertible Notes ⁽¹⁾
12

42

240

732

Total
$
1,255

$
1,347

$
1,260

$
1,707

_______________________________
(1)
The fair value of the 1.125% Conversion Option (the embedded cash conversion option), which is reflected in the fair value amounts presented above, amounted to $29 million and $476 million as of December 31, 2019 and 2018, respectively. For more information, including information on debt repayments in 2019 and 2020, see Note 11, “Debt,” and Note 12, “Derivatives.”

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Leases Leases
12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Leases Leases
As discussed in Note 2, “Significant Accounting Policies,” we elected the Topic 842 transition provision that allows entities to continue to apply the legacy guidance in Topic 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. Accordingly, the Topic 842 disclosures below are presented as of and for the year ended December 31, 2019, only.
We are a party to operating and finance leases primarily for our corporate and health plan offices. Our operating leases have remaining lease terms up to 9 years, some of which include options to extend the leases for up to 10 years. As of December 31, 2019, the weighted average remaining operating lease term is 4 years.
Our finance leases have remaining lease terms of 2 years to 19 years, some of which include options to extend the leases for up to 25 years. As of December 31, 2019, the weighted average remaining finance lease term is 16 years.
As of December 31, 2019, the weighted-average discount rate used to compute the present value of lease payments was 5.6% for operating lease liabilities, and 6.5% for finance lease liabilities. The components of lease expense were as follows:

Year Ended December 31, 2019

(In millions)
Operating lease expense
$
34

Finance lease expense:

Amortization of ROU assets
$
17

Interest on lease liabilities
15

Total finance lease expense
$
32

Rental expense related to operating leases amounted to $62 million and $75 million for the years ended December 31, 2018 and 2017, respectively.
Supplemental consolidated cash flow information related to leases follows:

Year Ended December 31, 2019

(In millions)
Cash used in operating activities:

Operating leases
$
36

Finance leases
15

Cash used in financing activities:

Finance leases
6

ROU assets recognized in exchange for lease obligations:

Operating leases
99

Finance leases
245

Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:

December 31, 2019

(In millions)
Operating leases:

ROU assets

Other assets
$
65

Lease liabilities

Accounts payable and accrued liabilities (current)
$
25

Other long-term liabilities (non-current)
48

Total operating lease liabilities
$
73

Finance leases:

ROU assets

Property, equipment, and capitalized software, net
$
228

Lease liabilities

Accounts payable and accrued liabilities (current)
$
8

Finance lease liabilities (non-current)
231

Total finance lease liabilities
$
239

Maturities of lease liabilities as of December 31, 2019, were as follows:

Operating Leases

Finance Leases

(In millions)
2020
$
28

$
23

2021
20

24

2022
14

21

2023
10

21

2024
5

22

Thereafter
3

289

Subtotal - undiscounted lease payments
80

400

Less imputed interest
(7
)

(161
)
Total
$
73

$
239

Leases Leases
As discussed in Note 2, “Significant Accounting Policies,” we elected the Topic 842 transition provision that allows entities to continue to apply the legacy guidance in Topic 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. Accordingly, the Topic 842 disclosures below are presented as of and for the year ended December 31, 2019, only.
We are a party to operating and finance leases primarily for our corporate and health plan offices. Our operating leases have remaining lease terms up to 9 years, some of which include options to extend the leases for up to 10 years. As of December 31, 2019, the weighted average remaining operating lease term is 4 years.
Our finance leases have remaining lease terms of 2 years to 19 years, some of which include options to extend the leases for up to 25 years. As of December 31, 2019, the weighted average remaining finance lease term is 16 years.
As of December 31, 2019, the weighted-average discount rate used to compute the present value of lease payments was 5.6% for operating lease liabilities, and 6.5% for finance lease liabilities. The components of lease expense were as follows:

Year Ended December 31, 2019

(In millions)
Operating lease expense
$
34

Finance lease expense:

Amortization of ROU assets
$
17

Interest on lease liabilities
15

Total finance lease expense
$
32

Rental expense related to operating leases amounted to $62 million and $75 million for the years ended December 31, 2018 and 2017, respectively.
Supplemental consolidated cash flow information related to leases follows:

Year Ended December 31, 2019

(In millions)
Cash used in operating activities:

Operating leases
$
36

Finance leases
15

Cash used in financing activities:

Finance leases
6

ROU assets recognized in exchange for lease obligations:

Operating leases
99

Finance leases
245

Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:

December 31, 2019

(In millions)
Operating leases:

ROU assets

Other assets
$
65

Lease liabilities

Accounts payable and accrued liabilities (current)
$
25

Other long-term liabilities (non-current)
48

Total operating lease liabilities
$
73

Finance leases:

ROU assets

Property, equipment, and capitalized software, net
$
228

Lease liabilities

Accounts payable and accrued liabilities (current)
$
8

Finance lease liabilities (non-current)
231

Total finance lease liabilities
$
239

Maturities of lease liabilities as of December 31, 2019, were as follows:

Operating Leases

Finance Leases

(In millions)
2020
$
28

$
23

2021
20

24

2022
14

21

2023
10

21

2024
5

22

Thereafter
3

289

Subtotal - undiscounted lease payments
80

400

Less imputed interest
(7
)

(161
)
Total
$
73

$
239

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251
+ Details

Name: us-gaap_LesseeFinanceLeasesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251
+ Details

Name: us-gaap_LesseeOperatingLeasesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Derivatives
12 Months Ended

Dec. 31, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivatives Derivatives
The following table summarizes the fair values and the presentation of our derivative financial instruments (defined and discussed individually below) in the consolidated balance sheets:

December 31,

Balance Sheet Location

2019

2018

(In millions)
Derivative asset:

1.125% Call Option
Current assets: Derivative asset

$
29

$
476

Derivative liability:

1.125% Conversion Option
Current liabilities: Derivative liability

$
29

$
476

Our derivative financial instruments do not qualify for hedge treatment; therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations, and reported in “Other (income) expenses, net.” Gains and losses for our derivative financial instruments are presented individually in the accompanying consolidated statements of cash flows, “Supplemental cash flow information.”
1.125% Convertible Notes Call Spread Overlay
Concurrent with the issuance of the 1.125% Convertible Notes in 2013, we entered into privately negotiated hedge transactions (collectively, the “1.125% Call Option”) and warrant transactions (collectively, the “1.125% Warrants”), with certain of the initial purchasers of the 1.125% Convertible Notes (the “Counterparties”). We refer to these transactions collectively as the Call Spread Overlay. Under the Call Spread Overlay, the cost of the 1.125% Call Option we purchased to cover the cash outlay upon conversion of the 1.125% Convertible Notes was reduced by proceeds from the sale of the 1.125% Warrants. Assuming full performance by the Counterparties (and 1.125% Warrants strike prices in excess of the conversion price of the 1.125% Convertible Notes), these transactions are intended to offset cash payments in excess of the principal amount of the 1.125% Convertible Notes due upon any conversion of such notes.
In the year ended December 31, 2019, in connection with the 1.125% Convertible Notes purchases (described in Note 11, “Debt”), we entered into privately negotiated termination agreements with each of the Counterparties to partially terminate the Call Spread Overlay, in notional amounts corresponding to the aggregate principal amount of the 1.125% Convertible Notes purchased. In the year ended December 31, 2019, we received $578 million for the
settlement of the 1.125% Call Option (which is a derivative asset), and paid $514 million for the partial termination of the 1.125% Warrants, for an aggregate net cash receipt of $64 million from the Counterparties.
1.125% Call Option
The 1.125% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to cash settlement features until the 1.125% Call Option settles or expires. For further discussion of the inputs used to determine the fair value of the 1.125% Call Option, refer to Note 4, “Fair Value Measurements.”
1.125% Conversion Option
The embedded cash conversion option within the 1.125% Convertible Notes is accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations until the cash conversion option settles or expires. For further discussion of the inputs used to determine the fair value of the 1.125% Conversion Option, refer to Note 4, “Fair Value Measurements.”
As of December 31, 2019, the 1.125% Call Option and the 1.125% Conversion Option were classified as a current asset and current liability, respectively, because the 1.125% Convertible Notes matured on January 15, 2020.
Subsequent Event
As described in Note 11, “Debt,” we repaid the aggregate principal amount of the 1.125% Convertible Notes, including settlement of the related 1.125% Conversion Option. In addition, in January 2020 we received $27 million for the settlement of the 1.125% Call Option.

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-URI http://asc.fasb.org/topic&trid=2229140
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Debt - Maturities (Details)
$ in Millions

Dec. 31, 2019

USD ($)

Debt Instrument [Line Items]

Net carrying amount $ 1,262

2020 18

2021 16

2022 722

2023 22

2024 154

Thereafter $ 330

5.375% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 5.375%

4.875% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 4.875%

1.125% Convertible Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 1.125%

Senior Notes | 5.375% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 5.375%

Net carrying amount $ 700

2020 0

2021 0

2022 700

2023 0

2024 0

Thereafter $ 0

Senior Notes | 4.875% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 4.875%

Net carrying amount $ 330

2020 0

2021 0

2022 0

2023 0

2024 0

Thereafter $ 330

Senior Notes | 1.125% Convertible Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 1.125%

Term Loan Facility | Term Loan Facility

Debt Instrument [Line Items]

Net carrying amount $ 220

2020 6

2021 16

2022 22

2023 22

2024 154

Thereafter $ 0

Convertible Debt | 4.875% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 4.875%

Convertible Debt | 1.125% Convertible Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate 1.125%

Net carrying amount $ 12

2020 12

2021 0

2022 0

2023 0

2024 0

Thereafter $ 0

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_TermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R88.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Accrued expenses and reserve liabilities $ 35 $ 39

Other accrued medical costs 11 12

Net operating losses 13 16

Fixed assets and intangibles 26 30

Unearned premiums 11 9

Lease financing obligation 5 30

Tax credit carryover 11 12

Other 0 3

Valuation allowance (24) (28)

Total deferred income tax assets, net of valuation allowance 88 123

Prepaid expenses (6) (6)

Other (3) 0

Total deferred income tax liabilities (9) (6)

Net deferred income tax asset $ 79 $ 117

X

- Definition
Deferred Tax Asset, Fixed Assets and Intangibles
+ References
No definition available.
+ Details

Name: moh_DeferredTaxAssetFixedAssetsandIntangibles

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(15)(b)(2))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(2))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredIncomeTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the unearned premiums reserve.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxLiabilitiesPrepaidExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 57 R84.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Derivatives (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended

Jan. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Derivative [Line Items]

Cash received for partial settlement of call option $ 578 $ 623 $ 0

Cash paid for partial termination of 1.125% Warrants 514 549 $ 0

Convertible debt, converted amount of instrument $ 64

1.125% Convertible Notes

Derivative [Line Items]

Percentage of contractual interest rate 1.125%

1.125% Convertible Notes | Subsequent Event

Derivative [Line Items]

Cash received for partial settlement of call option $ 27

1.125% Call Option

Derivative [Line Items]

Percentage of contractual interest rate on derivative 1.125%

1.125% Call Option | Subsequent Event

Derivative [Line Items]

Percentage of contractual interest rate on derivative 1.125%

1.125% Call Option | Current assets

Derivative [Line Items]

Derivative asset $ 29 476

1.125% Conversion Option

Derivative [Line Items]

Percentage of contractual interest rate on derivative 1.125%

1.125% Conversion Option | Current liabilities

Derivative [Line Items]

Derivative liability $ 29 $ 476

1.125% Warrants

Derivative [Line Items]

Percentage of contractual interest rate on derivative 1.125%

Cash paid for partial termination of 1.125% Warrants $ 514

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4D
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4D
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fixed interest rate related to the interest rate derivative.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeFixedInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=moh_CallOptionDerivativeAssetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=moh_CurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=moh_CurrentLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=moh_CashConvertibleSeniorNotesDue2020WarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Medical Claims and Benefits Payable - Components of the Change (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]

Medical claims and benefits payable, beginning balance $ 1,961 $ 2,192 $ 1,929

Components of medical care costs related to:

Current period 14,176 15,478 17,037

Prior periods (271) (341) 36

Total medical care costs 13,905 15,137 17,073

Change in non-risk and other provider payables 24 13 (106)

Payments for medical care costs related to:

Current period 12,554 13,671 15,130

Prior periods 1,482 1,710 1,574

Total paid 14,036 15,381 16,704

Medical claims and benefits payable, ending balance $ 1,854 1,961 $ 2,192

CMS Subsidies

Liability for Claims and Claims Adjustment Expense [Line Items]

Disposal group, operating expense $ 81

X

- Definition
Medical Claims and Benefits Payable, Adjustments, Change in Provider
+ References
No definition available.
+ Details

Name: moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (cc)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForLossesAndLossAdjustmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_MajorCustomersAxis=moh_CMSSubsidiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Finite-Lived Intangible Assets [Line Items]

Goodwill impairment charges $ 0 $ 0

Future Amortization Expenses

Future amortization expense, 2020 14

Future amortization expense, 2021 5

Future amortization expense, 2022 3

Future amortization expense, 2023 3

Future amortization expense, 2024 3

Health Plans

Finite-Lived Intangible Assets [Line Items]

Gross goodwill 445 445

Accumulated impairment loss 302 302

Goodwill impairment charges 0 0 $ 244

Future Amortization Expenses

Impairment of intangible assets 25

Other

Finite-Lived Intangible Assets [Line Items]

Goodwill impairment charges $ 0 $ 0 190

Future Amortization Expenses

Impairment of intangible assets $ 11

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillImpairedAccumulatedImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Debt - Credit Agreement (Details) - USD ($)
12 Months Ended

Dec. 31, 2019

Jan. 31, 2019

Line of Credit Facility [Line Items]

Aggregate principal amount of notes outstanding $ 1,262,000,000

Term Loan Facility | Term Loan Facility

Line of Credit Facility [Line Items]

Aggregate principal amount of notes outstanding 220,000,000

Current borrowing capacity 380,000,000

Term Loan Facility | Credit Facility

Line of Credit Facility [Line Items]

Maximum borrowing capacity 500,000,000 $ 600,000,000

Minimum principal amount of advancements $ 50,000,000

Current borrowing capacity 499,000,000

Amount outstanding under Letter of Credit 0

Term Loan Facility | Letter of Credit

Line of Credit Facility [Line Items]

Amount outstanding under Letter of Credit $ 1,000,000

Minimum | Term Loan Facility | Credit Facility

Line of Credit Facility [Line Items]

Amortization payment percentage 1.25%

Maximum | Term Loan Facility | Credit Facility

Line of Credit Facility [Line Items]

Amortization payment percentage 2.50%

X

- Definition
Line of Credit Facility, Amortization Payment Percentage
+ References
No definition available.
+ Details

Name: moh_LineofCreditFacilityAmortizationPaymentPercentage

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line of Credit Facility, Minimum Threshold for Advancements
+ References
No definition available.
+ Details

Name: moh_LineofCreditFacilityMinimumThresholdforAdvancements

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_TermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Balance Sheets - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Current assets:

Cash and cash equivalents $ 2,452 $ 2,826

Investments 1,946 1,681

Receivables 1,406 1,330

Prepaid expenses and other current assets 134 149

Derivative asset 29 476

Total current assets 5,967 6,462

Property, equipment, and capitalized software, net 385

Property, equipment, and capitalized software, net 241

Goodwill and intangible assets, net 172 190

Restricted investments 79 120

Deferred income taxes 79 117

Other assets 105 24

Total assets 6,787 7,154

Current liabilities:

Medical claims and benefits payable 1,854 1,961

Amounts due government agencies 664 967

Accounts payable and accrued liabilities 455 390

Deferred revenue 249 211

Current portion of long-term debt 18 241

Derivative liability 29 476

Total current liabilities 3,269 4,246

Long-term debt 1,237 1,020

Finance lease liabilities 231

Finance lease liabilities 197

Other long-term liabilities 90 44

Total liabilities 4,827 5,507

Stockholders’ equity:

Common stock, $0.001 par value per share; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018 0 0

Preferred stock, $0.001 par value per share; 20 million shares authorized, no shares issued and outstanding 0 0

Additional paid-in capital 175 643

Accumulated other comprehensive income (loss) 4 (8)

Retained earnings 1,781 1,012

Total stockholders’ equity 1,960 1,647

Total liabilities and stockholders’ equity $ 6,787 $ 7,154

X

- Definition
Medical Premium Liability Due to Agency
+ References
No definition available.
+ Details

Name: moh_MedicalPremiumLiabilityDueToAgency

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization
+ References
No definition available.
+ Details

Name: moh_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735
+ Details

Name: us-gaap_CapitalLeaseObligationsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredIncomeTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.
+ References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsNetIncludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (cc)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt and lease obligation, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investment in marketable security, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-06(3))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.
+ References
No definition available.
+ Details

Name: us-gaap_RestrictedInvestmentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R106.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Condensed Financial Statements, Captions [Line Items]

Net income (loss) $ 168 $ 175 $ 196 $ 198 $ 201 $ 197 $ 202 $ 107 $ 737 $ 707 $ (512)

Unrealized investment income (loss) 16 (3) (5)

Less: effect of income taxes 4 (1) (2)

Other comprehensive income (loss), net of tax 12 (2) (3)

Comprehensive income (loss) 749 705 (515)

Parent Company

Condensed Financial Statements, Captions [Line Items]

Net income (loss) 737 707 (512)

Unrealized investment income (loss) 16 (3) (5)

Less: effect of income taxes 4 (1) (2)

Other comprehensive income (loss), net of tax 12 (2) (3)

Comprehensive income (loss) $ 749 $ 705 $ (515)

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: srt_CondensedFinancialStatementsCaptionsLineItems

Namespace Prefix: srt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Fair value of assets measured on recurring basis

Debt securities, available-for-sale $ 1,946 $ 1,681

Total assets 1,975 2,157

Total liabilities 29 476

Corporate debt securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 1,178 1,123

Mortgage-backed securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 420

Asset-backed securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 127 82

U.S. Treasury notes

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 86 181

Municipal securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 78 114

Government-sponsored enterprise securities (“GSEs”)

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 49 163

Foreign securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 7 4

Certificates of deposit

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 1 14

1.125% Call Option derivative asset

Fair value of assets measured on recurring basis

1.125% Call Option derivative asset $ 29 476

Percentage of contractual interest rate on derivative 1.125%

Conversion Option

Fair value of assets measured on recurring basis

1.125% Conversion Option derivative liability $ 29 476

Percentage of contractual interest rate on derivative 1.125%

Level 1

Fair value of assets measured on recurring basis

Debt securities, available-for-sale $ 0 0

Total assets 0 0

Total liabilities 0 0

Level 1 | Corporate debt securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 1 | Mortgage-backed securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0

Level 1 | Asset-backed securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 1 | U.S. Treasury notes

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 1 | Municipal securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 1 | Government-sponsored enterprise securities (“GSEs”)

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 1 | Foreign securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 1 | Certificates of deposit

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 1 | 1.125% Call Option derivative asset

Fair value of assets measured on recurring basis

1.125% Call Option derivative asset 0 0

Level 1 | Conversion Option

Fair value of assets measured on recurring basis

1.125% Conversion Option derivative liability 0 0

Level 2

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 1,946 1,681

Total assets 1,946 1,681

Total liabilities 0 0

Level 2 | Corporate debt securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 1,178 1,123

Level 2 | Mortgage-backed securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 420

Level 2 | Asset-backed securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 127 82

Level 2 | U.S. Treasury notes

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 86 181

Level 2 | Municipal securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 78 114

Level 2 | Government-sponsored enterprise securities (“GSEs”)

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 49 163

Level 2 | Foreign securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 7 4

Level 2 | Certificates of deposit

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 1 14

Level 2 | 1.125% Call Option derivative asset

Fair value of assets measured on recurring basis

1.125% Call Option derivative asset 0 0

Level 2 | Conversion Option

Fair value of assets measured on recurring basis

1.125% Conversion Option derivative liability 0 0

Level 3

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Total assets 29 476

Total liabilities 29 476

Level 3 | Corporate debt securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 3 | Mortgage-backed securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0

Level 3 | Asset-backed securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 3 | U.S. Treasury notes

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 3 | Municipal securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 3 | Government-sponsored enterprise securities (“GSEs”)

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 3 | Foreign securities

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 3 | Certificates of deposit

Fair value of assets measured on recurring basis

Debt securities, available-for-sale 0 0

Level 3 | 1.125% Call Option derivative asset

Fair value of assets measured on recurring basis

1.125% Call Option derivative asset 29 476

Level 3 | Conversion Option

Fair value of assets measured on recurring basis

1.125% Conversion Option derivative liability $ 29 $ 476

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fixed interest rate related to the interest rate derivative.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeFixedInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value of financial and nonfinancial obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_LiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeFinancialInstrumentsAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Investments - Narrative (Details)
$ in Millions
12 Months Ended

Dec. 31, 2019

USD ($)

Investments, Debt and Equity Securities [Abstract]

Gross realized investment gains $ 13

X

- Definition
Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleRealizedGain

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 65 R102.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Quarterly Results of Operations (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Total revenue $ 4,274 $ 4,243 $ 4,193 $ 4,119 $ 4,664 $ 4,697 $ 4,883 $ 4,646 $ 16,829 $ 18,890 $ 19,883

Margin 578 561 583 581 664 566 673 615 2,303 2,518 1,810

Gain (loss) on sales of subsidiaries (52) 37 0 0 0 (15) 0

Net income (loss) $ 168 $ 175 $ 196 $ 198 $ 201 $ 197 $ 202 $ 107 $ 737 $ 707 $ (512)

Net income per share - Basic (in dollars per share) $ 2.70 $ 2.81 $ 3.15 $ 3.19 $ 3.24 $ 3.22 $ 3.29 $ 1.79 $ 11.85 $ 11.57 $ (9.07)

Net income per share - Diluted (in dollars per share) $ 2.67 $ 2.75 $ 3.06 $ 2.99 $ 3.01 $ 2.90 $ 3.02 $ 1.64 $ 11.47 $ 10.61 $ (9.07)

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684
+ Details

Name: us-gaap_GainLossOnSaleOfBusiness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 66 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Organization and Basis of Presentation
12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Basis of Presentation Organization and Basis of Presentation
Organization and Operations
Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). We currently have two reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve.
The Health Plans segment consists of health plans operating in 14 states and the Commonwealth of Puerto Rico. As of December 31, 2019, these health plans served approximately 3.3 million members eligible for Medicaid, Medicare, and other government-sponsored health care programs for low-income families and individuals including Marketplace members, most of whom receive government subsidies for premiums. The health plans are generally operated by our respective wholly owned subsidiaries in those states, each of which is licensed as a health maintenance organization (“HMO”).
Our state Medicaid contracts typically have terms of three to five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (“RFP”) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.
In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled; and regions or service areas.
Recent Developments – Health Plans Segment
Kentucky. On December 2, 2019, we announced that our Kentucky health plan subsidiary had been selected as an awardee pursuant to the Kentucky Medicaid managed care organizations RFP issued by the Kentucky Finance and Administration Cabinet in May 2019. However, in late December 2019, the newly elected Governor of Kentucky announced that he was canceling the Medicaid contracts that had been awarded by the outgoing Governor, including the contract that had been awarded to our Kentucky health plan subsidiary, and that he was reissuing the RFP for rebidding. We submitted a bid under the new RFP on February 6, 2020.
Texas. In October 2019, the Texas Health and Human Services Commission (“HHSC”) awarded contracts to our Texas health plan for the ABD program (known in Texas as “STAR+PLUS”) in two service areas, consisting of one legacy service area and one new service area. This would be a reduction from our current footprint of six service areas. We believe the initial term of each contract is expected to be three years, and such contracts are currently anticipated to be operational beginning on January 1, 2021, at the earliest. Under our existing STAR+PLUS and related Medicare-Medicaid Plan (“MMP”) contracts, we served approximately 97,000 members as of December 31, 2019, representing premium revenue of approximately $2,062 million in 2019. We are currently exercising our protest rights of the STAR+PLUS RFP awards with HHSC.
In 2019, our Texas health plan submitted an RFP response for the TANF and CHIP programs (known in Texas as “STAR/CHIP”). HHSC has announced that the STAR/CHIP contract awards are delayed to late February 2020. Under our existing STAR/CHIP contracts, we served approximately 114,000 members as of December 31, 2019, representing premium revenue of approximately $315 million in 2019.
Illinois. On December 31, 2019, we entered into a definitive agreement to purchase NextLevel Health Partners, Inc., a Medicaid managed care organization. Upon the closing of this transaction, expected to occur in the first half of 2020, we will assume the right to serve approximately 50,000 Medicaid and Managed Long-Term Services and Supports members in Cook County, Illinois. The purchase price of approximately $50 million will be funded with available cash, and the closing is subject to customary closing conditions.
New York. In October 2019, we entered into a definitive agreement to acquire certain assets of YourCare Health Plan, Inc. Upon the closing of this transaction, expected to occur in the first half of 2020, we will serve approximately 46,000 Medicaid members in seven counties in western New York. The purchase price of approximately $40 million will be funded with available cash, and the closing is subject to customary closing conditions.
Consolidation and Presentation
The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Financial information related to subsidiaries acquired during any year is included only for periods subsequent to their acquisition. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the periods presented have been included; such adjustments consist of normal recurring adjustments.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:
•
The determination of medical claims and benefits payable of our Health Plans segment;
•
Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;
•
Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;
•
Settlements under risk or savings sharing programs;
•
The assessment of long-lived and intangible assets, and goodwill, for impairment;
•
The determination of reserves for potential absorption of claims unpaid by insolvent providers;
•
The determination of reserves for the outcome of litigation;
•
The determination of valuation allowances for deferred tax assets; and
•
The determination of unrecognized tax benefits.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 67 R91.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity - Components of Share-based Compensation (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Pretax Charges $ 39 $ 27 $ 46

Net-of-Tax Amount 37 26 40

Restructuring settled without cash 23

RSAs, PSAs and PSUs (defined below)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Pretax Charges 29 17 39

Net-of-Tax Amount 28 17 35

Employee stock purchase plan and stock options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Pretax Charges 10 10 7

Net-of-Tax Amount $ 9 $ 9 $ 5

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after tax, of expense for award under share-based payment arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=moh_RestrictedandPerformanceStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=moh_EmployeeStockPurchasePlanandStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 68 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Property, Equipment, and Capitalized Software, Net - Additional Information (Details)
12 Months Ended

Dec. 31, 2019

Furniture and equipment | Minimum

Property, Plant and Equipment [Line Items]

Useful life of property plant and equipment 3 years

Furniture and equipment | Maximum

Property, Plant and Equipment [Line Items]

Useful life of property plant and equipment 7 years

Software

Property, Plant and Equipment [Line Items]

Useful life of property plant and equipment 3 years

Leasehold improvements | Minimum

Property, Plant and Equipment [Line Items]

Useful life of property plant and equipment 5 years

Leasehold improvements | Maximum

Property, Plant and Equipment [Line Items]

Useful life of property plant and equipment 10 years

Building and improvements | Minimum

Property, Plant and Equipment [Line Items]

Useful life of property plant and equipment 31 years 6 months

Building and improvements | Maximum

Property, Plant and Equipment [Line Items]

Useful life of property plant and equipment 40 years

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 69 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Leases - Components of Lease Expense (Details)
$ in Millions
12 Months Ended

Dec. 31, 2019

USD ($)

Leases [Abstract]

Operating lease expense $ 34

Finance lease expense:

Amortization of ROU assets 17

Interest on lease liabilities 15

Total finance lease expense $ 32

X

- Definition
Finance Lease, Cost
+ References
No definition available.
+ Details

Name: moh_FinanceLeaseCost

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest expense on finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense attributable to right-of-use asset from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 70 R95.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity - Stock Options by Exercise Price (Details)
12 Months Ended

Dec. 31, 2019

$ / shares

shares

Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]

Options Outstanding, Number Outstanding 405,000

Options Exercisable, Number Exercisable 280,000

$33.02

Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]

Options Outstanding, Number Outstanding 30,000

Options Outstanding, Weighted Average Remaining Contractual Life (Years) 3 years 2 months 12 days

Options Outstanding, Weighted-Average Exercise Price | $ / shares $ 33.02

Options Exercisable, Number Exercisable 30,000

Options Exercisable, Weighted-Average Exercise Price | $ / shares $ 33.02

$67.33

Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]

Options Outstanding, Number Outstanding 375,000

Options Outstanding, Weighted Average Remaining Contractual Life (Years) 7 years 9 months 18 days

Options Outstanding, Weighted-Average Exercise Price | $ / shares $ 67.33

Options Exercisable, Number Exercisable 250,000

Options Exercisable, Weighted-Average Exercise Price | $ / shares $ 67.33

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=moh_ExercisePriceRange1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=moh_ExercisePriceRange2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 71 R99.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Segments - Narrative (Details)
12 Months Ended

Dec. 31, 2019

segment

Segment Reporting [Abstract]

Number of reportable segments 2

X

- Definition
Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 72 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Goodwill and Intangible Assets, Net - Balances of Goodwill (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Goodwill [Roll Forward]

Beginning balance $ 143 $ 186

Acquisitions 0 0

Dispositions 0 (43)

Impairment and other 0 0

Ending balance 143 143 $ 186

Health Plans

Goodwill [Roll Forward]

Beginning balance 143 143

Acquisitions 0 0

Dispositions 0 0

Impairment and other 0 0 (244)

Ending balance 143 143 143

Other

Goodwill [Roll Forward]

Beginning balance 0 43

Acquisitions 0 0

Dispositions 0 (43)

Impairment and other 0 0 (190)

Ending balance $ 0 $ 0 $ 43

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillAcquiredDuringPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 73 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Accounting Policies [Abstract]

Cash and cash equivalents $ 2,452 $ 2,826 $ 3,186

Restricted cash and cash equivalents, non-current 56 100 95

Restricted cash and cash equivalents, current 0 0 9

Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows $ 2,508 $ 2,926 $ 3,290 $ 2,912

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_RestrictedCashCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580
+ Details

Name: us-gaap_RestrictedCashNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 74 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Segments (Tables)
12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Operating segment information

Health Plans

Other

Consolidated

(In millions)
2019

Total revenue

$
16,815

$
14

16,829

Margin

2,303

—

2,303

Goodwill, and intangible assets, net

172

—

172

Total assets

5,265

1,522

6,787

2018

Total revenue

$
18,471

$
419

$
18,890

Margin

2,475

43

2,518

Goodwill, and intangible assets, net

190

—

190

Total assets

6,165

989

7,154

2017

Total revenue

$
19,352

$
531

$
19,883

Margin

1,781

29

1,810

Goodwill, and intangible assets, net

212

43

255

Total assets

6,347

2,124

8,471

The following table reconciles margin by segment to consolidated income (loss) before income tax expense (benefit):

Year Ended December 31,

2019

2018

2017

(In millions)
Margin:

Health Plans
$
2,303

$
2,475

$
1,781

Other
—

43

29

Total margin
2,303

2,518

1,810

Add: other operating revenues ⁽¹⁾
621

871

508

Less: other operating expenses ⁽²⁾
(1,880
)

(2,243
)

(2,873
)
Less: loss on sales of subsidiaries, net of gain
—

(15
)

—

Operating income (loss)
1,044

1,131

(555
)
Less: other expenses, net
72

132

57

Income (loss) before income tax expense (benefit)
$
972

$
999

$
(612
)

______________________
(1)
Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income and other revenue.
(2)
Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, impairment losses, and restructuring costs.

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599
+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 75 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 389 615 1 false 105 0 false 10 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.molinahealthcare.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Consolidated Statements of Operations Sheet http://www.molinahealthcare.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 2 false false R3.htm 1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.molinahealthcare.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 1003000 - Statement - Consolidated Balance Sheets Sheet http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 4 false false R5.htm 1003501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.molinahealthcare.com/role/ConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.molinahealthcare.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - Organization and Basis of Presentation Sheet http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 8 false false R9.htm 2102100 - Disclosure - Significant Accounting Policies Sheet http://www.molinahealthcare.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 2103100 - Disclosure - Net Income (Loss) Per Share Sheet http://www.molinahealthcare.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 10 false false R11.htm 2105100 - Disclosure - Fair Value Measurements Sheet http://www.molinahealthcare.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 2106100 - Disclosure - Investments Sheet http://www.molinahealthcare.com/role/Investments Investments Notes 12 false false R13.htm 2107100 - Disclosure - Receivables Sheet http://www.molinahealthcare.com/role/Receivables Receivables Notes 13 false false R14.htm 2108100 - Disclosure - Property, Equipment, and Capitalized Software, Net Sheet http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNet Property, Equipment, and Capitalized Software, Net Notes 14 false false R15.htm 2109100 - Disclosure - Leases Leases Sheet http://www.molinahealthcare.com/role/LeasesLeases Leases Leases Notes 15 false false R16.htm 2110100 - Disclosure - Goodwill and Intangible Assets, Net Sheet http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNet Goodwill and Intangible Assets, Net Notes 16 false false R17.htm 2111100 - Disclosure - Medical Claims and Benefits Payable Sheet http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayable Medical Claims and Benefits Payable Notes 17 false false R18.htm 2112100 - Disclosure - Debt Sheet http://www.molinahealthcare.com/role/Debt Debt Notes 18 false false R19.htm 2113100 - Disclosure - Derivatives Sheet http://www.molinahealthcare.com/role/Derivatives Derivatives Notes 19 false false R20.htm 2114100 - Disclosure - Income Taxes Sheet http://www.molinahealthcare.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2115100 - Disclosure - Stockholders' Equity Sheet http://www.molinahealthcare.com/role/StockholdersEquity Stockholders' Equity Notes 21 false false R22.htm 2116100 - Disclosure - Restructuring Costs Sheet http://www.molinahealthcare.com/role/RestructuringCosts Restructuring Costs Notes 22 false false R23.htm 2117100 - Disclosure - Employee Benefit Plans Sheet http://www.molinahealthcare.com/role/EmployeeBenefitPlans Employee Benefit Plans Notes 23 false false R24.htm 2118100 - Disclosure - Commitments and Contingencies Sheet http://www.molinahealthcare.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 24 false false R25.htm 2119100 - Disclosure - Segments Sheet http://www.molinahealthcare.com/role/Segments Segments Notes 25 false false R26.htm 2120100 - Disclosure - Quarterly Results of Operations (Unaudited) Sheet http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnaudited Quarterly Results of Operations (Unaudited) Notes 26 false false R27.htm 2121100 - Disclosure - Condensed Financial Information of Registrant Sheet http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrant Condensed Financial Information of Registrant Notes 27 false false R28.htm 2202201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.molinahealthcare.com/role/SignificantAccountingPolicies 28 false false R29.htm 2302302 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.molinahealthcare.com/role/SignificantAccountingPolicies 29 false false R30.htm 2303301 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.molinahealthcare.com/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Tables http://www.molinahealthcare.com/role/NetIncomeLossPerShare 30 false false R31.htm 2305301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.molinahealthcare.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.molinahealthcare.com/role/FairValueMeasurements 31 false false R32.htm 2306301 - Disclosure - Investments (Tables) Sheet http://www.molinahealthcare.com/role/InvestmentsTables Investments (Tables) Tables http://www.molinahealthcare.com/role/Investments 32 false false R33.htm 2307301 - Disclosure - Receivables (Tables) Sheet http://www.molinahealthcare.com/role/ReceivablesTables Receivables (Tables) Tables http://www.molinahealthcare.com/role/Receivables 33 false false R34.htm 2308301 - Disclosure - Property, Equipment, and Capitalized Software, Net (Tables) Sheet http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetTables Property, Equipment, and Capitalized Software, Net (Tables) Tables http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNet 34 false false R35.htm 2309301 - Disclosure - Leases (Tables) Sheet http://www.molinahealthcare.com/role/LeasesTables Leases (Tables) Tables http://www.molinahealthcare.com/role/LeasesLeases 35 false false R36.htm 2310301 - Disclosure - Goodwill and Intangible Assets, Net (Tables) Sheet http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetTables Goodwill and Intangible Assets, Net (Tables) Tables http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNet 36 false false R37.htm 2311301 - Disclosure - Medical Claims and Benefits Payable (Tables) Sheet http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableTables Medical Claims and Benefits Payable (Tables) Tables http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayable 37 false false R38.htm 2312301 - Disclosure - Debt (Tables) Sheet http://www.molinahealthcare.com/role/DebtTables Debt (Tables) Tables http://www.molinahealthcare.com/role/Debt 38 false false R39.htm 2313301 - Disclosure - Derivatives (Tables) Sheet http://www.molinahealthcare.com/role/DerivativesTables Derivatives (Tables) Tables http://www.molinahealthcare.com/role/Derivatives 39 false false R40.htm 2314301 - Disclosure - Income Taxes (Tables) Sheet http://www.molinahealthcare.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.molinahealthcare.com/role/IncomeTaxes 40 false false R41.htm 2315301 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.molinahealthcare.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.molinahealthcare.com/role/StockholdersEquity 41 false false R42.htm 2319301 - Disclosure - Segments (Tables) Sheet http://www.molinahealthcare.com/role/SegmentsTables Segments (Tables) Tables http://www.molinahealthcare.com/role/Segments 42 false false R43.htm 2320301 - Disclosure - Quarterly Results of Operations (Unaudited) (Tables) Sheet http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedTables Quarterly Results of Operations (Unaudited) (Tables) Tables http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnaudited 43 false false R44.htm 2321301 - Disclosure - Condensed Financial Information of Registrant (Tables) Sheet http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantTables Condensed Financial Information of Registrant (Tables) Tables http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrant 44 false false R45.htm 2401401 - Disclosure - Organization and Basis of Presentation (Details) Sheet http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentationDetails Organization and Basis of Presentation (Details) Details http://www.molinahealthcare.com/role/OrganizationAndBasisOfPresentation 45 false false R46.htm 2402403 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) Details 46 false false R47.htm 2402404 - Disclosure - Significant Accounting Policies - Additional Information (Details) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails Significant Accounting Policies - Additional Information (Details) Details 47 false false R48.htm 2402405 - Disclosure - Significant Accounting Policies - Schedule of Premium Revenue (Details) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesScheduleOfPremiumRevenueDetails Significant Accounting Policies - Schedule of Premium Revenue (Details) Details 48 false false R49.htm 2402406 - Disclosure - Significant Accounting Policies - Due to Government Agencies (Details) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesDueToGovernmentAgenciesDetails Significant Accounting Policies - Due to Government Agencies (Details) Details 49 false false R50.htm 2402407 - Disclosure - Significant Accounting Policies - Quality Incentive Premium Revenue (Details) Sheet http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueDetails Significant Accounting Policies - Quality Incentive Premium Revenue (Details) Details 50 false false R51.htm 2403402 - Disclosure - Net Income (Loss) Per Share (Details) Sheet http://www.molinahealthcare.com/role/NetIncomeLossPerShareDetails Net Income (Loss) Per Share (Details) Details http://www.molinahealthcare.com/role/NetIncomeLossPerShareTables 51 false false R52.htm 2405402 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 52 false false R53.htm 2405403 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) Sheet http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsOnRecurringBasisDetails Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) Details 53 false false R54.htm 2405404 - Disclosure - Fair Value Measurements - Long-Term Debt (Details) Sheet http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails Fair Value Measurements - Long-Term Debt (Details) Details 54 false false R55.htm 2406402 - Disclosure - Investments - Schedule of Investments (Details) Sheet http://www.molinahealthcare.com/role/InvestmentsScheduleOfInvestmentsDetails Investments - Schedule of Investments (Details) Details 55 false false R56.htm 2406403 - Disclosure - Investments - Contractual Maturities (Details) Sheet http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails Investments - Contractual Maturities (Details) Details 56 false false R57.htm 2406404 - Disclosure - Investments - Narrative (Details) Sheet http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 57 false false R58.htm 2406405 - Disclosure - Investments - Available-for-Sale (Details) Sheet http://www.molinahealthcare.com/role/InvestmentsAvailableForSaleDetails Investments - Available-for-Sale (Details) Details 58 false false R59.htm 2406406 - Disclosure - Investments - Balances of Restricted Investments (Details) Sheet http://www.molinahealthcare.com/role/InvestmentsBalancesOfRestrictedInvestmentsDetails Investments - Balances of Restricted Investments (Details) Details 59 false false R60.htm 2407402 - Disclosure - Receivables (Details) Sheet http://www.molinahealthcare.com/role/ReceivablesDetails Receivables (Details) Details http://www.molinahealthcare.com/role/ReceivablesTables 60 false false R61.htm 2408402 - Disclosure - Property, Equipment, and Capitalized Software, Net - Additional Information (Details) Sheet http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetAdditionalInformationDetails Property, Equipment, and Capitalized Software, Net - Additional Information (Details) Details 61 false false R62.htm 2408403 - Disclosure - Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details) Sheet http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetSummaryOfPropertyEquipmentAndCapitalizedSoftwareDetails Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details) Details 62 false false R63.htm 2408404 - Disclosure - Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details) Sheet http://www.molinahealthcare.com/role/PropertyEquipmentAndCapitalizedSoftwareNetDepreciationAndAmortizationDetails Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details) Details 63 false false R64.htm 2409402 - Disclosure - Leases - Narrative (Details) Sheet http://www.molinahealthcare.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 64 false false R65.htm 2409403 - Disclosure - Leases - Components of Lease Expense (Details) Sheet http://www.molinahealthcare.com/role/LeasesComponentsOfLeaseExpenseDetails Leases - Components of Lease Expense (Details) Details 65 false false R66.htm 2409404 - Disclosure - Leases - Supplemental Cash Flow (Details) Sheet http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails Leases - Supplemental Cash Flow (Details) Details 66 false false R67.htm 2409405 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) Sheet http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases - Supplemental Balance Sheet Information (Details) Details 67 false false R68.htm 2409406 - Disclosure - Leases - Lease Maturities (Details) Sheet http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails Leases - Lease Maturities (Details) Details 68 false false R69.htm 2410402 - Disclosure - Goodwill and Intangible Assets, Net - Balances of Goodwill (Details) Sheet http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetBalancesOfGoodwillDetails Goodwill and Intangible Assets, Net - Balances of Goodwill (Details) Details 69 false false R70.htm 2410403 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details) Sheet http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails Goodwill and Intangible Assets, Net - Additional Information (Details) Details 70 false false R71.htm 2410404 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details) Sheet http://www.molinahealthcare.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsBalancesDetails Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details) Details 71 false false R72.htm 2411402 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details) Sheet http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableMedicalClaimsAndFutureBenefitsDetails Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details) Details 72 false false R73.htm 2411403 - Disclosure - Medical Claims and Benefits Payable - Additional Information (Details) Sheet http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableAdditionalInformationDetails Medical Claims and Benefits Payable - Additional Information (Details) Details 73 false false R74.htm 2411404 - Disclosure - Medical Claims and Benefits Payable - Components of the Change (Details) Sheet http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableComponentsOfChangeDetails Medical Claims and Benefits Payable - Components of the Change (Details) Details 74 false false R75.htm 2411405 - Disclosure - Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details) Sheet http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableIncurredClaimsAndAllocatedAdjustmentExpenseDetails Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details) Details 75 false false R76.htm 2411406 - Disclosure - Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details) Sheet http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableCumulativePaidClaimsAndAllocatedClaimsAdjustmentExpensesDetails Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details) Details 76 false false R77.htm 2411407 - Disclosure - Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details) Sheet http://www.molinahealthcare.com/role/MedicalClaimsAndBenefitsPayableReconciliationOfClaimsDevelopmentDetails Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details) Details 77 false false R78.htm 2412402 - Disclosure - Debt - Maturities (Details) Sheet http://www.molinahealthcare.com/role/DebtMaturitiesDetails Debt - Maturities (Details) Details 78 false false R79.htm 2412403 - Disclosure - Debt - Schedule of Long-Term Debt (Details) Sheet http://www.molinahealthcare.com/role/DebtScheduleOfLongTermDebtDetails Debt - Schedule of Long-Term Debt (Details) Details 79 false false R80.htm 2412404 - Disclosure - Debt - Credit Agreement (Details) Sheet http://www.molinahealthcare.com/role/DebtCreditAgreementDetails Debt - Credit Agreement (Details) Details 80 false false R81.htm 2412405 - Disclosure - Debt - Senior Notes (Details) Notes http://www.molinahealthcare.com/role/DebtSeniorNotesDetails Debt - Senior Notes (Details) Details 81 false false R82.htm 2412406 - Disclosure - Debt - Convertible Notes (Details) Notes http://www.molinahealthcare.com/role/DebtConvertibleNotesDetails Debt - Convertible Notes (Details) Details 82 false false R83.htm 2412407 - Disclosure - Debt - Interest Cost (Details) Sheet http://www.molinahealthcare.com/role/DebtInterestCostDetails Debt - Interest Cost (Details) Details 83 false false R84.htm 2413402 - Disclosure - Derivatives (Details) Sheet http://www.molinahealthcare.com/role/DerivativesDetails Derivatives (Details) Details http://www.molinahealthcare.com/role/DerivativesTables 84 false false R85.htm 2414402 - Disclosure - Income Taxes - Provision for income taxes (Details) Sheet http://www.molinahealthcare.com/role/IncomeTaxesProvisionForIncomeTaxesDetails Income Taxes - Provision for income taxes (Details) Details 85 false false R86.htm 2414403 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 86 false false R87.htm 2414404 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details) Sheet http://www.molinahealthcare.com/role/IncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetails Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details) Details 87 false false R88.htm 2414405 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 88 false false R89.htm 2414406 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) Sheet http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes - Unrecognized Tax Benefits (Details) Details 89 false false R90.htm 2415402 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 90 false false R91.htm 2415403 - Disclosure - Stockholders' Equity - Components of Share-based Compensation (Details) Sheet http://www.molinahealthcare.com/role/StockholdersEquityComponentsOfShareBasedCompensationDetails Stockholders' Equity - Components of Share-based Compensation (Details) Details 91 false false R92.htm 2415404 - Disclosure - Stockholders' Equity - Restricted and Performance Stock Activity (Details) Sheet http://www.molinahealthcare.com/role/StockholdersEquityRestrictedAndPerformanceStockActivityDetails Stockholders' Equity - Restricted and Performance Stock Activity (Details) Details 92 false false R93.htm 2415405 - Disclosure - Stockholders' Equity - Fair Value of Awards Granted and Vested (Details) Sheet http://www.molinahealthcare.com/role/StockholdersEquityFairValueOfAwardsGrantedAndVestedDetails Stockholders' Equity - Fair Value of Awards Granted and Vested (Details) Details 93 false false R94.htm 2415406 - Disclosure - Stockholders' Equity - Stock Option Activity (Details) Sheet http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails Stockholders' Equity - Stock Option Activity (Details) Details 94 false false R95.htm 2415407 - Disclosure - Stockholders' Equity - Stock Options by Exercise Price (Details) Sheet http://www.molinahealthcare.com/role/StockholdersEquityStockOptionsByExercisePriceDetails Stockholders' Equity - Stock Options by Exercise Price (Details) Details 95 false false R96.htm 2416401 - Disclosure - Restructuring Costs (Details) Sheet http://www.molinahealthcare.com/role/RestructuringCostsDetails Restructuring Costs (Details) Details http://www.molinahealthcare.com/role/RestructuringCosts 96 false false R97.htm 2417401 - Disclosure - Employee Benefit Plans (Details) Sheet http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails Employee Benefit Plans (Details) Details http://www.molinahealthcare.com/role/EmployeeBenefitPlans 97 false false R98.htm 2418401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.molinahealthcare.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.molinahealthcare.com/role/CommitmentsAndContingencies 98 false false R99.htm 2419402 - Disclosure - Segments - Narrative (Details) Sheet http://www.molinahealthcare.com/role/SegmentsNarrativeDetails Segments - Narrative (Details) Details 99 false false R100.htm 2419403 - Disclosure - Segments - Schedule of Operating Segment Information (Details) Sheet http://www.molinahealthcare.com/role/SegmentsScheduleOfOperatingSegmentInformationDetails Segments - Schedule of Operating Segment Information (Details) Details 100 false false R101.htm 2419404 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details) Sheet http://www.molinahealthcare.com/role/SegmentsReconciliationOfGrossMarginToConsolidatedIncomeDetails Segments - Reconciliation of Gross Margin to Consolidated Income (Details) Details 101 false false R102.htm 2420402 - Disclosure - Quarterly Results of Operations (Unaudited) (Details) Sheet http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedDetails Quarterly Results of Operations (Unaudited) (Details) Details http://www.molinahealthcare.com/role/QuarterlyResultsOfOperationsUnauditedTables 102 false false R103.htm 2421402 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets (Details) Sheet http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails Condensed Financial Information of Registrant - Condensed Balance Sheets (Details) Details 103 false false R104.htm 2421403 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details) Sheet http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedBalanceSheetsAdditionalInformationDetails Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details) Details 104 false false R105.htm 2421404 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Operations (Details) Sheet http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsDetails Condensed Financial Information of Registrant - Condensed Statements of Operations (Details) Details 105 false false R106.htm 2421405 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Loss) (Details) Sheet http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfComprehensiveIncomeLossDetails Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Loss) (Details) Details 106 false false R107.htm 2421406 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details) Sheet http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details) Details 107 false false R108.htm 2421407 - Disclosure - Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details) Notes http://www.molinahealthcare.com/role/CondensedFinancialInformationOfRegistrantNotesToCondensedFinancialInformationDetails Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details) Details 108 false false R9999.htm Uncategorized Items - moh-12312019x10k.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - moh-12312019x10k.htm Cover 109 false false All Reports Book All Reports moh-12312019x10k.htm moh-12312019ex231.htm moh-12312019xex1025.htm moh-12312019xex211.htm moh-12312019xex311.htm moh-12312019xex312.htm moh-12312019xex321.htm moh-12312019xex322.htm moh-20191231.xsd moh-20191231_cal.xml moh-20191231_def.xml moh-20191231_lab.xml moh-20191231_pre.xml a2019performancegraph.jpg footprint2019a01.jpg molinalogo2016a24.jpg ncqaa10.jpg http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true XML 77 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Employee Benefit Plans
12 Months Ended

Dec. 31, 2019

Postemployment Benefits [Abstract]

Employee Benefit Plans Employee Benefit Plans
We sponsor defined contribution 401(k) plans that cover substantially all employees of our company and its subsidiaries. Eligible employees are permitted to contribute up to the maximum amount allowed by law. We generally match up to the first 4% of compensation contributed by employees. Expense recognized in connection with our contributions to the 401(k) plans amounted to $28 million, $36 million, and $43 million in the years ended December 31, 2019, 2018, and 2017, respectively.
We also have a non-qualified deferred compensation plan for certain key employees. Under this plan, eligible participants may defer up to 100% of their base salary and 100% of their bonus to provide tax-deferred growth. The funds deferred are invested in corporate-owned life insurance, under a rabbi trust.

X

- Definition
The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 712
-URI http://asc.fasb.org/topic&trid=2197446

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-URI http://asc.fasb.org/topic&trid=2127225

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017
+ Details

Name: us-gaap_CompensationAndEmployeeBenefitPlansTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PostemploymentBenefitsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 78 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Financial Information of Registrant
12 Months Ended

Dec. 31, 2019

Condensed Financial Information Disclosure [Abstract]

Condensed Financial Information of Registrant Condensed Financial Information of Registrant
The condensed balance sheets as of December 31, 2019 and 2018, and the related condensed statements of operations, comprehensive income (loss) and cash flows for each of the three years in the period ended December 31, 2019 for our parent company Molina Healthcare, Inc. (the “Registrant”), are presented below.
Condensed Balance Sheets

December 31,

2019

2018

(In millions, except per-share data)
ASSETS
Current assets:

Cash and cash equivalents
$
836

$
70

Investments
161

100

Receivables
2

2

Due from affiliates
49

90

Prepaid expenses and other current assets
46

47

Derivative asset
29

476

Total current assets
1,123

785

Property, equipment, and capitalized software, net
327

176

Goodwill and intangible assets, net
13

13

Investments in subsidiaries
2,225

2,768

Deferred income taxes
10

39

Advances to related parties and other assets
76

40

Total assets
$
3,774

$
3,821

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:

Medical claims and benefits payable
$
—

$
4

Accounts payable and accrued liabilities
260

223

Current portion of long-term debt
18

241

Derivative liability
29

476

Total current liabilities
307

944

Long-term debt
1,237

1,020

Finance lease liabilities
231

197

Other long-term liabilities
39

13

Total liabilities
1,814

2,174

Stockholders’ equity:

Common stock, $0.001 par value; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018
—

—

Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding
—

—

Additional paid-in capital
175

643

Accumulated other comprehensive income (loss)
4

(8
)
Retained earnings
1,781

1,012

Total stockholders’ equity
1,960

1,647

Total liabilities and stockholders’ equity
$
3,774

$
3,821

See accompanying notes.
Condensed Statements of Operations

Year Ended December 31,

2019

2018

2017

(In millions)
Revenue:

Administrative services fees
$
1,038

$
1,138

$
1,317

Investment income and other revenue
18

17

16

Total revenue
1,056

1,155

1,333

Expenses:

General and administrative expenses
937

1,007

1,082

Depreciation and amortization
63

69

93

Other operating expenses
—

8

16

Restructuring costs
4

35

153

Impairment losses
—

—

39

Total operating expenses
1,004

1,119

1,383

Gain on sale of subsidiary
—

37

—

Operating income (loss)
52

73

(50
)
Interest expense
87

114

117

Other (income) expense, net
(15
)

17

(61
)
Loss before income tax (benefit) expense and equity in net earnings (losses) of subsidiaries
(20
)

(58
)

(106
)
Income tax expense (benefit)
9

(14
)

8

Net loss before equity in net earnings (losses) of subsidiaries
(29
)

(44
)

(114
)
Equity in net earnings (losses) of subsidiaries
766

751

(398
)
Net income (loss)
$
737

$
707

$
(512
)

Condensed Statements of Comprehensive Income (Loss)

Year Ended December 31,

2019

2018

2017

(In millions)
Net income (loss)
$
737

$
707

$
(512
)
Other comprehensive income (loss):

Unrealized investment income (loss)
16

(3
)

(5
)
Less: effect of income taxes
4

(1
)

(2
)
Other comprehensive income (loss), net of tax
12

(2
)

(3
)
Comprehensive income (loss)
$
749

$
705

$
(515
)

See accompanying notes.

Condensed Statements of Cash Flows

Year Ended December 31,

2019

2018

2017

(In millions)
Operating activities:

Net cash provided by operating activities
$
64

$
118

$
166

Investing activities:

Capital contributions to subsidiaries
(43
)

(145
)

(370
)
Dividends received from subsidiaries
1,373

298

286

Purchases of investments
(152
)

(136
)

(331
)
Proceeds from sales and maturities of investments
93

388

156

Purchases of property, equipment and capitalized software
(56
)

(22
)

(67
)
Net cash received from sale of subsidiaries
—

242

—

Change in amounts due to/from affiliates
38

6

(49
)
Other, net
1

—

—

Net cash provided by (used in) investing activities
1,254

631

(375
)
Financing activities:

Repayment of principal amount of convertible notes
(240
)

(362
)

—

Cash paid for partial settlement of conversion option
(578
)

(623
)

—

Cash received for partial settlement of call option
578

623

—

Cash paid for partial termination of warrants
(514
)

(549
)

—

Proceeds from borrowings under term loan facility
220

—

—

Common stock purchases
(47
)

—

—

Repayment of credit facility
—

(300
)

—

Proceeds from senior notes offerings, net of issuance costs
—

—

325

Proceeds from borrowings under credit facility
—

—

300

Other, net
29

19

11

Net cash (used in) provided by financing activities
(552
)

(1,192
)

636

Net (decrease) increase in cash and cash equivalents
766

(443
)

427

Cash and cash equivalents at beginning of period
70

513

86

Cash and cash equivalents at end of period
$
836

$
70

$
513

Notes to Condensed Financial Information of Registrant
Note A - Basis of Presentation
The Registrant was incorporated in 2002. Prior to that date, Molina Healthcare of California (formerly known as Molina Medical Centers) operated as a California health plan and as the parent company for three other state health plans. In June 2003, the employees and operations of the corporate entity were transferred from Molina Healthcare of California to the Registrant.
The Registrant’s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries since the date of acquisition. The accompanying condensed financial information of the Registrant should be read in conjunction with the consolidated financial statements and accompanying notes.
Note B - Transactions with Subsidiaries
The Registrant provides certain centralized medical and administrative services to our subsidiaries pursuant to administrative services agreements that include, but are not limited to, information technology, product development and administration, underwriting, claims processing, customer service, certain care management services, human resources, marketing, purchasing, risk management, actuarial, underwriting, finance, accounting, legal and public
relations. Fees are based on the fair market value of services rendered and are recorded as operating revenue. Payment is subordinated to the subsidiaries’ ability to comply with minimum capital and other restrictive financial requirements of the states in which they operate. Charges in 2019, 2018, and 2017 for these services amounted to $1,038 million, $1,137 million, and $1,317 million, respectively, and are included in operating revenue.
The Registrant and its subsidiaries are included in the consolidated federal and state income tax returns filed by the Registrant. Income taxes are allocated to each subsidiary in accordance with an intercompany tax allocation agreement. The agreement allocates income taxes in an amount generally equivalent to the amount which would be expensed by the subsidiary if it filed a separate tax return. Net operating loss benefits are paid to the subsidiary by the Registrant to the extent such losses are utilized in the consolidated tax returns.
Note C - Dividends and Capital Contributions
When the Registrant receives dividends from its subsidiaries, such amounts are recorded as a reduction to the investments in the respective subsidiaries.
For all periods presented, the Registrant made capital contributions to certain subsidiaries primarily to comply with minimum net worth requirements and to fund business combinations. Such amounts have been recorded as an increase in investment in the respective subsidiaries.

X

- References
No definition available.
+ Details

Name: srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract

Namespace Prefix: srt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683
+ Details

Name: us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 79 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Receivables
12 Months Ended

Dec. 31, 2019

Receivables [Abstract]

Receivables Receivables
Receivables consist primarily of amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for doubtful accounts is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.

December 31,

2019

2018

(In millions)
Government receivables
$
1,056

$
872

Pharmacy rebate receivables
150

146

Health insurer fee reimbursement receivables
5

141

Other
195

171

Total
$
1,406

$
1,330

X

- Definition
The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2196772
+ Details

Name: us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 80 moh-12312019x10k_htm.xml IDEA: XBRL DOCUMENT 0001179929 2019-01-01 2019-12-31 0001179929 2020-02-07 0001179929 2019-06-30 0001179929 2017-01-01 2017-12-31 0001179929 2018-01-01 2018-12-31 0001179929 us-gaap:TechnologyServiceMember 2017-01-01 2017-12-31 0001179929 us-gaap:HealthCarePremiumMember 2018-01-01 2018-12-31 0001179929 us-gaap:TechnologyServiceMember 2018-01-01 2018-12-31 0001179929 us-gaap:TechnologyServiceMember 2019-01-01 2019-12-31 0001179929 us-gaap:HealthCarePremiumMember 2019-01-01 2019-12-31 0001179929 us-gaap:HealthCarePremiumMember 2017-01-01 2017-12-31 0001179929 2018-12-31 0001179929 2019-12-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001179929 us-gaap:CommonStockMember 2016-12-31 0001179929 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001179929 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001179929 us-gaap:CommonStockMember 2018-12-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001179929 2019-01-01 0001179929 us-gaap:RetainedEarningsMember 2019-01-01 0001179929 us-gaap:CommonStockMember 2017-12-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001179929 us-gaap:RetainedEarningsMember 2018-12-31 0001179929 us-gaap:CommonStockMember 2019-12-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001179929 2016-12-31 0001179929 us-gaap:RetainedEarningsMember 2018-01-01 0001179929 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0001179929 2018-01-01 0001179929 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001179929 2017-12-31 0001179929 us-gaap:RetainedEarningsMember 2016-12-31 0001179929 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001179929 us-gaap:RetainedEarningsMember 2019-12-31 0001179929 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001179929 us-gaap:RetainedEarningsMember 2017-12-31 0001179929 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001179929 moh:CallOptionDerivativeAssetMember 2017-01-01 2017-12-31 0001179929 moh:CallOptionDerivativeAssetMember 2019-01-01 2019-12-31 0001179929 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2018-01-01 2018-12-31 0001179929 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2019-01-01 2019-12-31 0001179929 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2017-01-01 2017-12-31 0001179929 moh:CallOptionDerivativeAssetMember 2018-01-01 2018-12-31 0001179929 stpr:IL moh:NextLevelHealthPartnersInc.Member 2019-12-31 2019-12-31 0001179929 stpr:NY srt:ScenarioForecastMember moh:YourCareHealthPlanInc.Member 2020-01-01 2020-06-30 0001179929 moh:TexasHealthAndHumanServicesCommissionSTARPLUSProgramMember 2019-10-01 2019-10-31 0001179929 stpr:TX 2019-12-31 0001179929 moh:HealthPlansMember 2019-12-31 0001179929 stpr:TX 2019-01-01 2019-12-31 0001179929 stpr:NY srt:ScenarioForecastMember moh:YourCareHealthPlanInc.Member 2020-06-30 0001179929 moh:STARCHIPContractsMember stpr:TX moh:HealthPlansMember 2019-12-31 0001179929 moh:STARCHIPContractsMember stpr:TX moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 stpr:IL moh:NextLevelHealthPartnersInc.Member 2019-12-31 0001179929 srt:MaximumMember 2019-01-01 2019-12-31 0001179929 moh:DeferredIncomeTaxMember 2019-01-01 0001179929 moh:StructuredSecuritiesMember 2019-01-01 2019-12-31 0001179929 moh:CMSSubsidiesMember 2018-01-01 2018-12-31 0001179929 moh:GovernmentReceivablesMember 2019-01-01 2019-12-31 0001179929 moh:GovernmentReceivablesMember 2019-12-31 0001179929 moh:MedicaidExpansionMember 2019-12-31 0001179929 srt:MinimumMember moh:CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember 2019-01-01 2019-12-31 0001179929 moh:RetainedEarningsIncludingDeferredIncomeTaxMember 2019-01-01 0001179929 moh:MedicaidExpansionMember 2018-12-31 0001179929 us-gaap:RetainedEarningsMember 2019-01-01 0001179929 srt:MaximumMember moh:CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember 2019-01-01 2019-12-31 0001179929 stpr:TX moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 country:PR moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 stpr:CA moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 stpr:WA moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 stpr:SC moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 moh:OtherGeographicalAreasMember moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 stpr:NM moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 stpr:NM moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 stpr:OH moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 moh:OtherGeographicalAreasMember moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 stpr:OH moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 stpr:MI moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 stpr:IL moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 stpr:IL moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 stpr:WA moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 moh:OtherGeographicalAreasMember moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 country:PR moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 stpr:SC moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 stpr:NM moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 stpr:IL moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 stpr:OH moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 stpr:CA moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 stpr:SC moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 stpr:MI moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 stpr:MI moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 country:PR moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 stpr:TX moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 stpr:FL moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 stpr:WA moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 stpr:FL moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 stpr:FL moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 stpr:TX moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 stpr:CA moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 srt:MinimumMember 2019-01-01 2019-12-31 0001179929 moh:ConvertibleSeniorNotesMember 2019-12-31 0001179929 us-gaap:WarrantMember 2018-01-01 2018-12-31 0001179929 moh:ConvertibleSeniorNotesMember 2017-01-01 2017-12-31 0001179929 moh:ConvertibleSeniorNotesMember 2019-01-01 2019-12-31 0001179929 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001179929 us-gaap:WarrantMember 2017-01-01 2017-12-31 0001179929 moh:ConvertibleSeniorNotesMember 2018-01-01 2018-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryNotesSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsAssetsMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeFinancialInstrumentsAssetsMember 2019-12-31 0001179929 us-gaap:DerivativeFinancialInstrumentsAssetsMember 2019-12-31 0001179929 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:USTreasuryNotesSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:CertificatesOfDepositMember 2019-12-31 0001179929 us-gaap:CommercialMortgageBackedSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001179929 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialMortgageBackedSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialMortgageBackedSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:CertificatesOfDepositMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel1Member moh:MunicipalSecuritiesMember 2019-12-31 0001179929 us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:CertificatesOfDepositMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeFinancialInstrumentsAssetsMember 2019-12-31 0001179929 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member moh:MunicipalSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryNotesSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2019-12-31 0001179929 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialMortgageBackedSecuritiesMember 2019-12-31 0001179929 moh:MunicipalSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel2Member moh:MunicipalSecuritiesMember 2019-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001179929 us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001179929 us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeFinancialInstrumentsAssetsMember 2018-12-31 0001179929 us-gaap:DerivativeFinancialInstrumentsAssetsMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryNotesSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001179929 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:CertificatesOfDepositMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryNotesSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsAssetsMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeFinancialInstrumentsAssetsMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0001179929 us-gaap:CertificatesOfDepositMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0001179929 moh:MunicipalSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel3Member moh:MunicipalSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel2Member moh:MunicipalSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryNotesSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0001179929 us-gaap:USTreasuryNotesSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel1Member moh:MunicipalSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-31 0001179929 us-gaap:FairValueInputsLevel1Member us-gaap:CertificatesOfDepositMember 2018-12-31 0001179929 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2018-12-31 0001179929 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001179929 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001179929 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:RevolvingCreditFacilityMember 2019-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:ConvertibleDebtMember 2019-12-31 0001179929 moh:SeniorNotesDue2022Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2019-12-31 0001179929 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001179929 moh:A4.875SeniorNotesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2019-12-31 0001179929 moh:SeniorNotesDue2022Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2018-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:ConvertibleDebtMember 2019-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:ConvertibleDebtMember 2018-12-31 0001179929 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:RevolvingCreditFacilityMember 2018-12-31 0001179929 moh:SeniorNotesDue2022Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2019-12-31 0001179929 moh:A4.875SeniorNotesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2018-12-31 0001179929 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001179929 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:RevolvingCreditFacilityMember 2018-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:ConvertibleDebtMember 2018-12-31 0001179929 moh:SeniorNotesDue2022Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2018-12-31 0001179929 moh:A4.875SeniorNotesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2019-12-31 0001179929 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:RevolvingCreditFacilityMember 2019-12-31 0001179929 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001179929 moh:A4.875SeniorNotesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2018-12-31 0001179929 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2019-12-31 0001179929 moh:CallOptionDerivativeAssetMember 2019-12-31 0001179929 moh:A4.875SeniorNotesMember 2019-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member 2019-12-31 0001179929 moh:SeniorNotesDue2022Member 2019-12-31 0001179929 us-gaap:MortgageBackedSecuritiesMember 2019-12-31 0001179929 stpr:OH 2018-12-31 0001179929 moh:OtherGeographicalAreasMember 2018-12-31 0001179929 country:PR 2018-12-31 0001179929 stpr:NM 2019-12-31 0001179929 moh:OtherGeographicalAreasMember 2019-12-31 0001179929 stpr:NM 2018-12-31 0001179929 country:PR 2019-12-31 0001179929 stpr:OH 2019-12-31 0001179929 stpr:FL 2018-12-31 0001179929 stpr:FL 2019-12-31 0001179929 moh:OtherReceivablesMember 2018-12-31 0001179929 moh:HealthInsurerFeeReimbursementReceivablesMember 2018-12-31 0001179929 moh:PharmacyRebateReceivablesMember 2018-12-31 0001179929 moh:HealthInsurerFeeReimbursementReceivablesMember 2019-12-31 0001179929 moh:OtherReceivablesMember 2019-12-31 0001179929 moh:GovernmentReceivablesMember 2018-12-31 0001179929 moh:PharmacyRebateReceivablesMember 2019-12-31 0001179929 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-12-31 0001179929 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-12-31 0001179929 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-12-31 0001179929 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0001179929 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-12-31 0001179929 us-gaap:BuildingAndBuildingImprovementsMember 2019-12-31 0001179929 us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 0001179929 us-gaap:LandMember 2019-12-31 0001179929 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001179929 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001179929 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-12-31 0001179929 us-gaap:LandMember 2018-12-31 0001179929 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-12-31 0001179929 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0001179929 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2019-01-01 2019-12-31 0001179929 moh:ContractRightsandLicensingAgreementsMember 2018-12-31 0001179929 moh:ProviderNetworksMember 2018-12-31 0001179929 moh:ProviderNetworksMember 2019-12-31 0001179929 moh:ContractRightsandLicensingAgreementsMember 2019-12-31 0001179929 moh:HealthPlansMember 2018-12-31 0001179929 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-12-31 0001179929 us-gaap:AllOtherSegmentsMember 2017-12-31 0001179929 us-gaap:AllOtherSegmentsMember 2019-12-31 0001179929 us-gaap:AllOtherSegmentsMember 2019-01-01 2019-12-31 0001179929 us-gaap:AllOtherSegmentsMember 2018-12-31 0001179929 moh:HealthPlansMember 2017-12-31 0001179929 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-12-31 0001179929 us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member 2018-12-31 0001179929 us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2017-12-31 0001179929 us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2019-12-31 0001179929 us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member 2019-12-31 0001179929 us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2018-12-31 0001179929 us-gaap:ShortDurationInsuranceContractAccidentYear2019Member 2019-12-31 0001179929 us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2019-01-01 2019-12-31 0001179929 us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2018-01-01 2018-12-31 0001179929 us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member 2018-01-01 2018-12-31 0001179929 us-gaap:ShortDurationInsuranceContractAccidentYear2019Member 2019-01-01 2019-12-31 0001179929 us-gaap:ShortDurationInsuranceContractsAccidentYear2018Member 2019-01-01 2019-12-31 0001179929 us-gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2017-01-01 2017-12-31 0001179929 moh:TermLoanMember us-gaap:LineOfCreditMember 2019-12-31 0001179929 moh:A4.875SeniorNotesMember us-gaap:SeniorNotesMember 2018-12-31 0001179929 moh:SeniorNotesDue2022Member us-gaap:SeniorNotesMember 2018-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2019-12-31 0001179929 moh:A4.875SeniorNotesMember us-gaap:SeniorNotesMember 2019-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2018-12-31 0001179929 moh:TermLoanMember us-gaap:LineOfCreditMember 2018-12-31 0001179929 moh:SeniorNotesDue2022Member us-gaap:SeniorNotesMember 2019-12-31 0001179929 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0001179929 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-01-01 2019-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2018-01-01 2018-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2020-01-31 0001179929 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-01-31 0001179929 us-gaap:LetterOfCreditMember us-gaap:LineOfCreditMember 2019-12-31 0001179929 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-01-01 2019-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2020-01-01 2020-01-31 0001179929 moh:ConvertibleSeniorNotesDue2044Member us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:SeniorNotesMember 2019-12-31 0001179929 moh:A4.875SeniorNotesMember us-gaap:ConvertibleDebtMember 2019-12-31 0001179929 moh:CurrentLiabilitiesMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2018-12-31 0001179929 moh:CurrentAssetsMember moh:CallOptionDerivativeAssetMember 2018-12-31 0001179929 moh:CurrentAssetsMember moh:CallOptionDerivativeAssetMember 2019-12-31 0001179929 moh:CurrentLiabilitiesMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2019-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020WarrantsMember 2019-12-31 0001179929 moh:CallOptionDerivativeAssetMember us-gaap:SubsequentEventMember 2020-01-31 0001179929 moh:CashConvertibleSeniorNotesDue2020Member us-gaap:SubsequentEventMember 2020-01-01 2020-01-31 0001179929 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001179929 us-gaap:ForeignCountryMember 2019-12-31 0001179929 moh:EmployeeStockPurchasePlanandStockOptionsMember 2019-01-01 2019-12-31 0001179929 moh:EmployeeStockPurchasePlanandStockOptionsMember 2018-01-01 2018-12-31 0001179929 moh:RestrictedandPerformanceStockMember 2019-01-01 2019-12-31 0001179929 moh:RestrictedandPerformanceStockMember 2017-01-01 2017-12-31 0001179929 moh:RestrictedandPerformanceStockMember 2018-01-01 2018-12-31 0001179929 moh:EmployeeStockPurchasePlanandStockOptionsMember 2017-01-01 2017-12-31 0001179929 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001179929 us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0001179929 us-gaap:PerformanceSharesMember 2018-01-01 2018-12-31 0001179929 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001179929 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001179929 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0001179929 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001179929 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001179929 us-gaap:PerformanceSharesMember 2017-01-01 2017-12-31 0001179929 us-gaap:RestrictedStockMember 2018-12-31 0001179929 us-gaap:PerformanceSharesMember 2018-12-31 0001179929 us-gaap:RestrictedStockMember 2019-12-31 0001179929 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001179929 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001179929 us-gaap:PerformanceSharesMember 2019-12-31 0001179929 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001179929 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001179929 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020WarrantsMember 2013-12-31 0001179929 us-gaap:CommonStockMember 2019-12-31 2019-12-31 0001179929 moh:CashConvertibleSeniorNotesDue2020WarrantsMember 2019-01-01 2019-12-31 0001179929 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2020-01-01 2020-02-07 0001179929 us-gaap:EmployeeStockOptionMember 2019-12-31 0001179929 moh:EmployeeStockPurchasePlanMember 2019-06-30 0001179929 us-gaap:CommonStockMember 2019-12-01 2019-12-31 0001179929 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001179929 moh:EquityIncentivePlanMember 2019-06-30 0001179929 moh:CashConvertibleSeniorNotesDue2020WarrantsMember 2013-01-01 2013-12-31 0001179929 moh:ExercisePriceRange1Member 2019-12-31 0001179929 moh:ExercisePriceRange1Member 2019-01-01 2019-12-31 0001179929 moh:ExercisePriceRange2Member 2019-12-31 0001179929 moh:ExercisePriceRange2Member 2019-01-01 2019-12-31 0001179929 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0001179929 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0001179929 moh:ITRestructuringMember 2019-12-31 0001179929 us-gaap:ContractTerminationMember moh:A2017RestructuringPlanMember 2019-12-31 0001179929 moh:ITRestructuringMember 2018-12-31 0001179929 moh:ProfessionalServicesFeesMember moh:ITRestructuringMember 2019-12-31 0001179929 us-gaap:OneTimeTerminationBenefitsMember moh:ITRestructuringMember 2019-12-31 0001179929 us-gaap:ContractTerminationMember moh:A2017RestructuringPlanMember 2019-01-01 2019-12-31 0001179929 us-gaap:OneTimeTerminationBenefitsMember moh:ITRestructuringMember 2019-01-01 2019-12-31 0001179929 moh:ITRestructuringMember 2019-01-01 2019-12-31 0001179929 moh:ProfessionalServicesFeesMember moh:ITRestructuringMember 2019-01-01 2019-12-31 0001179929 moh:A2017RestructuringPlanMember 2018-12-31 0001179929 srt:ParentCompanyMember 2019-12-31 0001179929 srt:ParentCompanyMember 2018-12-31 0001179929 us-gaap:OperatingSegmentsMember moh:HealthPlansMember 2019-01-01 2019-12-31 0001179929 us-gaap:OperatingSegmentsMember moh:HealthPlansMember 2017-01-01 2017-12-31 0001179929 us-gaap:OperatingSegmentsMember moh:HealthPlansMember 2018-01-01 2018-12-31 0001179929 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-12-31 0001179929 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-12-31 0001179929 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-12-31 0001179929 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2017-01-01 2017-12-31 0001179929 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2018-01-01 2018-12-31 0001179929 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001179929 us-gaap:OperatingSegmentsMember 2019-01-01 2019-12-31 0001179929 us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001179929 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-12-31 0001179929 2018-04-01 2018-06-30 0001179929 2018-07-01 2018-09-30 0001179929 2018-01-01 2018-03-31 0001179929 2018-10-01 2018-12-31 0001179929 2019-07-01 2019-09-30 0001179929 2019-01-01 2019-03-31 0001179929 2019-04-01 2019-06-30 0001179929 2019-10-01 2019-12-31 0001179929 srt:ParentCompanyMember 2018-01-01 2018-12-31 0001179929 srt:ParentCompanyMember 2017-01-01 2017-12-31 0001179929 srt:ParentCompanyMember 2019-01-01 2019-12-31 0001179929 srt:ParentCompanyMember 2016-12-31 0001179929 srt:ParentCompanyMember 2017-12-31 shares iso4217:USD moh:member moh:county pure moh:segment iso4217:USD shares moh:state moh:Security moh:claim false --12-31 FY 2019 0001179929 P3Y 0.001 0.001 0.001 0.001 150000000 150000000 150000000 150000000 62000000 62000000 62000000 62000000 0.0245277 0.0172157 0.04875 0.01125 0.01125 P5Y 3000000 3000000 445000000 302000000 0.001 0.001 0.001 0.001 20000000 20000000 20000000 20000000 0 0 0 0 0 0 0 0 P3Y P5Y 0 0 0.45 0.45 0.31 0.31 0.023 0.023 0.006 0.006 0 P0Y6M0D P0Y6M0D 10-K true 2019-12-31 false 1-31719 MOLINA HEALTHCARE, INC. DE 13-4204626 200 Oceangate Suite 100 Long Beach CA 90802 562 435-3666 Common Stock, $0.001 Par Value MOH NYSE Yes No Yes Yes Large Accelerated Filer false false false 8928700000 60800000 <div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Portions of the registrant’s Proxy Statement for the </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:Arial;font-size:10pt;"> Annual Meeting of Stockholders to be held on May 7, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:Arial;font-size:10pt;">, are incorporated by reference into Part III of this Form 10-K, to the extent described therein.</span></div> 16208000000 17612000000 18854000000 489000000 417000000 438000000 0 329000000 0 0 407000000 521000000 132000000 125000000 70000000 16829000000 18890000000 19883000000 13905000000 15137000000 17073000000 1296000000 1333000000 1594000000 489000000 417000000 438000000 0 348000000 0 89000000 99000000 137000000 6000000 46000000 234000000 0 364000000 492000000 0 0 470000000 15785000000 17744000000 20438000000 0 -15000000 0 1044000000 1131000000 -555000000 87000000 115000000 118000000 15000000 -17000000 61000000 -72000000 -132000000 -57000000 972000000 999000000 -612000000 235000000 292000000 -100000000 737000000 707000000 -512000000 11.85 11.57 -9.07 11.47 10.61 -9.07 62000000 61000000 56000000 64000000 67000000 56000000 737000000 707000000 -512000000 16000000 -3000000 -5000000 4000000 -1000000 -2000000 12000000 -2000000 -3000000 749000000 705000000 -515000000 2452000000 2826000000 1946000000 1681000000 1406000000 1330000000 134000000 149000000 29000000 476000000 5967000000 6462000000 385000000 241000000 172000000 190000000 79000000 120000000 79000000 117000000 105000000 24000000 6787000000 7154000000 1854000000 1961000000 664000000 967000000 455000000 390000000 249000000 211000000 18000000 241000000 29000000 476000000 3269000000 4246000000 1237000000 1020000000 231000000 197000000 90000000 44000000 4827000000 5507000000 0 0 0 0 175000000 643000000 4000000 -8000000 1781000000 1012000000 1960000000 1647000000 6787000000 7154000000 57000000 0 841000000 -2000000 810000000 1649000000 -512000000 -512000000 3000000 161000000 161000000 -3000000 -3000000 42000000 42000000 60000000 0 1044000000 -5000000 298000000 1337000000 707000000 707000000 -1000000 7000000 6000000 -550000000 -550000000 2000000 108000000 108000000 4000000 4000000 -2000000 -2000000 37000000 37000000 62000000 0 643000000 -8000000 1012000000 1647000000 737000000 737000000 1000000 53000000 54000000 85000000 85000000 -514000000 -514000000 12000000 12000000 47000000 47000000 62000000 0 175000000 4000000 1781000000 1960000000 737000000 707000000 -512000000 89000000 127000000 178000000 -10000000 6000000 94000000 39000000 27000000 46000000 5000000 22000000 32000000 15000000 -22000000 -14000000 0 -15000000 0 0 17000000 60000000 0 0 470000000 -5000000 4000000 21000000 76000000 530000000 -103000000 -28000000 -6000000 56000000 -107000000 -226000000 263000000 -303000000 -574000000 341000000 2000000 45000000 -12000000 38000000 -21000000 -34000000 -15000000 51000000 -16000000 427000000 -314000000 804000000 2536000000 1444000000 2697000000 2302000000 2445000000 1759000000 57000000 30000000 86000000 0 190000000 0 2000000 18000000 38000000 -293000000 1143000000 -1062000000 240000000 362000000 0 578000000 623000000 0 578000000 623000000 0 514000000 549000000 0 220000000 0 0 47000000 0 0 0 300000000 0 0 0 325000000 0 0 300000000 29000000 18000000 11000000 -552000000 -1193000000 636000000 -418000000 -364000000 378000000 2926000000 3290000000 2912000000 2508000000 2926000000 3290000000 239000000 240000000 7000000 78000000 93000000 78000000 0 131000000 193000000 0 -23000000 -32000000 0 108000000 161000000 7000000 6000000 22000000 7000000 0 0 0 -327000000 0 0 85000000 0 0 15000000 0 0 242000000 0 0 -15000000 0 132000000 577000000 255000000 -132000000 -577000000 -255000000 0 0 0 <span style="color:#828282;font-family:Arial;font-size:14pt;">Organization and Basis of Presentation</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Operations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). </span><span style="font-family:Arial;font-size:10pt;">We currently have</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Health Plans segment consists of health plans operating in</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>14</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">states and the Commonwealth of Puerto Rico. As of December 31, 2019, </span><span style="font-family:Arial;font-size:10pt;">these health plans served approximately</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>3.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> members eligible for Medicaid, Medicare, and other government-sponsored health care programs for low-income families and individuals including Marketplace members, most of whom receive government subsidies for premiums. The health plans are generally operated by our respective wholly owned subsidiaries in those states, each of which is licensed as a health maintenance organization (“HMO”). </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our state Medicaid contracts typically have terms of</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">three</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>five years</span></span><span style="font-family:Arial;font-size:10pt;">, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (“RFP”) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled; and regions or service areas.</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent Developments – Health Plans Segment</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Kentucky. </span><span style="font-family:Arial;font-size:10pt;">On December 2, 2019, we announced that our Kentucky health plan subsidiary had been selected as an awardee pursuant to the Kentucky Medicaid managed care organizations RFP issued by the Kentucky Finance and Administration Cabinet in May 2019. However, in late December 2019, the newly elected Governor of Kentucky announced that he was canceling the Medicaid contracts that had been awarded by the outgoing Governor, including the contract that had been awarded to our Kentucky health plan subsidiary, and that he was reissuing the RFP for rebidding. We submitted a bid under the new RFP on February 6, 2020.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Texas.</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">In October 2019, the Texas Health and Human Services Commission (“HHSC”) awarded contracts to our Texas health plan for the ABD program (known in Texas as “STAR+PLUS”) in two service areas, consisting of one legacy service area and one new service area. This would be a reduction from our current footprint of six service areas. We believe the initial term of each contract is expected to be</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>three years</span></span><span style="font-family:Arial;font-size:10pt;">, and such contracts are currently anticipated to be operational beginning on January 1, 2021, at the earliest.</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">Under our existing STAR+PLUS and related Medicare-Medicaid Plan (“MMP”) contracts, we served</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">approximately</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>97,000</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">members as of December 31, 2019, representing premium revenue of approximately</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>$2,062 million</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">in 2019</span><span style="font-family:Arial;font-size:10pt;">. We are currently exercising our protest rights of the STAR+PLUS RFP awards with HHSC. </span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In 2019, our Texas health plan submitted an RFP response for the TANF and CHIP programs (known in Texas as “STAR/CHIP”). HHSC has announced that the STAR/CHIP contract awards are delayed to late February 2020. Under our existing STAR/CHIP contracts, we served approximately</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>114,000</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">members</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">as of December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, representing premium revenue of approximately</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>$315 million</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">in 2019. </span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Illinois. </span><span style="font-family:Arial;font-size:10pt;">On December 31, 2019, we entered into a definitive agreement to purchase NextLevel Health Partners, Inc., a Medicaid managed care organization. Upon the closing of this transaction, expected to occur in the first half of 2020, we will assume the right to serve approximately</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>50,000</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">Medicaid and Managed Long-Term Services and Supports members in Cook County, Illinois. The purchase price of approximately</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">will be funded with available cash, and the closing is subject to customary closing conditions.</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">New York</span><span style="font-family:Arial;font-size:10pt;">. </span><span style="font-family:Arial;font-size:10pt;">In October 2019, we entered into a definitive agreement to acquire certain assets of YourCare Health Plan, Inc. Upon the closing of this transaction, expected to occur in the first half of 2020, we will serve approximately</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>46,000</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">Medicaid members in</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>seven</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">counties in western New York. The purchase price of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$40 million</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">will be funded with available cash, and the closing is subject to customary closing conditions. </span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Consolidation and Presentation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Financial information related to subsidiaries acquired during any year is included only for periods subsequent to their acquisition. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the periods presented have been included; such adjustments consist of normal recurring adjustments.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of medical claims and benefits payable of our Health Plans segment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Settlements under risk or savings sharing programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The assessment of long-lived and intangible assets, and goodwill, for impairment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of reserves for the outcome of litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of valuation allowances for deferred tax assets; and</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div>The determination of unrecognized tax benefits. 2 14 3300000 P5Y P3Y 97000 2062000000 114000 315000000 50000 50000000 46000 7 40000000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Consolidation and Presentation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Financial information related to subsidiaries acquired during any year is included only for periods subsequent to their acquisition. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the periods presented have been included; such adjustments consist of normal recurring adjustments.</span></div> <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of medical claims and benefits payable of our Health Plans segment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Settlements under risk or savings sharing programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The assessment of long-lived and intangible assets, and goodwill, for impairment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of reserves for the outcome of litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of valuation allowances for deferred tax assets; and</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div>The determination of unrecognized tax benefits. <span style="color:#828282;font-family:Arial;font-size:14pt;">Significant Accounting Policies</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of </span><span style="font-family:Arial;font-size:10pt;">three months or less</span><span style="font-family:Arial;font-size:10pt;"> on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted cash and cash equivalents, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted cash and cash equivalents, current </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,508</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,926</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,290</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Investments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (“AFS”) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders’ equity as other comprehensive income, net of applicable income taxes. Held-to-maturity securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses and unrealized losses judged to be other than temporary with respect to available-for-sale and held-to-maturity securities are included in the determination of net income (loss). The cost of securities sold is determined using the specific-identification method.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our investment policy requires that all of our investments have final maturities of less than </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years, or less than</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>10 years</span></span><span style="font-family:Arial;font-size:10pt;"> average life for structured securities.</span><span style="font-family:Arial;font-size:10pt;"> Investments and restricted investments are subject to interest rate risk </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In general, our AFS securities are classified as current assets without regard to the securities’ contractual maturity dates because they may be readily liquidated. We monitor our investments for other-than-temporary impairment. For comprehensive discussions of the fair value and classification of our investments, see Note </span><span style="font-family:Arial;font-size:10pt;">4</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Fair Value Measurements</span><span style="font-family:Arial;font-size:10pt;">,” and Note </span><span style="font-family:Arial;font-size:10pt;">5</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Investments</span><span style="font-family:Arial;font-size:10pt;">.” </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Long-Lived Assets, including Intangible Assets</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-lived assets consist primarily of property, equipment, capitalized software (see Note </span><span style="font-family:Arial;font-size:10pt;">7</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Property, Equipment, and Capitalized Software, Net</span><span style="font-family:Arial;font-size:10pt;">”), and intangible assets resulting from acquisitions. </span><span style="font-family:Arial;font-size:10pt;">Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts).</span><span style="font-family:Arial;font-size:10pt;"> Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between </span><span style="font-family:Arial;font-size:10pt;">five</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>15</span></span><span style="font-family:Arial;font-size:10pt;"> years. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset’s (or asset group’s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed.</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment.</span><span style="font-family:Arial;font-size:10pt;"> Refer to Note </span><span style="font-family:Arial;font-size:10pt;">9</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Goodwill and Intangible Assets, Net</span><span style="font-family:Arial;font-size:10pt;">,” for further details. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Right-of-use (“ROU”) assets represent our right to use the underlying assets over the lease term, and lease liabilities represent our obligation for lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. If applicable, we account for lease and non-lease components within a lease as a single lease component.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Because most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Finance lease payments reduce finance lease liabilities, the related ROU assets are amortized on a straight-line basis over the lease term, and interest expense is recognized using the effective interest method.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The significant majority of our operating leases consist of long-term operating leases for office space. Short-term leases (those with terms of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. For certain leases that represent a portfolio of similar assets, such as a fleet of vehicles, we apply a portfolio approach to account for the related ROU assets and liabilities, rather than account for such assets and the related liabilities individually. A nominal number of our lease agreements include rental payments that adjust periodically for inflation. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For further information, including the amount and location of the ROU assets and lease liabilities recognized in the accompanying consolidated balance sheet, see Note </span><span style="font-family:Arial;font-size:10pt;">8</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Leases</span><span style="font-family:Arial;font-size:10pt;">.” For further information regarding our adoption and implementation of Accounting Standards Update (“ASU”) 2016-02, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases (Topic 842), </span><span style="font-family:Arial;font-size:10pt;">see “Recent Accounting Pronouncements Adopted,</span><span style="font-family:Arial;font-size:10pt;font-style:italic;">”</span><span style="font-family:Arial;font-size:10pt;"> below.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Business Combinations</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment on an annual basis and more frequently if impairment indicators are present. Such events or circumstances may include experienced or expected operating cash-flow deterioration or losses, significant losses of membership, loss of state funding, loss of state contracts, and other factors. Goodwill is impaired if the carrying amount of the reporting unit (one of our state health plans) </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit.</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, the dynamic economic and political environments in which we operate, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. If our qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, we perform the quantitative assessment. We may also elect to bypass the qualitative assessment and proceed directly to the quantitative assessment. If performing a quantitative assessment, we generally estimate the fair values of our reporting units by applying the income approach, using discounted cash flows. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the annual impairment test under a quantitative assessment, the base year in the reporting units’ discounted cash flows is derived from the annual financial planning cycle, which commences in the fourth quarter of the year. When computing discounted cash flows, we make assumptions about a wide variety of internal and external factors, and consider what the reporting unit’s selling price would be in an orderly transaction between market participants at the measurement date. Significant assumptions include financial projections of free cash flow (including significant assumptions about membership, premium rates, healthcare and operating cost trends, contract renewal and the procurement of new contracts, capital requirements and income taxes), long-term growth rates for determining terminal value beyond the discretely forecasted periods, and discount rates. When determining the discount rate, we consider the overall level of inherent risk of the reporting unit, and the expected rate an outside investor would expect to earn. As part of a quantitative assessment, we may also apply the asset liquidation method to estimate the fair value of individual reporting units, which is computed as total assets minus total liabilities, excluding intangible assets and deferred taxes. Finally, we apply a market approach to reconcile the value of our reporting units to our consolidated market value. Under the market approach, we consider publicly traded comparable company information to determine revenue and earnings multiples which are used to estimate our reporting units’ fair values. The assumptions used are consistent with those used in our long-range business plan and annual planning process. However, if these assumptions differ from actual results, the outcome of our goodwill impairment tests could be adversely affected. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting for business combinations requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within our consolidated statements of operations. Refer to Note </span><span style="font-family:Arial;font-size:10pt;">9</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Goodwill and Intangible Assets, Net</span><span style="font-family:Arial;font-size:10pt;">,” for further details. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Premium Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Premium revenue is generated from our Health Plans segment contracts, including agreements with other managed care organizations for which we operate as a subcontractor. Premium revenue is generally received based on per member per month (“PMPM”) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. The state Medicaid programs and the federal Medicare program periodically adjust premiums. Additionally, many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes premium revenue by health plan for the periods presented:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">% of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">% of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">% of Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Dollars in millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">California</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Florida</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>734</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,790</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Illinois </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,002</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>793</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Michigan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,601</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">New Mexico </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,356</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ohio</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,553</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,388</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Puerto Rico</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>474</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">South Carolina</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>583</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>445</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Texas</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,813</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Washington</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,361</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,608</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,286</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>738</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,612</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">_______________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">“Other” includes the Idaho, Mississippi, New York, Utah and Wisconsin health plans, which are not individually significant to our consolidated operating results.</span><span style="font-family:Arial;font-size:9pt;"> In 2019, “Other” also includes the New Mexico health plan. The New Mexico health plan’s Medicaid contract terminated on December 31, 2018, and therefore its results are not individually significant to our consolidated operating results in 2019. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certain components of premium revenue are subject to accounting estimates and fall into the following categories: </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Medicaid Program</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Medical Cost Floors (Minimums), and Medical Cost Corridors. </span><span style="font-family:Arial;font-size:10pt;">A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. In the aggregate, we recorded liabilities under the terms of such contract provisions of </span><span style="font-family:Arial;font-size:10pt;"><span>$74 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$103 million</span></span><span style="font-family:Arial;font-size:10pt;"> at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, respectively. Approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$69 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$87 million</span></span><span style="font-family:Arial;font-size:10pt;"> of the liabilities accrued at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, respectively, relates to our participation in Medicaid Expansion programs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In certain circumstances, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold. Receivables relating to such provisions were insignificant at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Profit Sharing and Profit Ceiling.</span><span style="font-family:Arial;font-size:10pt;"> Our contracts with certain states contain profit-sharing or profit ceiling provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any. Liabilities for profits in excess of the amount we are allowed to retain under these provisions were insignificant at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Retroactive Premium Adjustments. </span><span style="font-family:Arial;font-size:10pt;">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we must adjust our premium revenue in the period in which we learn of the adjustment, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Medicare Program</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Risk Adjusted Premiums:</span><span style="font-family:Arial;font-size:10pt;"> Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members’ risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members’ health status, risk scores and CMS practices. Consolidated balance sheet amounts related to anticipated Medicare risk adjusted premiums and Medicare Part D settlements were insignificant at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Minimum MLR:</span><span style="font-family:Arial;font-size:10pt;"> The Affordable Care Act (“ACA”) has established a minimum annual medical loss ratio (“Minimum MLR”) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations. The amounts payable for the Medicare Minimum MLR were insignificant at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Marketplace Program</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Risk Adjustment:</span><span style="font-family:Arial;font-size:10pt;"> Under this program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of operations. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, Marketplace risk adjustment payables amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$368 million</span></span><span style="font-family:Arial;font-size:10pt;"> and related receivables amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$63 million</span></span><span style="font-family:Arial;font-size:10pt;">, for a net payable of </span><span style="font-family:Arial;font-size:10pt;"><span>$305 million</span></span><span style="font-family:Arial;font-size:10pt;">. As of December 31, 2018, Marketplace risk adjustment payables amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$466 million</span></span><span style="font-family:Arial;font-size:10pt;"> and related receivables amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$34 million</span></span><span style="font-family:Arial;font-size:10pt;">, for a net payable of </span><span style="font-family:Arial;font-size:10pt;"><span>$432 million</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Minimum MLR:</span><span style="font-family:Arial;font-size:10pt;"> The ACA has established a Minimum MLR of </span><span style="font-family:Arial;font-size:10pt;">80%</span><span style="font-family:Arial;font-size:10pt;"> for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations. Aggregate balance sheet amounts related to the Minimum MLR were insignificant at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and December 31, 2018. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of the categories of amounts due government agencies is as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medicaid program:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medical cost floors and corridors</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other amounts due to states</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Marketplace program:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Risk adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost sharing reduction</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>664</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>967</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Quality Incentives</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At many of our health plans, revenue ranging from approximately </span><span style="font-family:Arial;font-size:10pt;"><span>1%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>4%</span></span><span style="font-family:Arial;font-size:10pt;"> of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. As described in Note </span><span style="font-family:Arial;font-size:10pt;">1</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Organization and Basis of Presentation</span><span style="font-family:Arial;font-size:10pt;">–Use of Estimates,” recognition of quality incentive premium revenue is subject to the use of estimates. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Maximum available quality incentive premium - current period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amount of quality incentive premium revenue recognized in current period:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Earned current period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Earned prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Quality incentive premium revenue recognized as a percentage of total premium revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Medical Care Costs, Medical Claims and Benefits Payable</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;">Medical care costs are recognized in the period in which services are provided and include fee-for-service claims, pharmacy benefits, capitation payments to providers, and various other medically-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Such medical care costs include amounts paid by us as well as estimated medical claims and benefits payable for costs that were incurred but not paid as of the reporting date (“IBNP”). Pharmacy benefits represent payments for members' prescription drug costs, net of rebates from drug manufacturers. We estimate pharmacy rebates based on historical and current utilization of prescription drugs and contractual provisions. Capitation payments represent monthly contractual fees paid to providers, who are responsible for providing medical care to members, which could include medical or ancillary costs like dental, vision and other supplemental health benefits. Such capitation costs are fixed in advance of the periods covered and are not subject to significant accounting estimates. Other medical care costs include all medically-related administrative costs, amounts due to providers pursuant to risk-sharing or other incentive arrangements, provider claims, and other healthcare expenses. Examples of medically-related administrative costs include expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses. Additionally, we include an estimate for the cost of settling claims incurred through the reporting date in our medical claims and benefits payable liability</span><span style="font-family:Times New Roman;">.</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;">Medical claims and benefits payable consist mainly of fee-for-service IBNP, unpaid pharmacy claims, capitation costs, other medical costs, including amounts payable to providers pursuant to risk-sharing or other incentive arrangements and amounts payable to providers on behalf of certain state agencies for certain state assessments in which we assume no financial risk</span><span style="font-family:Times New Roman;">. </span><span style="font-family:Arial;">IBNP includes the costs of claims incurred as of the balance sheet date which have been reported to us, and our best estimate of the cost of claims incurred but not yet reported to us. We also include an additional reserve to ensure that our overall IBNP liability is sufficient under moderately adverse conditions. We reflect changes in these estimates in the consolidated results of operations in the period in which they are determined.</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors and the assumed healthcare cost trend to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. Each reporting period, the recognized IBNP liability represents our best estimate of the total amount of unpaid claims incurred as of the balance sheet date using a consistent methodology in estimating our IBNP liability. We believe our current estimates are reasonable and adequate; however, the development of our estimate is a continuous process that we monitor and update as more complete claims payment information and healthcare cost trend data becomes available. Actual medical care costs may be less than we previously estimated (favorable development) or more than we previously estimated (unfavorable development), and any differences could be material. Any adjustments to reflect favorable development would be </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">recognized as a decrease to medical care costs, and any adjustments to reflect unfavorable development would be recognized as an increase to medical care costs</span><span style="font-family:Times New Roman;font-size:10pt;">,</span><span style="font-family:Arial;font-size:10pt;"> in the period in which the adjustments are determined. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Refer to Note </span><span style="font-family:Arial;font-size:10pt;">10</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Medical Claims and Benefits Payable</span><span style="font-family:Arial;font-size:10pt;">,” for a table presenting the components of the change in our medical claims and benefits payable, for all periods presented in the accompanying consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Reinsurance</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We limit our risk of catastrophic losses by maintaining high deductible reinsurance coverage. Such reinsurance coverage does not relieve us of our primary obligation to our policyholders. We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. Reinsurance premiums amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$17 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$16 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended December 31, 2019, 2018, and 2017, respectively. Reinsurance recoveries amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$18 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$33 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$24 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended December 31, 2019, 2018, and 2017, respectively. Reinsurance recoverable of </span><span style="font-family:Arial;font-size:10pt;"><span>$21 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$31 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$16 million</span></span><span style="font-family:Arial;font-size:10pt;">, as of December 31, 2019, 2018, and 2017, respectively, is included in “Receivables” in the accompanying consolidated balance sheets.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Marketplace Cost Share Reduction (“CSR”)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the year ended December 31, 2018, we recognized a benefit of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:10pt;"> in reduced medical care costs related to 2017 dates of service, as a result of the federal government’s confirmation that the reconciliation of 2017 Marketplace CSR subsidies would be performed on an annual basis. In the fourth quarter of 2017, we had assumed a nine-month reconciliation of this item pending confirmation of the time period to which the 2017 reconciliation would be applied. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Premium Deficiency Reserves on Loss Contracts</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We assess the profitability of our contracts to determine if it is probable that a loss will be incurred in the future by reviewing current results and forecasts. For purposes of this assessment, contracts are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. A premium deficiency is recognized if anticipated future medical care and administrative costs exceed anticipated future premium revenue, investment income and reinsurance recoveries. No premium deficiency reserves were recorded as of December 31, 2019 and 2018.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates expected to be in effect during the year in which the basis differences reverse. Valuation allowances are established when management determines it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. For further discussion and disclosure, see Note </span><span style="font-family:Arial;font-size:10pt;">13</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Income Taxes</span><span style="font-family:Arial;font-size:10pt;">.”</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Taxes Based on Premiums</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Health Insurer Fee (“HIF”). </span><span style="font-family:Arial;font-size:10pt;">The federal government under the ACA imposes an annual fee, or excise tax, on health insurers for each calendar year. The HIF is based on a company’s share of the industry’s net premiums written during the preceding calendar year and is non-deductible for income tax purposes. We recognize expense for the HIF over the year on a straight-line basis. Within our Medicaid program, we must secure additional reimbursement from our state partners for this added cost. We recognize the related revenue when we have obtained a contractual commitment or payment from a state to reimburse us for the HIF, and such HIF revenue is recognized ratably throughout the year. The Consolidated Appropriations Act of 2016 provided for the HIF moratorium in 2017, and Public Law No. 115-120 provided for the HIF moratorium in 2019. Therefore, there were no health insurer fees reimbursed, nor health insurer fees incurred, in those years.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Premium and Use Tax. </span><span style="font-family:Arial;font-size:10pt;">Certain of our health plans are assessed a tax based on premium revenue collected. The premium revenues we receive from these states include the premium tax assessment. We have reported these taxes on a gross basis, as premium tax revenue and as premium tax expenses in the consolidated statements of operations. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years, or less than</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>10 years</span></span><span style="font-family:Arial;font-size:10pt;"> average life for structured securities.</span><span style="font-family:Arial;font-size:10pt;"> Restricted investments are invested principally in cash, cash equivalents and U.S. Treasury securities. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate. See further information below, under “Recent Accounting Pronouncements Not Yet Adopted” regarding our adoption of ASU 2016-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Arial;font-size:10pt;">, effective January 1, 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Risks and Uncertainties</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our profitability depends in large part on our ability to accurately predict and effectively manage medical care costs. We continually review our medical costs in light of our underlying claims experience and revised actuarial data. However, several factors could adversely affect medical care costs. These factors, which include changes in health care practices, inflation, new technologies, major epidemics, natural disasters, and malpractice litigation, are beyond our control and may have an adverse effect on our ability to accurately predict and effectively control medical care costs. Costs in excess of those anticipated could have a material adverse effect on our financial condition, results of operations, or cash flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We operate health plans primarily as a direct contractor with the states (or Commonwealth), and in Los Angeles County, California, as a subcontractor to another health plan holding a direct contract with the state. We are therefore dependent upon a small number of contracts to support our revenue. The loss of any one of those contracts could have a material adverse effect on our financial position, results of operations, or cash flows. In addition, our ability to arrange for the provision of medical services to our members is dependent upon our ability to develop and maintain adequate provider networks. Our inability to develop or maintain such networks might, in certain circumstances, have a material adverse effect on our financial position, results of operations, or cash flows.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Adopted</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases. </span><span style="font-family:Arial;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (“FASB”) issued Topic 842, which was subsequently modified by several ASUs issued in 2017 and 2018. Topic 842 was issued to increase transparency and comparability among organizations by requiring the recognition of ROU assets and lease liabilities on the balance sheet. Most prominent among the changes in Topic 842 is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. In addition, Topic 842’s disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. Topic 842’s transition provisions are applied using a modified retrospective approach; entities may elect whether to apply the transition provisions, including disclosure requirements, at the beginning of the earliest comparative period presented or on the adoption date.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We adopted Topic 842 effective January 1, 2019, and elected to apply the transition provisions as of that date. Accordingly, we recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings on January 1, 2019. In addition, we elected the available practical expedients and implemented internal controls and information systems functionality to enable the preparation of financial information on adoption. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As indicated in the accompanying consolidated statements of stockholders’ equity, the cumulative effect adjustment was an increase of </span><span style="font-family:Arial;font-size:10pt;"><span>$85 million</span></span><span style="font-family:Arial;font-size:10pt;"> to retained earnings (</span><span style="font-family:Arial;font-size:10pt;"><span>$110 million</span></span><span style="font-family:Arial;font-size:10pt;">, net of </span><span style="font-family:Arial;font-size:10pt;"><span>$25 million</span></span><span style="font-family:Arial;font-size:10pt;"> deferred income tax expense), relating primarily to the transition provisions for sale-leaseback arrangements that did not qualify for sale treatment. Accordingly, such arrangements were de-recognized and recorded as finance lease ROU assets and lease liabilities. The difference between the de-recognized assets and lease financing obligations resulted in an increase to retained earnings. The recognition of these arrangements as finance lease ROU assets and lease liabilities will not materially impact our consolidated results of operations over the terms of the leases.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Software Licenses. </span><span style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, </span><span style="font-family:Arial;font-size:10pt;">which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. We early adopted ASU 2018-15 effective January 1, 2019, using the prospective method</span><span style="font-family:Times New Roman;font-size:11pt;">, </span><span style="font-family:Arial;font-size:10pt;">with no material impact to our financial condition, results of operations or cash flows. Adoption of this guidance may be significant to us in the future depending on the extent to which we use cloud computing arrangements that qualify as service contracts. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Credit Losses.</span><span style="font-family:Arial;font-size:10pt;"> In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Arial;font-size:10pt;">, which was subsequently modified by several ASUs issued in 2018 and 2019. This standard introduces a new current expected credit loss (“CECL”) model for measuring expected credit losses for certain types of financial instruments measured at amortized cost and replaces the incurred loss model. The CECL model requires an entity to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount the entity expects to collect over the instrument’s contractual life after consideration of historical experience, current conditions, and reasonable and supportable forecasts. This standard also introduces targeted changes to the AFS debt securities impairment model. It eliminates the concept of other-than-temporary impairment and requires an entity to determine whether any impairment is the result of a credit loss or other factors. We will adopt Topic 326 effective January 1, 2020, using the modified retrospective approach. Under this method we will recognize the cumulative effect of adopting the standard as an adjustment to the opening balance of retained earnings on January 1, 2020. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Under Topic 326, we will record an allowance for credit losses for financial assets subject to the CECL model. The most significant type of financial instrument reported in our consolidated balance sheets, subject to the CECL model, is “Receivables.” As of December 31, 2019, approximately </span><span style="font-family:Arial;font-size:10pt;"><span>75%</span></span><span style="font-family:Arial;font-size:10pt;">, or </span><span style="font-family:Arial;font-size:10pt;"><span>$1,056 million</span></span><span style="font-family:Arial;font-size:10pt;"> of the receivables balance constitutes receivables from state and federal government agencies. Based on our analysis, we believe that the credit risk associated with such receivables is nominal due to a very low risk of default. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The AFS debt securities impairment model will apply to “Investments” reported in our consolidated balance sheets. We believe that the credit risk associated with our non-government issued Investments is nominal due to the high quality of such investments. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The adoption of Topic 326 will be immaterial to our consolidated results of operations and financial condition.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of </span><span style="font-family:Arial;font-size:10pt;">three months or less</span><span style="font-family:Arial;font-size:10pt;"> on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets. </span></div> The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets. <div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted cash and cash equivalents, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted cash and cash equivalents, current </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,508</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,926</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,290</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets. <div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted cash and cash equivalents, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted cash and cash equivalents, current </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,508</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,926</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,290</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 2452000000 2826000000 3186000000 56000000 100000000 95000000 0 0 9000000 2508000000 2926000000 3290000000 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Investments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (“AFS”) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders’ equity as other comprehensive income, net of applicable income taxes. Held-to-maturity securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses and unrealized losses judged to be other than temporary with respect to available-for-sale and held-to-maturity securities are included in the determination of net income (loss). The cost of securities sold is determined using the specific-identification method.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our investment policy requires that all of our investments have final maturities of less than </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years, or less than</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>10 years</span></span><span style="font-family:Arial;font-size:10pt;"> average life for structured securities.</span><span style="font-family:Arial;font-size:10pt;"> Investments and restricted investments are subject to interest rate risk </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income. </span></div>In general, our AFS securities are classified as current assets without regard to the securities’ contractual maturity dates because they may be readily liquidated. We monitor our investments for other-than-temporary impairment. P10Y P10Y <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Long-Lived Assets, including Intangible Assets</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-lived assets consist primarily of property, equipment, capitalized software (see Note </span><span style="font-family:Arial;font-size:10pt;">7</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Property, Equipment, and Capitalized Software, Net</span><span style="font-family:Arial;font-size:10pt;">”), and intangible assets resulting from acquisitions. </span><span style="font-family:Arial;font-size:10pt;">Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts).</span><span style="font-family:Arial;font-size:10pt;"> Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between </span><span style="font-family:Arial;font-size:10pt;">five</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>15</span></span><span style="font-family:Arial;font-size:10pt;"> years. </span></div><span style="font-family:Arial;font-size:10pt;">Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset’s (or asset group’s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed.</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment.</span> <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Long-Lived Assets, including Intangible Assets</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-lived assets consist primarily of property, equipment, capitalized software (see Note </span><span style="font-family:Arial;font-size:10pt;">7</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Property, Equipment, and Capitalized Software, Net</span><span style="font-family:Arial;font-size:10pt;">”), and intangible assets resulting from acquisitions. </span><span style="font-family:Arial;font-size:10pt;">Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts).</span><span style="font-family:Arial;font-size:10pt;"> Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between </span><span style="font-family:Arial;font-size:10pt;">five</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>15</span></span><span style="font-family:Arial;font-size:10pt;"> years. </span></div><span style="font-family:Arial;font-size:10pt;">Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset’s (or asset group’s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed.</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment.</span><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment are stated at historical cost. Replacements and major improvements are capitalized, and repairs and maintenance are charged to expense as incurred. Furniture and equipment are generally depreciated using the straight-line method over estimated useful lives ranging from three to </span><span style="font-family:Arial;font-size:10pt;"><span>seven years</span></span><span style="font-family:Arial;font-size:10pt;">. Software developed for internal use is capitalized. Software is generally amortized over its estimated useful life of </span><span style="font-family:Arial;font-size:10pt;"><span>three years</span></span><span style="font-family:Arial;font-size:10pt;">. Leasehold improvements are amortized over the term of the lease, or over their useful lives from </span><span style="font-family:Arial;font-size:10pt;">five</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years, whichever is shorter. Buildings are depreciated over their estimated useful lives of </span><span style="font-family:Arial;font-size:10pt;"><span>31.5</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>40</span></span><span style="font-family:Arial;font-size:10pt;"> years.</span></div> P15Y <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Right-of-use (“ROU”) assets represent our right to use the underlying assets over the lease term, and lease liabilities represent our obligation for lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. If applicable, we account for lease and non-lease components within a lease as a single lease component.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Because most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Finance lease payments reduce finance lease liabilities, the related ROU assets are amortized on a straight-line basis over the lease term, and interest expense is recognized using the effective interest method.</span></div>The significant majority of our operating leases consist of long-term operating leases for office space. Short-term leases (those with terms of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. For certain leases that represent a portfolio of similar assets, such as a fleet of vehicles, we apply a portfolio approach to account for the related ROU assets and liabilities, rather than account for such assets and the related liabilities individually. A nominal number of our lease agreements include rental payments that adjust periodically for inflation. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Business Combinations</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment on an annual basis and more frequently if impairment indicators are present. Such events or circumstances may include experienced or expected operating cash-flow deterioration or losses, significant losses of membership, loss of state funding, loss of state contracts, and other factors. Goodwill is impaired if the carrying amount of the reporting unit (one of our state health plans) </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit.</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, the dynamic economic and political environments in which we operate, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. If our qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, we perform the quantitative assessment. We may also elect to bypass the qualitative assessment and proceed directly to the quantitative assessment. If performing a quantitative assessment, we generally estimate the fair values of our reporting units by applying the income approach, using discounted cash flows. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the annual impairment test under a quantitative assessment, the base year in the reporting units’ discounted cash flows is derived from the annual financial planning cycle, which commences in the fourth quarter of the year. When computing discounted cash flows, we make assumptions about a wide variety of internal and external factors, and consider what the reporting unit’s selling price would be in an orderly transaction between market participants at the measurement date. Significant assumptions include financial projections of free cash flow (including significant assumptions about membership, premium rates, healthcare and operating cost trends, contract renewal and the procurement of new contracts, capital requirements and income taxes), long-term growth rates for determining terminal value beyond the discretely forecasted periods, and discount rates. When determining the discount rate, we consider the overall level of inherent risk of the reporting unit, and the expected rate an outside investor would expect to earn. As part of a quantitative assessment, we may also apply the asset liquidation method to estimate the fair value of individual reporting units, which is computed as total assets minus total liabilities, excluding intangible assets and deferred taxes. Finally, we apply a market approach to reconcile the value of our reporting units to our consolidated market value. Under the market approach, we consider publicly traded comparable company information to determine revenue and earnings multiples which are used to estimate our reporting units’ fair values. The assumptions used are consistent with those used in our long-range business plan and annual planning process. However, if these assumptions differ from actual results, the outcome of our goodwill impairment tests could be adversely affected. </span></div>Accounting for business combinations requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within our consolidated statements of operations. <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Premium Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Premium revenue is generated from our Health Plans segment contracts, including agreements with other managed care organizations for which we operate as a subcontractor. Premium revenue is generally received based on per member per month (“PMPM”) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. The state Medicaid programs and the federal Medicare program periodically adjust premiums. Additionally, many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes premium revenue by health plan for the periods presented:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">% of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">% of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">% of Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Dollars in millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">California</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Florida</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>734</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,790</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Illinois </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,002</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>793</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Michigan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,601</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">New Mexico </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,356</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ohio</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,553</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,388</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Puerto Rico</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>474</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">South Carolina</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>583</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>445</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Texas</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,813</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Washington</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,361</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,608</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,286</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>738</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,612</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">_______________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">“Other” includes the Idaho, Mississippi, New York, Utah and Wisconsin health plans, which are not individually significant to our consolidated operating results.</span><span style="font-family:Arial;font-size:9pt;"> In 2019, “Other” also includes the New Mexico health plan. The New Mexico health plan’s Medicaid contract terminated on December 31, 2018, and therefore its results are not individually significant to our consolidated operating results in 2019. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certain components of premium revenue are subject to accounting estimates and fall into the following categories: </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Medicaid Program</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Medical Cost Floors (Minimums), and Medical Cost Corridors. </span><span style="font-family:Arial;font-size:10pt;">A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. In the aggregate, we recorded liabilities under the terms of such contract provisions of </span><span style="font-family:Arial;font-size:10pt;"><span>$74 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$103 million</span></span><span style="font-family:Arial;font-size:10pt;"> at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, respectively. Approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$69 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$87 million</span></span><span style="font-family:Arial;font-size:10pt;"> of the liabilities accrued at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, respectively, relates to our participation in Medicaid Expansion programs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In certain circumstances, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold. Receivables relating to such provisions were insignificant at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Profit Sharing and Profit Ceiling.</span><span style="font-family:Arial;font-size:10pt;"> Our contracts with certain states contain profit-sharing or profit ceiling provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any. Liabilities for profits in excess of the amount we are allowed to retain under these provisions were insignificant at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Retroactive Premium Adjustments. </span><span style="font-family:Arial;font-size:10pt;">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we must adjust our premium revenue in the period in which we learn of the adjustment, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Medicare Program</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Risk Adjusted Premiums:</span><span style="font-family:Arial;font-size:10pt;"> Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members’ risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members’ health status, risk scores and CMS practices. Consolidated balance sheet amounts related to anticipated Medicare risk adjusted premiums and Medicare Part D settlements were insignificant at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Minimum MLR:</span><span style="font-family:Arial;font-size:10pt;"> The Affordable Care Act (“ACA”) has established a minimum annual medical loss ratio (“Minimum MLR”) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations. The amounts payable for the Medicare Minimum MLR were insignificant at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Marketplace Program</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Risk Adjustment:</span><span style="font-family:Arial;font-size:10pt;"> Under this program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of operations. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, Marketplace risk adjustment payables amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$368 million</span></span><span style="font-family:Arial;font-size:10pt;"> and related receivables amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$63 million</span></span><span style="font-family:Arial;font-size:10pt;">, for a net payable of </span><span style="font-family:Arial;font-size:10pt;"><span>$305 million</span></span><span style="font-family:Arial;font-size:10pt;">. As of December 31, 2018, Marketplace risk adjustment payables amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$466 million</span></span><span style="font-family:Arial;font-size:10pt;"> and related receivables amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$34 million</span></span><span style="font-family:Arial;font-size:10pt;">, for a net payable of </span><span style="font-family:Arial;font-size:10pt;"><span>$432 million</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Minimum MLR:</span><span style="font-family:Arial;font-size:10pt;"> The ACA has established a Minimum MLR of </span><span style="font-family:Arial;font-size:10pt;">80%</span><span style="font-family:Arial;font-size:10pt;"> for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations. Aggregate balance sheet amounts related to the Minimum MLR were insignificant at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and December 31, 2018. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of the categories of amounts due government agencies is as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medicaid program:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medical cost floors and corridors</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other amounts due to states</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Marketplace program:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Risk adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost sharing reduction</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>664</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>967</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Quality Incentives</span></div><span style="font-family:Arial;font-size:10pt;">At many of our health plans, revenue ranging from approximately </span><span style="font-family:Arial;font-size:10pt;"><span>1%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>4%</span></span> of certain health plan premiums is earned only if certain performance measures are met <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes premium revenue by health plan for the periods presented:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:17%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">% of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">% of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">% of Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Dollars in millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">California</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Florida</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>734</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,790</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Illinois </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,002</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>793</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Michigan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,601</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">New Mexico </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,356</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ohio</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,553</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,388</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Puerto Rico</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>474</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>732</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">South Carolina</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>583</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>445</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Texas</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,813</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Washington</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,361</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,608</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,286</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>738</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,612</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">_______________________</span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div><span style="font-family:Arial;font-size:9pt;">“Other” includes the Idaho, Mississippi, New York, Utah and Wisconsin health plans, which are not individually significant to our consolidated operating results.</span> In 2019, “Other” also includes the New Mexico health plan. The New Mexico health plan’s Medicaid contract terminated on December 31, 2018, and therefore its results are not individually significant to our consolidated operating results in 2019. 2266000000 0.140 2150000000 0.122 2701000000 0.143 734000000 0.045 1790000000 0.102 2568000000 0.136 1002000000 0.062 793000000 0.045 593000000 0.031 1624000000 0.100 1601000000 0.091 1596000000 0.085 0 0 1356000000 0.077 1368000000 0.073 2553000000 0.158 2388000000 0.136 2216000000 0.118 474000000 0.029 696000000 0.039 732000000 0.039 583000000 0.036 495000000 0.028 445000000 0.024 2991000000 0.185 3244000000 0.184 2813000000 0.149 2695000000 0.166 2361000000 0.134 2608000000 0.138 1286000000 0.079 738000000 0.042 1214000000 0.064 16208000000 1.000 17612000000 1.000 18854000000 1.000 74000000 103000000 69000000 87000000 -368000000 63000000 305000000 -466000000 34000000 432000000 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of the categories of amounts due government agencies is as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medicaid program:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medical cost floors and corridors</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other amounts due to states</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Marketplace program:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Risk adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost sharing reduction</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>664</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>967</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 74000000 103000000 84000000 81000000 368000000 466000000 0 183000000 138000000 134000000 664000000 967000000 0.01 0.04 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Maximum available quality incentive premium - current period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amount of quality incentive premium revenue recognized in current period:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Earned current period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Earned prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Quality incentive premium revenue recognized as a percentage of total premium revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 186000000 182000000 150000000 156000000 133000000 97000000 38000000 31000000 10000000 194000000 164000000 107000000 0.012 0.009 0.006 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Medical Care Costs, Medical Claims and Benefits Payable</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;">Medical care costs are recognized in the period in which services are provided and include fee-for-service claims, pharmacy benefits, capitation payments to providers, and various other medically-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Such medical care costs include amounts paid by us as well as estimated medical claims and benefits payable for costs that were incurred but not paid as of the reporting date (“IBNP”). Pharmacy benefits represent payments for members' prescription drug costs, net of rebates from drug manufacturers. We estimate pharmacy rebates based on historical and current utilization of prescription drugs and contractual provisions. Capitation payments represent monthly contractual fees paid to providers, who are responsible for providing medical care to members, which could include medical or ancillary costs like dental, vision and other supplemental health benefits. Such capitation costs are fixed in advance of the periods covered and are not subject to significant accounting estimates. Other medical care costs include all medically-related administrative costs, amounts due to providers pursuant to risk-sharing or other incentive arrangements, provider claims, and other healthcare expenses. Examples of medically-related administrative costs include expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses. Additionally, we include an estimate for the cost of settling claims incurred through the reporting date in our medical claims and benefits payable liability</span><span style="font-family:Times New Roman;">.</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;">Medical claims and benefits payable consist mainly of fee-for-service IBNP, unpaid pharmacy claims, capitation costs, other medical costs, including amounts payable to providers pursuant to risk-sharing or other incentive arrangements and amounts payable to providers on behalf of certain state agencies for certain state assessments in which we assume no financial risk</span><span style="font-family:Times New Roman;">. </span><span style="font-family:Arial;">IBNP includes the costs of claims incurred as of the balance sheet date which have been reported to us, and our best estimate of the cost of claims incurred but not yet reported to us. We also include an additional reserve to ensure that our overall IBNP liability is sufficient under moderately adverse conditions. We reflect changes in these estimates in the consolidated results of operations in the period in which they are determined.</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors and the assumed healthcare cost trend to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. Each reporting period, the recognized IBNP liability represents our best estimate of the total amount of unpaid claims incurred as of the balance sheet date using a consistent methodology in estimating our IBNP liability. We believe our current estimates are reasonable and adequate; however, the development of our estimate is a continuous process that we monitor and update as more complete claims payment information and healthcare cost trend data becomes available. Actual medical care costs may be less than we previously estimated (favorable development) or more than we previously estimated (unfavorable development), and any differences could be material. Any adjustments to reflect favorable development would be </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">recognized as a decrease to medical care costs, and any adjustments to reflect unfavorable development would be recognized as an increase to medical care costs</span><span style="font-family:Times New Roman;font-size:10pt;">,</span><span style="font-family:Arial;font-size:10pt;"> in the period in which the adjustments are determined. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Refer to Note </span><span style="font-family:Arial;font-size:10pt;">10</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Medical Claims and Benefits Payable</span><span style="font-family:Arial;font-size:10pt;">,” for a table presenting the components of the change in our medical claims and benefits payable, for all periods presented in the accompanying consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Reinsurance</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We limit our risk of catastrophic losses by maintaining high deductible reinsurance coverage. Such reinsurance coverage does not relieve us of our primary obligation to our policyholders. We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. Reinsurance premiums amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$17 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$16 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended December 31, 2019, 2018, and 2017, respectively. Reinsurance recoveries amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$18 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$33 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$24 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended December 31, 2019, 2018, and 2017, respectively. Reinsurance recoverable of </span><span style="font-family:Arial;font-size:10pt;"><span>$21 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$31 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$16 million</span></span><span style="font-family:Arial;font-size:10pt;">, as of December 31, 2019, 2018, and 2017, respectively, is included in “Receivables” in the accompanying consolidated balance sheets.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Marketplace Cost Share Reduction (“CSR”)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the year ended December 31, 2018, we recognized a benefit of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:10pt;"> in reduced medical care costs related to 2017 dates of service, as a result of the federal government’s confirmation that the reconciliation of 2017 Marketplace CSR subsidies would be performed on an annual basis. In the fourth quarter of 2017, we had assumed a nine-month reconciliation of this item pending confirmation of the time period to which the 2017 reconciliation would be applied. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Premium Deficiency Reserves on Loss Contracts</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We assess the profitability of our contracts to determine if it is probable that a loss will be incurred in the future by reviewing current results and forecasts. For purposes of this assessment, contracts are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. A premium deficiency is recognized if anticipated future medical care and administrative costs exceed anticipated future premium revenue, investment income and reinsurance recoveries. No premium deficiency reserves were recorded as of December 31, 2019 and 2018.</span></div> 17000000 16000000 20000000 18000000 33000000 24000000 21000000 31000000 16000000 81000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Income Taxes</span></div>We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates expected to be in effect during the year in which the basis differences reverse. Valuation allowances are established when management determines it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Taxes Based on Premiums</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Health Insurer Fee (“HIF”). </span><span style="font-family:Arial;font-size:10pt;">The federal government under the ACA imposes an annual fee, or excise tax, on health insurers for each calendar year. The HIF is based on a company’s share of the industry’s net premiums written during the preceding calendar year and is non-deductible for income tax purposes. We recognize expense for the HIF over the year on a straight-line basis. Within our Medicaid program, we must secure additional reimbursement from our state partners for this added cost. We recognize the related revenue when we have obtained a contractual commitment or payment from a state to reimburse us for the HIF, and such HIF revenue is recognized ratably throughout the year. The Consolidated Appropriations Act of 2016 provided for the HIF moratorium in 2017, and Public Law No. 115-120 provided for the HIF moratorium in 2019. Therefore, there were no health insurer fees reimbursed, nor health insurer fees incurred, in those years.</span></div><span style="font-family:Arial;font-size:10pt;font-style:italic;">Premium and Use Tax. </span>Certain of our health plans are assessed a tax based on premium revenue collected. The premium revenues we receive from these states include the premium tax assessment. We have reported these taxes on a gross basis, as premium tax revenue and as premium tax expenses in the consolidated statements of operations. <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years, or less than</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>10 years</span></span><span style="font-family:Arial;font-size:10pt;"> average life for structured securities.</span><span style="font-family:Arial;font-size:10pt;"> Restricted investments are invested principally in cash, cash equivalents and U.S. Treasury securities. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate. See further information below, under “Recent Accounting Pronouncements Not Yet Adopted” regarding our adoption of ASU 2016-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Arial;font-size:10pt;">, effective January 1, 2020.</span></div> P10Y P10Y <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Risks and Uncertainties</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our profitability depends in large part on our ability to accurately predict and effectively manage medical care costs. We continually review our medical costs in light of our underlying claims experience and revised actuarial data. However, several factors could adversely affect medical care costs. These factors, which include changes in health care practices, inflation, new technologies, major epidemics, natural disasters, and malpractice litigation, are beyond our control and may have an adverse effect on our ability to accurately predict and effectively control medical care costs. Costs in excess of those anticipated could have a material adverse effect on our financial condition, results of operations, or cash flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We operate health plans primarily as a direct contractor with the states (or Commonwealth), and in Los Angeles County, California, as a subcontractor to another health plan holding a direct contract with the state. We are therefore dependent upon a small number of contracts to support our revenue. The loss of any one of those contracts could have a material adverse effect on our financial position, results of operations, or cash flows. In addition, our ability to arrange for the provision of medical services to our members is dependent upon our ability to develop and maintain adequate provider networks. Our inability to develop or maintain such networks might, in certain circumstances, have a material adverse effect on our financial position, results of operations, or cash flows.</span></div> <div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Adopted</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases. </span><span style="font-family:Arial;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (“FASB”) issued Topic 842, which was subsequently modified by several ASUs issued in 2017 and 2018. Topic 842 was issued to increase transparency and comparability among organizations by requiring the recognition of ROU assets and lease liabilities on the balance sheet. Most prominent among the changes in Topic 842 is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. In addition, Topic 842’s disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. Topic 842’s transition provisions are applied using a modified retrospective approach; entities may elect whether to apply the transition provisions, including disclosure requirements, at the beginning of the earliest comparative period presented or on the adoption date.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We adopted Topic 842 effective January 1, 2019, and elected to apply the transition provisions as of that date. Accordingly, we recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings on January 1, 2019. In addition, we elected the available practical expedients and implemented internal controls and information systems functionality to enable the preparation of financial information on adoption. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As indicated in the accompanying consolidated statements of stockholders’ equity, the cumulative effect adjustment was an increase of </span><span style="font-family:Arial;font-size:10pt;"><span>$85 million</span></span><span style="font-family:Arial;font-size:10pt;"> to retained earnings (</span><span style="font-family:Arial;font-size:10pt;"><span>$110 million</span></span><span style="font-family:Arial;font-size:10pt;">, net of </span><span style="font-family:Arial;font-size:10pt;"><span>$25 million</span></span><span style="font-family:Arial;font-size:10pt;"> deferred income tax expense), relating primarily to the transition provisions for sale-leaseback arrangements that did not qualify for sale treatment. Accordingly, such arrangements were de-recognized and recorded as finance lease ROU assets and lease liabilities. The difference between the de-recognized assets and lease financing obligations resulted in an increase to retained earnings. The recognition of these arrangements as finance lease ROU assets and lease liabilities will not materially impact our consolidated results of operations over the terms of the leases.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Software Licenses. </span><span style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, </span><span style="font-family:Arial;font-size:10pt;">which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. We early adopted ASU 2018-15 effective January 1, 2019, using the prospective method</span><span style="font-family:Times New Roman;font-size:11pt;">, </span><span style="font-family:Arial;font-size:10pt;">with no material impact to our financial condition, results of operations or cash flows. Adoption of this guidance may be significant to us in the future depending on the extent to which we use cloud computing arrangements that qualify as service contracts. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Credit Losses.</span><span style="font-family:Arial;font-size:10pt;"> In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Arial;font-size:10pt;">, which was subsequently modified by several ASUs issued in 2018 and 2019. This standard introduces a new current expected credit loss (“CECL”) model for measuring expected credit losses for certain types of financial instruments measured at amortized cost and replaces the incurred loss model. The CECL model requires an entity to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount the entity expects to collect over the instrument’s contractual life after consideration of historical experience, current conditions, and reasonable and supportable forecasts. This standard also introduces targeted changes to the AFS debt securities impairment model. It eliminates the concept of other-than-temporary impairment and requires an entity to determine whether any impairment is the result of a credit loss or other factors. We will adopt Topic 326 effective January 1, 2020, using the modified retrospective approach. Under this method we will recognize the cumulative effect of adopting the standard as an adjustment to the opening balance of retained earnings on January 1, 2020. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Under Topic 326, we will record an allowance for credit losses for financial assets subject to the CECL model. The most significant type of financial instrument reported in our consolidated balance sheets, subject to the CECL model, is “Receivables.” As of December 31, 2019, approximately </span><span style="font-family:Arial;font-size:10pt;"><span>75%</span></span><span style="font-family:Arial;font-size:10pt;">, or </span><span style="font-family:Arial;font-size:10pt;"><span>$1,056 million</span></span><span style="font-family:Arial;font-size:10pt;"> of the receivables balance constitutes receivables from state and federal government agencies. Based on our analysis, we believe that the credit risk associated with such receivables is nominal due to a very low risk of default. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The AFS debt securities impairment model will apply to “Investments” reported in our consolidated balance sheets. We believe that the credit risk associated with our non-government issued Investments is nominal due to the high quality of such investments. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The adoption of Topic 326 will be immaterial to our consolidated results of operations and financial condition.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div> 85000000 110000000 25000000 0.75 1056000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Net Income (Loss) Per Share</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table sets forth the calculation of basic and diluted net income (loss) per share:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions, except net income (loss) per share)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>737</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(512</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Shares outstanding at the beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>59.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average number of shares issued:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exchange of convertible senior notes </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Conversion of convertible senior notes </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator for basic net income (loss) per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Warrants </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible senior notes </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator for diluted net income (loss) per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>66.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss) per share: </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.85</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.57</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.61</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Potentially dilutive common shares excluded from calculations: </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Warrants</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible senior notes </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">_______________________________ </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">“Convertible senior notes” in this table refer to the </span><span style="font-family:Arial;font-size:9pt;"><span>1.625%</span></span><span style="font-family:Arial;font-size:9pt;"> convertible senior notes due 2044 that were settled in 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For more information regarding the warrants, including partial termination transactions, refer to Note </span><span style="font-family:Arial;font-size:9pt;">14</span><span style="font-family:Arial;font-size:9pt;">, “</span><span style="font-family:Arial;font-size:9pt;">Stockholders' Equity</span><span style="font-family:Arial;font-size:9pt;">.” The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. Certain potentially dilutive common shares issuable are not included in the computation of diluted net income (loss) per share because to do so would have been anti-dilutive.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(3)</span></div>Source data for calculations in thousands. <div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table sets forth the calculation of basic and diluted net income (loss) per share:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions, except net income (loss) per share)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>737</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(512</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Shares outstanding at the beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>59.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average number of shares issued:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exchange of convertible senior notes </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Conversion of convertible senior notes </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator for basic net income (loss) per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Warrants </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible senior notes </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator for diluted net income (loss) per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>66.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss) per share: </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.85</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.57</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10.61</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Potentially dilutive common shares excluded from calculations: </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Warrants</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible senior notes </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">_______________________________ </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">“Convertible senior notes” in this table refer to the </span><span style="font-family:Arial;font-size:9pt;"><span>1.625%</span></span><span style="font-family:Arial;font-size:9pt;"> convertible senior notes due 2044 that were settled in 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For more information regarding the warrants, including partial termination transactions, refer to Note </span><span style="font-family:Arial;font-size:9pt;">14</span><span style="font-family:Arial;font-size:9pt;">, “</span><span style="font-family:Arial;font-size:9pt;">Stockholders' Equity</span><span style="font-family:Arial;font-size:9pt;">.” The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. Certain potentially dilutive common shares issuable are not included in the computation of diluted net income (loss) per share because to do so would have been anti-dilutive.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(3)</span></div>Source data for calculations in thousands. 737000000 707000000 -512000000 62100000 59300000 55800000 0 1400000 100000 0 200000 0 100000 200000 500000 62200000 61100000 56400000 1400000 4800000 0 0 400000 0 600000 300000 0 64200000 66600000 56400000 11.85 11.57 -9.07 11.47 10.61 -9.07 0 0 1900000 0 0 400000 0 0 300000 0.01625 <span style="color:#828282;font-family:Arial;font-size:14pt;">Fair Value Measurements</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We consider the carrying amounts of current assets and current liabilities (not including derivatives and the current portion of long-term debt) to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to a three-tier fair value hierarchy as follows:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Level 1 — Observable Inputs.</span><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:Arial;font-size:10pt;">Level 1 financial instruments are actively traded and therefore the fair value for these securities is based on quoted market prices for identical securities in active markets.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Level 2 — Directly or Indirectly Observable Inputs. </span><span style="font-family:Arial;font-size:10pt;">Fair value for these investments is determined using a market approach based on quoted prices for similar securities in active markets or quoted prices for identical securities in inactive markets. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Level 3 — Unobservable Inputs. </span><span style="font-family:Arial;font-size:10pt;">Level 3 financial instruments are valued using unobservable inputs that represent management’s best estimate of what market participants would use in pricing the financial instrument at the measurement date. Our Level 3 financial instruments consist primarily of derivative financial instruments. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The derivatives include the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Call Option derivative asset and the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Conversion Option derivative liability (for detailed descriptions of these instruments, see Note </span><span style="font-family:Arial;font-size:10pt;">12</span><span style="font-family:Arial;font-size:10pt;">. “</span><span style="font-family:Arial;">Derivatives</span><span style="font-family:Arial;font-size:10pt;">”). These derivatives are not actively traded and are valued based on an option pricing model that uses observable and unobservable market data for inputs. Significant market data inputs used to determine fair value as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, included the price of our common stock, the time to maturity of the derivative instruments, the risk-free interest rate, and the implied volatility of our common stock. The </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Call Option asset and the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Conversion Option liability were designed such that changes in their fair values offset, with minimal impact to the consolidated statements of operations. Therefore, the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is mitigated. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The net changes in fair value of Level 3 financial instruments were insignificant to our results of operations for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and 2018.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our financial instruments measured at fair value on a recurring basis at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, were as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Treasury notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Government-sponsored enterprise securities (“GSEs”)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Call Option derivative asset</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,975</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,946</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Conversion Option derivative liability </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our financial instruments measured at fair value on a recurring basis at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, were as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Treasury notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">GSEs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,681</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,681</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Call Option derivative asset</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,157</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Conversion Option derivative liability </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements – Disclosure Only</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets. The carrying amount and estimated fair value of the Term Loan Facility is classified as a Level 3 financial instrument, because certain inputs used to determine its fair value are not observable. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the carrying amount of the Term Loan Facility approximated fair value because its interest rate is a variable rate that approximates rates currently available to us. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Carrying</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Carrying</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5.375% Notes </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>674</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.875% Notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>301</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Term Loan Facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Convertible Notes </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>732</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,347</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">_______________________________ </span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1) </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The fair value of the </span><span style="font-family:Arial;font-size:9pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:9pt;"> Conversion Option (the embedded cash conversion option), which is reflected in the fair value amounts presented above, amounted to </span><span style="font-family:Arial;font-size:9pt;"><span>$29 million</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>$476 million</span></span><span style="font-family:Arial;font-size:9pt;"> as of December 31, 2019 and 2018, respectively. For more information, including information on debt repayments in 2019 and 2020, see Note </span><span style="font-family:Arial;font-size:9pt;">11</span><span style="font-family:Arial;font-size:9pt;">, “</span><span style="font-family:Arial;font-size:9pt;">Debt</span><span style="font-family:Arial;font-size:9pt;">,” and Note </span><span style="font-family:Arial;font-size:9pt;">12</span><span style="font-family:Arial;font-size:9pt;">, “</span><span style="font-family:Arial;font-size:9pt;">Derivatives</span><span style="font-family:Arial;font-size:9pt;">.”</span></div> 0.01125 0.01125 0.01125 0.01125 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our financial instruments measured at fair value on a recurring basis at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, were as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Treasury notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Government-sponsored enterprise securities (“GSEs”)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Call Option derivative asset</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,975</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,946</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Conversion Option derivative liability </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our financial instruments measured at fair value on a recurring basis at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, were as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Treasury notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">GSEs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,681</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,681</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Call Option derivative asset</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,157</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Conversion Option derivative liability </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 1178000000 0 1178000000 0 420000000 0 420000000 0 127000000 0 127000000 0 86000000 0 86000000 0 78000000 0 78000000 0 49000000 0 49000000 0 7000000 0 7000000 0 1000000 0 1000000 0 1946000000 0 1946000000 0 29000000 0 0 29000000 1975000000 0 1946000000 29000000 29000000 0 0 29000000 29000000 0 0 29000000 1123000000 0 1123000000 0 82000000 0 82000000 0 181000000 0 181000000 0 114000000 0 114000000 0 163000000 0 163000000 0 4000000 0 4000000 0 14000000 0 14000000 0 1681000000 0 1681000000 0 476000000 0 0 476000000 2157000000 0 1681000000 476000000 476000000 0 0 476000000 476000000 0 0 476000000 As of <span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the carrying amount of the Term Loan Facility approximated fair value because its interest rate is a variable rate that approximates rates currently available to us. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Carrying</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Carrying</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5.375% Notes </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>674</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.875% Notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>301</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Term Loan Facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Convertible Notes </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>732</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,347</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">_______________________________ </span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1) </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The fair value of the </span><span style="font-family:Arial;font-size:9pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:9pt;"> Conversion Option (the embedded cash conversion option), which is reflected in the fair value amounts presented above, amounted to </span><span style="font-family:Arial;font-size:9pt;"><span>$29 million</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>$476 million</span></span><span style="font-family:Arial;font-size:9pt;"> as of December 31, 2019 and 2018, respectively. For more information, including information on debt repayments in 2019 and 2020, see Note </span><span style="font-family:Arial;font-size:9pt;">11</span><span style="font-family:Arial;font-size:9pt;">, “</span><span style="font-family:Arial;font-size:9pt;">Debt</span><span style="font-family:Arial;font-size:9pt;">,” and Note </span><span style="font-family:Arial;font-size:9pt;">12</span><span style="font-family:Arial;font-size:9pt;">, “</span><span style="font-family:Arial;font-size:9pt;">Derivatives</span><span style="font-family:Arial;font-size:9pt;">.”</span></div> 696000000 745000000 694000000 674000000 327000000 340000000 326000000 301000000 220000000 220000000 0 0 12000000 42000000 240000000 732000000 1255000000 1347000000 1260000000 1707000000 0.01125 29000000 476000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Investments</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Available-for-Sale Investments</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We consider all of our investments classified as current assets to be available-for-sale. The following tables summarize our current investments as of the dates indicated:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,174</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Treasury notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">GSEs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,946</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Treasury notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">GSEs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,692</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The contractual maturities of our current investments as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> are summarized below:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>957</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>962</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Due after five years through ten years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Due after ten years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,946</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$13 million</span></span><span style="font-family:Arial;font-size:10pt;"> in the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. Gross realized investment losses were insignificant in the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. Gross realized investment gains and losses for the years ended December 31, </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> were insignificant. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have determined that unrealized losses at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> are temporary in nature, because the change in market value for these securities resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">In a Continuous Loss Position</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">for Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">In a Continuous Loss Position</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">for 12 Months or More</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Number of Positions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Number of Positions</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Dollars in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">In a Continuous Loss Position</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">for Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">In a Continuous Loss Position</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">for 12 Months or More</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Number of Positions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Number of Positions</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Dollars in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>509</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">GSEs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>509</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>285</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>516</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Held-to-Maturity Investments</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pursuant to the regulations governing our Health Plans segment</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulation in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as “Restricted investments” in the accompanying consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value, and mature in one year or less. The following table presents the balances of restricted investments:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Florida</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">New Mexico</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ohio</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Puerto Rico </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total Health Plans segment</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> The following tables summarize our current investments as of the dates indicated:<div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,174</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Treasury notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">GSEs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,946</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Treasury notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">GSEs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,692</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 1174000000 5000000 1000000 1178000000 420000000 1000000 1000000 420000000 126000000 1000000 0 127000000 86000000 0 0 86000000 78000000 0 0 78000000 49000000 0 0 49000000 7000000 0 0 7000000 1000000 0 0 1000000 1941000000 7000000 2000000 1946000000 1131000000 0 8000000 1123000000 83000000 0 1000000 82000000 181000000 0 0 181000000 115000000 0 1000000 114000000 164000000 0 1000000 163000000 4000000 0 0 4000000 14000000 0 0 14000000 1692000000 0 11000000 1681000000 <div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The contractual maturities of our current investments as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> are summarized below:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>957</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>962</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Due after five years through ten years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Due after ten years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,946</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 453000000 453000000 957000000 962000000 171000000 171000000 360000000 360000000 1941000000 1946000000 13000000 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">In a Continuous Loss Position</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">for Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">In a Continuous Loss Position</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">for 12 Months or More</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Number of Positions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Number of Positions</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Dollars in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">In a Continuous Loss Position</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">for Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">In a Continuous Loss Position</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">for 12 Months or More</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Number of Positions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Number of Positions</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Dollars in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>509</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">GSEs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>509</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>285</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>516</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 222000000 1000000 167 0 0 0 143000000 1000000 72 0 0 0 365000000 2000000 239 0 0 0 509000000 3000000 285 412000000 5000000 298 0 0 0 68000000 1000000 52 0 0 0 87000000 1000000 90 0 0 0 127000000 1000000 76 509000000 3000000 285 694000000 8000000 516 The following table presents the balances of restricted investments:<div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Florida</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">New Mexico</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ohio</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Puerto Rico </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total Health Plans segment</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 12000000 32000000 21000000 43000000 12000000 12000000 11000000 10000000 23000000 23000000 79000000 120000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Receivables</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Receivables consist primarily of amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for doubtful accounts is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made. </span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Government receivables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,056</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pharmacy rebate receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Health insurer fee reimbursement receivables</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,406</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> Receivables consist primarily of amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for doubtful accounts is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made. <div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Government receivables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,056</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pharmacy rebate receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Health insurer fee reimbursement receivables</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,406</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 1056000000 872000000 150000000 146000000 5000000 141000000 195000000 171000000 1406000000 1330000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Property, Equipment, and Capitalized Software, Net</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment are stated at historical cost. Replacements and major improvements are capitalized, and repairs and maintenance are charged to expense as incurred. Furniture and equipment are generally depreciated using the straight-line method over estimated useful lives ranging from three to </span><span style="font-family:Arial;font-size:10pt;"><span>seven years</span></span><span style="font-family:Arial;font-size:10pt;">. Software developed for internal use is capitalized. Software is generally amortized over its estimated useful life of </span><span style="font-family:Arial;font-size:10pt;"><span>three years</span></span><span style="font-family:Arial;font-size:10pt;">. Leasehold improvements are amortized over the term of the lease, or over their useful lives from </span><span style="font-family:Arial;font-size:10pt;">five</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years, whichever is shorter. Buildings are depreciated over their estimated useful lives of </span><span style="font-family:Arial;font-size:10pt;"><span>31.5</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>40</span></span><span style="font-family:Arial;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of property, equipment, and capitalized software is as follows:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Capitalized software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>421</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Building and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>774</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: accumulated amortization - capitalized software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(351</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(320</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: accumulated depreciation and amortization - furniture, equipment, building, and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(179</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(213</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(530</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(533</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">ROU assets - finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Property, equipment, and capitalized software, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>385</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents all depreciation and amortization recognized in our consolidated statements of operations:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Recorded in depreciation and amortization:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of capitalized software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Depreciation and amortization of furniture, equipment, building, and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Recorded in cost of service revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of capitalized software and deferred contract costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total depreciation and amortization recognized</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> P7Y P3Y P10Y P31Y6M P40Y <div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of property, equipment, and capitalized software is as follows:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Capitalized software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>421</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Building and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>774</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: accumulated amortization - capitalized software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(351</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(320</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: accumulated depreciation and amortization - furniture, equipment, building, and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(179</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(213</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(530</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(533</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">ROU assets - finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Property, equipment, and capitalized software, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>385</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents all depreciation and amortization recognized in our consolidated statements of operations:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Recorded in depreciation and amortization:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of capitalized software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Depreciation and amortization of furniture, equipment, building, and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Recorded in cost of service revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of capitalized software and deferred contract costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total depreciation and amortization recognized</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 421000000 373000000 213000000 231000000 49000000 154000000 4000000 16000000 687000000 774000000 351000000 320000000 179000000 213000000 530000000 533000000 228000000 385000000 241000000 33000000 42000000 64000000 21000000 36000000 42000000 18000000 21000000 31000000 17000000 89000000 99000000 137000000 0 28000000 41000000 89000000 127000000 178000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Leases</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As discussed in Note </span><span style="font-family:Arial;font-size:10pt;">2</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Significant Accounting Policies</span><span style="font-family:Arial;font-size:10pt;">,” we elected the Topic 842 transition provision that allows entities to continue to apply the legacy guidance in Topic 840, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:10pt;">, including its disclosure requirements, in the comparative periods presented in the year of adoption. Accordingly, the Topic 842 disclosures below are presented as of and for the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, only.</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are a party to operating and finance leases primarily for our corporate and health plan offices. Our operating leases have remaining lease terms up to </span><span style="font-family:Arial;font-size:10pt;"><span>9</span></span><span style="font-family:Arial;font-size:10pt;"> years, some of which include options to extend the leases for up to </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the weighted average remaining operating lease term is </span><span style="font-family:Arial;font-size:10pt;"><span>4 years</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our finance leases have remaining lease terms of </span><span style="font-family:Arial;font-size:10pt;"><span>2</span></span><span style="font-family:Arial;font-size:10pt;"> years to </span><span style="font-family:Arial;font-size:10pt;"><span>19</span></span><span style="font-family:Arial;font-size:10pt;"> years, some of which include options to extend the leases for up to </span><span style="font-family:Arial;font-size:10pt;"><span>25</span></span><span style="font-family:Arial;font-size:10pt;"> years. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the weighted average remaining finance lease term is </span><span style="font-family:Arial;font-size:10pt;"><span>16</span></span><span style="font-family:Arial;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the weighted-average discount rate used to compute the present value of lease payments was </span><span style="font-family:Arial;font-size:10pt;"><span>5.6%</span></span><span style="font-family:Arial;font-size:10pt;"> for operating lease liabilities, and </span><span style="font-family:Arial;font-size:10pt;"><span>6.5%</span></span><span style="font-family:Arial;font-size:10pt;"> for finance lease liabilities. The components of lease expense were as follows: </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance lease expense: </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of ROU assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total finance lease expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rental expense related to operating leases amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$62 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended December 31, 2018 and 2017, respectively. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Supplemental consolidated cash flow information related to leases follows: </span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash used in financing activities: </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">ROU assets recognized in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating leases:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ROU assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities (non-current)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Finance leases:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ROU assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Property, equipment, and capitalized software, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance lease liabilities (non-current)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:102px;text-indent:-84px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Maturities of lease liabilities as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, were as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal - undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> <span style="color:#828282;font-family:Arial;font-size:14pt;">Leases</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As discussed in Note </span><span style="font-family:Arial;font-size:10pt;">2</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Significant Accounting Policies</span><span style="font-family:Arial;font-size:10pt;">,” we elected the Topic 842 transition provision that allows entities to continue to apply the legacy guidance in Topic 840, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:10pt;">, including its disclosure requirements, in the comparative periods presented in the year of adoption. Accordingly, the Topic 842 disclosures below are presented as of and for the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, only.</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are a party to operating and finance leases primarily for our corporate and health plan offices. Our operating leases have remaining lease terms up to </span><span style="font-family:Arial;font-size:10pt;"><span>9</span></span><span style="font-family:Arial;font-size:10pt;"> years, some of which include options to extend the leases for up to </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the weighted average remaining operating lease term is </span><span style="font-family:Arial;font-size:10pt;"><span>4 years</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our finance leases have remaining lease terms of </span><span style="font-family:Arial;font-size:10pt;"><span>2</span></span><span style="font-family:Arial;font-size:10pt;"> years to </span><span style="font-family:Arial;font-size:10pt;"><span>19</span></span><span style="font-family:Arial;font-size:10pt;"> years, some of which include options to extend the leases for up to </span><span style="font-family:Arial;font-size:10pt;"><span>25</span></span><span style="font-family:Arial;font-size:10pt;"> years. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the weighted average remaining finance lease term is </span><span style="font-family:Arial;font-size:10pt;"><span>16</span></span><span style="font-family:Arial;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the weighted-average discount rate used to compute the present value of lease payments was </span><span style="font-family:Arial;font-size:10pt;"><span>5.6%</span></span><span style="font-family:Arial;font-size:10pt;"> for operating lease liabilities, and </span><span style="font-family:Arial;font-size:10pt;"><span>6.5%</span></span><span style="font-family:Arial;font-size:10pt;"> for finance lease liabilities. The components of lease expense were as follows: </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance lease expense: </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of ROU assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total finance lease expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rental expense related to operating leases amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$62 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended December 31, 2018 and 2017, respectively. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Supplemental consolidated cash flow information related to leases follows: </span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash used in financing activities: </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">ROU assets recognized in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating leases:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ROU assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities (non-current)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Finance leases:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ROU assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Property, equipment, and capitalized software, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance lease liabilities (non-current)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:102px;text-indent:-84px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Maturities of lease liabilities as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, were as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal - undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> P9Y P10Y P4Y P2Y P19Y P25Y P16Y 0.056 0.065 34000000 17000000 15000000 32000000 62000000 75000000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Supplemental consolidated cash flow information related to leases follows: </span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash used in financing activities: </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">ROU assets recognized in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div>The components of lease expense were as follows: <div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance lease expense: </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of ROU assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total finance lease expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 36000000 15000000 6000000 99000000 245000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating leases:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ROU assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities (non-current)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Finance leases:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ROU assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Property, equipment, and capitalized software, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance lease liabilities (non-current)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:102px;text-indent:-84px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 65000000 25000000 48000000 73000000 228000000 8000000 231000000 239000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Maturities of lease liabilities as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, were as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal - undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Maturities of lease liabilities as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, were as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal - undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 28000000 23000000 20000000 24000000 14000000 21000000 10000000 21000000 5000000 22000000 3000000 289000000 80000000 400000000 7000000 161000000 73000000 239000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Goodwill and Intangible Assets, Net</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents the changes in the carrying amounts of goodwill by segment, for the periods presented. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dispositions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Impairment and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dispositions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Impairment and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the Health Plans segment, gross goodwill amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$445 million</span></span><span style="font-family:Arial;font-size:10pt;">, and accumulated impairment losses amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$302 million</span></span><span style="font-family:Arial;font-size:10pt;">, at each of December 31, 2019, and 2018.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">2017 Impairment Losses. </span><span style="font-family:Arial;font-size:10pt;">As a result of reporting unit quantitative goodwill assessments using discounted cash flows and/or asset liquidation analyses, we recorded goodwill impairment losses of </span><span style="font-family:Arial;font-size:10pt;"><span>$244 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$190 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the Health Plans segment and Other segment, respectively, in the year ended December 31, 2017. The Health Plans segment impairment losses were due primarily to certain health plans’ Medicaid contract terminations, and insufficient estimated future cash flows. The Other segment impairment losses were due to the expectation of fewer future benefits, and related lower cash flows, to be derived from certain subsidiaries. Such subsidiaries were disposed in 2018.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets, Net</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides the details of identified intangible assets, by major class, for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Carrying Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Carrying Amount </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contract rights and licenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>179</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Provider networks</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, we estimate that our intangible asset amortization will be approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$14 million</span></span><span style="font-family:Arial;font-size:10pt;"> in </span><span style="font-family:Arial;font-size:10pt;">2020</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$5 million</span></span><span style="font-family:Arial;font-size:10pt;"> in </span><span style="font-family:Arial;font-size:10pt;">2021</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$3 million</span></span><span style="font-family:Arial;font-size:10pt;"> in </span><span style="font-family:Arial;font-size:10pt;">2022</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2023</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2024</span><span style="font-family:Arial;font-size:10pt;">. For a presentation of our intangible assets by reportable segment, refer to Note </span><span style="font-family:Arial;font-size:10pt;">18</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Segments</span><span style="font-family:Arial;font-size:10pt;">.”</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">2017 Impairment Losses</span><span style="font-family:Arial;font-size:10pt;">. For the reasons described above, reporting unit undiscounted cash flow analyses produced intangible asset impairment losses of </span><span style="font-family:Arial;font-size:10pt;"><span>$25 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$11 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the Health Plans segment and Other segment, respectively, in the year ended December 31, 2017.</span></div> <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents the changes in the carrying amounts of goodwill by segment, for the periods presented. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dispositions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Impairment and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dispositions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Impairment and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 143000000 43000000 186000000 0 0 0 0 43000000 43000000 0 0 0 143000000 0 143000000 0 0 0 0 0 0 0 0 0 143000000 0 143000000 445000000 302000000 244000000 190000000 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides the details of identified intangible assets, by major class, for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Carrying Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Carrying Amount </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contract rights and licenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>179</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Provider networks</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 179000000 156000000 23000000 201000000 162000000 39000000 20000000 14000000 6000000 20000000 12000000 8000000 199000000 170000000 29000000 221000000 174000000 47000000 14000000 5000000 3000000 25000000 11000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Medical Claims and Benefits Payable</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides the details of our medical claims and benefits payable as of the dates indicated.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fee-for-service claims incurred but not paid (“IBNP”)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,562</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pharmacy payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Capitation payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">“Other” medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of operations. Non-risk provider payables amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$132 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$107 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$122 million</span></span><span style="font-family:Arial;font-size:10pt;">, as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for “Components of medical care costs related to: Prior periods” represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the period were (more) less than the actual amount of the liability based on information (principally the payment of claims) developed since that liability was first reported.</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medical claims and benefits payable, beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,929</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Components of medical care costs related to:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prior periods </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total medical care costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,905</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Change in non-risk and other provider payables</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Payments for medical care costs related to:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,554</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,671</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,482</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,710</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total paid</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,036</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,381</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medical claims and benefits payable, ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">________________</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">December 31, 2018, includes the 2018 benefit of the 2017 Marketplace CSR reimbursement of</span><span style="font-family:Arial;font-size:9pt;"> </span><span style="font-family:Arial;font-size:9pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:9pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following tables provide information about incurred and paid claims development as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, as well as cumulative claims frequency and the total of incurred but not paid claims liabilities. The cumulative claim frequency is measured by claim event, and includes claims covered under capitated arrangements. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Incurred Claims and Allocated Claims Adjustment Expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total IBNP</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cumulative number of reported claims</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Benefit Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="18" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,728</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,478</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,348</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,125</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:31%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cumulative Paid Claims and Allocated Claims Adjustment Expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Benefit Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,671</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,686</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44,460</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table represents a reconciliation of claims development to the aggregate carrying amount of the liability for medical claims and benefits payable.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:31%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Incurred claims and allocated claims adjustment expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: cumulative paid claims and allocated claims adjustment expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(44,460</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">All outstanding liabilities before 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-risk and other provider payables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medical claims and benefits payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our estimates of medical claims and benefits payable recorded at December 31, 2018, 2017 and 2016 developed favorably (unfavorably) by approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$271 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$341 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$(36) million</span></span><span style="font-family:Arial;font-size:10pt;"> in 2019, 2018 and 2017, respectively. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The favorable prior year development recognized in 2019 was primarily due to lower than expected utilization of medical services by our Medicaid members, and improved operating performance. Consequently, the ultimate costs recognized in 2019 were lower than our original estimates in 2018, which was not discernible until additional information was provided, and as claims payments were processed.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The favorable prior year development recognized in 2018 includes a benefit of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:10pt;"> in reduced medical care costs relating to Marketplace CSR subsidies for 2017 dates of service. The remainder of the favorable prior period development was primarily due to lower than expected utilization of medical services by our Medicaid and Marketplace members and improved operating performance. The differences between our original estimates in 2017 and the ultimate costs in 2018 were not discernable until additional information was provided to us in 2018 and the effect became clearer over time as claim payments were processed.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The unfavorable prior year development in 2017 was primarily due to higher than expected costs for settling certain claims with certain providers in states where we had recently commenced operations, such as in Illinois and Puerto Rico, or had instituted significant changes due to provider contract changes, such as in Florida and New Mexico. The differences between our original estimates in 2016 and the ultimate costs in 2017 were not discernible until additional information was provided to us in 2017, and the effect became clearer over time as claim payments were processed.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides the details of our medical claims and benefits payable as of the dates indicated.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fee-for-service claims incurred but not paid (“IBNP”)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,562</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pharmacy payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Capitation payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 1406000000 1562000000 1717000000 126000000 115000000 112000000 55000000 52000000 67000000 267000000 232000000 296000000 1854000000 1961000000 2192000000 132000000 107000000 122000000 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for “Components of medical care costs related to: Prior periods” represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the period were (more) less than the actual amount of the liability based on information (principally the payment of claims) developed since that liability was first reported.</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medical claims and benefits payable, beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,929</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Components of medical care costs related to:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prior periods </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total medical care costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,905</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Change in non-risk and other provider payables</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Payments for medical care costs related to:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,554</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,671</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,482</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,710</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total paid</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,036</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,381</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medical claims and benefits payable, ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:8px;text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">________________</span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">December 31, 2018, includes the 2018 benefit of the 2017 Marketplace CSR reimbursement of</span><span style="font-family:Arial;font-size:9pt;"> </span><span style="font-family:Arial;font-size:9pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:9pt;">.</span></div> 1961000000 2192000000 1929000000 14176000000 15478000000 17037000000 -271000000 -341000000 36000000 13905000000 15137000000 17073000000 24000000 13000000 -106000000 12554000000 13671000000 15130000000 1482000000 1710000000 1574000000 14036000000 15381000000 16704000000 1854000000 1961000000 2192000000 81000000 <div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following tables provide information about incurred and paid claims development as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, as well as cumulative claims frequency and the total of incurred but not paid claims liabilities. The cumulative claim frequency is measured by claim event, and includes claims covered under capitated arrangements. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Incurred Claims and Allocated Claims Adjustment Expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total IBNP</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cumulative number of reported claims</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Benefit Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="18" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,728</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,478</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,348</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,125</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:31%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cumulative Paid Claims and Allocated Claims Adjustment Expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Benefit Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,671</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,686</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44,460</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 17037000000 16728000000 16704000000 18000000 119000000 15478000000 15245000000 25000000 110000000 14176000000 1348000000 93000000 46125000000 1391000000 15130000000 16671000000 16686000000 13752000000 15220000000 12554000000 44460000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table represents a reconciliation of claims development to the aggregate carrying amount of the liability for medical claims and benefits payable.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:31%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Incurred claims and allocated claims adjustment expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: cumulative paid claims and allocated claims adjustment expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(44,460</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">All outstanding liabilities before 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Non-risk and other provider payables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medical claims and benefits payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 46125000000 44460000000 15000000 174000000 1854000000 -271000000 -341000000 36000000 81000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Debt</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contractual maturities of debt, as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, are illustrated in the following table. All amounts represent the principal amounts of the debt instruments outstanding.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Thereafter</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="27" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5.375% Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.875% Notes </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Term Loan Facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Convertible Notes </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>722</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">All debt is held at the parent which is reported, for segment purposes, in the Other segment. The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Current portion of long-term debt:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Convertible Notes, net of unamortized discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Term Loan Facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease financing obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total, current portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Non-current portion of long-term debt:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5.375% Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.875% Notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Term Loan Facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Debt issuance costs </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total, non-current portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,020</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Credit Agreement</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are party to a Credit Agreement, which provides for an unsecured delayed draw term loan facility (the “Term Loan Facility”), and an unsecured </span><span style="font-family:Arial;font-size:10pt;"><span>$500 million</span></span><span style="font-family:Arial;font-size:10pt;"> revolving credit facility (the “Credit Facility”). Borrowings under our Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Credit Agreement contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. As of December 31, 2019, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. Effective as of the date of the Sixth Amendment to the Credit Agreement described below, there are no guarantors as parties to the Credit Agreement.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Term Loan Facility.</span><span style="font-family:Arial;font-size:10pt;"> In January 2019, we entered into a Sixth Amendment to the Credit Agreement that provided for a delayed draw Term Loan Facility in the aggregate principal amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$600 million</span></span><span style="font-family:Arial;font-size:10pt;">, under which we may request up to ten advances, each in a minimum principal amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:10pt;">, until July 31, 2020. The Term Loan Facility will amortize in quarterly installments, commencing on September 30, 2020, equal to the principal amount of the Term Loan Facility outstanding multiplied by rates ranging from </span><span style="font-family:Arial;font-size:10pt;"><span>1.25%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>2.50%</span></span><span style="font-family:Arial;font-size:10pt;"> (depending on the applicable fiscal quarter) for each fiscal quarter. The Term Loan Facility expires on January 31, 2024; any remaining outstanding balance under the Term Loan Facility will be due and payable on that date. As of December 31, 2019, </span><span style="font-family:Arial;font-size:10pt;"><span>$220 million</span></span><span style="font-family:Arial;font-size:10pt;"> was outstanding under the Term Loan Facility. Each advance under the Term Loan Facility results in a permanent reduction to its borrowing capacity; therefore, our borrowing capacity under the Term Loan Facility as of December 31, 2019, was </span><span style="font-family:Arial;font-size:10pt;"><span>$380 million</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Credit Facility.</span><span style="font-family:Arial;font-size:10pt;"> The Credit Facility expires on January 31, 2022; therefore, any amounts outstanding under the Credit Facility will be due and payable on that date. As of December 31, 2019, </span><span style="font-family:Arial;font-size:10pt;"><span>no</span></span><span style="font-family:Arial;font-size:10pt;"> amounts were outstanding under the Credit Facility, and outstanding letters of credit amounting to </span><span style="font-family:Arial;font-size:10pt;"><span>$1 million</span></span><span style="font-family:Arial;font-size:10pt;"> reduced our remaining borrowing capacity under the Credit Facility to </span><span style="font-family:Arial;font-size:10pt;"><span>$499 million</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"><span>5.375%</span></span><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"> Notes due 2022</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have </span><span style="font-family:Arial;font-size:10pt;"><span>$700 million</span></span><span style="font-family:Arial;font-size:10pt;"> aggregate principal amount of senior notes (the “</span><span style="font-family:Arial;font-size:10pt;"><span>5.375%</span></span><span style="font-family:Arial;font-size:10pt;"> Notes”) outstanding as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, which are due November 15, 2022, unless earlier redeemed. Interest at a rate of </span><span style="font-family:Arial;font-size:10pt;"><span>5.375%</span></span><span style="font-family:Arial;font-size:10pt;"> per annum, is payable semiannually in arrears on May 15 and November 15. The </span><span style="font-family:Arial;font-size:10pt;"><span>5.375%</span></span><span style="font-family:Arial;font-size:10pt;"> Notes contain customary non-financial covenants and change of control provisions. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"><span>4.875%</span></span><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"> Notes due 2025</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We had </span><span style="font-family:Arial;font-size:10pt;"><span>$330 million</span></span><span style="font-family:Arial;font-size:10pt;"> aggregate principal amount of senior notes (the “</span><span style="font-family:Arial;font-size:10pt;"><span>4.875%</span></span><span style="font-family:Arial;font-size:10pt;"> Notes”) outstanding as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, which are due June 15, 2025, unless earlier redeemed. Interest at a rate of </span><span style="font-family:Arial;font-size:10pt;"><span>4.875%</span></span><span style="font-family:Arial;font-size:10pt;"> per annum, is payable semiannually in arrears on June 15 and December 15. The </span><span style="font-family:Arial;font-size:10pt;"><span>4.875%</span></span><span style="font-family:Arial;font-size:10pt;"> Notes contain customary non-financial covenants and change of control provisions. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"> Cash Convertible Senior Notes due 2020 </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the years ended December 31, 2019 and 2018, we entered into privately negotiated note purchase agreements and, in 2019, received conversion requests, with certain holders of our outstanding </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> cash convertible senior notes due January 15, 2020 (the “</span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes”). For each transaction, the difference between the principal amount extinguished and the total cash paid primarily represented the settlement of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes’ embedded cash conversion option feature at fair value (which is a derivative liability we refer to as the “</span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Conversion Option”).</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During 2019, we paid </span><span style="font-family:Arial;font-size:10pt;"><span>$794 million</span></span><span style="font-family:Arial;font-size:10pt;"> to settle </span><span style="font-family:Arial;font-size:10pt;"><span>$240 million</span></span><span style="font-family:Arial;font-size:10pt;"> aggregate principal amount, or </span><span style="font-family:Arial;font-size:10pt;"><span>$232 million</span></span><span style="font-family:Arial;font-size:10pt;"> aggregate carrying amount, of the 1.125% Convertible Notes. During 2018, we paid </span><span style="font-family:Arial;font-size:10pt;"><span>$911 million</span></span><span style="font-family:Arial;font-size:10pt;"> to settle </span><span style="font-family:Arial;font-size:10pt;"><span>$298 million</span></span><span style="font-family:Arial;font-size:10pt;"> aggregate principal amount, or </span><span style="font-family:Arial;font-size:10pt;"><span>$278 million</span></span><span style="font-family:Arial;font-size:10pt;"> aggregate carrying amount of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes. In both years, the cash payments included settlement of the related </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Conversion Option, and the mark-to-market valuation adjustments discussed below. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the years ended December 31, 2019 and 2018, we recorded a (gain) loss on debt extinguishment of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$(15) million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$12 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, for the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes transactions (net of accelerated original issuance discount amortization), primarily relating to mark-to-market valuations on the partial terminations of the Call Spread Overlay executed in connection with the related debt repayments. These amounts are reported in “Other (income) expenses, net” in the accompanying consolidated statements of operations. No common shares were issued in connection with the transaction.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes transactions, we also entered into privately negotiated agreements in 2019, to partially terminate the Call Spread Overlay, defined and further discussed in Notes </span><span style="font-family:Arial;font-size:10pt;">12</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Derivatives</span><span style="font-family:Arial;font-size:10pt;">,” and </span><span style="font-family:Arial;font-size:10pt;">14</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Stockholders' Equity</span><span style="font-family:Arial;font-size:10pt;">.” The net cash proceeds from the Call Spread Overlay partial termination transactions partially offset the cash paid to settle the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of December 31, 2019, </span><span style="font-family:Arial;font-size:10pt;"><span>$12 million</span></span><span style="font-family:Arial;font-size:10pt;"> aggregate principal amount of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes were outstanding. Interest at a rate of </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> per annum is payable semiannually in arrears on January 15 and July 15. The </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes are convertible only into cash, and not into shares of our common stock or any other securities. The initial conversion rate is </span><span style="font-family:Arial;font-size:10pt;">24.5277</span><span style="font-family:Arial;font-size:10pt;"> shares of our common stock per $1,000 principal amount, or approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$40.77</span></span><span style="font-family:Arial;font-size:10pt;"> per share of our common stock. Holders may convert their 1.125% Convertible Notes under certain circumstances and upon conversion, in lieu of receiving shares of our common stock, a holder will receive an amount in cash, per $1,000 principal amount, equal to the settlement amount, determined in the manner set forth in the indenture. We may not redeem the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes prior to the maturity date. The </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes matured on January 15, 2020; therefore, they were reported in current portion of long-term debt as of December 31, 2019. (See “Subsequent Event,” below.)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Concurrent with the issuance of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes, the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Conversion Option was separated from the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations until the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Conversion Option settled. This initial liability simultaneously reduced the carrying value of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes’ principal amount (effectively an original issuance discount), which was amortized to the principal amount through the recognition of non-cash interest expense over the expected life of the debt. The effective interest rate of </span><span style="font-family:Arial;font-size:10pt;"><span>6%</span></span><span style="font-family:Arial;font-size:10pt;"> approximates the interest rate we would have incurred had we issued nonconvertible debt with otherwise similar terms. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes had a remaining amortization period of less than </span><span style="font-family:Arial;font-size:10pt;"><span>one month</span></span><span style="font-family:Arial;font-size:10pt;">, and their ‘if-converted’ value exceeded their principal amount by approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$26 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$581 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and 2018, respectively. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest cost recognized relating to our convertible senior notes for the periods presented was as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contractual interest at coupon rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of the discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Subsequent Event</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In January 2020, we paid </span><span style="font-family:Arial;font-size:10pt;"><span>$39 million</span></span><span style="font-family:Arial;font-size:10pt;"> to settle the outstanding </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes, which amount included settlement of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Conversion Option.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cross-Default Provisions</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The indentures governing the </span><span style="font-family:Arial;font-size:10pt;"><span>4.875%</span></span><span style="font-family:Arial;font-size:10pt;"> Notes and the </span><span style="font-family:Arial;font-size:10pt;"><span>5.375%</span></span><span style="font-family:Arial;font-size:10pt;"> Notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture.</span></div> <div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contractual maturities of debt, as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, are illustrated in the following table. All amounts represent the principal amounts of the debt instruments outstanding.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Thereafter</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="27" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5.375% Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.875% Notes </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Term Loan Facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Convertible Notes </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>722</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 700000000 0 0 700000000 0 0 0 330000000 0 0 0 0 0 330000000 220000000 6000000 16000000 22000000 22000000 154000000 0 12000000 12000000 0 0 0 0 0 1262000000 18000000 16000000 722000000 22000000 154000000 330000000 The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets:<div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Current portion of long-term debt:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Convertible Notes, net of unamortized discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Term Loan Facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease financing obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total, current portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Non-current portion of long-term debt:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5.375% Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.875% Notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Term Loan Facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Debt issuance costs </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total, non-current portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,020</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 12000000 241000000 6000000 0 0 1000000 0 1000000 18000000 241000000 700000000 700000000 330000000 330000000 214000000 0 7000000 10000000 1237000000 1020000000 500000000 600000000 50000000 0.0125 0.0250 220000000 380000000 0 1000000 499000000 0.05375 700000000 0.05375 0.05375 0.05375 0.04875 330000000 0.04875 0.04875 0.04875 0.01125 0.01125 0.01125 0.01125 0.01125 794000000 240000000 232000000 911000000 298000000 278000000 0.01125 0.01125 -15000000 12000000 0.01125 0.01125 0.01125 12000000 0.01125 0.01125 0.01125 40.77 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.06 0.01125 P1M 26000000 581000000 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest cost recognized relating to our convertible senior notes for the periods presented was as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contractual interest at coupon rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of the discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 1000000 6000000 11000000 5000000 21000000 32000000 6000000 27000000 43000000 39000000 0.01125 0.01125 0.04875 0.05375 <span style="color:#828282;font-family:Arial;font-size:14pt;">Derivatives</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes the fair values and the presentation of our derivative financial instruments (defined and discussed individually below) in the consolidated balance sheets:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:35%;"/><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivative asset:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Call Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current assets: Derivative asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivative liability:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Conversion Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current liabilities: Derivative liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our derivative financial instruments do not qualify for hedge treatment; therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations, and reported in “Other (income) expenses, net.” Gains and losses for our derivative financial instruments are presented individually in the accompanying consolidated statements of cash flows, “Supplemental cash flow information.” </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"> Convertible Notes Call Spread Overlay</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Concurrent with the issuance of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes in 2013, we entered into privately negotiated hedge transactions (collectively, the “</span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Call Option”) and warrant transactions (collectively, the “</span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Warrants”), with certain of the initial purchasers of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes (the “Counterparties”). We refer to these transactions collectively as the Call Spread Overlay. Under the Call Spread Overlay, the cost of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Call Option we purchased to cover the cash outlay upon conversion of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes was reduced by proceeds from the sale of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Warrants. Assuming full performance by the Counterparties (and </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Warrants strike prices in excess of the conversion price of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes), these transactions are intended to offset cash payments in excess of the principal amount of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes due upon any conversion of such notes.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the </span><span style="font-family:Arial;font-size:10pt;">year ended December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, in connection with the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes purchases (described in Note </span><span style="font-family:Arial;font-size:10pt;">11</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Debt</span><span style="font-family:Arial;font-size:10pt;">”), we entered into privately negotiated termination agreements with each of the Counterparties to partially terminate the Call Spread Overlay, in notional amounts corresponding to the aggregate principal amount of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes purchased. In the </span><span style="font-family:Arial;font-size:10pt;">year ended December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, we received </span><span style="font-family:Arial;font-size:10pt;"><span>$578 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">settlement of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Call Option (which is a derivative asset), and paid </span><span style="font-family:Arial;font-size:10pt;"><span>$514 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the partial termination of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Warrants, for an aggregate net cash receipt of </span><span style="font-family:Arial;font-size:10pt;"><span>$64 million</span></span><span style="font-family:Arial;font-size:10pt;"> from the Counterparties. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"> Call Option</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to cash settlement features until the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Call Option settles or expires. For further discussion of the inputs used to determine the fair value of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Call Option, refer to Note </span><span style="font-family:Arial;font-size:10pt;">4</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Fair Value Measurements</span><span style="font-family:Arial;font-size:10pt;">.”</span><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"> Conversion Option</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The embedded cash conversion option within the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes is accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations until the cash conversion option settles or expires. For further discussion of the inputs used to determine the fair value of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Conversion Option, refer to Note </span><span style="font-family:Arial;font-size:10pt;">4</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Fair Value Measurements</span><span style="font-family:Arial;font-size:10pt;">.”</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Call Option and the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Conversion Option were classified as a current asset and current liability, respectively, because the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes matured on January 15, 2020.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Subsequent Event </span></div><span style="font-family:Arial;font-size:10pt;">As described in Note </span><span style="font-family:Arial;font-size:10pt;">11</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Debt</span><span style="font-family:Arial;font-size:10pt;">,” we repaid the aggregate principal amount of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes, including settlement of the related </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Conversion Option. In addition, in January 2020 we received </span><span style="font-family:Arial;font-size:10pt;"><span>$27 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the settlement of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span> Call Option. <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes the fair values and the presentation of our derivative financial instruments (defined and discussed individually below) in the consolidated balance sheets:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:35%;"/><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivative asset:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Call Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current assets: Derivative asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivative liability:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.125% Conversion Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current liabilities: Derivative liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 29000000 476000000 29000000 476000000 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 578000000 0.01125 514000000 0.01125 64000000 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 0.01125 27000000 0.01125 <span style="color:#828282;font-family:Arial;font-size:14pt;">Income Taxes</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income tax expense (benefit) consisted of the following:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>272</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>225</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total deferred</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(94</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Income tax expense (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>292</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (“TCJA”), in part, reduced the U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018. TCJA’s change in the federal rate required that we revalue deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally the new 21% federal corporate tax rate plus applicable state tax rate. We applied the guidance in SEC Staff Accounting Bulletin No. 118 when accounting for the enactment-date effects of the TCJA in 2017 and throughout 2018.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of December 31, 2017, we recorded a provisional amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$54 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the revaluation of deferred tax assets and liabilities because we had not yet completed our accounting for all of the enactment-date income tax effects of the TJCA under ASC 740, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes. </span><span style="font-family:Arial;font-size:10pt;">Upon further analysis of certain aspects of the TCJA and refinement of our calculations in the year ended December 31, 2018, we reduced this provisional amount by </span><span style="font-family:Arial;font-size:10pt;"><span>$4 million</span></span><span style="font-family:Arial;font-size:10pt;">, which is included as a component of income tax expense in the accompanying consolidated statement of operations. As of December 31, 2018, the accounting for all of the enactment-date income tax effects of the TCJA was complete. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A reconciliation of the U.S. federal statutory income tax rate to the combined effective income tax rate is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Statutory federal tax (benefit) rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(35.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">State income provision (benefit), net of federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nondeductible health insurer fee (“HIF”)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nondeductible compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nondeductible goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Worthless stock deduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Revaluation of net deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Effective tax expense (benefit) rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The effective tax rate was not impacted by the HIF in 2019 and 2017, given the HIF moratorium in each of those years. Our effective tax rate is based on expected income (loss), statutory tax rates, and tax planning opportunities available to us in the various jurisdictions in which we operate. Management estimates and judgments are required in determining our effective tax rate. We are routinely under audit by federal, state, or local authorities regarding the timing and amount of deductions, nexus of income among various tax jurisdictions, and compliance with federal, state, foreign, and local tax laws.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax assets and liabilities are classified as non-current. Significant components of our deferred tax assets and liabilities as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued expenses and reserve liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other accrued medical costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net operating losses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fixed assets and intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unearned premiums</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease financing obligation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tax credit carryover</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total deferred income tax assets, net of valuation allowance </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total deferred income tax liabilities </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net deferred income tax asset</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, we had state net operating loss carryforwards of </span><span style="font-family:Arial;font-size:10pt;"><span>$310 million</span></span><span style="font-family:Arial;font-size:10pt;">, which begin expiring in 2028.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, we had California research and development and enterprise zone tax credit carryovers of </span><span style="font-family:Arial;font-size:10pt;"><span>$8 million</span></span><span style="font-family:Arial;font-size:10pt;">, which will begin to expire in 2024, and foreign tax credit carryovers of </span><span style="font-family:Arial;font-size:10pt;"><span>$5 million</span></span><span style="font-family:Arial;font-size:10pt;">, which expire in 2030.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We evaluate the need for a valuation allowance taking into consideration the ability to carry back and carry forward tax credits and losses, available tax planning strategies and future income, including reversal of temporary differences. We have determined that as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$24 million</span></span><span style="font-family:Arial;font-size:10pt;"> of deferred tax assets did not satisfy the recognition criteria. Therefore, we decreased our valuation allowance by </span><span style="font-family:Arial;font-size:10pt;"><span>$4 million</span></span><span style="font-family:Arial;font-size:10pt;">, from </span><span style="font-family:Arial;font-size:10pt;"><span>$28 million</span></span><span style="font-family:Arial;font-size:10pt;"> at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, to </span><span style="font-family:Arial;font-size:10pt;"><span>$24 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We recognize tax benefits only if the tax position is more likely than not to be sustained. We are subject to income taxes in the United States, Puerto Rico, and numerous state jurisdictions. Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. We establish reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these reserves in light of changing facts and circumstances, such as the outcome of tax audits. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The roll forward of our unrecognized tax benefits is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gross unrecognized tax benefits at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Increases in tax positions for current year </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Increases in tax positions for prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Decreases in tax positions for prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lapse in statute of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gross unrecognized tax benefits at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The total amount of unrecognized tax benefits at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> that, if recognized, would affect the effective tax rates is </span><span style="font-family:Arial;font-size:10pt;"><span>$18 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$18 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$12 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. We expect that during the next </span><span style="font-family:Arial;font-size:10pt;">12</span><span style="font-family:Arial;font-size:10pt;"> months it is reasonably possible that unrecognized tax benefit liabilities may decrease by as much as </span><span style="font-family:Arial;font-size:10pt;"><span>$5 million</span></span><span style="font-family:Arial;font-size:10pt;"> due to resolution of a state refund claim. The state refund claim will not result in a cash payment for income taxes if our claim is denied. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our continuing practice is to recognize interest and/or penalties related to unrecognized tax benefits in income tax expense. Amounts accrued for the payment of interest and penalties as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> were insignificant. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are under examination by the IRS for calendar years 2015 through 2017 and may be subject to examination for calendar year 2018. With a few exceptions, which are immaterial in the aggregate, we no longer are subject to state, local, and Puerto Rico tax examinations for years before 2015.</span></div> <div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income tax expense (benefit) consisted of the following:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>272</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>225</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total deferred</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(94</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Income tax expense (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>292</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 204000000 272000000 -9000000 12000000 18000000 3000000 9000000 8000000 0 225000000 298000000 -6000000 5000000 -3000000 -85000000 6000000 -3000000 -9000000 -1000000 0 0 10000000 -6000000 -94000000 235000000 292000000 -100000000 54000000 4000000 <div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A reconciliation of the U.S. federal statutory income tax rate to the combined effective income tax rate is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Statutory federal tax (benefit) rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(35.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">State income provision (benefit), net of federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nondeductible health insurer fee (“HIF”)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nondeductible compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nondeductible goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Worthless stock deduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Revaluation of net deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Effective tax expense (benefit) rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 0.210 0.210 0.350 0.014 0.012 0.007 0 0.073 0 0.012 0.007 -0.028 0 0 -0.066 0 -0.010 0 0 -0.004 -0.088 0.006 0.004 -0.011 0.242 0.292 0.164 Significant components of our deferred tax assets and liabilities as of <span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued expenses and reserve liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other accrued medical costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net operating losses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fixed assets and intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unearned premiums</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease financing obligation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tax credit carryover</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total deferred income tax assets, net of valuation allowance </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total deferred income tax liabilities </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net deferred income tax asset</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span> 35000000 39000000 11000000 12000000 13000000 16000000 26000000 30000000 11000000 9000000 5000000 30000000 11000000 12000000 0 3000000 24000000 28000000 88000000 123000000 6000000 6000000 3000000 0 9000000 6000000 79000000 117000000 310000000 8000000 5000000 24000000 -4000000 28000000 24000000 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The roll forward of our unrecognized tax benefits is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gross unrecognized tax benefits at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Increases in tax positions for current year </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Increases in tax positions for prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Decreases in tax positions for prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lapse in statute of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gross unrecognized tax benefits at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 20000000 13000000 11000000 9000000 1000000 0 0 4000000 0 0 3000000 2000000 0 20000000 20000000 13000000 18000000 18000000 12000000 5000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Stockholders' Equity</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock Purchase Program</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In early December 2019, our board of directors authorized the purchase of up to</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>$500 million</span></span><span style="font-family:Arial;font-size:10pt;">, in the aggregate, of our common stock. This program is funded by existing cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase is determined by management, based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law.</span><span style="font-family:Arial;font-size:10pt;"> Under this program, </span><span style="font-family:Arial;font-size:10pt;">pursuant to a Rule 10b5-1 trading plan, we purchased approximately</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>400,000</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">shares of our common stock for</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>$54 million</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">in December 2019 (average cost of </span><span style="font-family:Arial;font-size:10pt;"><span>$135.30</span></span><span style="font-family:Arial;font-size:10pt;"> per share), including approximately</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>55,000</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">shares purchased for</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>$7 million</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">in late December 2019, and settled in early January 2020.</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Subsequent Event</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In January 2020 through February 7, 2020, we purchased </span><span style="font-family:Arial;font-size:10pt;"><span>1,533,000</span></span><span style="font-family:Arial;font-size:10pt;"> shares for </span><span style="font-family:Arial;font-size:10pt;"><span>$203 million</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">(average cost of</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>$132.69</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">per share).</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"> Warrants</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the Call Spread Overlay transaction described in Note </span><span style="font-family:Arial;font-size:10pt;">12</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Derivatives</span><span style="font-family:Arial;font-size:10pt;">,” in 2013, we issued </span><span style="font-family:Arial;font-size:10pt;"><span>13.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Warrants with a strike price of </span><span style="font-family:Arial;font-size:10pt;"><span>$53.8475</span></span><span style="font-family:Arial;font-size:10pt;"> per share. Under certain circumstances, beginning in April 2020, if the price of our common stock were to exceed the strike price of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Warrants, we would be obligated to issue shares of our common stock subject to a share delivery cap. The </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Warrants could separately have a dilutive effect to the extent that the market value per share of our common stock exceeds the applicable strike price of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Warrants. Refer to Note </span><span style="font-family:Arial;font-size:10pt;">3</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Net Income (Loss) Per Share</span><span style="font-family:Arial;font-size:10pt;">,” for dilution </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">information for the periods presented. We will not receive any additional proceeds if the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Warrants are exercised. Following the transactions described below, approximately </span><span style="font-family:Arial;font-size:10pt;"><span>310,000</span></span><span style="font-family:Arial;font-size:10pt;"> of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Warrants were outstanding at December 31, 2019. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As described in Note </span><span style="font-family:Arial;font-size:10pt;">12</span><span style="font-family:Arial;font-size:10pt;">, “</span><span style="font-family:Arial;">Derivatives</span><span style="font-family:Arial;font-size:10pt;">,” in the year ended December 31, 2019, we entered into privately negotiated termination agreements with each of the Counterparties to partially terminate the Call Spread Overlay, in notional amounts corresponding to the aggregate principal amount of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Convertible Notes purchased. In the year ended December 31, 2019, we paid </span><span style="font-family:Arial;font-size:10pt;"><span>$514 million</span></span><span style="font-family:Arial;font-size:10pt;"> to the Counterparties for the termination of </span><span style="font-family:Arial;font-size:10pt;"><span>5.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> of the </span><span style="font-family:Arial;font-size:10pt;"><span>1.125%</span></span><span style="font-family:Arial;font-size:10pt;"> Warrants outstanding which resulted in a reduction of additional paid-in-capital for the same amount.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total share-based compensation expense is presented in the following table. Except as described in the note to the table, we record share-based compensation as “General and administrative expenses” in the accompanying consolidated statements of operations. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Pretax<br/>Charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net-of-Tax<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Pretax<br/>Charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net-of-Tax<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Pretax<br/>Charges </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net-of-Tax<br/>Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RSAs, PSAs and PSUs (defined below)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Employee stock purchase plan and stock options </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">_______________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Includes </span><span style="font-family:Arial;font-size:9pt;"><span>$23 million</span></span><span style="font-family:Arial;font-size:9pt;"> relating to acceleration of share-based compensation for former executives in the year ended December 31, 2017. This amount is reported in “Restructuring costs” in the accompanying consolidated statements of operations. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Equity Incentive Plans</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the second quarter of 2019, our stockholders approved the Molina Healthcare, Inc. 2019 Equity Incentive Plan (the “2019 EIP”). The 2019 EIP provides for awards, in the form of restricted and performance stock awards (“RSAs” and “PSAs”), performance units (“PSUs”), stock options, and other stock– or cash–based awards, to eligible persons who perform services for us. The 2019 EIP will remain in effect until its termination by the board of directors; provided, however, that all awards will be granted no later than May 8, 2029. Concurrent with the adoption of the 2019 EIP, the Molina Healthcare, Inc. 2011 Equity Incentive Plan was amended, restated and merged into the 2019 EIP. A maximum of </span><span style="font-family:Arial;font-size:10pt;"><span>2.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of our common stock may be issued under the 2019 EIP.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Stock-based awards</span><span style="font-family:Arial;font-size:10pt;">. RSAs, PSAs and PSUs are granted with a fair value equal to the market price of our common stock on the date of grant, and generally vest in equal annual installments over periods up to </span><span style="font-family:Arial;font-size:10pt;"><span>four years</span></span><span style="font-family:Arial;font-size:10pt;"> from the date of grant. Certain PSUs may vest in their entirety at the end of three-year performance periods, if their performance conditions are met. We generally recognize expense for RSAs, PSAs and PSUs on a straight-line basis. Activity for stock-based awards in the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> is summarized below:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:36%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">RSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">PSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">PSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unvested balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>399,795</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201,383</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>604,310</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>71.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>243,353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>389,778</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>136.23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(139,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3,132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,528</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(153,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73.98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(55,640</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13,202</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(68,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90.45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unvested balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>447,680</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>324,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>771,758</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>102.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, total unrecognized compensation expense related to unvested RSAs and PSUs was </span><span style="font-family:Arial;font-size:10pt;"><span>$49 million</span></span><span style="font-family:Arial;font-size:10pt;">, which we expect to recognize over a remaining weighted-average period of </span><span style="font-family:Arial;font-size:10pt;"><span>2.2 years</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>1.6 years</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. This unrecognized compensation cost assumes an estimated forfeiture rate of </span><span style="font-family:Arial;font-size:10pt;"><span>15.9%</span></span><span style="font-family:Arial;font-size:10pt;"> for non-executive employees as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, based on actual forfeitures over the last 4 years. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The total grant date fair value of awards granted and vested is presented in the following table:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">PSUs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total granted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">PSAs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">PSUs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total vested</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Stock Options.</span><span style="font-family:Arial;font-size:10pt;"> Stock option awards generally have an exercise price equal to the fair market value of our common stock on the date of grant, vest in equal annual installments over periods up to </span><span style="font-family:Arial;font-size:10pt;"><span>four years</span></span><span style="font-family:Arial;font-size:10pt;"> from the date of grant, and have a maximum term of </span><span style="font-family:Arial;font-size:10pt;"><span>ten years</span></span><span style="font-family:Arial;font-size:10pt;"> from the date of grant. Stock option activity for the year ended December 31, 2019 is summarized below:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual term</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock options outstanding as of December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>405,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock options outstanding as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>405,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.4</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock options exercisable and expected to vest as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>405,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.4</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercisable as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>280,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.3</span></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The weighted-average grant date fair value per share of stock options awarded in 2017 was </span><span style="font-family:Arial;font-size:10pt;"><span>$41.43</span></span><span style="font-family:Arial;font-size:10pt;">. We estimate the fair value of each stock option award on the grant date using the Black-Scholes option pricing model. To determine the fair value of the stock options awarded in 2017 we applied a risk-free interest rate of </span><span style="font-family:Arial;font-size:10pt;"><span>2.3%</span></span><span style="font-family:Arial;font-size:10pt;">, expected volatility of </span><span style="font-family:Arial;font-size:10pt;"><span>38.4%</span></span><span style="font-family:Arial;font-size:10pt;">, dividend yield of </span><span style="font-family:Arial;font-size:10pt;"><span>0%</span></span><span style="font-family:Arial;font-size:10pt;"> and expected life of </span><span style="font-family:Arial;font-size:10pt;"><span>8.4 years</span></span><span style="font-family:Arial;font-size:10pt;">. </span><span style="font-family:Arial;font-size:10pt;">No</span><span style="font-family:Arial;font-size:10pt;"> stock options were granted in 2019 and 2018. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, total unrecognized compensation expense related to unvested stock options was </span><span style="font-family:Arial;font-size:10pt;"><span>$4 million</span></span><span style="font-family:Arial;font-size:10pt;">, which we expect to recognize over a weighted-average period of </span><span style="font-family:Arial;font-size:10pt;"><span>0.8 years</span></span><span style="font-family:Arial;font-size:10pt;">. The total intrinsic value of options exercised during the year ended December 31, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$2 million</span></span><span style="font-family:Arial;font-size:10pt;">. No stock options were exercised in 2019 and 2018. The following is a summary of information about stock options outstanding and exercisable at December 31, 2019: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:31%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Exercisable</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-Average Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number Exercisable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-Average Exercise Price</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Range of Exercise Prices</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$33.02</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$67.33</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>375,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67.33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>250,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67.33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>405,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>280,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Employee Stock Purchase Plans (“ESPPs”)</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the second quarter of 2019, our stockholders approved the Molina Healthcare, Inc. 2019 Employee Stock Purchase Plan (the “2019 ESPP”), which superseded the Molina Healthcare, Inc. 2011 Employee Stock Purchase Plan (the “2011 ESPP”). A maximum of </span><span style="font-family:Arial;font-size:10pt;"><span>3.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of our common stock may be issued under the 2019 ESPP, the terms of which are substantially similar to the 2011 ESPP. The 2019 ESPP will continue until the earliest of: termination of the 2019 ESPP by the board of directors (which may occur at any time); issuance of all of the shares reserved for issuance under the 2019 ESPP; or May 8, 2029.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Under our ESPPs, eligible employees may purchase common shares at </span><span style="font-family:Arial;font-size:10pt;"><span>85%</span></span><span style="font-family:Arial;font-size:10pt;"> of the lower of the fair market value of our common stock on either the first or last trading day of each six-month offering period. Each participant is limited to a maximum purchase of </span><span style="font-family:Arial;font-size:10pt;"><span>$25,000</span></span><span style="font-family:Arial;font-size:10pt;"> (as measured by the fair value of the stock acquired) per year through payroll deductions. We estimate the fair value of the stock issued using the Black-Scholes option pricing model. For the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, the inputs to this model were as follows: risk-free interest rates of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>0.6%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>2.3%</span></span><span style="font-family:Arial;font-size:10pt;">; expected volatilities ranging from approximately </span><span style="font-family:Arial;font-size:10pt;"><span>31%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>45%</span></span><span style="font-family:Arial;font-size:10pt;">, dividend yields of </span><span style="font-family:Arial;font-size:10pt;"><span>0%</span></span><span style="font-family:Arial;font-size:10pt;">, and an average expected life of </span><span style="font-family:Arial;font-size:10pt;"><span>0.5</span></span><span style="font-family:Arial;font-size:10pt;"> years. We issued approximately </span><span style="font-family:Arial;font-size:10pt;"><span>142,000</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>216,000</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>351,000</span></span><span style="font-family:Arial;font-size:10pt;"> shares of our common stock under the ESPPs during the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with our employee stock plans, approximately </span><span style="font-family:Arial;font-size:10pt;"><span>242,000</span></span><span style="font-family:Arial;font-size:10pt;"> shares and </span><span style="font-family:Arial;font-size:10pt;"><span>365,000</span></span><span style="font-family:Arial;font-size:10pt;"> shares of common stock were purchased or vested, net of shares used to settle employees’ income tax obligations, during the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and 2018, respectively.</span></div> 500000000 400000 54000000 135.30 55000 7000000 1533000 203000000 132.69 0.01125 13500000 0.01125 53.8475 0.01125 0.01125 0.01125 0.01125 310000 0.01125 0.01125 514000000 5900000 0.01125 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total share-based compensation expense is presented in the following table. Except as described in the note to the table, we record share-based compensation as “General and administrative expenses” in the accompanying consolidated statements of operations. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Pretax<br/>Charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net-of-Tax<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Pretax<br/>Charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net-of-Tax<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Pretax<br/>Charges </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net-of-Tax<br/>Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RSAs, PSAs and PSUs (defined below)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Employee stock purchase plan and stock options </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">_______________________</span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div><span style="font-family:Arial;font-size:9pt;">Includes </span><span style="font-family:Arial;font-size:9pt;"><span>$23 million</span></span> relating to acceleration of share-based compensation for former executives in the year ended December 31, 2017. This amount is reported in “Restructuring costs” in the accompanying consolidated statements of operations. 29000000 28000000 17000000 17000000 39000000 35000000 10000000 9000000 10000000 9000000 7000000 5000000 39000000 37000000 27000000 26000000 46000000 40000000 23000000 2900000 P4Y Activity for stock-based awards in the year ended <span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> is summarized below:</span><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:36%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">RSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">PSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">PSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unvested balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>399,795</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201,383</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>604,310</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>71.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>243,353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>389,778</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>136.23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(139,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3,132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,528</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(153,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73.98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(55,640</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13,202</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(68,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90.45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unvested balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>447,680</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>324,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>771,758</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>102.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 399795 3132 201383 604310 71.50 243353 0 146425 389778 136.23 139828 3132 10528 153488 73.98 55640 0 13202 68842 90.45 447680 0 324078 771758 102.01 49000000 P2Y2M12D P1Y7M6D 0.159 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The total grant date fair value of awards granted and vested is presented in the following table:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">PSUs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total granted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">RSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">PSAs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">PSUs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total vested</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Stock Options.</span><span style="font-family:Arial;font-size:10pt;"> Stock option awards generally have an exercise price equal to the fair market value of our common stock on the date of grant, vest in equal annual installments over periods up to </span><span style="font-family:Arial;font-size:10pt;"><span>four years</span></span><span style="font-family:Arial;font-size:10pt;"> from the date of grant, and have a maximum term of </span><span style="font-family:Arial;font-size:10pt;"><span>ten years</span></span><span style="font-family:Arial;font-size:10pt;"> from the date of grant. Stock option activity for the year ended December 31, 2019 is summarized below:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual term</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock options outstanding as of December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>405,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock options outstanding as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>405,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.4</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock options exercisable and expected to vest as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>405,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.4</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercisable as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>280,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.3</span></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 33000000 28000000 20000000 20000000 16000000 16000000 53000000 44000000 36000000 19000000 15000000 23000000 0 3000000 15000000 2000000 0 9000000 21000000 18000000 47000000 P4Y P10Y 405000 64.79 0 0 0 0 405000 64.79 29000000 P7Y4M24D 405000 64.79 29000000 P7Y4M24D 280000 63.65 20000000 P7Y3M18D 41.43 0.023 0.384 0 P8Y4M24D 4000000 P0Y9M18D 2000000 The following is a summary of information about stock options outstanding and exercisable at December 31, 2019: <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:31%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Exercisable</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-Average Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number Exercisable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-Average Exercise Price</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Range of Exercise Prices</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$33.02</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$67.33</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>375,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67.33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>250,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67.33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>405,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>280,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span> 30000 P3Y2M12D 33.02 30000 33.02 375000 P7Y9M18D 67.33 250000 67.33 405000 280000 3000000.0 0.85 25000 0.006 0.023 0.31 0.45 0 P0Y6M 142000 216000 351000 242000 365000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Restructuring Costs</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Restructuring costs are reported by the same name in the accompanying consolidated statements of operations. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">IT Restructuring Plan</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Management’s margin recovery plan identified and implemented various profit improvement initiatives. This included the plan to restructure our information technology department (the “IT Restructuring Plan”) in 2018, which is reported in the Other segment. In connection with this plan, in early 2019, we entered into services agreements with an outsourcing vendor who manages certain of our information technology services.</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of December 31, 2019, the IT Restructuring Plan was substantially complete. Under this plan, we incurred cumulative restructuring costs of </span><span style="font-family:Arial;font-size:10pt;"><span>$12 million</span></span><span style="font-family:Arial;font-size:10pt;">, including </span><span style="font-family:Arial;font-size:10pt;"><span>$7 million</span></span><span style="font-family:Arial;font-size:10pt;"> of one-time termination benefits and </span><span style="font-family:Arial;font-size:10pt;"><span>$5 million</span></span><span style="font-family:Arial;font-size:10pt;"> of other restructuring costs (primarily consulting fees). The final amount of costs incurred is lower than the </span><span style="font-family:Arial;font-size:10pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:10pt;"> we originally estimated and reported in our Annual Report on Form 10-K for the year ended December 31, 2018. Because more of our IT employees transitioned to our outsourcing vendor than originally contemplated, such employees were no longer included in the IT Restructuring Plan, resulting in lower one-time termination costs.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of December 31, 2018, </span><span style="font-family:Arial;font-size:10pt;"><span>$6 million</span></span><span style="font-family:Arial;font-size:10pt;"> was accrued under the IT Restructuring Plan, primarily for one-time termination benefits that require cash settlement. In the </span><span style="font-family:Arial;font-size:10pt;">year ended December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, we incurred </span><span style="font-family:Arial;font-size:10pt;"><span>$3 million</span></span><span style="font-family:Arial;font-size:10pt;"> of other restructuring costs, paid </span><span style="font-family:Arial;font-size:10pt;"><span>$5 million</span></span><span style="font-family:Arial;font-size:10pt;"> to settle one-time termination benefits, and paid </span><span style="font-family:Arial;font-size:10pt;"><span>$3 million</span></span><span style="font-family:Arial;font-size:10pt;"> to settle other restructuring costs. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$1 million</span></span><span style="font-family:Arial;font-size:10pt;"> was accrued under the IT Restructuring Plan.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2017 Restructuring Plan</span><span style="font-family:Arial;font-size:10pt;"> </span></div><span style="font-family:Arial;font-size:10pt;">As of December 31, 2018, </span><span style="font-family:Arial;font-size:10pt;"><span>$18 million</span></span><span style="font-family:Arial;font-size:10pt;"> was accrued for the restructuring and profitability improvement plan approved by the board of directors in June 2017 (the “2017 Restructuring Plan”). In the </span><span style="font-family:Arial;font-size:10pt;">year ended December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, we incurred </span><span style="font-family:Arial;font-size:10pt;"><span>$3 million</span></span><span style="font-family:Arial;font-size:10pt;"> of restructuring costs for adjustments to previously recorded lease contract termination costs, and paid </span><span style="font-family:Arial;font-size:10pt;"><span>$9 million</span></span><span style="font-family:Arial;font-size:10pt;"> to settle one-time termination and lease contract termination costs. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$12 million</span></span> was accrued for lease contract termination costs under the 2017 Restructuring Plan. We expect to continue to settle these liabilities through 2025, unless the leases are terminated sooner. 12000000 7000000 5000000 20000000 6000000 3000000 5000000 3000000 1000000 18000000 3000000 9000000 12000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Employee Benefit Plans</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We sponsor defined contribution 401(k) plans that cover substantially all employees of our company and its subsidiaries. Eligible employees are permitted to contribute up to the maximum amount allowed by law. We generally match up to the first </span><span style="font-family:Arial;font-size:10pt;"><span>4%</span></span><span style="font-family:Arial;font-size:10pt;"> of compensation contributed by employees. Expense recognized in connection with our contributions to the 401(k) plans amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$28 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$36 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$43 million</span></span><span style="font-family:Arial;font-size:10pt;"> in the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We also have a non-qualified deferred compensation plan for certain key employees. Under this plan, eligible participants may defer up to </span><span style="font-family:Arial;font-size:10pt;"><span>100%</span></span><span style="font-family:Arial;font-size:10pt;"> of their base salary and </span><span style="font-family:Arial;font-size:10pt;"><span>100%</span></span><span style="font-family:Arial;font-size:10pt;"> of their bonus to provide tax-deferred growth. The funds deferred are invested in corporate-owned life insurance, under a rabbi trust.</span></div> 0.04 28000000 36000000 43000000 1 1 <span style="color:#828282;font-family:Arial;font-size:14pt;">Commitments and Contingencies</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory Capital Requirements and Dividend Restrictions</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our health plans, which are operated by our respective wholly owned subsidiaries in those states, are subject to state laws and regulations that, among other things, require the maintenance of minimum levels of statutory capital, as defined by each state. The National Association of Insurance Commissioners (“NAIC”), has adopted rules which, if implemented by the states, set minimum capitalization requirements for insurance companies, HMOs, and other entities bearing risk for health care coverage. The requirements take the form of risk-based capital (“RBC”) rules which may vary from state to state. All of the states in which our health plans operate, except California, Florida and New York, have adopted these rules. Such requirements, if adopted by California, Florida and New York, may increase the minimum capital required for those states. Regulators in some states may also enforce capital requirements that require the retention of net worth in excess of amounts formally required by statute or regulation. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, our health plans had aggregate statutory capital and surplus of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$1,852 million</span></span><span style="font-family:Arial;font-size:10pt;"> compared with the required minimum aggregate statutory capital and surplus of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$1,110 million</span></span><span style="font-family:Arial;font-size:10pt;">. All of our health plans were in compliance with the minimum capital requirements at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. We have the ability and commitment to provide additional capital to each of our health plans when necessary to ensure that statutory capital and surplus continue to meet regulatory requirements. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Such statutes, regulations and informal capital requirements also restrict the timing, payment, and amount of dividends and other distributions that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based on current statutes and regulations, the net assets in these subsidiaries (after intercompany eliminations) which may not be transferable to us in the form of loans, advances, or cash dividends was approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$1,811 million</span></span><span style="font-family:Arial;font-size:10pt;"> at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$2,262 million</span></span><span style="font-family:Arial;font-size:10pt;"> at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. Because of the statutory restrictions that inhibit the ability of our health plans to transfer net assets to us, the amount of retained earnings readily available to pay dividends to our stockholders is generally limited to cash, cash equivalents and investments held by the parent company – Molina Healthcare, Inc. Such cash, cash equivalents and investments amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$997 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$170 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously billed and collected revenues. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Professional Liability Insurance</span></div>We carry medical professional liability insurance for health care services rendered in the primary care institutions that we manage. In addition, we also carry errors and omissions insurance for all Molina entities. 1852000000 1110000000 1811000000 2262000000 997000000 170000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Segments</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We currently have</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span><span style="font-family:Arial;font-size:10pt;"> Our Other </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">segment, which was insignificant to our consolidated results of operations in 2018 and 2019, includes the historical results of the MMIS and behavioral health subsidiaries we sold in late 2018, as well as certain corporate amounts not allocated to the Health Plans segment.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Margin is the appropriate earnings measure for our reportable segments, based on how our chief operating decision maker currently reviews results, assesses performance, and allocates resources. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The key metrics used to assess the performance of our Health Plans segment are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying margin, or the amount earned by the Health Plans segment after medical costs are deducted from premium revenue, is the most important measure of earnings reviewed by management. </span><span style="font-family:Arial;font-size:10pt;">Margin for our Health Plans segment is referred to as “Medical Margin.”</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Consolidated</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,815</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,829</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Goodwill, and intangible assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,265</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,522</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,471</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,890</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,475</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Goodwill, and intangible assets, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>989</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,781</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Goodwill, and intangible assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,471</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table reconciles margin by segment to consolidated income (loss) before income tax expense (benefit): </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,475</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,781</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,303</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,518</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,810</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Add: other operating revenues </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>871</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: other operating expenses </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,880</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,243</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,873</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: loss on sales of subsidiaries, net of gain</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,044</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,131</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(555</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: other expenses, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Income (loss) before income tax expense (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>972</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>999</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(612</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">______________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income and other revenue.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(2)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, impairment losses, and restructuring costs.</span></div> 2 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Consolidated</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,815</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,829</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Goodwill, and intangible assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,265</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,522</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,471</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,890</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,475</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Goodwill, and intangible assets, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>989</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,781</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Goodwill, and intangible assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,471</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table reconciles margin by segment to consolidated income (loss) before income tax expense (benefit): </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,475</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,781</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,303</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,518</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,810</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Add: other operating revenues </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>871</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: other operating expenses </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,880</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,243</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,873</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: loss on sales of subsidiaries, net of gain</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,044</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,131</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(555</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: other expenses, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Income (loss) before income tax expense (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>972</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>999</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(612</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">______________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income and other revenue.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(2)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, impairment losses, and restructuring costs.</span></div> 16815000000 14000000 16829000000 2303000000 0 2303000000 172000000 0 172000000 5265000000 1522000000 6787000000 18471000000 419000000 18890000000 2475000000 43000000 2518000000 190000000 0 190000000 6165000000 989000000 7154000000 19352000000 531000000 19883000000 1781000000 29000000 1810000000 212000000 43000000 255000000 6347000000 2124000000 8471000000 2303000000 2475000000 1781000000 0 43000000 29000000 2303000000 2518000000 1810000000 621000000 871000000 508000000 1880000000 2243000000 2873000000 0 -15000000 0 1044000000 1131000000 -555000000 -72000000 -132000000 -57000000 972000000 999000000 -612000000 <span style="color:#828282;font-family:Arial;font-size:14pt;">Quarterly Results of Operations</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> (Unaudited)</span><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes quarterly unaudited results of operations for the periods presented. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">For The Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Sept. 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions, except per-share data)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,193</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,243</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>581</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>583</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income per share - Basic </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income per share - Diluted </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">For The Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">June 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Sept. 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions, except per-share data)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,646</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,697</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,664</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>615</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>566</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>664</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gain (loss) on sales of subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income per share - Basic </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income per share - Diluted </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;">________________________</span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div>The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method and is based on the weighted-average common share equivalents outstanding during each quarter. Accordingly, the sum of the quarterly net income per share amounts may not agree to the total for the year. <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes quarterly unaudited results of operations for the periods presented. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">For The Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Sept. 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions, except per-share data)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,193</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,243</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>581</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>583</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income per share - Basic </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income per share - Diluted </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">For The Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">June 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Sept. 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions, except per-share data)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,646</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,697</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,664</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>615</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>566</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>664</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gain (loss) on sales of subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income per share - Basic </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income per share - Diluted </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;">________________________</span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div>The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method and is based on the weighted-average common share equivalents outstanding during each quarter. Accordingly, the sum of the quarterly net income per share amounts may not agree to the total for the year. 4119000000 4193000000 4243000000 4274000000 581000000 583000000 561000000 578000000 198000000 196000000 175000000 168000000 3.19 3.15 2.81 2.70 2.99 3.06 2.75 2.67 4646000000 4883000000 4697000000 4664000000 615000000 673000000 566000000 664000000 0 0 37000000 -52000000 107000000 202000000 197000000 201000000 1.79 3.29 3.22 3.24 1.64 3.02 2.90 3.01 <span style="color:#828282;font-family:Arial;font-size:14pt;">Condensed Financial Information of Registrant</span><span style="font-family:Arial;font-size:14pt;color:#828282;"> </span><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The condensed balance sheets as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, and the related condensed statements of operations, comprehensive income (loss) and cash flows for each of the three years in the period ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> for our parent company Molina Healthcare, Inc. (the “Registrant”), are presented below. </span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Condensed Balance Sheets </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;padding-left:16px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions, except per-share data)</span></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ASSETS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current assets:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Receivables</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Due from affiliates</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivative asset</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>785</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Property, equipment, and capitalized software, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Goodwill and intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Investments in subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Advances to related parties and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,774</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,821</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS’ EQUITY</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medical claims and benefits payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current portion of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivative liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>307</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>944</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,814</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,174</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stockholders’ equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock, $0.001 par value; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,781</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,012</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stockholders’ equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities and stockholders’ equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,774</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,821</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">See accompanying notes.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Condensed Statements of Operations</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Administrative services fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,038</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Investment income and other revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,056</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,333</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,007</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other operating expenses </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Impairment losses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,004</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,119</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,383</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gain on sale of subsidiary</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other (income) expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(61</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Loss before income tax (benefit) expense and equity in net earnings (losses) of subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Income tax expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net loss before equity in net earnings (losses) of subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(44</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(114</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Equity in net earnings (losses) of subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>766</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>751</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(398</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>737</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(512</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Condensed Statements of Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(512</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unrealized investment income (loss) </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: effect of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>749</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>705</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(515</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">See accompanying notes.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Condensed Statements of Cash Flows </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Capital contributions to subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(145</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(370</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dividends received from subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,373</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Purchases of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(136</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(331</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Proceeds from sales and maturities of investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Purchases of property, equipment and capitalized software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net cash received from sale of subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>242</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Change in amounts due to/from affiliates</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net cash provided by (used in) investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>631</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Repayment of principal amount of convertible notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(240</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(362</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash paid for partial settlement of conversion option</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(578</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash received for partial settlement of call option</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash paid for partial termination of warrants</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Proceeds from borrowings under term loan facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock purchases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Repayment of credit facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(300</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Proceeds from senior notes offerings, net of issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Proceeds from borrowings under credit facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net cash (used in) provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(552</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net (decrease) increase in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>766</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(443</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>513</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash and cash equivalents at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>513</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Condensed Financial Information of Registrant </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Note A - Basis of Presentation </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Registrant was incorporated in 2002. Prior to that date, Molina Healthcare of California (formerly known as Molina Medical Centers) operated as a California health plan and as the parent company for three other state health plans. In June 2003, the employees and operations of the corporate entity were transferred from Molina Healthcare of California to the Registrant. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Registrant’s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries since the date of acquisition. The accompanying condensed financial information of the Registrant should be read in conjunction with the consolidated financial statements and accompanying notes. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Note B - Transactions with Subsidiaries </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Registrant provides </span><span style="font-family:Arial;font-size:10pt;">certain centralized medical and administrative services to our subsidiaries pursuant to administrative services agreements that include, but are not limited to, information technology, product development and administration, underwriting, claims processing, customer service, certain care management services, human resources, marketing, purchasing, risk management, actuarial, underwriting, finance, accounting, legal and public </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">relations.</span><span style="font-family:Arial;font-size:10pt;"> Fees are based on the fair market value of services rendered and are recorded as operating revenue. Payment is subordinated to the subsidiaries’ ability to comply with minimum capital and other restrictive financial requirements of the states in which they operate. Charges in </span><span style="font-family:Arial;font-size:10pt;">2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> for these services amounted to </span><span style="font-family:Arial;font-size:10pt;"><span>$1,038 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$1,137 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$1,317 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, and are included in operating revenue. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Registrant and its subsidiaries are included in the consolidated federal and state income tax returns filed by the Registrant. Income taxes are allocated to each subsidiary in accordance with an intercompany tax allocation agreement. The agreement allocates income taxes in an amount generally equivalent to the amount which would be expensed by the subsidiary if it filed a separate tax return. Net operating loss benefits are paid to the subsidiary by the Registrant to the extent such losses are utilized in the consolidated tax returns. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Note C - Dividends and Capital Contributions </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">When the Registrant receives dividends from its subsidiaries, such amounts are recorded as a reduction to the investments in the respective subsidiaries.</span></div>For all periods presented, the Registrant made capital contributions to certain subsidiaries primarily to comply with minimum net worth requirements and to fund business combinations. Such amounts have been recorded as an increase in investment in the respective subsidiaries. <div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Condensed Balance Sheets </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;padding-left:16px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions, except per-share data)</span></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ASSETS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current assets:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Receivables</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Due from affiliates</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivative asset</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>785</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Property, equipment, and capitalized software, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Goodwill and intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Investments in subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Advances to related parties and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,774</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,821</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS’ EQUITY</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Medical claims and benefits payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current portion of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivative liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>307</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>944</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,814</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,174</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stockholders’ equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock, $0.001 par value; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,781</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,012</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stockholders’ equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities and stockholders’ equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,774</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,821</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 836000000 70000000 161000000 100000000 2000000 2000000 49000000 90000000 46000000 47000000 29000000 476000000 1123000000 785000000 327000000 176000000 13000000 13000000 2225000000 2768000000 10000000 39000000 76000000 40000000 3774000000 3821000000 0 4000000 260000000 223000000 18000000 241000000 29000000 476000000 307000000 944000000 1237000000 1020000000 231000000 197000000 39000000 13000000 1814000000 2174000000 0 0 0 0 175000000 643000000 4000000 -8000000 1781000000 1012000000 1960000000 1647000000 3774000000 3821000000 <div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Condensed Statements of Operations</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Administrative services fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,038</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Investment income and other revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,056</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,333</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,007</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other operating expenses </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Impairment losses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,004</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,119</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,383</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gain on sale of subsidiary</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other (income) expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(61</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Loss before income tax (benefit) expense and equity in net earnings (losses) of subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Income tax expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net loss before equity in net earnings (losses) of subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(44</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(114</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Equity in net earnings (losses) of subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>766</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>751</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(398</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>737</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(512</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 1038000000 1138000000 1317000000 18000000 17000000 16000000 1056000000 1155000000 1333000000 937000000 1007000000 1082000000 63000000 69000000 93000000 0 8000000 16000000 4000000 35000000 153000000 0 0 39000000 1004000000 1119000000 1383000000 0 37000000 0 52000000 73000000 -50000000 87000000 114000000 117000000 15000000 -17000000 61000000 -20000000 -58000000 -106000000 9000000 -14000000 8000000 -29000000 -44000000 -114000000 766000000 751000000 -398000000 737000000 707000000 -512000000 <div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Condensed Statements of Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(512</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unrealized investment income (loss) </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: effect of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>749</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>705</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(515</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 737000000 707000000 -512000000 16000000 -3000000 -5000000 4000000 -1000000 -2000000 12000000 -2000000 -3000000 749000000 705000000 -515000000 <div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Condensed Statements of Cash Flows </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Capital contributions to subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(145</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(370</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dividends received from subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,373</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Purchases of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(136</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(331</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Proceeds from sales and maturities of investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Purchases of property, equipment and capitalized software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net cash received from sale of subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>242</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Change in amounts due to/from affiliates</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net cash provided by (used in) investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>631</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Repayment of principal amount of convertible notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(240</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(362</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash paid for partial settlement of conversion option</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(578</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash received for partial settlement of call option</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash paid for partial termination of warrants</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Proceeds from borrowings under term loan facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock purchases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Repayment of credit facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(300</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Proceeds from senior notes offerings, net of issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Proceeds from borrowings under credit facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net cash (used in) provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(552</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net (decrease) increase in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>766</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(443</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>513</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash and cash equivalents at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>513</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 64000000 118000000 166000000 43000000 145000000 370000000 1373000000 298000000 286000000 152000000 136000000 331000000 93000000 388000000 156000000 56000000 22000000 67000000 0 242000000 0 38000000 6000000 -49000000 -1000000 0 0 1254000000 631000000 -375000000 240000000 362000000 0 578000000 623000000 0 578000000 623000000 0 514000000 549000000 0 220000000 0 0 47000000 0 0 0 300000000 0 0 0 325000000 0 0 300000000 29000000 19000000 11000000 -552000000 -1192000000 636000000 766000000 -443000000 427000000 70000000 513000000 86000000 836000000 70000000 513000000 1038000000 1137000000 1317000000 XML 81 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Medical Claims and Benefits Payable
12 Months Ended

Dec. 31, 2019

Insurance [Abstract]

Medical Claims and Benefits Payable Medical Claims and Benefits Payable
The following table provides the details of our medical claims and benefits payable as of the dates indicated.

December 31,

2019

2018

2017

(In millions)
Fee-for-service claims incurred but not paid (“IBNP”)
$
1,406

$
1,562

$
1,717

Pharmacy payable
126

115

112

Capitation payable
55

52

67

Other
267

232

296

Total
$
1,854

$
1,961

$
2,192

“Other” medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of operations. Non-risk provider payables amounted to $132 million, $107 million and $122 million, as of December 31, 2019, 2018, and 2017, respectively.
The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for “Components of medical care costs related to: Prior periods” represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the period were (more) less than the actual amount of the liability based on information (principally the payment of claims) developed since that liability was first reported.

Year Ended December 31,

2019

2018

2017

(In millions)
Medical claims and benefits payable, beginning balance
$
1,961

$
2,192

$
1,929

Components of medical care costs related to:

Current period
14,176

15,478

17,037

Prior periods ⁽¹⁾
(271
)

(341
)

36

Total medical care costs
13,905

15,137

17,073

Change in non-risk and other provider payables
24

13

(106
)

Payments for medical care costs related to:

Current period
12,554

13,671

15,130

Prior periods
1,482

1,710

1,574

Total paid
14,036

15,381

16,704

Medical claims and benefits payable, ending balance
$
1,854

$
1,961

$
2,192

________________
(1)
December 31, 2018, includes the 2018 benefit of the 2017 Marketplace CSR reimbursement of $81 million.
The following tables provide information about incurred and paid claims development as of December 31, 2019, as well as cumulative claims frequency and the total of incurred but not paid claims liabilities. The cumulative claim frequency is measured by claim event, and includes claims covered under capitated arrangements.
Incurred Claims and Allocated Claims Adjustment Expenses

Total IBNP

Cumulative number of reported claims
Benefit Year

2017

2018

2019

(Unaudited)

(Unaudited)

(In millions)
2017

$
17,037

$
16,728

$
16,704

$
18

119

2018

15,478

15,245

25

110

2019

14,176

1,348

93

$
46,125

$
1,391

Cumulative Paid Claims and Allocated Claims Adjustment Expenses

Benefit Year

2017

2018

2019

(Unaudited)

(Unaudited)

(In millions)

2017

$
15,130

$
16,671

$
16,686

2018

13,752

15,220

2019

12,554

$
44,460

The following table represents a reconciliation of claims development to the aggregate carrying amount of the liability for medical claims and benefits payable.

2019

(In millions)

Incurred claims and allocated claims adjustment expenses

$
46,125

Less: cumulative paid claims and allocated claims adjustment expenses

(44,460
)

All outstanding liabilities before 2017

15

Non-risk and other provider payables

174

Medical claims and benefits payable

$
1,854

Our estimates of medical claims and benefits payable recorded at December 31, 2018, 2017 and 2016 developed favorably (unfavorably) by approximately $271 million, $341 million and $(36) million in 2019, 2018 and 2017, respectively.
The favorable prior year development recognized in 2019 was primarily due to lower than expected utilization of medical services by our Medicaid members, and improved operating performance. Consequently, the ultimate costs recognized in 2019 were lower than our original estimates in 2018, which was not discernible until additional information was provided, and as claims payments were processed.
The favorable prior year development recognized in 2018 includes a benefit of approximately $81 million in reduced medical care costs relating to Marketplace CSR subsidies for 2017 dates of service. The remainder of the favorable prior period development was primarily due to lower than expected utilization of medical services by our Medicaid and Marketplace members and improved operating performance. The differences between our original estimates in 2017 and the ultimate costs in 2018 were not discernable until additional information was provided to us in 2018 and the effect became clearer over time as claim payments were processed.
The unfavorable prior year development in 2017 was primarily due to higher than expected costs for settling certain claims with certain providers in states where we had recently commenced operations, such as in Illinois and Puerto Rico, or had instituted significant changes due to provider contract changes, such as in Florida and New Mexico. The differences between our original estimates in 2016 and the ultimate costs in 2017 were not discernible until additional information was provided to us in 2017, and the effect became clearer over time as claim payments were processed.

X

- References
No definition available.
+ Details

Name: us-gaap_InsuranceAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for insurance products considered to be short-duration contracts because the contract provides insurance protection for a fixed period of short duration and enables the insurer to cancel the contract or to adjust the provisions of the contract at the end of any contract period, such as adjusting the amount of premiums charged or coverage provided, and on contracts on which amounts are paid but insurance risk is not transferred.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-URI http://asc.fasb.org/topic&trid=2303980
+ Details

Name: us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 82 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Property, Equipment, and Capitalized Software, Net (Tables)
12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Summary of property and equipment and depreciation and amortization recognized
A summary of property, equipment, and capitalized software is as follows:

December 31,

2019

2018

(In millions)
Capitalized software
$
421

$
373

Furniture and equipment
213

231

Building and improvements
49

154

Land
4

16

Total cost
687

774

Less: accumulated amortization - capitalized software
(351
)

(320
)
Less: accumulated depreciation and amortization - furniture, equipment, building, and improvements
(179
)

(213
)
Total accumulated depreciation and amortization
(530
)

(533
)
ROU assets - finance leases
228

—

Property, equipment, and capitalized software, net
$
385

$
241

The following table presents all depreciation and amortization recognized in our consolidated statements of operations:

Year Ended December 31,

2019

2018

2017

(In millions)
Recorded in depreciation and amortization:

Amortization of capitalized software
$
33

$
42

$
64

Depreciation and amortization of furniture, equipment, building, and improvements
21

36

42

Amortization of intangible assets
18

21

31

Amortization of finance leases
17

—

—

Subtotal
89

99

137

Recorded in cost of service revenue:

Amortization of capitalized software and deferred contract costs
—

28

41

Total depreciation and amortization recognized
$
89

$
127

$
178

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 84 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Net Income (Loss) Per Share (Tables)
12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Summary of denominators for the computation of basic and diluted earnings per share
The following table sets forth the calculation of basic and diluted net income (loss) per share:

Year Ended December 31,

2019

2018

2017

(In millions, except net income (loss) per share)
Numerator:

Net income (loss)
$
737

$
707

$
(512
)
Denominator:

Shares outstanding at the beginning of the period
62.1

59.3

55.8

Weighted-average number of shares issued:

Exchange of convertible senior notes ⁽¹⁾
—

1.4

0.1

Conversion of convertible senior notes ⁽¹⁾
—

0.2

—

Stock-based compensation
0.1

0.2

0.5

Denominator for basic net income (loss) per share
62.2

61.1

56.4

Effect of dilutive securities:

Warrants ⁽²⁾
1.4

4.8

—

Convertible senior notes ⁽¹⁾
—

0.4

—

Stock-based compensation
0.6

0.3

—

Denominator for diluted net income (loss) per share
64.2

66.6

56.4

Net income (loss) per share: ⁽³⁾

Basic
$
11.85

$
11.57

$
(9.07
)
Diluted
$
11.47

$
10.61

$
(9.07
)

Potentially dilutive common shares excluded from calculations: ⁽²⁾

Warrants
—

—

1.9

Convertible senior notes ⁽¹⁾
—

—

0.4

Stock-based compensation
—

—

0.3

_______________________________
(1)
“Convertible senior notes” in this table refer to the 1.625% convertible senior notes due 2044 that were settled in 2018.
(2)
For more information regarding the warrants, including partial termination transactions, refer to Note 14, “Stockholders' Equity.” The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. Certain potentially dilutive common shares issuable are not included in the computation of diluted net income (loss) per share because to do so would have been anti-dilutive.
(3)
Source data for calculations in thousands.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 85 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Debt (Tables)
12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Maturities of long-term debt
Contractual maturities of debt, as of December 31, 2019, are illustrated in the following table. All amounts represent the principal amounts of the debt instruments outstanding.

Total

2020

2021

2022

2023

2024

Thereafter

(In millions)
5.375% Notes
$
700

$
—

$
—

$
700

$
—

$
—

$
—

4.875% Notes
330

—

—

—

—

—

330

Term Loan Facility
220

6

16

22

22

154

—

1.125% Convertible Notes
12

12

—

—

—

—

—

Total
$
1,262

$
18

$
16

$
722

$
22

$
154

$
330

Long term debt The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets:

December 31,

2019

2018

(In millions)
Current portion of long-term debt:

1.125% Convertible Notes, net of unamortized discount
$
12

$
241

Term Loan Facility
6

—

Lease financing obligations
—

1

Debt issuance costs
—

(1
)
Total, current portion
$
18

$
241

Non-current portion of long-term debt:

5.375% Notes
$
700

$
700

4.875% Notes
330

330

Term Loan Facility
214

—

Debt issuance costs
(7
)

(10
)
Total, non-current portion
$
1,237

$
1,020

Interest costs
Interest cost recognized relating to our convertible senior notes for the periods presented was as follows:

Years Ended December 31,

2019

2018

2017

(In millions)
Contractual interest at coupon rate
$
1

$
6

$
11

Amortization of the discount
5

21

32

Total
$
6

$
27

$
43

X

- Definition
Schedule of debt instruments interest cost recognized.
+ References
No definition available.
+ Details

Name: moh_ScheduleOfDebtInstrumentsInterestCostRecognizedTableTextBlock

Namespace Prefix: moh_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 86 R108.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Parent Company

Related Party Transaction [Line Items]

Services revenue from subsidiaries $ 1,038 $ 1,137 $ 1,317

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=116637345&loc=SL114874292-224272

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_RevenueFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 87 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Revenue:

Premium revenue $ 16,208 $ 17,612 $ 18,854

Premium tax revenue 489 417 438

Health insurer fees reimbursed 0 329 0

Service revenue 0 407 521

Investment income and other revenue 132 125 70

Total revenue 16,829 18,890 19,883

Operating expenses:

General and administrative expenses 1,296 1,333 1,594

Premium tax expenses 489 417 438

Health insurer fees 0 348 0

Depreciation and amortization 89 99 137

Restructuring costs 6 46 234

Impairment losses 0 0 470

Total operating expenses 15,785 17,744 20,438

Loss on sales of subsidiaries, net of gain 0 (15) 0

Operating income (loss) 1,044 1,131 (555)

Other expenses, net:

Interest expense 87 115 118

Other (income) expenses, net (15) 17 (61)

Total other expenses, net 72 132 57

Income (loss) before income tax expense (benefit) 972 999 (612)

Income tax expense (benefit) 235 292 (100)

Net income (loss) $ 737 $ 707 $ (512)

Net income (loss) per share:

Basic (in dollars per share) $ 11.85 $ 11.57 $ (9.07)

Diluted (in dollars per share) $ 11.47 $ 10.61 $ (9.07)

Weighted average shares outstanding:

Basic (in shares) 62.2 61.1 56.4

Diluted (in shares) 64.2 66.6 56.4

Medical care costs

Operating expenses:

Cost of revenue $ 13,905 $ 15,137 $ 17,073

Cost of service revenue

Operating expenses:

Cost of revenue $ 0 $ 364 $ 492

X

- Definition
Health Care Organization, Insurer Fee Expense
+ References
No definition available.
+ Details

Name: moh_HealthCareOrganizationInsurerFeeExpense

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Health Care Organization, Insurer Fee Revenue
+ References
No definition available.
+ Details

Name: moh_HealthCareOrganizationInsurerFeeRevenue

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Health Care Organization, Premium Tax Revenue
+ References
No definition available.
+ Details

Name: moh_HealthCareOrganizationPremiumTaxRevenue

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
An assessment levied by a state government on the net premium income collected.
+ References
No definition available.
+ Details

Name: moh_PremiumTaxExpenses

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684
+ Details

Name: us-gaap_GainLossOnSaleOfBusiness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetImpairment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.1,4)
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_InsuranceServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.1-5)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestAndDividendIncomeOperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(1))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 235
-Section S99
-Paragraph 2
-Subparagraph (SX 210.12-17(Column E))
-URI http://asc.fasb.org/extlink&oid=34713774&loc=d3e574992-122915

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(c))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 605
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547
+ Details

Name: us-gaap_PremiumsEarnedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_RestructuringCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_HealthCarePremiumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_TechnologyServiceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 88 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Statements of Stockholders' Equity - USD ($)
shares in Millions, $ in Millions

Total

Common Stock

Additional Paid-in Capital

Accumulated Other Comprehensive Income (Loss)

Retained Earnings

Beginning Balance (in shares) at Dec. 31, 2016 55.8 57.0

Beginning Balance at Dec. 31, 2016 $ 1,649 $ 0 $ 841 $ (2) $ 810

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net income (loss) (512) (512)

Exchange of convertible senior notes (in shares) 3.0

Exchange of convertible senior notes 161 161

Other comprehensive income (loss), net (3) (3)

Share-based compensation $ 42 42

Ending Balance (in shares) at Dec. 31, 2017 59.3 60.0

Ending Balance at Dec. 31, 2017 $ 1,337 $ 0 1,044 (5) 298

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net income (loss) 707 707

Exchange of convertible senior notes (in shares) 2.0

Exchange of convertible senior notes 108 108

Other comprehensive income (loss), net (2) (2)

Share-based compensation 37 37

Partial termination of warrants (550) (550)

Conversion of convertible senior notes $ 4 4

Ending Balance (in shares) at Dec. 31, 2018 62.1 62.0

Ending Balance at Dec. 31, 2018 $ 1,647 $ 0 643 (8) 1,012

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net income (loss) 737 737

Common stock purchases (54) $ (54) (1) (53)

Exchange of convertible senior notes 0

Other comprehensive income (loss), net 12 12

Share-based compensation 47 47

Partial termination of warrants (514) (514)

Ending Balance (in shares) at Dec. 31, 2019 62.0

Ending Balance at Dec. 31, 2019 $ 1,960 $ 0 $ 175 $ 4 $ 1,781

X

- Definition
Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 55
-Paragraph 51
-URI http://asc.fasb.org/extlink&oid=117331294&loc=d3e34017-109320
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of other increase (decrease) in additional paid in capital (APIC).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockRepurchasedDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 89 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Investments - Balances of Restricted Investments (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Schedule of Held-to-maturity Securities [Line Items]

Restricted investments $ 79 $ 120

Florida

Schedule of Held-to-maturity Securities [Line Items]

Restricted investments 12 32

New Mexico

Schedule of Held-to-maturity Securities [Line Items]

Restricted investments 21 43

Ohio

Schedule of Held-to-maturity Securities [Line Items]

Restricted investments 12 12

Puerto Rico

Schedule of Held-to-maturity Securities [Line Items]

Restricted investments 11 10

Other

Schedule of Held-to-maturity Securities [Line Items]

Restricted investments $ 23 $ 23

X

- Definition
This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.
+ References
No definition available.
+ Details

Name: us-gaap_RestrictedInvestmentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=stpr_FL

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_NM

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_OH

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_PR

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=moh_OtherGeographicalAreasMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 90 R104.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details) - $ / shares

Dec. 31, 2019

Dec. 31, 2018

Condensed Financial Statements, Captions [Line Items]

Common stock, par value (dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 150,000,000 150,000,000

Common stock, shares outstanding 62,000,000 62,000,000

Preferred stock, par value (dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 20,000,000 20,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Parent Company

Condensed Financial Statements, Captions [Line Items]

Common stock, par value (dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 150,000,000 150,000,000

Common stock, shares outstanding 62,000,000 62,000,000

Preferred stock, par value (dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 20,000,000 20,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: srt_CondensedFinancialStatementsCaptionsLineItems

Namespace Prefix: srt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 91 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Numerator:

Net income (loss) $ 168 $ 175 $ 196 $ 198 $ 201 $ 197 $ 202 $ 107 $ 737 $ 707 $ (512)

Denominator:

Shares outstanding at the beginning of the period (in shares) 62.1 62.1 59.3 55.8

Weighted-average number of shares issued:

Exchange of convertible senior notes (in shares) 0.0 1.4 0.1

Conversion of convertible senior notes (in shares) 0.0 0.2 0.0

Stock-based compensation (in shares) 0.1 0.2 0.5

Denominator for basic net income (loss) per share (in shares) 62.2 61.1 56.4

Effect of dilutive securities:

Warrants (in shares) 1.4 4.8 0.0

Convertible senior notes (in shares) 0.0 0.4 0.0

Share-based compensation (in shares) 0.6 0.3 0.0

Denominator for diluted net (loss) income per share (in shares) 64.2 66.6 56.4

Net income (loss) per share:

Basic (in dollars per share) $ 2.70 $ 2.81 $ 3.15 $ 3.19 $ 3.24 $ 3.22 $ 3.29 $ 1.79 $ 11.85 $ 11.57 $ (9.07)

Diluted (in dollars per share) $ 2.67 $ 2.75 $ 3.06 $ 2.99 $ 3.01 $ 2.90 $ 3.02 $ 1.64 $ 11.47 $ 10.61 $ (9.07)

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

Stock-based compensation (in shares) 0.0 0.0 0.3

Convertible senior notes

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

Potentially dilutive common shares excluded from calculations (in shares) 0.0 0.0 0.4

Stated interest rate 1.625% 1.625%

Warrants

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

Potentially dilutive common shares excluded from calculations (in shares) 0.0 0.0 1.9

X

- Definition
Antidilutive Securities Excluded from Computation of EPS, Share Based Compensation, Amount
+ References
No definition available.
+ Details

Name: moh_AntidilutiveSecuritiesExcludedfromComputationofEPSShareBasedCompensationAmount

Namespace Prefix: moh_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Class Of Warrant Or Right, Stated Interest Rate
+ References
No definition available.
+ Details

Name: moh_ClassOfWarrantOrRightStatedInterestRate

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted Average Number of Shares Issued, Conversion of Senior Notes
+ References
No definition available.
+ Details

Name: moh_WeightedAverageNumberofSharesIssuedConversionofSeniorNotes

Namespace Prefix: moh_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted Average Number of Shares, Share Based Compensation
+ References
No definition available.
+ Details

Name: moh_WeightedAverageNumberofSharesShareBasedCompensation

Namespace Prefix: moh_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DilutiveSecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 40
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1930-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 28A
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetIncomeLossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesIssuedBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_ConvertibleSeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 92 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Investments - Schedule of Investments (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Debt Securities, Available-for-sale [Line Items]

Amortized Cost $ 1,941 $ 1,692

Gross Unrealized Gains 7 0

Gross Unrealized Losses 2 11

Estimated Fair Value 1,946 1,681

Corporate debt securities

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 1,174 1,131

Gross Unrealized Gains 5 0

Gross Unrealized Losses 1 8

Estimated Fair Value 1,178 1,123

Mortgage-backed securities

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 420

Gross Unrealized Gains 1

Gross Unrealized Losses 1

Estimated Fair Value 420

Asset-backed securities

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 126 83

Gross Unrealized Gains 1 0

Gross Unrealized Losses 0 1

Estimated Fair Value 127 82

U.S. Treasury notes

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 86 181

Gross Unrealized Gains 0 0

Gross Unrealized Losses 0 0

Estimated Fair Value 86 181

Municipal securities

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 78 115

Gross Unrealized Gains 0 0

Gross Unrealized Losses 0 1

Estimated Fair Value 78 114

GSEs

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 49 164

Gross Unrealized Gains 0 0

Gross Unrealized Losses 0 1

Estimated Fair Value 49 163

Foreign securities

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 7 4

Gross Unrealized Gains 0 0

Gross Unrealized Losses 0 0

Estimated Fair Value 7 4

Certificates of deposit

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 1 14

Gross Unrealized Gains 0 0

Gross Unrealized Losses 0 0

Estimated Fair Value $ 1 $ 14

X

- Definition
Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 93 R100.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Segments - Schedule of Operating Segment Information (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Segment Reporting Information [Line Items]

Total revenue $ 4,274 $ 4,243 $ 4,193 $ 4,119 $ 4,664 $ 4,697 $ 4,883 $ 4,646 $ 16,829 $ 18,890 $ 19,883

Margin 578 $ 561 $ 583 $ 581 664 $ 566 $ 673 $ 615 2,303 2,518 1,810

Goodwill and intangible assets, net 172 190 172 190 255

Total assets 6,787 7,154 6,787 7,154 8,471

Health Plans

Segment Reporting Information [Line Items]

Total revenue 16,815 18,471 19,352

Goodwill and intangible assets, net 172 190 172 190 212

Total assets 5,265 6,165 5,265 6,165 6,347

Other

Segment Reporting Information [Line Items]

Total revenue 14 419 531

Margin 0 43 29

Goodwill and intangible assets, net 0 0 0 0 43

Total assets $ 1,522 $ 989 $ 1,522 $ 989 $ 2,124

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.
+ References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsNetIncludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 94 R86.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Operating Loss Carryforwards [Line Items]

Change in tax rate, deferred tax asset, income tax expense (benefit) $ 54

Measurement period adjustment, income tax expense (benefit) $ (4)

Deferred tax assets $ 24

Decrease in deferred tax asset valuation allowance 4

Valuation allowance 24 28

Impact on effective tax rate if tax benefits are recognized 18 $ 18 $ 12

Liability for unrecognized tax benefits, potential decrease 5

State

Operating Loss Carryforwards [Line Items]

Operating loss carryforwards 310

Tax credit carryovers 8

Foreign

Operating Loss Carryforwards [Line Items]

Tax credit carryovers $ 5

X

- Definition
Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)(3)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLossCarryforwardsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_TaxCreditCarryforwardAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_TaxCreditCarryforwardValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of income tax expense for remeasurement of deferred tax asset from change in tax rate pursuant to Tax Cuts and Jobs Act.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income tax expense (benefit) for measurement period adjustment from accounting for tax effect pursuant to Tax Cuts and Jobs Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2A
-Subparagraph (SAB Topic 5.EE.Q2(f))
-URI http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817
+ Details

Name: us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318
+ Details

Name: us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 95 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Product Information [Line Items]

Claims paid $ 44,460

Benefit Year 2017

Product Information [Line Items]

Claims paid 16,686 $ 16,671 $ 15,130

Benefit Year 2018

Product Information [Line Items]

Claims paid 15,220 $ 13,752

Benefit Year 2019

Product Information [Line Items]

Claims paid $ 12,554

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ProductInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 4B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438
+ Details

Name: us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2019Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 96 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Insurance [Abstract]

Fee-for-service claims incurred but not paid (“IBNP”) $ 1,406 $ 1,562 $ 1,717

Pharmacy payable 126 115 112

Capitation payable 55 52 67

Other 267 232 296

Total $ 1,854 $ 1,961 $ 2,192 $ 1,929

X

- Definition
Capitation Claims Payable
+ References
No definition available.
+ Details

Name: moh_CapitationClaimsPayable

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount
+ References
No definition available.
+ Details

Name: moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Other Claims Payable
+ References
No definition available.
+ Details

Name: moh_OtherClaimsPayable

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Pharmacy Claims Payable
+ References
No definition available.
+ Details

Name: moh_PharmacyClaimsPayable

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InsuranceAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (cc)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 97 R82.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Debt - Convertible Notes (Details)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended

Jan. 31, 2020

USD ($)

Dec. 31, 2019

USD ($)

$ / shares

Dec. 31, 2018

USD ($)

Dec. 31, 2017

USD ($)

Debt Instrument [Line Items]

(Gain) loss on debt extinguishment $ (15) $ 22 $ 14

Net carrying amount of debt $ 1,262

1.125% Convertible Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate on notes 1.125%

4.875% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate on notes 4.875%

5.375% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate on notes 5.375%

Convertible Debt | 1.125% Convertible Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate on notes 1.125%

Repayments of debt $ 794 911

Repayments of principal 240 298

Repayment of aggregate carrying amount 232 278

(Gain) loss on debt extinguishment 15 (12)

Net carrying amount of debt $ 12

Debt instrument, conversion ratio 0.0245277

Debt instrument conversion price per share (in dollars per share) | $ / shares $ 40.77

Senior note effective interest rate 6.00%

Senior notes amortization period 1 month

If-converted value in excess of principal on convertible debt $ 26 $ 581

Convertible Debt | 4.875% Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate on notes 4.875%

Convertible Debt | Convertible Senior Notes

Debt Instrument [Line Items]

Debt instrument, conversion ratio 0.0172157

Convertible Debt | Subsequent Event | 1.125% Convertible Notes

Debt Instrument [Line Items]

Percentage of contractual interest rate on notes 1.125%

Repayments of principal $ 39

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the required periodic payments including both interest and principal payments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the required periodic payments applied to principal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentPeriodicPaymentPrincipal

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_ConvertibleSeniorNotesDue2044Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 98 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Financial Information of Registrant (Tables)
12 Months Ended

Dec. 31, 2019

Condensed Financial Information Disclosure [Abstract]

Condensed balance sheets
Condensed Balance Sheets

December 31,

2019

2018

(In millions, except per-share data)
ASSETS
Current assets:

Cash and cash equivalents
$
836

$
70

Investments
161

100

Receivables
2

2

Due from affiliates
49

90

Prepaid expenses and other current assets
46

47

Derivative asset
29

476

Total current assets
1,123

785

Property, equipment, and capitalized software, net
327

176

Goodwill and intangible assets, net
13

13

Investments in subsidiaries
2,225

2,768

Deferred income taxes
10

39

Advances to related parties and other assets
76

40

Total assets
$
3,774

$
3,821

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:

Medical claims and benefits payable
$
—

$
4

Accounts payable and accrued liabilities
260

223

Current portion of long-term debt
18

241

Derivative liability
29

476

Total current liabilities
307

944

Long-term debt
1,237

1,020

Finance lease liabilities
231

197

Other long-term liabilities
39

13

Total liabilities
1,814

2,174

Stockholders’ equity:

Common stock, $0.001 par value; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018
—

—

Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding
—

—

Additional paid-in capital
175

643

Accumulated other comprehensive income (loss)
4

(8
)
Retained earnings
1,781

1,012

Total stockholders’ equity
1,960

1,647

Total liabilities and stockholders’ equity
$
3,774

$
3,821

Condensed statements of income
Condensed Statements of Operations

Year Ended December 31,

2019

2018

2017

(In millions)
Revenue:

Administrative services fees
$
1,038

$
1,138

$
1,317

Investment income and other revenue
18

17

16

Total revenue
1,056

1,155

1,333

Expenses:

General and administrative expenses
937

1,007

1,082

Depreciation and amortization
63

69

93

Other operating expenses
—

8

16

Restructuring costs
4

35

153

Impairment losses
—

—

39

Total operating expenses
1,004

1,119

1,383

Gain on sale of subsidiary
—

37

—

Operating income (loss)
52

73

(50
)
Interest expense
87

114

117

Other (income) expense, net
(15
)

17

(61
)
Loss before income tax (benefit) expense and equity in net earnings (losses) of subsidiaries
(20
)

(58
)

(106
)
Income tax expense (benefit)
9

(14
)

8

Net loss before equity in net earnings (losses) of subsidiaries
(29
)

(44
)

(114
)
Equity in net earnings (losses) of subsidiaries
766

751

(398
)
Net income (loss)
$
737

$
707

$
(512
)

Condensed statements of comprehensive (loss)
Condensed Statements of Comprehensive Income (Loss)

Year Ended December 31,

2019

2018

2017

(In millions)
Net income (loss)
$
737

$
707

$
(512
)
Other comprehensive income (loss):

Unrealized investment income (loss)
16

(3
)

(5
)
Less: effect of income taxes
4

(1
)

(2
)
Other comprehensive income (loss), net of tax
12

(2
)

(3
)
Comprehensive income (loss)
$
749

$
705

$
(515
)

Condensed statements of cash flows
Condensed Statements of Cash Flows

Year Ended December 31,

2019

2018

2017

(In millions)
Operating activities:

Net cash provided by operating activities
$
64

$
118

$
166

Investing activities:

Capital contributions to subsidiaries
(43
)

(145
)

(370
)
Dividends received from subsidiaries
1,373

298

286

Purchases of investments
(152
)

(136
)

(331
)
Proceeds from sales and maturities of investments
93

388

156

Purchases of property, equipment and capitalized software
(56
)

(22
)

(67
)
Net cash received from sale of subsidiaries
—

242

—

Change in amounts due to/from affiliates
38

6

(49
)
Other, net
1

—

—

Net cash provided by (used in) investing activities
1,254

631

(375
)
Financing activities:

Repayment of principal amount of convertible notes
(240
)

(362
)

—

Cash paid for partial settlement of conversion option
(578
)

(623
)

—

Cash received for partial settlement of call option
578

623

—

Cash paid for partial termination of warrants
(514
)

(549
)

—

Proceeds from borrowings under term loan facility
220

—

—

Common stock purchases
(47
)

—

—

Repayment of credit facility
—

(300
)

—

Proceeds from senior notes offerings, net of issuance costs
—

—

325

Proceeds from borrowings under credit facility
—

—

300

Other, net
29

19

11

Net cash (used in) provided by financing activities
(552
)

(1,192
)

636

Net (decrease) increase in cash and cash equivalents
766

(443
)

427

Cash and cash equivalents at beginning of period
70

513

86

Cash and cash equivalents at end of period
$
836

$
70

$
513

X

- References
No definition available.
+ Details

Name: srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract

Namespace Prefix: srt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10
+ Details

Name: srt_ScheduleOfCondensedBalanceSheetTableTextBlock

Namespace Prefix: srt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10
+ Details

Name: srt_ScheduleOfCondensedCashFlowStatementTableTextBlock

Namespace Prefix: srt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10
+ Details

Name: srt_ScheduleOfCondensedIncomeStatementTableTextBlock

Namespace Prefix: srt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e526-108580
+ Details

Name: us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 99 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes (Tables)
12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Provision for income taxes
Income tax expense (benefit) consisted of the following:

Year Ended December 31,

2019

2018

2017

(In millions)
Current:

Federal
$
204

$
272

$
(9
)
State
12

18

3

Foreign
9

8

—

Total current
225

298

(6
)
Deferred:

Federal
5

(3
)

(85
)
State
6

(3
)

(9
)
Foreign
(1
)

—

—

Total deferred
10

(6
)

(94
)
Income tax expense (benefit)
$
235

$
292

$
(100
)

Effective income tax rate reconciliation to the statutory federal income tax rate

A reconciliation of the U.S. federal statutory income tax rate to the combined effective income tax rate is as follows:

Year Ended December 31,

2019

2018

2017
Statutory federal tax (benefit) rate
21.0
%

21.0
%

(35.0
)%
State income provision (benefit), net of federal
1.4

1.2

(0.7
)
Nondeductible health insurer fee (“HIF”)
—

7.3

—

Nondeductible compensation
1.2

0.7

2.8

Nondeductible goodwill impairment
—

—

6.6

Worthless stock deduction
—

(1.0
)

—

Revaluation of net deferred tax assets
—

(0.4
)

8.8

Other
0.6

0.4

1.1

Effective tax expense (benefit) rate
24.2
%

29.2
%

(16.4
)%

Significant components of deferred tax assets and liabilities Significant components of our deferred tax assets and liabilities as of December 31, 2019 and 2018 were as follows:

December 31,

2019

2018

(In millions)
Accrued expenses and reserve liabilities
$
35

$
39

Other accrued medical costs
11

12

Net operating losses
13

16

Fixed assets and intangibles
26

30

Unearned premiums
11

9

Lease financing obligation
5

30

Tax credit carryover
11

12

Other
—

3

Valuation allowance
(24
)

(28
)
Total deferred income tax assets, net of valuation allowance
88

123

Prepaid expenses
(6
)

(6
)
Other
(3
)

—

Total deferred income tax liabilities
(9
)

(6
)
Net deferred income tax asset
$
79

$
117

Unrecognized tax benefits roll forward
The roll forward of our unrecognized tax benefits is as follows:

Year Ended December 31,

2019

2018

2017

(In millions)
Gross unrecognized tax benefits at beginning of period
$
(20
)

$
(13
)

$
(11
)
Increases in tax positions for current year

(9
)

(1
)
Increases in tax positions for prior years
—

—

(4
)
Decreases in tax positions for prior years
—

—

3

Lapse in statute of limitations

2

—

Gross unrecognized tax benefits at end of period
$
(20
)

$
(20
)

$
(13
)

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319
+ Details

Name: us-gaap_SummaryOfIncomeTaxContingenciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 100 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies - Schedule of Premium Revenue (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 16,208 $ 17,612 $ 18,854

Texas

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue 2,062

Health Plans

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 16,208 $ 17,612 $ 18,854

Premium revenue percentage 100.00% 100.00% 100.00%

Health Plans | California

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 2,266 $ 2,150 $ 2,701

Premium revenue percentage 14.00% 12.20% 14.30%

Health Plans | Florida

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 734 $ 1,790 $ 2,568

Premium revenue percentage 4.50% 10.20% 13.60%

Health Plans | Illinois

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 1,002 $ 793 $ 593

Premium revenue percentage 6.20% 4.50% 3.10%

Health Plans | Michigan

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 1,624 $ 1,601 $ 1,596

Premium revenue percentage 10.00% 9.10% 8.50%

Health Plans | New Mexico

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 0 $ 1,356 $ 1,368

Premium revenue percentage 0.00% 7.70% 7.30%

Health Plans | Ohio

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 2,553 $ 2,388 $ 2,216

Premium revenue percentage 15.80% 13.60% 11.80%

Health Plans | Puerto Rico

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 474 $ 696 $ 732

Premium revenue percentage 2.90% 3.90% 3.90%

Health Plans | South Carolina

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 583 $ 495 $ 445

Premium revenue percentage 3.60% 2.80% 2.40%

Health Plans | Texas

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 2,991 $ 3,244 $ 2,813

Premium revenue percentage 18.50% 18.40% 14.90%

Health Plans | Washington

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 2,695 $ 2,361 $ 2,608

Premium revenue percentage 16.60% 13.40% 13.80%

Health Plans | Other

Revenues from External Customers and Long-Lived Assets [Line Items]

Premium revenue $ 1,286 $ 738 $ 1,214

Premium revenue percentage 7.90% 4.20% 6.40%

X

- Definition
Health Care Organization, Revenue Percentage
+ References
No definition available.
+ Details

Name: moh_HealthCareOrganizationRevenuePercentage

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(1))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 235
-Section S99
-Paragraph 2
-Subparagraph (SX 210.12-17(Column E))
-URI http://asc.fasb.org/extlink&oid=34713774&loc=d3e574992-122915

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(c))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 605
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547
+ Details

Name: us-gaap_PremiumsEarnedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=stpr_TX

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_CA

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_FL

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_IL

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_MI

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_NM

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_OH

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_PR

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_SC

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_WA

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=moh_OtherGeographicalAreasMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 101 R93.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity - Fair Value of Awards Granted and Vested (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair value of restricted shares granted $ 53 $ 44 $ 36

Fair value of restricted shares vested 21 18 47

RSAs

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair value of restricted shares granted 33 28 20

Fair value of restricted shares vested 19 15 23

PSAs

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair value of restricted shares vested 0 3 15

PSUs

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair value of restricted shares granted 20 16 16

Fair value of restricted shares vested $ 2 $ 0 $ 9

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value
+ References
No definition available.
+ Details

Name: moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 102 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Recorded in depreciation and amortization:

Amortization of capitalized software $ 33 $ 42 $ 64

Depreciation and amortization of furniture, equipment, building, and improvements 21 36 42

Amortization of intangible assets 18 21 31

Amortization of finance leases 17

Subtotal 89 99 137

Recorded in cost of service revenue:

Amortization of capitalized software and deferred contract costs 0 28 41

Total depreciation and amortization recognized $ 89 $ 127 $ 178

X

- Definition
Depreciation, and amortization of capitalized software.
+ References
No definition available.
+ Details

Name: moh_DepreciationAndAmortizationOfCapitalizedSoftware

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Depreciation and Amortization, Continuing Operations
+ References
No definition available.
+ Details

Name: moh_DepreciationandAmortizationContinuingOperations

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Recorded In Cost Of Service Revenue [Abstract]
+ References
No definition available.
+ Details

Name: moh_RecordedInCostOfServiceRevenueAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Recorded In Depreciation And Amortization [Abstract]
+ References
No definition available.
+ Details

Name: moh_RecordedInDepreciationAndAmortizationAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(2))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSoldAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(2))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of amortization expense attributable to right-of-use asset from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 103 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Leases - Supplemental Balance Sheet Information (Details)
$ in Millions

Dec. 31, 2019

USD ($)

ROU assets

Other assets $ 65

Lease liabilities

Accounts payable and accrued liabilities (current) 25

Other long-term liabilities (non-current) 48

Total operating lease liabilities 73

ROU assets

Property, equipment, and capitalized software, net 228

Lease liabilities

Accounts payable and accrued liabilities (current) 8

Finance lease liabilities (non-current) 231

Total finance lease liabilities $ 239

X

- Definition
Finance Lease, Assets, Lessee [Abstract]
+ References
No definition available.
+ Details

Name: moh_FinanceLeaseAssetsLesseeAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Finance Lease, Liabilities, Lessee [Abstract]
+ References
No definition available.
+ Details

Name: moh_FinanceLeaseLiabilitiesLesseeAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Operating Lease, Assets, Lessee [Abstract]
+ References
No definition available.
+ Details

Name: moh_OperatingLeaseAssetsLesseeAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Operating Lease, Liabilities, Lessee [Abstract]
+ References
No definition available.
+ Details

Name: moh_OperatingLeaseLiabilitiesLesseeAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 104 R97.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Employee Benefit Plans (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Postemployment Benefits [Abstract]

Maximum matching contribution by employer under defined contribution plan 4.00%

Expense recognized in connection with contributions $ 28 $ 36 $ 43

Deferred compensation plan deferral percentage of basic salary 100.00%

Deferred compensation plan deferral percentage of bonus 100.00%

X

- Definition
Deferred compensation plan deferral percentage of basic salary.
+ References
No definition available.
+ Details

Name: moh_DeferredCompensationPlanDeferralPercentageOfBasicSalary

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Deferred compensation plan deferral percentage of bonus.
+ References
No definition available.
+ Details

Name: moh_DeferredCompensationPlanDeferralPercentageOfBonus

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost for defined contribution plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942
+ Details

Name: us-gaap_DefinedContributionPlanCostRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PostemploymentBenefitsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 106 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies (Tables)
12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Cash and cash equivalents The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.

December 31,

2019

2018

2017

(In millions)
Cash and cash equivalents
$
2,452

$
2,826

$
3,186

Restricted cash and cash equivalents, non-current
56

100

95

Restricted cash and cash equivalents, current
—

—

9

Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows
$
2,508

$
2,926

$
3,290

Restricted cash and cash equivalents The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.

December 31,

2019

2018

2017

(In millions)
Cash and cash equivalents
$
2,452

$
2,826

$
3,186

Restricted cash and cash equivalents, non-current
56

100

95

Restricted cash and cash equivalents, current
—

—

9

Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows
$
2,508

$
2,926

$
3,290

Summarized premium revenue
The following table summarizes premium revenue by health plan for the periods presented:

Year Ended December 31,

2019

2018

2017

Amount

% of Total

Amount

% of Total

Amount

% of Total

(Dollars in millions)
California
$
2,266

14.0
%

$
2,150

12.2
%

$
2,701

14.3
%
Florida
734

4.5

1,790

10.2

2,568

13.6

Illinois
1,002

6.2

793

4.5

593

3.1

Michigan
1,624

10.0

1,601

9.1

1,596

8.5

New Mexico ⁽¹⁾
—

—

1,356

7.7

1,368

7.3

Ohio
2,553

15.8

2,388

13.6

2,216

11.8

Puerto Rico
474

2.9

696

3.9

732

3.9

South Carolina
583

3.6

495

2.8

445

2.4

Texas
2,991

18.5

3,244

18.4

2,813

14.9

Washington
2,695

16.6

2,361

13.4

2,608

13.8

Other ⁽¹⁾
1,286

7.9

738

4.2

1,214

6.4

Total
$
16,208

100.0
%

$
17,612

100.0
%

$
18,854

100.0
%

_______________________
(1)
“Other” includes the Idaho, Mississippi, New York, Utah and Wisconsin health plans, which are not individually significant to our consolidated operating results. In 2019, “Other” also includes the New Mexico health plan. The New Mexico health plan’s Medicaid contract terminated on December 31, 2018, and therefore its results are not individually significant to our consolidated operating results in 2019.

Amounts due to government agencies
A summary of the categories of amounts due government agencies is as follows:

December 31,

2019

2018

(In millions)
Medicaid program:

Medical cost floors and corridors
$
74

$
103

Other amounts due to states
84

81

Marketplace program:

Risk adjustment
368

466

Cost sharing reduction
—

183

Other
138

134

Total
$
664

$
967

Quality incentive premium revenue recognized
The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods.

Year Ended December 31,

2019

2018

2017

(In millions)
Maximum available quality incentive premium - current period
$
186

$
182

$
150

Amount of quality incentive premium revenue recognized in current period:

Earned current period
$
156

$
133

$
97

Earned prior periods
38

31

10

Total
$
194

$
164

$
107

Quality incentive premium revenue recognized as a percentage of total premium revenue
1.2
%

0.9
%

0.6
%

X

- Definition
Quality incentive premium revenue recognized.
+ References
No definition available.
+ Details

Name: moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock

Namespace Prefix: moh_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of reserves reported to other federal agencies or authorities.
+ References
No definition available.
+ Details

Name: us-gaap_ReservesReportedToOtherAgenciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph a
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599
+ Details

Name: us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of cash and cash equivalents.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 107 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity
12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Stockholders' Equity Stockholders' Equity
Stock Purchase Program
In early December 2019, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This program is funded by existing cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase is determined by management, based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 400,000 shares of our common stock for $54 million in December 2019 (average cost of $135.30 per share), including approximately 55,000 shares purchased for $7 million in late December 2019, and settled in early January 2020.
Subsequent Event
In January 2020 through February 7, 2020, we purchased 1,533,000 shares for $203 million (average cost of $132.69 per share).
1.125% Warrants
In connection with the Call Spread Overlay transaction described in Note 12, “Derivatives,” in 2013, we issued 13.5 million of the 1.125% Warrants with a strike price of $53.8475 per share. Under certain circumstances, beginning in April 2020, if the price of our common stock were to exceed the strike price of the 1.125% Warrants, we would be obligated to issue shares of our common stock subject to a share delivery cap. The 1.125% Warrants could separately have a dilutive effect to the extent that the market value per share of our common stock exceeds the applicable strike price of the 1.125% Warrants. Refer to Note 3, “Net Income (Loss) Per Share,” for dilution
information for the periods presented. We will not receive any additional proceeds if the 1.125% Warrants are exercised. Following the transactions described below, approximately 310,000 of the 1.125% Warrants were outstanding at December 31, 2019.
As described in Note 12, “Derivatives,” in the year ended December 31, 2019, we entered into privately negotiated termination agreements with each of the Counterparties to partially terminate the Call Spread Overlay, in notional amounts corresponding to the aggregate principal amount of the 1.125% Convertible Notes purchased. In the year ended December 31, 2019, we paid $514 million to the Counterparties for the termination of 5.9 million of the 1.125% Warrants outstanding which resulted in a reduction of additional paid-in-capital for the same amount.
Share-Based Compensation
Total share-based compensation expense is presented in the following table. Except as described in the note to the table, we record share-based compensation as “General and administrative expenses” in the accompanying consolidated statements of operations.

Year Ended December 31,

2019

2018

2017

(In millions)

Pretax
Charges

Net-of-Tax
Amount

Pretax
Charges

Net-of-Tax
Amount

Pretax
Charges ⁽¹⁾

Net-of-Tax
Amount
RSAs, PSAs and PSUs (defined below)
$
29

$
28

$
17

$
17

$
39

$
35

Employee stock purchase plan and stock options
10

9

10

9

7

5

Total
$
39

$
37

$
27

$
26

$
46

$
40

_______________________
(1)
Includes $23 million relating to acceleration of share-based compensation for former executives in the year ended December 31, 2017. This amount is reported in “Restructuring costs” in the accompanying consolidated statements of operations.
Equity Incentive Plans
In the second quarter of 2019, our stockholders approved the Molina Healthcare, Inc. 2019 Equity Incentive Plan (the “2019 EIP”). The 2019 EIP provides for awards, in the form of restricted and performance stock awards (“RSAs” and “PSAs”), performance units (“PSUs”), stock options, and other stock– or cash–based awards, to eligible persons who perform services for us. The 2019 EIP will remain in effect until its termination by the board of directors; provided, however, that all awards will be granted no later than May 8, 2029. Concurrent with the adoption of the 2019 EIP, the Molina Healthcare, Inc. 2011 Equity Incentive Plan was amended, restated and merged into the 2019 EIP. A maximum of 2.9 million shares of our common stock may be issued under the 2019 EIP.
Stock-based awards. RSAs, PSAs and PSUs are granted with a fair value equal to the market price of our common stock on the date of grant, and generally vest in equal annual installments over periods up to four years from the date of grant. Certain PSUs may vest in their entirety at the end of three-year performance periods, if their performance conditions are met. We generally recognize expense for RSAs, PSAs and PSUs on a straight-line basis. Activity for stock-based awards in the year ended December 31, 2019 is summarized below:

RSAs

PSAs

PSUs

Total Shares

Weighted
Average
Grant Date
Fair Value
Unvested balance as of December 31, 2018
399,795

3,132

201,383

604,310

$
71.50

Granted
243,353

—

146,425

389,778

136.23

Vested
(139,828
)

(3,132
)

(10,528
)

(153,488
)

73.98

Forfeited
(55,640
)

—

(13,202
)

(68,842
)

90.45

Unvested balance as of December 31, 2019
447,680

—

324,078

771,758

$
102.01

As of December 31, 2019, total unrecognized compensation expense related to unvested RSAs and PSUs was $49 million, which we expect to recognize over a remaining weighted-average period of 2.2 years, and 1.6 years, respectively. This unrecognized compensation cost assumes an estimated forfeiture rate of 15.9% for non-executive employees as of December 31, 2019, based on actual forfeitures over the last 4 years.
The total grant date fair value of awards granted and vested is presented in the following table:

Year Ended December 31,

2019

2018

2017

(In millions)
Granted:

RSAs
$
33

$
28

$
20

PSUs
20

16

16

Total granted
$
53

$
44

$
36

Vested:

RSAs
$
19

$
15

$
23

PSAs
—

3

15

PSUs
2

—

9

Total vested
$
21

$
18

$
47

Stock Options. Stock option awards generally have an exercise price equal to the fair market value of our common stock on the date of grant, vest in equal annual installments over periods up to four years from the date of grant, and have a maximum term of ten years from the date of grant. Stock option activity for the year ended December 31, 2019 is summarized below:

Shares

Weighted Average Exercise Price

Aggregate Intrinsic Value

Weighted Average Remaining Contractual term

(In millions)

(Years)
Stock options outstanding as of December 31, 2018
405,000

$
64.79

Granted
—

—

Exercised
—

—

Stock options outstanding as of December 31, 2019
405,000

64.79

$
29

7.4
Stock options exercisable and expected to vest as of December 31, 2019
405,000

64.79

$
29

7.4
Exercisable as of December 31, 2019
280,000

63.65

$
20

7.3

The weighted-average grant date fair value per share of stock options awarded in 2017 was $41.43. We estimate the fair value of each stock option award on the grant date using the Black-Scholes option pricing model. To determine the fair value of the stock options awarded in 2017 we applied a risk-free interest rate of 2.3%, expected volatility of 38.4%, dividend yield of 0% and expected life of 8.4 years. No stock options were granted in 2019 and 2018.
As of December 31, 2019, total unrecognized compensation expense related to unvested stock options was $4 million, which we expect to recognize over a weighted-average period of 0.8 years. The total intrinsic value of options exercised during the year ended December 31, 2017 was $2 million. No stock options were exercised in 2019 and 2018. The following is a summary of information about stock options outstanding and exercisable at December 31, 2019:

Options Outstanding

Options Exercisable

Number Outstanding

Weighted Average Remaining Contractual Life (Years)

Weighted-Average Exercise Price

Number Exercisable

Weighted-Average Exercise Price
Range of Exercise Prices

$33.02
30,000

3.2

$
33.02

30,000

$
33.02

$67.33
375,000

7.8

67.33

250,000

67.33

Total
405,000

280,000

Employee Stock Purchase Plans (“ESPPs”)
In the second quarter of 2019, our stockholders approved the Molina Healthcare, Inc. 2019 Employee Stock Purchase Plan (the “2019 ESPP”), which superseded the Molina Healthcare, Inc. 2011 Employee Stock Purchase Plan (the “2011 ESPP”). A maximum of 3.0 million shares of our common stock may be issued under the 2019 ESPP, the terms of which are substantially similar to the 2011 ESPP. The 2019 ESPP will continue until the earliest of: termination of the 2019 ESPP by the board of directors (which may occur at any time); issuance of all of the shares reserved for issuance under the 2019 ESPP; or May 8, 2029.
Under our ESPPs, eligible employees may purchase common shares at 85% of the lower of the fair market value of our common stock on either the first or last trading day of each six-month offering period. Each participant is limited to a maximum purchase of $25,000 (as measured by the fair value of the stock acquired) per year through payroll deductions. We estimate the fair value of the stock issued using the Black-Scholes option pricing model. For the years ended December 31, 2019, 2018, and 2017, the inputs to this model were as follows: risk-free interest rates of approximately 0.6% to 2.3%; expected volatilities ranging from approximately 31% to 45%, dividend yields of 0%, and an average expected life of 0.5 years. We issued approximately 142,000, 216,000 and 351,000 shares of our common stock under the ESPPs during the years ended December 31, 2019, 2018, and 2017, respectively.
In connection with our employee stock plans, approximately 242,000 shares and 365,000 shares of common stock were purchased or vested, net of shares used to settle employees’ income tax obligations, during the years ended December 31, 2019, and 2018, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 108 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Segments
12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Segments Segments
We currently have two reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. Our Other
segment, which was insignificant to our consolidated results of operations in 2018 and 2019, includes the historical results of the MMIS and behavioral health subsidiaries we sold in late 2018, as well as certain corporate amounts not allocated to the Health Plans segment.
Margin is the appropriate earnings measure for our reportable segments, based on how our chief operating decision maker currently reviews results, assesses performance, and allocates resources.
The key metrics used to assess the performance of our Health Plans segment are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying margin, or the amount earned by the Health Plans segment after medical costs are deducted from premium revenue, is the most important measure of earnings reviewed by management. Margin for our Health Plans segment is referred to as “Medical Margin.”

Health Plans

Other

Consolidated

(In millions)
2019

Total revenue

$
16,815

$
14

16,829

Margin

2,303

—

2,303

Goodwill, and intangible assets, net

172

—

172

Total assets

5,265

1,522

6,787

2018

Total revenue

$
18,471

$
419

$
18,890

Margin

2,475

43

2,518

Goodwill, and intangible assets, net

190

—

190

Total assets

6,165

989

7,154

2017

Total revenue

$
19,352

$
531

$
19,883

Margin

1,781

29

1,810

Goodwill, and intangible assets, net

212

43

255

Total assets

6,347

2,124

8,471

The following table reconciles margin by segment to consolidated income (loss) before income tax expense (benefit):

Year Ended December 31,

2019

2018

2017

(In millions)
Margin:

Health Plans
$
2,303

$
2,475

$
1,781

Other
—

43

29

Total margin
2,303

2,518

1,810

Add: other operating revenues ⁽¹⁾
621

871

508

Less: other operating expenses ⁽²⁾
(1,880
)

(2,243
)

(2,873
)
Less: loss on sales of subsidiaries, net of gain
—

(15
)

—

Operating income (loss)
1,044

1,131

(555
)
Less: other expenses, net
72

132

57

Income (loss) before income tax expense (benefit)
$
972

$
999

$
(612
)

______________________
(1)
Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income and other revenue.
(2)
Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, impairment losses, and restructuring costs.

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 109 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies - Due to Government Agencies (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Medicaid program:

Medical cost floors and corridors $ 74 $ 103

Other amounts due to states 84 81

Marketplace program:

Risk adjustment 368 466

Cost sharing reduction 0 183

Other 138 134

Total $ 664 $ 967

X

- Definition
Amounts Due to Government Agencies, Amounts Due State
+ References
No definition available.
+ Details

Name: moh_AmountsDuetoGovernmentAgenciesAmountsDueState

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amounts Due to Government Agencies, Cost Sharing Reduction
+ References
No definition available.
+ Details

Name: moh_AmountsDuetoGovernmentAgenciesCostSharingReduction

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amounts Due to Government Agencies, Medical Cost Floors and Corridors
+ References
No definition available.
+ Details

Name: moh_AmountsDuetoGovernmentAgenciesMedicalCostFloorsandCorridors

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amounts Due to Government Agencies, Other
+ References
No definition available.
+ Details

Name: moh_AmountsDuetoGovernmentAgenciesOther

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amounts Due to Government Agencies, Risk Adjustment
+ References
No definition available.
+ Details

Name: moh_AmountsDuetoGovernmentAgenciesRiskAdjustment

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Marketplace Program [Abstract]
+ References
No definition available.
+ Details

Name: moh_MarketplaceProgramAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Medicaid Program [Abstract]
+ References
No definition available.
+ Details

Name: moh_MedicaidProgramAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Medical Premium Liability Due to Agency
+ References
No definition available.
+ Details

Name: moh_MedicalPremiumLiabilityDueToAgency

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 110 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Organization and Basis of Presentation (Details)
member in Thousands, $ in Millions
1 Months Ended 6 Months Ended 12 Months Ended

Dec. 31, 2019

USD ($)

member

state

Oct. 31, 2019

Jun. 30, 2020

USD ($)

member

county

Dec. 31, 2019

USD ($)

member

segment

state

Dec. 31, 2018

USD ($)

Dec. 31, 2017

USD ($)

Basis Of Presentation [Line Items]

Number of reportable segments | segment 2

Premium revenue $ 16,208 $ 17,612 $ 18,854

Texas

Basis Of Presentation [Line Items]

Number of members served, approximately (in member) | member 97 97

Premium revenue $ 2,062

Texas Health and Human Services Commission, STARPLUS Program

Basis Of Presentation [Line Items]

Contract term 3 years

Health Plans

Basis Of Presentation [Line Items]

Number of states in which company operates (in state) | state 14 14

Number of members eligible for the health care programs | member 3,300 3,300

Minimum contract terms 3 years

Maximum contract term 5 years

Premium revenue $ 16,208 17,612 18,854

Health Plans | Texas

Basis Of Presentation [Line Items]

Premium revenue 2,991 3,244 2,813

Health Plans | Illinois

Basis Of Presentation [Line Items]

Premium revenue $ 1,002 $ 793 $ 593

Health Plans | STAR/CHIP Contracts | Texas

Basis Of Presentation [Line Items]

Number of members served, approximately (in member) | member 114 114

Premium revenue $ 315

NextLevel Health Partners, Inc. | Illinois

Basis Of Presentation [Line Items]

Number of members served, approximately (in member) | member 50 50

Purchase price of assets $ 50

YourCare Health Plan | Forecast | New York

Basis Of Presentation [Line Items]

Number of members served, approximately (in member) | member 46

Purchase price of assets $ 40

Number of countries | county 7

X

- Definition
Basis Of Presentation [Line Items]
+ References
No definition available.
+ Details

Name: moh_BasisOfPresentationLineItems

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Contract Term
+ References
No definition available.
+ Details

Name: moh_ContractTerm

Namespace Prefix: moh_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Health Care Organization, Number of Members
+ References
No definition available.
+ Details

Name: moh_HealthCareOrganizationNumberOfMembers

Namespace Prefix: moh_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Maximum contract term.
+ References
No definition available.
+ Details

Name: moh_MaximumContractTerm

Namespace Prefix: moh_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Minimum contract term.
+ References
No definition available.
+ Details

Name: moh_MinimumContractTerm

Namespace Prefix: moh_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number Of Counties In Which Entity Operates
+ References
No definition available.
+ Details

Name: moh_NumberOfCountiesInWhichEntityOperates

Namespace Prefix: moh_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of members eligible for the health care programs.
+ References
No definition available.
+ Details

Name: moh_NumberOfMembersEligibleForTheHealthCarePrograms

Namespace Prefix: moh_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of states the entity operates in as of the balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfStatesInWhichEntityOperates

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(1))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 235
-Section S99
-Paragraph 2
-Subparagraph (SX 210.12-17(Column E))
-URI http://asc.fasb.org/extlink&oid=34713774&loc=d3e574992-122915

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(c))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 605
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547
+ Details

Name: us-gaap_PremiumsEarnedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=stpr_TX

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=moh_TexasHealthAndHumanServicesCommissionSTARPLUSProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_IL

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=moh_STARCHIPContractsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=moh_NextLevelHealthPartnersInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=moh_YourCareHealthPlanInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_NY

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 111 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity (Tables)
12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Stock based compensation expense
Total share-based compensation expense is presented in the following table. Except as described in the note to the table, we record share-based compensation as “General and administrative expenses” in the accompanying consolidated statements of operations.

Year Ended December 31,

2019

2018

2017

(In millions)

Pretax
Charges

Net-of-Tax
Amount

Pretax
Charges

Net-of-Tax
Amount

Pretax
Charges ⁽¹⁾

Net-of-Tax
Amount
RSAs, PSAs and PSUs (defined below)
$
29

$
28

$
17

$
17

$
39

$
35

Employee stock purchase plan and stock options
10

9

10

9

7

5

Total
$
39

$
37

$
27

$
26

$
46

$
40

_______________________
(1)
Includes $23 million relating to acceleration of share-based compensation for former executives in the year ended December 31, 2017. This amount is reported in “Restructuring costs” in the accompanying consolidated statements of operations.

Restricted and performance stock activity Activity for stock-based awards in the year ended December 31, 2019 is summarized below:

RSAs

PSAs

PSUs

Total Shares

Weighted
Average
Grant Date
Fair Value
Unvested balance as of December 31, 2018
399,795

3,132

201,383

604,310

$
71.50

Granted
243,353

—

146,425

389,778

136.23

Vested
(139,828
)

(3,132
)

(10,528
)

(153,488
)

73.98

Forfeited
(55,640
)

—

(13,202
)

(68,842
)

90.45

Unvested balance as of December 31, 2019
447,680

—

324,078

771,758

$
102.01

Stock options, activity
The total grant date fair value of awards granted and vested is presented in the following table:

Year Ended December 31,

2019

2018

2017

(In millions)
Granted:

RSAs
$
33

$
28

$
20

PSUs
20

16

16

Total granted
$
53

$
44

$
36

Vested:

RSAs
$
19

$
15

$
23

PSAs
—

3

15

PSUs
2

—

9

Total vested
$
21

$
18

$
47

Stock Options. Stock option awards generally have an exercise price equal to the fair market value of our common stock on the date of grant, vest in equal annual installments over periods up to four years from the date of grant, and have a maximum term of ten years from the date of grant. Stock option activity for the year ended December 31, 2019 is summarized below:

Shares

Weighted Average Exercise Price

Aggregate Intrinsic Value

Weighted Average Remaining Contractual term

(In millions)

(Years)
Stock options outstanding as of December 31, 2018
405,000

$
64.79

Granted
—

—

Exercised
—

—

Stock options outstanding as of December 31, 2019
405,000

64.79

$
29

7.4
Stock options exercisable and expected to vest as of December 31, 2019
405,000

64.79

$
29

7.4
Exercisable as of December 31, 2019
280,000

63.65

$
20

7.3

Stock option plans, by exercise price range The following is a summary of information about stock options outstanding and exercisable at December 31, 2019:

Options Outstanding

Options Exercisable

Number Outstanding

Weighted Average Remaining Contractual Life (Years)

Weighted-Average Exercise Price

Number Exercisable

Weighted-Average Exercise Price
Range of Exercise Prices

$33.02
30,000

3.2

$
33.02

30,000

$
33.02

$67.33
375,000

7.8

67.33

250,000

67.33

Total
405,000

280,000

X

- Definition
Tabular disclosure of share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 112 R92.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity - Restricted and Performance Stock Activity (Details)
12 Months Ended

Dec. 31, 2019

$ / shares

shares

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]

Unvested, shares beginning of period (in shares) 604,310

Granted (in shares) 389,778

Vested (in shares) (153,488)

Forfeited (in shares) (68,842)

Unvested, shares end of period (in shares) 771,758

Weighted Average Grant Date Fair Value

Unvested, beginning balance (USD per share) | $ / shares $ 71.50

Granted (USD per share) | $ / shares 136.23

Vested (USD per share) | $ / shares 73.98

Forfeited (USD per share) | $ / shares 90.45

Unvested, ending balance (USD per share) | $ / shares $ 102.01

RSAs

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]

Unvested, shares beginning of period (in shares) 399,795

Granted (in shares) 243,353

Vested (in shares) (139,828)

Forfeited (in shares) (55,640)

Unvested, shares end of period (in shares) 447,680

PSAs

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]

Unvested, shares beginning of period (in shares) 3,132

Granted (in shares) 0

Vested (in shares) (3,132)

Forfeited (in shares) 0

Unvested, shares end of period (in shares) 0

PSUs

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]

Unvested, shares beginning of period (in shares) 201,383

Granted (in shares) 146,425

Vested (in shares) (10,528)

Forfeited (in shares) (13,202)

Unvested, shares end of period (in shares) 324,078

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 113 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Property, Plant and Equipment [Line Items]

Total cost $ 687 $ 774

Less: accumulated amortization - capitalized software (351) (320)

Less: accumulated depreciation and amortization - furniture, equipment, building, and improvements (179) (213)

Total accumulated depreciation and amortization (530) (533)

ROU assets - finance leases 228

Property, equipment, and capitalized software, net 385

Property, equipment, and capitalized software, net 241

Capitalized software

Property, Plant and Equipment [Line Items]

Total cost 421 373

Furniture and equipment

Property, Plant and Equipment [Line Items]

Total cost 213 231

Building and improvements

Property, Plant and Equipment [Line Items]

Total cost 49 154

Land

Property, Plant and Equipment [Line Items]

Total cost $ 4 $ 16

X

- Definition
Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization
+ References
No definition available.
+ Details

Name: moh_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of depreciation (related to long-lived, depreciable flight assets owned by the entity and used in the entity's principle business operations and capitalized assets classified as property, plant and equipment that are owned by the entity) that has been recognized in the income statement.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 114 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Leases - Supplemental Cash Flow (Details)
$ in Millions
12 Months Ended

Dec. 31, 2019

USD ($)

Cash used in operating activities:

Operating leases $ 36

Finance leases 15

Cash used in financing activities:

Finance leases 6

ROU assets recognized in exchange for lease obligations:

Operating leases 99

Finance leases $ 245

X

- Definition
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability [Abstract]
+ References
No definition available.
+ Details

Name: moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of interest paid on finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977
+ Details

Name: us-gaap_FinanceLeaseInterestPaymentOnLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for principal payment on finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_FinanceLeasePrincipalPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeasePayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 115 R96.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Restructuring Costs (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Restructuring Cost and Reserve [Line Items]

Restructuring costs $ 6 $ 46 $ 234

IT Restructuring

Restructuring Cost and Reserve [Line Items]

Cumulative restructuring costs 12

Decrease to estimated expected costs remaining 20

Accrued liabilities under restructuring plan 1 6

Other restructuring costs 3

IT Restructuring | One-Time Termination Benefits

Restructuring Cost and Reserve [Line Items]

Cumulative restructuring costs 7

Payments for restructuring 5

IT Restructuring | Consulting Fees

Restructuring Cost and Reserve [Line Items]

Cumulative restructuring costs 5

Payments for restructuring 3

2017 Restructuring Plan

Restructuring Cost and Reserve [Line Items]

Accrued liabilities under restructuring plan $ 18

2017 Restructuring Plan | Contract Termination

Restructuring Cost and Reserve [Line Items]

Accrued liabilities under restructuring plan 12

Payments for restructuring 9

Restructuring costs $ 3

X

- Definition
Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherRestructuringCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585
+ Details

Name: us-gaap_PaymentsForRestructuring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of costs incurred to date for the specified restructuring cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(d))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(1))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringAndRelatedCostCostIncurredToDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount expected to be recognized in earnings for the specified restructuring cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(1))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(d))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringAndRelatedCostExpectedCost1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_RestructuringCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RestructuringPlanAxis=moh_ITRestructuringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=moh_ProfessionalServicesFeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringPlanAxis=moh_A2017RestructuringPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 116 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes
12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes Income Taxes
Income tax expense (benefit) consisted of the following:

Year Ended December 31,

2019

2018

2017

(In millions)
Current:

Federal
$
204

$
272

$
(9
)
State
12

18

3

Foreign
9

8

—

Total current
225

298

(6
)
Deferred:

Federal
5

(3
)

(85
)
State
6

(3
)

(9
)
Foreign
(1
)

—

—

Total deferred
10

(6
)

(94
)
Income tax expense (benefit)
$
235

$
292

$
(100
)

The Tax Cuts and Jobs Act of 2017 (“TCJA”), in part, reduced the U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018. TCJA’s change in the federal rate required that we revalue deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally the new 21% federal corporate tax rate plus applicable state tax rate. We applied the guidance in SEC Staff Accounting Bulletin No. 118 when accounting for the enactment-date effects of the TCJA in 2017 and throughout 2018.
As of December 31, 2017, we recorded a provisional amount of $54 million for the revaluation of deferred tax assets and liabilities because we had not yet completed our accounting for all of the enactment-date income tax effects of the TJCA under ASC 740, Income Taxes. Upon further analysis of certain aspects of the TCJA and refinement of our calculations in the year ended December 31, 2018, we reduced this provisional amount by $4 million, which is included as a component of income tax expense in the accompanying consolidated statement of operations. As of December 31, 2018, the accounting for all of the enactment-date income tax effects of the TCJA was complete.

A reconciliation of the U.S. federal statutory income tax rate to the combined effective income tax rate is as follows:

Year Ended December 31,

2019

2018

2017
Statutory federal tax (benefit) rate
21.0
%

21.0
%

(35.0
)%
State income provision (benefit), net of federal
1.4

1.2

(0.7
)
Nondeductible health insurer fee (“HIF”)
—

7.3

—

Nondeductible compensation
1.2

0.7

2.8

Nondeductible goodwill impairment
—

—

6.6

Worthless stock deduction
—

(1.0
)

—

Revaluation of net deferred tax assets
—

(0.4
)

8.8

Other
0.6

0.4

1.1

Effective tax expense (benefit) rate
24.2
%

29.2
%

(16.4
)%

The effective tax rate was not impacted by the HIF in 2019 and 2017, given the HIF moratorium in each of those years. Our effective tax rate is based on expected income (loss), statutory tax rates, and tax planning opportunities available to us in the various jurisdictions in which we operate. Management estimates and judgments are required in determining our effective tax rate. We are routinely under audit by federal, state, or local authorities regarding the timing and amount of deductions, nexus of income among various tax jurisdictions, and compliance with federal, state, foreign, and local tax laws.
Deferred tax assets and liabilities are classified as non-current. Significant components of our deferred tax assets and liabilities as of December 31, 2019 and 2018 were as follows:

December 31,

2019

2018

(In millions)
Accrued expenses and reserve liabilities
$
35

$
39

Other accrued medical costs
11

12

Net operating losses
13

16

Fixed assets and intangibles
26

30

Unearned premiums
11

9

Lease financing obligation
5

30

Tax credit carryover
11

12

Other
—

3

Valuation allowance
(24
)

(28
)
Total deferred income tax assets, net of valuation allowance
88

123

Prepaid expenses
(6
)

(6
)
Other
(3
)

—

Total deferred income tax liabilities
(9
)

(6
)
Net deferred income tax asset
$
79

$
117

At December 31, 2019, we had state net operating loss carryforwards of $310 million, which begin expiring in 2028.
At December 31, 2019, we had California research and development and enterprise zone tax credit carryovers of $8 million, which will begin to expire in 2024, and foreign tax credit carryovers of $5 million, which expire in 2030.
We evaluate the need for a valuation allowance taking into consideration the ability to carry back and carry forward tax credits and losses, available tax planning strategies and future income, including reversal of temporary differences. We have determined that as of December 31, 2019, $24 million of deferred tax assets did not satisfy the recognition criteria. Therefore, we decreased our valuation allowance by $4 million, from $28 million at December 31, 2018, to $24 million as of December 31, 2019.
We recognize tax benefits only if the tax position is more likely than not to be sustained. We are subject to income taxes in the United States, Puerto Rico, and numerous state jurisdictions. Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. We establish reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these reserves in light of changing facts and circumstances, such as the outcome of tax audits. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate.
The roll forward of our unrecognized tax benefits is as follows:

Year Ended December 31,

2019

2018

2017

(In millions)
Gross unrecognized tax benefits at beginning of period
$
(20
)

$
(13
)

$
(11
)
Increases in tax positions for current year

(9
)

(1
)
Increases in tax positions for prior years
—

—

(4
)
Decreases in tax positions for prior years
—

—

3

Lapse in statute of limitations

2

—

Gross unrecognized tax benefits at end of period
$
(20
)

$
(20
)

$
(13
)

The total amount of unrecognized tax benefits at December 31, 2019, 2018 and 2017 that, if recognized, would affect the effective tax rates is $18 million, $18 million, and $12 million, respectively. We expect that during the next 12 months it is reasonably possible that unrecognized tax benefit liabilities may decrease by as much as $5 million due to resolution of a state refund claim. The state refund claim will not result in a cash payment for income taxes if our claim is denied.
Our continuing practice is to recognize interest and/or penalties related to unrecognized tax benefits in income tax expense. Amounts accrued for the payment of interest and penalties as of December 31, 2019, 2018 and 2017 were insignificant.
We are under examination by the IRS for calendar years 2015 through 2017 and may be subject to examination for calendar year 2018. With a few exceptions, which are immaterial in the aggregate, we no longer are subject to state, local, and Puerto Rico tax examinations for years before 2015.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 117 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Commitments and Contingencies
12 Months Ended

Dec. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Commitments and Contingencies
Regulatory Capital Requirements and Dividend Restrictions
Our health plans, which are operated by our respective wholly owned subsidiaries in those states, are subject to state laws and regulations that, among other things, require the maintenance of minimum levels of statutory capital, as defined by each state. The National Association of Insurance Commissioners (“NAIC”), has adopted rules which, if implemented by the states, set minimum capitalization requirements for insurance companies, HMOs, and other entities bearing risk for health care coverage. The requirements take the form of risk-based capital (“RBC”) rules which may vary from state to state. All of the states in which our health plans operate, except California, Florida and New York, have adopted these rules. Such requirements, if adopted by California, Florida and New York, may increase the minimum capital required for those states. Regulators in some states may also enforce capital requirements that require the retention of net worth in excess of amounts formally required by statute or regulation. As of December 31, 2019, our health plans had aggregate statutory capital and surplus of approximately $1,852 million compared with the required minimum aggregate statutory capital and surplus of approximately $1,110 million. All of our health plans were in compliance with the minimum capital requirements at December 31, 2019. We have the ability and commitment to provide additional capital to each of our health plans when necessary to ensure that statutory capital and surplus continue to meet regulatory requirements.
Such statutes, regulations and informal capital requirements also restrict the timing, payment, and amount of dividends and other distributions that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based on current statutes and regulations, the net assets in these subsidiaries (after intercompany eliminations) which may not be transferable to us in the form of loans, advances, or cash dividends was approximately $1,811 million at December 31, 2019, and $2,262 million at December 31, 2018. Because of the statutory restrictions that inhibit the ability of our health plans to transfer net assets to us, the amount of retained earnings readily available to pay dividends to our stockholders is generally limited to cash, cash equivalents and investments held by the parent company – Molina Healthcare, Inc. Such cash, cash equivalents and investments amounted to $997 million and $170 million as of December 31, 2019 and 2018, respectively.
Legal Proceedings
The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously billed and collected revenues.
We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.
Professional Liability Insurance
We carry medical professional liability insurance for health care services rendered in the primary care institutions that we manage. In addition, we also carry errors and omissions insurance for all Molina entities.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 118 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies (Policies)
12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Consolidation and Presentation
Consolidation and Presentation
The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Financial information related to subsidiaries acquired during any year is included only for periods subsequent to their acquisition. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the periods presented have been included; such adjustments consist of normal recurring adjustments.

Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:
•
The determination of medical claims and benefits payable of our Health Plans segment;
•
Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;
•
Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;
•
Settlements under risk or savings sharing programs;
•
The assessment of long-lived and intangible assets, and goodwill, for impairment;
•
The determination of reserves for potential absorption of claims unpaid by insolvent providers;
•
The determination of reserves for the outcome of litigation;
•
The determination of valuation allowances for deferred tax assets; and
•
The determination of unrecognized tax benefits.

Cash and Cash Equivalents
Cash and Cash Equivalents
Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.

Investments
Investments
Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (“AFS”) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders’ equity as other comprehensive income, net of applicable income taxes. Held-to-maturity securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses and unrealized losses judged to be other than temporary with respect to available-for-sale and held-to-maturity securities are included in the determination of net income (loss). The cost of securities sold is determined using the specific-identification method.
Our investment policy requires that all of our investments have final maturities of less than 10 years, or less than 10 years average life for structured securities. Investments and restricted investments are subject to interest rate risk
and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.
In general, our AFS securities are classified as current assets without regard to the securities’ contractual maturity dates because they may be readily liquidated. We monitor our investments for other-than-temporary impairment.

Long-Lived Assets
Long-Lived Assets, including Intangible Assets
Long-lived assets consist primarily of property, equipment, capitalized software (see Note 7, “Property, Equipment, and Capitalized Software, Net”), and intangible assets resulting from acquisitions. Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts). Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between five and 15 years.
Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset’s (or asset group’s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed. Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment.
Property and equipment are stated at historical cost. Replacements and major improvements are capitalized, and repairs and maintenance are charged to expense as incurred. Furniture and equipment are generally depreciated using the straight-line method over estimated useful lives ranging from three to seven years. Software developed for internal use is capitalized. Software is generally amortized over its estimated useful life of three years. Leasehold improvements are amortized over the term of the lease, or over their useful lives from five to 10 years, whichever is shorter. Buildings are depreciated over their estimated useful lives of 31.5 to 40 years.

Intangible Assets
Long-Lived Assets, including Intangible Assets
Long-lived assets consist primarily of property, equipment, capitalized software (see Note 7, “Property, Equipment, and Capitalized Software, Net”), and intangible assets resulting from acquisitions. Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts). Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between five and 15 years.
Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset’s (or asset group’s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed. Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment.

Leases
Leases
Right-of-use (“ROU”) assets represent our right to use the underlying assets over the lease term, and lease liabilities represent our obligation for lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. If applicable, we account for lease and non-lease components within a lease as a single lease component.
Because most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Finance lease payments reduce finance lease liabilities, the related ROU assets are amortized on a straight-line basis over the lease term, and interest expense is recognized using the effective interest method.
The significant majority of our operating leases consist of long-term operating leases for office space. Short-term leases (those with terms of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. For certain leases that represent a portfolio of similar assets, such as a fleet of vehicles, we apply a portfolio approach to account for the related ROU assets and liabilities, rather than account for such assets and the related liabilities individually. A nominal number of our lease agreements include rental payments that adjust periodically for inflation. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Goodwill and Business Combinations
Goodwill and Business Combinations
Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment on an annual basis and more frequently if impairment indicators are present. Such events or circumstances may include experienced or expected operating cash-flow deterioration or losses, significant losses of membership, loss of state funding, loss of state contracts, and other factors. Goodwill is impaired if the carrying amount of the reporting unit (one of our state health plans)
exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit.
When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, the dynamic economic and political environments in which we operate, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. If our qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, we perform the quantitative assessment. We may also elect to bypass the qualitative assessment and proceed directly to the quantitative assessment. If performing a quantitative assessment, we generally estimate the fair values of our reporting units by applying the income approach, using discounted cash flows.
For the annual impairment test under a quantitative assessment, the base year in the reporting units’ discounted cash flows is derived from the annual financial planning cycle, which commences in the fourth quarter of the year. When computing discounted cash flows, we make assumptions about a wide variety of internal and external factors, and consider what the reporting unit’s selling price would be in an orderly transaction between market participants at the measurement date. Significant assumptions include financial projections of free cash flow (including significant assumptions about membership, premium rates, healthcare and operating cost trends, contract renewal and the procurement of new contracts, capital requirements and income taxes), long-term growth rates for determining terminal value beyond the discretely forecasted periods, and discount rates. When determining the discount rate, we consider the overall level of inherent risk of the reporting unit, and the expected rate an outside investor would expect to earn. As part of a quantitative assessment, we may also apply the asset liquidation method to estimate the fair value of individual reporting units, which is computed as total assets minus total liabilities, excluding intangible assets and deferred taxes. Finally, we apply a market approach to reconcile the value of our reporting units to our consolidated market value. Under the market approach, we consider publicly traded comparable company information to determine revenue and earnings multiples which are used to estimate our reporting units’ fair values. The assumptions used are consistent with those used in our long-range business plan and annual planning process. However, if these assumptions differ from actual results, the outcome of our goodwill impairment tests could be adversely affected.
Accounting for business combinations requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within our consolidated statements of operations.

Premium Revenue - Health Plans
Premium Revenue
Premium revenue is generated from our Health Plans segment contracts, including agreements with other managed care organizations for which we operate as a subcontractor. Premium revenue is generally received based on per member per month (“PMPM”) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. The state Medicaid programs and the federal Medicare program periodically adjust premiums. Additionally, many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.
The following table summarizes premium revenue by health plan for the periods presented:

Year Ended December 31,

2019

2018

2017

Amount

% of Total

Amount

% of Total

Amount

% of Total

(Dollars in millions)
California
$
2,266

14.0
%

$
2,150

12.2
%

$
2,701

14.3
%
Florida
734

4.5

1,790

10.2

2,568

13.6

Illinois
1,002

6.2

793

4.5

593

3.1

Michigan
1,624

10.0

1,601

9.1

1,596

8.5

New Mexico ⁽¹⁾
—

—

1,356

7.7

1,368

7.3

Ohio
2,553

15.8

2,388

13.6

2,216

11.8

Puerto Rico
474

2.9

696

3.9

732

3.9

South Carolina
583

3.6

495

2.8

445

2.4

Texas
2,991

18.5

3,244

18.4

2,813

14.9

Washington
2,695

16.6

2,361

13.4

2,608

13.8

Other ⁽¹⁾
1,286

7.9

738

4.2

1,214

6.4

Total
$
16,208

100.0
%

$
17,612

100.0
%

$
18,854

100.0
%

_______________________
(1)
“Other” includes the Idaho, Mississippi, New York, Utah and Wisconsin health plans, which are not individually significant to our consolidated operating results. In 2019, “Other” also includes the New Mexico health plan. The New Mexico health plan’s Medicaid contract terminated on December 31, 2018, and therefore its results are not individually significant to our consolidated operating results in 2019.
Certain components of premium revenue are subject to accounting estimates and fall into the following categories:
Contractual Provisions That May Adjust or Limit Revenue or Profit
Medicaid Program
Medical Cost Floors (Minimums), and Medical Cost Corridors. A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. In the aggregate, we recorded liabilities under the terms of such contract provisions of $74 million and $103 million at December 31, 2019, and December 31, 2018, respectively. Approximately $69 million and $87 million of the liabilities accrued at December 31, 2019, and December 31, 2018, respectively, relates to our participation in Medicaid Expansion programs.
In certain circumstances, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold. Receivables relating to such provisions were insignificant at December 31, 2019, and December 31, 2018.
Profit Sharing and Profit Ceiling. Our contracts with certain states contain profit-sharing or profit ceiling provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any. Liabilities for profits in excess of the amount we are allowed to retain under these provisions were insignificant at December 31, 2019, and December 31, 2018.
Retroactive Premium Adjustments. State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we must adjust our premium revenue in the period in which we learn of the adjustment, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.
Medicare Program
Risk Adjusted Premiums: Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members’ risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members’ health status, risk scores and CMS practices. Consolidated balance sheet amounts related to anticipated Medicare risk adjusted premiums and Medicare Part D settlements were insignificant at December 31, 2019, and December 31, 2018.
Minimum MLR: The Affordable Care Act (“ACA”) has established a minimum annual medical loss ratio (“Minimum MLR”) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations. The amounts payable for the Medicare Minimum MLR were insignificant at December 31, 2019, and December 31, 2018.
Marketplace Program
Risk Adjustment: Under this program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of operations. As of December 31, 2019, Marketplace risk adjustment payables amounted to $368 million and related receivables amounted to $63 million, for a net payable of $305 million. As of December 31, 2018, Marketplace risk adjustment payables amounted to $466 million and related receivables amounted to $34 million, for a net payable of $432 million.
Minimum MLR: The ACA has established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations. Aggregate balance sheet amounts related to the Minimum MLR were insignificant at December 31, 2019, and December 31, 2018.
A summary of the categories of amounts due government agencies is as follows:

December 31,

2019

2018

(In millions)
Medicaid program:

Medical cost floors and corridors
$
74

$
103

Other amounts due to states
84

81

Marketplace program:

Risk adjustment
368

466

Cost sharing reduction
—

183

Other
138

134

Total
$
664

$
967

Quality Incentives
At many of our health plans, revenue ranging from approximately 1% to 4% of certain health plan premiums is earned only if certain performance measures are met

Medical Care Costs - Health Plans
Medical Care Costs, Medical Claims and Benefits Payable
Medical care costs are recognized in the period in which services are provided and include fee-for-service claims, pharmacy benefits, capitation payments to providers, and various other medically-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Such medical care costs include amounts paid by us as well as estimated medical claims and benefits payable for costs that were incurred but not paid as of the reporting date (“IBNP”). Pharmacy benefits represent payments for members' prescription drug costs, net of rebates from drug manufacturers. We estimate pharmacy rebates based on historical and current utilization of prescription drugs and contractual provisions. Capitation payments represent monthly contractual fees paid to providers, who are responsible for providing medical care to members, which could include medical or ancillary costs like dental, vision and other supplemental health benefits. Such capitation costs are fixed in advance of the periods covered and are not subject to significant accounting estimates. Other medical care costs include all medically-related administrative costs, amounts due to providers pursuant to risk-sharing or other incentive arrangements, provider claims, and other healthcare expenses. Examples of medically-related administrative costs include expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses. Additionally, we include an estimate for the cost of settling claims incurred through the reporting date in our medical claims and benefits payable liability.
Medical claims and benefits payable consist mainly of fee-for-service IBNP, unpaid pharmacy claims, capitation costs, other medical costs, including amounts payable to providers pursuant to risk-sharing or other incentive arrangements and amounts payable to providers on behalf of certain state agencies for certain state assessments in which we assume no financial risk. IBNP includes the costs of claims incurred as of the balance sheet date which have been reported to us, and our best estimate of the cost of claims incurred but not yet reported to us. We also include an additional reserve to ensure that our overall IBNP liability is sufficient under moderately adverse conditions. We reflect changes in these estimates in the consolidated results of operations in the period in which they are determined.
The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors and the assumed healthcare cost trend to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.
Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. Each reporting period, the recognized IBNP liability represents our best estimate of the total amount of unpaid claims incurred as of the balance sheet date using a consistent methodology in estimating our IBNP liability. We believe our current estimates are reasonable and adequate; however, the development of our estimate is a continuous process that we monitor and update as more complete claims payment information and healthcare cost trend data becomes available. Actual medical care costs may be less than we previously estimated (favorable development) or more than we previously estimated (unfavorable development), and any differences could be material. Any adjustments to reflect favorable development would be
recognized as a decrease to medical care costs, and any adjustments to reflect unfavorable development would be recognized as an increase to medical care costs, in the period in which the adjustments are determined.
Refer to Note 10, “Medical Claims and Benefits Payable,” for a table presenting the components of the change in our medical claims and benefits payable, for all periods presented in the accompanying consolidated financial statements.
Reinsurance
We limit our risk of catastrophic losses by maintaining high deductible reinsurance coverage. Such reinsurance coverage does not relieve us of our primary obligation to our policyholders. We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. Reinsurance premiums amounted to $17 million, $16 million, and $20 million for the years ended December 31, 2019, 2018, and 2017, respectively. Reinsurance recoveries amounted to $18 million, $33 million, and $24 million for the years ended December 31, 2019, 2018, and 2017, respectively. Reinsurance recoverable of $21 million, $31 million, and $16 million, as of December 31, 2019, 2018, and 2017, respectively, is included in “Receivables” in the accompanying consolidated balance sheets.
Marketplace Cost Share Reduction (“CSR”)
In the year ended December 31, 2018, we recognized a benefit of approximately $81 million in reduced medical care costs related to 2017 dates of service, as a result of the federal government’s confirmation that the reconciliation of 2017 Marketplace CSR subsidies would be performed on an annual basis. In the fourth quarter of 2017, we had assumed a nine-month reconciliation of this item pending confirmation of the time period to which the 2017 reconciliation would be applied.
Premium Deficiency Reserves on Loss Contracts
We assess the profitability of our contracts to determine if it is probable that a loss will be incurred in the future by reviewing current results and forecasts. For purposes of this assessment, contracts are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. A premium deficiency is recognized if anticipated future medical care and administrative costs exceed anticipated future premium revenue, investment income and reinsurance recoveries. No premium deficiency reserves were recorded as of December 31, 2019 and 2018.

Income Taxes
Income Taxes
We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates expected to be in effect during the year in which the basis differences reverse. Valuation allowances are established when management determines it is more likely than not that some portion, or all, of the deferred tax assets will not be realized.

Taxes Based on Premiums
Taxes Based on Premiums
Health Insurer Fee (“HIF”). The federal government under the ACA imposes an annual fee, or excise tax, on health insurers for each calendar year. The HIF is based on a company’s share of the industry’s net premiums written during the preceding calendar year and is non-deductible for income tax purposes. We recognize expense for the HIF over the year on a straight-line basis. Within our Medicaid program, we must secure additional reimbursement from our state partners for this added cost. We recognize the related revenue when we have obtained a contractual commitment or payment from a state to reimburse us for the HIF, and such HIF revenue is recognized ratably throughout the year. The Consolidated Appropriations Act of 2016 provided for the HIF moratorium in 2017, and Public Law No. 115-120 provided for the HIF moratorium in 2019. Therefore, there were no health insurer fees reimbursed, nor health insurer fees incurred, in those years.
Premium and Use Tax. Certain of our health plans are assessed a tax based on premium revenue collected. The premium revenues we receive from these states include the premium tax assessment. We have reported these taxes on a gross basis, as premium tax revenue and as premium tax expenses in the consolidated statements of operations.

Concentrations of Credit Risk
Concentrations of Credit Risk
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those
investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents and U.S. Treasury securities.
Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate. See further information below, under “Recent Accounting Pronouncements Not Yet Adopted” regarding our adoption of ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, effective January 1, 2020.

Risks and Uncertainties
Risks and Uncertainties
Our profitability depends in large part on our ability to accurately predict and effectively manage medical care costs. We continually review our medical costs in light of our underlying claims experience and revised actuarial data. However, several factors could adversely affect medical care costs. These factors, which include changes in health care practices, inflation, new technologies, major epidemics, natural disasters, and malpractice litigation, are beyond our control and may have an adverse effect on our ability to accurately predict and effectively control medical care costs. Costs in excess of those anticipated could have a material adverse effect on our financial condition, results of operations, or cash flows.
We operate health plans primarily as a direct contractor with the states (or Commonwealth), and in Los Angeles County, California, as a subcontractor to another health plan holding a direct contract with the state. We are therefore dependent upon a small number of contracts to support our revenue. The loss of any one of those contracts could have a material adverse effect on our financial position, results of operations, or cash flows. In addition, our ability to arrange for the provision of medical services to our members is dependent upon our ability to develop and maintain adequate provider networks. Our inability to develop or maintain such networks might, in certain circumstances, have a material adverse effect on our financial position, results of operations, or cash flows.

Recent Accounting Pronouncements Adopted and Not Yet Adopted
Recent Accounting Pronouncements Adopted
Leases. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Topic 842, which was subsequently modified by several ASUs issued in 2017 and 2018. Topic 842 was issued to increase transparency and comparability among organizations by requiring the recognition of ROU assets and lease liabilities on the balance sheet. Most prominent among the changes in Topic 842 is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. In addition, Topic 842’s disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. Topic 842’s transition provisions are applied using a modified retrospective approach; entities may elect whether to apply the transition provisions, including disclosure requirements, at the beginning of the earliest comparative period presented or on the adoption date.
We adopted Topic 842 effective January 1, 2019, and elected to apply the transition provisions as of that date. Accordingly, we recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings on January 1, 2019. In addition, we elected the available practical expedients and implemented internal controls and information systems functionality to enable the preparation of financial information on adoption.
As indicated in the accompanying consolidated statements of stockholders’ equity, the cumulative effect adjustment was an increase of $85 million to retained earnings ($110 million, net of $25 million deferred income tax expense), relating primarily to the transition provisions for sale-leaseback arrangements that did not qualify for sale treatment. Accordingly, such arrangements were de-recognized and recorded as finance lease ROU assets and lease liabilities. The difference between the de-recognized assets and lease financing obligations resulted in an increase to retained earnings. The recognition of these arrangements as finance lease ROU assets and lease liabilities will not materially impact our consolidated results of operations over the terms of the leases.
Software Licenses. In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. We early adopted ASU 2018-15 effective January 1, 2019, using the prospective method, with no material impact to our financial condition, results of operations or cash flows. Adoption of this guidance may be significant to us in the future depending on the extent to which we use cloud computing arrangements that qualify as service contracts.
Recent Accounting Pronouncements Not Yet Adopted
Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which was subsequently modified by several ASUs issued in 2018 and 2019. This standard introduces a new current expected credit loss (“CECL”) model for measuring expected credit losses for certain types of financial instruments measured at amortized cost and replaces the incurred loss model. The CECL model requires an entity to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount the entity expects to collect over the instrument’s contractual life after consideration of historical experience, current conditions, and reasonable and supportable forecasts. This standard also introduces targeted changes to the AFS debt securities impairment model. It eliminates the concept of other-than-temporary impairment and requires an entity to determine whether any impairment is the result of a credit loss or other factors. We will adopt Topic 326 effective January 1, 2020, using the modified retrospective approach. Under this method we will recognize the cumulative effect of adopting the standard as an adjustment to the opening balance of retained earnings on January 1, 2020.
Under Topic 326, we will record an allowance for credit losses for financial assets subject to the CECL model. The most significant type of financial instrument reported in our consolidated balance sheets, subject to the CECL model, is “Receivables.” As of December 31, 2019, approximately 75%, or $1,056 million of the receivables balance constitutes receivables from state and federal government agencies. Based on our analysis, we believe that the credit risk associated with such receivables is nominal due to a very low risk of default.
The AFS debt securities impairment model will apply to “Investments” reported in our consolidated balance sheets. We believe that the credit risk associated with our non-government issued Investments is nominal due to the high quality of such investments.
The adoption of Topic 326 will be immaterial to our consolidated results of operations and financial condition.
Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.

Receivables Receivables consist primarily of amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for doubtful accounts is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.

X

- Definition
Risks and uncertainties.
+ References
No definition available.
+ Details

Name: moh_RisksAndUncertaintiesPolicyTextBlock

Namespace Prefix: moh_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Taxes based on premiums.
+ References
No definition available.
+ Details

Name: moh_TaxesBasedOnPremiumsPolicyTextBlock

Namespace Prefix: moh_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 05
-Paragraph 4
-Subparagraph (a)-(d)
-URI http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_BusinessCombinationsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for accruing health care costs for a prepaid health care service provider.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 405
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612
+ Details

Name: us-gaap_HealthCareCostsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investment in financial asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_InvestmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for leasing arrangement entered into by lessee.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980
+ Details

Name: us-gaap_LesseeLeasesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534
+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 119 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Investments
12 Months Ended

Dec. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Investments Investments
Available-for-Sale Investments
We consider all of our investments classified as current assets to be available-for-sale. The following tables summarize our current investments as of the dates indicated:

December 31, 2019

Amortized

Gross
Unrealized

Estimated

Cost

Gains

Losses

Fair Value

(In millions)
Corporate debt securities
$
1,174

$
5

$
1

$
1,178

Mortgage-backed securities
420

1

1

420

Asset-backed securities
126

1

—

127

U.S. Treasury notes
86

—

—

86

Municipal securities
78

—

—

78

GSEs
49

—

—

49

Foreign securities
7

—

—

7

Certificates of deposit
1

—

—

1

Total
$
1,941

$
7

$
2

$
1,946

December 31, 2018

Amortized Cost

Gross
Unrealized

Estimated Fair Value

Gains

Losses

(In millions)
Corporate debt securities
$
1,131

$
—

$
8

$
1,123

Asset-backed securities
83

—

1

82

U.S. Treasury notes
181

—

—

181

Municipal securities
115

—

1

114

GSEs
164

—

1

163

Foreign securities
4

—

—

4

Certificates of deposit
14

—

—

14

Total
$
1,692

$
—

$
11

$
1,681

The contractual maturities of our current investments as of December 31, 2019 are summarized below:

Amortized
Cost

Estimated
Fair Value

(In millions)
Due in one year or less
$
453

$
453

Due after one year through five years
957

962

Due after five years through ten years
171

171

Due after ten years
360

360

Total
$
1,941

$
1,946

Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains amounted to $13 million in the year ended December 31, 2019. Gross realized investment losses were insignificant in the year ended December 31, 2019. Gross realized investment gains and losses for the years ended December 31, 2018 and 2017 were insignificant.
We have determined that unrealized losses at December 31, 2019 and 2018 are temporary in nature, because the change in market value for these securities resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.
The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December 31, 2019:

In a Continuous Loss Position
for Less than 12 Months

In a Continuous Loss Position
for 12 Months or More

Estimated
Fair
Value

Unrealized
Losses

Total Number of Positions

Estimated
Fair
Value

Unrealized
Losses

Total Number of Positions

(Dollars in millions)
Corporate debt securities
$
222

$
1

167

$
—

$
—

—

Mortgage-backed securities
143

1

72

—

—

—

Total
$
365

$
2

239

$
—

$
—

—

The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December 31, 2018:

In a Continuous Loss Position
for Less than 12 Months

In a Continuous Loss Position
for 12 Months or More

Estimated
Fair
Value

Unrealized
Losses

Total Number of Positions

Estimated
Fair
Value

Unrealized
Losses

Total Number of Positions

(Dollars in millions)
Corporate debt securities
$
509

$
3

285

$
412

$
5

298

Asset-backed securities
—

—

—

68

1

52

Municipal securities
—

—

—

87

1

90

GSEs
—

—

—

127

1

76

Total
$
509

$
3

285

$
694

$
8

516

Held-to-Maturity Investments
Pursuant to the regulations governing our Health Plans segment subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulation in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as “Restricted investments” in the accompanying consolidated balance sheets.
We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value, and mature in one year or less. The following table presents the balances of restricted investments:

December 31,

2019

2018

(In millions)
Florida
$
12

$
32

New Mexico
21

43

Ohio
12

12

Puerto Rico
11

10

Other
23

23

Total Health Plans segment
$
79

$
120

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2209399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2324412

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2176304
+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 120 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Goodwill and Intangible Assets, Net
12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
Goodwill
The following table presents the changes in the carrying amounts of goodwill by segment, for the periods presented.

Health Plans

Other

Total

(In millions)
Balance, December 31, 2017
$
143

$
43

$
186

Acquisitions
—

—

—

Dispositions
—

(43
)

(43
)
Impairment and other
—

—

—

Balance, December 31, 2018
143

—

143

Acquisitions
—

—

—

Dispositions
—

—

—

Impairment and other
—

—

—

Balance, December 31, 2019
$
143

$
—

$
143

For the Health Plans segment, gross goodwill amounted to $445 million, and accumulated impairment losses amounted to $302 million, at each of December 31, 2019, and 2018.
2017 Impairment Losses. As a result of reporting unit quantitative goodwill assessments using discounted cash flows and/or asset liquidation analyses, we recorded goodwill impairment losses of $244 million and $190 million for the Health Plans segment and Other segment, respectively, in the year ended December 31, 2017. The Health Plans segment impairment losses were due primarily to certain health plans’ Medicaid contract terminations, and insufficient estimated future cash flows. The Other segment impairment losses were due to the expectation of fewer future benefits, and related lower cash flows, to be derived from certain subsidiaries. Such subsidiaries were disposed in 2018.
Intangible Assets, Net
The following table provides the details of identified intangible assets, by major class, for the periods indicated:

December 31, 2019

December 31, 2018

Cost

Accumulated
Amortization

Carrying Amount

Cost

Accumulated
Amortization

Carrying Amount

(In millions)
Contract rights and licenses
$
179

$
156

$
23

$
201

$
162

$
39

Provider networks
20

14

6

20

12

8

Total
$
199

$
170

$
29

$
221

$
174

$
47

As of December 31, 2019, we estimate that our intangible asset amortization will be approximately $14 million in 2020, $5 million in 2021, and $3 million in 2022, 2023 and 2024. For a presentation of our intangible assets by reportable segment, refer to Note 18, “Segments.”
2017 Impairment Losses. For the reasons described above, reporting unit undiscounted cash flow analyses produced intangible asset impairment losses of $25 million and $11 million for the Health Plans segment and Other segment, respectively, in the year ended December 31, 2017.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 121 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Derivatives (Tables)
12 Months Ended

Dec. 31, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Fair values of derivative financial instruments
The following table summarizes the fair values and the presentation of our derivative financial instruments (defined and discussed individually below) in the consolidated balance sheets:

December 31,

Balance Sheet Location

2019

2018

(In millions)
Derivative asset:

1.125% Call Option
Current assets: Derivative asset

$
29

$
476

Derivative liability:

1.125% Conversion Option
Current liabilities: Derivative liability

$
29

$
476

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 122 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Leases (Tables)
12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Components of lease expense and supplemental consolidated cash flow information
Supplemental consolidated cash flow information related to leases follows:

Year Ended December 31, 2019

(In millions)
Cash used in operating activities:

Operating leases
$
36

Finance leases
15

Cash used in financing activities:

Finance leases
6

ROU assets recognized in exchange for lease obligations:

Operating leases
99

Finance leases
245

The components of lease expense were as follows:

Year Ended December 31, 2019

(In millions)
Operating lease expense
$
34

Finance lease expense:

Amortization of ROU assets
$
17

Interest on lease liabilities
15

Total finance lease expense
$
32

Supplemental lease information
Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:

December 31, 2019

(In millions)
Operating leases:

ROU assets

Other assets
$
65

Lease liabilities

Accounts payable and accrued liabilities (current)
$
25

Other long-term liabilities (non-current)
48

Total operating lease liabilities
$
73

Finance leases:

ROU assets

Property, equipment, and capitalized software, net
$
228

Lease liabilities

Accounts payable and accrued liabilities (current)
$
8

Finance lease liabilities (non-current)
231

Total finance lease liabilities
$
239

Operating lease maturities
Maturities of lease liabilities as of December 31, 2019, were as follows:

Operating Leases

Finance Leases

(In millions)
2020
$
28

$
23

2021
20

24

2022
14

21

2023
10

21

2024
5

22

Thereafter
3

289

Subtotal - undiscounted lease payments
80

400

Less imputed interest
(7
)

(161
)
Total
$
73

$
239

Finance lease maturities
Maturities of lease liabilities as of December 31, 2019, were as follows:

Operating Leases

Finance Leases

(In millions)
2020
$
28

$
23

2021
20

24

2022
14

21

2023
10

21

2024
5

22

Thereafter
3

289

Subtotal - undiscounted lease payments
80

400

Less imputed interest
(7
)

(161
)
Total
$
73

$
239

X

- Definition
Assets And Liabilities, Lessee [Table Text Block]
+ References
No definition available.
+ Details

Name: moh_AssetsAndLiabilitiesLesseeTableTextBlock

Namespace Prefix: moh_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_LeaseCostTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 123 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Fair Value Measurements (Tables)
12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair value of assets measured on recurring basis
Our financial instruments measured at fair value on a recurring basis at December 31, 2019, were as follows:

Total

Level 1

Level 2

Level 3

(In millions)
Corporate debt securities
$
1,178

$
—

$
1,178

$
—

Mortgage-backed securities
420

—

420

—

Asset-backed securities
127

—

127

—

U.S. Treasury notes
86

—

86

—

Municipal securities
78

—

78

—

Government-sponsored enterprise securities (“GSEs”)
49

—

49

—

Foreign securities
7

—

7

—

Certificates of deposit
1

—

1

—

Subtotal
1,946

—

1,946

—

1.125% Call Option derivative asset
29

—

—

29

Total assets
$
1,975

$
—

$
1,946

$
29

1.125% Conversion Option derivative liability
$
29

$
—

$
—

$
29

Total liabilities
$
29

$
—

$
—

$
29

Our financial instruments measured at fair value on a recurring basis at December 31, 2018, were as follows:

Total

Level 1

Level 2

Level 3

(In millions)
Corporate debt securities
$
1,123

$
—

$
1,123

$
—

Asset-backed securities
82

—

82

—

U.S. Treasury notes
181

—

181

—

Municipal securities
114

—

114

—

GSEs
163

—

163

—

Foreign securities
4

—

4

—

Certificates of deposit
14

—

14

—

Subtotal
1,681

—

1,681

—

1.125% Call Option derivative asset
476

—

—

476

Total assets
$
2,157

$
—

$
1,681

$
476

1.125% Conversion Option derivative liability
$
476

$
—

$
—

$
476

Total liabilities
$
476

$
—

$
—

$
476

Fair value measurements of senior notes As of December 31, 2019, the carrying amount of the Term Loan Facility approximated fair value because its interest rate is a variable rate that approximates rates currently available to us.

December 31, 2019

December 31, 2018

Carrying

Fair Value

Carrying

Fair Value

Amount

Amount

(In millions)
5.375% Notes
$
696

$
745

$
694

$
674

4.875% Notes
327

340

326

301

Term Loan Facility
220

220

—

—

1.125% Convertible Notes ⁽¹⁾
12

42

240

732

Total
$
1,255

$
1,347

$
1,260

$
1,707

_______________________________
(1)
The fair value of the 1.125% Conversion Option (the embedded cash conversion option), which is reflected in the fair value amounts presented above, amounted to $29 million and $476 million as of December 31, 2019 and 2018, respectively. For more information, including information on debt repayments in 2019 and 2020, see Note 11, “Debt,” and Note 12, “Derivatives.”

X

- Definition
Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2C
-URI http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 124 R105.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Financial Information of Registrant - Condensed Statements of Operations (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Revenue:

Investment income and other revenue $ 132 $ 125 $ 70

Total revenue $ 4,274 $ 4,243 $ 4,193 $ 4,119 $ 4,664 $ 4,697 $ 4,883 $ 4,646 16,829 18,890 19,883

Expenses:

General and administrative expenses 1,296 1,333 1,594

Depreciation and amortization 89 99 137

Restructuring costs 6 46 234

Impairment losses 0 0 470

Total operating expenses 15,785 17,744 20,438

Gain (loss) on sales of subsidiaries (52) 37 0 0 0 (15) 0

Operating income (loss) 1,044 1,131 (555)

Interest expense 87 115 118

Other (income) expense, net (15) 17 (61)

Income tax expense (benefit) 235 292 (100)

Net income (loss) $ 168 $ 175 $ 196 $ 198 $ 201 $ 197 $ 202 $ 107 737 707 (512)

Parent Company

Revenue:

Administrative services fees 1,038 1,138 1,317

Investment income and other revenue 18 17 16

Total revenue 1,056 1,155 1,333

Expenses:

General and administrative expenses 937 1,007 1,082

Depreciation and amortization 63 69 93

Other operating expenses 0 8 16

Restructuring costs 4 35 153

Impairment losses 0 0 39

Total operating expenses 1,004 1,119 1,383

Gain (loss) on sales of subsidiaries 0 37 0

Operating income (loss) 52 73 (50)

Interest expense 87 114 117

Other (income) expense, net (15) 17 (61)

Loss before income tax (benefit) expense and equity in net earnings (losses) of subsidiaries (20) (58) (106)

Income tax expense (benefit) 9 (14) 8

Net loss before equity in net earnings (losses) of subsidiaries (29) (44) (114)

Equity in net earnings (losses) of subsidiaries 766 751 (398)

Net income (loss) $ 737 $ 707 $ (512)

X

- Definition
Income (Loss) Before Income Taxes And Equity In Net Income Of Subsidiaries
+ References
No definition available.
+ Details

Name: moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net Income (Loss) From Continuing Operations Before Equity Method Investments, Extraordinary Items, Noncontrolling Interest
+ References
No definition available.
+ Details

Name: moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684
+ Details

Name: us-gaap_GainLossOnSaleOfBusiness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetImpairment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of income (loss) of subsidiary attributable to the parent entity.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeLossFromSubsidiariesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fees earned during the period for providing management services.
+ References
No definition available.
+ Details

Name: us-gaap_InsuranceAgencyManagementFee

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.1-5)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestAndDividendIncomeOperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.5)
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_RestructuringCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 125 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies - Quality Incentive Premium Revenue (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Accounting Policies [Abstract]

Maximum available quality incentive premium - current period $ 186 $ 182 $ 150

Amount of quality incentive premium revenue recognized in current period:

Earned current period 156 133 97

Earned prior periods 38 31 10

Total quality incentive premium revenue recognized $ 194 $ 164 $ 107

Quality incentive premium revenue recognized as a percentage of total premium revenue 1.20% 0.90% 0.60%

X

- Definition
Amount of current year quality incentive premium revenue recognized.
+ References
No definition available.
+ Details

Name: moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of quality incentive premium revenue recognized from prior year.
+ References
No definition available.
+ Details

Name: moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount Of Quality Incentive Premium Revenue Recognized In Current Period [Abstract]
+ References
No definition available.
+ Details

Name: moh_AmountOfQualityIncentivePremiumRevenueRecognizedInCurrentPeriodAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum available quality incentive premium current year.
+ References
No definition available.
+ Details

Name: moh_MaximumAvailableQualityIncentivePremiumCurrentYear

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Quality Incentive Premium Revenue As A Percentage Of Total Revenue
+ References
No definition available.
+ Details

Name: moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Quality incentive premium revenue recognized.
+ References
No definition available.
+ Details

Name: moh_QualityIncentivePremiumRevenueRecognized

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 126 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Fair Value Measurements - Long-Term Debt (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Carrying Amount

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Estimated fair values of long-term debt $ 1,255 $ 1,260

Fair Value

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Estimated fair values of long-term debt $ 1,347 1,707

5.375% Notes

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Percentage of contractual interest rate 5.375%

4.875% Notes

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Percentage of contractual interest rate 4.875%

1.125% Convertible Notes

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Percentage of contractual interest rate 1.125%

Senior Notes | 5.375% Notes

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Percentage of contractual interest rate 5.375%

Senior Notes | 5.375% Notes | Carrying Amount

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Estimated fair values of long-term debt $ 696 694

Senior Notes | 5.375% Notes | Fair Value

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Estimated fair values of long-term debt $ 745 674

Senior Notes | 4.875% Notes

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Percentage of contractual interest rate 4.875%

Senior Notes | 4.875% Notes | Carrying Amount

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Estimated fair values of long-term debt $ 327 326

Senior Notes | 4.875% Notes | Fair Value

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Estimated fair values of long-term debt $ 340 301

Senior Notes | 1.125% Convertible Notes

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Percentage of contractual interest rate 1.125%

Term Loan Facility | Carrying Amount

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Estimated fair values of long-term debt $ 220 0

Term Loan Facility | Fair Value

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Estimated fair values of long-term debt $ 220 0

1.125% Convertible Notes | 4.875% Notes

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Percentage of contractual interest rate 4.875%

1.125% Convertible Notes | 1.125% Convertible Notes

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Percentage of contractual interest rate 1.125%

1.125% Convertible Notes | 1.125% Convertible Notes | Carrying Amount

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Estimated fair values of long-term debt $ 12 240

1.125% Convertible Notes | 1.125% Convertible Notes | Fair Value

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Estimated fair values of long-term debt $ 42 732

1.125% Conversion Option

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Percentage of contractual interest rate on derivative 1.125%

1.125% Conversion Option

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

1.125% Conversion Option derivative liability $ 29 $ 476

Percentage of contractual interest rate on derivative 1.125%

X

- Definition
Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611
+ Details

Name: us-gaap_DebtInstrumentFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Fixed interest rate related to the interest rate derivative.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeFixedInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 127 R101.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Segments - Reconciliation of Gross Margin to Consolidated Income (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Segment Reporting Information [Line Items]

Total margin $ 578 $ 561 $ 583 $ 581 $ 664 $ 566 $ 673 $ 615 $ 2,303 $ 2,518 $ 1,810

Add: Other operating revenues $ 4,274 $ 4,243 $ 4,193 $ 4,119 4,664 4,697 4,883 4,646 16,829 18,890 19,883

Less: Other operating expenses (15,785) (17,744) (20,438)

Less: loss on sales of subsidiaries, net of gain $ (52) $ 37 $ 0 $ 0 0 (15) 0

Operating income (loss) 1,044 1,131 (555)

Less: other expenses, net 72 132 57

Income (loss) before income tax expense (benefit) 972 999 (612)

Health Plans

Segment Reporting Information [Line Items]

Add: Other operating revenues 16,815 18,471 19,352

Other

Segment Reporting Information [Line Items]

Total margin 0 43 29

Add: Other operating revenues 14 419 531

Operating Segments

Segment Reporting Information [Line Items]

Total margin 2,303 2,518 1,810

Operating Segments | Health Plans

Segment Reporting Information [Line Items]

Total margin 2,303 2,475 1,781

Operating Segments | Other

Segment Reporting Information [Line Items]

Total margin 0 43 29

Other Operating

Segment Reporting Information [Line Items]

Add: Other operating revenues 621 871 508

Less: Other operating expenses (1,880) (2,243) (2,873)

Less: loss on sales of subsidiaries, net of gain $ 0 $ (15) $ 0

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684
+ Details

Name: us-gaap_GainLossOnSaleOfBusiness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 128 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Statement of Comprehensive Income [Abstract]

Net income (loss) $ 168 $ 175 $ 196 $ 198 $ 201 $ 197 $ 202 $ 107 $ 737 $ 707 $ (512)

Other comprehensive income (loss):

Unrealized investment income (loss) 16 (3) (5)

Less: effect of income taxes 4 (1) (2)

Other comprehensive income (loss), net of tax 12 (2) (3)

Comprehensive income (loss) $ 749 $ 705 $ (515)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 129 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Statements of Cash Flows - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Operating activities:

Net income (loss) $ 737 $ 707 $ (512)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

Depreciation and amortization 89 127 178

Deferred income taxes 10 (6) (94)

Share-based compensation 39 27 46

Amortization of convertible senior notes and finance lease liabilities 5 22 32

(Gain) loss on debt extinguishment (15) 22 14

Loss on sales of subsidiaries, net of gain 0 15 0

Non-cash restructuring charges 0 17 60

Impairment losses 0 0 470

Other, net (5) 4 21

Changes in operating assets and liabilities:

Receivables (76) (530) 103

Prepaid expenses and other current assets 28 6 (56)

Medical claims and benefits payable (107) (226) 263

Amounts due government agencies (303) (574) 341

Accounts payable and accrued liabilities 2 45 (12)

Deferred revenue 38 (21) (34)

Income taxes (15) 51 (16)

Net cash provided by (used in) operating activities 427 (314) 804

Investing activities:

Purchases of investments (2,536) (1,444) (2,697)

Proceeds from sales and maturities of investments 2,302 2,445 1,759

Purchases of property, equipment and capitalized software (57) (30) (86)

Net cash received from sale of subsidiaries 0 190 0

Other, net (2) (18) (38)

Net cash provided by (used in) investing activities (293) 1,143 (1,062)

Financing activities:

Repayment of principal amount of convertible senior notes (240) (362) 0

Cash paid for partial settlement of conversion option (578) (623) 0

Cash received for partial settlement of call option 578 623 0

Cash paid for partial termination of warrants (514) (549) 0

Proceeds from borrowings under term loan facility 220 0 0

Common stock purchases (47) 0 0

Repayment of credit facility 0 (300) 0

Proceeds from senior notes offerings, net of issuance costs 0 0 325

Proceeds from borrowings under credit facility 0 0 300

Other, net 29 18 11

Net cash (used in) provided by financing activities (552) (1,193) 636

Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents (418) (364) 378

Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period 2,926 3,290 2,912

Cash and cash equivalents at end of period 2,508 2,926 3,290

Cash paid during the period for:

Income taxes 239 240 7

Interest 78 93 78

Schedule of non-cash investing and financing activities:

Common stock issued in exchange for convertible senior notes 0 131 193

Component of convertible senior notes allocated to additional paid-in capital, net of income taxes 0 (23) (32)

Net increase to additional paid-in capital 0 108 161

Common stock used for stock-based compensation (7) (6) (22)

Common stock purchases not settled at end of period 7 0 0

Details of sales of subsidiaries:

Decrease in carrying amount of assets 0 (327) 0

Decrease in carrying amount of liabilities 0 85 0

Transaction costs 0 (15) 0

Cash received from buyers 0 242 0

Loss on sale of subsidiaries, net of gain 0 (15) 0

Details of change in fair value of derivatives, net:

Change in fair value of derivatives, net 0 0 0

Call Option

Details of change in fair value of derivatives, net:

Change in fair value of derivatives, net 132 577 255

Conversion Option

Details of change in fair value of derivatives, net:

Change in fair value of derivatives, net $ (132) $ (577) $ (255)

X

- Definition
Amortization of Debt Discount (Premium) and Sale Leaseback Financing Obligation
+ References
No definition available.
+ Details

Name: moh_AmortizationOfDebtDiscountPremiumAndSaleLeasebackFinancingObligation

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash Paid During The Period [Abstract]
+ References
No definition available.
+ Details

Name: moh_CashPaidDuringThePeriodAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash Paid For Settlement Of Conversion Option
+ References
No definition available.
+ Details

Name: moh_CashPaidForSettlementOfConversionOption

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Common Stock Purchases Not Settled At End Of Period
+ References
No definition available.
+ Details

Name: moh_CommonStockPurchasesNotSettledAtEndOfPeriod

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Details of change in fair value of derivatives
+ References
No definition available.
+ Details

Name: moh_DetailsofchangeinfairvalueofderivativesAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disposition of Business, Receivable from Buyer
+ References
No definition available.
+ Details

Name: moh_DispositionofBusinessReceivablefromBuyer

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Disposition of Business, Transaction Costs
+ References
No definition available.
+ Details

Name: moh_DispositionofBusinessTransactionCosts

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gain (Loss) on Disposition of Liabilities
+ References
No definition available.
+ Details

Name: moh_GainLossonDispositionofLiabilities

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Increase (Decrease) in Medical Premium Liability Due to Agency
+ References
No definition available.
+ Details

Name: moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Increase (Decrease) in Carrying Amount of Assets
+ References
No definition available.
+ Details

Name: moh_IncreaseDecreaseinCarryingAmountofAssets

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Non-cash Restructuring Charges
+ References
No definition available.
+ Details

Name: moh_NoncashRestructuringCharges

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Notes Issued, Fair Value Adjustment Increase (Decrease)
+ References
No definition available.
+ Details

Name: moh_NotesIssuedFairValueAdjustmentIncreaseDecrease

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 55
-Paragraph 51
-URI http://asc.fasb.org/extlink&oid=117331294&loc=d3e34017-109320
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959
+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684
+ Details

Name: us-gaap_GainLossOnSaleOfBusiness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetImpairment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) in health care insurance liability balances during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The fair value of notes issued in noncash investing and financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_NotesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).
+ References
No definition available.
+ Details

Name: us-gaap_OtherOperatingActivitiesCashFlowStatement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash (inflow) outflow from investing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for purchase of marketable security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562
+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliatesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ProceedsFromLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromLongTermLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_RepaymentsOfLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The fair value of stock issued in noncash financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586
+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=moh_CallOptionDerivativeAssetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 130 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Investments - Available-for-Sale (Details)
$ in Millions

Dec. 31, 2019

USD ($)

Security

Dec. 31, 2018

USD ($)

Security

Estimated Fair Value

In a Continuous Loss Position for Less than 12 Months $ 365 $ 509

In a Continuous Loss Position for 12 Months or More 0 694

Unrealized Losses

In a Continuous Loss Position for Less than 12 Months 2 3

In a Continuous Loss Position for 12 Months or More $ 0 $ 8

Total Number of Positions

In a Continuous Loss Position for Less than 12 Months | Security 239 285

In a Continuous Loss Position for 12 Months or More | Security 0 516

Corporate debt securities

Estimated Fair Value

In a Continuous Loss Position for Less than 12 Months $ 222 $ 509

In a Continuous Loss Position for 12 Months or More 0 412

Unrealized Losses

In a Continuous Loss Position for Less than 12 Months 1 3

In a Continuous Loss Position for 12 Months or More $ 0 $ 5

Total Number of Positions

In a Continuous Loss Position for Less than 12 Months | Security 167 285

In a Continuous Loss Position for 12 Months or More | Security 0 298

Mortgage-backed securities

Estimated Fair Value

In a Continuous Loss Position for Less than 12 Months $ 143

In a Continuous Loss Position for 12 Months or More 0

Unrealized Losses

In a Continuous Loss Position for Less than 12 Months 1

In a Continuous Loss Position for 12 Months or More $ 0

Total Number of Positions

In a Continuous Loss Position for Less than 12 Months | Security 72

In a Continuous Loss Position for 12 Months or More | Security 0

Asset-backed securities

Estimated Fair Value

In a Continuous Loss Position for Less than 12 Months $ 0

In a Continuous Loss Position for 12 Months or More 68

Unrealized Losses

In a Continuous Loss Position for Less than 12 Months 0

In a Continuous Loss Position for 12 Months or More $ 1

Total Number of Positions

In a Continuous Loss Position for Less than 12 Months | Security 0

In a Continuous Loss Position for 12 Months or More | Security 52

Municipal securities

Estimated Fair Value

In a Continuous Loss Position for Less than 12 Months $ 0

In a Continuous Loss Position for 12 Months or More 87

Unrealized Losses

In a Continuous Loss Position for Less than 12 Months 0

In a Continuous Loss Position for 12 Months or More $ 1

Total Number of Positions

In a Continuous Loss Position for Less than 12 Months | Security 0

In a Continuous Loss Position for 12 Months or More | Security 90

GSEs

Estimated Fair Value

In a Continuous Loss Position for Less than 12 Months $ 0

In a Continuous Loss Position for 12 Months or More 127

Unrealized Losses

In a Continuous Loss Position for Less than 12 Months 0

In a Continuous Loss Position for 12 Months or More $ 1

Total Number of Positions

In a Continuous Loss Position for Less than 12 Months | Security 0

In a Continuous Loss Position for 12 Months or More | Security 76

X

- Definition
Debt Securities, Available-For-Sale, Unrealized Loss Position [Abstract]
+ References
No definition available.
+ Details

Name: moh_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAbstract

Namespace Prefix: moh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 131 R87.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Statutory federal tax (benefit) rate 21.00% 21.00% 35.00%

State income provision (benefit), net of federal 1.40% 1.20% 0.70%

Nondeductible health insurer fee (“HIF”) 0.00% 7.30% 0.00%

Nondeductible compensation 1.20% 0.70% (2.80%)

Nondeductible goodwill impairment 0.00% 0.00% (6.60%)

Worthless stock deduction 0.00% (1.00%) 0.00%

Revaluation of net deferred tax assets 0.00% (0.40%) (8.80%)

Other 0.60% 0.40% (1.10%)

Effective tax expense (benefit) rate 24.20% 29.20% 16.40%

X

- Definition
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Health Insurance, Percent
+ References
No definition available.
+ Details

Name: moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective Income Tax Rate Reconciliation, Worthless Stock Deduction
+ References
No definition available.
+ Details

Name: moh_EffectiveIncomeTaxRateReconciliationWorthlessStockDeduction

Namespace Prefix: moh_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

ZIP 132 0001179929-20-000026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001179929-20-000026-xbrl.zip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
NX6L;7O@&*]+6SM^BF!J,!F,Q@+<;]#T[H_:":7A?&\K M5B]K2IOE07GS;W2\5)A1IEOI48!WO86_=W$^L-06EAJ G$IF+I67I+.MKB)C MLD>)_+SP*M96\&$9K*V\*6K92W^*&VICBK(G*QBPSKFQ$B2)@8^.T*E.]Q']T(S%)%;ZDMV.YL!5R,NH]NQ\;U=,$ H=>US;0 MN#421@X7YNB]&+%T+?1GLN9ZG^;=F4G[C8<_@M:;1:'$QLFZ3GCPU$.67S!M M6&AWXKQ*9G;[=5GEQMK4SK%@QNS,2?&!+'6 (I$2 ZQ M'["7UOBP+7;537_6%MDHXF#@JO/FH*2)B (ES8TD9,'?5==/?&R'NG#F^]UKZ36,[A$DG:L_(%<3)/F-><.8L@) MC"]*=:=$I\(%3JJ+-0QJY-(X<5X97\='=PJSC"_%SWVC:E&9I&@:+,UEP MD'_X?<_OO3W:-V\L_E^V@;[W M\C3H,#V/AL#1S3P-3+9/9?:E"!? M\?:$#T$"T1SNV;+E>HD.>AZQ/0_O/2(QG)_\,">YSI8H"A&18?'Z0J' M3%Q3^[1SQ)T74N1Z%\2K!0):H+_;B)S3<<3&SF^-Z0_U%&Y]9\RMJIKMQ1Y; M,_97L[Y/5%_3!#PQ%_A]TH:/5%1#)):DN,9:S+B]Y>/%58UTQ'(SZ2@884K3 M&&T\U2[[Q5;R3!1B]L35]<\CH:SO]][T;\91 */%#(32C+)FD+ -OG?"V*"U;DBJPH-*H.WR_*3LA4&]H:R_P^X+)J M>:+123_ZS_#\D+[;$:=CWU !'\0:[?WA"FUR"B6!&B'G^$/;T>35.(0\4X<3 MT6I=KR%%_59XMNW4UZUPE7!G+JTGH2CJ!B"(70/5[06Z8ZJ&B9 MIW8#$#BH.'I6T0K+)AHU"'?\ET%DX!#>A9U?VPF+^_'M OTMU?D&S\$*%GA3 M%;%R4PN\YMD?& (NPKS;N'VB<>Y"ZRDA# ,X2_R[_^7?RL/_GA+%OFH&9?:B MR/0EL*-577$[$>H\@3K+6!A ['XGY(+T#O3&BO_Q2E3# ;XL)\\RHS>S&2 7 M?LM\/V[(5S)">O/75Y7^>2T=QKSE!D9AV6+I=M6G7_D!!'&@+$1H6#4XD(X: M(C5EA!Y%L*$JA&OG]3" >&'7TJ>'<57B:P]E43\?U-US5THO&"O4]_XQ-=<9 MV6M4"6,G"4N)H##85T?%#C=51PT?:/WG"/=L1 M?@CR_G"=$(4[>Z>JQ:O :S[R"^VM-+TW,RNH!/T<1V_3NLA6"^1UFD.+NL77F*Q:>> MNN^DGMVXO/+66MB&>7 M)#WFEA8M^8UU-7ZG#,@++B$R.*/[3_WN9-U\IR6=8O.?%944&X_\*>H5>!@N MY\402*8*>'YB"SR3;=&KAV-;PN(,0"GRZC'F__YII)_R19[)T!"5G'9YU MJRTIKCCJRY-?"O(EJ$]<=JF<.A>8QF6;E>-VK3@,8XH@\=MY]55QNE[[-79U M'<(W)XI<[5L%G&7#AI$:!W!U4@^;B>)4F3=.]F?GTG=# MPNGB.M)/%U?Z!OCLB_!ZN%1?WW0*+/50Y+^H8YKFQ@#(M>8L,[@F-+H$?9K7 MUC,\#UKI!P77G62M_6":%=V1O+%%0=NBCEM5F8!FDP];0WK7KG M7!>6,;=)Y?-/!J2YFI^4,1*KX&L[LQ3+LN6?X+6X0&%NC3XMP3W9;B*1]5V\ ME<-#3SX*=!3RT\2/%XQIF%YR*O]0D3DB;UL]IK%JQ9FDVI=/^.SHE_0TO@SY M3D5@X84;76@ ,4/@D*&2RNL>!X>XQJ\_0*IW#-M2ID?N:[7%-7MGXW \XN%4 MWFB@CI5#H58:TY2]8%+^W&A_^ M#KIP97WU4WI>K9+#:478!3I^' HDIA"#'Z6^^L96?2O5?8]C)B5"?2!W\YS& M!1M01_V-S3]-H^/K3RIWF33IR@G"JCRA"SK 5[='C99[ M,^#V9>HJ>'ZH#?<-N1'>N_61@#^]<3+8\4,V2A+N4KOM_TMAZK\5JG8#:W!^ MTU. (&0U[(^18/&FR;/]OJPX+9,XWA=?,G%5AP^,-.J#?N7U!Q*?Y07' M@_(6/)G+SGW:WI^\"+O].B7,DP.RDLS,G5O!Q@" CQDQ $[=C HX^V_!W.9? MR/?C8HT;[5@F, !Y.:YJ:S5_=94 W/:' MC<0DWF\GT'3[M74SRW@!PT?3!KSCL!X8N+*?88LRL.IA.W5M9*A_!C\_F>SI MP(G XE'WS^OXZ6::7A(YG(R4__\E*OF2D4QA85Q_['$*?Q%A;W2/HF?AYP$9UF<_4>WHR!/5&2<*:SU_" 0]8EVOR.[4I=1(1NI#Y.W7?0S[%5=N^H8&62XE_,B0]Y M)L*_KTM+GJ#]I11'P6HO_:>PGC6AN[']2?5&D?F4H#PTH%G2=R3;_63X1KF^ M(6IZ8%Q.YI>EJ6$7JYU2Q"&V_< 1 RD?WF\HY"W[D7/3OM>@P&9-4UVL68C% MS^(>F.,SDM$ UJFSE?F/:C]_"\ME[NF_8MGXTY3"6]<8)XJEPB0AQD_S_@WC ME5<=ZF[_[H 18\PZ=3G1F"[^VY\ MK($/E1Z 'D(*A"L7_R1)C+*GW22(G2RZ7I_1AV-U:)>7R,W).IC-><] M&/F4-0=4'T_@^(5.@4)(["T7_W8S%5)VUFU06>2=;W32CB;!>&IA2$%*V[M& MH6L1EUVG)QH&Q!T0,F[;"-0'G:" M9;:\?(OIJLI0-6,BL2-<)CHQ>J6P#9&F;-ZPV7'4\Y)]7*;:B:T;@9'KS]D# M089^3HQ&GC&"EZ712#5/E!LAR(&V)?WF/5M-0G='3IW9!_;-T]!YW%>0D8?\Y^A%%;@KN^][]85XTPH\."E#0:0K5X.RH0+L]LAL#L1LI$TWPL7BADC MR%^HW2>9G1&1+O\_^E"G8Y[[^J@!9(,7D!D4UV3XUJ%PL,G4WX_+-U)C6U9DGE.-O_E!_27.@\D_#:)]#OG6>-@6Z$OTTSAY?498QMXD MU49])9][B5SM3NM>I "U$N M=W>6UX !&%3>X>O75CE13V7]MLP;C9 QW=D&'0,G#,#V;][ABNQBM2R[H[RV M--,]7-[Z2=3,C2Q7[Y$,&<#A7.I.>7I?:[#KH!\TG@@KF6'?F[X_0 8*BD[L+*F ?34(]HGU_6^%:^ZQKW_EK-ZE_,;Z8%W8GH#3D4 M%EDO*+O/:WMH5#07NS-W?#.@"D?$83$&<+;O1>,C(? %):3!>G$ZW8TS_ TA MR+2K!-U,+N6KF/FM;Y_]K[KK"F MOC?=("@*""I%.B@@TI4F2(FH= %!>HOT$GJO 4%ZD]Y[EQ(I >G2>PV]!P2D M!!)J@! .OSDS<\[,F>=_IOW/U;EX;_;%?IZ]]EK?][[K:\#QXV-)V;S&ME 0 MR%(.:*V\=2RE?"Y6Y">LF:MU M7TT=+-VCZ')&]+PRHE,2?PJKQ/:U2L= NG#)D"WF-'NN(.[N;W.-=DY290,/ M^J.)C((\Z#.EUY\J>!6L]RZX3NDP=G8P6Y4>K;KTW#J5:JLC 0Y&JVN [IL1 M*>):BR*&QM-+_N:#U9#V!;) 27+<<'TV8>10Y_]QS#P3@=D]=0V^,22HH;Q[K]/O+?P&[K_)DDZ;%;+ MEW[*4!Y]E]/W;M$_MBO$/:S7@U):/>QS?-@4VB"1\.*OKF)/*[=KTKE\C8_I MA2H3O?FS9:D."8!GX[H_9;,4)(9>4FH0"7S'#=CO:TDZ3?&MJ$_Q\9E> W2< M!896-(U5CK[7JH+**BACL2 .4>'E&P'TZ<'_EO:(MXPU--,;)=+CP-_#T<$3 M>H#^S8963#&I3;C;^I1>A+TE:C-KE55@ZBZWJOGYXLNJA?>!QZJ&?OH8/X3T MF6QAJE5D&>,$>!]^?+.XC62"_R2!N-Y)HTF+$2URUK2:N<[%(,[JB BK#TZ M3@([^L/[%N/R!5.IJ@FY;,^;!%U?AW234>RXI=VOG9^:Z,V-P22?\VW4\L2Y M!^L_PEZMC]QV6::Y*A!W1E3P*N*55A83KOCOQ!(GU2<[O8@E=OYI*T+(;&\2 MF3&3HJJM2"8#3OJHY,48Q#U(]Q8RD6C%8>O=.HV-NXP.Z0(]%%==^^-38=%% M&UU\!\T722R-HB0A3DP?G;NU\F"1 M)I269?2N7!IEO-9QMN=-V6\\\$]3:B[-$K)>3Y 6^X+=*5!@MR=&F;<2617\ M\?@6Z;,\[3!E\P:;86L2_+@#Z!VFB%23BHI_OBD5[ZI[WM+BONF,C M6E]H?'U/&I?T6Q!DGM? S)' MZOXAX]6'2+4?7Z18EF[X:8'E"/*7!@T[JL+#AW*-*^@^56#I0'&NHNC=:\"8 M)7[(59D0G0I&R05)"G^?+1\A77/)J21&?EK+.\2J_R61M6II,=Z0W;#W4M60 M+H;.BLN9J.A'HW35I"G?D\0B3H?*2HC,77)FO$'R$2DH/13^@NJB0HS+TH\- MS1(_C!8_W/09!:D>'KT5REA+-"6Z)]'5.?%A0.V?7R*#*R)#RG\K'06EAD" M Y#4CY@N,5#,C) !SV&F7OMKUR%PHP&G5FVV/>O[/=.PF+KUYUC""F?U?][4 M"QZD=.KF\\W5 VEOR(5*1O M6HSXY,)+(<[]* 9[7V<=1 8AV[T&/"P_B8@2'MB.&UC*>JSG-#[ZNMK\/O:V M;>3P-0 /OQ6,5)D+0?"%2E)C^-=ZNPZL#Q4]3P?!S]'L<]HYFFSHLY@/M][@ M!_977 .")*G:%-O7YJ '/"S3QW]X>5UN_9J7]7S*&C?*Q%K*^DV&4"QL1(HQ M537%7 #JI;!8A!7JF/5IZ*1C9U<;=E.2K)LIK/5V:_VK,"P \NUO)4;^>^"4 M)8"QR/58>VI?T=S4;&3/W#$@68P)J1KVN5R/"6@\",0.AGZZU%(RA(S;%3N1 MG<)++B)C'$&:-_;U[CC(T","\3BH64E@U+FH_!7?-%CSY2-?.7KR?:E*.O6K M5&XVF^WYJ>X;U^ZVR99\_X26S9K M[V=> :$"FDT*7@8QB/=X]&.%L[?TR;KY@B1Y;\1!9Z;QHN7,8[BAOEY'67'N M3^/PH;VN9W* /"<94# M7".'.%;//1,/9G$N?3\M'F9=&LJ7..FYG+1< _JPOPHU>-O5J=AS*"^ I9!! M((F0D"WN)C>S)DU-#*FD-DXW[$9S=3$]@CS$Y!UUTFZ%%DXG< [365O6HX;I2!DT$2"&NR(, MZM%>,P)DW;L5/QM0;5^AOHI_/KY7N;JX9]ALK>SX*5Q))%:293 MOD$C/5=\._]<'B=+*.U.CE6 [[=-8_ [BG$-O>Y,N"\.G._1R0$6D<30$,>N MJP7E:3MCIH166U!M]B&P$SL$J9!NX>K=++Z0SF @*DP!\*L B)#=HYT5"J)4 MBDR//" ?I>2?_ Q4TSRY3?.9ZV01DNC=F:;263==7NQ'M9.DNC!*7WU?19J8 M/I2:ZN/8,!>^OU>E:,&N4X4Q;A>G1>_ ZZ1 ^12^.Y2,2QRX!MQBBDF^YXB. MZ'XFO,C2=$@=<_#T^XMK0&O"#)X>1&3Z*9HPRD?J^YN%U=9)7EX3VT(G*,L+ M$0D1H3 -&?':]P/;&Z$7B58\C5+P&=&O>ISSOOU*VJX\1_S#PSB-"D_GDS@4( MQUE="2,N.UUR=A;J=%WB#HK9U?B30]16VZ6;!$6HX('KM4Z/YJ^2]"B_*'A& M<#9P+P)4^E@(@2Y?)JN@V;L[*V'91O V"YC](V+%;;N"!01FW9@]J#/[93U> M5#YKHN3/OC[*PT1(8(*ZW4%W($3L=8OV=:.GS >RVF"'2"@QLW';[*PZ& M9"*@/ %&M_UVF0'NGH*N2&:&:&TC&XMRP19WAV8>E3\'SAL#KI1\A=:)@QK1 MYC7\OKW-*5"X9[=/M-\U@/>OFO,Y1+4?TK[XAL[74Q^K2OO$7G[^R[!/^KQ: M88_@07;N!6_2(#*2Y_.>!756C1(\'_Q\LJ"/_.WXSE/<[W/VT]!' M#]OB(EF1RI!?Q+36M)F#=E85M8.E3X(<4ZE[/L;D:)E+]H%3_E>"5\O!*E^P M29R8@87*)%^N2I;$V]F4(7X1 DZ4.\D=DGN$/_L.5A./D_>V\JQ?@X(/>"OC M!*M;79,6J'EG!ZHD%TG(H!4 KXV_%?W]3^(^9[D4Y[V3[M?_*,@&(:]]""Z5Q>%B'T%,$F\LPZF3' MR+H'1J.KZO[APD0/[E=U$C'(@[.L3\Q_9$+G+\[4I4$+":GH7U=.5M MJ0=KPF'WM$07PXNH'/S"OC&E."R0.4P.8.M@'*JEG$Y+3+/:)&;BG<0JE(J( M-)6+8Z(Q%"Z&/51HD$&8!;9?I%UO(B8E7L7H;XJCS-;3Y3GT<'^/9@HU:PM1 M%GYMVR4,Y>([L-L(T A^40XQ=D!&,C5,%&4PR)?PS+4^;7Y1:V'H+?WJC%$# M/;A&AF75;99DG+ /FOEZ[%!F M,ZB^/'YRZ(_%U#M2Z"3WU@:"1->1%%JYJK M]"FX#R?1:P(VITY=*VL:4+X&H!['S7G>[ <]>K86)O7L=U/E,#HUJLT1EY^A M/_I((ZDA.5H3RWRPZ-YNW:Z']ZMDW3GS+NYOW6HUA!;[2+FX$L\*D9_!Z!3! MI]< +\M',E?Z,_U;XQ,9+7[O3K/O[US.?N>Y!G!= R;BL>.IT@;P6N\*55[3 M+R8/]9@]B]+4PT4F?WS460RB8<4;%2U6+'IGW;1_DDDZ CQ0+%L@QW VF&#P M0>RTSMD=E9!1+7*9$+1Y_L[$<]7W:;U!/)/-RP(3D>#!NRP-L:/5T 1^OP<2 MW6;R:*Y?#K^OZD&-$K&"?2:$. ([4B"+@>.OM6+8S8()V3T=>.[CD>*3YI$Q!^)5A)YUWF8CFISTIYDO:WF;IZ'T7U2"MSX1UX!10=-J=>%?* MGE1$RUMPBH%I.'A824/C2Y_8(^X3II7*G3-)SOH)5^3K[EC705 =K*(Q6;OP MB%%4U7'!Q^;-'C41UVH9(J=84UAE3,?O@=E*+H[W]J'<;8HUL6\4O3E7[*MV&>6'^ P?E4= MU9OE-=-S#7C<++W&%S3/^,6LV/ J6JNY32]!7=XHV[)^=L- X4<[FW9T5*_N M!?!4!_/%$4V,X,GL/FYU*S01KW/GOSOQHHNA/^@-@(Z!4*I/",[-((?(#VMK MQ.':?GNJ.R\*V4P4?3+_+F5XH?,G*VWYXO2/UPF%JC[A>-#?P<+]$Y@X< O9 M1'N;8Q589Q.[*NL'0TD7@<^O 09T@!+DJ,83=<<^B!<19J3MDR2W;ZB/ /K= M#JW73E*L%7S@-++A2#CWLT3T&^;3'F^MC4S?:45=C> WD),_V^TUENVW8.M"D469I>J\"S7U\J6G#&.VTI@ M '#*1R@!L7$7&M?H/D2@9 -R88FFU;3OG?@29),W:QK2 >3!9 UZXDF??E%3 M*K<)]$Z=SJ:.CJRXA9QDWU^=)N3H'%?&(0]P?-XG/S0PUX J5SY2:Z]G3<6+ M(%V#08(_I_7$)-_Z&5$T\C(T3V4,,ZDO'[X-7_^ZH:R@ZF9YMJM:'%;,*90_ M3&,)WU&]D0+.J"/PCZ_J>.U]Z/*DC$Q(ZNOYZ^<+%RA4:ZKN3OPP^3)6"DTJ0WI* M/L(,_CKL+7UG9/^]:%K>=I71J]E&N%K<]-; KV]O"%%0";\Y83\JK,(44K#* M,P?CN,L.14;6HTJBG@ .RQB5G40&R<=, MZ+?@.!KL[7$(3:<50\7&TGE58]K:B&)>4[Z.B8:I;/X1>E_7J&+&B';\'MMCWL]$47=4+I<"6#*;$EI"WOG(76S#X,5B"#VD^ M_Y#.8&B&O%7>BI7Y_I *NS_@F CP"Z"5&CC$^7G]>:_>-0 4>S)W0(*HF:_= MF?*IY"B:1KJ V*$KB]@AE%\[$QT&:1<=@]@M#6KD$E FP*NG!Q2]S9T49E>CK_; L:JB39^1__3FVVRMVU&+4LW,)"[D&8 A[-5&;(3]4\PTN ME9&\>EX\?N2'7_)--;@+WY&4LI3TTS"% A.M9S%-!A/'\&*=7=VHHJPA_7DI MUZ?OM=?9/XOT_]IB*-M;F<\_]:U&/PX^$-?*?^=SL9E-Q#GW:U.NP/_%P'?R M0P*UH5N.,P'*X'4@"496%YU4R! <4J2_XZ[\-A2YSA-Y9C(NV\"L-8:HD0C;PN?;@#L]=]R-+63T++&)3EZ(57_8+SE_=N\IJ MLZ@ (E:^FO@]^#/O.Q-6J9.U9B6\Z&FI,D@;]U.?].>(BM/+J)BPE1K[0,FG M5NYF+MX&?+J6*7H[5%:_$^.9.%SU"6EZW&\YCH4?%69^C-(B]KY1?94AD_!5 M^H[*^\:B$R53Y[16%Z"V04CQY@DE;)WLSB[CK9E*05NGX7+7NPZZPD^^?!I/ MB+XKF5<%_L/"QEKXV 5BH9:QK00OJ6#+5W&QQ:3WS&]%I@W#*I1]9?<<0ID? MQ8:. 43P([_=4?GT)0X\TV:R$O;)X]6:OA=K4_:'F2J['6" 43S=-4 (>( _ MWTQ;8>65.1)1JFM-Y53[V*VZ?&S@:T!EP0.IB_"MBI @7?Y\\+,8%;Q4S?;U MTO6,] 1=VV5D1=IY!=GT#E<$!HA^MK!6[U^+A-S%AIG>X4KW.]_@1^V0.2XR MO15#&Q1"3$04,C)88;(G(XPMXAK/9_(.:%CAAT;2%.H,_][PXW\4MUZ0W&7Y M:UQ1!;IW=2NTE0Y3IMG0-)$F0>3=3SMQL21@7S5;_4QVD=FQ=GT_P]095*@Q MZK'[RXNORYYL.&]WN@U<]2UXGB$V,42&@#Z :W(0#2540QKR.?\626:.]@W^ MJ :3,^B%KSUB%P1]M@\42 G<'/ M0;P>ZF^W/4=_70-"^'T^8J(*+9&VXA?N*6QM'AZ'JZ!F1;=18@P:Y$YB0)N0 M:3FX)'N4Z)/,$-33BZ>;KL$Z89!Y43SEF96(BCF5F&IEQGA_0-\I_#/TDZ_>^W#KH]7?BCG7I6Z<#=KV36ZWUDJKC/A$QWX M24 JXI:6R)G#-0A]V'1-S^=*C">'^=:6+MOG"-$G^1=!Z;>JR-%M= M*7,.M837&4W[6G-TFYZ0+^>"_L1^[64?=D&O)(WF\93V9UQPZZVKO#8+NK:O MC2>5'WEZX!7W]K#$\6&E04L-]FY;R#)]+Y,":%9 O:DFR>K0T9J8O;WH0X M=XLS'_XLU\1[)<_G:0<_V#YGO!$/6N-,2?^">RA96#B6Z'-3_9!W%KOUWB'7 M380@ ^\/'C#HG186" 5A0+K54\=-P;63W!LZ.:EOQ+3IH\D(O!GOKDXV+2@- MAO#Q;RU4U%>!]EX!C2\MYC8NV5,W?/.-#L_6Q=Q=1D2[=5$K(0<^6E!MRPL7 M0]>3XT$"!>4[FR+]$OX[*I_O0\(\9A#*@>A!!"[0\MEKY2CNL'+FB7$M;[E( MJ=L))$Q"*1M.\J.$0H2=*W-^-UN 3+PI LP^Z6K99SH)NU7=3W[KKJF:, >! MZ8.&,Z&CF-<%I75KDTU,WV7]7SIUM;_-2V2@2YHY,(,.;(V<49UZ*06GYVU/ MP(:#$XGUI%V9.Y4_Q+#TQR!N+_T0X\7K[_\..\G!L",>_TSR/(8[BI>/[$]4 M1\;'!ZE10/##-[#2E\+;K])_CQ\4P0O$0XL8;?RDQD,FXT$TH@H%&1M-0.]\ M&6HOU7QYW9?R;',\#X\RY;GYW[R)$X[\L8C/0<,(0QJ280C+MB6YZI,U(Y3: M)M;/,P1JN )G>0E9H.*^X!EQE55?EAXJ=ZJS4TY64^VD;8WWW[\O^,NT_QKQ MTPTT6=>=066'/4/%A-J<6#Z)]K2-H(S61XJJM;3"H.OVP;1;7VB?M88]JTNL M*QRNX@ZJRF#$(V3,K^IQU$_+%W8KM<_)(0-= X(CIJ#[Y>MISX\'521TU\#O MC]A>!O9]Q#H;(A!^5/,>C7-VQQN)Y>$<1P4&;:*_B\@<7L:);)5"LYKI4%GP MWF6&\ /YJ:]>A6V#GE;.-+/43;9/0MY\=!N53-R7)$=+M&26OY8LM;5'7+U= M>5%8B:KZ4(9UV#K@:#^CWYKV%Z/E^#;,T,7!K5S=MR MIGG'\6DL4A,8A&7*\V!7HJ*E2@87SN/_[+6E-ACV?_5R9]A?5!RM)ZAQ0\2R M@NTRV-B$87J2WR]O-K2:I<=6+W1N4!$S2+3S<%$X"4%"L[55@ MR6C-V^DE$[8%XMNC[_T^K[C<:!1Y!/A@ !M=U?(_![<[4W8W1W#;O2[CZ .F M0"=70B1Y0GJSB"?$W]E=YD_FZ$2:$+S%=/:0 H,Z29U'O+5Z+%)<:7J:-2^ MH-U#H"?J3##1FI+_(AJ;UCM^<*AR]%KW_VR4_=\-A?XQ+$N>ASEXNS:3$ZZ4 M=*'R>@.9JRX %*_"SRH^DH1!I27-X^5C.1T2$M*:]#R];DR/W(]*]S7VKY_1 M!P%"%;=6>0=W+<)T:K[ZF-'A;K6K( PH*57COR;D-_*7*5"6#B1*>_0+7M&< MT_F:2*9[.UJXDDNYVK-(I7- M\K^R,[*T_R'ZH55K2ZB&ID343NS9"='ETBD8P2+[+M7-H@E%;K6.H++W>E?] M0G%DJ+/0]T[OV+H+:Z\!Y@$&95_ CSSYOTG:9Q(G?2QWKY>XB^A:YT!P[[A* M1G#T5>G $QRF&P\*9_2 /'P[/K(WNFG0KV;>1VZ25PA*OAU?'\P26E%E81DT MM!#RP:D/\%GEPSE^\U9@YPE_+C%4I8&'%-;KS G.K@A42U5)Q5L<0L30QQ5WINC)M=+F&DR-7)-;DXX6Q-.@^/P<'X WJYZ@"F*%3-6% M_M/?M5M)E]CE4D"U!,=\M]8Z'6/]!*JN;7_X9B#2]#/^B).3BOB9$%0:8+[M M14&K=%KL3/SBTF?-/<8_?(%2'D!:;,D^"8=E$JJ@;_^HG[19:_XJ?,!KMBB@ M2_'QM@2[8J T'%$-(ZD;R^NEL.FN>P[ B^^G=R]+^#>DK1%F2SWB'4JSK40% M5S3=X9G-X%!5!1RHY\K"?+%E6 DX"2V&FTWS##?1N&#NF/Z4&I3)9V'U?T-S MH/NI_G6;<_JCWR5*O=[ OAO:T7)TFH410\0$GT(8IYK%[9!M]8Q6K>TN[5]? M(F6(FDUM5Z+E=T37V7_M'E]0YH<6?7]G[O?$7(1HSOR9MN[I9E3=E'5EVQW* M$]D]%;3S)9_F3Y1PH3"/?6JEX*9SQP?"4:9Q_T6)R3/K<\,*J]>PY:#ONCO" MY"T5R/(R00$9A[X=I[M8ZY?:'FLE PF-. L9E=3)@9>U:)<+"2V7,]#&ECFD M7E7?OH,IU.T:0"')M*V+92. RSS:807N%!NRZELP6\1FY00N-W%B!QP21444 M7?STQJ JY I"VV(]\H+8O[(][B#^3OSP7Z2V9?E88@3RL<:HA7F0[,9.$EK^ M*MO[9Z ]R^??7]K5-*0(7+8#AR%V'O&=];B',]!:6S6FFATJM92BR!>?RR7: MVZ'3UN>RIR57:7J:MEJ]64R)FFLBNEMJ5=^REX.8!&.SAFN=6M"]XDP% R^7 M>PQ[RLX,EU5P]\Y5Z%!'/>/:6%8^-2!E8\_".>SN4^ M>YKM#ZQQBUA%*BJ@;6,BF?2;Z ;JTC[JRF7IR!NS*=IW?G/^Z;N^8 M5_GJ@C;)MYJ>-ZM1>''R0#4GKRSPV[977<;6QL\V.$ 7<),+*-? CSFSN_!\)>G*&:]: MJ/G)]."^U VC>X+\#UT.T4.6DLY*?7-&)5/M;!8%-><#%N4F>,>(94P0C]EJ MLE.^!1:10I2AD_810%*;5@X/WEWIIG!1UL6:!<'"@/(^IP:NOD\#<:+SP]'@ MM968;(+CE:\7*B$5W'L'O*XM3ILZ";4XB[GQ6S$UG-]QJ/U$/\]V,OKV^G; M<:O^T4[@2O )O!W3'U/H9PJ,PVOT6C>C M*%1!@I ?_]6H[K\'E$'K4+(82H]7>N-IATH2?.4;]>"4! $9&CEV0BAA\<[K M:22[(6<^.U5!(\UD,>V/1%&;J=:C0[9)KA^$S/3XD>9Q+4VG, S(%K6[)M< MYPFJBRU_;Y<7=>N@H0BP#& 72\;!XHF M6-N163* 4.?![:U2%A,'W[*!D:>X\DWHV=F^;S;^)&C^1SX;G5B+QM*$VX:O M&#:FZ$]>. ;_0OT_RC^X$M$'G0M,#'-X@G%S.R_:'2F+7&^:5AD(SHPW;U"!D?OTL*"D)Y1!CE2N, K9S[-@[^\&N+B31 MG++RH)(%]E5TGKCIMGY6)ZO63DB ((TXUVH+_OLDC2R#5RKU-58?/XM&"[W] MY3:R.!.3+>_T5L)NM &UEG#5^K2B98'-3RS=157:Q_&RY%]W:OL[ :_G1J,K MY6#UQS_#72?3!P-4!=466GMEVNGIG>ZR!X+HL>I7,=A/J^="!BKO'H)I;S?) M,P5YW9R!GTU?@TP8R+S *^U)$>X*#:U M< [,^4S"D84(BS\0B?66%-_%R@4@;D6EYYO$@<*T&Z[VV9H8WW>S7@)W0&=%U/ ME!IO!(CB&)[96ZD^,[SH-^PT?:LFRSMT$6+>=4'% :)ICX^>\C^WC0IX17(L MPFJQ."--]%>U*D>3P-"0TP5-%J.VS7O/O&M 65&=WW3O%J@S>^X:L":T%57; M&R+5-@'I]"89+='O>JK]M@_HD65.D.[8A"_:#8F,3GB8=9_'9?TEO*=?M*#< M4Y2,;*R/8X3"?&,$[GXXWW_C/PP=3_YF"/+_X[\/^LE=HV'S?!TQ]^M@%>YJ:S$DQ0TR)=L$;3 N?$-&)5VD^=A>%W74Y'S0#NJ+0RHNK,?O? M".$Q7LCVB6+#9JM)MP\H@45S=K[!G36'*F55 X,X RQR03&3^:H!B[>QCQM& M X!+EX*BUX#Q*4[<(H@L*E_I5,E!CLY^;KC+FG6!EV8^ MKZ9-$^UX#VI=WY.U7DQ^6Q)AU''.\N4ZVH*'0$2L-=Q7+OA<2/O!8FSVVLOEK++K)$MCUIIVE M;N.DDO.?[A^%S3HR2]>529D*CAF)*8K*B_?\"_U MM+]7'.^_!9[)O7P!CEB;B>-!&EB82\I>H:=*,B!YJ ^ '_08K5G,Q_RXUEQ__."@_.I];\JGX6-*NQM;8N>[NZ9V: MV,^7P,BBT)*K@]3BD&6_N:O5A8L9>?M+(LQ#VS5RZ\;C^-MXRV*A&CI5_?@# M(C3(^!-HGNV^46/,4(!ZFOBZBPTUQ+BP>O,:80.A-3@LRG@:]8/+T04]E.-.1TD.S#3:R?XAF2F@S-$KT-UKG?U-'<$=5]P=#'HV\WO\R!G2E4UZ MW"2W->E:840E:9:D^-,XJK4AY@MF:EA,"TWV!68^!J'$>'=3_GX^ :D8, )4,_(%;>W>TM3-113W7TZ(OZ5DK_ MO#P-S5D%D !+B0)U>MCLE[NDR[D2:RE0O XM'GO.SQ\P'I]9 M$"WCO5;P_9OU]"NUNXCF^J1WXR:)VMF_:'_$LT;N5);W.;0K*V18$$XT?SH@ M')>F(/E[WO'\5\&U#HJG);-VPGLF8X@\RTB,DZ?C[!+'BBZ2YE/CD[YG3F,@ 'Z2A-LG2^IM=DQ'-0 M]XCDD*6[T%T#'N%&=64CF@UR/9XM_&(D1S\.]P$663$23U*]X*$"ER"AO,T1 M5N(ENE+\2'4WFJ\"I(X&UX">T?FTR]71:'&PD6/A_(H5+7L0MU"ZV?MX)+G! MXO*PS<-4^:O9V1"BH-93@6]<4SA^GQ?UF'84[K+ST\IPP2!KW5E26E1CL+=B MF6>*8L6[:[4Q+9A7%'0SC2+ ML**)$Z:0&NU1HS*).)6M=&_-NJ=R$7A'^56KV&+J'#+)*: 5,%06,1,&X;5R M@]#%(V9"]C=U7,0B=*X!,-X]Y.\Y1X?DMT;T]IW5748^2$";*(,6LEV0-F0O M>5T4,GJZ:Y57Y5>S1V+^SM/.S=:.%-%#1G^DX:HRQPB^E##I0'GL'(XB@F&> MITNR'8ZS/;IO1Q@]3!J7&D5,C8YD*%!#>)LMBNN/.R[](K))3E0(%7V?Q=OZ M_O8K:*=VBY06=/*G0(\F$:Z_86+:U;4(A!W0>CQNE\3'T+SJ8 IS6IS?.5F:G(U7E6DR5^R^T1/E>E1D+& W#J--#,FT=WO=LK#,TP MU=I2YA$'[W:C31#>(4WUM;>@_%Y=Y/B47P:1L,[%Q=<"4$<7=Y.% TEJ!R7H MM ,[&F?"?=Z5+5@Q,DZ5V^[;VK@KGFTTPJP*8M_K9Y:^/ +TF%1&()*[8JC\ M.B;13)U^#-< D^5=-UK;R@:3<@_(M)XBN$PT2SM<_-$@ERRG/+'%HQ=FKD . M DT9V.6KW59^U-4L6K8K4U8=K>Z>=!$=4SX_VPLFC74D?"FNV9ZJQW[UV?Q) M>R\E',N'$?5<7:'<7>9#OPHK0"='NGHP5_G*ET^/<'F+*-:ZH3K*VV7.S=Q$ MV2*.QCX2%O\_4B/_[>KF>NY_ %!+ P04 " #]>$Y0\SF/QQH$ #T$@ M%0 &UO:"TQ,C,Q,C Q.65X,C,Q+FAT;>U86T_C.!1^AE]QIJ-!B]0T5Z"T MF4K0IE!M*57)B)U'-W$;+XZ=<5Q*]]>OG30(%J:SW 9I- ^4V#Z7+\=?OQ[; M_] [[X9?QP$D,J4P_G(\''2A9ICFI=LUS5[8@]/P; A>P[(A%(CE1!+.$#7- M8%2#6B)EUC+-Y7+96+H-+N9F.#%U*,^DG.>X$\M/,(K5_RW_ M@V% CT>+%#,)DX2 D3GB+6+M9R\@]NV58FVQJ]\NSX"!A*E6]N]?M'3:_G[GO.P=[>VSUC[QFL];Q3:3^"J_JH\I,"<-&@O6[M&S'^O0PG:]G'@-Z) BBC]A/ MA4JFIZN<=S(7:QLQ''B?VA+?2 -1,F>MHLHO!54,EV6"*:>Q"A#\=3HX'H3@ MN T;X#[>GPGML7K]S_R1HBH6;U";[OGH(AB%<-Z'P:@7C /UH8:3X&1P$0:3 MH%=]+X^ZW?,OHW P.H'^8')V6\:7 MCYZ#KM9]7D[T4NR6SUCKOR:@@N,42< MY5J/) >98" LXB+C FG)@^D*!)YA@5FDEPJ+&:>4+[5H3?"B&5G&EE MRUOWWTFB*55I,*49BF/E][EFU8IQGJ&H&J\QKTT,R3,E%=E-NYJ8R9;CE5F?N$EVXS]25X+^/L3V#S"^!9,>YP+\T>WO-7> S..,*&H)3C*A,(B1P'08L:K3AD?VLPN9@HT(T\JT%K/O$$PU5+8-P;<%D2L]H<*2:PQCBA@@%J^7TXSR M%<8J-8^N8+P048+RTJI=F/UFZ=NRU/VE6.JXMMO<>R)+#S>S]' C2^L_(NC/ M[C:4Y/.%4!V%ZB]D#G%Q_GE6/U?K]/%4+)!8@>W5BP/2,^/484EDHC#E&8YN MNR#=%*E=*1'.U.ZP2'FKL%6/L^'GJU[LCHZ"9S,54VT:PWGA070SK0Z2.KX4 MG )7)+X3OZR,IL:F\*I%HXM8 2L:,I+#$6,+Y3TIO$OJ[7RT]ZVV;1E_[BII M$ 6<%48",-.>/1SA=(I%:>;:]?)!4ZKQO(-*19)BBJ@D3+9DUWP-D&9NEB4,)J.+L'S<06G6AJ_J]'("P^'X975],<(AUT298XKS M.G15<$4+1M [HWJMK_$33G-O= 'Q\.KA?>Y MJI!<0&T[1$Y0J/SL*,,_! #)R#8 % &UO:"TQ,C,Q,C Q.7@Q,&LN:'1M M[+WI=N0VEB[ZN\]3\*B[S[+7E92/%\6 (EC)(,,< M--2Z#W\WP"$8(3(&*28&4=VV)0$D@8UOC]C8^/G_OHP#Y@G%B1^%OYQPY^P) M@T(O&OCA\)>3W^Z=,_7D_W[Y7S__[[.S?QJWWQ@K\K(Q"E/&C)&;H@'S[*5%>19?5Q,. 'PF#PH&GERZ9?]XJO9PF,L_@\ M4W4SH\EK[ ]'*<.S/%L.*6\?I3!?F'.8_'(R2M/)YT^?GI^?SY^%\R@>?N(T M3?OT@ONY3I]XEM/.6.Y,X,K7 M/"9G?IBB&"5I\RMJ'1H>3QXG9_Y#]/;1)!U_*AI;'DL6/98T/^9[9TDZJ!Y[ M>8B#\P1YY\/HZ5/1B!_CYAY+)_&"YXK6\A_\ G7V!5X6QP"^US-8XO87S?=J MF$" W&8J0T-#=R]]")K[XY:&!X:9&S<_@%L:'HBSYNYQUD1^3"DW"!;0$5K+ M?QKH"+-,6N>?M.#$"V*T "FDN>%1WXW\YF_AEJ9O 9_X8BXR!AB;RAT\M MU ^?V@:TF(8S71H&F,2S#T_7+VYC1P)9_,;%H"YZ+ !VU6VQE"EZ+) TI<#V M?;=E4>L]&J:4)6=N[,51@!J07&ML>'3@>9.HY:MY6PO7) \-G%9R#30V#W/H MNI,9PM>'638V?=%[/$N:EAE_D+0U<2GR L\-/*%-GE;M#0^_)-/YU70RS[+< MIW]>?KN#%1F[F-52-_1014[D+\96K4,3 R61R'/*S(?)X\6GA4]%C^GW)C'R ML/71^HSVJ5C^3]/.LQS8.MBJN8'SXA;)$#<)!LR-Z>ND"9Y54Y.B0M"C[3/Y M]!I$D->@. HAY#4IC1D5WDJ+^5Z+7K3<6F@633/?@-5:8230J^%%;MQ" VAH MZ(Y>O%'SMW!+PP.1-WEL4>JD:<'<%L^I54LLT1#MVJ%1V!0-C9I]X#_ZP"3@ M@9Q-W+C!0'[3I1GPC5]MDL 55W(+>+B%@8$*9VVU&CU- ZR,GJ:!HO&_ M6M0[;FGZ#@P@R283KWU\I+GI6W]E?OK:\C72UL3[+VT$Y$!PAH$?(NPV3H?7 M-JXF7( ,?6A1([BI:0Z#-DF$6QH>:'/H>XK$@6:IEF?(-Y^-"@1PO+\:%) M*H'WJ9+93D_ J;+XH\IX76X6X1XOYTV[X-*G;20LRH*'1)LL_GV3C M412T/#K7:8&5QB\VTO@F-92. M]M8&X7?Y!XZ+YCJ(X76'&9;?F M$;1^O0FM_JC-1(>61N'0QD6X9<''C+#K?-.Q[RC]L;Q: _@/+0HL(N$09OLTT#?V6J8,#4V"HTUN-&+_<7*6>0O#.Z2Y21!G+=$= M:&A6D:WJL%CL.-+;84O+$I5#6U M]9J#56]X9=:CQ,T/;H+J7_+"P:/?HB*G[8UV;\M#39TK1V:YT]4>%1BT1I3S MQN8E>!P%+6JC:&PV 2?M)N"DZ9'2VV]EYEJ'9M.FQ6LN6UJ(TAB(*XG2'(S+ M6P9^W*!IID_B]B8)F42/CRU"$C>U^)R+I52]1Y/R;Y$%"^*\"V97M3>%@F!4 M_@(.F@\"5799FHQ:V*'6H^&#XV@T\[EQ!$SJCI ;I"//C=&Y%^4&"L?/RM5V M9L@;FU#=(ND;!7T8A2LH>G"+YY0]\$?RT")>\[9&JR>))BWR+F]K#!D](BPR M4.MZ%;YTU;$:8ZN_W^KE%Z9#JTW1$@EK<5>JI@4^Q=+-AN9 2(C29?2 +F]$ MP1))T$3^(&QSEDA3D]?;LL1I$QU*8VVA)=TN&6"FE8PR1M2, M8EI$OV;J86VP4%6TS*Q%$H:-DA#4=[L!4K8V:4W_\:DMEREA''3VGLALEC%(])T!B_ M1SICU9EAA"W:,>_>XF0NS(NHV97+G!T5SFQ-=&,H?L?+>Z MU1)O=FA0FU6 &DT"O O;0B5H^?1V/]9WAVU;2-#2A#FW)50-#F]+"^1X?:@E9-JI@P1MK(-5+.->G)E__U M'S^#,SB __['SV.4N@SN?8;WQ<#M-Z,PQ5.X!U_LA/'RWWXY2=%+^BG/)?Q$ M'DS]-$!?RB3&GS_EO\.K/Q7O_ODA&KQ^^7G@/S%)^AK $CW"R\X>W;$?O'Z^ M]\?_9?/^",H MSG_T!P,4DA^A_2IW'?.1OZ2WV.9V+$RIOXM_W%LG3.B.\1N1_UF'D0_PZ)W M'9XP/JR,XWKIF6%KMJK*LF**FF0[DL;JLFKKLFVJHFCRQMGS][.5.IXPN0;\ MY014YN>'"%;7#1_=((%)D/_\_&EFT.^8@TE"7*GC)YX;_('E6U.,OERE+PH"M5TEG4\^7)VQO& MH\/N\1-/NX;>"P:./"W MI#9NAW4XA>4%R9 X3M$%SC'88AU' M="21LTV.TP2QHI^I3@F]K./)%SR"CP_9#H$K7TVL:]W@(AR@E[^AUQED9<">C&=#9P/ MC9+D#@WQKXG^XB=_CJ/1GU])(.LF /S$HT?4%Q.&1H_7_JA/\[&6(K%,/)[ M%(]K$U8=6Q(X10&,"P:O&ZIFZ;;-JX*L6(8@R]6$EW4\^7(CM&'*P1\&HY<9 M@+LT=K$&O+AR3I@L]/-I9\D $'\W/KF-!H\ \WR-#T1=4D;4Z!P)H'P6!J$JZ(LN:HK"JJK*" M:(E"L;8FC%ZIYKFLX];GN0<06(XB"+JMB)9LRJK.6+*V$"#S2?0L'44QF$R#VM18R>8-UA8$SC8XT0'+1&>+Y31TWN:KJ2WK M>/(%1'[^OZU,;]/+OH FEFJ9EL+)G")IBF. D:,69IJBJZP]%8C+.FZ5)HM9 M?L'T-)!4NJ:Q(J\ZFJKKIFF5*ZD)LC%=\F4=MSV]'2ZYI!B2*(N2(PN6) H2 MKQA&R;B684X5_;*.[Z/)F;PI)K_.4KP[B(^PU:8G:\"N',=+.I@F@N$XK&66 M0IM3M:D66];QY(O,;V]VVUGP9I(8)F\+&L^*K*W(BJP).LM6HEH0]:G3MJ3C M%DFR"HLWSXZU=5;3=<[6. 7K(%63JW4$=I[B>5G'[A$D:$T^R\FA,-QD!U9Y0 MG/H/ ;I#H1_%5U&*$BM#^-AG3JCJ-=^B<)B"9X-?A^,TY$5E8^U%N+V9QK,# MJ3V2_X@/T-[BR#U7([C.&[QDEG4D5A,O@JQ5 M]D;Q=FJ+XF%06U8U0*LE<;+E2()C81LD9V1'TX6IC;JL(Z$VI_"*XJ4HW*6R;O17'R&"B*T=$L6.!9 :AF6H)ME M2(,U%&NJ+Y9T)/0588I[H>Y&1<>;1=H(I4V-Y433D,&P-B5>UV70N@4!=544 MIN'491US)(,QLUU*.W[HAIZ/(V8SY)ZN1.P_ ;L^H8:>B9XD*&TEW_3)%S2H MTZ_NNF.0X4BF(3JJS6LB;W 6QSF&*#LL:T\5V[*.2^FU+":'%?:M&PY1I;Z+ M\%KS]( !A5IH,#E851./5Z9R7==S2G-4:VW\@\%S2Z],LP"HB_Q-^W[=9(MD:RTL";SF.I/,\*\B<;>&YZX)D$H$=*RCA@K'S7H MUP[1WY"$4)CJRC%(2^ T4^),!=O&JFU;VM118^7:KMR2CMV(TJ]-'];49$FJJK-3CW=)QYT'ZM>'@FD(BB&9( 1%7> U01:-*BZGBN84 M"DLZ=B-6OS9]5--400DJFJA;O,.9IB8)U0KSM8W@91UW&:Z?G>6"4*6C&["8 M"@]"RQ!AU(*FE(NJRTHMEK>L(]XU/O2 _ZQ>)O2&%8+&=+G*: $2=8DF)+NEAR+6?KM6C] MDHY;(<6*?/UF5JJA@/>B:"PK2+)ALP)KB>6>JB9*TTC'LH[;FM7N%AA\==&4 M915TD\4+/"?;>B66-=&:6O/+.FX+ZZO,JGGC091,2=%9W3(%R3'@'Y:OTF98 MUIE&9I=U[!P;-]-#LB564'$$6E8LR6)M2RA]=]U4N*D!LZSC/GFY>6HVIRO@ M;HJO8.89NH0>OB8+E*+8J.S*OL39GR)6!;8O3 MI5[6<0$]/AB4K,(8-W$T07'ZBL,4J1X.[+\R?T+"&J]O M].%@.ULQA!/\=_ MP3^U1#9:W]H8XN0T0^$XT%.JP!DLIX/1HELLEOX"CMU.C;QE'1?E&^Z#8-^0 MFR! N\-TDU=<41@'D4UC1YVQ8-7N-%4V6G89%E'=<, M"J^XNZC,[B[JSVX\>$,<>SP)HE>$"#LU$X4PF0$T'&#.1&%" JEZ'.-URFD^ M[7+COI)-"/PQQ_5CXB?KH'''$_Q4@N.O'O"^Y3_Y Q0.WNPGF DG>-D0;-4 MT^99T;18#6Q, 9QBF:WM)RSN^!$AUDI1M8,4Q>G]-B^;ML$+IFXH@N#(0"C9 MTC2#M92I];JLXWH4Y3N/T']$ ;PF\--73-%+]P6+H;H!K8!7IX.-H,BRS J* MY& [0=,%71!5UISJVV4=<:1'7&>?<"7:'C16E]'6,!Q--D7> #97-)4W14(R M602G2M"YJ61=UG$[M.T2;G/U6??L65,$(]^V1,.T3%NT65D#DFF.J'"ZPTVS MK9=UQ+05U@E0'AUNW]!6-S1=$H$VFBTZNN&P,!\@&::AR-O6-/J[K./:M!4Z MB]M;/_GNQ C5,PS>2@3-L4U5-17',$16T(#/=1Z#4>=-SC#XZ;[#LHYY0I>P M:=(>)&Q7(ZVM.JJH:R;H?A/O3,DB;V$L"KQA*:PV%0C+.FZ)M-U!;8,\X!RP M447+D7A'40W5X@D8)5,S)5;B:_)@<<=\-TCN+VK?DE90!([G),WA!5Z7>=44 ML005;4/C%$6>!JB7=5R?M"N$/*;$W1BIKG/J_ H=T^0BS,^ASF=O&#+/<98I MZZHMBZJ@J3H81KQ@Z)QM@A*O'0=>TO$]08^-,NK#G*>LZJK/ . M;^BRRLH2ZRB.*,DLP,(06%7D-*&VP;&D(SCO[!_R)6NM&_+8*/-MG5R"PQF* MPW*"JHB&)G&Z@ 64*JFVI%O*-#JTK&,[N3[-GH^/RZIER9>?<>%&4FMN[ +] M&%+U]/,HQJ0<1Z.SLC[<^0M.&,I;<7TV8$X?Z(>/X7^:?47^M?HGR*])E,7D M-U('[W.Q9#D5:L>625&!O LBQY;Q'\J_8"<\]1]]%#/D3U(U3?)C^2UEH ><.S+?5'D#YV?N\>W%2?K:E-H#J M>^4?"LHT$>H"9_+^G7/0 ZL<(J7R$H;I%SQ,7.:'5:I7%BWOG'@1Y^8/>](8 M'/*9P&YJTE/!?XCSGF$+93VV4#;*%G63X- )I:Y'*'7SA%*FVP$W<33(O/0Z MOD/QD^_-JL=[Y(W"*(B&KT5KH2)W1>&*?'G:*?E3_K7YP$808^ M=,FO^X-Y?6Z:U\F74JFW3.SG3XWOSH?RZ:8-[4-N.OI),;)?C-0D@[QY<;C^DM=J M\ASE,K^97Q>7MF$#;+75O46IZX=H8+MQZ(?#Y"B7N'F2?7/]*3 ."QC[U_^- MI1^H,MBY,MBPV_-^#V!:J^,:7[&$N\5HA&GYA"Y"+QIW)!JXKJ6WZKS[(!ER MIYG['S?D#MYQGB'3!]FF-F^J*O>O*K>VSD3S*53S'83F4P[$#:)QC=W&OO;K M%+W/]J5BOE-6\'QM3RKF]R?FM[#%H5 'I[L.SO[W0N6#WQ;<;(0X5WG4NSE$ MM;=1[^;=)C#5?,=JZJ[O[%)W:)?;O)MU@M\OZ:EUM#?K:&OZH(:& [=WMJ ' MW^4C4'OG^*W_]>,"5"/N4B-N.%[P3B.(JL,#4(<;WB%X9]HCA<(!0.%0E]"!15RAR#D M#B+M@O)[IS39NVU?NLEXK#;N^O$URO.=BYR]0\=39[>[NKQ!S$_O,9]>?(XK M#-=NI0^"O+;NM"NY-[I;2[YHGB=?8**?ETRT%X*_X:09!O:JK04A;R!(Z46*Q\QE]1-(S=R?*MP9&2)'Z(DT3WP+A/B0580NH+W?T-/*,AK%][ E$(4)Q>A=]X-$.&J MC*VD./F":?'YXMLBA*R!U!9*YB!=2LJ=J<(9W.U>%?+LW_FR$.@2E%[],=OK MSD.A"U^KKI,M_^!$,?+O7]*Q&5E_[:6%K#>C#%^N-8%!O%ZY8U1A M_!Z]N$E.)CTNW-]]^N[N),8XZ5&VW:=HY0MX_ M[]T)878]?X3=0D[0"A+X_I]=0,(R67C_SR[N?*+TGAJUE*SMDMF[>S]>9N\2JYN9;1:J-@( M,[]>W)CP)+Z8M)#MJTG'8]:,BPW<%K)MDC7>)7>7/23^H#-KGXOL^MDZG[_&CVA."2Y156'CB"D=J[SW33( M\;2 "+V0(?,[;A15G475]K=E6R\RQ@M_B0;@COD#^V7B$H)V8]';+S'&"]DR MJ2XNXF(/SP^G'M*2L$.1:.L_1G'HNQ=!X(>1GURAYTOTXGO1]RYZ+78^CFH'[8Q[ (4.MA?5 M6A)\IJ;)YH+=U#0YB+!=[S,=:-;! 447%R.2Q$7BUS]O;GL,RH((GV]NCQ^7 M^Y>4J^>.FWJ/04DDI:E31!Z2[OZ]]XC\O0>([(CN)HB\,_N.R#OS^!&Y?QFI MK()(C#%2CG>F)49NF0C>7ZAB]"PBS?%C>/_%9U:7JE>7/89J?D;M\O@1N7^I MNKKE21'9!T3NW_)<'9'77_N.R.NO%)$'@DAJ>5++\X QO)+W1*5J;Z3J_GVA MU1%Y>=%W1%Y>4$0>DG=>.R';4T1N[%SL 2.R2]XY160?$+E_.W)U&4EW*ONP M4[E_&;D2(JEW3KWS \;P2GJ>9LKU+%-N_]I^=?N39H'T(0MD_XAV-/M3>V#\B5[1"7W;TVN+B-IYE ?,H?V+R-7]V^HC.R#C-R_?Z/2>[HH#-91E50P]4$P M[5]5KG/==M\1V0<']V#N\% M)4>C9^9OLK+00]IP):(9A4\H3OV' -VAT(]B&*E6&^U>&^S6-YQUNQ_7C?[A!!GQ3_?@5 MUL"-O='K-_2$@AF)4O6Y"($%$]*!S^DT[9-?NNP&<]@JVTV\ (^^!]-(KA\M M-(D2OV,R:C6J3<7- K)M*PO3I$!90O8M1ABW@6%@3Q[_=36\,OYM$81+% M:&##&.-)["XOE=DMR"\3ZYV%]HZ)GH28+2'D)[Q_)[]46@*'^7W4U1?@!F>,]0WC]( M4@"L X"C]J&HQW(P%IX9Q9,H=E/4:4!USZA;2/>CP')/7&7JF.XCT.* 1O"' MX51-]%U\[3CG0'2+#];ZC MP1$S]6H3/HK%WYB)TIGEWXU1T2, \/T#P HQX/X!H&>V8?>V$H[?6MT]EJG# MO5],]\?AWGT,G.PM==S8[UX$? '5*8[?%10].@^V>W%1ZE-O%>%44N\#U%12 M;]J:/I;-S^[9T70[=CM9)-3RV'M"";4\MGJRXXCS\;IGDM ,P8_*]CZ!3:*7W46"W5WME M=&=JCWXU5;W[<*6IZMWXSA3-A-G/=A3-A-FT3#XN[=X]Z4SMC>W)Z2,\=MX] MH4T/PA_;EC_=8-^5DJ:QGMTJY>./]>PC.81N-1Y4Q@C=:MR1:V5#[\$ #19; M0/U#_(X]K'66@2+]G25R:0+@OJKAT@3 S0<.J.0^B-!![R1W'V%)0;!W%^TH M<=4]UXPB?>M(/X;P:_> 30/"FZ_%04^H[!G4O3JAV#9VWNVTHX0DA0 >U;7-'>JS\73.H-G MBL.> X"&20]].^+VT&Q3&]P>A\*.P. /A^;Z^PAM<.7"K0F4R>V MM&FTF!ZV/$9@'UP.^^$CG1Y.ZZ2+0I%.SR7U([!$D4X/T!^MP4(W@;:!YR/< M*.\>M.G6/;UI]0AA?>R9XKNWLZFT/@ KFTIK>MOJ$89)J+2F%=N/R_Z@AY?H MO90]$=Z]W8?OP:8YW:+>?:8_%6X'Y'!1X7:,)5H.MR#*\0DTZE'WL9K>X>.8 M7J]RF!XTE<&;E\$T&K1?:4RC0;188->Q3.7R-B*9-*-K7T%+FM&U>3Q3.V._ MJ.Z/G=$3P4K%V"[%I=RNVJ$FYC4,"=/_H *)8O=\_VKWQ>0S[[=V1W7W) M .CCZ4-ZUF_-3)^C* #5RW)++3?=7!*G"N'A&F[B)[/+[<;QJQ\.;T'8Q2D: MZ.,H"]/J:O/?"31V=PG20FC82>J/@46N'ZLG6NE2 M/?0M"H=@$(XQ7]V_3M#,&V_14Q0\ ;5-,!Q]H++G!T"7(X76.O3;D(731/WI M@!:2_QB0C:?=$ 8QW61D1N$3MNX> G2'0C^*28S)RA#/\NR\<;X=V;D:C]0& MBMN[Q1MO%R /C*RX INR\_<@_#?&I(WK?\3,^08+;_;,]Z:N:D,[#C9LH_6N M^>[@-..;E3X&AML&XW2% W8.Q:Z HD4*Z^*YJDAOV( *XL^11.?\KZ$$:F:.<22-S>]\2WB=7 M]6M/Z!!QO?]MH?W8A!MSPK;"%]0/ZQ$+]BGV04.---1((Q_[L^+H=L\A;?=T M$!34KN^ B#M*HWZ/$24:Z.UR..G@V/-H8TG4USX$-J2^=@^,_QVF]5"NZY"[ M39GNP!(LZ;[)46)Z_R[6E@.X] QA=\\0[L?,I_8&M3<.0C8?J9%?EBB8HN'6 M3[X??1&'11,_X$H.6S_*L0 .>2PT"*XG*9!RVI744C^FU<^CC@LG>AR+O8[" M[<[2;DRS=7PA5PR<=WUA-[ _T/&%;@O-=GUEWQ-R[LI2+JN9= EV[] =HH[? M#+.L:-+B:79UH;%;F\3IGW>IFQ(7YU<4#6-W,O(]-R_LEZ23^,_KKX>^CC") MSZV3./F"9_'Y^FM7':'ERX2EZW4Z0O%,"RXIW T^7+)^6,@NFM[Q+JR'XPGQ MZY\WMQU?PF(BGV]NN[I8VFK"\NJRXRM%A.7595=UVO)EHL*RDPN[HK%"^>_0 MQ235:0?#4ROJ-.H =$+T.=^.89F<;\$KW2-"/"'!NV^1&R9Z M."BB07A;UT/^D_L0(.-U^G.UNUX9DM.VCIB095CK(].O69IOYM]5#MXH-+XB M-TA'%R'>_X\=A&Z1/W[(XH1P58\ALQY=*)0 2C"Y'_2:.X!/IZTT 'P82VG]E_H2D5K^^25G_AMP$ MC:)@<#&>Q,!F'&3BAPG7_"O,_18M-IKH'(%:DX36!:0&>(\ MO@YF%:\%G)5FWC<(;4/@&9D/% R'T*W\D8J^32!X)<)2!'\7<3/[B)P% [=@L.6 M8VUKQ4;<<'#$:SZ=7E?Y_+T+VUT+NC,F[F$*>+KP/17E95@-NI4_6N@)!1%Y MP(R2H];N*\^^;_* :O@#Y_?W+BSE]\/A]PW#8LL1J^Z:"(<8IJ+1U6UB]<@V M[_<-UKYOWK^IS@D+DJ)O_A,:S&U')\;KI?NO*#8#-TFF%8;@9;'KI;?^<)0F M8'M\\SV\(.%0'\:H2^BL%2Q9E0)%]:&52=!%U?M1@ W/L'ZQ%IHBJATRIAR]&7ZCRKD<$449+0B(_'X(-LHZM M_,*IU<^^U.;616%OY4M:S^%-1+6^5I-XXR1WY!^IZ_H&Z M>?] 69G7*2IVP_W*=C4^7>1#6.3M'2JAZ[SW=3[@$!!%Q2%P_Q:\^=7U.+79 M.Z"UK7Q)J4 _"-:=$>C*>@)=V;) 'T5Q.LAB%]]E08HTN*&'RAA%HGL>6: _ MD!O/;JCCYZR5GL-?[!B,UB-*;:/]/50Y"I6Q$Q@I%$;M5.FBFGKC7%(8]0)& M6]Z5H$JM'TIMVWL75!KU0AIM>7-\.S":HY=&4=1*E"[*HJ:(+!5'QRN.#BCF MV[3?2Z'7$^CM=T=Y;]"CMOQ>;/D#@]Y.%"XUW [ <#LP=;L72X_*O/W+O/U# M;WZ7D%IZ/;'T]K\/N<+=U?+KP.W-8UU' M6PLU=@*[M;YZR '@%5#7=G]]3V'71@Z*NPWK5---1F""/*$XQ6>5WM"=70>& MM1?A]N. XHH4V@DR&PG<55V\ CJI+NZW+MZ/!4AE(I6)AVLI4B^X7U[P?NQ" MZH_TW1_9LL67\Y'C>GX @YI!SRUZBH(G/QS.]NF'P'M+ERD0%A+FF&7@3J]- M:ZR\1N&ZEQ)ME!L.=*=P+C&'>E+4DSJN?!^*:(KH[LKH"TSHOW/_XX8"MW]( M3_W"["%!?V7P=?L)_O76;YQMIPRQ=X98)S&F>7%K?FS3ZN["?^!9S(L;\Q]R M5S9G+DZC+@*UX=_CT6X2D>M$5[ZA%*@Q.^4^0[")'L>-O'U?04\%Y5YNOJ5R M^/#L=(O:Z=1.[[F=7N?&W%)?F1OG#?L=QH':@2**- :TG#J'R4;'HE?VDOYY M=+O^AZ01CC()8!MIGT9^GE42?!6@'KHI-: =0*.'PDD[OEKA]_=^,87GL=DTOE M5G?UB^1(_40 M(I2'AM,#VCF:U\47H1>-T;W[HF?I*(KG\QS(W31Z.,"64_ _6>PG ]_#8J9; ML&R>90T/BZ?906V[[D([48S\86A&69C&K\>UNDUSZ^*2-NSZZL]N/*A4"%9' M]G@21*$W:61]_TFB[V1FR!\,9@;#LC?1'NQF=IPX(D" MY+ 58%"7I2,W[EK&90L 6F;5FZ5?:"W0I3]FZ^ ]PO\H%KYQ3I3CJ<[O M$_9:?(\2.,;EIT*?6OO'S_'SAS74:.0XJ1O/ROXK@YF8T7@2A?!K,E>&8SR.P@X"8.'TZE4QYN;75SBL M( 'R=(YNP6 5.5"?5R^6'^MQ@9XX[=R)4V&C=D A!"SDU4[Q4:VP7ZTPL\#[ MUPI4,ARP9#@ZF*Q$K!;L%:3E-JKAV.O'NX9 M/2JLCST!8[%T)SQS$7IX7D_'(=?;IM1!B4[X5Z#^9C?]36$]WA>VP?M3(YUL MR1E@XPRPB@0"DT*&^49=4?;DWVCP6SA <4U88O9)C%?[!<6>#_91['MH>O,1 M$2%OFKAN86L+A"DD41MENN@H-&V/440=/Z(.)X*V1XG&4_RUX(^G$HTBJEN( M.B")MO*1&)IFM+DE[\AQ&+KDQQ6%F=HM).DU\](L]L,AEI&5GKBXGVGKUJHW M3BN7\HWSZJ+-L' IS2A)]7 ?T/QTYNKNM+8]=)[%(_]T)V&(5< A8X1^::Y MP]AX2Z>9*[B:";6A7=T%(%U$YZYB5:5B9R]B9\NG"I:)';RH-W'TB!),*S>X M@Q:PKQ,'O;G6I0^H:!(X&!^+2;1]B=-[M7@=HGN@6$W8&RA$C_Z;^['ZBM*R MXS)"4:Q^).Q#K3AJQ1U53.F=^*;BF(KCSN/[2.%(E__=XHUZ0]0;.FA,KQZI M.3HK\A",M^W';9(XQAEN%$L4NQV]54K16P>PF?BGTWN$7P$L\/8+E(I^.!X>(9 M4G%&(;$?2.Q?2JSN65!(4(-]HT9/E40 M13-%<^?4]8?1W%,@'A4(/AP-IB"@5AH%P1$8-[O:%Z+&S?$;-_L7:>K?^;_? M6SM#TP<, '$M V"FKM)F""5TA%#*>H32-DXHKB.$6L^D9(7-^Q7=(!3'[MOV M[@3K:>NQGK9YUM.ZP7IK:[V-LY[6#:VGK:?UM,UK/:T;,DI;3T9MKRX+S?K; M>M;?@06&&F,"=.%[&@>@"W_<+C/.[I9I=O>.L[OES:?H*W01=[R(RH<7,0O] M? 434DFPOA1CY"99C+X48R7MY5O*MNE[\8O>O#1+!DUO])-(Y#GE\V]WUIHO M'+\!3/D@3I(@9I3%'DKR7T?('8"<^OD3T.K+S^1?;DX5VV -SE1EUM9X2>=E7185U61M M@3=,06.%$WC(G7D0_L4DZ6L ,COP0W0V0KAJ_&>.9__[IT<01&>)_V_TF6,G MZ4_P< +2L^Q.6A_=L1^\?M9Q,EM#_X?X$WP-/U5^M/;IO''I*+ L/',#?QA^ MQM<5H+C^'77-<>'^Y-?G_ L/43" %_QV=7%O6\S=O7YOW\T.>-]#N[/-WVXO M[B_L.T:_LAC[G^97_>I7FS&O+R\O[NXNKJ\V-%Y^S?'RS>/]W4U&?CA,H_"4 ML<[-G[B# 7SN+$"/Z6=V\I(_[X?8JB"_US\0XINW@Y_* M9])H@E_Y@E^9N@\!8CP4!$7K+R?L"?D=!NZ5OS?0!=>X2)@K],S<1F,WG!_M MV(V'?I@/S\W2J/Q#3 9$_O+L#](1](;)/T0QM/$+VFK/-;ROX\\@>PP#\5RRI! MQ]5EE1^.P.)*WS[Q?_Z3D]F?YL35+#VV.=5B[8L^W.2%(>8L\Y\L^5^?2'$0 M4R5(_T3DPAOEU2J]WHB67:@(!\0:4\X@_S=8"6$4$CO.]XAM,)!87N9X3D.R MJIT]?S]S7"\]4VPP&!Q1E126-0R;%1164!U#5DS)4%3%.&%"%_MS ^1_MB(O MPR8L+EH,HC'W4F[1XTQD: /3X=BSOU7K,3.1+_5)?N03S.KZ: ZPZARFU=DU M)L+Y@W93PWA_N'3C[\QUB'[W""( MTH?H!4MS31'EG]KDQAH*;0?+]*\L2?W'USJYN37E!=\_<_'9[]YM^=<_<7S/@3MR#S\!P G-]RW#2#X,?F6N'N?]J,S5/H_(R=/,> M-W.:(&Y:1:XF4 NE69<](C\KNC9$,P?H@1WZ*SK @1(#7Y]B=G"QA,V[*9IHM6:(B"!RO.*RD@*SIL JDLRKK +: MSI!911$-5GNK[6[1T$]2?"4XOCQ^(QI/;M9XE]??+JYTYJNM?[O_:NJW]BES M<66>;TH#MGQU#5]R%3WXX1BO_0+K1%:!B1Z9N*(^XR9,,D$>3I(:,'[(^&G" M>",WAG&L& ]F/[2;KS;P9H>T/E7I!R[&Z' FPO OK8 2I. 0HPY%E1L#E'D"5!%VS#P-N[/*_?EHLCS]PA(ET;1..%,A(_(O+PZ]@Y3BKQ#435Y!X2MF2AF(ERW@_E7%OO) MP/#&"5)\9]O,&;N@Y&T67KR+,M<>\@-A^3,RV8"9BUFPND:&VUJ+?0H MBY(C.X)J63*GW*!PR!G*]T2$13)M" M3%$!3IPJR+:E@]6H6H8E8H(9IJ5*-M=@DA8$(V;5=7P#3@^HGP\Y2^N3U03A M!*\-?7?+9%V+JE,88B)*O.& =<\:HFY*LJICJMJ:S#F2K;92]28"Z@3_KS]9 M[("^@V0:J[+\KJBUKXT!TOFS#R3T/6P6%E3%VP*3&&#J3]R 02_(RU+_">\6 M/.)[*-?(#=_)?L;JF(-%K3 G:2;+ZQIX?H*IJSITX3'F)%;B.!&XNXXY+.WT M&+D;1YDD;QMC/Z[!DAHXPY6@8Q70F9+..8[#\X:LJ1+6#!*O&3)GSZ96?XO M8KP91>%FDE9F)R *TID@RW+?>'&Z*_I__E/E.>6GA$E1@":8S$Q^K/R4 1X- M,FR,,B[ D\&I>IL]N;$+!BZ.//LH*38C48P&S"2+DPSO2J81 SVP%9_[+QS_ MP\./6$2E(\3H7OIY9Q-^UU9 9[7O'^ O"*H\3D# M&,480#CGTT\#LM5O@UW-F(&;) <2X]@K56*7",Z[US'T_6'>JNDE3:Z*G! " M%/O%&X&[#W\(F=]'/OSEMI+./0L8KF([27)M8\T0#$ZR-,'D6#"95-MBX1^% MY479-#6G;CN5]3XX_H'PZ0+;"2()F;&K[@?0WN-"<_.\"K:E#\8HHW.EF;XK&3F ML^VFO+C S.>U S'SCSJ;CR8V'M:J-ZBBM:1>\ZLW+NC6'-,:J9/K:YJ&@Y7K MEB/+1WD1#O#6,F(>7AEOA,"4&./**7ZN+&LY]7["N,PSB."S[V'T#)] ;A*% M.+\^23(_3!/N;_-0(*+K%2JW9K*!@U\7C]=UW32;N$L%A[FK0I: MO$-]-I_Z6W?=E]N/'%L+4(-[96BV(2N.#=:C8AB"JJJV+7"RZ5BBX[S=,_H= M5N%O>!'NBC6X($NPP*;_ U>77&@9?H!.6U@_<1/K-[6A/E:&:B^\%D8I_.6O MS,>6+1BTC_CT;DS.CB<++%T!9P'-_HD"U;9BK%18?3X =6E$PL(@2>-VU;;1 1_XB"+$S=F)S CI,%H@%SR28E MPSL*CNR#Z9Y'B*2%SG'>#]R/^Q,VXZ S@-9P2+I.8N0A$M#E>(84D4F8'^!]C_!/DGDC)AE%^" ; MDY?!AF?<='X6SV[R5GB0AXN)_ CJ.APP/_"UV3X@!'3-'OX%<\$/D?Z/Y*KU M\F7DYCLR$C)2-TD9C64&[FO2>X4N3A6Z+2NB(?&<:%J\;6NFHN3<*O.@YU7# M?LNM9A;C8NMY:1 1 R8_GO5'7TC0C1],%V>8,051!41L"+TN6C06 RLN\S8M"TWFD:N'Q MNA?R@ J HQ( Q(,.W!ATO^MY( !B?/,&813L/H>-?P5'(#QK:("69 RB SX3 MEVH#X$)NZSC%]@3BQU;YV* DPFZA=O*)V4:<;CK*B*J9C MJ:!:;$L5X#^\Q%H*KSJ:)8"5V5R%*S:!5X=1_+K.?B-YFK"W5SR-MQZ_-8N( MPS[R^G'QOXZ-EZY]JX6/0.3'@SJRL>\^I>-5D9G9@O7=REBWN7 MVV(YVU8&6?YK86IU8O:[*/3*P;^GD1S35BQ),TU=4G7;ED33D<"1XP315'C# M:#B]2$AM9 G8ELF" ,[&B[P>BDFT,XY?$0BA(?^T%T.C\Z/SH_.K]]EW?=7DST M$8+N$;)* -X*3(=*(R9(\<@FC1N$ ;SE45?7+70J\>X&_ M%;SBCS_[\&GX+!.B9QP3C=&3GQ#O)G1##VMA\'EPX2_<&=\S/'#C0<+@,^K^ MH#FCF.&$']P?&X.0S*;V.CX8+.]^D#P9H2 H,'M(NWQ6V@]_DJ]X!!=S@$%&.88W2CE'G"9YDP0NNGG1@ #4D8(;LZ MCSB[ AY)2B#/EC"&/_Y/%J)\T@)[NOZU2GAX7A1$\>M?*G)*1!S@7Y*'P>W%&"!Y]E,7,.$IP(AL^&1&\YJ(989$.O!"%6!(GH)N9 MOS)2G/F4["B[$Q# +SZP#8)'/K1G^U^%!'#(YBJLPKP(T*;.OB!;!OR/U<&9 M4G63,PP>U_L&QTK7)$UNW:B^(!.!/&'PE-?D3OC8>I)@' MTPJ27T[.I!,&SQS>)\_>'15FXT&4%CU/OJBG&J^>*R6WEQ/YPL#D _CA@\E: M/SRX6"%F$Z -7D"T#N)G^+T.HP_PR^24( #C#E>5'XD9:3 M2J?,1>B=XS.9'0#YC^<')G)TLB+OG(V#'F)@N->X'I\7<.R,0J-1;..6&&BX6*B]F%7"RSIRK+GK*X?M8<(W^0@==BS^JP[<2- M"P4%=G/^#I"]* :%-27*&IB?CFL#I27H+3O[+%!!3ZX=<,"!GEP[K%7?W\FU MM6MVKCPF\NOL&6+KVOSMTKZZO\.WS%S?WES?ZO>VQ1A_,+>V8]_:5Z8].X-9 MO[O5.7Y[3V(RK;JJ$I MBLJ9MLG*O"D8F@A6 Y@&AL$I9^QTIT366+ 1%):5>& 84S,4'7>U-4M3>!NL M<@0*?8*W>.(,G1R I7>#=VN+'+T6%7\#]M37 (M=GKB$++3 M7&[ L64N+B[RY?,3Q@'[@N'8L[^=XJE6XW=<$FRBCN'C0);(D MT33-%@2!5UE3E S14#G9%GC%XBU.,GG#QL^X,U]W#2;)[NY \[BF@,5 M:]SUJ'C*8Y/2:+FCC-Q]S3C7MY>$"[9V/_5\Z\/W>$@==%!VYGTLR/]5%S@?7$MR<.T"[/V;I-TWN=?S/A9I &T]9M2: MS=(;=XC:C'+J?M*I=GZJC;),:)-E^RBYMBE&QD;RJ@1H%>9C6)P [?C4QV8H M< &N6W$Y^X%"?E9]M:8W$!]?[/HRC+!RC.XQ^ZPY#E$V%UR007:)DJ*JFL(YCJ;9F MV2;'&N(V=,=O88R2*'A" [SI^IBG^.+-ZTXIDO5P=A6EC#Z9!##ZAP U88XJ M!SK5XYCJT2@'OM^Z011U5;(5T^),71)$3=,%5F)EC@/S5C$D9QNZX2:.)IBL MJ%O*8%->Q7*2"RSU*NA4CW.J1Z,XA'XK#EN1>,YT5$G YT$%1<,7QDJ.))LL M_-50MZ$XOJ&A&^!43@^1LJS]U!_+*4_U1\^$:H^F>C3Z0^RW_F!-A>5XGM4D MG9<<@=,X26=M4[,=0W!XA]V&_KCT0\3;.X8UX(#4E1<4FG MVNE,P)4%ZILDN+4DK,2:$KXQ2S!42Y(-1=,42]!M6^9L4]2,=4,[[QH,25O, M5^SBHD7.4@E$IWH<4ST:VU0Z4-MTYIT<;J^? CHC?]F1_6J9EB :CJ7AL*VE MV)JCFKQ@F"+GL#PK&5NQ7_.R2?CLZFUK%0O[K\Q/7T^A1T#.6]9.CC*7;IKB M Z3X7HG\0D3F)HN]D9OD]3'R9VM7<77*--Y4@&7YTM( 2\\D>X^F>C1*3#Y0 M);8C!>4("J]SDL"+CB'IK*H*-F\8LJ;KILVKXE84U%U9C=2,0G+ND6@@IRHE MBB_NZJ5*6;X8 CV%T"\YVZ.I'HU*4?JM4A3.9 7;DCG6%"11LG1#L%E95U3. MLEG)Y+?C\X3ND-3LJ1P='+K/D@17/\2.C!ZZP6OB$P=FJFI PWRLM>XSRU* MLB E7:XG*/]"/YT;TS8E5E997C9X20#7QA(TVS)-S=$Y0S)MT$0"U41TJL/11#T_#V<)@FR9@BV!!I(IQ3/1I-H_9OIUY,5; TW[.YRR:3@/SNQJ_]C:8M7Q.1 MGLONE[CMT52/1K-H_=8LNJC*HL$;FF;+DFT9FB69JBSI@NWPO*QMY>B=2>Z5 M2? =85B?@-/B#F-4:!AR%9R>W_;FXC]$8?DKD(L\4-O*J?R=3JD@FCY+92V= MZG&KE9Z'QF2-Y3C%Y%E>EB3.X#1;8O?2M6H:W+=\4687Q-8O[JS3PID.>4UD2H0.M7CG"H]QC=WC,_459ZW))D7 M!$EF!4/0.,LV5,NT1546UMWI?M=@9H[QT7-\O>3+'DWU:&Q8CNVW#^7).[.\ M#)'Y%0,<1]2[%43?V-4,2Y>'&KH]$[T]FNKQ:)F^7^FS!RTS52UF-)Z@,.EO MN(1J$2I:^SO5X]$BAUJ)>^:=^RTZL@]-4Q0#>66NGT/P8$;^!)^B,V$U7#]D M#!0B<&UP1E#>3CRCR*I^^%P_>@>&YB/_3\"3@YT^,1C(-0<2H/Q4^^U]-L5ZI5J*CM[U1ILM+< MF395$37+ 2' "I(I2" %;-5@)3?5X[-I# M+3J^([M6!&/)44U5X151DFU=ETV#DU6'4WG9MB5[.[O((__!+XI+-%2=8.Z\ M$1ID04]MV^5+HDE4L]"I'N=4]XKD32N7]8J!%Q/;C7[9\%2=*!XS''OV-^8N M&X]QG: #@?&>BC-\2G%S]7?R[]JH C]$9P5'<3S[WQ\=U<\/\:5)4Z2%%L11=N01-Y2=453#);7=)-5>.%=%T2]9T!? M[@ 3;MI\8)S\*ZSV[P[+XF,.I/H[AXT&7\ MP2\GB<[R#NLHJFDZG"0:MF8XIF8Z$B]R,_8?0PS,"VO463*$YQ:9NIH/PAQ1UP?6F> M_:GZ,_F=^^E'QH/WN7Z8X(MWGMUX)LA+\^?QVQXS+!L8]$1Z/[@)S 6^69"#<9,D M&T_RWG@@-P9D5SAX96*R<D.,$BC&*M# M)HJK\3RZ7GJ^: (>H-$-DHAY0"!OX$_^HP]C?'AEGJ-XD#!)YHU@F"6YAYD_ MP&<^3DO:%'_/YSG_5UQS%N\]I"B9;WI @0]4>?-WE*3^N.F!G+)O_@PVSG,Z MFO\K( V%@S>=)X$;OOUCC 9^PYMA:?_5],5G/PC>_"W*@L'\'[W&/[KA_)_& M[FOU)PR"Q >!X +:43P&;KD%P)/D-,"1YV88++! & FP\C C#V'NR!#&@X_7 MAB&@?EW 6J=X19=P'O[ ,'/Q-5T(U;$,_$'.N.,OX>%BIL2)W/#)B@4!=5A@ MQ05;P0P!MH^/P,()B$: &) !0Q@/&V819F,$MFK"? ^CY[ 0&?G/K4+D?A0E MB%G8J62G4^8A2ZM)!4!>+%+2Z)2,'3],^"0"(M=8H!")"2(I&;F\ BDR%;VI MGP;0KUA%7"N9F4/@&HH_GK]X(Y=SZT)[9Q;L"C #P/C$D',1%GJ16-4*NQ[] )H1L!/P3GS M=,[\=GYW7OXZ)HFQ/\V#^ZU#0^'>&[CG8&8&KR$\[&&#(B9AB1)G@,ZBW#S1 M9:";ICC$8GM69*_ #F 5)=CL2(F-.4!CS%+XWLDHB[&]-LB\NBF6_]7'H#O- M=8$[^%>6I,3RBM%?&9A;A=+$;Y]$*=80H-SP*P=^ F_$5CFH",PL*(Q!QI-G MX>,CH#;H/-(0"ZQ$^,/0XPK@H=,@%TU9X>0&L03?+' M <8A ,"?5BZJLZ!75%V%CY2F^8!QQSB1"#28^TJ0!Z\ GP2!LXA_BXN$5GBD MQMCSO/43135%-1XX K_ (\=!Q].C-R *L6 >8]<,9*T7)5@04L10Q, ;,#+< M!S_ 2A7[P+D#GUL +H@?-P%EC)$P0+A"- :3ZWE9['JO#/C/@?_O7-_&),Y0 M$W9O&M\8&$G^L4SJ5:GX9$P.(=#,%:!D@G^7U,6''CP PS)/56IO=I -[\N&:.^F&- M)<;80,8!QC(.6$ =FOQQ<0U'$:L$9)-Z+L %,0'K*89S_1WHQ4](%?4' !X7Q[M!WDU%*=D? [L@K7GEM5?B*#H. 8#G0^+E#''V$Y"V\ ,(U)1Y M!'$7#HF0&Z!'%":S!@6)+R.&:&0UF"LD3%$C-F ':H"&=$U;9F'9^ECO>+.U*P M"9!?F#( F.5F 39Q ?'):Y*B<8Y-@E=<,I^X^@3H$>-FZ2B*"_,9\],$;XZZ M ?Q8[)+&.&!0;D 5W(99T05%,,?(.#!=]P=AB&#E8"^1NH$4[%,WD(2=)L1R MJ"!;Q<"(!P?(3+()29PH3%R,U\G(C)W[R,8[&6"R/LP"GKE61,[Q[[^*-OQSPDS+6FT>'SW#PF6SHAF?@ M-(*9[.7?H#BG.&\*=^22',,\ F<,(/":7XG%H/#)CZ/+J;?'!"[ ^0&-_$(@5_UKW$+#RJ/*WE4;[33,*]!XUN"F8*YDJ*7Q)Y[ \P6MV0),[.B&@O MBF-_$,4YJ$CR+MGM +D?1VZ^=U=#&0F^Y-O/N1DR1N 9#J(@&OI%V8E)=<:DG"T[,:A<15\M)':;Z-7=NG!JLHRM(R*QB'"[%^R0A/3MPXSSTE MC$F&"X9XR%Q&0&6W#%M3-J"VS%JVC)N>$:%:&=/X@&F>M4M,FRJ25\^2K5L1 M\,O0C:O@H.N-.#>*PB^,S=-7>][;>=Z@H]Z>*]$X+JIB].>\]*IN'K0H$!N M&>G(_4V0HP,\12*:PS+\!Y@;5/SD%6O"9 M#0RXFPS&'3&WOA>]W6%)HB";9NGCQ(^'%.\ZXV,_9:0YSS.JCC;=7E_:=SH3 MN,^GM>;<=B@3LPL?<)@%;AK%F!<*4SQ]G4:P04FX^7O)H8O\D$1]3_\9N83% M\D- %/+4]'Z+^1QH(7K&<9(<_P.P 1*^< I=V AC_"Y &+WYJ@E6XK+[8&&$YTKTVS^E/0[ M3S\6UOI7(@K(807F(O3.&9[EM-I)G/^/X9J.I*YWWO8PCLU2WN^+NLM3$O&9 M@3R65*@O4&TX9VM0'7ZHB\?":.,)*Y?0P0>%64@^2&BY-&Y(>&"BX7$N*3DD0 M91B3'W,PP2/_1F7F:)+OD;O>7QF8YB1/I+5Z#\54GZ24%XU)-9PB=R@/SV)D M/68).9%43RZ.T=D X=/Q8!L6#X!NK!V]P\6/@FB8U(\BY8YB96%7,6^/9" - MT>G\86VPH[%5/9QS'/%9J20Z P+BP]^3[ &&C7,]XB$BT4!0O%1.4DS#&VII MIFZ&3W*>XD"MCY[A!\ [:0@0N4J( +B>R_^$C<)AE4I7;+L\PBQ.F<0-O?R8 M7@WRCS%"_X9&\!9]7 <$YSCESF+^[NI<(,'[:YZ5A.LRY%&]/$Z,I3,U'"E\ M<)G57^=!4."Z(\A%=VH68CQ1,9>)D/7'DBT\@J M 0P,#V\T%.GO YP@X3]D>6TD>&0^)(R/,_L#WXU]1)U=BK%9F>6'S&-18R*O M'$9RRJ>R*B'G1(GB ^35(OS%"TY+Y8GC,E[]M/WI=,LL)O7/*/@H^/*!XWQN M9@ &F0M8"UQ_/.-_@&_C@DB+)B, %'@6(4JH:J3(F1Z'=)^BN*B?4=_.#*J" MB^ 'Q ]^L15$Y-!<)B')JD*#/'EPND4Z?4-1FK%>>@>0^0R('('K6U5(%4*X*;;'Q2TS3MM3ZX? ME 'K^DFQQ[P<+#X='.+].#3)04$J;V+1B(W(_*R7.R&O_'=^FG*:*(L;BQJD M>*?.S1V5*$N!'7(#%%^V_0!&0$CV^7'0)_4,/ #G%)$=EK&$Y"\5:F[QZJ<<>64X/!>2)*>_;RV75Y%CG%Q)9P\ MS32OHYS? 4]2L/- )6&#.>R&^)0[E:5TXZ^>L?3XZ'L^"KW7O"@PCMA@[4L" M@!$^XIUG-A>YR+C$+TGH=8ISBC.5A![6%\7\<(FTY(D,Y#ZA7AWN3AI M6&WN/;M@J]*"M%2=SH8'R3E[\%[ !LN+#Q:^2%YP8I!7GP %F8%K_4J#-!0\ M>.#3(_,@AVI[NTD6Y]O_N+Z:^U(>UG$3Z)J,: /RMT'9N:X>6EA+;W_;M$$5[A+;..7AN$[GS2U#;SH";\Y<'53\.9NY@29+R-G+ M&/DACE$^XLN$O"@(\JK; W@T,Q,-)/E!,OF!=&2'%4R M9%YA-8DU;$Z5%//QQ-\"VW^!@L%N&HP MB8[R+,N?[XIMWH?!^P( 9,\S\G**Y+'QCO5>(;*^O,]D/!]E\OKS_,[EW2(0[HCBOS0O_&?+WX]>LW M^.<]EQ$W#!;7'T=Q_?-\/MS:^]ZXM.3Y?).8_%[_8(CKMP0SG^0*-WAC/O_< M6H)R &:#\_-TJC\0WYC._E+'@3@6"#&0Q2##,+.$TD@!= M,*E_.9%.V@,'^2=$_K]K88:YMO8F7OKP8\MC&3E\9R,4_!R6Z[\7<*__*2 E&-RGB6R5-_7CH^"_L0&FM MJ$0W68%.E4Z53G7Y5)?+I\.S:#81TEIJS]Q'J1LPM_FAE@/%"+5P6RS^I&/RF:>RN:# NM>;2PJP2D0 M"B ('Y+S1V-IZSA!\<-2G,IM:G"]"R7BN4@%\E&OL'"N=,^BWF.0^ JE.!<7 M)Y9.4,Q8?I#A-+P[O"M(.>60X;&S."%W+BH4"A0* 7V7)Z_\.C-F;FY R!+ M\T9K>:_MPN\=R1 G7_YL_M_L!([QK*BV@2/(99QY-V="W[6^9=B>'/<@U2EQ M);08)>3 WKC>6EQ91 Y:H!CSBSLL+HDLZ].3;=*E)T(I7%KAPA\X7'#\, 7/ M,T_@KD.E.%GS@.LJH_(W4E*C"3(IV5?/D=8R/ M]R47Q[CPEB"G_)0P:1:'+C$"2)5OGY0/Q<7(\.$SE"2D(_]3A8SB$@P_R4OJ M(7Q?4=&89 F^@KDL%^D7E\+DQ]R>W=K%GQ/_*2(W(N3U'YD18.L!#;/P_+T' M>#Y&[XV?U:K1N[@N!!\#)$5O\%RG5U.2>Z:!4B6YJV-^/KF@+K_<)QF-"RXG MIY%.B^-!(_<)%25AT> 49T#B.H3X.%WR>3-D7$M7S(.V@BNGUU\K92 M1:G$UB1G)PI3$+3Z8WQ\$^4WI34,R9O^FE2;O@Q<4_IV\H"DL?_"\ MX$1>1@JRD+J;M:)VN%RGB^6P&\Q4XLY24'?%^QGWPO/41\-MZ?HKMVG_!4[*IER%#>&26KU=LWKMO"1??E>,6]Y3D!<0(4X;]M0 K(/,P_47 ML-3%@A:C,,DA\N &I 9#,D(H/S\:?(BSTU&#-X+ M(/YVDDWP9>75C0BS5WV,W)C<:XG9YI%8W> JEF\G-P-C7=%>:**XQ74"A@P8 M(D59E V5AM@P U%NV02W?)P[PA'&=G[O05[*\@$;QN0J#A(L*DKI, ,0[D$T M(3U3Y([S=G*C$B[D>UHX8KF5P:3/Y YUTCEVP\0E%[*"-+_(2QP^PI> C?[* MW#C-;\K2"WA!%66#JXBG"8Y;V,$_1'%WV>* M!!$>)U5ODMFJ-XPHG[(L.W6#B^HPN36T\D"@X0)?@QSY2>U5=9=BIG9+^W D M=G8XY/:3XCU!A%D'Q>-I62DB8G)IDDQ/ 7R[O[NKS@&4Y6YP&:4H^@[_RL+T M]9SY'3%YE5,&U-=HYK9Q,P7B6>W)D\&'2IU)]!2 M=]L)J3+7=1'T&$7I) 8&/"UJ-KT3>_523_E&>KV:QIHO.\4Q;S$LC*T6[#* MV)W@<'#T?#Y?SGQS1"YVT(&N_GC()+&'1US0"$_)9;GS?TV&)PP N*VI&$DQ M"$'&!U\+C:J4NWCP]NTC9!/[,M>_W3)W]J^7]M6&:D%M+-;J93$VPW# U'U" M.XZ-@O[=\1=CA%41,0D3-"0[&9$6^3"E+DAU=2*IFJ+Z)K$,XJ_GA/F;W@1 MDV^-AXF?X!O@6?495TE^Q"8HB:950;&Z0U9"M8QJ%.;NHY_./H'__A'B\3NC'2 ,'%;/ MA4GIGH>-03S/&P"&!][C.X=1I^A(+",%ML'17^K)=*%_U!UQ+?I\IZ'T.-VTN6WDFCL-]T[M--I M%\@B-LT;6+528#Z&]RX2\*>:1.*ZFZ3!^^:SIC/7RNQ-L;R=+^F!";E>8%DX M%62N'UC>JV6V%2F\LV.)V\4@Q[X7@0B#2U:QCJA[DXS>'>MY;= MLE&HB)M6HP\9A!>5M^A,9IW8P\RZ^6N1=[ZGG5_( MRMQ\TZ_HOC;=USY8#4;WM>F^=N^W-^F^=D\7OK?[VM-+P(\[+B3)TM'$A0X* MCP?E:'<'CS+[WHV;P\/C7FVD#ZZ# Q3T!^[:&>;EQSIUC<^6][.%]X;>#U:2 M'KO /#P0"9S0-1#UPDXL#V(?MU;F>;J;??1"C^+QL,5D!Z3AI>^-_*$;'H?* M?7?*Q,'*MF,780<((I7:;8?@S^*=O$OTXGM1]US:+BGF]Z+]\/3R0:'_D(1L ME^#(]SWK\3#MQ.N1'QV%>N?5SITSH#;BH8%(8#OG:!RFC;CI6W$RF%+$W(+1 M>-QJDE,V?G[Y8,4;-=O^?_;>M+F-*UD3_BL5GO8[=@S(2W"7_5Y'0!1I\5YM M+A:2*%C?OSDDYEGJ0(HD2 I@11Z[G2+)%!UEMR7)]>? M'GFV_O2X_X0BP$_)=/LS+B?TNBI_&KG9XTU-W6,3 M8NM'1$?'C\[V7T^S[:[9 ,;$_C9IV=WO(RU[O.,?23I1\R#F6H,(&RR@DR^VH6.HF;TR_MQOWNGC?*W': MB]I@XM'[LW=1FF,R)<:SH7F^P],MW7C% 7VOB <5_STH2,4X'\R53-.H7U0A59.&"^;L!)&I2>#+>%1$K_K<]R]*/XFSO8/M+'+L&8[L? M$6/LKC]CZ+0H]N_MT":9=H4981,3G0_C2=Z)7B=EB?^;S9*.&ZG:B?ZHXHD, MN_HS*7D66Q8.="H[T=4D&4QX5%N2T=:281UC3G%"'_6#IXCLP8:#<"!9/C.8 M>Y^-=89L>>L1H[+#FTP8O?; EY!P*.M;D%SW="=+="?_5QPEP__\H3PYW#\X M>;9W]GSWY/3@Y/GSX].SH]W#W=,7.WNGSW9[+\ ;\4W4Z@TV%[#D'?#%=D9' M@Z.1_+&)7_+Z_.+B_.V;ATX7,AZG903 MW&=I4A['+&*0/" 23V75B:;TWY$9C42!,QD4=-VL&,,1TP$-C.%$99@;N%7. M(.,*G0+]?1#!Q8?WO0^GO_]SO@MSQ\?Z,]63SO5GQHBV7AL=T0&)C-'@\(QD75$^EHLSZLDR_ ) MG!B='GF%9%)B!'Q2\B,@" VQSJQ(Z ^8.+[B3C\0.^K1T_J3+*F2N&)!S&/4 MA9<+\*8?D)XW=FNW^T +>/WYX"YC?WPRG[-_.!G;!'C(J#V\5 M[;F=(7Q?W#\H3%Q:>I>AP%$Y$<.UX21VG'/66?#.B,_&13PM;SA^]4N4=4<' M;$-K:TEK/=YI% __B@$+Z/WSL0'US"8D-C<$M"&@:Y?YCJS3&B3D**=O,H,9 MU#@##%;>T,^&?FZD[!J*#HXL%WI8-4;&5#51]>=,0$=THSROR)K+JE^A!S<$ MMR&X:UUL]0V\O$J&''>&LU!69,J7'1MC+\P6D=^@+@P, M!MZ;6VJ%.H=)VVZ;!B\X]CHDUJWB8FPD ]%R>O(9'+8:_I+UE1#4HF^1Y^@= M*E(C'>O^&1N%S;,XC_*M.2KG*>%P83^"(,(UHC[27?]5Q M0=^#+)9PQ S*7H/DXJ3CV9^00,*OB#@6$CPX0GJJ!;[CH[(Q>TE\[>ZL1^CI MP8)Y+J/FXC$1G3IINS'MOZR)2)(L[B>(RFJN+!HF0\T*TJGWYW3&9E!+3 ?? MS(@=)&H7C>IL& O%([[!L6'K.<;#:9(ES$X(02!F".:J!U5M'<9\5B73Y-_L M U1;15)^)*%W:6BU:W?XQ(OMAD:,=3]B8R\P1L MAWLCGG>D7Y)Z:KG$*;11U-WY$4(00U$V]N>&ACX7-4;9)(GC*7UM'O&4J*TJ M_J0JP6GA(L[&[ CM;1\S:>UO;VAK0UN?7^DKI]4R\J7)RLVGH9!Z)C*J^R/[ MR:M:E!MB^CZ(Z=2Z4&09D4V:UG#F)#X3Z+U=H:F#'T6414,S2_,Y3$I(,?-I M8,J2C-59 JDW-AF\.#-\2*_YT3)8>IHDUBX3 M/ZVO3_\RM#1:AY17H,375_>4'1^*0=A%/K E,317DH%?)=-9RN$?^JT&V[>C MB[K_ET9U[%O2^*K4$J-QG7(@CEZB$;!)?$D;"\HH1ZGYE$A0@RN);=@!)YD4 M47Z5^<@^[%TZ':Y>,W2WB0V&:"J)7J,53'-\Q)Z?1##TT(MH%L]YXQQNB[52 MLX/WX1KH_Q\/8U$XYI.@RZ>+G :5P.T_#-Y ME7)E?+,X#:X9',T;87,$1[)A@CLMHWY%#E9,2BZ M_XMXOJ2M5%*P7MI@,+WM<.='(0K_*W;BZ! DYJ1G0;\/10V_893F.8=:#R2. M0.((94KXWZ.C']>*FOZDHXQAGR8S')0+&J?(OH@YGT1:.B1.;+///763;&ARK6G2$4]O M;(:=Z#F]D914 76-VQXZ8NP]?Q'0(OWD;1.FL)# 1(DX^BIRI#5GDWG)RFV( M1\-Z 0G2J_J&+*,DA_Y3JY#,K3@IK*5"KQ(CAPQ*5EW5?(8'$6W7)5@AM!>K M20Q1FY?R.S$"I4IB0>328P= M826ABN@\*^N"1?<[H2/'(BQY-:RD>5YN4=4S0,RE/(@^1QYQ9'#ZB;Y8@GJV5HI9+H9&5F^M.,^L7\;L MQ.1M4O+4#=>_!&9YX/_[#3CV"]QL?"^3EF"X-X&J\UV2I89!P*2'!Z+[Y$,D M BI1=&A+ZNX=_Z@:QXF$&7B27H,;^S(GK5L1Q]NZ4(&VI#';*VN1,QK$^-KM M-I/"F%7?6=U^PI%^=914U> M"TPN1,](1WDRX:"?#ZAQE0TQ";K_X3R'#,U&&6WL7V2:51)\(9Z=Y25MTZKB M]V=>$^&8&$]0-9F M5*<,$(""/GTPSBJWX42 &'2BI"K]B4SC.3^C;^1Z[BW1LVZ"H54,Z0Y B5+ M'*Z5'#BF/CL323Y4&8(RKJ&Q=8Q49$G# _6OH MO&%NO'RY,+I+ FIE,FG$/4%>0#G0&)PA"%_+WC9 M3R(2;57!J[R,>MF83-]2GR*/I96KI>IS/<.D@.8E#=S4V[KB-Z;ZF>FC00'8 MAN^LMPYBB\1V=]24*&RQJ(AOK_Q\>H*(/TFE(L(^-D-A!!T=2L5IFY( NW+1J"![0NLZV.$Q04LA?T*A41AB\M)D ME00+FN65\-<;3_U;MW.\MQ,1(:>X='K6BN2.Q:_**>LN"\*!>?OFQPO%@3NN7"V]H@?I=+9OB8IEW#>?]5DL^[MA%S7Z#T@%C>" M@2$V+^G>+2@'_UC_S/^JB9"4@SD) +$GP8Z62)Y6<'&\X+C_2D="^Q$+C M7G^P%UJ$P,F\"MLPY,^I'4X"8\8J*"JD/>P*M;@ 9]%L/++*;OGC&AE(^N5? M@1@:)W9S-M=)Y@F:5>)T)&T=?)BVQ(#O#&N @($5CRQ,4NGC_?T[:#*P7G"=>!^LM"HES5)>F^NG8#=2XX46C'^ M\N7%B9/C;(281@1,T-+DP6',9*1QE""9%OWT,4/=#S&BN@BE;;^[^-![_[_> MO?K#&XF*"]AP)#O26BB]E[F$,5(S#GQ>_IPT-M'?N 4O^(/M_\OK%%8]%PD- M:R[DD *-L+7/=11SR1$9JTV?5N3DGP;>06(TR2!*(8VDJTC=BX9>:QB)WR). M>,?0FY2L+42WO (BWU8#T-82#MLV62-EVL?V7S&9QH75Q/3?K#\,*ZS$E-77 M9ID_V'%H-/@ZNK386H%W2CK:::IW('G+,J]?OPLL'SVF0.U]Y6TUE.)7?O>S MQB"!K_12:S;$UQD@MS(COO+B_[;;V3G=N52F=; M 7R+S9G2VK:>T[RWJVXZ::"5 ;K6J6S.H;HMUYAEW5=;FW[ (6CDW3A=BIHI M%D2]W&OL_0B<*%#DGYSD>H< M/#@S_8+EM[A1UTC/YO/*:ZW_K\QFW>[^MY-,7UL!+)>#*]L :RT^][H'CU-X MKGM,RK-9:GS14V7&TA7Q6E?'KU,!JV@PRX)2EJ=$\>VYD-*?/C)%KZ9%0FBJ&C2< M+VVFKEG"DQ!&P+9BUP56>N?:L'-WA>C*\<[>M=$5?^JWCK'L=O:^>8QEG5CG MA]]ZDMC'465SF]T*6V.6Y-<&[))R$4F,RCF#1T?QD-L8E/#@,N%1_9I,*5.2 M*ATE69QQ)Q*">IR*)A>9[A+-!%?:'Z.(Y;P0ZXF5:W5DJZ=6913<>\/0A2^( M1M-\QI6UZ[V]'W[SDQ)6%Z;>@=[=MV%QB)LW\67\5T[_4RE'!F,99G&)1IV4 M9&,I^7UG7&;\H^_:20H216\$.<:VHT45,J)<[E 8"7Y;>1[6BR27 M22!HK8?BN<=<0YN7(P-8W"6ZXJXNM# :(1AX'KL-! 2 20$N7:.G0] M=[FW((O1RJ VXD9S47OKSM?_35=<#SZN#BA-7.UT^FZ@TEO>&O2 ?5?;B2R3 M80*I,(D1Y"1+J+0%HNSU:1#7-,"\=Y""&TU07#[MQ8%<189M6I#6VGG MOG[&6DDZ7WL! E6.M&\_$5@*LK0DX48>:7X%A+>.RTK[ W"!:^(>!!)T'[\' MF3GWVM8)T9?0T3O 4E);-;"LA%/*:/6H;(!;]Y37U3C'E^T;.U&S#,')D.6/ MT>CX%V[*]I'Z51<&9VM?@K,&LQ5&*_M\H"6(&: Z+VA6AKS!%^G4G:-^V&G" MK:TK%UFPN*\= Z9KV%0-^#S8I+>(X[T0VA;[#RNOJZ+ >/SOR%SY16TE74Q MWHFR*R751A=^ R;;COZ8J<0?D$6I.0])L!9Q5L8#46NAV,P' Z(WVY#)*KR9 MZK48C60'U%/1N!R'\].>[L5[/]AA+;/BUWVY;N9=,@:V^8#$RD78/W\A_?-E MH[H$8&XG*#^:!+TY+S- 9N'+ M;F$XBQ?U3Q+I'!^PO$W27%/H#\BP]\B<*WYO__ ;1$R71"N^\@I*A#Z^\CNY M5%;A9J\,6M4R!YIZ(SFVNT=/U%']/I);\M1@GIUF1IRF+*C_U@Q9X M\TW>?[><@,L*'+)TUEA'<8&'V=9(;7C4^\LPBWV[\B0GRM:2#0_"/)/G4-$++PJL6$UDC&AUNI>D##8'K0J;D9!?JV#>*C+K*MP"N,A9P%UN6V"IDY_%*J4R2X?"9+C_E M$D9TF%L%A!4N6UCC]%=W)@Y;C'7X4.U[[I0;O4[2@2.C*@2=I75^= )A R3B M'\-BN0FQ: Q6&)T M>[DCS]0B;*[);#[]#B;/UY?,4VO!(-?%[CRDI0+-^7C72X8'368[1 MVB).<:SHJ4WL((\10GE\5 +<)IGB+.B9+^-4(PQN;;9)J/$D3;'YI\C"+Q/D M65BOL,T!'X*-#LE_60[F'A-_?ERC7:_8;VO@D_Y_O1I MF.5KAVNY+ CCQKCWAI,I9PQT$*)A:VQD)"LLDKI17#HAZ[;NGMQM(] MDN9)GHT+SJES.Y]#B/&BYX3C1F60]5)P3\>+"TV/)Z\O?-V=^TX3[@E6J&@: MD>>+EZ0:32+[(B":)B5;L\UD)KTYQ"-UO>)\,U)X,T5SI";HR/@;(T?GWJX( M!NY[:KKB8:S+S*?!A,'IN6Z%O*E/O7[];M01S.X*HC[JN0#N$RS$IL:@"D09B+$>I68A611IL M$D0^VG+$U_4J[\ .=&+43J@*3$37O=PD#3R8W<(T^6@XC!%G#;2X!0*7O/NH M(&KK\#QYD2;3.JT2;,*BW?FXFC 8,P8)TX%FZQD!-1]K6+T!>!>*7XGS")CC M'$W?A40R+3Z=PR+SJ%[>/*MGBEIO.^\CIIC/.U.;:V&Z?[X2-CL(1H/_) M$0->PX&S24)T%C$6\AG_<,D $8) M9X($3"-RMA$1"D(W4OW"]-%8 MB#7OR:S)2?YOR8%O0X:%9PAQ74I6JS&T^P\%DJSIGC8Z(>?^";+"3=96K)<0(>Z M!D2,(WLZK8][]IX(G7@X')SW&L/@A!@5C?&%TH;?(!:^.2[]H4TS&HT&) 0@ MS&(1V*IOON/%\NY&&?GN(B:)*\U&O<^8')8QI(V#QEDLSCX^/MZ49K>NU?;W MOB:'(AG#M;H W Q*_B6@BRN61JKF';.8^ (1.A&0?T@9AY";$L'Z1@_-IE)I*9\[" MT)-B'!&JXC.]=IV/6KKNFMH=6PI@T;UB]FYH=$UIM"F\5Z;4/XWH<(410I2+ MZ5'@'1&?0DP-)#OFB2D@6"8]4>Q,H*5\=D.#WQL-LK7P@*3'/=LL#64RSS7B M,"2]3F2C>VW!2M\G4@[*[KDGOUVUX-%BPC:&P,D/9>FP2MM@VJ)&26-F&HKF:%1TD3KY09QR9&^ M4M/SR+1=RLW!![J,TU9$%*N1@:$(CZ3)%,FHA!$*ETL* M-QYO"='QIH3H89@JG##(LLPV7?E>:=O"O9AU#0<0MJF.!&)=-<8L-$E[O64- MHJ0L17GG@B[3DK*2S BSSJA*A=7!VH&4)EG$;,VTODCL*J*$G[U,212XK'\#0#Y IPWVT)%>0>68[7$%% M0T2WQ3<$6_./XF0'TF+U@.-#4I%;3O*"++4 ,0PY5%9LI8E+4$EFL\D('7KM M*+CP.I/02SJEQ!L>- >LTC)?T 1\L/P7;$^+BZ:<]9N2;N5,4.S69M7C+2[N M454B]=[_]^F'=Z]Z)YMBI(=)NO3CP<=>DS>$ RPNR^5 M'3V?JQ0 &*)3-[,M@'Z)!1CFWT;[0P!.H-498F.2N!Z8@$-L 0M$N"V6#HLN MV:B:PNK!PF=EH[O3#_'4'MY_>XP ]PKPV*KE58PQT%BYCN?@:O)YJ^_@BCO] MKXS]VM+:0$9UEJ=(=T;>*+\,&C.J>.XL[<37:YPYTD7PFGP*";]N"@278==F$[C8\I&%W1TO]&NF0O>Y.B%>!BNWNWH_HPB\8W)Z]$SQ\ M2YX"0 &KW/0-+MP)KOQ,-:Z>M[=^&P=9^C28V3!(LV>+EA7?]^N1] M9'O8,+>7,\SR#BFVLWT.;-O'?D*U)0\^-,%<$G_5AV0XF- M3)_65Q>FS[)!M\=?;-0ZH"9F:L2=X_HXZ7IR12 ,8<1Z9:U2>-^D/.$KU2(L MEA[X%C0+TJ/SA$+-X&84MC./BB;EDL]0$5VBUKZ\#?J"8%\G!88Y_J,DO1 <@B*(54%H(C:WY,*X_N:4Q;QWL MS<)B;H!6Z*P/C9WXAA# SYU @_,9?>:9HDNL+?G9:-M%4 "GX0$%HLK[7+%+ MN@ %OC8ZUK D&I&XCE1VEE%)NB"=MYYF"\'I(U,=7)S/ H=RZ0-=2;XN4)N0 M=#;===]K@@ ["*C"&![738[B0+]K49I=""5_*3.I>A1+'\)@P4DY$[A@S1&= M.:?I+!Z QQ1OTW_?.G9G9[Y3P!HX@@7ZG*VS9=^Y>/ZZ,3E@>90[F(ZZQ%SW MAN-]A+66',P-PCDKRCQ\3AJ1QV>&=F3@\AP%B3PZ"!8?1 ^" M]//\]9<Q?E%=/;V??3N_>GK M\S]>1^]['TXOOJ)Y^J$!(2 5*EK#6"Y.:FPC!/?GK?(L.^2T](/J?GDH;3Q@ M=VK)$02O:%2F[-CO)RQ^^>=P#1F73C1>V=V18I9[*]UIK9:4R#C)9'G(N=M? M,+_+;Z26Y]FS[<.=9WM'!S_^V@?D28$X51K/2O.+_<<"L?JR(/H([N _?SBV MY4!+JH#D14=[/P8U0\V_=3_SI\_][=[_=+.O?;G220BM5;_4HKKP9R7,\%=R M4[M")@'E(58%8.9?)IBCO$0[7J>(6)[$AF74BF78ASG7?5MC=%V]U%>.H[=.OM)ON;F?_L#V[]4Y;NNGAKRQQEOGN]W()CUC2 M;GAK'7EKKW.XN_.N;6BT/HJ8*D>+N]10>6)5V]I^M$H!9/TVZ5J2YKK+P45'F ML^[!DZ#,U6R\[GI*R0\Y0-I6N9=&I')O]BD:YC62=W<)5:X6J_IF'M5-C^#> M=WP_''G8V=U9%GJ]\[[OY1HW1O0]AST:H^NDMQ MRQVK>>1'?/CVY?(2^?^*A4=_,,1UHS'-=3-T(FE]&/,@SJGM]!V@C'(62YMR MH\%%,*D!.XTV%E,ZD.DY2I3X8:CF%#!^/U*[@27-0X'0=(<&XB23\GOZD+ZH M2,J/T8A6EQ>*5:!5UZ6V&NN+N7>'/E:CSYC;!F$CR<=)N\,;](YK0OS@9A<@@%.Z=RU M/-I15X"+GZ(J'073&(\34*COS3G3PQ.P*.G!63)JM(T!+?3;*K%#7U8VMM,E M5AWTUCW>V5Y]FA\=V,HO[ASLW^'53Z8;22+6:]2-)N)WL:V_L_J\@>M&!33( M^K-3 !H3DRM J,:N24EG 80B.YS/K,,#9%2 '4A]K>BVA?^E-#LGV2C5L?': M*8[-U%62ZG1>6C;@M#(5 0)0CE)7.B5,IXA&QFS1GK=4&/N#%<&IQ?@D23$7 MRW:KRQ30ZXYH.^JQ$&.59UMKG QM(,I[4(9KI:B*3)Y5P\W<9V MN$>_'HY-%0UJ% '3R^)/[F""6OT 4IG;*73*7]YNO6 )'H!BR!'1OV,_P"AB M? R[3**(),2/#U$G6J*\7MBJW40@F[%M#/WU0\Q*CV?+;/K'.EI.[MK/2IG_$^2F?PM)FNHF!F9R^P5& )U@) F.HK+DB=1L!QGX"DY#5*^;&J-C;5E6!O* MK06?0T\P;"&9S'-SQV(1,> !1?O>70S\N_D6.T=K(]B_6@-A'"7#__RA/.D= M'KQX<=0[/7NQ<[#__.1X]_CX^>'9WN%^;[_[_& '/3#Q_2NM.S2][8R.!D>C M9<6WKTY_/[]XU?MP_H_3J/?F1?3N[:OS#^/XB.OOCS8OS-[^ODSWQPV\O!#-& APVA&/-_TF< MDNX#0-GF M.O<:,\\<)$IS&KF(R0Z_L$JJ&GOAD8'Q5.=%B6.KVLNI\5R&:X. QGHFE*D*+A3$ &BKYGD9-%VM_^."D1\IR$[@Z %6=1$CLMKMUP(D965F"HIG2363$/I MP:T4C&:2C 02!K(JG'CO$A1NKF<08E."7H 4,%EQ8)U,HJ#C23*N[#+56:<-,;@YF*@TF2#NDS\*NA4Y=M?#/-XY$3 M#ZNYQ,WCE0ARK,9A/\T''V7BB[<'?7P\'*QIU5MH3\8\"%DG*1@)86^(Z D2 MT7O.^S>H:&&R[E5>?/R5=<^& IX>!;Q"1-*J(%]JD"8C4]&M^)2HGQ^_4(KQ MP#-Q'CC"T3L[>_O^1>_YJ]/HI/?^E/3P_09H'CY/ CZ>&8%91"SZ ^+FZ[2' M'WX[#W!;);(+>GNG.>Z*@QX,'4<")XVO^*\65D]G#I^$Z$V]L%ZF!+ZZS+%T M WDDLE+PN9"Q!$N+#@BG8SX-$@Q8D.2"5XIXI3A*Y".59'D7T9GQ2'TOS\\< M&)Q/T8 K%"(:;I'.TEROLT?6A%;O4)[CDKQ7 >I3G'&?8>+QUW&5%XBM\]^[ MSQY;VC J,UE.A=DL"6&XRMW-$_T*0$X^4[TPP:-V!?8=^12-+E0VYJ %E M&(/&,6T3'[A1W_YAY*D,3!LE-GA,D@F;P0C@-(P-OR QF0\=_#\MJ!/^C=-G MI=1<+RX%U&OCBH )+Y&6 ZE>Q>P$ :K3FJX*P*BB4%-XB_1G'Z87C!G8J-'+D"L><+D*8YTFQ51' M/KQ@C-*!/L!=E%VWO<2;79PD&@N#C]B1$DQB\>"C/8/F"R5M.K1S#HC MZKSH4<+'6@:3J/2&!6O88E[:R+;++H,R'B2]+V'MJ0@D%6M5\QL8G9/$62.$T%&]X9 M/#**TB/:4Q6N"[L=()0T;AW.DKB;!W"CIC6@/ MBG*8ZRTX\@W5/4FJX^&%MH+=$,40%8PM#>JT07+(+[G.5Q-C\26;CZBM0R'@ MAC">(&&\?[2+ H6%W/D25R^2:"1 M(2M+K>+0K[LO$:5\Y))$']HA%SO&0Y1,!W$5D]N1<[4B9\^"N;\HL,'XRRT> M.]1>VX:$GR )GY:XM:2<6/&&8BG\FV>4<(Y^EN=I*9Y30.*:Y5?*#[0G3ZHA M]9@1@2&[C^>P%G8N6 M/(ER+U'D65R6$)4(\;AQGIC=ICXKD;J$**WC^J@C& ]=6?O'\U?G)]')R][[ MW^]W@N_]CWG*W)C;W2--M%P3_D+F$-&[.)(HUQ7Z*I/LKSH;:&LS"O:=\_+" MS?S!3;XD-R3ED3EF4!<(,=KLRXN7%R[[P@ZOP_,\A1:7-$'*3C+@]YYC@7MD6G-I/F=D3O16@N(R^)NR J MC4QB6)EQP_AD,1I^\0_EL=Q(N@Q) .1!UNC,] LYS7U[FE<\" Y5R6.)#MK1 MX5P.)H-)87/#I]-!K.%8))R>G\@JDW5C'+8XB\4\O(,$DB>1B7TZ06H9XLFZ M4>&'YNE:H>,:I^I2[L9&60W.@<51,ITF8PU/:_N.G4N5)A\QX(V#S>P%QY:: M9D(Z R8=EU>4=I@RM[:M?LO/<L"/ -NFR%Y&RP=L]#F0JJ.#SF2[[NPCO>UA]P M=J6QB-;FB/0L+0.].TD73_($7<0 M# 'FO(4R# +&J8F95R">2SI^^FEH;&$SSSYV(Z)S'H;ZI__IJDKJDVM@&YO(AH%"'(6)-<,BB:C>2/QLR:0"R ,\@Y5\JY MQF"(>M5("S=ECX[RY'F .FK>MG2F$!9E9=D)Y9'YS+5VVC2*3PAV)*4N<52K M8+[A[NGI_N[>P>'1\?,71WM[O6[WY-FSO6?/=Q]5T]W; M=Z?O>Q_.W[ZYQ;2Y;V____V/WJOS#_]<;RIZ6XNM(M$P,@^ 2Z36#OKAN.38 M-ZS17\:%@?(7VU3GNUH6=5WG5\9BKFQ'/7;B;-V%L)9O .YV+;Q2 ^3HB@W< M@:0YO-9[8Z7*23YE8UTJM/ZNR^B5U@&W?L6;D[_WK&/1+@9[30YF,J#_JF&0 M:6G8"4PB5"TD8DQWM-(,)1-7<:&857DQCC-MMU=#$4/K8:+!>*G&MG=;^5F/;(5&[[(-H/RD\4&;G0(BLXAEY.;.,M!#BBTN&0K MR-+N-8N0VY^2X50K?EI(]!Z61/8K81^IF:G9A*]+*;L[V I1@LIY69GIFM_Q MGWSP"1F8KI0%9CV#U\#+=8="!V'/!&=!IBII_%A\%/%>O76IV'A\/7$T+B24 MYGMM;>5.DGU$+';:KXO2.^*P5_G?)822]8/LR^5B2>*X\J1T'D+' )_.?K:? M9W4I!? -DN6=QH,);SN<8?U@EZ5CHNA^DBE11C'XSQ^RP;_BN+NS_==L_$-$ MBVO]1M^KK]S??48/E/CN ?\;NIV>]3C4Y+OW;_]Q_N+T_?WJ]OL@?D4V7(Y@ M".$=3HNWR7*/BL0V*>:5DSF:F0IM%I)#9;U8-!S?8-)V-)O,2SC6BN#E?@2S MU#.@/.8E@+Q2MEH'Y'LC_!,\5KX5%]-XP$"*?T),%^!8!+XX:*WN:%WX[XDH MU@I+K;TV7*U'GF(IP2ZGJ#C+1PNOH2@'\JD$6&;K6!OMAM#3&>-*T+$YR&?& M&A[V"-PMX:)]_C$9P9R)B_#XW".1]-GR@3^FD19I<,TB-$UFN$"#Z>*Z!P37 M2"\54!]Z+)V=H!E(U:9&S\5Y$A>>O@-83NA8>;> 8;J/#$IDO=2D::K&X/KP M4J8#U&%*!3E3?-A I-MBXY#+-9.L3+B>TD:K,C* 6"LPXD+()1Q<"*EN";T\ MGIA"&T;X>XTI?+-2T'=.5*Z7U/G3M' HF1%(I$XAJL48:4IYX/31HQ+&Q9IJ M\NUJDD]9\*B[81MH+'.+0H@D.>WU!U[+J(4*@2L!TW?7O-UB8W(XE^B5$<8: M2[4Z[_IG(.+8-X)S*.4<@C4I]>+% N1D /W(2,%S"RL<5I8/\BE0Q.0A?:OA M((K"L#*$M!6\?J%_M!=AL3Q5I[,#UFEH=J\([5H8[[*#MVSIUVBMM/)).K?/ M*QE84QMIK6C4_$QL\2_;N[_-6L1NA>&,Q[!J85@YB=_6I/H=2&6!^R=7:SOB MP)@G**^5U'PN%?.4/S."_IXE90X:*,*,;%W6W$%?$9- ^3;ZQ%#X*J2V7UAJ^6V@\/(#5)5U.4HEC M2NY>";2=;#!?+Y-D=6'WTII]Z[0=EG6"_RFW'=Z>,U3%W)3>BR"8%-@=0Z)^ M9QR%:-[.EFAB(+F@+INWSE$,7BF\%PMPKWCKEO&FIIKDPX8!WJ+*#O/U,#'( M3PV3>)SE,'2W+#2B-<6]A-%*W-BBJS\5JNLY#^.=%4KK';6 \/-N48QPI4IJ M572N() H0JDLG6]E!I%/*]%"TDCCOK1,SIV"@0\VM8YA1V43^H%(HIJ!N!CY M8%#/;+@2^;1X!A>DEOXY2]Z(!\ZPO@Z1S3 AWWA,GXJ)FM/80D,SWB:'5"3' MZQ9A9:TC_V%#-G(J4; UETC[\3/G:\W3?Z)V&A5DN<#]:]+MC4#BF+. MDLG?;0 7GL;)M+0S Q* G[E'6(_5REW^:V'Z<-W]%]3*2M+0U"21Z!XSJM,1 M,4QC"6M%(%HC(#RL.6+/\UDPSX(T#^D +NL< MX$OM;JJ;;/CF!!,\K5$:N6._G;#QSC^'K\O@O:>-%W9W),1W;[6CK=5*)+&[ M0_O4D38#.O=X5II?[#\6-NS+3?W_EK>%9/:63TS89:=K\TU;(QK6IQ'M4J!W'MMC6#<:>-+TG[_Q/0 MT:>-B0 N>_S$YX;?B BZ.]^ "%:;B MAKU[(H;'[C ._0'4Q9T.ZN%)YL_>YI9L>_LK2:%GQY;U< MPB.6PAO>6D/>VCTXW-[;W_#64^:M>]WXPY+CT<%VNU?_7G;HK^DN6[P/\?'C MM[[ QT2Y&ZWPC2RN;F?W:%E>;:,5-KRUX:V[65Q[N]O=@PUO/67>>DP6U_[V MO1+CX["XGE*YV/(J^%M'W]>/-+N=P^-5O(&UE8=/0.P]8G+:[V[OKA)%W)#3 M([)0'U@B[:X4GMA0T$8@+?,$.MV]59SL#3EMR&F9?MO?WME(I_4BIT=&0MW] MQZ7?OHO"A1/7T'W7^JK'$Y7H=KK[JS3W;&)DZR3]GB)E[AYO=X\VE/G(*?.I M4./Q]J8NZK'3XE.4DJ2_CS=511O*7#_*W-W?7BGHLJ',=:+,IT*-1]M/@Q:_ M:3[UCG?PEN<=V4W=[KO_?UG/KMDPIE%^!M7W<%;]\-M/7;1CU+-KV/N;=DX] M+.$?[K;QDV]$^%_8Y]K*XB<@VJ;-5T56 M:E[;'EW;,*\!MGPGS,3'TSCSI>VO;V=-=Z_S[!Y4Q6WVO+9*Y/L-_GY5]ET- M^^5)\O9J1W$_^GE_9_O92N5"*Q_(O5S\1BJLC51X1#FC[L[.]LXW.8/U[NG; M$/]:J,3O2^L]=&*BT[V'6-S&HMVP[\:B?506;;>[?;"Q:#=286/1?L<6+0=J M_X-'O;G?#[\TGN[>YQ?^GV7_::[V5M/HPI-VTP&OF4X7+:Y^V2RYW7VY'J6: M&\>Y:0D_?/XTF]?48!V=Q'>[:Y:*KQL3.HK(OK#"X+[_JLLJ&!4.Q(W'DZ3+.%QC#R0.^=1YGY4MPR/Q5/L MR&[YA/N+S+F4J:8Y%^2%([$Q*S@K,5?W]8U>;9?;D9G9G^+I+#4=]YB(OYM@ ME&1NWV.&]4!G^?ZKIN.LYABA7A<8Q-J1T;Y^5&?'#I51AF&M"R."%QG^DDZWG&.Z?TLY@,^K_#S>Q?^C;[\^ M?7%^TGL5O>Z]Z?U^^OKTS8?U&AF*2<#3I"PQ!S "H7CJN)R6J MX1G3N".9X?QTGSYG+@U_'?-6>2S[*!_4/*M\ M#)LA S%LE3-,*2V(9!NDG>&VRZB6-6(.*+$PKRP!U?)85E)9R0"SLA.CX[2) MV$# =5).\-6XY&V1;;(%!N@L7?(LI1.DC0XF>3*0Q9OI;!+CV*X9Z>Z>#+[% M /A9GM!ZZ"%Z/'/F,%*QM!H96#PKZ#24R7F8@,< P$YS?:4=]Z#Q\F=,?3G!85T7Y8K- 'Z?E]+ KG9P:\ M))G^S:?@ED4WW)@9B^<'Q+!6LW#E1WSXML.2_ZB2-/FWW,)K/W1XG38G7#O. MZ2*$9?-9E4Q!G?$ TXSQJVM(/" #^K]X, %/#L'') M,3'ZI4GSF1FVE2#>-B[B*;VNQMCS,E+#X;:E]-<0]@^_?<#L#25S0.97QR%3S!5%$ FZ03Y<- MQK:NJ__YAM9:VW5:D65>$T%GWR,5%_8>*/6_&(KO^7.+V*YR7,ZDEQ@ZW=>2?+8@#7G?*C%,'O M\EF=KKD$#BR:4,"27$ _D *=L] MD.A>KX(ENT>_D@UBBC&4,)0[R=OSC,X@&=:P$/A%(K82U?PLFMC"X!$G8G+H MF]@H)R-1)*8=D[.3IQ5+ _E(]L20F+51R**=CJAEZ)5PD<89? E.(8@+I(]+9I3KRII(O=DZU%=^E<-_)^TIP\F#I-M\C0 M-/9,X8V(8+%G7)G!)-.M8>U7>?&17IV7ALY ]N[V1BZEEGW;M M?&?T$8Z1.,-4KU%8'@*&%D[2 P$(\5?(3O&.#&_B7JGR@0,&YV_.WKY_W?MP M_O9-].'TY.6;MZ_>_O[/]>.K?DU>/*0SB\F9R8;L?X9.),MD,X V2#)(TX0AJ@FM66)?4#)@P84PF'H5^%MHZGNN8C>! MS%CZ$'U<%0T^+OPDWFQ@JPL!_ZLV+NB&#P_C*K9:N3 (7@;OORZ6GAA'Z;*"&%_"9HU@!)^V"Q-X M(1,5= ;0V^P;=NP:)LDL0MQFE$@\CWD,ITIT$%=U(\88K.7!=%=W53.,3 %C MY2M)+Y8R1#N%B''U&JV)T3Y9OF_BP/'<'K(-DI!2*/GCY-.)C"VCRSJEE[!M MQ^8)G1^9/4+P1, C\?":+Q^158=/TU/P6OJ6(7.@(H$($RXZ,_VBQAW"#V&W MF0?>T4;8P8QI(7Q[WF :%T9HE7<:!Z^;TX5F0Z(1B%XAZM(%ES5R=\WFZ=<% MO:@@80MV=6^3 #%=V7+>_,P3_;%U:$O#K;H,=B'$Q9PB _Z\PWAC A""N75# MNA).#_I>E*8-FKF3Y6NX,N IO6H-.F"[K3BZC95WX#*G)K 7\,B"7 0U"KYP M :,Z&P2F^I2NC*^M@K<-FX1-YS*PG84_Y90A&X6^H :WHQY]:!P&!*^]W]); MW"IXR#*>)L&.Y,99;FJ X7,/9/M%E@);6EP (4MU9$H;5D@6H_OKH-B6"=Z" M>#9A&4NG-,YQWN1#3)/*GC&L21:E]"-1%9WC0 2/O4A6)W3?FNPPV80-%O-) M M3N38F;W' U^8)OK MY/3-A_>]5^?_^_1%=''Z_A_G)Z<7ZT68?SJO8%6!9_6 9BC8U;4&$$?QFG+- M,;2:/67=+\D8$H=B5A=E#5)G+;C\>TZ:JJ'G4HW]6CS]+*_(&R8>8B^L+^XT]>)ZT.^2F"7_5QPEP__\H=P_>WYT?+!_O'-T=')PL'/< M.]M[<7S6V^_MOSCKG>WO(K@:W_]>[B [=D9'@Z/18JR$A,G;U^]./YQ_./_' M:73R]LV+<[AR%U'OS8OH],T_SM^_?;-:%O@&LG!EV3*"5KDD,Q2RWEL:B),1 ML;/='T3.D02!*8NX7EXB]#6-X820B1?EQ3C.U \3'Q_F7<3E!8E8 \)"[,Q\ M+NUK'7UZ\/;DFTSI1 M=P0DM4AAFZLX5>LMIWM:_CGU#3M-!W4[NJ@XSSS6U#I]HV0_G"3>W+K7.-OX M*BZ&8AWI,X/2$>35D2=D/X(])?O-N&B4&^"#SEAT/G]F*H23?-U).2!RX46W MW?@.*0NH'VQ7PW8E462)][&N0!0KE? %R%QU13SWU2@BID$/3OAO1^_(@LN8 M2*PC7\UG&N$;3'*<:]RH(G"!]5A<<[(0_8;ZAHF5"<\G[G63^*&5TM1XBM6O ME^18PC_IJ&>?>#^CZ6859E976E9 QQA/P<"#?)PEMM2@=?:->@U[1S96J#$+ M1P((.-+.^-:O)D;=P)RC9BZ"9!^94S'U)=EPS72 U\(!:VRU)).-0$ MI"HM^/IDQ?]%/B@;]=:/5=\Q;@9$)FUMW_$17_ ^RMY5R8/CV%6U&0\4/R8P M1QZK^XO"R'"'<[L"SK! X'.TD@SUC8PD6@#9-X320D M0B?1X6@9>UT\@(]O+D!/I2,X28H!^92H2#_)O'YI-N1J#?*DMNJ0M MVNB(K*RP<*YAD&W3,IQ)1W_/V.ASPIS4":GS(I^*?<2!4_QCO<(T=^5;7QVS M5GQ;.,N8:!HU!:DG.\ZF#(J\U"I#.(X%JJS 4D(" 85V7*71%^GL)?S;D*I" M*IO047*<* ANZ1++R;WGU;X=5?"6R#(9K!-AO,JOMDB&P%FQQB;"^F2Y&5!# M8+]K:,9H74-2BC%]&9>XKK_R0@5=L,\@"=316J]$R^&X&#!VD9FL9LO,:01K MQ2\7CNR"I'[ERU^)=RT1B^OD57TA7K%[=';6/7CVXF3GQ?[!\V[OV>'>WM[S MLY/>P=G1V<'SG<<4KWA_^OL?KSC?_+5"MJO'YD,:9*]1Y:1&KX5X:5$356#L MR1EHMC3D&.O(;D?OY8OJ!S4TN:T]:)=Z. _L4H*AK"__JHGON'0*IDG>^%D$ M:Q"CCV* M,@MCWYR496WL@3C[C*O!9O0IS3X0GP[:;RY)2HBQL]I@S$R_-WO1['"#^\/(U>GJ/R(^J=?%C!\'HP!CS/HNZS M9X<=DMG9F OS3$:D8*0*1XV,\TR;@:)W*,K1F 1;%A+OMK_JD1ORDU9"\^ZU M]/CG[:B7IHN<'K@N_/&0/O(:02HY0\\<&A\LF\^J\E_6JREO__CAF_+X_6Y/ERZI,-;->+>KC?O?DCUM,2MHNF'S64;]YE++E\L*"X?0^4\&3J1 M28FVBCRSP3Q-#+4"2:%?Q5^-;<[>&MS-:!0+,<3^-*/*23?)[.SK-.TYSP)_ AJ)8B-_-TD&?Y%-%& M.H@36QZLWVM:%["FK'G!Y<+(RC32A_3XNM22%MC3:"FZL!Z3NY&7%^XZZ&,=EY9%ZQS2/?)L)/;B7Q%7-MF8?I$9 MY[K@7;_:^EN^3GB"I@CR=C.R3E,IP73W<$L!+8=#/NS=>OE": M*O7.$%V2=()U[6S(ZLIG*>5#=-<<$?T,-P5')7ZYN-#L/%;,T&'QGC:M!DNP MY<6E70&$L/VZVK@%-AD5<>U[TQ&[\%Z6+_4#B9?8E_:OV3IV M[>5*N7R"ZRF0L)'*>%NYKOZ[]=W)FZ3;ZC1<>)1@P^'7(DF1-T[D3F%+4V#A['WOCQ<<6.@]_^/B-'K5^_/"Q1G.>J_H5R>O>N>O+Q!M M6&]2?FZDQ.C*.!_.^ED2A+.1/FDGAX3T,3_\6@-;++I;(07$\O*Z%)&*TMX\ MXP@"FKVU&='U;0N/<)T!"79C6Z;QU9!=%E<3$^5M?4P&'T%MTF91::/)).DG M(GX4],&W-]GGG-%O#1DZ[&#V4$@L4G"&9D:2V,^HBL-7L@PGJ++H.,YB=DJN4Q2,!SOSNIA MK:)V[')=&B%WNC+74F%6*M^RV MHU>NW)^K/K7,:8$2[-TO:&]6W)S"248@TX]9?L5K22IIM)+65HZYD9ZG3Y23 MO$Y5C3WBFI8V'OWW6M-R[U(3%(2*-ZG!]M[4E:\H)YYFR\"75+ ^E6!6NZK0 MUF;A4RR1K-50IZ[^2@0&V5&59A%$1D' M:48RR 63%REB;XGJ=G@ER/C?!6C M#ZNR]:BA':;YS-E/ M-BR*&EO2$#.F//0GES]+FADQ^4Y$(I/M0CRLSC*#8X>[%911%@NYD MCE,@!1F7F@ATFM3YPEG'1$SP\W%=H.@V:_>1.@9GEB37P(YK1AV-JT MQ$-CAH:R&E3:T80B\-%2&E:S /D_DNRR%VN9T2$M_Q)V9.CTQD&.DSZ75 )& ML9#_M.6H-1?TAG7C/A?+X5DU$\3C4(M$3FR+?$@X@TT4#6S=?%+7QYF3DNQ] MHJ+H0V"4AF84(-#BCWJ#LUP0B43QN&X<+K47.FQP7&CH+C63V3+J&U>J!@?V M^D>TM0RSKG5XM2.G\06Q6,GJ-Q7C#K#-.K L>. M1>EYAKIQD-WODM>48T:WJIKU<\7L@\,LN_"!+VO:HTJ?Y%X)M3_)E[?RPDZ0 M]+[>DMC ['*5"A'G[L^W3CD;@)]VQ9:K%;-RZ]NWZEAK(EO]O4Z(IJ8W?,(/ MOVD^3B]XT>XFWX)="]I+G\/I%:N4#$+4HNE ' -@)AU9JO)$_BWVP@94H%)\ M,9[(_K &H\/W!54ZYBA/H?5;9:ND=^ T ]HS8L%=&Y*&AQC5.Q7KSW9,D(*U M#EV.U@6O8-F_"A50)PCN.'-"SC_WE[),_[1JD#D6&(AY]HPDWR]-MZRN!OG;R[.W_S.@9B+MZ_^'.-^*BV!39/?7 MH*SP1"_S?;N=\H7> _W%W]ZVACN_HK3Z4N_P[MF+LZ.]L^.3W:.#[NY9[_G1 MR7[O^&!OK_=\Y^#P[#'5XK[]\/+T?11 0#TFM7;Z^MVKM_\\O6?HA/LORF%C M:$7V>4'&%A?$[W4[',5<619<(7*@:(.?DBDC D7=G<[.SHX"KAF+&F5_Y'92 M*+$I&4AP_ZO:FK'NS]'^WL'6WN'AH<1# M)!0TEYR*U?)ED,ZPZR/=[PR>$P8TM3]N+YO!LF['_\^\EMR1 &'CB*Y,G_/ M<;4:TR_SY:ZNKK:GG-OP;LPV.56KQ@@ V$W^6R9U'AX)4:^-3"!QLF@/V$LG MFNL^A_E5EN;Q4!OV$V[GGR4>J;^7934K=Q3Q<)V32[MTHK_79,H:Q!"7_/WO M0F4G"OS=_L0Q'A"GH%)I\2;#81B4!B$>(:5#),71=,'RZ8]CA@EF_:NV>$0NY0 M*2L2+KG]]^)+9;/#?%"KV3U+>?('N2(P_N<"IRA?KO)?HFNRA9V5I62OJK)? MZ!F((= EO#=!\9?/A DN KWZH\=>MILG<9II:9>%:<@87-DW4<+U<:!8@A7" M]4$^O8ED&DZ$'T.7!ZI T&T[6JN^VNLM[<>21#Z\>Q+9-O@]V]O=>_'\^/3X M^=G!T?.3WNF+,_JAUSTXZ!V]Z!ZTG8HGDGU^:/_F_?G%?T=GO9,/;]^OX"4\ MD-6P3,%#86EE!2@.T,>^35Z@'8%R!QSI09'T(05,FDO/&PK1-'*\ )]*5C@C M'W%!<4M.M#J: I@%$^+1E"Z.8;%0Q$C US+$0"PN,6',4HNV M#-2>K33//W*W=Q G:;?@7:GR7%@[U_>EI;E"2M2WP_!0*VCBPK#HYV(GSB%X M@*@R5'QQ.@>H-(M8D=IE$$2&XJ\S"U@KN=X^5_YH6::BS5]*FAIFL>J^MB%> MV#SA\EM4>#J^0BX$XX^-N+NB:9CYJ2?Z(5N7@V?4&0"1\$ZM)Y(_Z2P53A=+ M^:I](=Q 8WC2X)*MPV8"G)=-0%Y%(,V;=RH+3L8*>!?_K&;2O5@2&M M19NA5F/'F"\C521!ADKQ=:4OH"KBH6!Z:89,. 4%>T2Y^>"COG5H@!BN<6&V MEOG7@")735Y81IT+M!?(C7,\:RR8EHC4/VUC+',E/;W.W#RY'%A'ME?D+V)D MODV3729%+DE;B8M+27#IOUJY4NK"C&%_JUG4ON+U.2MN'W'1&3(-CK7WCJ?Q M!,D^E[/ U7\PGV(%L*'U5BC>"-)5H&N7KZ+C&_,1RW]DYX#+ LR MB5*JS%8D'6WN2PGC%'AZ+JCM'U9B])\F798]AIQV0.&QD^$2;RC5IEOIYT/' MZK2@3O@W^IF^+A[\XE(@"8W*CU$$P5[47)"#VBLZBCGJ:+090H6LB9V2T\^J M,W.6C)"30:\$V?@G* +#!WO\%:FA":_I68<'65 M"YZ182 RJ1 EP9(P C%7W202OY8'N(NRZ[:7>+.+$P#3PN C^GPA,10KZ!DT M7RC5=%Y/B)9+2HLSAV,ME=%8 ?@JM%2M5><@ .P>S*-L]6:YBC5; M$@J;D)_GZU+-098GBN(!@:-^@ GIEN6N M_B4>YC/+KGI1D;.N6H:PRBQH*9^,G0QSD:N&\*6 M!P<6@GIJAIXX/"JI-;C)44&@F/P[J;*7!RX#1Q604A4MD)6%>XA]#YH-XLM< M!T301]F1@96>IAV/K5^C8)FD96V6F\B6UFV,WQ?OVJMTW\K,F)D+E4#DD+ I MO38W*]BTSML-%_)5\B2GA7D^V: M1^^306[AJ18.VPJ X:KYOV>'/ZXJP958J[SB&E1>DY4Y*-Z*I"5X(<.X'1$! M4=,6G&5_B3A031109!( M7'\\AFE2F84WKYY%_5MW9_M JK[S;.4,*GBKD3U=\4F'!W>Y4[G/UMET[,6N M^.#/T<.*C^1@@(]+:,&S#I$P,D4V<"/G/G*B$RI"2*LRE)9V-&PP*(=W#U>[ M\24;"&_.$EG\&)LZ"0Z=J];K2H $D[,MFWHS\GY")S=,^OD[R)I) :Z;DMTR9:R/35%I6][X " M,2I\V;2[GZ9Z)&(/LC%DZUB7X''SEEV=:QO6FA0(,!U^=BT>,HLSRZ-Q'1=$ M5B:84>DWPT?8-UZG%^X@MZ/32W1WV)A3>$]+/FZM8ZTWSM!":NLH[8OGGWN? MM6U+;,V9$Q#*2 _'8B?8?D9URVTO@YL1! Z0"CJ2\>A58-'T=E#EW@''=FQ4 MPZ-TP_<7& G;;9BPZ:&XWK;QY^)#[_W_>O?JCPMG>N.+8N+;3<%C5ASPYJ"< MU@8:JW9("NS&QIXS?/7#TL7\!QK*W6)!(29-*%MI[NLS!35\[>'UA@->+\7C,^"G3<0(0E-T= MNC*)#75 !?\59SPCK'O0X;^*UWV6YD4RC-O^O8N/2%B)IZ3:"($E*76V@[#8 M2X@!BVE^(\I0G1>79)4:)/ M12K[^9@E(A;U,N=JZ;-NZH^I6[+H85G1;D\BQ-=?(RT4BK2V>R5EP]Y!XOY0 M_$&%O$PWX'H B+;I3#;N(UGAK,)@/J,?V8#QC&&"Q^8V-"S-=^ [P$-)K1(F MY?G C'HM)@VDOI;6.'\>!L <&N_:B,6;QJ2NC"04@VDW:J@$&!N!P>-[*0)W1:9- MP@SD9TGDL $[R4-L#?+6B6)\2.Z7W?F)1%I9IC$2?.%# R2?V8X1@WTI?!7B M5_V%09?B8;!TEKAM(9Z#G>*,Y:?YE0DVX>!*'#U*1(J'GF,#_I#P7M'[_ U( M8L4+CVT>WI40NF]M1_C/>E>?-N)=Y8QDI4W>E()?$,S><[U&8'=[=ZVK"UW$ M)30A&EKNBNZ?7.+:=D)9MX+.M68$&W5TV)?@ 5^JP%+E?OXC+:Q%G):&[I/6 MKR<[3EC*0-5KCTN:D^(L,UI0D31)5$@G%N6.I^BKKV4$+(5]9O&>78ANB/GJ MC!4P1JFT*RCH:VTN23PL$)@'^IF.Q5ZTW67^$WX=G:!<4Y^I(X?M@IOL/O>L M)>:+U.@4DGY<1A77)A-\Z87CS6^94/AZG'E#>>ZB=IS/-*7LT5;+*XJ9'_"+ MVFN)"ND"I:5I3>W8F,,@HN'IMG1TQY5SC==9SG0Q%\,HT M6ID8!:L"V M6\RT;LCJ))EIN9-]: M(L/4. "8EMIX_/&K+--9$8Q$\D,9]^I*[1F\U20E: MZ._>@LE68K!UD+4]]AM02@9D/9[FQQD<]/I/)0>A1PVB8B!4GK1EKUPP#$JU M)1>RH#::L$R<4UVA$NT*L?8%""0.T=G"S0*!8HV1AMI! MR(,?X-$2.];1U/&>J# -,+Z$\]OO$T51J_V>9/)>=T]XJ;L5<2#]Q/NX"H"* M2) F%C8@F:J9:AQ.OWX9Q<$D'TOA3>$:-MKL&VU+I/XX]-_ 'OBCRVG'-L^< M/W_SSH$/+R$H_,N-[(,#@*,F8!QN&+2=:.G?0(8?.<'\ M=<9O%KPG39VX0Z'[FU7VUEA,0@@7";><_(3? \ R3+[%X4=^[H3C9\+93WX8 MJ4)P!2!38;V*C)I\Z]"WNCA*;:%8D2$0);,V_ M_A4=!U.>0CH4_0?MA\\:7H MH[0VV;_C8-,NF.A>%>AO5S4R,K1_*&@,R?'6>.-M0(JU'@.CYE2PM?(9R74' M@P.Z#132,K&G%XZ[%P,*+C:':$+MPE"7^A5<;8\1A&7YC#8)$;OH03FQ88U"+XHDGX<11EJ$ M4\^&,BU//"@+R(;^"*)$8']"%2MH74>_S_W8XIAS"$"3Y!*WVXY^3RX5*I%';CRT#@ M*IZ'S(H;V;:&X!UVBV\_NTJF/1ZA-?01B[ <@2=3\CKR0. O [_CL18\!=2' M'P)Y=VWFP0DM%JP!0\ED*F $VJ%XZT3OYZ.0 +RZ#32&@T/449(2*^%FG$O@ M' -)EA3"+)/&6+ RFQ?;@+B3R#GJ M&8I"RS,L6I?N3^5MQY7XFT\Q<7=?ZO@DSE4IAI#$0,?JIC<",[K5IQ!<"9,% MP6$31:+N1ZQ!6^R2SG4P7-.\4E/V:#.949#!.H F#YQ(K M)#Y\;_7ZW>.#[>.5:V:MH@YJ7+\Y&!-\((9N1A=9(*HX M9J$6% ?:5SVPP]4/K-.*I6-]9+2G7,;.<[C7\$C5@-,1LB9K56K_[=GVP2[( MT%FF@47[V:W>I>B\N[V_.G9?[-J:Q./_6W?[V<'7@].Z0XWQ-7W_R\PJU^]_ MEQFIX;I6'#EXL/M-1@X>/^61@Q 0DODGZ@WC>'[&76.^=2=:LJ-O.HAR0Q7W M3Q6!=0$"8>#L=&XQ(D@DUSS%;J0BPT6.-[3Q]&FCSEP)[2RN,)3/T8D&@LA= MTR#_1EI\#Q1AFMQ.(-JKINZ)##O5F(+Z-&/INKC^P M6J4D+^BVX/)*/_Q:,L$8&XZ99QOB>/K$$81> >;'/J\,P+$&"P\$(LLVX2%/ M03D(MR?;CE1;ICLV:"5EC<6-J1LB^@Z(J&'IACT5BB!S"02JN&;)PJ@Y;7<".'@,&XYI5]5F;ICX))]?Q8\%EWG,SJ6\@0HIZM89YSE33Z:-)GD>8!0 M'0*TM%H@'>\$"-^M5D%+OURD#7_9*)P1T;X6&8HT&'B*(!UFY\8 716U>PS8 MW[AFO[4OW#9P\+FNS[8MV(Z&H($F:0YUT7FD_M$Z?$>ZB,XUD=4O;45'6'1U MS5.7K5,>Z/NDI!=78P>-OB$9RQ#>!$HR4.>((3A<=W_=V39*NPI;41UF\5WM M:[.0/ZS^OF($D;\XH^=1:H/EP+W%/* Y]@"YSX.H?!L GU)\R77B05LP&OD' M$PPR ,$QII0DDZ6Y+5RE$/!4^QJF.LA5U8(^:T1" Q6ZKXD+$-.7 J@4^-I MZ7+G'O2R++0\*/P7ZO#&+) ;[2M6U M%U3J&PE672V,($#:RL%"= TEK+75N M)+1162R3$F2&@E:LM^9*!TU$ESQDW>+'+'0:OZ$[4C3WW1U!#/R: YE7D\XO M0S6T"(ANH2?H;Z5':6WN]!U1"C)@E<56(&TXQK 3:4^V!U%:C+$+;D!.O_0] MNH AVR7:ZCF\Q+1 !GU84A2JLQ]S@ /J*@/=$@7*)1SF8K_=ZH%O &GCR7:B MMYO0W?$@UUR/G3=1K>DD@:M-S*M[?BOM1HS\3:?KX, 9G2B-=6!O61QM M+3W;CLAH244M\S[H%_;!'WBH!GEDS M+B37Q T)GH]"B'0)%_%13WDOOB6,S&M;_;^D1E@X.614/I4&%8#E6R-]EHQ3 M$;"F7&1MY2='.BI&*UKP(I$>7*QI-*2.-HL! \*43;:Q+$$W2F9A- ">3"&; M1LFM*B'2#D#"B64V/5$8=\O8KPI.HQ?T[H+YU.W'U4.Q>R"6(/;+= (]?O,R M5^7TWOB!1)>LQF'B:!<./VH22Y)[Y '=!:2Q*Z@N#'L54O9,KDQG8@0#(N4( M]2#763[>2(\LAQ-.4Z,'I\3'"7I ^QGC>K!?GI^Y%NS")--^30X6&P5@3):N MKO%/\GNX\ MKM1W=BS@2+@F#+ZIZ$Y&(1B=EHC3>SK^RWR# 0QN%0*7TT=-JT,(NV148+11 M,1HM3];1$8_R^&A&^BDO;>-M4)Z.03D*UJ_-UA@4U]H4$$[*DB=+L=IB\L9[ M_1\Z88D,WN%NS5,ZOC#1,4;P:ZN>V4"6:_%N\MH"U;+F:W9O'.Y98F.29AUH=#Z;CC<('YD) MPB_W 2H$J[[%TOF6I7_EQ^LIO;62W>.=QE*(B].8)P):@!DM75X470UY1!J= M6=?*)<^D"*Y400T;L9(.I'L$\<)OBO&3+<(Z+0TY ;6] (%8C"@QH&L&?4\J MLY4FEV81-.I:G+MF"_62/KFU.4*@@O_+>0#+>RSJ%W M3C0RJY$^+QRZ[&8T6 M"YJ%!2Q5"F(S6"5X3Q.,[P7WI@'SI&5 M.K0,F5I@B@&1?A:A[% M^BC5'WX["]0=P+/(6F$S9TO"63R(8T$(?YD/)8XH'U;G2KG#9GL"CZ7P#$ ;\Q":EF1X0>K1>P;V+JG%LI6^?.=IQ_>]D#=P&,F,3W% M@9^AR<.(*HT5+A4F'1\>S0C1"8MT=U9!\O$:H:38GZ4.T9,&CGZJGH1^EAQK3>2% M#Y*%63'%VFR)F/JL9+H#Y]_=[,M$);&B$=TDMBQ/X@[CSV&*"N!-I6G"8=EP MLLOAU:6"5F#*[+\M[3L%+M.FK)U]O5FWB"91+0Q@=#/6"]'-R\8QZNV&8T0: M-:(<3(TL&&E4:O95H$A,+$D#S;8J9; M<&O4ROC<1[[@+'[)9UD;+74SUX]!?8K2ST5U5WSZB=[&TXFOP@.Y!O_*3;)? MF_WSG'$[JZ@!\VM2)WHE/Y',."VA&3.K#X?.Y#'N*-J'9(=728"5,R>^O85^ MF1G&O@.NBQ]:7:J<1H'(X8'H$(E3YHSN7/0V=G96=4&6G*2NM2[(--T5P?R:0PT]:?&HOF:JV=]S!)O*$-@6K.3 M7>84 YM94XC8U,DH]/70E0I1L]=\@O>-Q.;Z! UN7$CB63X8X_>:H3-),* K MERW8TA5$ 56B.=_+)]P"\.YE%S7+2SN-+RA):U[.^ARAX-*"IBWDL?JG?"(J M]<5X\3W,4W]R9?03/JT9T^!(;>:4P>/%NPF5 /(8&_5L.+K8CLK[5*K. MDB$O*DS48A4DBMKA')]N"_ MV1E,.NF2*"=-35B]ZF;^) KN'4IP+H5QZ1N=TD=\BQ'20PGB<+6'>KZEP[=D M\WQJ1W"V<&D:(H7%A@56I2N=YER>(XG8ID22.ACQG:4281B,UL3O82>A'D7T M$'?Y 6F,"ZZ$1\3)^H^\"!/)8&-2&UH19:N$ F,NH-(I9I]5IL&);:;KA#ZZ M%M*$8^,$R%;T$L(6<9;EJ [B/[(16O(8T\*.E%@<_ZTCH5+#%9SM8^TX<6PG M;'B)')Z^7Y,M:!6AI2#*N&H&LY]G,=J@;(C55R6&-GY+:@;"3>O(R.U>F8/+[-#)=L4+[)(00\,2_X9>.8"W;YJAF*3P:^ MC!@NWHZR$>*PU:$+)+AL.N>B^'LTA0F[.YO"A*]C:GYP[D1AMIQ?\8*% 4H_ M,QES1IH5.O$Y*^@/J M['+,GN54D0< A9,$TY-@LEYH;[+>LG-'R\#D MS(82$$?DNO#?%+,CDTG@(^G<09#DXODN,Q9'-$,?OXRO. MB^ DQGVL<_?^PRXO2:-?6K-V$ /J1+@#1$?$J&6734J'47%]Q]"R)XU<=?OR MXUDU$+5S/R>R,"B-B[6[SUQ8RI:CUEGFS&"ZZY8,(64A90$NB?59D0/&ER)2 M%HQX<-\ ,C$0U=KG),$+<584LHH>/[?36-S8R$!C<=XCA,,7]24BR/=FM%19 M(4ET:5M;-D-.1NJN,@GA6X>=&I*Y@<=.AR^P/PT\=JVC6$1B=[4=.K]:&CSH M9%.\"-U9,(NV6ASG@3^9]1SD3[2;D&-9[VDW$M\W:&!7R H9T?5I?MX>H"+R[<2\P]PT12L2K( M^ZW#D9TZX":H^N<1ZCJ;FRS J43.9;E.\ 79U,6O$N7&&"-2>M>MN0R=?2L6 MF*^@:/3B+!Q0$,+O&VXX2*QEQ-5 K1X 'EA GOA8GF_MPCAX(IDPV5R'NKE) M7-]O)2ZG(WVD81H,#/>#NO$O>._7\F9<;6D A7G)E0GQ==G6L'W(5P>PYN)>8JN;65T/E[W)5Q+TPQXD5QVF MW"+B:K%SE7;H'_1-,TG?G(INI'?_-&V)1:*AR&.=?^69L=W#TM8X>]6OCCX$R=O2$6J/&-.,\K:ULNEZ@NCG'_/5?U?74R!HSD!TEV+0,5%WH MAGY54V[9(? JU<,CND1/ECIY_CAL^ZO."A19*",PIN3S^;I1F.!57=@,"!:N MSUP9">-!DUZJ$#6B*7'IT365/EXF=7BT.H9U S8D&]/YG",\9.U63*N,FN"X*M%R6_GIA-^ MI4[89?Q\CLZXP:)^N$_8U$L^>JW$Z]6@911,"Y]H&9+*-#+9H?_"3;D)IW)0 MK?S-1JC=NHG5!K>LDI,0< .?"#5E?GRXK]>4:MDD!C5;M-%&#;7YPAPYC]FQ9"K>VMP>ZQLG)7AKMSA< M5C$82R?6""?^X+VA-+K1D]T,!#;8V\/M+)MIA[&PX5Q1#8RJTS_-LZ12D6+) M"-E% =*"=% BPYG_:11Y5EW8!G2 )D[RUEF(1^(VS _ITR/-9?!;S9_92LS, M%]+.P\2Z'T9-@H/E0P 2T'2-%.J&QU]*H3F7GS),S4"VV!A V@G*JP/. FP> M JEXY"5I[*FQ&5;HZ"23@FH!$>)/T3L=Q6?:M-)4]AA1:)U(TCY@U.7-$]RO MR.(8@TMSKIV5X@L["=B:E);WO'4*5JGD%E3U.[-ZJ%V% 829@Q.^Q'S/ZBHO M/MIT=AM2F$4]8&=:FL$+QVHAAAQ3W.;4&HZA:&9,EJ'!/;LX#M! M )8D9R0G6 :VL*^_%6_O&QH%+F.13VS@297]J_LQE-I=?BQ5YV(R@A92UK3EN21Y,K.^=(!D:"(,@BP ML$A6Q?SX]VQW 4AM(&6!%+*[,FT2!"[N/?ORG#BZQ1@66,TL=R3.9\$ MK8J0< 3GQCEXA2="W@J]6G64D)VZL@H[S9#!&1H.HTAP]@A3120;%FT*=O6M M1Q09$+I%Q)GD7%Y#X9%8-3Q?J.HXS-B"1'.8'T+VD^K8E:$*>%2SU%JF<)U& MR1H+EM?83QCTV$O(UVOD$C28ZN?(IABW*O)LZ2.F+KQ2%7!P2T-,X_865I,5 M-F^=$\;M.F&\FI 'D9VNC5!A"8O.YA""8T.A2'&49<10G6V@2:B^+E=%#%F*%).L%38@T MRI=C5A0SM//2EE>S1JM^ZK5!'!1XZG2XV=)#2YFP7%WY9=,T1Q2G3&1I+W MN<6)EUQ)I)2A0*?:B*2+T/7(9@@301O$-\*BG\Q3I7?JAK1 2_8V'KH/=66- MJ27KZ@XA.=E[N]9H>-2-BU2;I%R21[XR5QP)SBHGM_@FU!Q&WUF; '=V'=H$ M0A.3I=-F!]RN #L>(D82T2NY,CPFB'>;'!?]<-O 0=8CLY(M5W:,X!N=C61& MT6?.GMJ=6KDJ/N3P_)6?2CT8_@;S-9FVN_/GPS4 MK.NVM9XEZG/XTX,Q(GM M?(A##RR;J*:-:&SA/-K!,M5]S4;97$FT-:^S1IP5:\K[$>$Q$@R>#&4PPSP0 M+(Z/ )T,LK/ R.9/GQH*P0/1DS)S\,7:]Q.DR#7;8E2=*1$D\.BM#$C#M)XA5[%2U,54H5F'*#6*,@ MDI&J<#A);2IX @F8YIZASA'8 5CESCVB:ABVP1 EA%GE4=*AG\2M6/%?1)/WVRD'XX#G2/+$R&*&I3[KLQ$!M.=T 7Q7[9<4$46>0=\ MZF%$T4^FA*?KAH\V$&H)\5#31,[G], CO[&\+0T"S+%._)-J&Y/"YD0P)*G@ M5*:P<=VO@=%SC2"<+PN-'%WI8-6LF2 (5*HUF="PIL.(T:MN^.N._:5RF,U$4ZP;TR;Y%[FLI,FUH$ M_7Y-9R] &KF>Z&B$O3T41^!8W_VA[USIKL2_5'Q#3[NWR(_#.'/(RW/(<,@] M^&:$R8E;"]PJ*K?P?J#N$;!264Y/";CDTX#4[L6$51VK\ZF9LAB5MZ@2.SQF M-W*29V':0L& X@,UR7EB3?FYKYHAT"CEGW('K6J=S5L+U6^/^BIY,!6/4K9Z M3C10P)3"D]D,MG/A]FD O@7;=T3H!_Z4#6CX;\/ $=K9;0,&!BFT.0L +'NC&&M8><6#1 MQB.T>85P85-9WE3/)UHPTY;-Q*17O]$8&E; W70141N)VC)=(I-PE-NJ238H M(A;I-"PG2O]DR%-1J8 8XPT45Z#6"G/6Z@C(D;)YALS_X21"Q$JV5K(KY>^: M^!\!AX:.F:-I O5$15A]8_?*&/O"-J0XO&BGJGG!3 $Y>/><>\T8N(@.BA6K M>O,4L%Z!NX#D9>M8NXZE!RJ6R=/ZA4Q8U0WMB@]3">F'1E\^W$H-4E!LJ"*/BKI$7>-?,/P;-AW!*N$I+B4\4#8R2B+7O:$M1 M&NC-%]:8@3I,.OX4$1484EUG,UD*27%JH>K2BD$6LP-X#R3CB')-[#6A'D2\ MM*;SC>)@EC/EPKF$/'HAD=;:.P(B^H'"ED,:,UW4S7^$EYD4(T_:@PB M^7C5 Z5A)]I)5TR@1$+@SN.K KEJEN"8X4!_Q ML>I"-P!E-;ICCE5T&"V6L!QUL>V/(7;[IEQ"B^:)ZEV]9]\8CS_1/ 0VV!>? M:9$I6ZA>XQ;"X\@DG+.Z]"T?9C:X\S% M$ T43E&KH@9E"C:<_<_'7XG8S(B03( (LC2IS9A3@SBUN!^$("<]XRG],_(Q M9"3'8,*':EL+D%<-O?$<%\/SL!HQ+DW?EBYCNC6MDBS2<8%4J&"G:)D T.K2 MZJ T"B6B8X!#GR4$7X3E&&*$+'B(V&=6$AJ+D,-$#Q/:CZ9@7]VR5P2[\37S M8M (Y_XP:CI,R(MNFR?@+-2(CP_1,I>B%@E92C4X6F0Y,_G.*7L.%R4C<+3?RC<(< =X99"]253"?$ZS$!OF?X>2GV;K%['8&./S G:==7=Q],L1VPUF-XB M57E[$1%_7WA#@G4H$K-:>9GPV\],#OTY7PFK(A8X6 <]&0&,'>9&5NG-9!(C MK$46AHN;KW-AG%SI(GOR5HYJ0J($<$ M%C,:ADKXJ*RB/3X)@WL$@TE#@+"/ZV=K@^K$;I\<3GA QK&Q;446V<>4D*OH M&/MZ*WZ4#RM8\>]' ,36=\=Y.ZU8<&$S%;/P.#60H]@;M6#;G)'BV>I9I=2 VY^P.?>Q>$% M%ZC8:\[GK>X:BA >.'@+*8(;?W3U!/GLRBV=ZS)9$:(91RU7@G]PWPM2$?"* MH!#:.]O+8"'D^EP0L<>"72^V=,V-B"D]!Z*[[!P(95^-(XS/8_5]+ C:C *P MAX:+BZ0)E(R4B3(:70-5@F-<>86HNK!SJ2')E%QD6MT2@V+RL9=O@-09)"S5 MU4@H:!.!^KH!><@ V,7R:TJ,,6[7C(P\FE!E?\SG]&*L(:7HO1N!S,!_6L&59.YK7IBFO/JJ1-SQ8[L&'BL^7'47&* M?W.-/L?A3'QFTV0S@1=5D;Q3H*-2#QK&M?B7JZ8T(/MRCUQ M9G6IR9"FLZ,CW]#U?-BT3J.MU45SO(#YB;U<;EROSZHF+W2C21F;2IN 1"40 M(5S"E"ISN'%#[B/:*]\_D4E25["0;T4G/>7&N=3G_)U-/FENW<6Z,!D!8&KG M\H/,T=>^,VGPT&3">56Q2"$9,:('ED-L%B"K'0*JBPA $G=(2A4*?'*#+YYZ0/!ZO60(.] MW(0;KIF84O.1HA6B;,N;(*/K.F*RD0#N$.=#<_1K@1K+.X^*MJT91_G:?D(0 ML6*$? _ACX+0M[ .6,3+JYA?+NG^M0^:W7-2_4NNTD0E'NW;4 M$Z*.XGX.?X\(M7AP/)O&_>T1:+),K MM->2XF!&B,+@3F,+/VUKV)_);S>)_CR.(>A\^HQKS:UO9N$:A;DBUVPTW5TR:/ M;1V*/.JS)W0NS(GQ2U[-HU+=@N&=S+!4Q %%Q*5"=ON1V A)83H7E5EQK8^; MI!2T4QZG*P%@D,/IY%^9U,>"FAN-?3*]C'_1/5TBG#T\J&HAOV)_ST+K[/PSK6^085" M?[."!>Q)QU'HRG76&YM0WHT['***L$9A^@F&"R2^IW$S&KHPFFN)L(P)WI@P MD!AKD>!(JLUK.8]T09[/O04#B&JXQ'C'""NZMUSO!QXKLIIR]+D#UX(H\>(8 M*!R[U'#+N#5:M4-=^5$071,C:E\9/):9 (I-@9<1?(F2V Q4& 3&;S1G9Z&2 ME.$1[BR=9::_#$]Q2Z0&-7"3W9-XWG?*!GG,#<>?3K^BS8 )AL3N_0FHAU6@ M3:6V6NJ^>?(>]_SE.YP,[2OD+& H8::F8Z"(_;%RPQ[QBG$8 ?4JZ2F\2AJ( M9"W*N ;S,\I:85PJ\X.]92;.[Z8ZV2D"N+C#[\0,C$S&3<+6DW@RHY%Z3Y%1 M9A)73F"),E!AJX*OP3%^GG3UM@N,GNI#\L;IW+\.$XH/8&*P!/^'8:Q0_(X1 M8LGZ5YE&5*7J:A[PXF(8EB9LD Q=& %WS?0]0L+$ST;>5:J"CA;4D)5 JLX. MZ^H.C _&LXB8#F?4 JE/8'^Y=Q-D3G@GA>:8_9%""-H 'B#LARH]%&)@,7>) MU=F33F*L[&5^X+*+W&Y31M8M/KEQ?^L:;#96F2AYN/@:532?>Y I7Y+H.=]) M!HT;*M%"G= BU5X0:,%8 HJ%$HSEW:J]!9A'RJ2D<$:FS")F M,"^$?5TE,&D+5-]6_D!R.KP(BI';@P+>J+4>TYE, I7ZF"YY"9H/H,I[R+>*$)46RM1=8<:>P)+LHE>LF<85UXS:EUM W]-+SO MD+.FN8>RX:AOAR7Y8,ZK\.2)1'C8G49#'(.KDO/5XY,Q7*%GWR+^./8_ NVI M&+J"T"^L)MG+D3-MUV=-8JUVB(.,V#CA>6)N_-V9DOU(+LQJRJ!Z[66KH(CX MVIUMECR:)O/4Y:"B:J5:$#:UA$"72_PF;F:BADFA[ U$)#AB!JVN$ MFDC0QL*M60;F\M"^H&'AT@*7I5S+K2=IVM?EAI/,QXD(+W/(GDXB5?NV56F* M0C!;F<4".@3G?Z<*$A"&P[9#696I>BN$4,'[#_9+8$8B^5;'"SXY6!+[5 M.1I[LXQ[>%V<,Q-/JY>/S+5<+;32]<$QKDX14^?S\=>]/6T&_A&[T^G6%\\= M3K8^!7X UOD>5D"QAR%QT2#@UES"GTT\54780/IKJ .FF.F8"=C,_^--\*&A,"L4GR"9 MOSLF)*6+5H%[Y0#4$1QSJ)&#, $[HO8F7#^N6.$'$D(8&ZLH3/3\G(C[, IC M@A2\)[HE=)DWG(3<Q0V2*#=A,+7&\6I40PP&,$XR MO/((@ZRIQL;B2Q2I:$3*N:TA8SE3)6T@IH -4K')V8ZEB(A FA*"=QS!6^3; M4'*X75.&_?JM/%JL"M4RYL'LH>; M0(!*F6-N_$A)=T*68(_F?;O50A9[WV]A\P&5S.HKF2NS&5W0;O9SQFG^4NW/ MNHQQRMPU(^P"G'WBLL=,]9BP"2"7\3P)0G1(/$@!':->K=5BL@9;6F:!N7-Q M>IYY84*C'PIH RY:6>92+\)JPOD>1K>XCCNNS*>,DFB/Z(J1GRPQEI"0LY>% M=\\)50'J&,8T63RP5H2Q(Q)75P0WA%)12S'V1Q#O4,IGTA23EG?:6^?*''SS MC,KZT1#EWV+[@C=Q@[&9J@);0GL) G\?VRDXE^W>XE&,W*G+DTT8<9% 3-33 ME#\P]O+%NOE3X.>J4:H$M-MT_IS@ZO@K77$CDU-<#71.$H72,2S!8*-I_W/P M6@3-2FH(P3S@8[3\X346$G&#G'&C23!D$@6V2 MN0P-1EO3*'2JNF(RJOC2+27?[LW!YB%A>5QQ+GM)NGP":PIR-?:*XD%ZN@UM MUJJV4O8C\!2L41Z&\+1O::U$C4N3=)?MB6A\2:DB6&A^6RP(M-1PP%Z50/9B M/\MV<>TICTH8H:?*= X>M?C(5%6K+%(MC%7V7$C;Y)WI.0@_8DX#.X^5 ,O[ MC[$RQ6QS7H'9Y%/8S4:L5JZR1+)1 M/+8/%."UC(OS5&*(!"X=%_>]N=>H=%,==8JR="B3R,P,BK=8K_WN]T_>T"4' MQ&#!YJ$.YP,FII 5/Y;*-IU1MQ%3 Z/+3&R*B:Q@KR"4@4>7D5E"QI2A.%+UEJWC8I)/#Z23@0*1E.C$ M'D85C#FEI W1,@DA3,#@VQGQ0WN&-6B)]&C](V=8L4KA(T"##8U%8PJ#.1MD M/)UUY%VY,?=\IMX4JP(8)!2WP@T)=#1#=(>$BI.1-.9&M%@ESK8/:4 R),NE MMDML75.$8((N)IEL *ONQ$8EN3U/">KLYS0>&FV8H M^;LC?/<&KE)A3Y.(5_Q+)^B%E-U+*!V .\Y>IA&KN7"'+3"49,C5=& SE^G/ MU&AT%G0IGHD0JT8Q9PPTQA;_H&P'[!P$-F50/4)U_Y5[WQB<0@59Q@3[%WKH M/")?S<$?\F^DW:X!?O$PXA"IEL;45D=:D4I8+:Q GI8944Q7BWC6[>KJ.,R0!,: MA"9FO64/I-:A28M?BNB],O>-A ?S[QP--S2F<#1.!:)/J4>L(%I,^/!&.''V MVN@+T#9@7TB=4!&)WP)%S+&QG6VG#)S(:NE3%(PDVK$M,-4Y":\PCLPD<^EM M-F8_M6K^;!EQN;B/!@D4J^G%U=5CD2C6FL/+9 *9BR@9);+ B%!(E@H9$CW_ M^V]1E,N%VB:#5J)^P/H<;"*!]2*-?J<>3CQ8=I>_-2^:!8Z4@B \S<\9J 7G M0B2/XDF5@OC\^4*E()[V>'C>&996DX \#BFG#,3TA\28)A(M4183Y4,Y5"5; M8*)9RFJB.8<<2[N=1%3 A$XM26_PX,)K$!0FR*8@4;DOVLT$+OO*,X=OQH)I ME:M]?B,\)=;]+"*UG9IWO_^?S >"G#[Q#N]^5W,6\[UX^1IVZ9*[HB)* LS M[3&QFGRP+LUA [W&NR@T7:4H"KT^HE$H8DNSD#.:D'Q-4;W8'E)HR?&AEO?8 MIXX/("D\]@@MF<^4C2T5U<&* [&5J='GH%K4.W(ZE 6:95B M[UV8%]YD=/* $5/_R LL+4!5Y._*FUZYZ.C_Q4=?NM[$@.BI$*25SZ_: M*D7*8R!\9/MM"CN(4.Y4T*U8A5KP3-R5OUU9C:D(>67K*;L0G9A<4?3$!",K M/;/Z22&O(U-0@JTH/+4R/XL193WWH+E#,5!SJ7B)](*XBM.M;#:_4>LZ$N9" MO9$,6BMDL%UZ;5VT($H2Z]!P&!SD[B/S,0]"-?4;I*!HS]&/ZM"S@L!T_-@&XH;0F^0![R M5+LCR1VX!XS=!2<^%*?"--Y[Q5HS_9H*FR8T4ZJEO5U;.F?HE^C0G<2&C!]$ MO\6*VSR.+D\2X/1AIN%0O9%5 )U/7,*>4MP$-_ JD@8&])L5IS-(&&'_.5B: M@4 JY-,>O?[ M(\"U[S!8,K"8E":IE+_<4*.T:Y$80T:_H^&PYWE ^C$41-!Y(@9PUYM$) MI$@99.;U-04:E1/TB(3,E3);.BQ0+3E.H5V$"SA20T*Y6;7G()]'X%%%MY0R MIQ%**C-LOZ+ ,^DI&?2:/B=1Y': *GYH@%=#H$\NKA/I-+G\^[W/;-1H).^$$TCSL1$% M=(!C@7Q6I)X4 MDHT74LP#@A9C&5B :=5#\>GA!8ZJ^^6;FN[[&$>GJAB 6X]\Q1(,A+ 4H(R8_;2=:$AA)R;090-4:+,22HK*&P4 M/RF=7#97S'4L:?T+9W=?T*T/?W!:M>%<'.Y;28C%5D,-$//T:L(<[_S:YB+TV^WZF*V'OVI>F
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ϝ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Έ&6Y=62HC0;+C -ZO4A;"NV^,^C M/MN52FK787O<\]PP:2I^\Z&+PTBJ3V^IKL'&>8!\>6Y]*_YXCAR=CZ? 0&1 M 7**F%UL;1G1(8< ML3[HUO*ND#+%F11;/>N]C-%%/;1<_[?#T+"Y87=3P;3Q29;\V&52##=G#SF'_/! M//\TOKU;7-W\-E]#5]V$=T\-A\O[Y2J,H%EUOS1?G&F(L=/2424\Y%)Z[&C% M0"LQ36EJOP/OOY=226=X[2$\F(P'+:[]PS(A@AYPQ '%B#"8A->Y4@.8,)NT ML/([P%\'/$U8#.5Y ;'Y.HEJLEPU\-W4&3N HCK#,R* =M(*8;WG@G,GJ*PH M%UK&'!STZO*K931UP-MTAP>!]O%PD3_/%2XS@VL<(QPAGF23O0OB,LM"T660=E;/S^0P!S#$K6V(@3[!&C-A*L1(B>8P) MWKRHSGO!2ANL3'M(#K^/).K=N.OJ\F U_7]?WGJ^KG-2XM*\[1<"^,%P$:C&D1#J' M@ZE6<< ;%!/_T4M/OM/XCXZX?@;W;)4W, M%M7+&)'VQ;\?7W&\3HVH1S\KUAT)MJT)U.@_EVL[_WCIRB;39,8JQ\.^C9UA M''BBD:A.P<*?+FE 26+4G0R*/3CK@-\G'J;_DH_&PZ"IB_Q^O+S?KL\N\R^S M=3?"/8?AQP=FEFC@RQ+ @'#E,.#.5>8?I8(FW0*[MZ1;A$LG_$UF7@^'L^5T M,;\>/)8!#.59^G!8+(.?Y9,6(6X=,0IP+1Q3,KM_34%V,94MNGE MH74'BJD[=B<+JBQK#P86_'.\N#-!D\[N\V+[UAS'6YWAF;788*J)XX 2'5XX M0D!%.;,DINA$#P-1.H!9!UQ.9G'-IK=?\N+>YE\7J]#0AW'IDI:H/J%>@X@7SC,5$@_?RU+L+FZM#AJ>/A6JTB1X: MEE%0F@W04V&(=]0$DLF64A35K;N'9^(= *M%[I[O(*+1 40FC1:!*H&5\"XX MV=C(ZK:(\?#*)#T;[_Q(M$,'\&2>GF.[JW69LGM &2=(";&0"4VM865)QGJY3%H]T=5;? Y%8J>QU]M[;Q:<#HR,F.\O)FP5G'.RD!4#QC?OC6, MQ!R!]MWGZP97[3(\72K=3FNN%L2.CLT@XHA HPE&T$ 8?)'M_25#DB9-WD]J M(G4#L;89GC2NX!EWZ@<7[!R4&:@"!# X;(E@X>?(O+RE!(>=W7D+7):BF=$IMP@%/ M"JFA=I2598-M<$R!JZ@4"L< M>GA.T ',6N?Q^=R_1FY?QI&TTGH G'"$"AK>DY@ D_+4J0U^/R'LG%5IUT5] M[_)%&:SZB64Y(0QQXW6"IO2]%"*<0@0 &*OLSCV]!N>7@'+N^PITU [#_V:8GA M9SA%7"USKI:+NUDQ_E<^J@>PUZ,RHAQ4MNQHYRDP$O' T V=SJJHAB<]3!%( M!:M(-I\-3HU/I=\,RR0 0$,D2!D#8R0SR*J*4DS9Q<6%I(74Z9P^SPGU"=MA MO0FRH(ZEU%@@I8DQ7#.X:;T8J >$QN"LIX= '>*L$YZ?!W$-]L7# S-+ U&6 M*.VE*AMS>H1$1:UF4=Y7+T/_$R(LDM?G1-:'^7S9&%7K01E'W"# H"=!:PM) M%(*@HC(0GC3B_R(1=1*?SXFF>@;7D9$95I0KCX(Q8+%'RAKF646O<5&EN1H' MEUPDKDYG]MD.B;8\FE_=5-V8>M'":+N89N=";X9E2D'N&'?:*D3+_8,KC*D0 M!"*L;+U2F1U3N^IZ58>^=<-G)3R%MBSJ)36"!%! R(8B;A37*4]YDCKC$<)] M9;G>3^/Y[^K[^%! ZJ%AF53!-'=,>&^Y 41 @_6&4FFL MN+!N,Z>*>6\&831'TV.GRN7^$K[?SNX'XUUEL^L,RP34WF ?WC$DRH,$6Z; M;2BU!%V8WFE'Z'N1%,W?$PO)F,%D;$#&S5&!9??K!+; MC$468$.\H':S=$61O%AHQ$AQUA5[4^D8%]8V&I4Q&M6:GS44K5Z9^5Y;?3TX0/F'\-=#]M#;AS/. MN*) 01.\/@]IH(3"#55:4QYS3]I#%+5D!47S,14ZRE9\"-*:WJIA /TZON.X;]E\L@Q8+0$,KZ0++C\E1A&**JX8YV*J6/?[ M%OX$8,P2$!P5@@W!X MQ=E@M,9<7O0R<2@AA'L@KW3'%T]=GL+?)WF][E]-AF?6:(Z5A9X$TC'UCF"Q MH=R7.N'2E.UYX?/F(*1U":7"9F!749;&L/GZSP_3-QTX#A8,J#4^,U)0*30S M!I?>G<8$L(IV:**,R/IZ5*[1.^+XJ.[PIXZ1VY@ZHT!RY+D*EA+G$"K$ M7'7NY3T',?U>>ECMJ1>P/)/L4JG,OP_&TWG)R7Q^-77?2Z8MQ_.[]:5S2>D! M[7ET;##W03#U.>0>(X0)Q5ANSD(P$!;'./7U P1?[N1?_ARP[4I&*7%9+OMJ M6KY85S=Z.1]/\X/G2?N&9 1)H(5'D'EA#.1<2U%16/:53Q)4^*='80NB.7%7 M+ZNM!4)7?2:7P\6R",298&7<[O15CHS(@M6+O6".P&#V:FK*RI+5DHE&,=Y) M#^M4]0)&[8HDF0K;],$-QL&K=KD?[A\&X^+^<'7&.L,S[353Q&,#A2'&8FHH MJ"@/UD5,T;3&^<]_.D^E PFEPN:JI,D.GE1AAMM[K0, K3U'QJQ2WC*#!4"& M4HJ 4QL>0.)$3"$V^9?*/(C1KH1TOA/'+3&;.E U;GOJ3Y)I++@AT#&N!12, M*(EEQ06F=(Q"A> OC=KX\+$E09T/KH&E^?A;&7W2[&#\V;B,H[!Q2&"DETX! MSH3UOJ*5(A$3^57_NB;A@7@7,#B*M-,9?CYP71=Y,#1&U0G]IBUCL$>>-;MN MA+HZ$X:=PANFA0R[0LEE![BI=@I$+8SQIWMY/W,6.'8@B?/A]#]6J5@F2&"<1T@AL7SV%X84UWN@09HDD<#[E5Z=Q:2,56&?"C$M+ MF30*>.Z1]TY*82KN.*DOKBWC611A!Y(X'TX/=CYM!-"#,V6<4,TY\PI0)2$$ M7OCJP@D1Z6,*:O6RQL-9D-FF",ZJ.LNWZ5GDT>9-:ZHO=\^2*11(MI(RXZ$* ME@JA?!/&A+'C49MX#^]RSJ4B6V%^_S)H6LF>"ST$QRSBMC&4L) M8ISIQ@Y+]Q5LTV8]=".#,R/QP_1;/F\KE^O 9!F 5E',K-9.E#7(N?#5S15F M#EY<7]3N<[G:XW:RBDR#Q\W5@!K^UW)KVLU=2" =.7 9L,\'\U]8& 9-Q3< MJU\&9>3'XO'JIBD0F\Z5.6M4L)++)D5$0XN)PQ5/".<^IGQF+]5?2E!V+(RS M:<= 6# O%H_7D\%T$:@JJ^8_' FCJ#]))K ->Y&@)AA"V'FJO:ZLRM.,5@\(;E5_=?)@&SS+\\\/T\_+K?#P:#XIU>P=U MC(,0Z^K-IM-F#GH"K/0$"NEU63=#5,<,1(2MYK+.R,^D0#N62FI=ZF?%<^I6 MMYT[6%A#H=:<*>/06 "!IXIP1RQ &I&*'XR[& _\U"2%B\%IIZ+HGR/>B@.> M2:.1(XI:8I!AAAKL7,4%HU1,#%H/6V,EA&-G,C@S$K?I9FT<"1V8+!/>AMV" M!).;(QT\1J99Q7A*C(P)Y.UE=$7W1T+M<3L5!C_E#QNM?G5C9N'5*19EW/N1 M7,$#HS(HB/)"08<#N48ZLVK/L:83<96F:%3J_*PN\?"FQV1;O#\Q5F=%Z& \ M"F; YWRQF%0UC5=KF9=)M0\',J=KCLX@L(@)YQT BF!OJ&.5\4"9CXJ2/34L M\2)@U)T,SN$;UU=9!T9EBA(=K ^#G U0+WTH6<4>48*4KJAE" M,?6(^UNW@3TVPU9@I8XPX%'P@2[PV DO-%*_XH8V/Z9W8O"3"Q6*P?4GT[U*J MEK+7V6P MUK?!I'R?5@7#QL-@;Y<_4-/1RP^>/7F=%^/9Z&T&RW"R+-N:NN_!=9K>YI^" M[>YN;O*#=ZMI%Y)A*B$)EK4(VY/D5F'F424-B:,J'#8/M.K\C6CQ5K;7VVY]P9:K!&OCL,XM";&HVI\$OFPDG3 7;'X4R"[(?/_W$ % M3 +EG+/("VL)%$\U3#DE:7O6KX'JIMU&$/8&ILU8GPJFGY*QN6!P9(&-7 M96V_W.5KT^( 4FJ,RE85^((FIT*59()@$>5H]TF[M"KAMP41 MXMB:#BSKS)$Z2'GQ9"8(4YYZSKP3EF%ML*JJ;XLRJC!)W-V[ATD,3U/:WZ5: MW=1B?XJ;GXYVG!&5/5(FL_FRR&M8/+%39U(+;#4*=I\/7((D,*ZZQ!;(1 41 M][(2>LLV>$+>)SN7GBWR>7EEF(_@ >0]?RR3QA$+$4224XL5)$Q6E$CM=-+^ MQ=V;3.D$__J@^72>GVAA/_M&/Q@7_QA,EOE3Z>O79WA[#.YFDV0 "R>P9UQ( MKI ,SJJJ"AQ)BD7,Q5D/6ZTG!U/G$DFEJ%Z48%>CT;@4]F!2V@(?IIO*7*]B MH5=EW;;!]SXOJR<<*HK6UE=DB &A$%.66^;+DDF85C&Q$GH>XU/VL%S5V13D MF>25[(2LC#L\OC4_?RSC5%D7K!BJA/> M@3U%I%YOPE3G0;VOTXU&:N&FHZN;M;NU[SRL_@P99@(Z* 1'X2^$6$%T=0HD M)<+DLN+.]U!3I8;/V\;T&?#!BBD[BSHE'&"* [8U:2"4,2TV>Q@@ MV*+7>P;NGZ@97YNQXV !%,5C^<[>E^6G9S=[.WTT&9XY19W#6# 5OEY@[36M M"ALI3&%,[D\/G=^T\C]0[+XE>9P(KJHUYVP:U/[#;+ZR-&L ME0H;XAE4#F*V-3Z5\CXF>+F'#O#9 -6Z)$Z$THMOKUJ\?BD&TWF@+'QH9O.] M2JK6V,QBA0#G7 **G!:4&EUQ1Q,75:KIU )XW?L 9\-5%S)I$UI/';M*INGE M8UXT0=>.X5FP.B' % "-G/7*6(*K #W-"4R3:3R"]IL3JZHIXP0 M8P00'&A.GP*IM?(JIFI)T\P.ULR"N91FC8&(B@'J8?)."_YA M]UQ.I:;L=J5/R'_Z['"0Q]&QF78,0Z>X959)SDPP JJ\7@THB#EXZ)&WV"D: M9MWR_ EG_^/G-^P.+\COJQ_M_,EFGCFLPR^MY+9G:3W]%P& MG3-A\V5(\8!((05QK*+'!M(N0P%T+NVW.7@G\SC5QK)*4-WS8H?U7]U\&7R_ MGA4KH2X6Q?CKL7J&N]62]^0&0 9A09JS) %&G -S89_A& <8_[T M\ 0J%4;/(YUSH_NW:1'VO?&_\M%_S"9E@M\S?V+;J4(5X^!4W*[C0]>76SJ_ MF15E"/ )>(_^SLQ[;ZB$6D DK!68,2 K'GOK8[*3>JBEDR.SYIN16H[O]5U) M^Y:4?-685:: MHH9ZYIC3!'@&*SHEUVDK*JQWMQF+1IWAI^>K;SHS43MXNJX"6<=]U0*Y:PGUG/.J:A5X*+C,[(O1WIMOWPP\U)8:0 C!%C& MC# @@'5-D2#&Q%S/]]#7B);KFY#;"&:>J/CGQ>(9+,*_7D,B?%1>VHV6P\55 M\3DOOHV'N?H^WG5*N._1C)6.BL!<*L"LTY!)0"I*'#07EE1UJAAGK7(Q 1[* MV]G- N=V=A\,]L.@>/M\)JA2!D,I@"2$?]+?O]U9Z#.D1$9]BHP"%'@PSLD$'$8L8H^9LB%7#BV M).-9%SQ-A9DO^?!N.IO,;A\WY!_%S)X1F4.>"JP8U@)R[8QP3&_HDXA$=E.-YAIAZ?I4LI>1W[4L5NW#V<$$V@!$D9SJZ271!!<4:4\B"DWUR.DM&2D MM,;'5.CXE'_+I\M:63FO'\UT\)$ULY8R9+C6F(&R ]&:(LU$4O/U3)4E:@OU M35> *%ZFR_-:[8ES-RBF^9'J-V^>S7Q)DZ/.6TV#?A5.P,'!9NTDT)KIC;:LH^3 MDV(+G^>GH.3-Z$Q@RHT5&@K*:1D;Z&%E MF:G@#<9HCAYV$>P0);&L35=D+:RS[&!2F>C[<71L2.8H#V^"0\%N X)"H)&L MS' E#8NYQNMAJDIKVTY+_$Q=EB^X=79<5N6?CM;GSINKD.GM0>P<&YQ)ZAEU M4 O.RUA#S#'>OB= H*1U$%(8MRWBJ&7>IG:%:KA &5<40V^9419A!$18.]R^ M$SZJ@FSCTM;=7\JVAHT3^9?N\GZ^.B=RWQ_RZ;R64[QO2(:Q! YBPBV#-/B' M&+J*11K"J)H!O2K^V8%SW!)/4Z+FZN;OL]GH^1GCY]ED5SF>XX,R#:@"BAA( MH>/&$89$=?2LE=,7P,-@K3\%V@>'?,??(/72D6Y-_*]SLZ(1EOUIH,#J##)" 4$-( M4(-4*^B9V:I"[V.Z2_?026X5&-VP.%WN$4GDS!MH8;W Z7V69O.40XD+X>+5;K!OMI%^Q_.A UD M>8T,X4PI;+T'8D.5T4[&W"@W=Y[?'V"B.9K,L TV^!_C26D^?0BBFMZ6%7E7 M)=P^W#\,QL7]X72..L,S+P32!C" @_6EA64<5B:]H2YMHZ=WB*4.>'RNPYH& MAS09AQ9 :#A@EFAK';;^$*#B(O)J6C>E+[[8MU=N-@1_'R/U:@@P\ S8C'E MSD,NO:?5D;4AEL;<6_?0D6KQ,*\ECB;+3JPN*6K5_=CQ=.8QMA@3ZB$BB@C! M!9<571BBF*N!]]%R^%2DQ#,S:0KK-CVMP6W!X8%9P#V@%F#CD#=4P11JUQ.A:E3X+2?1@4P<@Q0I8@&06-[PJK@5 NY3V,9ORH]G:9X0OMP:HO+ MZ;:PRE(KZ]::V30L?!G6_I2.OJ[3\ZS9ZR_CZ:P8+QZ?A0F]G*5L8[YX_"5? MW,U&ZWXLJQSW@]MCLE5DGC*%)?9..(PTMAG=@0XM#$L9<^O?P=+-%<,2P,14DRJR@H#;GUWGQ^6Y0 MJX7TOB&9$,Z7J412:>"P%@3!"O2.4QD3H]BX1=8[TR,M\?19OQU#IK3V)H*-O_,Q[=W87DJJ//!;?[K MLBR,<'6S6OG\:KF8+P;3LHIEC5VKZ5290=@09)BU961O6"!E3QR&("9CIWE' MCW>VG77,[+[![]CVUVB>3'$1_,VR8QP5")0]F5AUD^DAUS'Q3+VL@] =6$Y$ MY2EB.#,D-VK\#2G-0;EOILR;L@^*P 98CARW7K/*L/"<\IA;HEY&_Y\;EBT) MX@F89ZPGNFI.?3>;!&G/UZ=L+Q=YGKXT;U?5K!O-_O$9Q0AA[H"!!G')*1.& M.ZN$,T8!(VHEC7=,?\.:H\!!CI5RED.G'9="XHJB8'V:*'.H?W9WRU(^7(&T M&6M3[33;1:Z)+BLXM7'KP^&@579U68X$XIP15M&D0=1-10_1$BG7MQ7L MH[B9"B%J-%KU,QY,K@?CT8>I&3R,%X/)4;0<')<1%'9OB:7AB 7S73%<1@^O M:#7(^ NI7]H-N0T><9TU(0::@ASK$R]&%#57!2 M8PJQ-M[8+@Y#L>SN=PBK-C(8B\J&MT)*[RT%C&U?" %B]J[&#EB*N\M4L(GA ME$*A6SDX RF,598+XM0)\5I*K&D.VC_S^4F M ^K+;,\9[S-Z;/YU\<_QXNZ)7)\/%LOBD'IMZRLRPC"GB&@%.0)EJRP(JI,< MQR"+N2;L80FP5+ ^DWB2YL+WLG,\HL1JH12U#&BFB?.F\M\<"-*+@',/JY"E M@G-:J9S9UEB91U5:2+[J>1YH/E:7L_ED&?7""BHIA0(+CZ#&RFZY@FW,O43S M[,"+P6KG@D@6T+&^O"N+7-_S@"T],GS30QPF("-*$$4N4UX*KBD@-1K=,;YRA>#ER3":1/QN]J/XFT M;E=S9(@Y9HCQD OKG"?!'? ;'G@J553&1^-4H\M!95<"Z!,(7UV4OW Q2X,\ M$I_'IL_*]Y4:@I$Q 0@&2HFJU]=S[J.:X1FS'[O=PC.N##R\"EQM!88 -S&*RH M\MY$-41J?!MT81"*Y7;B;+6@+J\'M_G+-=1.1IM76)[GP[_=SK[]/,K':QB' MO[Q&;_@H6WWA@1RS-\^4"=B($J$08]QZ@Q%"&EA"*$# MR:?\85;LP^NN1S-D@AD=E(@T1E'# "%,;(A0PHH8+[M',8CM2C^"@1VCX+K: MH^Q@<>SE?_%L!@&@,JP;&LFDA] 9"BHR+(VJH=&CP/=V<1##P8Z!\*483.*:1))020Y'U&!@K .85,3C\]3)BV%O>%.*8V!$BW'01C#L_GFS* M%>Q!PNO',DX%-PI:HAS'% L$*:X6[W!4;9,>E:1O!P&1S.M4\I_RVU7WRNGB MU\']OCUAUZ.9HP8)KUPP; RAD@0+QU=$((AB,NUZ=%7?)@*B&-@I"LK[TR(H MI94@5A'SICSQ+Q[-;'08% ='9H)I( A"3-"@T1C#!+NMBI-1ASP]NO]N$R-M M\K-3R'P9?/\P"DP9WXR'J\76V#_VC,D %F7M&VJ(-M0Q'6SD:B?4P7J.B?KI MT=5SFS!IAY.= D2-1D$D\\T?'\?3'!X$QX[G,X:@) XBRJG%Q JEH:W(X09< MR"5OF\"(YV)B4*"&H$"99MAB2Q%@WNC@4$LD*^M)"QK5I*]/EZS=HJ(I&U.@ MPH2_7A5?9G_L"ADY\'3&C2O]*!.TGW'.0$#!EA0M88R:Z-/=90>(.)F)*?"P M,G^NBNMB]FT\'1ZV0W3_&S\<=5)V#:K%%LW91T0<7=X(9P;F.Q/TQ"&1R?3>; M'CZU?/U89C"63BOM25!A2@J &=HLWBAFHZK07=RQ923W.A+])MWJ$:*O7\:+ MG85/=SV60400QY1+XPC57*FPE56+A\'\C1']Q9U71G*O(]%_*09E--/GQ_NO ML\D>N;]X)D- :DF)1\R(L$HJ':B.6$TP=V,J#<"+.X",85W'+[O[/KP;3&_S M W<4NQ[-F"G]&&N)X=IHB"F0;DN$T5$18A=WLM@"!SLU^_^93R;_>QI;PB?.>,1D3D DN)('4DK)[%_7;K2RXP3'-9^"%GBRVP\I.$?*/ MV609!%*L[EJ+7?GW>Y_-,,.( U >ATGGE2X[LV[(L([;J*(T%WJJ&,?"3I%@ MED7)A76D1;FI!:$L#P-B]Y!@^5#,K2#0 XV,E0SZBCV!6RJJ"M^%GBVVPLF. M[[L#)P.1XV^Y'2P&FP4?N>C>-20SAB%("7'E9:SR(##G"?.(1W4QN] #QE8X MV7DX5&$&B_QV5NS*2=CS9$8Q-I8ZR@#V$@A*I:UB_"S1-B8H"EWHD6(, SO% MP.?[P62BE_/Q--]9GVS/DQD6$OM /X7RX"3896:>$N9U9Q";[;+#TYT3-,D=''GD;'LZ];! M?.JR4B(0D[( 7:,%/9/TYA%.5L7MQY9>O\[#CI9OX4VYN/ M]..G4A;Y=)A_R;\O=/BFW_?@IO;X3!-E.=+8>V4MQN&?OCJS=PBIJ#.LBSO5 M[(JMW:J=L.!B,/DP'>7?_W=^V/!X]6R&&:!.* P8LD8ZYI2M KP<%:\;RC=" M![[0$\XX%G:$!!50.RJ1ZR>#?7O-BV0$8JY8-K(^Y!L,7 M=X89P[J.=Q _G@\'D_\W'Q0^?++O5&+/TQEUU@6#2?E NP'* ["-X/.$R)BB MP?CBCBK;86(2/*SSC.LCXMGS&9$ 4\6\%A81KK4R6WA[86E4/?V+.[%LBXU= MQ4"N#]*?$'LXT7_?XYG"&@5[&2H)D2/$.TNJ=!&/L8RYTL 7=X+9$A>?()&@ M7,[SJ=%P35 MBNSOAL*/L^GME[RX+Q=^R+<[^'Q&K*?(<0(D9CTZL8F6XH2 M_[%BGK7/U.0OY;.Z?[_.%OG":H9-9P(QC%W #@%# 599;2I"H]#51. MENT.;1[)SG,!9=WQM@%4-BUR*8#&>>Z<1TPQH8@E4!UF6CI:F 7Q>];X&E MJ>#R>?EUGO_7,C#)?]Z=!K8 MQ6[4#D?/B)BC>]+>,9DP&@M@&/60,2,))UA7-!()HSH<] \UT9(^CIR3^'HF M[!S=G'8^GSG)"(:(>HL]IX!HJK;[.'4^IEKD^\!,4QD?1LU)7$V%F)=Z]LC6 M]/;AC)-5C _0$$E!G0N:V%94<6J2-OA]7[M2-#// Y$RR_#H?K1O2(8T@]!; M'EP#I#V3PDBW=1&,BJK\TW>X-!/Q0;27("*N]DQ!;Y\K&YQM2H$%1U1[Z>H0>)]-9 MUTP^$2^*_$UP^FP-!_&QY^F,A$]%>%,4A]!Y&%X9LK7:@I*-RM5JWN)[\7ZP MT Y#3Y3]&^2A@\+?]WBPV;TQ0$NJJ53<$"$%?K*^4$QP9.\MBTCYM\334S>+ M_5J(D,,;Q?&1F>08:J*YT1Y18A3W;&MN!2T7HQ1Z%.S0S1;1.GO/8X)^'$_S M#XO\OKZKLAV1$0,4A!Q(PSCV96,VNCUS5#[J%*WW\&G37SF5H^=!S"J%.9\O M/@T6^:I0XN@Z+X:E#&_KWQ\?FB1CP9:"3&FOA-:&0$4!JKA@K$ICNY[%5CD! M"0>1U2*;4X'M4_XP>%SE)ES='.G]^?K13!O)+?:D5+2,>R^15UN'T$1%=/;^ M6#\>.I'L/(\V6D>BCH?7ZZ5OFC0/=I5(:S9!AI23C@!( A<9Y-8ISROJA9"41/IQGKO\[+5GVE)'?UK6D\1T8%)<'+ MX%I#;XB53L#M[2_6*L8P[U'IAT3P:HW//<):L B'.WLD-9XC8]YS#X"S4"I) MK(/LZ5:0BJB;CL9E)-+??"5!VTFE]R(/K';,DRF$)08:"N8\ M"FP(SLOVS3,DJL! X^H3[Q]U[7+[['KN4U[>,P23H$P?*8V"8!J$G_QK)>FU M*W.2[JLS;\:8,,AZX(RB1$@9[%A2\2K\+"KSHG'IB_8?@FKOJN',T3WCLFT#4X)4IA0P 0@E@,F*SJQ8#'N7T]?[!AAO\[H M:HFM[R]+AQI#!- J>!C&4QFV4@B;%N1<,U>G&5_?9ZX.XYPH M"0S 3$BE$0;"5#1:"6/\L1YB)UK2M7-UFO'U?>7J!%(8\@X:J)0B&"C@[8:V MX%^:"RMGT(*,:^7J-./JB8B9%XMG: G_>HV4\%'VJ>SLM&O'SC&.(G+6: M F0\)Y0;2JHU.TRBBHGV#PGM[3PQ7.Q<\GNUPJLG,H10<(:\"/]1(ID#%E1: MTW,!+\3N.%%6KR5]$L^ZE/4OX^GX?GE_4-HOG@FT*ZJ#I^L8L$A *+&M4.[# M_/;"Y-U48K-V^-:IS ??C\O\^3.9"KN1UTYK+(668:>3%*_7;@'1.DT^S/N0 M>03?SE5XYI0*11P%<>::^1<,Z)BCKJH\S$'FT<[0BX7IVB9AQ-AI=G+\M1W_+MPYD7C@HE MF- 46A+>(17=?"X89ZDS2F ON2L;.V -#\ )G-0 ?(S;49K"7V1)=0=M-ONEV,89 M6M^">>7C 5OL&31<8B>99- Y;BO) (9)O3W'OMPD4J8#/(>)"VI>PHHI SVB M $!!M ($ @[V4B'J54JPV8B:??9GP21#.@Q1T@I9*KV?)D&9*G'PI&6 R!98QYH,K<+(Z%7=1C^KCI (Z/E! *"**#)=6$LZX M54!7KA 1%N6I8G*ABUD6R(<@8$UZ!4>E)Y(R2XVGR!MC:+4N$X62[L NQ#'L MECP- !UCEA9O59C))@( KIB!37FACH611!=&KY]YS(H6L5[2P'PD?H[UY ML[PJV_U>UQ#TY',!*JD9IAXAYJ"0@'"J*WDISMO<;<#FKK75ONH/W%Q+>_7. M[I^[8KG9-1IS_UPM[J\?C**#X5V#4^>&" :HK11U"HE&16JS)_>(^ XGESC M@X[X<(1E'<.=BW"/7_&AEEM5HN'CNKB=W]^>8-K99P.@0@,F)8?4<&(CC?!(IQ^"=8WR@$M9LU4K>,F8U4"5\??1Q(+62U/)98CD64]O5MO9 MX@+9DXYK=M/UW6Q[OYYOY]/I;*X5=@8X),K.M 0R8*BW0$AL.%>FWE%1CH.Q M-IW--<<8*60LPUA@CZ(S12WPD%$4R90W8GNPBA6U%5RCLWDS0"\I;X@!R#%W M## (&1+(.L(JE(Q6$VM6G:3;.AE#S>"\M(PA*J4&Q%!!XY\VFC2/II1W;&)E M*=(47+.S>2-$LQ6DJ-&N[>AG Z',:6289[A,C-'(^@HB 8B<6"&*5,4^KT*1 M".?%))49ZZQ0 E,$N6$*8B\KJ11,"K4=H1?:,4F2\E=0:>H.\ DL$-Y?8N2^I];JB Y2$L*X7%)I526AE"1E71FAH9*BXKJ1^\T0 M;1FZUE5;6<6THY"4Q;<)-V6%8^;V+RL!UWGJ>@[=5+BVQNHTE6V&:$OU=]-1 MF@F .*!6$VNLB,1'!%2O:F"23=%XJQBTPW@; G0#:L;$'<>9(%1! Y#12)=' MZY60TE&:8AB,T(+L5-=)2+94<QH9\F]!#&EHE$,>604"LQ5X9*Q_,;>RUYI/N3-^EP]$6 MT6$8TW\/:4V(E51RI#@74$>CW!\,*0+PY$HN);.A?1_I9E!?TF5UR8E5KWYZ4COH1O]4BH)VIS7?E_V)XD_ S@>-\H^M%!YLWQ? M_+/]\G>Q^%Z\6RVWW\Y=)+<>-PB"HCH))Q!2+[$JCQLKK B5*5'OC??,2US; M&(09K)")#FW*\CC*W+%!>=D. M]/'2,7[[R>9"K08, &-OA:3&:H.M0$3CRC91$)&4>B.-L\M^#4JV@'VTI/2K M^Y.7\FW&"XIB'OUXR3USIHQS):8ZXE-()=69;IRS]DM0L@7JXV7D_'NGJV0Y M7F .:R8E9I:*:()K!NAA"Z$1K 1&-N[._6LPLCGJ(V2DNMD6ZVY)^63(@"5G MT1>D"D,EH0%<2K%'2"LJ?IE.WAEXF0)\]E2*SU??BNO[1?'AYK&$4TFK($@+ M:(A$PD(0EP9/Z3X.C1G$'_5_O<"T"L@T$IAIJJ'G'D93D.S#)9C%.&FG&6F\ M2(J":Z15- /TDM(J/$?6*A6]6V9D=&6]CO_>2Q9_.,$,G-:ZK9-6T0S.2TNK MP'�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
(-GUMD_:A%76EKJK2O!:N(=&WX^;",T4[75> 3-U#C OW6>"C MQS9E]D7A^M/7;XE]._.@XZIL\]8B-$AV*O)GFT^$=VT!!< A0HR;:<\O BDA M&S=GY.QV;A*T]\LL0>]L>/!Z8;LBJT@)L4UQ9&9_(7! C"_2,\Q-.L:7_B.+ M;4>+8 L]9GOL7C_11EDD8\9ZS9\'#)4](G=_D3]OP2BUSJOP_./L*]=L/BY7 M#[V?<2AZ6@>?F_A0:1,?Z^DDG=Z84M[;NH.' S<3#ESI)K1/:Y[)*8K2)WT, MRIJ-XO'RU&.,J!-):7V1N@'$;XH-"HA4=!]6>-MD<-3,ETWK4 "6%$!\YL:@ MI8>R]>02&5K7;@C:;40/B;H M?6RM<7);+/\XRLZUM!7@#+_MAM3V_/"UBHI%Z37=+8#XZ(.S]IZ2;=))P1M0 M\(TOW,FVR ;NV.RUK;Q?&(_]^ J3?36SSI[?+0+;N^"=?VT1F+J!0H#G?&&X M:213=>27.>M[=V7/Z(4RH6\'(1+ U]7@C4H,D74H1HB@ ,DWB@)PI@!>R^=C M)(X.T(<\!/XZ81*R\ ;.;VHK:#>Y2^P9U9"@)?2RQ89YH?BR$>-73879E$RW MGZ'8#%(6_#9KN&"_#"T72./E?&V2R/JQ 2?K>2>Y1^URT'K !_,[3BY).SKT M^_=&/%)IU. :\_%15LFZ@Z*-M$PB=LR?PVZ^P\8R2CYY@+NS+Y/]])BCA2#F9T3K+*$6C4- 8??V6@^5I=?77)[4X^T(.CA-H&! M9+K@>]IAOKEG!_5$1\L-QEM[-\RPH:I,EZ@-O1:3_+=^$/Q92%#"WWH!1K:& M"N6*_N%-$_(:Z2OYAE?^7&2D!X2=BW%&LQR5-+]\;!']/MZ.IQH5*N-AR_]Y M=IM*D3T7#UZ0K9F=>4=FQ#-'9*4DYJ\G>,H.-N5.=+EP(3\'IMYD,'U6V4HM M.!BWBTX"^9:0ZWREE<#0&V2L.5;:-)&H2D"!<^'""2U'TQ5/# [QJM@N3I C&I>B3;!=\^K M_I6!K8!6>Y'KSTZIE.;1NEZ(;'R;-)XIM_/6YQA73\T?,]'88=,8N!/IJW1? MX+Y;<$D&;<\:BUUA;].K+:B-\Y6+)/\:%N2)BOK?*EC\3FRTYO-!PZ#23%A M836W(R7HA5WSV4-:;#;7.B=2$M1=_3D(B1F$E"[]I&F5!S=W?XYL85\,.;-8 MPFY6MKSEZ9U%7'!6CC)(>0&,C#]CX*>K[=LP:P[1MP3?TZD6V#R8BWT27OS MG._"3T#)P]K/)AKF:T:/KWW087R8%E ==&HX=V68^^Z^]-%_QX,H80]_IH7G MTJ[\G@Z#M+:.U#3;2MWP7@=]')MQMWZFXUKWMEPGC2!W4!4%\#Z5$T4!T!%9 M<*:AA4Y.NU_LFUEE;VE#NW8 MW%@+V \T9U4G-NJ13V.&UCOM"K]N6^2YP1QL_HH& MR=]H,/5%\TV^1 H2QO$[.@3K;S,_+:AK\(CQ43"7K*5FLQO5JRQB?S*-OB90 M#K<0 ,[$H5MY:+V&FHY24!E3TS8.1\[^([Q#SG4=NV;H2[Q40O29=B8//.PN_[@AOUY;:9IKBA#,K M(:9+BP6?4T0*"%7X?"T"-+OK.?<#O,I21EVLO<#'99&0NC6J#^+U::$)Y]X8 M*VS>UHU3%V!E];3GM.$V6C*1N1(.A?DQ5U2M2IL*S(%"DD"A$(F+K]98#H[@ MY\73;,537Y58U-Q88)6,V*3&?=.D3OL-[S!!M MJ$]M8$\!<'] 5*([0T4I@(5!^@/6W\W]6/[0*R0.^H=COG^MNG'AX5"^XH?G MFP.&*DM^ZX*>(^<^W^_O<.\N%N%T;;G+ZW>J:#HT45U77"+7(#;\8\*]11W+ M_=MC2!F]*Z![.:M/UFPNASTH#UGZ( J;?B2I??-07NU[Y /-/JWB7/^V)/(/ M$(VN,=2IUS']LZ@]+'F4P?.-K<7T4M?M.@_E+RZ*TB=Y6>O;@F#D:O1I"KR M60D/ 9)?*EG=7[ K19:42A:!/\(5I4'G)1A_(7UET[+UP-\PM8VM&!'$7OC5 MM&=;8U?;?I@28H^%"P\C@8QKU3I[7Y,<[MY'G7W(WVQ_=B7< M?C+TJ"CT2JFA-1<%L'LB@5K;VW*' KB]@UYH3,7U3F?X"CT\_@!@W?HB.= E?.2./W2.W3-6\G%J/='!X3,)$5("RQ="['Q5\ M>_81A5N'J<)>8?O&^!>%(L*@!,/$[1[QX0J3#E/2#/V&E,KZ M6M;L*6UUVH?;A>A9@4-^P7ST7CYTQ^DD"E#]69V9ERE6$S_4##R;@?M8S1P8 M<>0HYR:V-MVZ83(MU!SY&"S.\=*YBM.]R%:'5/2M@E"\T"7F2"ND?/[K3TT/ ML#?X"FJJB;^X46,&,QX]?N>"XB7PB*H8D>WM?&OV7.XFBK[$TD$,MFQYR&V/ M8?'U?%<$HZND2PF61XJ4DMX7\.'65UEM!..7%915,^\@RSJJ^ MGC??]\X4/G).AO;A01D6/@GBIIT)<10 3F*;&%FWL%^$&_95V6?G_(,W;G M&J KB+*98B+[=Z+2B=*CL,7\2?PE@G4M<>@;#F5(=Y=WUIGO>6^?^RUDK5G9\_,GF?V3)[9O\U? M?,VA;)08$2)6_394,J0I6K%;M\T>2VLK180[# M+*FQA)__="1CPGFE! WTD43-@&%O:V17"+(#AYI>R QDIS3E!YJ.U/D<(W_P M3 MB?Q37.S+I_,#\2J[83K@1/ 97*#B4)UMOHO5!AA- M$T'I[7Z)ZUKMXC_1S'6J_MM-.F![&Z&3EY.2M;^*H$0"_[\ ]:7$JH-B[9O4 M*X3R$)8515?K;X'BN*;]M&OE"J3O8RQ9,)%'F$?M>UT8@JYMGXXD"UE4JX_ M)D/T^W")J[0GG V;N/:V.?%'JY[X\5\=$NZ$5[;";; Q ^QT7D2@?H&-[ZLB M@U)/0KY@R?SK5>QP.V'&YT/BK2W>/O^N$91]@/[#+A5_ @*#MFT8)B3OZ.JE M.0\LRVF%9CFUO!_]HJ MDG//+6L=13U+!XBCLZZ8/3?#T@&'^Z9Z=_2T$^%] MSE(#3_)*DYGBK;9E[*AMY43;9P5OTOC/@OS+;$4"):L,[=KB55MP3-@ =M^. MU:!YTVP(W6J.48#G+E9I]+V73K =#7_WNM) []F+=NY2K[[1_I**?8*Z+LE_ MR8SO?6[Z\<_LY >N8HG].R*9VIHQBDH/):UIY^S66LR"H#HD&#D8)53_%:R MA.1%@-:OIABL2_ET+0Q,?* M0+AR!RKQ>1$S>OP]UK7&V?)1B8JFOM"XY1HBRC:0L<98'=A'O?W8;GM MZFIV%WRD[H.763_N2&5Z=4CP%L*)G4AN*-0GEX):]2^Z%5?L*6-MP'DAC/I4 MI^H<4W^CA!-T'4:H0R&ZNCTJAZDH"5@[CMCQE/9R4L?U!0N^M1?IXC4X;\]4RV/1$D1X(XQ8I"9 @36C((>9E-;1R MU\X\+8:*?>Z!SM7W>E]I8.?35=F=O_EM]3FC>;I3C?"@NYQE<;0%-?H7GX)Q/VN^"E$Y%8?&]89H]ZJUZ/6 M]V#_Q(!ID1$U-$0U4;3UZHVBO/GS"3$ 2?3BEXI^F.V=%=3V@<44C8,J0P>$ M/L(K3\C+BQ0L*Z+1?.G#6Z41(WJ1:5+W'E,+!V/(*S:(%N&Q@@X\,&(+ C5 MK[NM2Z_.EP]Q+\M=FSRI4.9@%"\:?D_ES-OO2J)E9!=)326QGQEI0=B_ ]_; M[U.A%!/=^J;GUM[(ZQNL#3X89-F0+T[FF'\_;,K???X],R.127GOY56?8'Y? M^08ABL0#X@(6]RC>T#R*_Z,(1UET ._0JW93YA)MV^K&7LG:^J3+Y02]=-VMBN_)FUM<15EYY$U^W<[ZXVOT0I9 MQ:?NJ%Y]T3[9,AW>O*AVN>0U..AKW[/<)20.FJQ\FQLTKK48)7J8]]KOQ"8> M-^2]XE3QXA%DZS]SP:?#5F; M *ML;'):WQ8]?PJR,A9V.UOJY&9R2<5=\GTY1?F%4X&EBWTK6M_G>*5"RPB9Q=8@C:,?AW0LD"JSQTRW:B1O?/ES_K2)BSH,@+WB(TZZUAS*KQ%Q M1[5R.+WM0VUE39PF-CGF&W5EV%K%GV_>-?BH;TH+[=R@I^"I:?FUM#P0AV5) MVAD+K7V^T\W FV''39+-[V-AASE]&E,)'3""FW5',=%X$,WQ MIR:64!CI0B 0..[BDQ)_.D)7I:\5^?A[8E"_4E]5.M(Z5=&W4E$I*>"LO-9II>=V!( M^O[\FA4=P%+'3@D6ZY%CC M.Q70::5X(="5ILA>'S?^NV3ULPT\6*II9;^4+&+^VV"1;!NU'_-2[%.16U2( MX=2YMXFW)QJ;'O5X;YD&Z%9]F?P:@?_:SIF;6?WL#YB+DPJ4@HAFRE MI:O9&NB;"I&GUY3F(XT?BKW]T?1SZ@;42?FEH+: N31/4_[T\/2P=B1";21U M!GR<74RMIS*]7#@%[?..()Q6ZQ/X^)C01TU'S]\5PX(-<"@_B-SZM3,2]C8+ MGDL'_%!#TZIE-\X^O(VT,GLOUHT0RY:+F2V'NAGXJ;K(K@;QTP)Q-)HB93CM MK]7I%VD=_:B%'CI@?086*SRZITC=11U0H:1\Y\P3J+(MZ.XF;)^"F]$FJ\72 M 6I0.@#&3W6QNG3D;WZN_R ^&]:71@?@#E-\ON0H0/2^L!8= %>D U"Q-#F8 M_2)N\W#CW2&AVG.R7OZG3$@'_(\7\=\PH?;_> G_+1,*_X^0$/9?2:7_=Q/* MMH XFZ-Y)7D?7\:Y;:BLTX]-27IE\W9(AOK69%PXL<5RR8F[/$&U>_$^*@* M^)E 7Z)\3GU/VT)XH#C&-CZQR"&U#3KS\2H3<%PWAJVY/*9!<;G; 5*%G<9NZ$?V+]G#B7Y-*+-CN\)GW.^87GJ7;GBR?R[]F=0X]'>J]"; M-^UR>L>,C26K\AGQV6" [*M*_#[]JJJD67%?+Z@B8:#AGU=:D+T^_R: M=-3/];4:H-\.DJ"[KRT\UM*X9QZ12:0#J&),#U'6HE5Z?>4SGF[X%M? @]X/ MZS:PP\6'@ U/45;P/N%%@=>]G*D0B+TG^NE^%[>DU_E[/W>=_/8["A8@$H3Z MG+:"L<"+@W/Q094=<5(7$JZUMYL;JXL +U*T6_;*AE2D@XI:FX.8IKFCI_8= M79/F+#]V!1_]@7KOI#>9GH.\!93U4F\WDLFK/56\"\1YH_'GA'-?!&H1NF&0C9_?D9>9YQ,<83RX?LD_2_0&:.*7+N&9@K4A.]LRB?PN% MM>3+A(#"BE2QBO.7P)P&(KFOV*E[0@VZAJ0#$B=QZ(V&&FDE$ZPW9*#YZ1.Y" MDJ1.D@G1JZ,%NR*M<%D:3N^8MK4]O<&X0/;"K M,7E_'3G3ALDN1A0!;GG(]*%V.E'1FHG+G,E],7'JB B7U7-8*X M*#^N2/Q9&O8PV$?3G2>?*49R()F+09V0@^II;]4Y(3 0^Y%= II4N_=.?JTA;>5[5_ MN*W3N>8KV!/L'WB-8D[2;K%C0!>7U"D6=1:#A;CKJX@3 U8] JE*>OE\8*>C M[)<7S"9+W*W/,UHA@<>VH_O"S)$O*!IF0YXKT+.+:-UL.J!96;XZ2O0V$G&L MMDNJB!HJ?-LBK[ZN>>H:O"A!&:3*70 $G5B(FC=,.7' 4=U?4CO M)&@NP>RF47J?S:5S$HR8;X$\,Q">:?;0K74.9\6L?9TA^TV(FTI5?+=-0GH) M(]N=9N1[%@Q3B(4Y6R/.K"ZU(^Q2T'8T&"Z7-7E7H'L/PE@$G M9I0(%CPX=A5_-4%?K1X5)@0&?$LM,J\R?1KD\V+\Y+%-N:]OKEJ;F2I!W]:& M*)L,[A""9+OH@"1Q[&95=)Z1W@1$)H4JB)K:LSBX-5Y;->NVU2@$8EH$ MXU?6C_B6&$8(*271.-3/C ?>J1F1OUP1?\:Z4Y3[+6C=T6SB0:NK%VOHQJNC MBJJ%)0<15/9IV5/+F+;>O"<%(.X!9[+"CD**_X.JJYV!M76==Y*=0#D+[!<+ M"MTU3^\DUSC#)Q$45^K6R?U:,&(%2I'L>K1B]2_.%/ZE<;50Z #2J1?D,LD MRPA5/6>LR,%0J"RWRW-U=RI?]RU#7"O?'*PT6!GV:V(JGGK:A@[8,#VO&A55 MG%L\[N]5@.L\B^[BC)Q]Q:PU\-CMRI=$!J5&T>'4O.S31IIGP_[QC]L+%[1T M&[]LGCFZ9L-6A_X8/%BC3ZO?5_.E PP'5M?D6;46=#)N2D-$0&+O?Q(+"DY* MC)IW[.!.!.KBZ0 >FR:>-W4:'E.R5;YN.Y:#$$+>.[O,RGA4P+F4?$1"$7=^1 M_11^TXNZDD[R:06R^W('\0D>^N_5Q!4>V),RTS#=!X.N3F,;ESM^?IF=\@ F MDVG"0V(4-OEB88T15ZG/Q-[/W/6%#Q*EBU<4,N&.)L^]JVV$F";:_!O2B>A6 MM-WUTH9?5/YI:?4FPG3:J32P7JT24JLK]V>*(K^!CE9"RL)B:\R9^SY1$$\D M[7W7KHNR;!\Q"G885(4$OSP4[A8T1HY?VDGOXUQIG>'UXZD\KT8=XHQO%RD) MGCB+X_:MU26JAVVKPJQJN?W-TAAM; W+OFS,V.6YA'00CZ/4U02H%N.%\;TJ'_5D/$;_-! M3I;-,;'G#'.E3('F#XN*=(YRWII"+XB%-Z.XXT^#."DOFF@B Q6\U#OX?/UZ MPKM%XS5)4.AP^\C1-RPF'+5#Q=GS% MDC&VQ<_;+5HJWD.T6T;LU"<59QY0.]C.9!;M2%L![@6#-623QCO\D[8K(3 M1QO70!F7*)UX=B:*K ')+:?P5::++(NWCW?RQO@NX5+W$TXQ1^7Z4#\Z@* K M/YO*O#1B)SA2(C%4)$.P)W&_RA/;[HF^SC[^;K0[7W%"ZGO'UQ4[IP(KG(OP M,15&O& ?CUFU2WPBF/F00MU_7)\[.('=XLG!4^QAL.R26YT MP'/@0.72F/PB;@(<1( ;^\JVUYBWLAY7M==,G-8[)YA@M=P+-O_Y27CB9T'+ M2AQHSS!&+OU%ZZVU<"=/L6$YK5!9 O%.=$^,[KF=8X90#3OM?16*3^O>0I.M MN1ZILB]2FGO%N([/$YV29+W<;W'N!H.?Z9O"\^>67\0P)K3YKC<)OT*=KJ # M(F\)(:>_4A_99X-#+$OFJD@LA;X.L9:$E$?72AWY&648]KL+O!W:_4TN#D*P M]P@K@VC4N-\VV"3OYMVK\_H5F#&QH,#UW,E:8:!O5SN?X)@^8!!X]D@U41>K8_!05)4,\*$37WI].T+* MZF+3:3.M5,[[D2HMYVPC=#&MKRNN;P/+T2T3>OJ4NZXJIA[3OMO8&?F&ST(Y MQ>.=T@V=0O+< U+PFKN9UROT/UWMNG8NWR/^8HI"?52L2SS'%8,T(UUYF=AM MVZU?6ROJW$M6X5%>ZFS8B:+4AC0HU,O+K=X^SOY\O,30[@./H2-YE%#]:72A( HI(\*?PEC<%W3S@*8U9;),S= MA$_7,ZE&?A]Z9/=1/E+JE^*8_HI64RMTKC&/2?)U@O YLB$F'!^'F@DE%OA: M5J9%[T)GD'7E?$6_EB#.!0/G9+([-2I'5$[G]*[%OSQ6X_XHQF3+&XVD7GMS MS73N;HZV9KYFK=;*9%6/_RZUS[>R)FQOA#_-SRS +\$ASJ+7="@FA-W]3M$P MR>S#I!2,-2B;[^>83#;Y>=X'EC#5J:W]%J9ER1#*M:FQ53E!#R\]2(!N=>IR MP(7<"9?!SF,Y!66GQ3)$KT1<=#B8?H)T.V?[V;PWDQ(PS7Y]DJ=?Y8%4?(10 MLR&G3.W5$:SAY@-P][N'J8M/<%PNMUUNG MD"*I3F/FM. +=$##UTL(38O]*W1 7ZOZSK#P,^ N)9RVE\G<_;GL+7LP2$%F MVCLF(X\+O/J[W/?T8:)J$O0>MC MO+_\\DK$L,G+3,:AI_'26E>SXSYY%@+_ M-#S[K]0,%E]='9R8+B9U =?BJI=P(\5_'A__#4&E:M !00^/ :5]SE0XH<_Z M@3M^WESJN%])_EWX&P%;+U#[B=HDL1]LW^92J6CDYV',;).\6'7RH@3#?[5\DJJ;\*A?^)3NVBROZ)AA;_E_;?2KMT3B/?C.%=S&E_OO+_V&TS MG](8S \\A0P+#]]JPH\8Y^GN"\">G:^:5BF"M*_Y>\U7S<1>B+6/->6X;6K* M"V![R?S/S/R_@J#_)EJ>)W^^R5*7_TI[89T BX/1'8GTE?]C 7_F7Z^Z?N9; MV&9E&.)YJ@=JBPI_,% T&(B^\>D*RU20KBB 24(N3<_LI&*6O#/B6C\,! V; M/$]LJ)X^Q7Y&\]!M:HD-\:]N2KV]<)/EZ26!U\MGT;8%OIL:_8&<-)G:^FN^ M0=)F6Q,1MO&)C:>Q1Y(7M7E[%-=R<;>M*A)^&9G*Q9JA;0>*MB4OJZPH_S"> M/L?\?CSF\[NIE]I'W;5<)A12O9\:+"_^2_!HK<=U98PK>L"KP1,-0O"V8 &B M^'O7U11SOID3]P6$KT$<'>B CG4EA5FM*]JKB *5>#DK@+^37G=M727:TT2D+7OV&5+^PTB21.M"G.8PE MI<@N@#].HJ$Y=,")S1L$]Z8:@5\6LH^BJ#3*,U)V6P9##:DJ37#0VQ/\"1>^54MC M6CQYI5JW\?R.F\N:3N\$HTA#_ C^\R M\F)8WYU%;93\YQPJC&08^H0HGQQ>K/LB=TSF=:XM".+D5OHTX)FC\6H[2%3I MQZ4C7Z=F!V*2;'"'R5D\D3&/FWW.=?Q0V#%&&R_3E[D;76>TLO1K[^*YO07^GK MOKG2=]^*NDZR!B[!N&E7K,GH^EERRMEPYR?8[OB(.+C9)0\RCE-J9/C[*#A[=ME*L86=&I$6K M?11LB&5]]^1CSKXFOW8V2/&\_ MQCV4\C6GJ,"<<*,%V,G2PQQP<8"X]?^7;Z9!,O M[SDN::SYMT/[L$$9;GR7-H?3 9"N@^#PR6._Q=0# @Y-[?>ML5,!/1)6) $A MB^4^CW7W*[UC;UY77-D-/[^- M^ QS@O.")Q4HSU,F11(E8[4DL6E&'F>:VYUGWA;('TVZC<>&/F? 8+] MN>DWGCXY^P>0KTL2 AG' &>-)8\OWMDS_L6@*3[U&YWL%^_5'TJ_,<8T 3Y6 M4.IK FPED0ZXH,GW-Y^/"H3]O]<>_OZ?)7!NW_MG?%..:BO%X_^13_.>C1T[,/DU&ZGN" M#GJN9^T8%H#7S=0N'.2JP"G6PCRP\JJ@-!K7K+K+A@<2AGDZ]LD'&Q-@%D0' M1-29$S<-20:Q3C.J_FL#P+#DFG%UYUJE\N_2?+099Z 40(PM(KZ$_R'S$'Y[ZU6(0=9CHF>3!<>Y'2]5&5D1A8$]]$81QR^!_2P]X)C M!>5.LF/F;4>NW+'X'GS5)! 7$%9S#9'SV1 MP3&T,%(GF>W"HSLW/C&FH5(8\^0C(\=NZK0\8BP/CXB0K5CIT6@>V7DT:MT" M/B7W[67_/4"L T/9I8=,.-:!^FL<]J:F#PNR&6XW,@X@GQO0H-3#C;6Y_;*J M2LHB2E*]SNI25KG4/X,XNA*7\QE4TSWR'+=$1GX;TUO JK9*7@AYP%%_4ECR M<4)"G[Q_%& >AK?V594>&*?8:UIP3Q X94O;*NX2ZF<8H1..NU%;$JER=$!8 M _O VH7$KA8^Z2^_'B"OR7%?$]&^DMOV]HGO8]0E58^VP,U]KT6TU2J*K7CU M8S)9LG:_*R@\24HAUT%X9X"9I"\['5>>19F99FH+NJ [)-_'I@=SD-!OO@2K M$*F,)6?5.!D@?J(NLPBGD&]\$/.N - M5+=5D=-.FQ8JW*D"7Q$3EF4;FZO)V+:2#5-CB=?^/B!"K JK,1T* 169-0N+ MFS.%.V!#M/.Y-NK4!=0NNO!E?,0'(#@Z IIN3+7Y#FH^M%*O& M9Z) GEMTP( -2N],/7R;9+U=3\VWPO\;KGYZX729EG*XF2"JRV A)KV:XJK!G M'[6+:D.=4S'"8R]\MJ3>C[8=[J%V<8W **T!UN-H#Y*H:T'98.)"L_?A X9KL5)1Q]R.Q@O&Z)$_?4H0YUE8R'AA MY<\>[HDXM;3T)!M4E6H:Q=D%>7:DA5$$'G QO%ZL=1MM^ MUP\6"](T>FB@6<.*?33'A!9P;(C(^V988[ANSAG8LZM(43YVUD@G\P]XD?_0 MBFY,0=GX6SP]6:].\*.0NSB'>!C&F[!9'K.;YCMQ^$O(2YELQC-X8(@;@5 L M3DP.E>,NZQ0XW9G7W,6I)#9\QXZ14Y>QQ 5-E:0#F'OL@YP.HY>U1+(/@=^V MB7PSQH>5EX$E&LEBHU(%^@/[J$)DP;5),A5>9](.0M):>^T!8R"!X& MN2=\@J$=HC>+A,,R9$B&37#FEJF>XVL!"M4D@V*H5Q"S=>=5!7+9U8=N%EH, M3W5%%Y@]>AX\\YP[@-(!++1G]U6^Z>U1#C\#]N'&E!=XZ8? -#J U7GG[NZ M-:K"HI46D(F)V05^>.E^,B**=HEJ1\IKC6=84=@C5SKE6B^1;['TY5B+RM2\*>\NVBC* M3'II8F\/*:EMP7'6:>=2HHV(:Q]+K'V-<>:DAIH4/O0H'BHF/:7+<;6K(EDB M\<[38R9918.;5"5SVL1.4&ON%KB+I$\+'PKFIRA.X5A\'5F9<2T85[+S6ZEB M#Z2SR1DV M;/."U$T)E/^N7BNN AY=+*_/;2O15NK2CQ6\*+E5/HB/^@FKZ Q[/@!7BD:< MU\J449*/SZ'JD,3JHRE0PY'B.D7[ G##I<2U_57WA/-(_D2AVXS>!A:!'2/O M9@_F=W90;-8'2S3^HT\KXO.FX;O!RO G5M0;Q*"2%+\\+,5:,]JPX?&.0MGH MO8OIX>=K0EN$BR&@6ZIAK_):GN1:'JKM:FR9M55K6?OK?M/;1^KZR$9/<>7P MER>5U,<\-BFIVU$#'K-)\=!?O9P+?WSOQOIWY8>?U,$$Q3O#"!4$GIX,$YZWK!=<& M6Q/5EA3O6G+B1;HD==$L)@+":?5!PM.RQRBPMNEQ<(U0>E&T]P0[EF ,D\I8 M^2X@G*/A1Z0#6OA"@#GH<,_"=RB.Z,KDGPH\1ZY%4+L1/17N-P8K'Y@F&=; M7D"W:>*/]5("]J!4$ MVW'^N*:2HZF[X4XUUP*.L4')%]TA?+92V5ILP V&%)1=*W9SL]#,U63^(O,4 MD+C:-1>8'?+3X':GL-E2#7=ZUI)N+FCD(6@OT,5(NEB$0^OE-C,/[PKFZYBO M< L&U!^;&VGOXOG,=VOF6$W>F.F[PB)?X4N/_1A?-ZF\LKV6S\6=PU^5B%K9 MI+*K%3.7_PF>ZTMR_F0G$D,'W&BF \#0"+7+Q(SDU'N<2QC'R&(N"WGG$DM9 MR&QDLM:QZ\<'7RH>T>)G.EJRKD&QG@&>"[Q+<:%=3.W0**^OC^G,L>[P$&EM M= @^>"EV\DF,S'0V0LD(9^O,!R$7VQ?8C#:I93]-%"ONCC@WQ0GA=)586V/. MG/G*FZWQRW.=%92?MZ3P$#1RK;;&VOJ\SJ_:%-=+4\\^Q@M5RABY&QFAO\]H M%7EP%OP!FNO;-Z3U>OX&M 47EZ%,8FKON=^,$>2#F)LGN(H-NB%XL4O-OW3K MVG\8$' -;@P3[V<94K?Z,#[M#:+$C%C(DW.#J]1KB&]+YGQ?OSN7$"Q;SAV) M>RGGC+<1R%>]=6:9K,9(G/$_:(!RK+ ='Q1UGLRVU@ 27_%]D/[?*GC."S: MH_>%^?H6JZ+)D)0L0NIQ3>W@6,: Y=MKKSX\_N:T5G7SQ\+1N/D2T_/S7SYG M5:5W/PE#$W)N=+3B019V@+S(&PW\(A(%=-I..LR3XIL]KBHHY[M+3(G%BH: MF:J8>OM+:&PZFT*BCM+,*[N 9S-]G'W3W]>+MP6YJ-8!DL[7*4]*3B C[FY< M_2Y=5\4HW3C)(R4DC^&/VH&(W!VL4V.D4-SD"1ZMCX$ M]HFI#.3:9OO=OKL@,.7_:/&/X;"2<#1F>R>4QD6IM1@4WU?(?I)C,X[MJ;1V MB#QSO8KWM/OMJ1CSG\^#?P$YY4XII^FA.#6"I&D?,^VTOW8]88&-X2!)#MT M?@N&P3_@<)&3/^=AED<4N *+8T0%!Z''%(EHM:1-N< M6:?H!6K/Q$?!V;2*I_/%]?G;:S)BH?DM4+=H+P%W2:GP66SU:][>FUN 3=MU MPB-22RN*C:KA <''>NM95O1N?E\3OG&"[:CLV^E5R4 MI9@'<]%Z2P?I #S?0'!+7@\Y6AE:VC:'[?RT'NN-MU;MD%L_[YI#PUW6J :T*'"D<<%3U"$Z;PX]79 M*5W6I%M+I,EE3#K&[B3B0I2&XPIOS*D7I6?_"+U%![P,9J7X9/7D84 *>]$& M,IP!/5J3EV7$HYREFL^BCS'HK&A7K3T.$'.HPB MVN/)UC^FH^:%2]N^.41ZMY8HX$,80IDREXQL Z6)S[:+YQ1NKO!_ >'J5)\_)9Z9(8H M$=?&?G8EU0YY5!AC)]T/@WLO!39QCVU M<'QM^V!V@A?!J,14VO"CE'DYBS:+-PUOQLA9 M?7(5E.5LOG"]]&%F^*FW=U_>V@(8VP1>(P;-PZ'VZJ&>ED7%)P2 M[YJ3J>3+U@V=V53;WT!;H@WS" HK!)%T&-LB=B;;<,==D/X+;^3TM?8NX>MK MOX7YS42^OOCCQ[F0MSHBHE,A8,<$KK_)3I(+]._KYSQ]FAKUX%_>K)$@4%7L MY([)F9'B/.WX_(3&P8QI<,MA**FV00?@CMOL/XP./JOOA,]>8OQOQUG?GSC3^T^48%-:KUDAM:TG MO8T6RTIH2[MAK>?A(NJL][>0S63<*:JZ$U\.*E1ND0/"^M)B:^NA=+3;52)J M>8?3>ZO/9?L_<.B?H728 <0?AA&C)) Z,6P)..:A3W[SC=8=WVD):SCCQA@P M([>O'AHL,#BS00@4R<5*C%EUN%IYNJCU=MM^Q@?CG^K:?51"//Y[=H_Z#E"% MB05+51A?HEVBE'2NXFDK.L!1>T[S J],(9*A;/R%<1,QK\6[:J.)_8WVZW_20_8?9WK(=(S,#]_=2:%1Y/Y*[X/ZTTK%_TE[MP5X_CQ/_Y_I MY2?I@#_*KO['Y06X _\RC_9?V/+[(UN78?\GHG\K[T*&7W_?20U.JXU>9QF= MM+'=!3HG3[<)YF[$/1V_/UGGJM8 MG!!-;]@J8IZJ7NM();/_$ULJ"!0EME=+<;JHL0VLSX:(A4A4#]J_[>#[5'!9 MLCF$ >!^&0UG#E3\.F9C.>&K\:"ZXGLU>"PS33\V42]L?^#;^Z87$_'RJ^K_ MR'.\0 -%#Y]^?UDY#<4$\C'GZ!#0E<.XNBU'W-'\"UPQ&GB2*A_@*"VC(IS3 MYR)C1[PCGL9_/IU&K;T_X[N M]QA&:\@HI&'(E/QTU6)&(JGM+'/S^)^K%X92A$DDV?V.W2%/EC\A1M&>LNY0C(3*$+>O.)QD\ET@US7.6%L]/B)R/HLB2@RD=TZ>@'(&J0X'* M,T NRH99/P*A LI9X7EA@['<];C14:5[-J)3,NXD827JO5CWX!(=<.P P]HV M)C]R&+RA!#W5=9T1J9Z&V+LCM#Y\+&$G3#\T)<:S7L\D0[-ADS7$2J06H%(V M[W8"5AOO/T=5/1S.,NC596O\"&\QL)F0AO5MZ=,! M+<(/^H&7@R>%9+X3RP,E8^O,"RG:]QI(3&/;U@2A/6M+M9Y2MR[MSL;.17!' MA6QT:CN<:-ZQE^1;V)9QB6@*CY%:55$MRBT=27W7?P/?8M!?+N>'??^,OUK M9/!@!N2C1XJB [ IXUV)<[H[YH:DZ]=7M[EW2I0XS^HN("FVF;=G62KK20Z5I?T MX F*K;'^,8XU&O&I@.M?6Q\KS&QEJ1U4^],!C4BU7/*5GEN%DHD&PS\: M%\Z[^^9T)R'[U@0_;AWCVNAHA6*?R=$!C+;+0ES$AJ\UA.+>5(>R$8(1K%]F MW._%RW*6<)L"ZAB+UM1Q\*B:>*!;&<7\\U)-<@[^P'MKHDFL-7DOJ,YM)*&# MUX^E=T *7"%@[R=*K,[=TJ^7(E D]J@UD0$]FE[H/5JEJE#4+ED="VXL=T$Y M1NN3CE8Q[SW7+Y1.Y;JBA)B$,-V3-S'L;NPVI/MVRY MU%0)'<#0]D+>K8KJ MK9:4U6!!@>X[L1JWS] X!14@&N:I$#6TX4"@^N-[@SVJ4>,_>+H_A9EV"21^ MX!7( %<-OCH97'$@;=J;]2NK/9!U8(:+^FN"^8&AA(R&?1<4(@D-0I* MD7U:LG+FVMNRH*A3]@#RQ5K98[11(:'A;&)/7*%3H+SD8L4/+]:[O:,P)XS= MY%W1J"/=^^VKI)>-#@Y#'3C=CF+4!@2%,)A)J0W80N%1VRNC>\S_"NOJ#RVP M90:!*;0F\A#$"B@*M Y](99O _K]#9?/5_,<'[ ._<,1=R9>;,:G$6@3"GMW MWX+([")TZQ<&>-86S&/EE1N/3WMJ.Q-R-%7[HJ6[0J% 8DOID7=6B1!/0+:0>G1N TW[Q+<4+.XV?BL2PC.876PXE Y%LGZ-FC:[LF]E*\9\8T'\"EUP<.W2!B]W-.]X MA)*+GNW+<2YAFI*- MKV2/ C(%2DSW&//[RK-:M;DYQ?5;/C43)7Z./.\QGKI>J*O9;"#K><\AATML MZ-!C)X;\W7O+A>"+OM,=^+Q7VR@N%P\;P[PE;H2/BG=!L>3%F+>?(XX>Z"!$ MD0?E@<+N;A ZH$Q%5Z@4J6!6A5%)UD&:%_OPZS)$^*6YF_+.??2(,J_]MD'U M9GV/V[;'.2,^J?#O6^J1>&9\PE3D,YUYH/C81[K5-1GSRT?UT@(B'#?&%==+ M.4Y<:0$I1V 3>KPG10^^U*GBU2.2&SB'/-.?,]74Q^N'FX(UK95D[%17^,IO M>L_$_LRY,Y4:=&9]3SGX\1;$FPZ0/'2>&>6:@6/LA(4I12(UM7M/(K*HJ!>N MD..*YC:2Q8I$/6$IY-ATM[0,>WZ[XZX+*E+=U>'[2*!Z+L5']WMI71(P7&_8 ME7K'T=@W,WE$=SKY:J+]_(D3G4N?7MTW?&]+!UAA-P51P";@AEI:5@.$*$Q( MRUJ>Y"&N8C+2"I:MTB?>\& ^[2FDT>+S.N1ZSNI?^6CYCO/6Y>=,XO"90Y_+ M8]!? >3&+O')Y-E/2ROJU W+X0@KZC*870C6_JKI6QT>5<6C/V:-U"(17%Q'_Y9YER*\R@=#H%X&YRU=!Z5.M"._C(*Y,*9PTE MX,?';@F&@^P3)L"##=RT@6 >2N4TQQ>064W.I_*QANPG:I_=RMI@KHD?4BUT MGKH+EQ]3>1W58.Y=JQSTDPY(F=T_TUT$S][? J+S7HS\U33^C28A!\/\!)X+ MM*$$?/:%MNSX"/&3N(HW;<=M&B-?0%78RU(.W %:C>N[!L]K7QQ:A,)OBYAB M%[2B0$T'O%K/3&!'62TA9RU/139=:S_WZ8:P<52C4^+E+E+;T:IOAF?+WB0)7[VM9?A@EMDX ML&!];P3W@;!'8Z8#$K8FN#:A+^D UPD>&AM]7S#T$)_!6XK M2$TIUSD+9/*S.S.A7^^MTN%>%06L4DC#"ZJWDF^Y1>=C?$-ZFVD+>FE6Y6-. M@>3LZY C=\1Q=TTU&)KD%O9K<3ETP(8M#:\]"9+YO3?$9S58UAV4-Z"A>#U; M==VD!R-K\O7B+195(\5\5Z6A%_U4* J=OU:5]03B5NS2B4AR$A'5AC@=*W*_ MM \T:9UX>?+@\*V#ZO+9R#+MF3D5)C&8\P'G5%%Z,<,>WB#^JVCRTMJVJL)T M+\^'MU$;6C]S(H[.2'QBM/%I!K[QF3QUD"$'#\=4MN4//1X0'723<>U2L4ZW M<#-NTA56=)<>]BJ0DDPS^$(28D6@FQK M:DWMT?C0L\WDP G_0;Z'V4VSM,LY4/56RX MOL6Y8P7.Q4G"$M5 I/75I1E!:WQ\4ZSRW89^\]8&ANIO-0E>3.^L;.2NOGE\ M[I'W]9N[VD+O?RZARG QG]%%6WJQ/IJ'CMD//'-FAFMC $A@E#6"ABBX]O&7 M9U (P,=&YMV[$P;%N(4U5.]E:N2<390@)[(+.&"XK@*=66BJ=YJ&1S7PN%C9 M]L1PTWA(1UR0A;YKQ:*W68J>F(2,>]X4VIZA*1[$49\@-$G&@_I#E HVF M UB]FY7$WZM\B?SPLR3K(E>RQ0!IF&CH1\L]V!*0 MFJ1F^TO=23@RF)647.:$7^=>2@6^\H*=A7-.]'!V'7PQ?;DI?;N])^8V?SG< MI94(6PV88>5I%>+N1VQ/\ '#)WE)*I/B91N<0,+)] _?-,Z+/'ZH.\MIF!,4 MH,FQHP09P(46[SPOA#4Y=$WJJZ&*UW1T^ M$0Z)O:R&-JCW3\M.#,AD\U^X_2 <%._M\WBMXP[0H-]X.N.@>!?V=B@5N]>/ MZ"R?VT>,5BV8$MMKP?F4N9+ME94@F5ZLL:VTL:2SJX#*E2>;:L]U=N/P&8WF M(!**[%5#&:8#3@REV(E%#=C*#,QCIB]7#%=7?0=EG7"T^-BH>S;$]!OV!05= M960JZR>WCULHW]^+4ENIV5*3.M2!]?0;DF)$A?XC(%CV6.&B\K.X$7'(8XO& M[%?SW*_97BLQG2>MF*GQT-H;Q(>H(D>#KZ.M=1('6+T/XS5NS.6&GVC"Q7,8 MDZ2=UT]8SH2CK&F7)2BR*7I'=KPWJ++0OOG ,CP=,!HWTXQ, MKBE)F8&+ $OKRFO+ZH(NJ7CPNFIF%W;,4_%#;O@4T':N+YI\H8%4A491PCV^ MCE?!P2"Q242N]/B*Z(W==IU//U0R%T*R/S'T<6V;GMU-'ZK)A8\7[S)CK.2W11H_/X[%7-KGB@"\U6:17&:^ MK#V.E-4+YH?9I8?8;:\O4-;._M,P_X]-S9O2MB^,H=J19*,JP7!.M0RO\MS5 M.&75'C?IP#:/VF[^NM;WZ,SV@*VBV #RA?+A5.N(NCM@\C#I^.=B:VER7(I9 M6-$0D_]BNWCYU]9VP&','-HG+;9[&UM KD;-_[RD.E>I1L M80\4M4@%2WS>^4ZYULM78?9:S2 I^'.=5X+<5\?G[M+DR^D EDB_O!5VA'.# M_"UH1#:).Z?$RDXA52Q.M#[2/I$[OH<_@OF$>TO&\%;HV7TJ'< /W FMY)I M-=8;3EUVX@>1)75ZQ9I?)WQI07>]]*]6]A;G%D_\2NQO24S\R!#[['RRJ:!' M9_N5Q8/8-5>[R4T]4MZHEZ^7JB/15NV#J,;QK&NBRBS9\T8Q:H=9$VO0-4WQ MI)IM*@36\ .L!<_#>Z(4/%!,P4)T0',>Q1[?=R((M?]H7Z@?$CPVYV?G=F/3 M=7QT95"\]LJEPG>?TI(FDGB_YG!].]3UE[^M^&!,I%1.R5*L@"Q47;PL$N9X MN'-9ZCJ149(]&T@6M[&$6J&/7--[J-478@O1[)%%=8]=O=)\!L0'9V^Y)]X4 M*WN%[\I_"[5DA+_CZLA'Y#CG@)6+MZ@*U*;E(C*:=*AKT$ M1VRMJF..+[]0_O9VIK,E(8[_5;Q_'\EI];5L1,,5_1E# MROV$M'UOG&T<9N:!I=N9G_%.8\E3/TY$;#,# )\^H0=,C"!U51N'FRMTF&Z6PKI]20M.#9$TL8\S"NQW?Z ;X]/BXJBE$0R$5^= M\R3O+VT?[@DT_W"J<)O8KNP2_*JO(OG&$)4!:L_VBL2W?A^7BP&E5HS4^%J6 M)$XZ)O#Q;*H_UWD:OCYKIDB]^B"F)@(FH"URR$S&)S=K+6"%CLRHXD>Y#+=G MGNW7/=X"^ ,./#0Y=Q#!2#J@$TFK\3RV1IBCN ;6J3_]6,EJU64Z$NCB)7@7 M]W# :5-D\.B5D9%K*B"V_LLM5]\F[A)VP+F48_N7QZBG2 Q#YX==MWF?? O@ MUXS6"L-,B>C-#%.J#Y09Q#'>D)23XE MAC6NW&WO'B8PW(!3^VC5514EK^NL*^=?;(1\WY;?*CY;[.35 _#?5 US<#0 M%%"S\?! GOU+R)=4C2E!)WW2(]7U<(>2]01VZ"4-G9]_]/:TH MOAJ]JDE;V-7U!=1'XI7@-II:W0%\0-5@;JW.*&]QQ]_[/3[4XK1UQ4Z([KD2 ME6;$NX>W;[9[)-F5.^WS3>+ R0VB(W7.:/_=88B79#BMQT1#@#L>*@"0^G#T MY$G97IU%R66^RS\':H)@O71 QN?#,)*D&ZRWY]2MQG(0*Z\>3B9S. MSN%74 M[WGEIA7J0_)"DPG2\R".+-B-'=&P2\$T[9RG8'BI\HHY)K2%,J M@WB^XA\*"U),Y7LD[#KUV)ZQ..C%?UQ]Y_B4\-5'"I\++5UJ^F(-LK]:+_,] MH#GX/PZUPK1+Q%[ B-UTY.0$JC80/'$ U#-E]5?!YV^]X2O.R&91,+1W+G/^ MA;4Y"@IL'K0Y8F>VB&J^>LNQ?BVJQ#$MB [XV;I1:#U('/T=UH?_AI*SVVQ- M=>5YI"U6W^3I;289P\G&3C)1)[Y; FX2//9@)-.>OZ__OQV'HG&F2]*"2M0- M:5?B*?<]$;OD[P?JE(+92YEL_]OWOWW_V_?_KSY9^!8X?O P;L_^&\)JYDN, M"#K@3=Y].@#^WZX;:4W)>;@8PQ%F(O1=SO24.F7K]4$;S>2AR*F_*[Q'%L%^ M6.W0:E&T-RXYC,R;?;$X7D@#"\6NSSA( ?*4#GC8$*U?.HA/L+_1)^X=0FB. M8Q>O9ZM3)->GW0:&C5REY+68I](!X7E#^+BUY78S7<]*I;913)'!I&^'4H=_ MI++UTJ<855RGTR!%W)H\BB)2"U(*O]I(8B%/WGM^;S2S M4]J:KOE.$_6]#Y'!/HIOW5->0BN> AW#X.X]379]M9;-B.8JFS(A53P[6ZGN_?#$LZN]FH=9[KM3#+QWI2( MIEIG6NHQM93-3 AMC#A+V]T\ZM$^[6>D$",S7?=JW*RL(K4AVK CP9:,NK$? M,^>;![%#[7M'-V#VX$"JV\$7JA+Q=?/_P]Y[1S79=/W"42DJ3>G2I2.](QV5 M+B HO41 I 2(]!:(@O0. M)1NG3I+9$.(H)T0PU-*8&$&B DA_M^V_V>YWG. M6N>\ZWSGG/4]?\Q?>U\SU\PN,WO6GM^>"7S'8.'>7H98ZK&5R6 K9C'JWPUQ MFR57,QZ^I:F&*$0GHB21\-O8O;XLBO7%S"*SWWLOTP.+$#DA-A_=N21$TZ]? M*Q&/<-V /<"^43#;%LW-(.&[ZZ@)'8%(YK=AF_P>;W66"X*\J00[:T2 M[8'QUEY\;#PG(],M0\8^R-!NIU^6$F])?/]9(M/*>X NA]W<%UX\R;Z%.I!^ M9RHK%#1' /""]NM.P'VCT0B_KDNI(&IBCN2*6IH^&\\1R2U)UA,_NG-D=[^: M"YF(NNVQ4L/@(4HFZDHYF^O^8TD)*CT _[ JT74 M][3EQ\ =M.TGW$K@[4TQW4<%T;H*1:YQV&NI;U*QIGD0_8O"B179MQ 091CR M.LYX.5?E05-0[%R4N^V"]X$&^6-3$*U:^G/XO.)*]HF#=&!FY7GM#6[ MC8W<((QD-Y-;CJQ?B,"/JJJ7:04) 34KSP)HD4GBKO2DH?(QN%6,I)H/$AHO MZ.SC%N#@1?]&"%RZ.6+K3@!T/GG\),\W06,UQ2/GP*89D]V=1XT%8NYS3GGS M5W6PRKX1J3STGQXI?NLBLI;40DK=I#8?L.:E8Y"NN A_"R8 K@0F*!^V!JO0 M9R"#<)F'LK$J3M-H&W'%?MM:Z]Z^(@\^5./_2P1!$!8Q9F:Z+8Q57!U1O/J#@%PRAN,K(0\ M0#='&@T= :F=Y5V6^(-,VCL3[LKGAW]EUMXQEQE?&IMYX//4-57)]9[F.\XRNP V]6 ,6N9E M_C+\S0M'D9&/YBF]:ZEK5:!A3(!"B 3P'+QZTIW1LUW8$GO126 M73+RG^?]LW6B# )>W$T*T/(]Z*CN.9EYK;W1$7D,PWJ4XW0ZT+SYI9LSILF5 M6=$I('_SZ861[-/':U09)V]>&02BS929(#J359"G-7T%+L?*/!B^\)*VUKZ. MY-JT(Q[>)6ZJ_)W?RH]#UF?,M+L3;T&%PZZ(,+-9"L708>8?!9CTE*\&Y4[K?7USJU$/K^ MW\5'($&.Z!D;@QWS/9S2"AD!<)4 %N-R,2""D>=..U?4 MP-4ETA*I(.7K9 M4Z2.;=0I*J$'5NC@;U;#]-"[K?9EHJ]MQBHLMHI12BK-;" M]HR7SLZ%\<[4C;JC!$!*,X[F4/2;7GNSB)*7N8=_A5YV;S/33=V[D\M-EJVW MNCC4:,2?/ KWI4GR)^4:A\EB@&%KL+&JAB4JB R&(C%"I-'\IZEA8VN+EI4% M,35/%/\3R90/15\CB"NR@9$$P*TC*N*M.V.-!X%XDO$J/FI+G52]]24:14#2 MC=2OI.O;87L/%A?SXRQQ3#.#U@Q'QRFXS!/12!SX([;BV8P42N0$99HEW(T M#JRWG4JD43(( <#OPM(&JQ"G!\>&Z&%LD!DVEYN-?;)#Z>,B2%RWI*O<8NB: M%"[PG#WT?;ODODNV.?Y1\WP:I[ "O;TM7.SD\;L9;I?^\*HFOZP ;[^/ MYF8:=VK<<77U]A?YP\"^R3^@[8]0IEVE_8B%J>-LD*.D4O?0U5CSMRZR\F"* M",#K@"H9^"C: UAQNKFA?WP:(@#'DLY;SG"XWU&Z7ZDGVH_0J"_:8DIK[,VW MK\MR$N'.6M2*:3!?"G<@?CWPY+I2/9 &.]&M+-(V(R50I4BSPBJ_K:MWNTKD M9WF;6V:'.JD>-K[FPM!5V=B?2VPR(*B^J%S;/,O-[<^' M@DLY]4 ^S)I";JD]@N1A1S7Z55OJ&NZ"+[Z5#WV]:>#[-_75/?#*V%:D2H2P M2Q[75$@/SU?%NOXD;<+Y:FTSNE4G6'\#I+T*.JT0(/ZWJ" M .<_)/L_EP3'M' <;BDP[1N\P;-CV!K1().)#F# BL)MI8NEX^#>&:.>BH<. M<#%Z'^7G2<]S9+27;ZGU!?AUJ;S-DZW%'$>7^Y=0T3@'AE1=6[ : 57H\&8A M*;%/G\R>US5\#5!,-^;Q_#'SV+G?T-.S,<5WN\8@X^EHA4VQ_#LDD[N.7LGT MD.#VP?CTD?(GC&:,U"B)DY]\?[UWDX4;;%3&CRA\'LE0>OZ8=-6B\6 )8YN M[U66GVX( E-J5KH(E&GR'2G;QTN%6';:'5\W;)EO4U72S M;?HT&K7M>+0G7 1XBW_ *F!9;)$.*VZRAAB2TH^6UD*(O$P6ZH4OK=\$90@ M4;[)J-G5";:/11A*N"W2FO3)M(]N>.-$)4=0=O1[FCI::GU2[F5OEJQ3+N1> M-SLS = ],.[C9@LQ=RC8FIG0]"BKKKGG8M3%5&\9W&X/-G9(D%)^FWS>\7JQ MZES=G]028_(!:8_\46FSH =)7G1>?9(N+%Q52&(@@?1\(C'(U06H?X&K5NUK M>_74\*G)O^'.%#_PL:8OID>QBJ#JK:658/?IS:9^A!625P@,JD*1DZL1L,1N::*&"/4#*@V.C+8T7] MGL^=KS_G"C]WIZ]I=6FFU>[%1W/GR- 2+PM![E0J;-:.%&*S! .D6W)2=UF3=LR<%[?2*@:E# MRAOY?R*N79%;0PO [)*TGJMNCWCD,[N*-!J$P63JZYJS=O=7-=IC&(7'.E+N M1X=^*EM+";J)/0:_Q0O]>=3@NHV3>79(]VE+;4^9OL@M54FN.Z$5=[YT@:O1&+_HQGI_5GMNI$FY3A69HQU1]XTBH1 MD!0#^U)%T!HXEK@P3H<,H$HV$[.IXII(@4WM7;R7ZYU(MF7ZV>)WW;#M)W/S M>>OF/)$K3BNS71RO"GF^IMM^*6F*/X.W/\*C&]?&401 LS0!0'1& 3N]B/S M'T]1> %KT8NQT H7AJMD9(QL&RM/BILT8LRS;]Z0 QS2H1>^AY7[AZV61F=K M_? )JJ&VQ YKY_KH^J_MNZ*F%R@&T^K??EV]"SO1GQK&*:$3:E:HJ"X*>_)8 MI_.6G6'\D2:3U'>8%C$L6DUC'X8HN\XX[I#F/+/>MP:_) #VGQ$ EI!(VNP9 M4/%)$]R@]WRU&WA;BIWE#@%05[W69O:\N=4QR-GN(7O:.7&.()\^,E\P)$_9?<[LUZS^"< >;:E MTPNK/#%UT3YVXNVLFG"W2BF52!A7;6WLXTF^<;UY!H:#KKLMWSP^"ABZ]FFL MBQ2'X@JSQGUC??$-<)QLD,3= )Z0)ART*LB:W>VWC=P/1=U*4)9);J"(Z*'Y M- +/+CPSE)PD9U5[!69$:OWJQYF[8SW*M MYZJ\:5\23@4C/--[7H'%":\PXC158J1 [=:V5;Q:U%/"2=;I24C5':])#*). M-(01B^S@*;!D?O%H7NZI:(?;UKSL6_?EU D+6P2G_Z$.>: MOS5^, 9:-#T >FW@*O,_G-U1M\/R3A_W=+71-14+U6_=FNUB[:T'< <0N3#6 M$AWD_$H=];(T]K3Z['+"*YHED*N>CPM4PZ\0 /?XZPF 1"V5>>"ZNE:#S37AW M:$)@TNL>HA>FZ@3 =;U?.)PE=$D/3POMI@D@ %3HETXFH.$ KW9:D;%"MO=% ML^V^*.9@\3YO*/KM(G2TK_GB< FIB;LKFW^ <2, @F6Q3TCOKU=?1X@%8C33 M.^(KPF9B?O_G 1.Q#\ JOU;F\&=@= %E$"*+RYB(&,#68:KY/_J!/ OOV98S MH\\5P>ND6X(?+T\JO ?X$&'X7LF?)5[_TO_K^PL%^ZI\C)N(^-B+'Q.L"H'_ MXZGE66#V:TIU7JV^^5(=B;^5/7J*O3S@P[+_K ;[ET$ O\K^2?\G_9_T_^?I M>__BJ0S_DU>X,FIH3?571_8_1QXT^RWOGA$0[.=8BD!8 P=YVK.N&[,AOR"8 M'I"8O19/1<0S/)B W+<3:JA2GGE<;^)(?YQ4:1AA9YXP!7B1HJTT5 W_/[DV M>:-X)0X"P .:1O=26-G2?YSWG@Z@*&R Q5"-9_O?P=U35O'*/ 2 /P$@GQ : M^N_)KG1(_+V+QA!*?[[>&3S[-,3L.*LS;@2L!#^V7D4EZS.2F$6Y!H:J"U;, M^OJV[M(:NTD:-D]+S5F>:QZXN7\T7PDN]N,"/%O>E^.J,O_D7/I2Q[FBX&., M /G?@QOYHPD4OQ,S4N4K&)&'<5Y\%EE'$P HGF4P??^+@;>'!JAR$T7<6#%. M6VP NC!( *092!C%I(_LS6GL8:G26H:J9E9V4X#1QXC/3:HPAK]?"78P2[/\QZ.M< 8,N(M#P1Z M:%'%/ ;U31_EV3X$.% M8.[WQ7-@FAH@EB4_U0M!@0G)#LO#V;=&_-./(Y[Y^ E@\06TN^*]_D /\OV M4S'C-*;V4#@#B+3"'2E+5B.!E^>T7@^EVIL+$A9FHZ*ZGG)0=(W<.IG.33V? MFEFF/I'%5Z).\_4-U6G_K@I=!A$'!U09-4H"4Z?YJR23WOEQ2PQNE1:N_N=6 MK6CH4 YW\6LW41@?V"H!O)O*]^!.'=,0AXE(D=N!M]3"*9D9IS*W3@7@F^_ M7@BWFR7EWEU;OF+A_&W\)S1?=$._O.@D, 2>?'9;N\6]/V [!FNMX@R-,K6A M'-.>^@)ICC!R,#S,/E%FR*KJX(8&RRUJQ;-7CA8%PE6D/X+*!81>4SZJ?OBI=HD>UX( MGUIYZ-O +YI%C["S%^0O;TKHDW8*AWCXSZVRQT*;%7'X*JJ6BOB>;(P1 2M'2+X=-6-' HK-(!_Q49NG-"3$= MNNH$Q;IZ0?7EC'P,>SS:VY8?E1!WH.E8JMH<*+^P)T$D1'^5_I:[=-ZR#[J MS(( R%0<-E"91H5H?OJA3L?SGY&_IWV '5TA)>]J#5->\5]Q*OI3^(W"?U-= M\<_VU'Q*&4-V)%4<6JW]Y:B ^&.RF=C@?;;)AK^I>K?%__$UJP&E]=?\%I1PG@GQCEV+-G4->_Z\*OEB.?@3D[NA,V(&EW6A"?75 M;;LPB((ZPFEQVICCSN7\6Z 0N92)QY@79\55Z[D#4>S!WT"='B"7NBONZ.5; M7T]_^V\:AQ#A+&<:@Q*C396YL<7EPI&O&Y@KE$3V9=*]@N[D.3#%]GXC[JFF M(UF=3 B:F"S\;!$T=N(13!".X7$RZ+T"+PJ0KW?A2FRMN^R86NIA26W3&#OLYLU1.[WJB4[[@WK[6.91N5 =XGL#).YB#*"9E0^A_ M\,4<##'<'K&E$5K4FJ-<-MV8E;.Z#'SH>%/1>]T6=(>R\HX1#<'*NTLC^\6- M=3&RB2,VE&NF:7Y?RH53*!\3UT*;>] M=8N[]4.$E"_]O;U<]C,DMG>56 MJ@27UD_OA^2'%.V]A-<$99SM*V.PT',EK"!RL;AB2T;^F6Q;0G&9U1;)_MDB M0Q:5"ML+<3E5$R%RMU_E0])ULEUP@)4FF!QV$[T3#08T1\B,+W/*A;E?+P23 MM>=02HY !E9%$]B$T%.).*YI(.T'#$D#(FZ3;B.[V*)JZ%$]#6-Q@.\ZK7I'_EHW^PB2223IP+?Y]DG#P+2$?IC M0486C71K\'V3F;6Q-B ,?BIA<-!ZDH(EZU[M-0(-(U'\H.H\RZT'WU4:TKB8 M'[]?B/.(.RQ7E%Y.I,2*NVN\^>#@+_,4U'P+@ M1G/_9,>T::^LP(I<\A'W([7[](.R;@;OV*T\LL[L@O#/S M.Y?NCC/T[R$$UE+U$ #DTL@.9=;Q^)^=^!^2%S%*!(#+7//H0K/RRT79HX$[ M56?\UQ);L ^7!8=!EO=QS,A3%(HK1="?>^*Y0S@W]^"GXI GO2FJVZE9S9?G MT]5N&N>S\ P3JHUEGU;8Z MS VOB2 -A+'6 V0B6$^MF6L#[O;A)\9R-?#F M**:T"T[J?]#CZ72"X(ES:I)T;FHV.:Z[L<.9?%/L34R^$$HI0JD"J1(+9.KP MP6@B%UO=5H1]![2;)QH( "K],Z7*5UIM[V9H*A2'[J6\NAGG:M<):D O]1G0 M.-OP32E*%ON'SG0=(V82(6JLW]N/^9F'=$'>R33D[=IV 2^)HUB>OC,N*OZ% M]:SY"O3+>_LG I<^L'0Q&(2$OL%?1^>_1>%4W)!5(BM#7,WF61O]]$&E;Z^P MU-L" JX\\;O=M6;7*(2_@Y7O,7.SF>A&",/*-[0%8!'=/-F0,-?X#A'/GE"O MP6T@NW_-<1$F-Z^J8*00^W7)/&'R=YW+[=G-VAY[C^-RF?;T]Z<[WTL]H]*, M5>]+1Q;AGF#4F_+YP@\7?&>ZST*J5JCHAP.@Q_S7T]PR/-5" F GA$@^?M8_3'5"NLNU;QG_HR$!*I!HU-[5=?;,%$J)$X:R%64H,X^[TQB939\Z M?(X.'XNS$^;H)->*3;(H"[X MIFSL8Q#()PY16&[ZB"-XFER;]<;:_I6J5;FREB'KGX)G/#7?!RAX/D*KUS^2SXTV%W8XT$_,#^9IP\ 3=E%P!LO"M"2JU7-BR<-%CS?WV(Q+DP6_(^^UBO(N6^GZ_ MY@/G11;T=!J2E5=)5+TV3'?"+H [87SJJOH=/V=VEP1:^I=R+.08[:^*,??D M3UBN3;\ =J%.>GY ^87SXT]K71^Y^H8Y]R.W\^C,A"F>VA9N\AD8Q&6F,5;E\V]36::0<*1>@$7W=F]\R/.\ MP1V_-%7!1MV'+&^X%_:;)$A(@BADD8EO#_V]M78456Q?2IFSN=TO>,LUIU!N M?L?,*X/SRMJ@Q\*DL>;XEHVU\V>I)L_'V1W1U[M\2%_/+LL^ MN=&U]L/(,%5?O-;6::J0@:GQ_IS;XI"Y,DU=7W8*FPY!5HMW3]1:;]+>%[X)G6H7T);2;MR%L_L;\/HMJIWAT;[QYY+-OO?[@UX6_6MH=SIQ_&4XQ6W:11GD+ MRUI'D!YP)AHU)/C$PSL^='6=T%GL(0?>[HT?B4 DBZR$=\0M%X2:Q,7R^ F MJ<+U$ >;+V@%H\1V6%O?Q0B\_QB?HF]SO)!UO@,G YZU(I<^5QTWDG;7L/4@ M!]V.^ ^7Z%Q\$<151Q,#KF[CZG-,7^F^%O"\YK@E&(;E.M? K@ZP,S5NDPE+ MZK:G6J?<+YJH]@GE^+':I$9;Q7RO.Q,5,_V5)T*N:^=3P16LB7(&>K@[D.GW-0/T\66$\9K;6KC@C6'5M4+N M-]=_D3/NCBXJYB11@._TBWNDM'\V/=0%YB8P3;I,EM^8*/_Z+MN9YY/?A/6E MG49>VBE-A_DRD$PFS9$N/?/C]IP;)X;<(CIA=UKU4 M:Q^#45SJ3&*?:(2G?UXPF?K$KDBA?;%J5NQ@!K&N@*18W'LUGWZ [[7[@/C& MW_*)X0WQ0(L):1!*?G'/:(+HX]<5IYY&^'M:K:XT8;>G+[2^KR_]BZ$RWN%-?1>>[N)N)D^]2ALCMSUL:O=K'KI(*'%\\SMIXJ3 M?3A/9#J)[PP;LYRFRZTI]A!N!( SO7.,Z]"W8H?Q5!=^<)-LB7A$9=U3T?2N5]F M3*S!Y4=?,I\D]UF4<8H)N.F.[\58 M][-YFIRW YGG;2Y=+ZX!Q>^UK\BM^49 MF *Z'\*,M;;5Z@^W#Y^$-ST,> B=>YQGV[)PTIR^]7/-8R)F<$<6!5D%WVZY MWLQ,^IZ3N\S5*S2@W\6"OX#TC\#V_"VX07L_OR,H:#+$$NJ--TXL\Z]_TCPI M8J>1^,+S<_736FYC*/9QH^C> $ N4GDS?8'U[, MXN)4U.5RZ-J>O$%E@#8 M>Z.)X[7(.%DE &#$@'\R_5_)!)Q2%"W>SC QE4]( T&][+X=UUO-5<9?DT#9 MO4U\E\;-XD-*EPVZ=$;IXI6^>/IQCGC7[SGT"M??D1GUQ3&2X2OK^,"/%+.XN@OWXT=.+$@6JG5G(VPQ\(-'<^;[]X6OXUC!U7^"+U)AL/(VP[CF& %BZFO@? MJJ=2,Z8NC55;3AM'>?]8'KGN/%W/_%Z8)),JC;;H>5OU/ E7RT9Q,]9T^5S! MV6T9G1Y+3F-!H:Q5./'1..AYWUMNX@TQ;87 %X?E! !28A(.9[] _W'[/FR$ MQT%/OA2>70"R>Y1)QA09Z'IMV,>D+B@5(DPSI;8?O=;Z0DP<>B4%<"VONZFC M";^)J\C_RW?_\:^OY:F$X6W0>XK_?^1A+8$W%WW('R%"PBK!>E#M$%I[Z9P3_!F MILZ?\%Q_7_JDY9:F6-WET5MZ8)'2Y0L:P_1%NN;PW8;9(O'^TGLQYOJTMZY? M>Q/C<](-)]WRE:4WS:/^45VYZX[ @P(:?N?=%V'>>_S5E'C45W&2 $!GN@"7 M$O%86FBW0SDT1.5\^0EGXZ7R@DFVFCT6;+ JC]I;$^20VJ43=G[/XL*80DTY M! !OYJ[1-@-O0EB#[81V(7<_SIO'EL+H]S=_2-DA3P-\T_J/=Q?TS/[^ZDA+ M!=\<[FFS;LHN=D8[M_E\#GAE8?& ,X:'O?M3 4 IW&I_[KQTOQKZ=ZZW@ M3W+A,'@W_VLK ? 7F_AW3?XGSS]Y_DL\'SZ6/PR60A?%+4F6V2<:\1>(>%D, MX,)KH-OM!,!OC4_&G7_-:/GSFO1?:_/XLZ/>K%@#>Y19T"QM&N4!Q4->*W-D MSGG??:.&:< +S'1<]UY)4)$DE/LY!^]V!_*>\^+7O9;X:R*4%2':F.K(52H$ M"06[R21LI'1V4^,*6RGW-7W3ZS9FJK][EV^U?%_QLLFO#IE8Y,&"EG,Y3TRQ M4"\OXNIDMX!REZV)I.5(7IT M##WEVHP17%4R/4["D+Z!B4,,9JJDJ@SZ0A@:QKTK"(!:V,>[D0816DD-,7%: M\[H)MP.ZAFIJO"GLV&\[6?A6N-]QVZLJ;(T'EID^^<(.8:I0M@%OUYS2^ 1! M+?G./E[\(Z#[/UN'X'$1=G.%/=00JV-]L[O_0IJY-?T(;.\K"*:UTQ1HS*!H MD+5*D#<5+\'//+7$F6'6TQN)W[$1C;ERMS5V-$8C=I$I9DBN/93KX$X!,2NI MU,?3W(S\Y9JS^%+:[&UPW^R99PQ&,!'1WF,X5W2C<+MJY89HO@&^YYQ3>MY3 MB-/N&U&V+]'=SXQY@2];X)'0QL.VB R'3]A68==*@PCN&7>3[I$3,$.5^Z?P M8J57A3D$:O.0Z$\NLB>],!Y,KK,\V?Q MBAL\B;R/J?5)%@I)L?&L;A>N2RM);<"S!=&1?%5#&P.TRBI),<;4 C//@+ = M=SM4TE=0L SX(&[UZ7W:X'NP;8NXBE^<:>73G?,B_-$K_1-\TTW^CTG=_[ L MRNEP?WY#?]UR/H+J*3H-E9>GR.58PIP:4-?W)0@MG*9D:%O,XAT&_+3LM5^8<>3>LW)/K7%]TLQ?5&V-1T! MP RU>9CBX:P,7X<.G@7&G-:L.*+2BC=A#.G;72:R\GU;<[/6C0M]'V1\,?-? M/Y4+4%:R5.]$EX8!Y5[<0YOAG8^EABM=YX!T9=;G914:Y9N%9RY\53RMX5@%)9K-78O6N4& M3G0E6$?07_1(5[HE2\'8(=XLM3N"^\V )ZBYBH?ACASLK8:.MK;/?__8_U+3 M(X_#L)DK-1'R]Z<:G+QU@WD1TZ#8;)2+!J?YNY"M:?ZIJ;@4K[!!QM_.RIP0 MN^D.2?1>%U-\0@;8;464SF9V$V/IPIPEJ.W.X,5P\Z'8$RI W/AE:#Y^VNQP M 3EV8LL^!N_.'YT)#BDS0EY9@[\HSBSQ5\1:@-*F M&PY&C*^\$@(^A=!=E"ORU?@WFXP[MLDT+8%"ES3:SJ4&SA]IO18CJ[_[]L. MW-=WG U/WF5(&4^EGBK%\=FDW>=_EJ+7E +V;5;*B]G/C\MOH(Q%-WW%CY,R M1<84:#E$:HKKD _N%M0^;W_%$/ ]L)S5OSKU(;8+R4[M'V0RX[U@B;+03\MO MFJ]J^/(P?-[SY@MD@!PI8&TE0=OSP%+5>%.GL*BH-;T*^/3SQPX#S8N*#M8R M_Q[CB5\P>L0]GD_.68D_?X&;OYT>T*GJRZ1':VA^T[67JUX=8*?F0"-;QJ4& M@488[^E%]_SB4VI46F83ET(XHBZ2RXMF_[73.QY29T'*-!?CB30! 9Z2A+/< M8KJO_M 5W[ 5!<'S6.?JPF!YXKRSQ97O3NN-Y-G=;>^^[SB^2;5:P?F.,SQ+ MV7V1IT(BG:5- G/]=;NQ'PF3W \>3WED?$;3\6*E8/9P2R#I:WUWB@BJ^D/$ M^KU7P6IKP13*_W(Q*SBLK 11Q6CV=%(J/7VD1SWQN#DB8*]1R?/ANH:Q%ZT M4UN]8OQ^Z(V!#]70%;X!86@/E+B#;J7"DEF)SQQ#/!)'/;=EPFC+&FHK&-(T&/X8V- >H+ M^%0'#R*QMZZWQ@8MU!WP0H?;7RJI*/"3BS33';:5SJ8,=HM=CDV1FIV6 :/' MT (HKELEOM\[I)N$/,-.?<3)UK4T M.O?F\>:-E$Q(_>3(8)!@3QLX20Q"NH8]>*Y[AF3$U^9(0^H@U+1D'#)VD+=&WU+ %HRQR-K8V @ MF,-EQ'=8#&U82U,:I3S@L1Y<"!6_&&TS3 [SWI+,^K:E]" F8=&[K3G&Z23 MD]]GOEC_^N @%\TRIKPY2'?>HD >"!M M5/6?W_>KJ:G3/A'[PU_4"%U\A-T&0FS1>O$)J5"2W,K-P'=,57'-.A8T0H^0 M0!;4W43.3OT8ZX[&\\9KZ\.C/X/ZE470>WU!2]3;3!+^/?W3Q]._LSR'CP4= MPMR_F$<+UU?L ;ZARQIDVRCJ"GDM5I&R@7V M(V_*RDB0L5$$)ZO3FS0?U0,KF-P4+O]7Y9064E$6\A4OU#F!Y^D5/?1)[5UD MF9"*?3PBPI6UR&U.AM\+Y]&_/G1T%9:$UH]5B< Q?W"6%6:>-S-3 W$]TGXP MQ%3.Q<'R(M!DB@XRLC2*ISK]3&O4G''*0P T%?Q-N:^_-,6EE:6N]\I"+B%, M>=M/SGF:4F9"'.#)&\$?')N=='Z]FGO]\[=7S'Z[RFQ,MPHE+-EG)<#=/K4' M53@L._LE@%1M3)^ X9 ?4.#,YSPJ>SI+D_IT2_H MZ%G=Y685K?)2SZ]?VU:F??5D"BR\Q]/JY-[0ES)@W\UY/7WC 5T&<1@]^'UJ MS$#S1:PMD'*T>&2E*:GIC6.ANJ+OE<>>EE:9XY [E&IRQ$IM,Q.TAO5M^ ;0 MOBMP9A4ZP@9&1R*53GJ"=?L0Z<4UO)W0%85#>);6#NQ;76WZR0U,EW3305 M^;9G4=6#39F;XQ?MM+;'[)6V12TNXE'2#X4PVTUPD+7ON6F3Y0*/B%NA;MD/ M)OKH?$I3NZ2?+ EIA\&T*=KF4$MH"K-;.WQ;-^3Q::'513S3M@%LXC"?H3K- MMMS">]/-FF>JA3,J^H)X6:JVXGZ(N;JB!3W846%_?T,-#9 M(S,?5HO?5DTYW \IL+W)KA)4F1IBI]LXZ4-UVBP#S)\00#)^ASB1C U/Z T< M*0%PLPYD&S>= ]/6 UI&1YKY6 -?S)BKTWFFIGH&?;:GHTWY M&_R?$651"/\4GD5MT?BFNIV[.^2DW<_T.9(&U %S?TN:I@; MNOB^O?O\:.D,]HL4G8_TQUHB@S5Z4 3 '%-Z<;!'^>*B+L.[5*O'GK.J^E/+ MY"_0@C%8TW,)371-+X*^&;1".EGMAG)LA,=LC8NSY#TG#6ZQL;V;K'$#4L[% MQ:>\JN[T24>@3TGF5#B.[T&:=G_1JA\](OAI4.-60$W?7B@:!YR$*!VCC-QD M]<='>E.$<[2/,ZVGC&4&D:'\5S[+Y/YD%:, XX31S^"4':3%6$_+P;WO>=SQ M(O:O'["2QPVE$>'F=$*]AHA.JJMC[J^M%"Q&T3%YE&WSGX]JG/UTA0%_S:/A MU_#?=)?A=YQ@@DRG[5-NN[O58+>0 1;?!#[S*V:W(#_<)%Y06][U""=-U,8, MA(G@K(,+=-T^-26TN7W+$/4 7U4:6B#K:Y)Y97R%6IR[@HU$+(#5FE;',[LC MMSO^YC.:>/ZB;%CNXM[4T?T:@+_)KZXV[K/@J_Q% MRRQ458&4.5@C)NS5O\E_-$00)SVMS,'S>=.&WXWR+M'QC(D?O=WN]-9]!G<+ MB>&#&F-7S&]09AWV]@J0"NNH-^8M&C73YIY;I/ZRS57/EGG'Z>$-R KC'2.] M'GZMN8;G,PV&VH)N%V"\*]ME1&H)3>Z&<&"M\F]"A/U*" GF;J@8.BE MAH MWXIVR'LY/_?$T>40\&*& CUP; >,R+LW!GE(%67YI+,I847IP9W*5;,7!\\. MW M>LB@OHM(&&8G"=M^9Q!1]S'DZ 4Z9_95[TYCGSG=9#S^#^J#&C8"!OKVP M9(A-&_K0M*THRSV[9%AJ_R*%5E:BG>/1#<&KMU^9U2+\()W7B5QQ NC+B:-% M\I'-'7IJKC:VK%^[.47B!=MV#?N7&:\&)>=AJ]MB[J\/#P63E#V--S57]Y)^ M>397A\RCN7@_TXV7&8=8M>TAI)VD!2O.*R2=8E^:>/ +W$S,DLAS?TCOBOHM M(7.\1(^GJ^F+U;O9'ZS>,*Q H0H<$>YPF8#-+ESEDGGP J;[_&+>/B?A.,:] M:/Y=]I3KHU<-7/K/"HF'!1BAFD_0\%E=6$*:SK3E>W)JY M%O&0Z[[00[;67YWJ%Y&%T-$;T+UZO+3+7_.9HZ"UA^!3I.C%,;0_<4>)&>^O M2P $YV/*RPJN_[].@OY_,E9%#$:E'TR*E1W(8T>[UU62B=[>[I'WR583#, E MGTSIU' DOH^1+YZ*U#CCJL'W_(#_>@L_^4D ,*G\1XHELO"]0)9_OIPK9B?+:?7!SA8M^2^EL\43 (J7HH6-8J=%WW0$?(!HH4=*HQ05(-(4O'O05(_U MCJ"F^QJG5B2,#ES)B.Q5T2@FTIYS,L&%H"?T,C,9M9MCVNL=V;_2FOK?JVH- M[?JSCIA:7FG]#]V1@MK^7CKH!I[O$ #Q/",[]+X'!D(Q==UQNX%(U2$YMJG4 M93BS$_P61+34/U:MDP&A4#?)8;PBQ6XM#O6+TI#+4/Q<"'22S2.&)0#L_0QUMH].A0<<+P)V M OG^*LT??S'?R&65*'G2WM$;L_X9/7ZK3WZ PYB#4FGZX" Z%<'7/6E'# 4]T_\P\&D5K/ MDXV3\VB(^R4=YH&YIMJ Z2M]RP._L<+&,:HA8BY/U#T:3?EGGX?,B*&_26:/\;B4="0!6& ML_ZY&-^$5, ;]G\T;[[W+7R>RSX;[\1LDSSYKXK^16L*_SJVBPO_5?;_"I'] M?T^W_R>([/GS_W?]T/\:\4KH..,7LQXB&UIV_?>MR&CJA4O\3W"Q'P'0T!Q^N2%+8J^MHCCX M,KD12CW]+7BI!YN76R]_S0AKP%&GY?+TF]47S4E;RG)3HC@E!:]4&DU'ZFNH M[)>X;;D#':-05&EEYVP-C@R8;Z\Y3'=#*7OFAX4> ; LJ[F9_U;YOK^7&3K_ M[1'[+9/VOL=3,E)UP=FEG.;^*V+JJ9]6NG89Q83R7.@8>=X]Y5G(*@3*G- MZAH?L]7;\3]TM!,0_%^Z[A6DB.E98G (_5A,UOY&CSZ8>EL^KZ*H6&!4_G9EXQ0E^AR@K M-X>^#X5LO*[Z34>\UOL+X]K-#V66OTW927!^E1(1K+34>JY$ *!E3XAJF*MA)\C19OQ5V,%A!9[>\:U* MHY#W*%;'V[9LJ3\%87X!$Y5!LCCR,S M^V>H4\_&18&]&&HA=Y5K?7LDQ,5(2+S[! M)&A3](FMI;^O!HN"^[I"6(Y#G(Q.GC;KXF^",>MM^XY;K+13YX6;^N5$?P,3 MC#TY;D,SQ$@OQ5EH1D,4"K:8BD'JS^,1Z3X@@[J@>&[1H%RC87-&_FK(/9<97:LP(+FW4**N(O=M'(T:+FZO<9_%+F0& N1KJ%@ MT%;F4-DT:::O>T3/<=JW IL!)N,R>@B *[/J0/I75:U\;.M MYZS)3CQ)NJ+L ORE8,/AYT'CEX+N8%VABF8:>'UX8>L.,2YZ("+J^H@ZD8=R M$=+=3K5D. !@WNE0Z$[C* QX_VN+U4_@(7K.+G3R$#F>(GGGM MLPVJH=B6 %D,A->X=RZ]C5@JKDBAWX0,%TUTQ5L=X!, M0\WC;TTULLK/]D+ 2:LBY#XV#4V'B>%&R043K.YJ?,!Z)\^SRY1>)WO99!!4_\RIFU M%_H]$IQ+JZ;/0J@]"0"55MAJ>C.XB@"@O?2=Y!!Q]$GW">*DCVPND0P+MF"* MST_T26^?L@M5;TS4VV=D?NF*(C>KV<7D'%>2[47F*;%3=G"]S+LV@Y+.97\T M@?B.D6IOW24*/3O.@=1=KQ6&%YMAA(I6FWT6&K6-)\4+/@E5P M.FV4GF3P*;L3<\YJNF)6*#N#LQ?VTZ^>Q_W/8O6V>'C MP'WXK"3P](3%K6T=*M=7@U4)VA((FA\Y@J\*$@!?SA/CP1TW5EJ5.?PW#+"/ M< 8>&))ML\F2<44],'>2A5II9Z:EC^3MNDD9AJ]$M^:/J]N/N= J41VB%2 & M^=R(\B)+[<+9N7F$]:;$; _/_NX!#XEY;DE&CF+,IZHNNL.:"%S0!_]VDYG# M$=YSE%\;W=>?6[=/]6&/BZ^%#P.8USG6M>G&# WF=18R%D A DLC6S0G)[M_ M@ ]36 XY_4/\;!P6$]D%O;.5S]!AZ6./7'CLO,B/@9S)%'L<:U^5>;\Q#E51 M>&7_C;ID-Q/R$J[VNWS]Y!VNZJ01VBD(&8#Z97PG #Q]S[/A@[A1#&D/E&D( M;=J==0M-V23JVD"A;VGYIGC!2I?X!\Q7*X7'P8R;_]H-<^U[KPJS?N,/NVQ;XE?@I#M]S6%]UT M=4UO><<5F88Z_\_,DB''%$2%M$7+;_-U>(Z5GW]-Y_BQ+!=2-&X//9L*W1$ MI;2;"'-$0U BIY9JVI_@4HIBOQ@W/LDW\URZZ)2EO1/H'4BWN5WW0QI*OF41OIN_LAT+IW6YIM,*"[-*,#.;LSK5&IS@_/6R#YST M)NE>9*PRK4L>W8]#5D<;]&(5E!,B.X7BGMH][#\0=E=-^B)RLR'OJ1"?DQ". M4C)/<*^&U?_\ =8-^?-HZ3:00D4W?%4S?SA [#N29EW50.B+]Y[>1.,>%>[A MA$^%E/JD*T=+ABZL&=;@'3]+KA7^X@FKEI+&LU_E92F>L;IG)P'09[B&>Z)I M)<<$ *H5;I#UW\K[[J"FM^W?@(H>Z8IT# J(2*]*5Y$F3;J$IE(E0*2W0*ST M(D% :J2+-*FA&9 BTDNHH8^XY]Y[SNV]^,_>]>6_>'YGD M.UE[K[4^W[W6VFMFSV>K*E7!PD+X1ANI@KSFX\[X1](SK.OBFS+H:BJ0DY"< M.LU4K,!*8/@/*09):\>4N:UP/UL.L5TW8$MJ1^BN\%>*MIM,2]>B4'P6I$() M"9>W$,;>GE*?8X!O-7 I:AWI0OSI8_=%<<;\^CYS(4S\>_834VY 8!FZ@J9 MN(O.]2D%+!80:I04$I5VJ2+IJ;.8L+Z3YQ3JLPATB3%>3608,0N M;..'&%S[4:QB@!-,5!)UN[SH@OK7;FZJ=6/_;NSL*Z73\\+ \V#.@N1L6VTZ M,Z1I'[BK/0]9!1S=?K).:>+(-U89$T[ Q[I$,Z3:,8WD1F-,A8]%K=O5< MQZG=^H-O/%B+>\S?#(=?H-^OT?MW-*LR^.?8D+B*5S-EF@@J*<08C9U5I!^; M9VNQY3BDAV[H1*,60) >KD%UDML\F@(@J1%H^K&.$1_\4>)LW^K=ZT[83%E; MNG@6(\V9H?CV]SC/KV.\]Y$KW:3Y=6T"*:N.$O=SAT02-N)OUZZ)Q,VO+\]OA"^HB MO1V"3_VYQ]J.:YT* ^46)')?O[P8P;DZPSE:_0NV=I2F4 04T\.4DV:+/!G\ MK;3\2_JSYVV,XIXK$ZHN!F&!1X H6<9?8"U2/KB[:VL'O*@AOB:XLA#.CEX\ M[4GN#QOC+>SU%5D*I5%&4;ZQR;X3I:F(6T7% MD<6Y4A^_/O \LUM,HJ@7:&/E=R[4&^#\W?A0039J 6*;D0O#[C%A/!+2P^:9 M4 Y\E.:\M8-X6/A.G9B8NPA-\GL7-B!!'!DSP6OIZ>!6%V47$-_@$($9/\O6 M6PSE^= KED)7?SWJG47UQ,YJXX/4-PO&\.X>>XV'RUO,=:'#6U>9A.*?7Q+F M\[J8M;/+\O71_4M:;_[&1>5*%:O-G[ 94/!KN_?RD*7=\5!P)*09 MHM1ZTG"RVX/O@]@JE[U+;[6F0/FS*;22(2&AY2(CWB8#.ZUC?N+FL W[QB9. M=*EN&V/XMH7_;H]?T-GC[1$&#NZ4N8 N;E0LL3(HO&^-Z<"*GM#764]CM0?6 M"96G&$'J+3SB#$<;^TVJ4<,J9_U/MRCLMS' MC#&0:U!B[F.K27L-XH/ME>G#Q:8\,+H"/-A4/TJ>5,G]7\5?S/5V!;/R$C"G M^G'\K8'4[B2/=F<,PT<AG*;R.W;?>T9XIK^0((ODJ#Z['@;>7BI@Z"J/M)HE"D])!,< MY+W'-K!6D=?;W9*'6QCV1>T8L_NT/EA*O*6;6)JH+Z6W#>I45-Y=7:O/]'%5 MOVMZZ0S:T\A-KD;;UGQQA])?23'$QHA_#@%^&MUM^+IS(-:KU+DIT#?, ?!> MT^:EFHH'56^+XSSPE6THI>$J+E7:&)A)L$E58&CB03;A&Y;]ID^2J0@S_S:= M/_?FV8['PJD;JDX(ZK5!"C!ILAT4%XFV'4[U%T\P&7&2GF#QBU"OA*B K69)6![J[_XT&E:$(27H-1).'8:=FO)T MJ6'%6UM-BL]$RD<_EPK)Y[BQWE';DTJLLYN/8307&.VK\LG'(";]?1@1U-*7:)6]!1I5NKK^Y-QZRM>6D63H&^ #?R-X0# M(K@S383A.1RN 0%&P0AB(9#&9^. M9^X&EP63NU(-QK*-6ON !@/4Y4L_;@SUW;M_-L-4;M''T7+MRTYPK.D^(!IE[3. K:= MH5S%U3U,J#CL$GTIZO6,I+4^#*=FM\)B! MJZ!(IKSG(M!GJ8>+6"HB[M_\\ M,G;F5#4RDD6LD_.E,5]E.< NZ9$.T%-;5@#@K [ATGA9QL^P8T+KO_8!8$45 M^^:>?J[Y;YA0@,[NQ]_-$[,B):X-F396SOQYP-8$Y-?UZ M;OP]=9Y@4L--3"WWL\BZ@\SCO^(.]W-^-IY-P(/=FRP863OX!X/:G&[K"8ST M^E^*4*H/OZUG9APX?Q\CYY0&^NT6(2:V?CV?_D'U-W54+5 ]DIW3\>I'HC=E MK6UO)V&6W.=0@V*]C:N75[CGBA@"Z,Z\#V&A7!HX9/IF7N_^>L\O#A9P)2LX MN%!GQ8KB![!QH@%:J?W:[Y +X-QY?%>G:=4UNP=HM#A$>[N9+WY%SFR%> M%E!1 HN3&N*XYPS?!8;-XN.M#>1>/,ZVL@B_/_XR4@NG6W&7;SO43TYB0ID! M?-PX_'(H8.E/HQ@LW@HZ1!2*MQ:*1%87?^QL(C_,A0/:Z.X.;%[R@C-^"DD[ M ORK]Z9[AZCNN/5]IHR2I>/6UPN(0$G@=9&'P.HABBP>V59SD:5A9)/'V+BJ MODZ+V^)#A%$SBV3HZT1ZH6O%M NI2\GS36V?=)KW,Z'*6&F88.O!Q:XY;;"4 MGFIBB"YQ[E>:W47NN6//;?_5<]$,"IJ![\Y6F9;]W2;@;W$!*%*W^,>PWU'[GRW*OQ!5 M.7V0I\+E/[.]X!<+M9R',+J8^PU,/DXR\V,"?>V4\6,=DT-RL=/)] MV^:5COK=F:R\B0G=+<\*RW=5;S5RO#H:Y;BIJ9:;;O\IDHLTMVR/&]VHJ"/ M9,B!EIG9=^0\:Y/Q=G*'#1TA8R5<25D6\92BDV^]*O2N.G%J8&K-_!'S5>E+ M=6;,[4M%#X>O+*_I4Q5,0R4)TFJ/?&;/^$<9XK&DA'9C[8=@!_F$_K>P+'W# MFVZO*FL,ZJ73Q[XU_0F#9%G*CZ;O8%A29F"L6*_**.6\;=ETUL)L17[4>W\_ MH@^>(>W#^-3C^IB:%&XOC'7;H,YYZA S,\"+#?#(VI]2 ]C(9L@=4IA^.>O" MQ?:_2!VW'/XGF:>?&)3I]Y]>9?\!T>.$^N/'SX="V#]*A%ED]9^KRP7G(ML_ M5Y/_/:(VD6\F*]+MN8,&;_;Q_??705"?O9K][!6+F5Y'5)6B]=TM_32+CV'W M*FO(;NU%4^^2V%57B@KE38X SH2;G,/F2DW,T&NC&(=F@AC<;?GOO%S.C6(G-' MGB2;BJJ$2XF8,$!!4.RBLI&9QS! ?R5&0XF\2'?S^7.AWD,F\7\ M-1W/_P4?/Q"$\@('6XG&J8B,^/ON&*3 M1!124@T@3D+*ZZ_Z=L'CZBRO^<;2,'[2B7R3$UR_+X.F<-RU*IR$C/B M4"R3=Y6"L_R5W^H> >AWFI@K?S&Y06=O'UWQ^M9\V,D'(P? !7G!DF"#[)"^3+8!I: % M")NE'NR@ -OM6_-),Y[.0YBJMHW:_OS3 -%>3S<0"OBQRA^?:6$N2@E4/_&9HORD<*QO D0]+O4'(J/V\ M:&;;5H:AQ8KFYQ#$;0>KTY2E-?$\HQFNF.OC0P[#2MCLVT.(MW0),;4+%]8Y M]S:"Y_3<2=HL]:C$AZ(E)8F;R04S/WS'!BV?7K)X4RA(=?,K7QZ( -E S#6Q M^V?OF=CVG@:QKL(#0)8FFT*0_3WTNF2)PYH?SD_LK[ M4J09J9]P7ILT?Y!1"BXG&6ND681.ZE:BAOQ6,3$Y5.DVURI%5I2$>$^,#7W2 MM#Y(A J6K1'.FVLH&8I]UB M4ZD6)5:YV0\GW$]68\O9.#GX>\:9!0:>WW"\GO,$8#E&&)O?=S= MR?7]R9W#Q+@,"BW!L@,)"GM5Q<@(]KW(XQ;T16'Z5=N ,W%2[D[\&SO.[,V' M<#_[$;S;/O*F;> =K:G ;A5 M[?G9">.63([1'5&CL7LC,PN:(UNR[UDMLJ^AK3X41XY'.P ,GTH$:Y>BYPU: M,@3G&5X$Y3KOL27+C9EONXB-E19CM;5$J$P-D;$W^C\I!-X2@MBCP,E'@!H> M@T"]CJ;Y %BZ?E_DU=R_NH;[= ^LIB-H(T")9O,:IUX\I$\O3X4H. MMRIF78:(ML37Z;=(!(.[JF8QBFT@\3:#P6 /M\[4A7^LM!N^(*Y4VV4NEZ/J+!,SXN9,GMHRYVI'K MI**0*(*8GDYBH.V2\*&YDLLL\2V!6 (K\']$SZ5?,[JU*QSEO*LSR=6@8^&V M4'T^62OWLCH47L)V9'WYCZ*\54S4? M!OANB)G,,6^[33^+QJ(*CP"A'J1 [UI7AN>Z'M9I2V]GIH)S^H0^EJ?U;#.8 M+WUVM8LVM"/?@"J@74/:&4,7Y! 3;CD!4E-ZEP_B\Z39\7VPI2S1ABV&+T7@ MIO5Y\#:L+)[6'K&[9?O]L#X3@NV/S53&AR2)0-):(%B^('[#@P@Q,0HI:4KG M575,=/B/&P)35X'7]85?'-N13S@IY:(B&MHEE[GP>=]AD=,;>5ZVV,]XAEV' M9;;J:I\GX!$-K?D $-^KRA#2Z>8.5;'(C M#1I)(\O#/E4&W,YDC#)4(;0O6$[YLE9N7-,^-<:TF5AD\-@A M'$V>M'U;+W U3[4V9$WF$"V7;PRJF1-L)ELVP__U/AQ%/N,[[D%)X:9Z"WP MT)P_.Z%OU@@\#7Z#![9LT4-EK+7\?3]OQ.9)35DW)DOUH;58KCX:DN:>"Y$= M07]+MD^>@I]#(8^3NT1VI!#+?U\RDC2\#Z2X M'(<.AXX CN<-G!3O8)5P= ZO:#P0J>4JK!1?0G\KXLSG^0W0PS(RA9[''^4K<<#0,;'+S.>![*C#>/]J$W(]\?9"6NF,CEXS ! M-Q,V-D 73P#DX(%V\BNRQD8'".BI(LNI5J\L>RN7\RYE_'Y>';QU*;>[UM;F MWT@]/5M(&SO"K"\)+IV-A*V0+N<.YR(,#D=G%Z']!$4BG+ 5T\A8?+R^09KS M9[P;K#F#U&(3O08KE[,HJV)0 MRCLU;D%)&I,G[(7?M 1GBM> E6-/?70LP\5D1")V.:J=X(IU"V^LNAH M=+$_,6'*]2W:@JBV?YE-H#1VXF#BG66]F:K8. RB704XXNU@:YPRJT6=VBS+?'2B(J!I M0;=J1>SK'.PRY3&U\^#ITN-W! L=2V;6G>&,O1(CFF.*K$OE;Z^C.6?(+>30 M0:?A$9_I$C0[,3E/S'),JG26CQ!W]SEEWY#!K>=QV+C%P 7>L$1"]\$)&PO M4P+<]BP.U:(J#:J;3F[M38?8JU:*E06704_@-;(*9ZQ42?36*&!RN0-^CK1I1XH+)?9._ M6./:E6[U(&'Z%(NA1>JI/Q <7F0D&XL50N8G2PSN$AC*(3[YJ\G2[=G?S'4@ MTIUQ29MF,\6#ZK$F-'V!G 6$R^2V3 D2!QZW0^^H,ZUC5(<&;7YO-3WL"JK% M2-E/"%UK#3ADHH55>$3NJO)0+N$1;451EG%,JS#7VIJ8N5CG38%GE (RH5*C MRX)!WOAUL+ 3_ !U;+(32DXP;H/DFML#=K]3IR?S/AO?5]G0(P M9KUOR.H.R9LM.OKN'"6W5/IS\W(C>:X,1X7MYX+>&W7%>40_QRU]V;!( MZ;/H3J@M5VW3#UY#)>#[6^KI4OE3?9_9V8E%<;4^%&B\Q7GRB=I[/CB7!S_W M8D9')CA/_ZSHC>FJZHW]S&"0K)/1N5?Z]]MK1A*6]8GFWY5>$(M)&5A;FF]- MXT3?&HQ>[ =#-ZCVQ<(:9_N8)$VUTTEGOEHWO$AL]7I^&W&;Y$$XT3;+I )L M"C\"S+.C=WYL\FW+=,N-ZD9YUJ[S%0/K.G'5XS F(TEK]$Y92!H9.? ^![: M;0NRLY.DJ%W*)/]2ITJ[ZB+5)18GCB\:3_3M\5NA.TUG5B57 V7?@'PSSG\E M8)KE.CC\G![D?)SJ>7*#HQE@4J?^65W39DDC\3Y6P'2XD5-;HUNC?C;8X"WT M-/FV?X<5::3H,<%9SL\O,#?B@8QPC.OEQU?&>LXA4\LE@COZ[*H];Y=.?_:R MB2#?A=X>HW"]:RVXY0"QRP'G/B[#R@Y3"HNM6]G:-%3R!1)PFEHMNZ@ M5=A(!NK6P U.^L2T;]\[E:,_=M1H60_GQC1"V^KA7/R;6^EF^27SP8(V36AQ M'ZXS$'>93EVBF\(FTU<-I7;C+W,*/+(1=)E6VHJP.04O>=#!GE(FTPV(>4G/BN'_*ATI>9 M&/L"*;6?W<]V8*]'Y!-, G/-,*ZIO62Y<"@GIM.0]O;WZQA=E#;[*;'$%/.3 MUZZ*K%=\2F@]Y!RB"#L)Y,<[L"(>\_?+(Y^Z12NFEYM^JU.:>V"?,#7J"J.' MBI]M/G^GROSY0;76\@1YT+O_4_ZV"L%165LIED'S0E^@D_HOOA%T'PHO&=89 M(@%!3Y](*>.%=OX>KN)D'V4B3@"=O M7VBLC>OIDD:H#=6I7G#)O$IHVEC']UFS6248CNP*9]R8F1E?:YHPLL[_LFWJ M('"?E>\DX/[WVZE$& ]%"-_4EE\!8WJJ.L_WF%4X M3BWPG6NDY.8K>HPVKLP#?X8J&Q0TNE$B U;<+FX\[N(=]4I/1FEJ,6D*GV:^ MGM:TY,K+P<&E4T,(7YS0VH5Q_#P'1'2W\XZ@HI9HY#24TPM JG8O'ZN##>.B@= M$AVT*I22>"%1.J0#HD+!RYU@+S.TC[*:/O(3"GT'89?J/;O((;=U MC9$J_-YU.U[[$YW=%,6?S%D*H-5ZV6B0>R9<^QIH,J8\1S$YN&CPEJ/=LZ?2 MS86><96&2V-UAGFFCWZ-4YVD;LT9\AKT\]P1 /\DMKQI5=-/ZZ5Z,>&B2I] MHZ2H4L4L,U8ME<(O+:++)8@[]3'E0?FK:21"ZR!/Y?+ZX6E\%\9R=73@,0B3 M(:?G[^(H5,SOX]:FOK1-_KAD=>.SU4> US8GWRI"VA 04VOX]')6*Y2J06C,M#]_7D%G!FF?Y3'WNKWK\6 M6GAR7:]-WW3V.(W7,^CBS]5P*:]-X==>S>"IW.L]A<]9AQ2Z)!,&6 MG?-/4&N ;^FC\RPEB$F8:%"4E(MQFZZG=I4:^7UWX>J+;Z58%VU>X3=XA MUX=HW*8@..42TKIP6>ZZA$U4.O7-YCX#([!L")>_M:E'%@9B?6>MQ1K12+9( MZ)&&D">C@G9^A&S]C%0U]Z$JYI1XOK?OQ>++?"5/\"GC59[_I"1;VUCV MJ7Q*PQL IKS/MS@"=.0"-\6_9S^G^^=;.M"Y@\4.\1FX2TYV\'8-;>75IG$0 MC/*C]5?^$:^>;V6ZARWH(\!*'Y \9WCPJN (T)^NNM?\SD^I+W*G?T-4]1 Z M_Y,)!_C[,.J5E$&;E-]E<\BT!D< Q W8UK.;5ML*PFC5CU5'@!_;83_)2!X^ M/@)LKS >X*_29CJI!SH161%' )4GO]*!_#X[U;^Q1"P@X\(JXG?U?YC]5+]T M]B?IW]5K_F'VIW7+WN;Y?]#_^^SWV/Y_DJ+PB_L\C^B_.3)$Y0[-^!'YVO !QO0 % @ $9:P 9F]O M='!R:6YT,C Q.6$P,2YJ<&=02P$"% ,4 " #]>$Y0\SF/QQH$ #T$@ M%0 @ 'H&@$ ;6]H+3$R,S$R,#$Y97@R,S$N:'1M4$L! A0# M% @ _7A.4*C\["C#/P0 R<@V !0 ( !-1\! &UO:"TQ M,C,Q,C Q.7@Q,&LN:'1M4$L! A0#% @ _7A.4(U&'&"5$0 8H$ !< M ( !*E\% &UO:"TQ,C,Q,C Q.7AE>#$P,C4N:'1M4$L! A0# M% @ _7A.4'.^%;AX!0 F5, !8 ( !]' % &UO:"TQ M,C,Q,C Q.7AE>#(Q,2YH=&U02P$"% ,4 " #]>$Y02%O8G8$( !_* M%@ @ &@=@4 ;6]H+3$R,S$R,#$Y>&5X,S$Q+FAT;5!+ 0(4 M Q0 ( /UX3E!/@+8O? @ -TH 6 " 55_!0!M;V@M M,3(S,3(P,3EX97@S,3(N:'1M4$L! A0#% @ _7A.4&A]<03Z! X1D M !8 ( !!8@% &UO:"TQ,C,Q,C Q.7AE>#,R,2YH=&U02P$" M% ,4 " #]>$Y0O0(A:_<$ "G&@ %@ @ $SC04 ;6]H M+3$R,S$R,#$Y>&5X,S(R+FAT;5!+ 0(4 Q0 ( /UX3E"*:K6]41P *E6 M 0 0 " 5Z2!0!M;V@M,C Q.3$R,S$N>'-D4$L! A0#% M @ _7A.4/+YG/!20P [>H" !0 ( !W:X% &UO:"TR,#$Y M,3(S,5]C86PN>&UL4$L! A0#% @ _7A.4*?G4^58JP 87D( !0 M ( !8?(% &UO:"TR,#$Y,3(S,5]D968N>&UL4$L! A0#% @ M_7A.4*@68' 1=0$ ?[L3 !0 ( !ZYT& &UO:"TR,#$Y,3(S M,5]L86(N>&UL4$L! A0#% @ _7A.4-LQV5+Z^0 )M4, !0 M ( !+A,( &UO:"TR,#$Y,3(S,5]P&UL4$L! A0#% @ _7A. M4&+()!I/-P -U< !4 ( !6@T) &UO;&EN86QO9V\R,#$V M83(T+FIP9U!+ 0(4 Q0 ( /UX3E!B27:=6"8! $9N 0 + I " =Q$"0!N8W%A83$P+FIP9U!+!08 $0 1 &D$ !=:PH ! end XML 133 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details) - USD ($)
$ in Millions

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Insurance [Abstract]

Incurred claims and allocated claims adjustment expenses $ 46,125

Less: cumulative paid claims and allocated claims adjustment expenses (44,460)

All outstanding liabilities before 2017 15

Non-risk and other provider payables 174

Total $ 1,854 $ 1,961 $ 2,192 $ 1,929

X

- Definition
Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Outstanding Liabilities Relating to Prior Years
+ References
No definition available.
+ Details

Name: moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InsuranceAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (cc)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 4B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438
+ Details

Name: us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438
+ Details

Name: us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of aggregate reconciling items for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438
+ Details

Name: us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 134 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Medical Claims and Benefits Payable - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Insurance [Abstract]

Medical claims and benefits payable $ 132 $ 107 $ 122

Favorable (unfavorable) adjustment $ (271) (341) $ 36

CMS Subsidies

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Disposal group, operating expense $ 81

X

- Definition
Medical Claims and Benefits Payable
+ References
No definition available.
+ Details

Name: moh_MedicalClaimsAndBenefitsPayable

Namespace Prefix: moh_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InsuranceAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437
+ Details

Name: us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_MajorCustomersAxis=moh_CMSSubsidiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 135 R83.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Debt - Interest Cost (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Interest cost recognized for the period relating to the:

Contractual interest coupon rate $ 1 $ 6 $ 11

Amortization of the discount 5 21 32

Total interest cost recognized $ 6 $ 27 $ 43

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InterestCostsIncurredAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph 8
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_InterestExpenseDebtExcludingAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

Commitments and Contingencies (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Statutory Accounting Practices [Line Items]
Aggregate statutory capital and surplus	$ 1,852
Required minimum statutory capital surplus	1,110
Net assets of subsidiaries subject to restrictions	1,811	$ 2,262
Parent Company
Statutory Accounting Practices [Line Items]
Cash, cash equivalents, and investments	$ 997	$ 170

Leases - Lease Maturities (Details) $ in Millions	Dec. 31, 2019 USD ($)
Operating Leases
2020	$ 28
2021	20
2022	14
2023	10
2024	5
Thereafter	3
Subtotal - undiscounted lease payments	80
Less imputed interest	(7)
Total operating lease liabilities	73
Finance Leases
2020	23
2021	24
2022	21
2023	21
2024	22
Thereafter	289
Subtotal - undiscounted lease payments	400
Less imputed interest	(161)
Total finance lease liabilities	$ 239

Stockholders' Equity - Additional Information (Details) - USD ($)		1 Months Ended		12 Months Ended
	Dec. 31, 2019	Feb. 07, 2020	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2013	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchased of common stock				$ 54,000,000
Cash paid for partial termination of 1.125% Warrants				514,000,000	$ 549,000,000	$ 0
Unrecognized compensation expense	$ 49,000,000		$ 49,000,000	$ 49,000,000
Unrecognized compensation forfeited rate				15.90%
Weighted average grant date fair value of stock options granted (usd per share)				$ 41.43
Common stock issued during period (in shares)				142,000	216,000	351,000
RSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum award vesting period				4 years
Weighted average period of unrecognized compensation expense				2 years 2 months 12 days
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of unrecognized compensation expense				1 year 7 months 6 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum award vesting period				4 years
Unrecognized compensation expense	$ 4,000,000		$ 4,000,000	$ 4,000,000
Weighted average period of unrecognized compensation expense				9 months 18 days
Stock option expiration period				10 years
Risk free interest rate				2.30%
Expected volatility rate				38.40%
Dividend yield				0.00%
Expected term of awards				8 years 4 months 24 days
Options exercised, intrinsic value						$ 2,000,000
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield				0.00%	0.00%	0.00%
Expected term of awards				6 months	6 months	6 months
Employee purchase price as a percentage of stock price				85.00%
Maximum annual contribution per employee				$ 25,000
Risk-free interest rate, minimum				0.60%	0.60%	0.60%
Risk-free interest rate, maximum				2.30%	2.30%	2.30%
Minimum expected volatility rate inputs for fair value measurement				31.00%	31.00%	31.00%
Maximum expected volatility rate inputs for fair value measurement				45.00%	45.00%	45.00%
2019 EIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued under ESPP (in shares)								2,900,000
2019 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued under ESPP (in shares)								3,000,000.0
1.125% Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stated interest rate	1.125%		1.125%	1.125%
Number of warrants issued (in shares)							13,500,000
Striking price of warrants (USD per share)							$ 53.8475
Class of warrant	310,000		310,000	310,000
Cash paid for partial termination of 1.125% Warrants				$ 514,000,000
Number of warrants terminated (in shares)				5,900,000
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized	$ 500,000,000		$ 500,000,000	$ 500,000,000
Repurchased of common stock (in shares)	55,000			400,000
Repurchased of common stock	$ 7,000,000			$ 54,000,000
Average cost (USD per share)			$ 135.30
Share-based compensation (in shares)				242,000	365,000,000
Subsequent Event \| Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchased of common stock (in shares)		1,533,000
Repurchased of common stock		$ 203,000,000
Average cost (USD per share)		$ 132.69

Receivables (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Financing Receivable, Past Due [Line Items]
Total receivables	$ 1,406	$ 1,330
Government receivables
Financing Receivable, Past Due [Line Items]
Total receivables	1,056	872
Pharmacy rebate receivables
Financing Receivable, Past Due [Line Items]
Total receivables	150	146
Health insurer fee reimbursement receivables
Financing Receivable, Past Due [Line Items]
Total receivables	5	141
Other
Financing Receivable, Past Due [Line Items]
Total receivables	$ 195	$ 171

Leases - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Leases - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Lessee, Lease, Description [Line Items]
Operating lease term	9 years
Operating lease renewal term	10 years
Operating leases, weighted average remaining lease term	4 years
Finance lease renewal term	25 years
Finance leases, weighted average remaining lease term	16 years
Operating leases, weighted average discount rate	5.60%
Finance leases, weighted average discount rate	6.50%
Rent expense		$ 62	$ 75
Minimum
Lessee, Lease, Description [Line Items]
Finance lease term	2 years
Maximum
Lessee, Lease, Description [Line Items]
Finance lease term	19 years

Stockholders' Equity - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Shares
Beginning balance, outstanding (in shares)	405,000
Granted (in shares)	0	0
Exercised (in shares)	0
Ending balance, outstanding (in shares)	405,000	405,000
Weighted Average Exercise Price
Beginning balance, outstanding (usd per share)	$ 64.79
Granted (usd per share)	0
Exercised (usd per share)	0
Ending balance, outstanding (usd per share)	$ 64.79	$ 64.79
Outstanding, Aggregate Intrinsic Value	$ 29
Outstanding, Weighted Average Remaining Contractual term	7 years 4 months 24 days
Stock options exercisable and expected to vest (in shares)	405,000
Stock options exercisable and expected to vest (usd per share)	$ 64.79
Exercisable (in shares)	280,000
Exercisable (usd per share)	$ 63.65
Exercisable, Aggregate Intrinsic Value	$ 20
Exercisable, Weighted Average Remaining Contractual term	7 years 3 months 18 days

Restructuring Costs	12 Months Ended
Restructuring Costs	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Restructuring Costs	Restructuring Costs Restructuring costs are reported by the same name in the accompanying consolidated statements of operations. IT Restructuring Plan Management’s margin recovery plan identified and implemented various profit improvement initiatives. This included the plan to restructure our information technology department (the “IT Restructuring Plan”) in 2018, which is reported in the Other segment. In connection with this plan, in early 2019, we entered into services agreements with an outsourcing vendor who manages certain of our information technology services. As of December 31, 2019, the IT Restructuring Plan was substantially complete. Under this plan, we incurred cumulative restructuring costs of $12 million, including $7 million of one-time termination benefits and $5 million of other restructuring costs (primarily consulting fees). The final amount of costs incurred is lower than the $20 million we originally estimated and reported in our Annual Report on Form 10-K for the year ended December 31, 2018. Because more of our IT employees transitioned to our outsourcing vendor than originally contemplated, such employees were no longer included in the IT Restructuring Plan, resulting in lower one-time termination costs. As of December 31, 2018, $6 million was accrued under the IT Restructuring Plan, primarily for one-time termination benefits that require cash settlement. In the year ended December 31, 2019, we incurred $3 million of other restructuring costs, paid $5 million to settle one-time termination benefits, and paid $3 million to settle other restructuring costs. As of December 31, 2019, $1 million was accrued under the IT Restructuring Plan. 2017 Restructuring Plan As of December 31, 2018, $18 million was accrued for the restructuring and profitability improvement plan approved by the board of directors in June 2017 (the “2017 Restructuring Plan”). In the year ended December 31, 2019, we incurred $3 million of restructuring costs for adjustments to previously recorded lease contract termination costs, and paid $9 million to settle one-time termination and lease contract termination costs. As of December 31, 2019, $12 million was accrued for lease contract termination costs under the 2017 Restructuring Plan. We expect to continue to settle these liabilities through 2025, unless the leases are terminated sooner.

Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($) claim	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Product Information [Line Items]
Incurred Claims and Allocated Claims Adjustment Expenses	$ 13,905	$ 15,137	$ 17,073
Incurred Claims and Allocated Claims Adjustment Expenses	46,125
Total IBNP	1,391
Benefit Year 2017
Product Information [Line Items]
Incurred Claims and Allocated Claims Adjustment Expenses	16,704	16,728	$ 17,037
Total IBNP	$ 18
Cumulative number of reported claims (in claim) \| claim	119,000,000
Benefit Year 2018
Product Information [Line Items]
Incurred Claims and Allocated Claims Adjustment Expenses	$ 15,245	$ 15,478
Total IBNP	$ 25
Cumulative number of reported claims (in claim) \| claim	110,000,000
Benefit Year 2019
Product Information [Line Items]
Incurred Claims and Allocated Claims Adjustment Expenses	$ 14,176
Total IBNP	$ 1,348
Cumulative number of reported claims (in claim) \| claim	93,000,000

Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Cost	$ 199	$ 221
Accumulated Amortization	170	174
Carrying Amount	29	47
Contract rights and licenses
Finite-Lived Intangible Assets [Line Items]
Cost	179	201
Accumulated Amortization	156	162
Carrying Amount	23	39
Provider networks
Finite-Lived Intangible Assets [Line Items]
Cost	20	20
Accumulated Amortization	14	12
Carrying Amount	$ 6	$ 8

Debt - Senior Notes (Details)	Dec. 31, 2019 USD ($)
5.375% Senior Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate on notes	5.375%
4.875% Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate on notes	4.875%
Senior Notes \| 5.375% Senior Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate on notes	5.375%
Aggregate principal amount of notes outstanding	$ 700,000,000
Senior Notes \| 4.875% Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate on notes	4.875%
Aggregate principal amount of notes outstanding	$ 330,000,000

Fair Value Measurements - Additional Information (Details)	Dec. 31, 2019
1.125% Call Option
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of contractual interest rate on derivative	1.125%
1.125% Conversion Option
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of contractual interest rate on derivative	1.125%

Investments - Contractual Maturities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Amortized Cost
Due in one year or less	$ 453
Due after one year through five years	957
Due after five years through ten years	171
Due after ten years	360
Amortized Cost	1,941	$ 1,692
Estimated Fair Value
Due in one year or less	453
Due after one year through five years	962
Due after five years through ten years	171
Due after ten years	360
Estimated Fair Value	$ 1,946

Condensed Financial Information of Registrant - Condensed Balance Sheets (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 2,452	$ 2,826	$ 3,186
Investments	1,946	1,681
Receivables	1,406	1,330
Prepaid expenses and other current assets	134	149
Derivative asset	29	476
Total current assets	5,967	6,462
Property, equipment, and capitalized software, net		241
Goodwill and intangible assets, net	172	190	255
Deferred income taxes	79	117
Total assets	6,787	7,154	8,471
Current liabilities:
Medical claims and benefits payable	1,854	1,961	2,192	$ 1,929
Accounts payable and accrued liabilities	455	390
Current portion of long-term debt	18	241
Derivative liability	29	476
Total current liabilities	3,269	4,246
Long-term debt	1,237	1,020
Finance lease liabilities	231
Finance lease liabilities		197
Other long-term liabilities	90	44
Total liabilities	4,827	5,507
Stockholders’ equity:
Common stock, $0.001 par value; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018	0	0
Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding	0	0
Additional paid-in capital	175	643
Accumulated other comprehensive income (loss)	4	(8)
Retained earnings	1,781	1,012
Total stockholders’ equity	1,960	1,647	$ 1,337	$ 1,649
Total liabilities and stockholders’ equity	6,787	7,154
Parent Company
Current assets:
Cash and cash equivalents	836	70
Investments	161	100
Receivables	2	2
Due from affiliates	49	90
Prepaid expenses and other current assets	46	47
Derivative asset	29	476
Total current assets	1,123	785
Property, equipment, and capitalized software, net	327	176
Goodwill and intangible assets, net	13	13
Investments in subsidiaries	2,225	2,768
Deferred income taxes	10	39
Advances to related parties and other assets	76	40
Total assets	3,774	3,821
Current liabilities:
Medical claims and benefits payable	0	4
Accounts payable and accrued liabilities	260	223
Current portion of long-term debt	18	241
Derivative liability	29	476
Total current liabilities	307	944
Long-term debt	1,237	1,020
Finance lease liabilities	231
Finance lease liabilities		197
Other long-term liabilities	39	13
Total liabilities	1,814	2,174
Stockholders’ equity:
Common stock, $0.001 par value; 150 million shares authorized; outstanding: 62 million shares at each of December 31, 2019, and December 31, 2018	0	0
Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding	0	0
Additional paid-in capital	175	643
Accumulated other comprehensive income (loss)	4	(8)
Retained earnings	1,781	1,012
Total stockholders’ equity	1,960	1,647
Total liabilities and stockholders’ equity	$ 3,774	$ 3,821

Cover Page - USD ($) shares in Thousands, $ in Millions	12 Months Ended
Cover Page - USD ($) shares in Thousands, $ in Millions	Dec. 31, 2019	Feb. 07, 2020	Jun. 30, 2019
Cover page.
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	1-31719
Entity Registrant Name	MOLINA HEALTHCARE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-4204626
Entity Address, Address Line One	200 Oceangate
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Long Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90802
City Area Code	562
Local Phone Number	435-3666
Title of 12(b) Security	Common Stock, $0.001 Par Value
Trading Symbol	MOH
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 8,928.7
Entity Common Stock, Shares Outstanding		60,800
Documents Incorporated by Reference	Portions of the registrant’s Proxy Statement for the 2020 Annual Meeting of Stockholders to be held on May 7, 2020, are incorporated by reference into Part III of this Form 10-K, to the extent described therein.
Entity Central Index Key	0001179929
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value (dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares outstanding	62,000,000	62,000,000
Preferred stock, par value (dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Label	Element	Value
AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (1,000,000)
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	7,000,000
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 85,000,000

Debt - Maturities (Details) $ in Millions	Dec. 31, 2019 USD ($)
Debt Instrument [Line Items]
Net carrying amount	$ 1,262
2020	18
2021	16
2022	722
2023	22
2024	154
Thereafter	$ 330
5.375% Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate	5.375%
4.875% Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate	4.875%
1.125% Convertible Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate	1.125%
Senior Notes \| 5.375% Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate	5.375%
Net carrying amount	$ 700
2020	0
2021	0
2022	700
2023	0
2024	0
Thereafter	$ 0
Senior Notes \| 4.875% Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate	4.875%
Net carrying amount	$ 330
2020	0
2021	0
2022	0
2023	0
2024	0
Thereafter	$ 330
Senior Notes \| 1.125% Convertible Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate	1.125%
Term Loan Facility \| Term Loan Facility
Debt Instrument [Line Items]
Net carrying amount	$ 220
2020	6
2021	16
2022	22
2023	22
2024	154
Thereafter	$ 0
Convertible Debt \| 4.875% Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate	4.875%
Convertible Debt \| 1.125% Convertible Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate	1.125%
Net carrying amount	$ 12
2020	12
2021	0
2022	0
2023	0
2024	0
Thereafter	$ 0

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Accrued expenses and reserve liabilities	$ 35	$ 39
Other accrued medical costs	11	12
Net operating losses	13	16
Fixed assets and intangibles	26	30
Unearned premiums	11	9
Lease financing obligation	5	30
Tax credit carryover	11	12
Other	0	3
Valuation allowance	(24)	(28)
Total deferred income tax assets, net of valuation allowance	88	123
Prepaid expenses	(6)	(6)
Other	(3)	0
Total deferred income tax liabilities	(9)	(6)
Net deferred income tax asset	$ 79	$ 117

Derivatives (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
Derivatives (Details) - USD ($) $ in Millions	Jan. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Derivative [Line Items]
Cash received for partial settlement of call option		$ 578	$ 623	$ 0
Cash paid for partial termination of 1.125% Warrants		514	549	$ 0
Convertible debt, converted amount of instrument		$ 64
1.125% Convertible Notes
Derivative [Line Items]
Percentage of contractual interest rate		1.125%
1.125% Convertible Notes \| Subsequent Event
Derivative [Line Items]
Cash received for partial settlement of call option	$ 27
1.125% Call Option
Derivative [Line Items]
Percentage of contractual interest rate on derivative		1.125%
1.125% Call Option \| Subsequent Event
Derivative [Line Items]
Percentage of contractual interest rate on derivative	1.125%
1.125% Call Option \| Current assets
Derivative [Line Items]
Derivative asset		$ 29	476
1.125% Conversion Option
Derivative [Line Items]
Percentage of contractual interest rate on derivative		1.125%
1.125% Conversion Option \| Current liabilities
Derivative [Line Items]
Derivative liability		$ 29	$ 476
1.125% Warrants
Derivative [Line Items]
Percentage of contractual interest rate on derivative		1.125%
Cash paid for partial termination of 1.125% Warrants		$ 514

Debt - Credit Agreement (Details) - USD ($)	12 Months Ended
Debt - Credit Agreement (Details) - USD ($)	Dec. 31, 2019	Jan. 31, 2019
Line of Credit Facility [Line Items]
Aggregate principal amount of notes outstanding	$ 1,262,000,000
Term Loan Facility \| Term Loan Facility
Line of Credit Facility [Line Items]
Aggregate principal amount of notes outstanding	220,000,000
Current borrowing capacity	380,000,000
Term Loan Facility \| Credit Facility
Line of Credit Facility [Line Items]
Maximum borrowing capacity	500,000,000	$ 600,000,000
Minimum principal amount of advancements		$ 50,000,000
Current borrowing capacity	499,000,000
Amount outstanding under Letter of Credit	0
Term Loan Facility \| Letter of Credit
Line of Credit Facility [Line Items]
Amount outstanding under Letter of Credit	$ 1,000,000
Minimum \| Term Loan Facility \| Credit Facility
Line of Credit Facility [Line Items]
Amortization payment percentage	1.25%
Maximum \| Term Loan Facility \| Credit Facility
Line of Credit Facility [Line Items]
Amortization payment percentage	2.50%

Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	$ 168	$ 175	$ 196	$ 198	$ 201	$ 197	$ 202	$ 107	$ 737	$ 707	$ (512)
Unrealized investment income (loss)									16	(3)	(5)
Less: effect of income taxes									4	(1)	(2)
Other comprehensive income (loss), net of tax									12	(2)	(3)
Comprehensive income (loss)									749	705	(515)
Parent Company
Condensed Financial Statements, Captions [Line Items]
Net income (loss)									737	707	(512)
Unrealized investment income (loss)									16	(3)	(5)
Less: effect of income taxes									4	(1)	(2)
Other comprehensive income (loss), net of tax									12	(2)	(3)
Comprehensive income (loss)									$ 749	$ 705	$ (515)

Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	$ 1,946	$ 1,681
Total assets	1,975	2,157
Total liabilities	29	476
Corporate debt securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	1,178	1,123
Mortgage-backed securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	420
Asset-backed securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	127	82
U.S. Treasury notes
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	86	181
Municipal securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	78	114
Government-sponsored enterprise securities (“GSEs”)
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	49	163
Foreign securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	7	4
Certificates of deposit
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	1	14
1.125% Call Option derivative asset
Fair value of assets measured on recurring basis
1.125% Call Option derivative asset	$ 29	476
Percentage of contractual interest rate on derivative	1.125%
Conversion Option
Fair value of assets measured on recurring basis
1.125% Conversion Option derivative liability	$ 29	476
Percentage of contractual interest rate on derivative	1.125%
Level 1
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	$ 0	0
Total assets	0	0
Total liabilities	0	0
Level 1 \| Corporate debt securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 1 \| Mortgage-backed securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0
Level 1 \| Asset-backed securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 1 \| U.S. Treasury notes
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 1 \| Municipal securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 1 \| Government-sponsored enterprise securities (“GSEs”)
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 1 \| Foreign securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 1 \| Certificates of deposit
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 1 \| 1.125% Call Option derivative asset
Fair value of assets measured on recurring basis
1.125% Call Option derivative asset	0	0
Level 1 \| Conversion Option
Fair value of assets measured on recurring basis
1.125% Conversion Option derivative liability	0	0
Level 2
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	1,946	1,681
Total assets	1,946	1,681
Total liabilities	0	0
Level 2 \| Corporate debt securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	1,178	1,123
Level 2 \| Mortgage-backed securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	420
Level 2 \| Asset-backed securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	127	82
Level 2 \| U.S. Treasury notes
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	86	181
Level 2 \| Municipal securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	78	114
Level 2 \| Government-sponsored enterprise securities (“GSEs”)
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	49	163
Level 2 \| Foreign securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	7	4
Level 2 \| Certificates of deposit
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	1	14
Level 2 \| 1.125% Call Option derivative asset
Fair value of assets measured on recurring basis
1.125% Call Option derivative asset	0	0
Level 2 \| Conversion Option
Fair value of assets measured on recurring basis
1.125% Conversion Option derivative liability	0	0
Level 3
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Total assets	29	476
Total liabilities	29	476
Level 3 \| Corporate debt securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 3 \| Mortgage-backed securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0
Level 3 \| Asset-backed securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 3 \| U.S. Treasury notes
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 3 \| Municipal securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 3 \| Government-sponsored enterprise securities (“GSEs”)
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 3 \| Foreign securities
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 3 \| Certificates of deposit
Fair value of assets measured on recurring basis
Debt securities, available-for-sale	0	0
Level 3 \| 1.125% Call Option derivative asset
Fair value of assets measured on recurring basis
1.125% Call Option derivative asset	29	476
Level 3 \| Conversion Option
Fair value of assets measured on recurring basis
1.125% Conversion Option derivative liability	$ 29	$ 476

Investments - Narrative (Details) $ in Millions	12 Months Ended
Investments - Narrative (Details) $ in Millions	Dec. 31, 2019 USD ($)
Investments, Debt and Equity Securities [Abstract]
Gross realized investment gains	$ 13

Property, Equipment, and Capitalized Software, Net - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019
Furniture and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Useful life of property plant and equipment	3 years
Furniture and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Useful life of property plant and equipment	7 years
Software
Property, Plant and Equipment [Line Items]
Useful life of property plant and equipment	3 years
Leasehold improvements \| Minimum
Property, Plant and Equipment [Line Items]
Useful life of property plant and equipment	5 years
Leasehold improvements \| Maximum
Property, Plant and Equipment [Line Items]
Useful life of property plant and equipment	10 years
Building and improvements \| Minimum
Property, Plant and Equipment [Line Items]
Useful life of property plant and equipment	31 years 6 months
Building and improvements \| Maximum
Property, Plant and Equipment [Line Items]
Useful life of property plant and equipment	40 years

Leases - Components of Lease Expense (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Leases [Abstract]
Operating lease expense	$ 34
Finance lease expense:
Amortization of ROU assets	17
Interest on lease liabilities	15
Total finance lease expense	$ 32

Stockholders' Equity - Stock Options by Exercise Price (Details)	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding	405,000
Options Exercisable, Number Exercisable	280,000
$33.02
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding	30,000
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	3 years 2 months 12 days
Options Outstanding, Weighted-Average Exercise Price \| $ / shares	$ 33.02
Options Exercisable, Number Exercisable	30,000
Options Exercisable, Weighted-Average Exercise Price \| $ / shares	$ 33.02
$67.33
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding	375,000
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	7 years 9 months 18 days
Options Outstanding, Weighted-Average Exercise Price \| $ / shares	$ 67.33
Options Exercisable, Number Exercisable	250,000
Options Exercisable, Weighted-Average Exercise Price \| $ / shares	$ 67.33

Segments - Narrative (Details)	12 Months Ended
Segments - Narrative (Details)	Dec. 31, 2019 segment
Segment Reporting [Abstract]
Number of reportable segments	2

Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Cash and cash equivalents	$ 2,452	$ 2,826	$ 3,186
Restricted cash and cash equivalents, non-current	56	100	95
Restricted cash and cash equivalents, current	0	0	9
Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows	$ 2,508	$ 2,926	$ 3,290	$ 2,912

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2019
Postemployment Benefits [Abstract]
Employee Benefit Plans	Employee Benefit Plans We sponsor defined contribution 401(k) plans that cover substantially all employees of our company and its subsidiaries. Eligible employees are permitted to contribute up to the maximum amount allowed by law. We generally match up to the first 4% of compensation contributed by employees. Expense recognized in connection with our contributions to the 401(k) plans amounted to $28 million, $36 million, and $43 million in the years ended December 31, 2019, 2018, and 2017, respectively. We also have a non-qualified deferred compensation plan for certain key employees. Under this plan, eligible participants may defer up to 100% of their base salary and 100% of their bonus to provide tax-deferred growth. The funds deferred are invested in corporate-owned life insurance, under a rabbi trust.

Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Beginning Balance (in shares) at Dec. 31, 2016	55.8	57.0
Beginning Balance at Dec. 31, 2016	$ 1,649	$ 0	$ 841	$ (2)	$ 810
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(512)				(512)
Exchange of convertible senior notes (in shares)		3.0
Exchange of convertible senior notes	161		161
Other comprehensive income (loss), net	(3)			(3)
Share-based compensation	$ 42		42
Ending Balance (in shares) at Dec. 31, 2017	59.3	60.0
Ending Balance at Dec. 31, 2017	$ 1,337	$ 0	1,044	(5)	298
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	707				707
Exchange of convertible senior notes (in shares)		2.0
Exchange of convertible senior notes	108		108
Other comprehensive income (loss), net	(2)			(2)
Share-based compensation	37		37
Partial termination of warrants	(550)		(550)
Conversion of convertible senior notes	$ 4		4
Ending Balance (in shares) at Dec. 31, 2018	62.1	62.0
Ending Balance at Dec. 31, 2018	$ 1,647	$ 0	643	(8)	1,012
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	737				737
Common stock purchases	(54)	$ (54)	(1)		(53)
Exchange of convertible senior notes	0
Other comprehensive income (loss), net	12			12
Share-based compensation	47		47
Partial termination of warrants	(514)		(514)
Ending Balance (in shares) at Dec. 31, 2019		62.0
Ending Balance at Dec. 31, 2019	$ 1,960	$ 0	$ 175	$ 4	$ 1,781